

The logo for the American Thoracic Society (ATS) 2023 conference. It features a blue icon of three curved lines on the left, followed by the text "ATS" in bold black and "2023" in blue below it.

ATS
2023

Final Program

Washington, DC | May 19-24
conference.thoracic.org

The American Thoracic Society Would Like to Acknowledge our 2023 Corporate Members:

CHAMPION				CHAMPION
BENEFACTOR		 		BENEFACTOR
PATRON			 <small>A Member of the Roche Group</small>	PATRON
SUPPORTER				SUPPORTER
FRIEND	 <small>Biotherapies for Life™</small>		 <small>INVENTING FOR LIFE</small>	FRIEND
FRIEND				FRIEND
FRIEND				FRIEND
FRIEND				FRIEND
FRIEND				FRIEND
FRIEND				FRIEND
FRIEND				FRIEND



For the 2023 ATS International Conference, this disclosure information for all individuals in control of content was requested and received by ATS in advance of the Conference, reviewed by appropriate ATS reviewers, and session chairs and others in positions of authority were instructed to manage and mitigate identified faculty conflicts according to procedures overseen by the ATS Ethics and Conflict of Interest Committee. Please click the link below to review the ATS 2023 International Conference Planners Disclosures.

<https://conference.thoracic.org/speakers/resources/2023/disclosure.pdf>



Join Us to Discuss Climate Change and Child Lung Health

June 19, 2023 | Stanford University and virtually

A child struggles to breathe during recess—because of a wildfire raging hundreds of miles away. Asthma diagnoses spike in increasingly dense cities, filled with people fleeing the effects of climate change. Preterm births rise along with the temperature, causing higher rates of bronchopulmonary dysplasia. Clearly, climate change is altering everything in our world, and child lung health is no exception.

Join us for a wide-ranging discussion on the impact of climate change on child lung health. This free, one-day symposium will feature experts from around the world. We will delve into the latest research and hear real-world examples that shed light on how clinicians can prepare and respond to this coming crisis.



Children's Health

Pulmonary Asthma and
Sleep Medicine Center

Learn more and
register for free



Welcome to ATS 2023

Welcome to Washington, DC and the 2023 American Thoracic Society International Conference. The conference attracts investigators, educators, and clinicians and is truly the destination for adults and pediatric pulmonary, critical care, and sleep medicine professionals at every level of their careers.

This is our first time in Washington since 2017. Much has changed since then, and you won't want to miss the opportunities to learn, network, and connect. Because it engages attendees across many disciplines and continents, the ATS International Conference draws a large, diverse group of participants, a dedicated and collegial community that inspires each of us to make a difference in patients' lives, now and in the future.

By virtue of its size — ATS 2023 features more than 5,500 original research projects and case reports, 400 sessions, and over 900 speakers — participants can attend sessions and special events from early morning to the evening. At ATS 2023 there will be something for everyone.

Don't miss the following important events:

- The [Opening Ceremony](#) featuring a keynote presentation by Stephen K. Klasko, MD, MBA. During his career he has been dean at two medical colleges (Drexel and University of South Florida), president of a University (Thomas Jefferson University) and CEO of two academic health systems (USF health and Jefferson Health).
- The [ATS Research Program Benefit](#) on Saturday evening where you can reconnect with old friends and make new ones.
- The [Keynote Series](#) which highlight lectures on selected topics in an unopposed format to showcase timely and diverse topics which relate to pulmonary, critical care and sleep medicine.
- [Respiratory Health Awards](#) which include the Trudeau Medal, Distinguished Achievement Awards, and Amberson Lecture.
- [ATS Plenary Session](#) which will feature a keynote address by Timothy Caulfield, professor of Health Law and Science Policy and best-selling author.
- [Assembly Membership Meetings](#), which are open to all attendees.

These events create a sense of community among the International Conference attendees, which is precisely what our founders had hoped when they established the world's first respiratory society.

Finally, we wish to acknowledge the hard work and outstanding efforts of the members of the International Conference Committee, Education Committee, Assembly Program Committees, and ATS staff. The success of our conference depends on the dedication, creativity, and support of these individuals.

We welcome you to the International Conference and hope you take advantage of all Washington has to offer.

ATS 2023



Greg Downey, MD, ATSF
President



Andrew Halayko, PhD, ATSF
Chair, International
Conference Committee



Debra Boyer, MD, MPHE
Co-Chair, International
Conference Committee

It's time to disrupt the vicious vortex IN BRONCHIECTASIS

Learn about a **comprehensive management approach** that focuses on all 4 primary drivers of bronchiectasis in order to disrupt the vicious vortex of disease progression^{1,2}:



Impaired mucociliary clearance



Chronic airway inflammation, primarily neutrophilic



Chronic airway infection



Lung destruction

Visit us at **Booth #609** at **ATS 2023**
to learn more about the key drivers of bronchiectasis

References: 1. Flume PA et al. *Lancet*. 2018;392(10150):880-890. 2. O'Donnell AE. *N Engl J Med*. 2022;387(6):533-545.

Contents

1
Conference
Faculty and
Planners
Disclosures

3
Welcome
Letter

7
Program
at a Glance

8
General
Information

10
Exhibit Hall

11
Industry
Programs

13
Networking
Opportunities

15
International
Poster
Sessions

16
General
Sessions/
Awards

17
ATS 2023
Session
Introduction

18
Conference
Sessions



PH-ILD reImagined

2023 UPDATES IN DISEASE STATE, TREATMENT, AND DEVICE OPTIONS

6:30 - 8:00
PM EDT **SUNDAY, MAY 21, 2023**

RENAISSANCE HOTEL

WASHINGTON DC DOWNTOWN
POTOMAC BALLROOM (SALON 1-3)


SCAN TO REGISTER



AN IN-DEPTH REVIEW OF THE IMPACT OF
PULMONARY HYPERTENSION
IN INTERSTITIAL LUNG DISEASE
TREATMENT, AND DEVICE OPTIONS.



JAMIE RUTLAND, MD
West Coast Lung, Rutland
Medical Group



STEVEN NATHAN, MD, FCCP
Inova Fairfax Hospital



COLLEEN A. MCEVOY, MD
Washington University
Physicians



Medical
Affairs

Program at a Glance

FRIDAY, MAY 19

8 a.m. - 4 p.m.

- [Postgraduate Courses](#)

5 - 7:45 p.m.

- [Respiratory Innovation Summit \(RIS\)](#)

All Day Educational Events:

- [Fellows Track Symposium \(FTS\)](#)
- [New Faculty Boot Camp \(NFBC\)](#)
- [Resident Boot Camp \(RBC\)](#)

SATURDAY, MAY 20

8 a.m. - 4 p.m.

- [Postgraduate Courses](#)

4:30 - 5:30 p.m.

- [Opening Ceremony](#)

5:30 - 6:30 p.m.

- [Networking Exchange for Early Career Professionals](#)

6 - 7:30 p.m.

- [Annual ATS Research Program Benefit](#)

All Day Educational Events:

- [Respiratory Innovation Summit \(RIS\)](#)
- [Fellows Track Symposium \(FTS\)](#)
- [New Faculty Boot Camp \(NFBC\)](#)
- [Resident Boot Camp \(RBC\)](#)
- [Student Scholars Program](#)

SUNDAY, MAY 21

8 - 8:45 a.m.

- [Keynote Series](#)

9 - 10:30 a.m.

- [Scientific Symposia](#) (including: Basic Science Core, Clinical Topics in Pulmonary Medicine, Clinical Year in Review, Critical Care Track, JAMA/NEJM Session)

9 - 11 a.m.

- [Abstracts Sessions: Mini Symposia](#)
[Poster Discussion Sessions](#)
[RAPiD: Rapid Abstract Poster Discussion Sessions](#)

9 a.m. - 4:15 p.m.

- [Abstract Sessions: Thematic Poster Sessions](#)

10:15 - 11:15 a.m.

- [Medical Education Seminars](#)
[Meet the Expert Seminars](#)

10:30 a.m. - 3:30 p.m.

- [Exhibit Hall](#)

11:30 a.m. - 1 p.m.

- [Adult Clinical Core Curriculum: Sleep](#)

11:45 a.m. - 1:15 p.m.

- [Diversity Forum](#)

12 - 1 p.m.

- [Meet the Expert Seminars](#)
[Outside Organization Sessions](#)

1:15 - 2:15 p.m.

- [Unopposed Exhibit Hall Time](#)

2:15 - 3:45 p.m.

- [Scientific Symposia](#) (including: Basic Science Core, Clinical Topics in Pulmonary Medicine, Critical Care Track, Pediatric Year in Review, NEJM/JAMA Session)

2:15 - 4:15 p.m.

- [Abstract Sessions: Mini Symposia](#)
[Poster Discussion Sessions](#)
[RAPiD: Rapid Abstract Poster Discussion Sessions](#)

4:30 - 5:30 p.m.

- [Awards Ceremony](#)

5 - 7 p.m.

- [Assembly Membership Meetings](#)

All Day Educational Event:

- [Student Scholars Program](#)

MONDAY, MAY 22

8 - 8:45 a.m.

- [Keynote Series](#)

9 - 10:30 a.m.

- [Scientific Symposia](#) (including: Basic Science Core, Clinical Topics in Pulmonary Medicine, Clinical Year in Review, Critical Care Track)

9 - 11 a.m.

- [Abstracts Sessions: Mini Symposia](#)
[Poster Discussion Sessions](#)
[RAPiD: Rapid Abstract Poster Discussion Sessions](#)

- [Breaking News: 2023 Clinical Trial Results in Pulmonary Medicine](#)

9 a.m. - 4:15 p.m.

- [Abstract Sessions: Thematic Poster Sessions](#)

10:15 - 11:15 a.m.

- [Medical Education Seminars](#)
[Meet the Expert Seminars](#)

10:30 a.m. - 3:30 p.m.

- [Exhibit Hall](#)

11:30 a.m. - 1 p.m.

- [Adult Clinical Core Curriculum: Critical Care](#)

11:45 - 1:15 p.m.

- [Women's Forum](#)

12 - 1 p.m.

- [ATS Advancing Adult Immunization Initiative: Immune Boost! Addressing Vaccine Hesitancy and the Landscape of Vaccine-Preventable Diseases](#)

• [Meet the Expert Seminars](#)

• [Outside Organization Sessions](#)

• [Pediatric Clinical Core Curriculum](#)

1:15 - 2:15 p.m.

- [Unopposed Exhibit Hall Time](#)

2:15 - 3:45 p.m.

- [Adult Core Curriculum: Sleep](#)
- [Recognition Awards for Scientific Accomplishments](#)

- [Scientific Symposia](#) (including: Basic Science Core, Clinical Topics in Pulmonary Medicine, Critical Care Track, Nursing Year in Review)

2:15 - 4:15 p.m.

- [Abstract Sessions: Mini Symposia](#)
[Poster Discussion Sessions](#)
[RAPiD: Rapid Abstract Poster Discussion Sessions](#)

5 - 7 p.m.

- [Assembly Membership Meetings](#)

All Day Educational Event:

- [Student Scholars Program](#)

TUESDAY, MAY 23

8 - 8:45 a.m.

- [Keynote Series](#)

9 - 10:30 a.m.

- [Scientific Symposia](#) (including: Basic Science Core, Clinical Topics in Pulmonary Medicine, Clinical Year in Review, Critical Care Track)

9 - 11 a.m.

- [Abstracts Sessions: Mini Symposia](#)
[Poster Discussion Sessions](#)
[RAPiD: Rapid Abstract Poster Discussion Sessions](#)

9 a.m. - 4:15 p.m.

- [Abstract Sessions: Thematic Poster Sessions](#)

10:15 - 11:15 a.m.

- [Medical Education Seminars](#)
[Meet the Expert Seminars](#)

10:30 a.m. - 3:30 p.m.

- [Exhibit Hall](#)

11:30 a.m. - 1 p.m.

- [Plenary Session](#)

12 - 1 p.m.

- [Research Integrity in Medical Education: Lessons from the Tuskegee Experiment](#)

• [Meet the Expert Seminars](#)

• [Outside Organization Sessions](#)

• [Pediatric Clinical Core Curriculum](#)

1:15 - 2:15 p.m.

- [Unopposed Exhibit Hall Time](#)

2:15 - 3:45 p.m.

- [Adult Clinical Core Curriculum: Critical Care](#)
[Scientific Symposia](#) (including: Basic Science Core, Clinical Topics in Pulmonary Medicine, Critical Care Track)

2:15 - 4:15 p.m.

- [Abstract Sessions: Mini Symposia](#)
[Poster Discussion Sessions](#)
[RAPiD: Rapid Abstract Poster Discussion Sessions](#)

All Day Educational Event:

- [Student Scholars Program](#)

WEDNESDAY, MAY 24

8 - 9:30 a.m.

- [Scientific Symposia](#) (including: Basic Science Core, Clinical Topics in Pulmonary Medicine, Clinical Year in Review, Critical Care Track)

8 - 10 a.m.

- [Abstracts Sessions: Mini Symposia](#)
[Poster Discussion Sessions](#)

9:15 - 10:15 a.m.

- [Meet the Expert Seminars](#)

10 - 11:30 a.m.

- [Adult Clinical Core Curriculum: Pulmonary](#)
- [Outside Organization Sessions](#)

11 a.m. - 12 p.m.

- [Meet the Expert Seminars](#)
- [Pediatric Clinical Core Curriculum](#)

12 - 1:30 p.m.

- [Adult Clinical Core Curriculum: Pulmonary](#)
- [Scientific Symposia](#) (including: Basic Science Core, Clinical Topics in Pulmonary Medicine, Critical Care Track)

12 - 2 p.m.

- [Abstract Sessions: Mini Symposia](#)
[Poster Discussion Sessions](#)

General Information

REGISTRATION

For your convenience, there are two registration locations:

Walter E. Washington Convention Center, East and West Salons (Street Level)

This location includes Express Registration, Assisted Registration, Membership Desks, Information Desks, and ADA Accessible counters. Express Registration is designed for attendees who are ready to pick up their badges. Assisted Registration provides on-site support for attendees who want to make changes to their registration.

Registration Dates & Hours

Thursday, May 18	5 - 7 p.m.
Friday, May 19	7 a.m. - 5 p.m.
Saturday, May 20	7 a.m. - 5 p.m.
Sunday, May 21	6:30 a.m. - 5 p.m.
Monday, May 22	7 a.m. - 5 p.m.
Tuesday, May 23	7 a.m. - 3:30 p.m.
Wednesday, May 24	7 - 11 a.m.

Marriott Marquis Washington, Level M1

This location includes Express and Assisted Registration Desks. Express Registration is designed for attendees who are ready to pick up their badges. Assisted Registration provides on-site support for attendees who want to make changes to their registration.

Registration Dates & Hours

Friday, May 19	2 - 7 p.m.
Saturday, May 20	7 a.m. - 6:30 p.m.
Sunday, May 21	6:30 a.m. - 6 p.m.
Monday, May 22	8 a.m. - 5:30 p.m.
Tuesday, May 23	8 a.m. - 3 p.m.
Wednesday, May 24	7 - 11 a.m.

BADGES

Name badges must be worn for admittance to all ATS 2023 events. Please return to registration if you have lost your name badge. There will be a \$50 fee for replacement badges.

Conference badge holders are coded as follows:

Blue	Attendee
Purple	International Attendee
Yellow	Exhibitors
Brown	Spouses/Partners/Guest Postgraduate/Early Career
Green	Professional Courses Respiratory Innovation Summit (RIS) (Friday and Saturday Only)
Clear	Press

SESSION LOCATIONS

ATS 2023 sessions, special events, assembly meetings, and committee meetings will be held at the Walter E. Washington Convention Center, Marriott Marquis Washington, Renaissance Washington Downtown, and the Grand Hyatt Washington.

Industry Sponsored Evening Symposia will be held at the Conrad Washington, DC, Embassy Suites by Hilton Washington, DC Convention Center, Grand Hyatt Washington, Renaissance Washington Downtown, and Washington Marriott at Metro Center.

EXHIBITS

Exhibits are in the Walter E. Washington Convention Center, Halls A-B (Lower Level). Badges must always be worn for admittance to the Exhibit Hall.

Children under the age of 12 are not permitted in the Exhibit Hall.

ATS INTERNATIONAL CONFERENCE OFFICE

The ATS International Conference Office is in the Walter E. Washington Convention Center, Room 158A (Street Level).

SPEAKER READY ROOM

All speakers are required to check in at the Speaker Ready Room at least four hours before their presentation. Speakers can view, edit, and upload presentations. This area is restricted to speakers only; conference name badges must be worn for admittance.

For your convenience, ATS offers two speaker ready room locations:

Walter E. Washington Convention Center, Room 156 (St. Level)
Marriott Marquis Washington, Senate (Level M4)

Speaker Ready Room Hours:

	Walter E. Washington Convention Center Room 156 (Street Level)	Marriott Marquis Washington Senate (Level M4)
Thursday, May 18	1 - 6 p.m.	Closed
Friday, May 19	6 a.m. - 6 p.m.	1 - 6 p.m.
Saturday, May 20	6 a.m. - 6 p.m.	6 a.m. - 6 p.m.
Sunday, May 21	6 a.m. - 5 p.m.	6 a.m. - 5 p.m.
Monday, May 22	6 a.m. - 5 p.m.	6 a.m. - 5 p.m.
Tuesday, May 23	6 a.m. - 5 p.m.	6 a.m. - 5 p.m.
Wednesday, May 24	6 a.m. - 1 p.m.	6 a.m. - 1 p.m.

PRESS OFFICE

The press office is located in the Walter E. Washington Convention Center, Room 154 (Street Level) and is open to members of the press.

Press Room Hours:

Friday, May 19	8:30 a.m. - 5 p.m.
Saturday, May 20	8:30 a.m. - 5 p.m.
Sunday, May 21	6:30 a.m. - 6 p.m.
Monday, May 22	7 a.m. - 6 p.m.
Tuesday, May 23	7 a.m. - 6 p.m.
Wednesday, May 24	7 a.m. - 2 p.m.

General Information

TRANSPORTATION

Washington, DC is home to some of the most stubborn traffic in the United States. Driving can be challenging, and the parking fees are costly. Taking public transportation, bus, or subway, is safe and inexpensive and the easiest way to move about the city. Details on Metro, ride-sharing and taxi cabs are below.

Metro: The best way to get around the city is the DC Metro. The trains and stations are clean and safe; you purchase farecards before you go down to the platform. Visit <https://www.wmata.com/> to plan your trip.

DC Circulator: The bus fare is \$1 a trip (or 50 cents if you're a senior). The DC Circulator can also help you connect to Metro stations for a more flexible transportation solution. The DC Circulator comes about every 10 minutes. Bus stops are identified by a red/silver circulator sign. Visit <https://mail.dccirculator.com/> to plan your trip.

Capital Bikeshare: Capital Bikeshare is DC's bikeshare service, with 5,000 bikes and over 600 stations. Designed for quick trips with convenience in mind, it's a fun and affordable way to get around the city. Visit <https://capitalbikeshare.com/> for pricing.

FIRST AID

ATS Hotels: Contact the hotel's front desk for any emergencies.

Walter E. Washington Convention Center: A first aid station will be staffed in two locations:

- Exhibit Floor, Hall A (Lower Level)
Thursday, May 18 to Wednesday, May 24
- Hall D (Level 2)
Sunday, May 21 to Tuesday, May 23

CHILD CARE FACILITIES

Visit www.care.com or www.sittercity.com to search for trusted local care in the area. You can use your hotel address to search via zip code. The convention center is located at 801 Mt Vernon Pl NW, Washington, DC 20001.

The child care service providers listed are offered solely as a convenience for conference attendees. ATS provides no endorsement or assumption of responsibility or liability related to the services.

FAMILY FUN IN WASHINGTON DC

Washington, DC is a family friendly destination filled with many fun-filled activities for parents, care givers and children. If you are traveling to DC with your family, be sure to check out free-family things to do here.

INTERNET ACCESS

WiFi is available throughout the Walter E. Washington Convention Center and Marriot Marriott Marquis Washington.

LOST AND FOUND

Please be aware of your personal items at all times. The ATS is not liable for personal items lost during the Conference. There will be a lost and found maintained in the ATS

International Conference Office in the Walter E. Washington Convention Center, Room 158A (Street Level). Unclaimed items will be turned over to the Convention Center at the conclusion of the Conference. Items lost or found at any of the Conference hotels should be reported to the specific hotel.

BAGGAGE CHECK

Temporary baggage check for attendees will be available in the Walter E. Washington Convention Center, Salons A-C (Street Level).

Sunday, May 21	7 a.m. - 5 p.m.
Monday, May 22	7:30 a.m. - 5 p.m.
Tuesday, May 23	7:30 a.m. - 5 p.m.
Wednesday, May 24	7:30 a.m. - 3 p.m.

NETWORKING AND COFFEE BREAK AREA

Power up with healthy snacks and drinks from 11 a.m. to 1:15 p.m. in Coffee & Connections (booths 637, 709, 2209, and 2541).

POSTAL AND SHIPPING NEEDS

Located in the Walter E. Washington Convention Center, the Capital Business Center services include copying, computer rental, faxing, and limited shipping services via FedEx, and DHL for small packages.

INTERNATIONAL MONEY EXCHANGE

Most major banks offer currency exchange services. ICE Currency Exchange is available at the Dulles International Airport and Ronald Reagan Washington National Airport. Services include currency exchange, money wire, travelers' checks, photocopying and facsimile services, telephone cards, and limited offerings from the U.S. Postal Service.

The Ronald Reagan Washington National Airport ICE currency exchange is in the National Hall on the Concourse level of Terminal C, at pre-security.

Dulles International Airport has various locations:

- Terminal: Departures-Ticketing Level, East and West
- Concourses A/B: Gate A32
- Concourse C: Gate C8 and C12
- Concourse D: Gate D16
- International Arrivals Building (near the exit, opposite the baggage recheck counters) Hours vary by location
Tel: 703-572-3336

Telephone cards are available for purchase at most major convenience stores throughout the city.

The Exhibit Hall

Explore new product, devices, innovative technology and additional learning opportunities.

Learning opportunities abound in the [ATS 2023 Exhibit Hall](#). Gain practical knowledge to advance care and research by attending booth demonstrations, Industry Theater Presentations, Guru Bars, and visiting the over 200 exhibiting companies.

Why visit the ATS 2023 Exhibit Hall?

- Find the latest innovations or learn about the newest advances
- Compare all relevant products and services in one place
- Take part in interactive hands-on demonstrations
- Speak with medical affairs officers and medical science liaisons
- Obtain patient information from the Public Advisory Roundtable exhibitors

EXCITING OFFERINGS in the ATS 2023 EXHIBIT HALL

Fun Zone

Booth 743

Head over to the Fun Zone where you can challenge your friends or colleagues to a game of "Pop a Shot", giant Connect 4, and more! The Fun Zone is the perfect spot to take a break and be entertained!

Sponsored by AstraZeneca

Industry Theaters

Industry Programs are the optimal opportunity to learn about brand launches or current therapies, findings of a focused program on disease awareness, or about a company's current pipeline activity.

There are 8 educational theaters on the exhibit floor, [click here](#) for a list.

Join us for a Toast to Innovation

Networking Event

Tuesday, May 17, 1:15 – 2:15 p.m.

Celebrate where the industry gathers.

Professional Headshot Photo

Booth 2601

Complimentary for everyone. Headshots are emailed the same day.

A professional photo is a good marketing tool for the hospital, medical group, university websites, brochures and other communication channels.

Coffee & Connections

Power up with healthy snacks and coffee from **11 a.m. – 1 p.m. Sunday, Monday, and Tuesday.**

There are 4 locations inside the **Exhibit Hall: booths 637, 709, 2209, and 2441.**

Sponsored by Polarean Imaging

Thematic Poster-Exhibit Hall Lounge

Booth 125

Networking, break, and work area bringing our Poster Hall and Exhibit Hall together.

NASA Hyperwall

Booth 125

The Hyperwall is a big beautiful "wall" of high-definition screens used to display NASA's latest and greatest data visualizations, images, videos, and other presentation material. Existing Hyperwall stories highlight themes in Earth science, heliophysics, planetary science, and astrophysics. Stop by to view the latest data visualizations related to air quality and atmospheric chemistry.

Your Solution Center

**Walter E. Washington Convention Center
Halls A-B (Lower Level)**

Exhibit Hall Hours

**Sunday, May 21
10:30 a.m. - 3:30 p.m.**

**Monday, May 22
10:30 a.m. - 3:30 p.m.**

**Tuesday, May 23
10:30 a.m. - 3:30 p.m.**

**Unopposed Exhibit Hall Time
1:15 – 2:15 p.m. daily**

Industry Programs

Industry Theaters

11:30 a.m. – 2 p.m.

**Walter E. Washington Convention Center
Exhibit Hall Floor, Halls A-B (Lower Level)**

Enjoy lunch while enhancing your educational experience during ATS 2023. Listen to industry experts discuss the latest information on products/services or disease awareness related to pulmonary, critical care, and sleep medicine in one of four theaters in the Exhibit Hall. Complimentary box lunch is provided by ATS (while quantities last).

Guru Bars

Every 30 minutes from 11:30 a.m. – 1:30 p.m.

**Walter E. Washington Convention Center
Exhibit Hall Floor, Halls A-B (Lower Level)**

Guru Bars provide an intimate learning environment fostering dynamic interaction between attendees and subject matter experts. These learning experiences consist of burst sessions of 15–20 minutes fostering a rich educational experience. Every session includes a 10–15 minute problem statement, mitigating factors, the host's perspective/solution, and a challenge or question posted to attendees.

Industry Supported Evening Symposia

Sunday and Monday evenings in ATS 2023 conference hotels

6:30 – 9:30 p.m.

Industry Supported Evening Symposia complement the content offered by the ATS and provide an opportunity for attendees to further enrich their learning experiences during ATS 2023. All full-conference participants are encouraged to attend these evening programs.

Complete details on these presentations may be found at:

- [ATS Conference News](#)
- [Industry Program Listing](#)
- [Mobile App](#)

The use of cameras and audio recording equipment (including, but not limited to, cellular phones, film: digital and video, and tablets) is strictly prohibited in Industry Theaters and Guru Bars at all times. Credentialed members of the press who have received a special badge from the ATS are permitted on the floor but are restricted by the photography policy.

ATS 2023



ATS 2023

Respiratory Innovation Summit

RIS Co-Chairs



CECILIA GONZALO, MBA
Partner Oberland Capital



TIM WATKINS, MD, MS
Vice President, Clinical Development; Head, Fibrosis & Pulmonary Diseases - Inflammation Therapeutics, Gilead Sciences

The Respiratory Innovation Summit unites innovators, investors, clinicians and advocacy groups who are leading the charge to create powerful new treatments for deadly and crippling diseases of the lungs and airways. This meeting historically attracts 275+ global leaders representing all facets of the respiratory industry, including representatives from start-ups, business development, venture capital, government, academia and clinical medicine.

Agenda Highlights



Dr. Asha N. Chesnutt



Dr. Russell Bowler

KEYNOTE ADDRESS

Using the Apple Ecosystem for Health Research

Dr. Asha N. Chesnutt, Clinical Specialist, Apple Health

Dr. Russell Bowler, Professor of Medicine, National Jewish Health

26 companies and 70 poster presentations

Panel Discussions

- Venture Capital
- Business Development
- Biomarkers and Innovation

Over 10 hours of networking and collaboration time

Federal agencies presenting at RIS 2023 will include: NHLBI, NCATS, FDA, BARDA and NIH Foundation

We'd also like to thank our Pioneer Sponsor, Boehringer Ingelheim Pharmaceuticals, Inc., for its generous support.

Networking Opportunities at ATS 2023

NETWORKING SUPER CENTER

Collaborate, educate, connect, and learn in the new Networking Super Center located in and near Hall D (Level 2) in the Walter E. Washington Convention Center!

Stop by the Learning Studios for specialized programming hosted by the [Center for Career Development \(CCD\)](#), [Clinicians Center](#), [Science and Innovation Center \(SIC\)](#), [International Participant's Center \(IPC\)](#) where you can participate in studio talks, panel discussions and networking opportunities. The Super Center is open to all ATS 2023 attendees.

Outside of Hall D you'll find the [ATS Center](#) where attendees can recharge, meet with colleagues and ATS Center for all things ATS! Stop by to ask questions or join us for one of our 'Ask-Me-Anything's' about making the most of ATS, both at the conference and year-round!

Special Saturday Learning Events

The Pulmonary Function Testing Committee will host a Leaders in Pulmonary Function Testing Town Hall at ATS 2023 in the Learning Studio on Saturday May 20, 1 – 4 p.m.

The International Health Committee will host the Respiratory Society of Americas special event Saturday May 20, 1:30 – 4:30 p.m.

ATS COMMUNITY (VIRTUAL NETWORKING)

Continue the conversation on-line in the ATS Community. Discuss ATS 2023 sessions and topics. In the ATS Community you can collaborate with your peers through discussions with questions on cases, the latest research, emerging technologies, best practices, and more. If you have questions on how to post or navigate the ATS Community, you can visit the FAQ section.

THEMATIC POSTER HALL/ EXHIBIT HALL LOUNGE

Stop by the lounge in between the Thematic Poster Hall and the Exhibit Hall in the Walter E. Washington Convention Center, Halls B and C (Lower Level).

The Exhibit Hall and Thematic Poster Hall are open to all registered attendees. Visit our industry partners booths, and view thematically related abstracts in a poster format.





The lounge offers attendees the opportunity to meet up with colleagues, view the NASA Hyperwall, network and recharge while discussing the many opportunities available to engage in the latest advances and discoveries in respiratory science, patient care, and global public health.

CONNECT ON THE MOBILE APP

- Easily chat with other attendees
- Edit your profile and find recommended sessions, exhibitors and individuals with similar interests
- Scan an attendee's badge to quickly exchange contact information.
- Access ATS Community



You can access more information by clicking the icons below.



Learn more about RSV in your patients with GSK at ATS 2023



Sunday, May 21, 2023 | 12:30 pm – 12:50 pm | Guru Bar #1

GSK Guru Bar – RSV: Exploring the Mechanism of Disease and Burden in Older Adults

Join us for an RSV Guru Bar focused on the pathophysiology of RSV infection, inflammatory immune response to RSV in adult patients, and the clinical consequences of RSV in adults with underlying cardiopulmonary conditions.

Join Dr. Rutland after the Guru Bar for an RSV Virtual Reality experience at Booth #1909 from 1 pm – 3 pm



Cedric "Jamie" Rutland, MD

Pulmonary and Critical Care Physician
National Spokesperson, American Lung Association
Rutland Medical Group, CEO and Medical Director
Medicine Deconstructed Productions, President




Monday, May 22, 2023 | 12:20 pm – 1:05 pm | Medium Product Theater

GSK Product Theater – The Clinical Impact of RSV on COPD and Asthma

Join us for an RSV Product Theater focused on the epidemiology of RSV infection and manifestation of RSV disease in your adult patients with COPD and asthma.

Learn more about RSV disease in your patients



Join GSK US Medical Affairs for a webinar on RSV



REGISTER HERE



Trademarks owned or licensed by GSK
PSE-US-1662

International Scholars Poster Colloquium

The 2023 ATS International Scholars Poster Colloquium: Where the World's Most Promising Respiratory Health Researchers Meet

Saturday, May 20 8 a.m. to 1 p.m.
Walter E. Washington Convention Center
Room 103 A-B (Street Level)

The ATS International Scholars Poster Colloquium is an annual event that brings together the best and brightest minds in the field of respiratory health from around the world. This year, the prestigious award for the International Trainee Scholarship will be given to a select group of early-career researchers who have submitted the most outstanding abstracts in the field.

With participants from 22 countries and 13 Assemblies, the 2023 Colloquium promises to be an exciting and educational experience for all attendees. The event will feature interactive

sessions with some of the world's most promising investigators in respiratory health, providing early-career researchers with a unique opportunity to learn from the best.

The ATS International Scholars Poster Colloquium is an important event for anyone interested in respiratory health research, and this year's event is not to be missed. Don't miss your chance to witness the exceptional work of these talented trainees and to be a part of the world's most important respiratory health event.

Supported by AstraZeneca



Call for Input

Submission Deadline
5 p.m. ET, Wednesday,
June 28, 2023

Call for Abstracts

Submission Deadline
5 p.m. ET, Wednesday,
November 1, 2023

General Sessions/ Awards

OPENING CEREMONY

Saturday, May 20
4:30 - 5:30 p.m.
Walter E. Washington
Convention Center
Hall E (Level 2)



ATS 2023 kicks off with the Opening Ceremony, featuring a keynote address by **Stephen K. Klasko, MD, MBA**. During his career he has been dean at two medical colleges (Drexel and University of South Florida), president of a University (Thomas Jefferson University) and CEO of two academic health systems (USF health and Jefferson Health).

The Opening Ceremony also features:

- ATS President **Greg Downey, MD, ATSF**, will provide an update of the Society's major accomplishments for the past year and priorities for the coming one;
- The latest class of **ATS Fellows and Research Program awardees** will be recognized; and
- Presentation of several ATS Respiratory Health Awards: **Public Service Award, World Lung Health Award, Jo Rae Wright Award for Outstanding Science** and the **J. Randall Curtis Humanism Award**.

RECOGNITION AWARDS for SCIENTIFIC ACCOMPLISHMENTS

Monday, May 22
2:15 - 3:45 p.m.
Walter E. Washington Convention Center
Room 202A (Level 2)

As part of the ATS Respiratory Health Awards, the **Recognition Award for Scientific Accomplishments** recognizes outstanding scientific research contributions in basic or clinical arenas to enhance the understanding, prevention and treatment of respiratory disease, critical illness, or sleep disorders and recognizes exemplary professionalism, collegiality and citizenship through mentorship and scientific involvement in the ATS community.

PLENARY SESSION

Tuesday, May 23
11:30 a.m. - 1 p.m.
Walter E. Washington
Convention Center
Hall E (Level 2)



The Plenary Session will feature a keynote address by **Timothy Caulfield**, professor of Health Law and Science Policy and best-selling author.

Timothy Caulfield is a Canada Research Chair in Health Law and Policy, a Professor in the Faculty of Law and the School of Public Health, and Research Director of the Health Law Institute at the University of Alberta. His interdisciplinary research on topics like stem cells, genetics, research ethics, the public representations of science, and public health policy has allowed him to publish over 350 academic articles. He has won numerous academic, science communication, and writing awards, and is a Fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences.

The Plenary Session also will include the ratification of the 2023-2024 slate of officers as well as remarks from outgoing president **Greg Downey, MD, ATSF**, and incoming president **M. Patricia Rivera, MD, ATSF**.

In addition, four awards will be presented, including:

- **Outstanding Educator Award**
- **Research Innovation and Translation Achievement Award**
- **Outstanding Clinician Award**
- **Philip Hopewell Prize for Leaders in Global Respiratory Health**

SUNDAY RESPIRATORY HEALTH AWARDS CEREMONY

Sunday, May 21
4:30 - 5:30 p.m.
Walter E. Washington Convention Center
Hall E (Level 2)

The **Amberson Lecturer, Trudeau Medalist** and **Distinguished Achievement awardees** will be honored. The Respiratory Health Awards recognize outstanding contributions and achievements in pulmonary disease, critical care and sleep health. For all awards, there is a special emphasis on efforts that have the potential to eliminate health disparities.

ATS 2023 Sessions

2023 WASHINGTON, DC

ATS 2023 in Washington, DC offers the latest in pulmonary, critical care and sleep medicine for ATS members and other physicians, scientists and health care professionals.

SESSION ADMISSION

Badges are required to attend all conference sessions and events.

Admission to Sessions

Sessions are held at the Walter E. Washington Convention Center and Marriott Marquis Washington. Your badge allows you admittance to ninety percent of the sessions and events without additional fees or tickets. It also entitles you to entry to the Exhibit Hall.

Admission by Tickets Only

The following require pre-registration. Additional fees may apply.

- [Medical Education Seminars](#)
- [Meet the Expert Seminars](#)
- [Postgraduate Courses](#)

ATS 2023 MOBILE APP

The full Conference program is available to iPhone, iPad, and Android users through the ATS 2023 Conference app. View and bookmark sessions and speakers, and create your own personal conference itinerary. [Search for ATS 2023 in the App Store or Google Play.](#)

Many thanks to AstraZeneca and GSK for support of the ATS 2023 Meeting App.

EPOSTERS OF ORIGINAL RESEARCH

Speakers presenting original research based on submitted abstracts have been invited to prepare and make available an ePoster of their research. The ePosters provide an opportunity to view those posts you may miss during the conference. The ePosters that have been prepared may be viewed by conference registrants online at <https://cattendee.abstractsonline.com/meeting/10703>

PUBLICATION OF ABSTRACTS

The research and case report abstracts presented at the Conference are available electronically on the website of the American Journal of Respiratory and Critical Care Medicine hosted by Atypon. The abstracts in the Final Program contain the publication number for each abstract to facilitate online access. Abstracts may be accessed at www.atsjournals.org/series/ajrccm-conference where ATS members may log in using their username and password used to access regular journal issues. Non-members may access the site on a pay-per-view basis.

FACULTY DISCLOSURES

In accordance with policies of the Accreditation Council for Continuing Medical Education and ATS, everyone in a position to control educational content (planners and presenters) of all International Conference sessions designated as CME has been instructed to complete an online faculty disclosure form. Please contact ethicsoffice@thoracic.org for more information.

DISCLOSURE DECLARATION

It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers and presenters comply with the **ACCME Standards Integrity and Independence in Accredited Continuing Education**. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships is present. The most recent policies regarding potential conflicts of interest as well as the mechanisms to mitigate or resolve such conflicts can be found at [COI Policy for Official ATS Activities \(thoracic.org\)](#)

CRITERIA FOR SUCCESS FOR FOR CME AND MOC DESIGNATED ACTIVITIES

[CME Certificates of credit](#)/attendance will be awarded based on the participant attending the activity, completing and submitting an evaluation and attesting to the credits earned. A CME certificate will be available upon successful completion of all three components. For [MOC points](#), participants attend the session(s), complete the corresponding evaluation and pass the post-test for the activity with a passing score.

RECORDING OF PRESENTATIONS

The use of cameras and audio recording equipment (including, but not limited to, cellular photos, film, digital, and video) is prohibited in the Exhibit Hall. Photographs may be taken during sessions or poster presentations, provided that the photographs are strictly for personal, noncommercial use and are not to be published in any form. Attendees are prohibited from using flash photography or otherwise distracting the presenters or members of the audience. With regard to posting presentation images on social media, if a presenter requests images not be posted, conference attendees must respect those wishes.


Conference Sessions



ATS 2023 INTERNATIONAL CONFERENCE MAY 19-24, WASHINGTON, DC

This session portion of the ATS International Conference Final Program is published by the ATS as a service to attendees. This publication contains the programs and speakers for the postgraduate courses, scientific and educational sessions presented at the conference.

While every effort is made to ensure accuracy, ATS makes no warranties, expressed or implied, related to the information. Information contained herein is subject to change without notice.

The information contained in this program is up to date as of April 14th, 2023. For the most current session information, please visit the [online program itinerary](#). Look for  to view more information about ATS events, assemblies and sections.

Please see our full CME and MOC accreditation statements on the following page:

<https://conference.thoracic.org/program/cme.php>

19	Friday Postgraduate Courses
23	Saturday Postgraduate Courses
37	Sunday Conference Sessions
126	Monday Conference Sessions
216	Tuesday Conference Sessions
304	Wednesday Conference Sessions



ATS
2023

INTERNATIONAL
CONFERENCE
WASHINGTON, DC
conference.thoracic.org

Friday, May 19


[Click Here to Access the Program Itinerary and Add Friday Sessions and Presentations to Your Calendar](#)

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 7

PG1A CRITICAL CARE ULTRASOUND AND ECHOCARDIOGRAPHY I

 This is part 1 of a two-part course which includes PG1B on Saturday, May 20. Those registering for PG1A will be registered for PG1A and PG1B. Pre-registration and additional fees required. Attendance is limited.

Member: \$1230	In-Training Member: \$935
LMIC Member: \$1165	LMIC In-Training Member: \$655
Non-Member: \$1640	In-Training Non-Member: \$1060

Assembly on Critical Care

8:00 AM - 4:00 PM **Walter E. Washington Convention Center**

Room 150 A (Street Level)

Target Audience

Providers of critical care or emergency medicine

Objectives

At the conclusion of this session, the participant will be able to:

- apply ultrasound at bedside to assess critically ill patients
- apply ultrasound to guide common ICU procedures
- diagnose alternate etiologies of shock in the critically ill patient

This is a 2-day postgraduate course that consists of didactic lectures and hands-on stations. The focus is primarily bedside transthoracic echocardiography, with some diagnostic ultrasound. The topics include basic and intermediate critical care echocardiography (including hemodynamic measures), assessment of fluid status, procedural

guidance for vascular access and thoracentesis, venography. The hands-on stations will include both healthy models and laptops that can demonstrate abnormal pathology.

Chairing: M.J. Lanspa, MD, MSCR, ATSF, Salt Lake City, UT
X. Monnet, MD, PhD, Le Kremlin-Bicêtre, France

8:00 Welcome and Introduction to Critical Care Ultrasound: Training and Competency

M.J. Lanspa, MD, MSCR, ATSF, Salt Lake City, UT

8:15 Basic Physics, Artifacts, and Knobology

Z. Shaman, MD, Cleveland, OH

8:45 Transthoracic Windows and Views

J.C. Klick, MD, Burlington, VT

9:15 Basic Evaluation of LV Systolic Function, Measurement of Cardiac Output

C. Bennett, DO, Rochester, MN

9:45 Basic Evaluation of RV Size and Function, Pulmonary Embolus

D. Pradhan, MD, ATSF, New York, NY

10:15 Break

10:30 Practical Skills Session: Hands-On Station I

Apical Window

Z. Shaman, MD, Cleveland, OH

J.C. Klick, MD, Burlington, VT

C. Bennett, DO, Rochester, MN

D. Pradhan, MD, ATSF, New York, NY

S. Sarzynski, MD, MHSc, Bethesda, MD

P.K. Mohabir, MD, Stanford, CA

Parasternal Window

T. Brakke, MD, Omaha, NE

A. Leibowitz, MD, Boston, MA

L. Rapoport, MD, MS, Santa Clara, CA

S. Bain, MD, Seattle, WA

D.A. Sweeney, MD, La Jolla, CA

S. Cha, MD, Baltimore, MD

Subcostal Window

G.B. Allen, MD, Burlington, VT

X. Monnet, MD, PhD, Le Kremlin-Bicêtre, France

A. Sarwal, MD, Winston-Salem, NC

N. Panebianco, MD, MPH, Philadelphia, PA

J. Kasal, MD, St. Louis, MO

J.E. Pittman, MD, Salt Lake City, UT

12:00 Lunch

12:30 Lunch and Clinical Cases

S. Sarzynski, MD, MHSc, Bethesda, MD

12:45 Chest Ultrasound

P.K. Mohabir, MD, Stanford, CA

1:15 Valvulopathy and Endocarditis

T. Brakke, MD, Omaha, NE

1:45 Basic Assessment of Diastolic Function

A. Leibowitz, MD, Boston, MA

2:15 Break**2:30 Practical Skills Session: Hands-On Station II :****Lung Ultrasound**

D.A. Sweeney, MD, La Jolla, CA

D. Pradhan, MD, ATSF, New York, NY

N. Panebianco, MD, MPH Philadelphia, PA

G.B. Allen, MD, Burlington, VT

S. Sarzynski, MD, MHSc, Bethesda, MD

P.K. Mohabir, MD, Stanford, CA

Cardiac Output

J.C. Klick, MD, Burlington, VT

S. Cha, MD, Baltimore, MD

A. Sarwal, MD, Winston-Salem, NC

Z. Shaman, MD, Cleveland, OH

L. Rapoport, MD, MS, Santa Clara, CA

S. Bain, MD, Seattle, WA

Diastolic Measurements

A. Leibowitz, MD, Boston, MA

X. Monnet, MD, PhD, Le Kremlin-Bicêtre, France

C. Bennett, DO, Rochester, MN

J. Kasal, MD, St. Louis, MO

J.E. Pittman, MD, Salt Lake City, UT

T. Brakke, MD, Omaha, NE

This session and the International Conference are supported by In-Kind grants from EchoNous, GE HealthCare, FUJIFILM Sonosite, Teleflex.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL**POSTGRADUATE COURSE**

CME Credits Available: 6.75

PG2 BRONCH DAY 2023: A COMPREHENSIVE, HANDS-ON GUIDE TO BASIC BRONCHOSCOPY, EBUS, AND NAVIGATIONAL BRONCHOSCOPY

R Pre-registration and additional fees required. Attendance is limited.

Member: \$600

In-Training Member: \$380

LMIC Member: \$420

LMIC In-Training Member: \$270

Non-Member: \$700

In-Training Non-Member: \$500

Assemblies on Clinical Problems; Critical Care; Pediatrics; Thoracic Oncology

8:00 AM - 4:00 PM**Walter E. Washington Convention Center****Room 143 A-C (Street Level)****Target Audience**

Adult and pediatric pulmonologists and intensivists, thoracic surgeons, physicians in training, allied health professionals: anesthesiologists interested in improving their skills in diagnostic and therapeutic flexible bronchoscopy and EBUS

Objectives

At the conclusion of this session, the participant will be able to:

- diagnose and manage adults and children with benign and malignant respiratory diseases
- improve knowledge of basic flexible bronchoscopy and strengthen procedural skills
- understand the indications for linear and radial endobronchial ultrasound and the skills necessary to perform these

This course is designed to provide a comprehensive introduction to diagnostic and therapeutic flexible bronchoscopy. Participants will acquire the knowledge and skills to improve their proficiency in bronchoscopic techniques and be introduced to linear EBUS, radial EBUS and navigational bronchoscopy. A series of lectures will be followed by intensive, hands-on training. Through the use of physical and virtual reality simulators participants will strengthen their procedural skills. This course will be of particular interest to providers seeking to refine their bronchoscopy skills and who wish to review the data behind the various bronchoscopic techniques. Audience response will be used during lectures.

Chairing: C. Argento, MD, Baltimore, MD
A.V. Gonzalez, MD, MSc, Montreal, Canada
D. Dibardino, MD, Philadelphia, PA
R. Semaan, BS, MD, Pittsburgh, PA

8:00 Introduction

C. Argento, MD, Baltimore, MD

8:05 Optimizing Basic Bronchoscopy Skills

C.R. Macrosty, DO, Chapel Hill, NC

8:30 Maximize Outcomes in High Risk Patients

K. Van Nostrand, MD, Atlanta, GA

8:55 Role of Flexible Bronchoscopy in Management of Hemoptysis

C.R. Lamb, MD, Burlington, MA

9:20 Pediatric Flexible Bronchoscopy for the Adult and Pediatric Bronchoscopist

C. Spencer Grant, MD, New York, NY

9:45 Break**9:55 The Fundamentals of Lineal EBUS**

A. Demaio, MD, Baltimore, MD

10:20 Navigational Bronchoscopy: From Fluoroscopy to Robotics

L. Frye, MD, Salt Lake City, UT

10:45 Bronchoscopic Lung Volume Reduction

P. Lee, MD, Singapore

11:10 **Questions and Answers**

11:30 **Lunch**

12:15 **Practical Skills Session**

Bronchoscopy With Biopsy and Needle Aspiration of Endobronchial Lesion

M. Weir, MBChB, Philadelphia, PA
C. Kapp, MD, Chicago, IL

Bronchoscopic Management of Hemoptysis

C.R. Lamb, MD, Burlington, MA
N.M. Patel, La Jolla, CA

Management of the Difficult Airway and Trachostomy Tubes

E. Volker, MD, MSPH, Denver, CO
C.R. Macrosty, DO, Chapel Hill, NC

Techniques for Foreign Body Removal Using Flexible Bronchoscopy

D. Dibardino, MD, Philadelphia, PA
A.V. Gonzalez, MD, MSc, Montreal, Canada

1:30 **Break**

1:40 **Practical Skills Session**

Navigational Bronchoscopy: Radial Endobronchial Ultrasound Electromagnetic Navigation Bronchoscopy

R. Semaan, BS, MD, Pittsburgh, PA
Speaker to be Announced

Navigational Bronchoscopy: Robotic Bronchoscopy

A.A. Wagh, MD, MS, Chicago, IL
E. Malsin, MD, Chicago, IL

Endobronchial Ultrasound Anatomy

O. Kalchiem-Dekel, MD, New York, NY
V.K. Holden, MD, Baltimore, MD

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

B. Husta, MD, New York, NY
Y.B. Gesthalter, MD, San Francisco, CA

Endobronchial Valves

A. Demaio, MD, New York, NY
A. Sarkar, PhD, Chicago, IL

3:45 **Questions and Wrap-Up**

C. Argento, MD, Baltimore, MD

This session and the International Conference are supported by an independent medical educational grant from Olympus Corporation of the Americas.

This session and the International Conference are supported by in-kind grants from ERBE USA, INC., Ethicon, Intuitive Surgical, Noah Medical, Olympus Corporation of the Americas, and Pulmonx.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 6.25

PG3 PEDIATRIC SLEEP-RELATED BREATHING DISORDERS: STATE OF THE ART AND BEST PRACTICES

R Pre-registration and additional fees required. Attendance is limited.

Member: \$600

In-Training Member: \$380

LMIC Member: \$420

LMIC In-Training Member: \$270

Non-Member: \$700

In-Training Non-Member: \$500

Assemblies on Pediatrics; Sleep and Respiratory Neurobiology

8:00 AM - 4:00 PM

Walter E. Washington Convention Center

Room 152 A (Street Level)

Target Audience

Clinicians including pediatricians, family practitioners, intensivists, pulmonologists, sleep medicine physicians, researchers, allied health professionals, nurses, nurse practitioners, respiratory therapists, and trainees (all levels).

Objectives

At the conclusion of this session, the participant will be able to:

- describe the current and emerging understanding of SRBD in children and apply this knowledge to clinical practice and research
- recognize the interplay of pediatric SRBD and chronic pulmonary conditions
- integrate new treatment options into the management of pediatric SRBD to ensure personalized patient-centered care

This, first of its kind, course will provide a state of the art practical, evidence-based, and comprehensive approach to the evaluation and management of pediatric sleep-related breathing disorders (SRBD). There will be a mix of interactive didactic sessions (highlighting the intersection of basic science, translational and clinical aspects of pediatric SRBD), panel discussions, and hands-on stations. Small group, case-based, breakout sessions will give participants the opportunity to interact with national and international experts in the field. Hands-on stations will provide learners with a unique "real-time" experience with advanced diagnostic and therapeutic modalities as they relate to pediatric SRBD.

Chairing: Z. Ehsan, MD, Kansas City, MO
C.M. Cielo, DO, Philadelphia, PA
S.L. Verhulst, MD, PhD, MSc, Edegem, Belgium

8:00 Welcome, Introductions and Overview

Z. Ehsan, MD, Kansas City, MO

8:05 The Future of Pediatric Sleep: Challenges and Opportunities

D. Gozal, MD, MBA, ATSF, Columbia, MO

- 8:25 Recognizing OSA in Children With and Without Respiratory Disease**
U.A. Katwa, MD, Boston, MA
- 8:40 When It's Not OSA - Understanding Sleep-Related Breathing Disorders in Children**
I.A. Perez, MD, ATSF, Los Angeles, CA
- 8:55 Polysomnography for the Non-Sleep Doc: Looking Beyond the AHI**
J.E. Maclean, BSc(Hons), MD, PhD, Edmonton, Alberta, Canada
- 9:10 When Polysomnography Is Not an Option: Alternative Testing and Where They Fit In**
R. Bhattacharjee, MD, San Diego, CA
- 9:25 Break**
- 9:40 Overview of Non-Surgical Treatment Strategies for Sleep-Related Breathing Disorders**
R. Ersu, MD, Ottawa, Canada
- 9:55 Overview of Upper Airway Surgery for Sleep-Related Breathing Disorders**
S.L. Ishman, MD, MPH, Cincinnati, OH
- 10:10 Overview of Skeletal Surgery for Sleep-Related Breathing Disorders**
S. Susarla, DMD, MD, MPH, Seattle, WA
- 10:25 Shared Decision Making in Pediatric SDB**
A. Bandyopadhyay, MD, Indianapolis, IN
- 10:45 Breakout Groups/Case Discussions**
- Group A - Medical Management of OSA/SRBD**
S. Hawkins, MD, BS, Aurora, CO
- Group B - Surgical Management of OSA/SRBD**
O.M. Vanderveken, MD, PhD, Edegem, Belgium
- 11:36 Lunch**
- 12:36 Overview of Non-Invasive Ventilation in Pediatric SRBD**
R. Amin, MD, Toronto, Canada
- 12:56 Practical Skills Session**
- Pediatric PAP Mask Fit and Adherence**
D.L. Olmstead, BScN, MN, NP, Edmonton, Canada
T. Cranford, MHPE, RRT, RRT-NPS, RPSGT, CCSH, Kansas City, MO
- CPAP and APAP**
U.A. Katwa, MD, Boston, MA
S.L. Verhulst, MD, PhD, MSc, Edegem, Belgium
- Bilevel S, ST and VAPS**
R. Amin, MD, Toronto, Canada
A. Sergew, MD, Denver, CO
- 2:16 Break**


- 2:45 Practical Skills Session**
- DISE Directed Surgery and HGNS**
O.M. Vanderveken, MD, Edegem, Belgium
- CPAP and NIV Download Interpretation and Adherence**
G.R. Nino, MD, Washington, DC
M.S. Xanthopoulos, MS, PhD, Philadelphia, PA
- Heated High Flow Nasal Cannula**
S. Hawkins, MD, BS, Aurora, CO
- 3:50 Closing Remarks**
Z. Ehsan, MD, Kansas City, MO

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 6.5

PG4 STATE OF THE ART MANAGEMENT OF NONINVASIVE VENTILATION FROM HOSPITAL TO AMBULATORY CARE

 Pre-registration and additional fees required. Attendance is limited.

Member: \$600

In-Training Member: \$380

LMIC Member: \$420

LMIC In-Training Member: \$270

Non-Member: \$700

In-Training Non-Member: \$500

Assemblies on Sleep and Respiratory Neurobiology, Clinical Problems, Critical Care

8:00 AM - 4:00 PM

Walter E. Washington Convention Center

Room 150 B (Street Level)

Target Audience

Health care providers who care for patients with complex pulmonary-sleep disorders and chronic respiratory failure syndromes including noninvasive ventilation; physicians, advanced practice providers, nurses, respiratory therapists, and fellows.

Objectives

At the conclusion of this session, the participant will be able to:

- define new strategies for inpatient to ambulatory evaluation and management of complex inpatient pulmonary-sleep disorders
- define strategies for evaluation and management of common chronic hypercapnic respiratory failure syndromes including neuromuscular disease, COPD, obesity hypoventilation syndrome
- develop expertise on management of noninvasive ventilation including advanced respiratory assist devices and home mechanical ventilators

This combined didactic and skills-based course aims to highlight hospital to ambulatory management of complex pulmonary-sleep disorders and chronic hypercapnic respiratory failure syndromes. The skills-based section will focus on state of the art management of noninvasive ventilation including home mechanical ventilation. Attendees will have the opportunity to learn device algorithms, modes, interpretation of device

downloads, and apply these skills towards specific disease states to optimize patient care.

Chairing: M. Cao, DO, Stanford, CA
 B. Selim, MD, Rochester, MN
 S. Sharma, MD, ATSF, Morgantown, WV
 J.H. Hansen-Flaschen, MD, ATSF, Wynnewood, PA

8:00 Introductions

M. Cao, DO, Stanford, CA

8:10 Atrial Fibrillation, Arrhythmias, and Transition to Ambulatory Care

R. Mehra, MD, MSCR, ATSF, Cleveland, OH

8:40 ILD Awaiting Lung Transplant

B. Selim, MD, Rochester, MN

9:10 Hospital Sleep Medicine and Transition to Ambulatory Care

S. Sharma MD, ATSF, Morgantown, WV

9:40 Noninvasive Ventilation Management Post Surgery

B. Selim, MD, Rochester, MN

10:10 Break

10:25 Noninvasive Ventilation in Obesity Hypoventilation Syndrome

B. Mokhlesi, MD, MS, Chicago, IL

10:55 Advances in Noninvasive Ventilation for ALS

J.H. Hansen-Flaschen, MD, ATSF, Wynnewood, PA

11:25 Updates in Noninvasive Ventilation for Stable Hypercapnic COPD

J.M. Coleman, MD, Chicago, IL

11:55 Lunch

12:45 Practical Skills Session

Respiratory Assist Devices: Differences Between S/ST/PC

D. Zielinski, MD, Montreal, Canada

M. Kaminska, MD, Montreal, Canada

Differences Between ASV vs VAPS

B. Selim, MD, Rochester, MN

A. Sahni, MBBS, Chicago, IL

Home Mechanical Ventilators

M. Cao, DO, Stanford, CA

J.M. Coleman, MD, Chicago, IL

2:15 Break

2:30 Practical Skills Session

NIV Downloads

P. Choi, MD, Ann Arbor, MI

S.L. Katz, MD, Ottawa, Canada

Daytime Ventilation Modes

L.F. Wolfe, MD, Chicago, IL

B. Lussier, MD, Dallas, TX

Mechanical Airway Clearance

K.A. Provost, DO, PhD, Buffalo, NY

J.P. Brown, MD, PhD, Salt Lake City, UT

This session and the International Conference are supported by in-kind grants from ABM Respiratory Care, Baxter, Breas Medical, Inc., and Movair. All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).



ATS
2023

INTERNATIONAL
CONFERENCE
WASHINGTON, DC
conference.thoracic.org

Saturday, May 20


[Click Here to Access the Program Itinerary and Add Saturday Sessions and Presentations to Your](#)

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 7

PG1B CRITICAL CARE ULTRASOUND AND ECHOCARDIOGRAPHY II

 This is part 2 of a two-part course which includes PG1A on Friday, May 19. Pre-registration and additional fees required. Attendance is limited. See PG1A for course fees.

Assembly on Critical Care

8:00 AM - 4:00 PM **Walter E. Washington Convention Center**
Room 150 A (Street Level)

Target Audience

Providers of critical care or emergency medicine

Objectives

At the conclusion of this session, the participant will be able to:

- apply ultrasound at bedside to assess critically ill patients
- apply ultrasound to guide common ICU procedures
- diagnose alternate etiologies of shock in the critically ill patient

This is a 2-day postgraduate course that consists of didactic lectures and hands-on stations. The focus is primarily bedside transthoracic echocardiography, with some diagnostic ultrasound. The topics include basic and intermediate critical care echocardiography (including hemodynamic measures), assessment of fluid status, procedural guidance for vascular access and thoracentesis, venography. The

hands-on stations will include both healthy models and laptops that can demonstrate abnormal pathology.

Chairing: M.J. Lanspa, MD, MSCR, ATSF, Salt Lake City, UT
X. Monnet, MD, PhD, Le Kremlin-Bicêtre, France

8:00 Vascular Ultrasound: DVT Evaluation
L. Rapoport, MD, MS, Santa Clara, CA

8:25 Vascular Access
S. Bain, MD, Seattle, WA

8:45 Tamponade
G.B. Allen, MD, Burlington, VT

9:15 Using Ultrasound to Assess Intravascular Volume and Fluid Responsiveness
X. Monnet, MD, PhD, Le Kremlin-Bicêtre, France

9:45 Ultrasound for Diuresis and Dialysis
D.A. Sweeney, MD, La Jolla, CA

10:15 Break

10:30 Practical Skills Session: Hands-On Station III

Vascular Ultrasound

Z. Shaman, MD, Cleveland, OH
J.C. Klick, MD, Burlington, VT
D. Pradhan, MD, ATSF, New York, NY
S. Sarzynski, MD, MHSc, Bethesda, MD
J.E. Pittman, MD, Salt Lake City, UT
L. Rapoport, MD, MS, Santa Clara, CA

Tamponade Evaluation

P.K. Mohabir, MD, Stanford, CA
T. Brakke, MD, Omaha, NE
A. Leibowitz, MD, Boston, MA
C. Bennett, DO, Rochester, MN
S. Bain, MD, Seattle, WA
G.B. Allen, MD, Burlington, VT

Volume Status

X. Monnet, MD, PhD, Le Kremlin-Bicêtre, France
D.A. Sweeney, MD, La Jolla, CA
A. Sarwal, MD, Winston-Salem, NC
N. Panebianco, MD, MPH, Philadelphia, PA
J. Kasal, MD, St. Louis, MO
S. Cha, MD, Baltimore, MD

12:00 Lunch

12:30 Lunch and Intro to Neuro Ultrasound
A. Sarwal, MD, Winston-Salem, NC

12:45 Abdominal Ultrasound
N. Panebianco, MD, MPH, Philadelphia, PA

1:15 Goal Directed Management of Shock Using Echocardiography
J. Kasal, MD, St. Louis, MO

1:45 Incorporating Echocardiography Into CPR
S. Cha, MD, Baltimore, MD

2:15 Break

2:30 Practical Skills Session: Hands-On Station IV

Abdominal Ultrasound

D.A. Sweeney, MD, La Jolla, CA
Z. Shaman, MD, Cleveland, OH
D. Pradhan, MD, ATSF, New York, NY
S. Sarzynski, MD, MHSc, Bethesda, MD
G.B. Allen, MD, Burlington, VT
S. Cha, MD, Baltimore, MD

Echo in Shock and CPR

C. Bennett, DO, Rochester, MN
T. Brakke, MD, Omaha, NE
L. Rapoport, MD, MS, Santa Clara, CA
A. Sarwal, MD, Winston-Salem, NC
S. Bain, MD, Seattle, WA
J.E. Pittman, MD, Salt Lake City, UT

Ask the Expert

A. Leibowitz, MD, Boston, MA
X. Monnet, MD, PhD, Le Kremlin-Bicêtre, France
N. Panebianco, MD, MPH, Philadelphia, PA
J. Kasal, MD, St. Louis, MO
J.C. Klick, MD, Burlington, VT
P.K. Mohabir, MD, Stanford, CA

This session and the International Conference are supported by In-Kind grants from EchoNous, GE HealthCare, FUJIFILM Sonosite, Teleflex.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 7

PG5 SEVERE ASTHMA 2023: IMPLEMENTING CURRENT GUIDELINES INTO PRACTICE

Pre-registration and additional fees required. Attendance is limited.

Member: \$440	In-Training Member: \$255
LMIC Member: \$310	LMIC In-Training Member: \$180
Non-Member: \$540	In-Training Non-Member: \$380

Assemblies on Allergy, Immunology and Inflammation

8:00 AM - 4:00 PM **Marriott Marquis Washington**

Archives (Level M4)

Target Audience

Pulmonary and allergy physicians, physicians in training, and advanced practice providers who care for patients with asthma.

Objectives

At the conclusion of this session, the participant will be able to:

- discuss how to interpret clinical guidelines recommendations
- identify adults and children with asthma in whom monoclonal anti-IL5 antibody, omalizumab, tiotropium, and macrolides are indicated
- describe a NIH clinical trial testing personalized treatment options for severe asthma

This session will provide a comprehensive, pragmatic overview of the latest guidelines for severe asthma management from GINA, the NAEPP and ATS/ERS, with a particular focus on how they can be incorporated into practice. Course faculty are experts involved the creation of these guidelines. The course will incorporate interactive case-based review and panel discussion.

Chairing: P. Akuthota, MD, ATSF, La Jolla, CA
M. Kraft, MD, ATSF, New York, NY
B.D. Medoff, MD, Boston, MA

8:00 How Should I Interpret the ERS/ATS Severe Asthma Guidelines?

A. Bush, MD, ATSF, London, United Kingdom

8:30 Anti-Eosinophil and Anti-IL-4/IL-13 Therapies in Severe Asthma: What Do the Guidelines Say?

M. Castro, MD, MPH, Kansas City, KS

9:00 Omalizumab in Severe Asthma: Where Does It Fit In Now?

A. Bush, MD, ATSF, London, United Kingdom

9:30 Case-Based Panel Discussion

M. Kraft, MD, ATSF, New York, NY

9:50 Break

10:05 Long-Acting Muscarinic Antagonists: Good for All With Severe Asthma?

P. Akuthota, MD, ATSF, La Jolla, CA

10:35 Macrolides in Severe Asthma: Underutilized in the Age of Biologics?

P.B. Gibson, MBBS, Newcastle, Australia

11:05 Frontiers in Clinical Trial Designs in Severe Asthma

L.C. Denlinger, MD, PhD, Madison, WI

11:35 Case-Based Panel Discussion

P. Akuthota, MD, ATSF, La Jolla, CA

11:55 Lunch

12:35 GINA and NAEPP Guidelines: Differences, Similarities, and Implementation Challenges

J.A. Krishnan, MD, PhD, ATSF, Chicago, IL

1:05 Break

1:15 Severe Asthma Case Discussion

N.L. Lugogo, MD, Ann Arbor, MI

3:15 Panel Discussion with Guideline Co-Chairs

B.D. Medoff, MD, Boston, MA

BEHAVIORAL • CLINICAL**POSTGRADUATE COURSE**

CME Credits Available: 6

PG6 TOWARDS DISMANTLING STRUCTURAL INJUSTICE IN PULMONARY AND CRITICAL CARE MEDICINE - A PRIMER ON HEALTH EQUITY RESEARCH**R** Pre-registration and additional fees required. Attendance is limited.

Member: \$440	In-Training Member: \$255
LMIC Member: \$310	LMIC In-Training Member: \$180
Non-Member: \$540	In-Training Non-Member: \$380

Assemblies on Behavioral Science and Health Services Research; Health Equity and Diversity Committee; Section on Medical Education**8:00 AM - 4:00 PM** **Marriott Marquis Washington****Independence Ballroom, Salons A-C (Level M4)****Target Audience**

Clinicians and scientists interested in health equity research and examining the relationship between social determinants of health and outcomes in pulmonary, critical care, and sleep medicine.

Objectives

At the conclusion of this session, the participant will be able to:

- construct a research question grounded in equity theories and frameworks
- propose a research agenda using tailored methods that center marginalized groups
- create a dissemination plan that maximizes reach and policy impact

Structural inequities lead to poor health outcomes for marginalized patients with pulmonary, critical care, and sleep related illnesses. The goal of this postgraduate course is to engage non-equity investigators from all career stages and provide them with a primer on doing health equity research. This session will leverage case studies and facilitated small group exercises to introduce principles of health equity research and allow participants to apply these principles in real time to practice developing their own health equity research proposal.

Chairing: J. Odackal, MD, MSc, MA, Westerville, OH
D.C. Ashana, MD, MBA, MS, Durham, NC
M. Sharp, MD, MHS, Baltimore, MD

- 8:00** **Introduction to Seminar and Learning Objectives**
- 8:15** **Health Equity Research Theory and Framework**
C.E. Brown, MD, MA, Seattle, WA
- 8:45** **Breakout Session #1: Generating a Health Equity Research Question**
- 9:15** **Break**

9:45 **Social Determinants of Health**
I.L. Riley, MD, MPH, Durham, NC

10:15 **Centering the Margins**
M. George, PhD, RN, New York, NY

10:45 **Selecting and Applying Quantitative Methods in Equity Research**
S.O. Okelo, MD, PhD, Los Angeles, CA

11:15 **Unique Aspects of Qualitative Methods in Equity Research**
T. Bryant-Stephens, MD, Philadelphia, PA

11:45 **Lunch**

12:45 **A Mixed-Methods Evaluation of Disparities in Clinical Communication**
D.C. Ashana, MD, MBA, MS, Durham, NC

1:15 **Breakout Session #2: Generating a Health Equity Research Agenda**

1:40 **Break**

2:10 **Panel Discussion: Writing About Health Disparities**

2:50 **Advocacy and Policy**
C. Fuller, ScD, MS, Atlanta, GA

3:20 **Breakout Session #3: Writing a Health Equity Research Proposal**

3:45 **Review and Wrap-Up**

CLINICAL • TRANSLATIONAL**POSTGRADUATE COURSE**

CME Credits Available: 6.5

PG7 UPDATES ON LUNG TRANSPLANTATION; WHAT PULMONOLOGISTS NEED TO KNOW**R** Pre-registration and additional fees required. Attendance is limited.

Member: \$440	In-Training Member: \$255
LMIC Member: \$310	LMIC In-Training Member: \$180
Non-Member: \$540	In-Training Non-Member: \$380

Assemblies on Clinical Problems, Allergy, Immunology and Inflammation, Critical Care**8:00 AM - 4:00 PM** **Marriott Marquis Washington****Independence Ballroom, Salon D (Level M4)****Target Audience**

Providers caring for patients with end-stage lung diseases, that might benefit from lung transplant. Pulmonologists, thoracic surgeons, physical therapists, pharmacists, transplant pulmonologists, surgeons, and trainees interested in lung transplant.

Objectives

At the conclusion of this session, the participant will be able to:

- better understand the indications and proper timing of referral for lung transplantation as well as optimization of patients with end stage lung disease prior to listing
- understand the process of donor selection and optimization, peri-operative care of lung transplant including mechanical ventilation and ECMO support
- recognize various causes of acute and chronic allograft dysfunction and how to utilize the current methods to diagnose and treat them

This session will provide updates and cover important topics of lung transplant that are highly relevant to ATS attendees. The audience will learn about indications and proper referral, donor selection, operative care and complication as well as immune mediated rejections and long term outcomes of lung transplant.

Chairing: C.A. Hage, MD, ATSF, Pittsburgh, PA
C.M. Shaver, MD, PhD, Nashville, TN
J.F. Mcdyer, MD, Pittsburgh, PA
P.M. Shah, MD, Baltimore, MD

- 8:00 Introduction**
C.A. Hage, MD, ATSF, Pittsburgh, PA
- 8:05 Indications and Timing of Referral for Lung Transplant; Who and When?**
L.J. Benvenuto, MD, New York, NY
- 8:30 Optimization of Lung Transplant Recipients; How Can It Be Achieved?**
M.R. Anderson, MD, MS, Philadelphia, PA
- 8:55 Is My Patient Ready for Listing, Science or Art and How Can We Quantify Readiness?**
G.S. Dhillon, MPH, MD, Stanford, CA
- 9:20 Panel Discussion**
- 9:35 Break**
- 9:50 Donor Management and Selection; Is There a Perfect Donor for My Recipient?**
E. Cantu III, MD, MSCE, Philadelphia, PA
- 10:15 Perioperative Care of Lung Transplant, Mechanical Ventilation, ECMO and Other Critical Care Treatments**
J.C. Salgado, MD, Miami, FL
- 10:40 Primary Graft Dysfunction; Is It Just a Post-Op ALI or Much More and What Can Be Done to Minimize Its Risk?**
J.M. Diamond, MD, MSCE, Philadelphia, PA
- 11:05 Panel Discussion**
- 11:20 Airway and Vascular Complications Mimicking Acute Rejection**
M.M. Crespo, MD, Philadelphia, PA
- 11:45 Lunch**

- 12:45 Acute Cellular Rejection; Updates on Diagnosis and Management**
M.E. Snyder, MD, Pittsburgh, PA
- 1:10 Antibody Mediated Rejection; What's New in Risk and Management?**
Speaker to be Announced
- 1:35 Biomarkers and Therapeutic Targets, PFT, BAL, Liquid Biopsy and Biologics**
J.L. Todd, MD, MHS, Durham, NC
- 2:00 Panel Discussion**
- 2:15 Break**
- 2:30 CLAD; Diagnosis and Management- Anything New or All Doom and Gloom?**
E.D. Lease, MD, Seattle, WA
- 2:55 Quality of Life Post Lung Transplant; How Much Are We Really Helping Our Patient With End Stage Lung Diseases?**
J.P. Singer, MD, MSci, San Francisco, CA
- 3:20 Retransplant for CLAD; Indications, Outcomes and Ethical Implications**
V.N. Lama, MD, MS, Ann Arbor, MI
- 3:45 Panel Discussion**
- 3:58 Concluding Remarks**

CLINICAL**POSTGRADUATE COURSE**

CME Credits Available: 6

PG8 INTERSTITIAL LUNG DISEASE: DELIVERING OPTIMAL, PATIENT CENTERED CARE

 Pre-registration and additional fees required. Attendance is limited.

Member: \$440	In-Training Member: \$255
LMIC Member: \$310	LMIC In-Training Member: \$180
Non-Member: \$540	In-Training Non-Member: \$380

Assemblies on Clinical Problems; Behavioral Science and Health Services Research; Environmental, Occupational and Population Health; Nursing; Pulmonary Circulation; Pulmonary Rehabilitation

8:00 AM - 4:00 PM

Marriott Marquis Washington

Capitol/Congress (Level M4)

Target Audience

This course should be broadly relevant to those who provide clinical care for patients with ILD. This will include fellows, general pulmonologists, ILD specialists, and advanced care nurses.

Objectives

At the conclusion of this session, the participant will be able to:

- be able to apply a consistent, effective strategy to ILD/IPF diagnosis
- understand the range of therapeutics available for ILD and how and when to prescribe them
- be able to integrate a holistic and interdisciplinary approach to ILD patient care

This course will provide a practical approach to the diagnosis and management of patients with ILD. It will bring recommendations and guidelines into a usable strategy that will facilitate the care of patients with ILD. This will occur through didactics, simulated MDD, and panel discussions of difficult cases with audience engagement through audience response which will provide a range of learning strategies to help the largest number of learners.

Chairing: M. Kreider, MD, MSCE, ATSF, Philadelphia, PA
S.K. Danoff, MD, PhD, ATSF, Baltimore, MD

8:00 Introduction

M. Kreider, MD, MSCE, ATSF, Philadelphia, PA

8:10 Clinical Evaluation of the New ILD Patient

S. Sood, MD, MS, Philadelphia, PA

8:35 New Guidelines for the Diagnosis of ILD

K.I. Aronson, MD, MSci, New York, NY

9:00 Recognizing CT Patterns

S. Hobbs, MD, Lexington, KY

9:25 Patients at Risk for ILD

R.K. Putman, MD, MPH, Boston, MA

9:50 Break

10:20 Natural History of Disease and Monitoring

A.O. Adegunsoye, MD, MS, Chicago, IL

10:45 Speed MDD

S.K. Danoff, MD, PhD, ATSF, Baltimore, MD
K.I. Aronson, MD, MSci, New York, NY
S. Sood, MD, MS, Philadelphia, PA
L.P. Hariri, MD, PhD, ATSF, Boston, MA
S. Hobbs, MD, Lexington, KY
V. Steen, MD, Washington, DC
A.O. Adegunsoye, MD, MS, Chicago, IL

11:55 Lunch

12:55 Therapies for Pulmonary Fibrosis

T.J. Corte, MBBS, BScM, PhD, Sydney, Australia

1:20 Therapies for CTD-ILD

F. Castelino, MD, Boston, MA

1:45 Non-Pharmacologic Care in ILD

M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands

2:10 Break

2:40 Tough Cases

M. Kreider, MD, MSCE, ATSF, Philadelphia, PA
R.K. Putman, MD, MPH, Boston, MA
A.O. Adegunsoye, MD, MS, Chicago, IL
T.J. Corte, MBBS, BScM, PhD, Sydney, Australia
M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands
S.K. Danoff, MD, PhD, ATSF, Baltimore, MD
V. Steen, MD, Washington, DC
L.P. Hariri, MD, PhD, ATSF, Boston, MA
S. Hobbs, MD, Lexington, KY
A. Calypso, MSN, CRNP, Baltimore, MD

3:50 Wrap-Up

S.K. Danoff, MD, PhD, ATSF, Baltimore, MD

This session and the International Conference are supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 6

PG9 FUND ME: OVERCOMING THE BARRIERS AND CHALLENGES TO SUCCESSFUL CAREER DEVELOPMENT AWARDS

R Pre-registration and additional fees required. Attendance is limited.

Member: \$440	In-Training Member: \$255
LMIC Member: \$310	LMIC In-Training Member: \$180
Non-Member: \$540	In-Training Non-Member: \$380

Assemblies on Critical Care, Behavioral Science and Health Services Research, Clinical Problems, Nursing, Pediatrics, Pulmonary Infections and Tuberculosis, Respiratory Cell and Molecular Biology; Supported by MITT

8:00 AM - 4:00 PM

Marriott Marquis Washington

Independence Ballroom, Salon E (Level M4)

Target Audience

Early-stage investigators (fellows, junior faculty, advanced practice nurses, PhDs) interested in submitting clinical, translational, health services, or implementation science F, K, or other career development awards.

Objectives

At the conclusion of this session, the participant will be able to:

- compose a competitive mentored grant award application with an emphasis on innovative research and training plans that highlight the candidate's potential as well as the strength of their mentorship team and institutional environment

- formulate and articulate integrated training, mentoring, and research plans that outline a clear path forward for future independent funding and career development
- gain a better understanding of the grant review process, including resubmission, through participation in a mock study section

Writing mentored research awards can be paralyzing and stressful. In this session, participants will learn fundamental skills needed to develop a competitive mentored grant proposal, including how to write compelling specific aims and develop integrated research, mentoring, and training plans that outline a clear trajectory to future awards and independence. Participants will gain an appreciation of the review process through participation in a mock study section and interact throughout the day with a diverse faculty composed of previous awardees, experienced mentors, grant reviewers and program officers from various funding bodies. This session will be broadly applicable to potential applicants with any clinical, basic, translational, or health services research focus.

Chairing: E.M. Viglianti, MD, MPH, MSc, Ann Arbor, MI
S.J. Denstaedt, MD, Ann Arbor, MI
H.L. Lindroth, PhD, RN, Rochester, MN
M. Long, PhD, Columbus, OH

- 8:00 Introductions**
E.M. Viglianti, MD, MPH, MSc, Ann Arbor, MI
- 8:10 Anatomy of a Career Development Award**
H.L. Lindroth, PhD, RN, Rochester, MN
- 8:25 How Do You Know You Are Ready to Write a Mentored Grant?**
D. Sheppard, MD, San Francisco, CA
- 8:35 What Are Potential Sources of Funding for Mentored Grants?**
D.K. Costa, PhD, RN, Orange, CT
- 8:45 Panel Discussion: Tips From Successful Grant Recipients**
K.O. Lindell, PhD, RN, ATSF, Charleston, SC
- 9:20 Break**
- 9:30 Integrated Career Development and Training Plans**
T.S. Valley, MD, MSc, Ann Arbor, MI
- 10:00 Small Group Breakout: Career Development/Training Plans**
S.J. Denstaedt, MD, Ann Arbor, MI
- 10:50 Break**
- 11:00 Writing Compelling Specific Aims**
J.A. Bastarache, MD, Nashville, TN
- 11:30 Small Group Breakout: Writing Specific Aims**
E.M. Viglianti, MD, MPH, MSc, Ann Arbor, MI
- 12:00 Research Plan Basics**
T.J. Iwashyna, MD, PhD, Baltimore, MD
- 12:30 Lunch**

- 1:00 The Other Sections: Facilities, Budget, Animals, Humans and More**
K.M. Ridge, PhD, Chicago, IL
- 1:25 Questions and Answers With NIH Program Officers**
M. Craig, PhD, Bethesda, MD
- 1:50 NIH Scoring**
E.M. Viglianti, MD, MPH, MSc, Ann Arbor, MI
- 2:05 Mock Study Section**
S.J. Denstaedt, MD, Ann Arbor, MI
- 2:45 Break**
- 2:55 Post-Grant Review: What Happens Next**
J.W. Christman, MD, ATSF, Columbus, OH
- 3:10 Making the Most of a Career Development Grant and Other Nitty-Gritty**
C.T. Hough, MD, MSc, Portland, OR
- 3:25 Disparities Across Grantee Populations**
N. Kaminski, MD, ATSF, New Haven, CT
- 3:40 Panel Discussion and Wrap-Up**
M. Long, PhD, Columbus, OH

CLINICAL

POSTGRADUATE COURSE

PG10 QUITTING IS WINNING: TOBACCO AND E-CIGARETTE CESSATION

R Pre-registration and additional fees required. Attendance is limited.
Member: \$440 In-Training Member: \$255
LMIC Member: \$310 LMIC In-Training Member: \$180
Non-Member: \$540 In-Training Non-Member: \$380

Assemblies on Environmental, Occupational and Population Health; Behavioral Science and Health Services Research; Nursing; Pediatrics; Tobacco Action Committee, Pediatric Advocacy Subcommittee

8:00 AM - 4:00 PM

Marriott Marquis Washington

Independence Ballroom, Salons F-H (Level M4)

Target Audience

Clinicians, trainees and multidisciplinary allied health personnel.

Objectives

At the conclusion of this session, the participant will be able to:

- describe the differences between various types of tobacco, nicotine, and vaping products and how this affects risk and nicotine dependence
- appropriately evaluate and treat patients of all ages with nicotine dependence, utilizing both behavioral and pharmacologic interventions based on new guideline recommendations and best practices

- improve the quality of care provided to those with nicotine dependence by understanding how to develop inpatient and outpatient treatment services

The primary goal of this session is to provide learners with up to date, evidence-based knowledge and skills in the assessment and treatment of nicotine dependence. The course will provide timely information about tobacco products, associated risks, and how this knowledge informs the approach to tobacco cessation. The treatment approach will be individualized and evidence-based, and will span all age groups (adolescent to adult) and practice settings (inpatient and outpatient). Timely updates about regulation/policy, cannabinoid use in e-cigarettes, and EVALI will be shared. Course faculty include multidisciplinary clinical, research, and advocacy experts. Participants will attend breakout sessions to refine new skills.

Chairing: S.C. Sadreameli, MD, MHS, Baltimore, MD
A.E. Lang, PharmD, Fort Eustis, VA
M. Eakin, PhD, Chapel Hill, NC

- 8:00 Opening Remarks**
S.C. Sadreameli, MD, MHS, Baltimore, MD
- 8:05 Product Overview: From Cigarettes to ENDS and More**
S.C. Sadreameli, MD, MHS, Baltimore, MD
- 8:30 Tobacco Policy and Regulation Updates**
G. Ewart, MHS, Washington, DC
- 8:55 Questions and Answers for Talks 1 and 2**
S.C. Sadreameli, MD, MHS, Baltimore, MD
G. Ewart, MHS, Washington, DC
- 9:05 How Do We Take an Effective History?**
S.D. Krefft, MD, MPH, Aurora, CO
- 9:30 Motivational Interviewing as an Approach to Cessation**
M. Eakin, PhD, Baltimore, MD
- 9:55 Questions and Answers for Talks 3 and 4**
S.D. Krefft, MD, MPH, Aurora, CO
M. Eakin, PhD, Baltimore, MD
- 10:05 Break**
- 10:15 Treatment of Adult Nicotine Dependence**
A.E. Lang, PharmD, Fort Eustis, VA
- 10:40 Treating Tobacco Dependence in the Pediatric Clinic**
H.J. Farber, MD, MSPH, ATSF, Houston, TX
- 11:05 Questions and Answers for Talks 5 and 6**
A.E. Lang, PharmD, Fort Eustis, VA
H.J. Farber, MD, MSPH, ATSF, Houston, TX
- 11:15 Lunch**
- 11:45 Breakout Session**
- 12:45 EVALI: Diagnosis, Treatment, Prevention**
M.E. Rebull, PhD, Chapel Hill, NC
- 1:10 E-Cigarettes and Cannabinoids**
A.P. Tackett, PhD, Columbus, OH

1:35 Questions and Answers for Talks 7 and 8

M.E. Rebull, PhD, Chapel Hill, NC
A.P. Tackett, PhD, Columbus, OH

1:45 Break

1:55 E-Cig/Tobacco Cessation Approaches: Inpatient Consult Service

H. Kathuria, MD, ATSF, Boston, MA

2:25 E-Cig/Tobacco Cessation Approaches: Adult Outpatient Clinic

T. Fisher, DNP, APN, Philadelphia, PA

2:55 E-Cig/Tobacco Cessation Approaches: Pediatric Outpatient Clinic

A.M.H. Casey, MD, Boston, MA

3:25 Treatment Approaches Panel

H. Kathuria, MD, ATSF, Boston, MA
T. Fisher, DNP, APN, Philadelphia, PA
A.M.H. Casey, MD, Boston, MA

3:55 Concluding Remarks and Dismissal

A.E. Lang, PharmD, Fort Eustis, VA

BASIC • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 6

PG11 A HANDS-ON INTRODUCTION TO STUDYING THE LUNG MICROBIOME

 Pre-registration and additional fees required. Attendance is limited.

Member: \$440

In-Training Member: \$255

LMIC Member: \$310

LMIC In-Training Member: \$180

Non-Member: \$540

In-Training Non-Member: \$380

 Registrants must bring a laptop to the course to view the course material.

Assemblies on Pulmonary Infections and Tuberculosis; Allergy, Immunology and Inflammation

8:00 AM - 4:00 PM

Marriott Marquis Washington

Liberty Ballroom, Salon L (Level M4)

Target Audience

Research scientists interested in designing, performing, and understanding the analysis of lung and airway microbiome samples using sequencing-based techniques.

Objectives

At the conclusion of this session, the participant will be able to:

- apply research design and analytical approaches needed to conduct culture-independent assessment of microbiome communities in respiratory specimens
- integrate microbiome sequencing results with current culture-based models of respiratory infection and re-evaluate disease paradigms

and apply this knowledge when designing studies of the lung microbiome

- apply a combination of basic science and multi-dimensional computational approaches for investigating microbial function and mechanisms of disease. Audience will be equipped to prioritize mechanistic approaches to the microbiota

This course provides an up to date and accessible introduction to microbiome analyses for trainees and investigators. The course will introduce methodologies used to study the lung microbiome using culture-independent methods. During the session, participants will learn how to design, execute, analyze and interpret a lung microbiome study. Experiences will include didactic sessions, facilitated small-group discussions on designing and executing lung microbiome studies, and demonstrations on the use of statistical software to analyze microbiome data. Attendees will be provided with a set of microbiome data as well as annotated code for hands-on analysis.

Chairing: A.A. Pragman, MD, PhD, Minneapolis, MN
R.P. Dickson, MD, Ann Arbor, MI
L.N. Segal, MD, New York, NY

- 8:00 An Introduction to Thinking About the Microbiome**
R.P. Dickson, MD, Ann Arbor, MI
- 8:45 Contaminomics**
M.J. Cox, BSc(Hons), PhD, London, United Kingdom
- 9:15 Integrating Microbiota Findings With Our Disease Models**
A.A. Pragman, MD, PhD, Minneapolis, MN
- 9:45 Break**
- 10:15 Longitudinal Microbiome Studies**
D. Bogaert, MD, PhD, Edinburgh, United Kingdom
- 10:45 Studying Viruses and Fungi in Lung Microbiome Studies**
R.G. Collman, MD, Philadelphia, PA
- 11:15 Hands-On Microbiome Analysis - Part I**
C. Brown, BA, MS, Ann Arbor, MI
- 12:15 Lunch**
- 1:15 Hands-On Microbiome Analysis - Part II**
C. Brown, BA, MS, Ann Arbor, MI
- 1:45 Microbial-Host Interactions**
L.N. Segal, MD, New York, NY
- 2:15 Metagenomics and Metatranscriptomics**
C. Langelier, MD, PhD, San Francisco, CA
- 2:45 Break**
- 3:15 Introduction to Integrative, Therapeutic and Environmental Applications in Microbiome Studies**
S.H. Chotirmall, MD, PhD, Singapore

3:30 An Introduction to Microbiome Analytics for Integrative Microbiome Studies

J.K. Narayana, BS, MS, Singapore

3:45 Consultation Session

BASIC • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 6

PG12 MOLECULAR TARGETING IN COPD - FROM BASICS THROUGH MULTI-OMIC INTEGRATION TO NOVEL THERAPEUTICS

R Pre-registration and additional fees required. Attendance is limited.

Member: \$440

In-Training Member: \$255

LMIC Member: \$310

LMIC In-Training Member: \$180

Non-Member: \$540

In-Training Non-Member: \$380

L Registrants must bring a laptop to the course to view the course material.

Assemblies on Respiratory Cell and Molecular Biology; Environmental, Occupational and Population Health; Respiratory Structure and Function

8:00 AM - 4:00 PM

Marriott Marquis Washington

Monument (Level M4)

Target Audience

Basic science researchers looking for novel druggable targets in COPD. Clinicians (clinician scientist) interested in novel approaches to treat COPD.

Objectives

At the conclusion of this session, the participant will be able to:

- understand genetic susceptibility, disease heterogeneity and pathological mechanisms underlying COPD
- learn about novel molecular pathways currently being targeted for future therapeutics
- learn and understand how to use current technologies to delineate novel targets for drug discovery

COPD is the third leading cause of death worldwide but there are only limited symptomatic therapeutic options available with no causal treatment able to reverse or prevent the progression of COPD, revealing a high unmet medical need for novel therapeutics. To combat this problem a thorough understanding of the molecular mechanisms behind COPD are crucial for the development of new targets. Here we present leading avenues of investigation that will enhance the participants understanding of COPD patho-mechanisms and how the integration of cutting-edge technologies can help in our stride towards finding more efficient therapies.

- Chairing:** Y. Tesfaigzi, PhD, Boston, MA
E.R. Neptune, MD, ATSF, Baltimore, MD
I.M. Adcock, PhD, London, United Kingdom
M.P. Goldklang, MD, New York, NY
- 8:00 The Future of COPD Research - How We Can Model Susceptibility, Exposures and the Resultant Endotypes?**
A.O. Yildirim, PhD, Munich, Germany
COPD Setting the Scene
- 8:16 Air Pollution - The Forgotten Etiology of COPD**
E. Coffman, BS, MPH, Durham, NC
- 8:36 Genetic Susceptibility**
B.D. Hobbs, MD, MSc, Boston, MA
- 8:56 The Pathological Mechanisms of COPD**
P.J. Barnes, MD, DSc, ATSF, London, United Kingdom
- 9:16 A Multi Edged Sword - Heterogeneity in COPD**
J.A. Wedzicha, MD, ATSF, London, United Kingdom
- 9:36 Break**
Immune Targets in COPD
- 10:07 Adaptive Immune Cells in COPD**
F. Polverino, MD, PhD, Houston, TX
- 10:27 Specialized Pro Resolving Molecules: A New Approach to Resolution of Inflammation**
P.J. Sime, MD, ATSF, Richmond, VA
- 10:47 Novel Immune-Therapeutic Targets in COPD**
T.M. Conlon, PhD, Munich, Germany
Metabolic Targets in COPD
- 11:08 Mitochondrial Dysfunction in COPD**
C.R. Kliment, MD, PhD, Pittsburgh, PA
- 11:28 Disease Pathogenesis Stems From Altered Immunometabolic Processes**
S.M. Cloonan, PhD, New York, NY
- 11:48 Lunch and Group Discussions**
Lets Regenerate the Lung
- 12:49 Remodeling and Tissue Repair**
C. Kim, PhD, Boston, MA
- 1:09 Silencing Senescence**
M. Lehmann, PhD, Munich, Germany
- 1:29 Novel Transcriptomics-Guided Approaches for Druggable Targets**
R. Gosens, PhD, Groningen, Netherlands
Tricks and Tools
- 1:50 Ultra-Resolution Biomedical Imaging**
T. Hackett, PhD, ATSF, Vancouver, Canada
- 2:10 Break**

- 2:40 Workshop 1 - Translational and Multidisciplinary Lung Microengineering**
K. Hajjipouran Benam, PhD, Pittsburgh, PA
- 3:10 Workshop 2 - High-Throughput Omics Guides Therapeutic Targeting**
M. Sauler, MD, New Haven, CT
- 3:40 Closing Discussion**
I.M. Adcock, PhD, London, United Kingdom

This session and the International Conference are supported by an independent medical educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL

POSTGRADUATE COURSE

CME Credits Available: 6.75

PG13 HUFFING AND PUFFING: BEST PRACTICE AND STATE OF THE ART IN CPET AND PFT

- Pre-registration and additional fees required. Attendance is limited.**
- | | |
|--------------------|--------------------------------|
| Member: \$440 | In-Training Member: \$255 |
| LMIC Member: \$310 | LMIC In-Training Member: \$180 |
| Non-Member: \$540 | In-Training Non-Member: \$380 |

Assemblies on Respiratory Structure and Function; Clinical Problems; Pulmonary Rehabilitation

8:00 AM - 4:00 PM

Marriott Marquis Washington

Liberty Ballroom, Salons I-K (Level M4)

Target Audience

Current and future directors of PFT and CPET labs, attending physicians, respiratory therapists, clinical physiologists, trainees, fellows, and other interested health care providers.

Objectives

At the conclusion of this session, the participant will be able to:

- integrate/incorporate the principles and practice of pulmonary function diagnostic tests
- improve and develop greater confidence interpreting pulmonary function test results in clinical practice
- apply and improve the performance and interpretation of cardiopulmonary exercise testing

This course will focus on clinical physiology, combining guidelines from the new technical standards published in the past three years and interpretive strategies document published in the last year with interactive experience in small group settings focusing on the performance, interpretation, and reporting of pulmonary function testing (PFT) and cardiopulmonary exercise testing

(CPET). We will combine didactic lectures with case-based instruction, small group discussion, and live demonstration of cardiopulmonary exercise testing. We will use a multidisciplinary team approach to facilitate case discussions including content experts, clinicians, physiologists, and pulmonary function laboratory medical directors from around the world.

- Chairing:** T. Decato, MD, Torrance, CA
M.C. McCormack, MHS, MD, Baltimore, MD
H.B. Rossiter, PhD, Torrance, CA
- 8:00 Blows and Flows: State of the Art in Spirometry**
S. Stanojevic, PhD, Halifax, Canada
- 8:30 Pump Up the Volume: Interpretation and Assessment of Lung Volumes**
A.S. Niven, MD, Rochester, MN
- 8:55 Insane in the Membrane: Demystifying DLCO**
T. Decato, MD, Torrance, CA
- 9:20 Turbulence Ahead: Updates in Bronchoprovocation Testing**
T.S. Hallstrand, MD, MPH, ATS, Seattle, WA
- 10:00 Break**
- 10:20 Don't Forget About the Kids: Essentials in Pediatric Pulmonary Function Testing**
C.L. Ren, MD, MBA, ATS, Philadelphia, PA
- 10:50 Putting It All Together: Small Group PFT Case Discussions**
R. Clay, MD, Clackamas, OR
A.S. Niven, MD, Rochester, MN
K. Jakharia, MBBS, MD, Chapel Hill, NC
- 11:40 Lunch**
- 12:10 Start Me Up: CPET Patient Setup and Demonstration**
C.D. Mottram, RRT, RPFT, Rochester, MN
- 1:10 Dancing in the Dark: CPET Reference Values**
H.B. Rossiter, PhD, Torrance, CA
- 1:40 Blinded Me With Science: CPET Data Display and Interpretation**
D.A. Kaminsky, MD, Burlington, VT
- 2:10 Break**
- 2:30 What I Like About You: Typical CPET Responses Among Disease States**
K.E. Sietsema, MD, Torrance, CA
- 3:00 Express Yourself: CPET Small Group Cases**
T. Decato, MD, Torrance, CA

CLINICAL • TRANSLATIONAL

POSTGRADUATE COURSE

CME Credits Available: 6.25

MOC Points Available: 1.5

PG14 STATE OF THE ART: LUNG CANCER IN 2023

R Pre-registration and additional fees required. Attendance is limited.

Member: \$440

In-Training Member: \$255

LMIC Member: \$310

LMIC In-Training Member: \$180

Non-Member: \$540

In-Training Non-Member: \$380

Assemblies on Thoracic Oncology; Clinical Problems

8:00 AM - 4:00 PM

Marriott Marquis Washington

Liberty Ballroom, Salon M (Level M4)

Target Audience

All providers caring for patients with lung nodules/lung cancer (pulmonologists, thoracic surgeons, radiation oncologists, NP/PAs). Those interested in the translational research being done in this field.

Objectives

At the conclusion of this session, the participant will be able to:

- understand the racial and gender disparities related to lung cancer screening, diagnosis and treatment
- understand recent developments in lung cancer diagnosis
- understand recent advances in the treatment of lung cancer

This course will provide a comprehensive review of topics in the evaluation and management of patients with lung cancer. We discuss recent developments in tobacco control, updated guidelines and practical tips for lung cancer screening, and minimally invasive diagnostic approaches for patients with lung nodules. The treatment of early stage, locally advanced and metastatic disease, highlighting novel/minimally invasive approaches as well as the use, and toxicities of immunotherapy will also be covered. Attention will be given to the impact of lung cancer on underrepresented populations as well as the rising incidence of lung cancer in non-smoking females. Interactive tumor boards will be held to highlight these topics and facilitate audience engagement.

Chairing: D.J. Feller-Kopman, MD, Lebanon, NH
N.T. Tanner, MD, MSCR, Charleston, SC

8:00 Introduction

D.J. Feller-Kopman, MD, Lebanon, NH

8:05 Engaging the Community in Lung Cancer Screening & Tobacco Cessation

P. Galiatsatos, MD, Baltimore, MD

8:30 Addressing Disparities in Lung Cancer: The Rural Population

R. Hasson, MD, Lebanon, NH

- 8:55 Lung Cancer Screening: Ensuring High Quality and Improving Uptake**
R.S. Wiener, MD, MPH, ATSF, Boston, MA
- 9:20 Getting to the Nodule: Updates in Advanced Bronchoscopy**
J. Thiboutot, MD, Baltimore, MD
- 9:45 Break**
- 10:05 Interactive Tumor Board**
D.A. Arenberg, MD, ATSF, Ann Arbor, MI
- 10:35 Biomarkers in Lung Cancer: From Early Detection to Prognosis**
A. Vachani, MD, MS, Philadelphia, PA
- 11:00 Addressing Disparities: Lung Cancer in Women**
N.T. Tanner, MD, MSCR, Charleston, SC
- 11:25 Updates in the Surgical Treatment of Lung Cancer**
D. Molena, MD, New York, NY
- 11:50 Lunch**
- 12:50 Updates on SBRT for Lung Cancer**
C. Abraham, MD, MSACI, St. Louis, MO
- 1:15 The Role of Immunotherapy in Lung Cancer**
S. Scott, MD, Baltimore, MD
- 1:40 Interactive Tumor Board**
D.J. Feller-Kopman, MD, Lebanon, NH
- 2:10 Break**
- 2:30 Minimally Invasive Palliation: A Focus on the Airway and Pleura**
U.S. Chaddha, MBBS, New York, NY
- 2:55 The Top 5: This Year's Most Important Articles**
G.A. Silvestri, MD, Charleston, SC
- 3:20 Panel Discussion With the Experts**
G.A. Silvestri, MD, Charleston, SC

This session and the International Conference are supported by an independent medical educational grant from Merck & Co.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BEHAVIORAL

POSTGRADUATE COURSE

CME Credits Available: 6.5

PG15 TEACHING SKILLS FOR BUSY CLINICIANS: EFFICIENT AND EFFECTIVE TEACHING STRATEGIES FOR ALL CLINICIANS

R Pre-registration and additional fees required. Attendance is limited.

Member: \$440

LMIC Member: \$310

Non-Member: \$540

In-Training Member: \$255

LMIC In-Training Member: \$180

In-Training Non-Member: \$380

Education Committee

8:00 AM - 4:00 PM

Marriott Marquis Washington

Liberty Ballroom, Salons N-P (Level M4)

Target Audience

Physicians, Physicians In-Training, Advanced Practice Providers, Nurses, Pharmacists, Respiratory Therapists, Medical Students, anyone who teaches

Objectives

At the conclusion of this session, the participant will be able to:

- identify and define effective strategies for teaching adult medical learners in different clinical settings
- describe educational strategies for promoting critical thinking, giving feedback, and mentoring effectively
- review and practice strategies to improve your white board teaching and your PowerPoints

Teaching is a core component of medical practice, from teaching patients about their medical conditions to helping students and trainees develop their clinical skills. Most physicians, however, have not had formal training on best practices in medical education, and are not aware of evidence-based strategies for teaching medical learners. In this postgraduate course, medical education experts from the American Thoracic Society will review effective and efficient teaching strategies that participants can incorporate into their teaching activities. Through an interactive, hands-on approach participants will learn about and have the opportunity to practice the teaching skills covered in this course.

Chairing: M.M. Hayes, MD, ATSF, Boston, MA
J.B. Richards, MD, MA, ATSF, Cambridge, MA
J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil

8:00 Introduction and Overview

J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil

8:15 Utilizing the Science of Learning to Improve Your Teaching

M.M. Hayes, MD, ATSF, Boston, MA

- 8:45 Tips and Tricks for Creating the Perfect PowerPoint**
 B. Coruh, ATSF, Seattle, WA
 A. Trainor, MD, Boston, MA
 K. Montemayor, MD, Baltimore, MD
 M.C. Ferrera, MD, Boston, MA
 J.B. Richards, MD, MA, ATSF, Cambridge, MA
 M.M. Hayes, MD, ATSF, Boston, MA
- 9:40 Break**
- 10:00 Two Tips for Teaching Critical Thinking**
 R.M. Schwartzstein, MD, Boston, MA
- 10:15 Using Advocacy Inquiry to Give Effective Feedback**
 M. Soffler, MD, New York, NY
- 11:00 Teaching in the ICU: A Team Based Sport**
 W.G. Carlos, MD, MSCR, ATSF, Indianapolis, IN
- 11:30 Two Tips to be a Great Mentor**
 T.S. Wang, MD, ATSF, Los Angeles, CA
- 11:45 Lunch**
- 12:45 Two Tips for Teaching Physiology**
 J.B. Richards, MD, MA, ATSF, Cambridge, MA
- 1:00 Teaching in the Clinic: Tips and Tricks for Optimized Outpatient Education**
 E. Kelly, MD, Dublin, Ireland
- 1:30 Creating a Wicked White Board: Tips and Tricks to Enhance Your Chalk Talks**
 J.B. Richards, MD, MA, ATSF, Cambridge, MA
 K. Montemayor, MD, Baltimore, MD
 A. Trainor, MD, Boston, MA
 M.C. Ferrera, MD, Boston, MA
 M.M. Hayes, MD, ATSF, Boston, MA
- 2:20 Break**
- 2:30 Pro Tips for Procedural Teaching in a Busy Environment**
 D. Kelm, MD, ATSF, Rochester, MN
 J.I. Mcsparron, MD, ATSF, Ann Arbor, MI
- 3:00 Two Tips to Incorporate Diversity, Equity, and Inclusion Into Your Teaching**
 R. Esteitie, MD, Saginaw, MI
- 3:15 Teaching With Technology in 2023**
 A. Cooper, MD, Columbus, OH
- 3:45 Wrap-Up Questions and Answers**
 J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil

NETWORKING SUPER CENTER



The Networking Super Center is open to all attendees from 1:30 p.m. Saturday, May 29 2:00 p.m. till Wednesday, May 24th.

Stop by one of the Learning Studios for specialized programming where you can participate in studio talks, panel discussions and networking opportunities.

The Super Center includes, the ATS Center, Center for Career Development, International Participant's Center, Clinician's Center and the Science and Innovation Center

COLLABORATE, EDUCATE, CONNECT AND LEARN

4:15 p.m. - 5:30 p.m.

OPENING CEREMONY



Walter E. Washington Convention Center
Hall E (Level 2)

ATS 2023 kicks off with the Opening Ceremony, featuring a keynote address by **Stephen K. Klasko, MD, MBA**. During his career he has been dean at two medical colleges (Drexel and University of South Florida), president of a University (Thomas Jefferson University) and CEO of two academic health systems (USF health and Jefferson Health).

Dr. Klasko was named a distinguished fellow of the World Economic Forum in 2020, the #2 most influential person in healthcare in 2018 by Modern Healthcare, the #21 most creative person in business by fast company in 2019 and has been a Becker's top 100 healthcare leader for the last 5 years in a row.

At Thomas Jefferson University, he led a system that in eight years went from a two hospital, one campus university with \$1 billion in revenue to an 18 hospital, two campus university with almost 10,000 students and a Medicaid and Medicare Advantage health insurance plan, making Jefferson the first "integrated delivery and financial network" in Philadelphia. He led the integration of Jefferson's extensive academic pulmonary program through a significant donation to create the Korman Respiratory Institute and led the integration of that institute into a partnership with National Jewish.

He has written six books from 1999 to 2023 each one advocating for transformations in patient centered healthcare and innovative medical education. His book UnHealthcare: A Manifesto for health assurance has been translated to several languages.

Dr. Klasko has written more than 100 articles for business journals, blogs and podcasts on the need for more equitable healthcare and "healthcare at any address" and started the Philadelphia Collaborative for health Equity which has been replicated in several other cities.

He was featured in the European Business Review for his exemplary leadership during the COVID crisis in an article called Leadership Plus penned by the chair of leadership at Wharton Business School, Michael Useem.

Also during the Opening Ceremony:

- ATS President Greg Downey, MD, ATSF, will provide an update of the Society's major accomplishments for the past year and priorities for the coming one;
- The latest class of ATS Fellows and Research Program awardees will be recognized; and

The Public Service Award, World Lung Health Award, Jo Rae eWright Award for Outstanding Science and J. Randall Curtis Humanism Award will be presented

Many thanks to Boehringer Ingelheim Pharmaceuticals, Inc. for support of the Opening Ceremony

5:30 p.m. - 6:30 p.m.

THE NETWORKING EXCHANGE FOR EARLY CAREER PROFESSIONALS




The Network Exchange is a welcome event for all Early Career Professionals (residents, fellows, post docs, IP members, and other medical professionals) and takes place on Saturday following the Opening Ceremony. This one-hour event allows attendees to network and mingle with peers as well as provides information at the start of the conference. This event includes cocktails and appetizers.

What to expect at the one-hour event?

- Come mingle with colleagues, mentors and peers
- Learn about the ATS Road Map for Early Career Professionals
- Learn how you can become an ATS member for FREE and much more

This event is sponsored / organized by the Members in Transition and Training (MITT) committee.

 **This event is free to paid conference registrants**



ATS
2023

INTERNATIONAL
CONFERENCE
WASHINGTON, DC
conference.thoracic.org

Sunday Morning, May 21

[Click Here to Access the Program Itinerary and Add Sunday Sessions and Presentations to Your Calendar](#)

MEET THE EXPERT SEMINARS
CME Credits Available: 1

 Pre-registration and additional fees required. Attendance is limited.
\$100 Member/Non-Members
\$70 LMIC Member/LMIC Non-Members

10:15 a.m. - 11:15 a.m. **Marriott Marquis Washington**

- MTE2 IS OBSTRUCTIVE SLEEP APNEA EFFECTING MY BRAIN; LESSONS FROM BENCH TO BEDSIDE**
C. Lal, MD, ATSF, Charleston, SC
Howard University (Level M1)
- MTE3 CYSTIC FIBROSIS IN THE ICU: BPH, BACTERIA, AND BEYOND**
G.R. Winter, MD, Birmingham, AL
Georgetown University (Level M1)
- MTE4 CARING FOR CHILDREN WHO RECEIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-MALIGNANT INDICATIONS**
C. Towe, MD, Cincinnati, OH
A. Gupta, MBBS, MPH, Minneapolis, MN
Judiciary Square (Level M3)
- MTE5 LUNG NODULE: HOW CAN WE INCREASE THE BIOPSY DIAGNOSTIC YIELD**
W. Hadid, MD, Lexington, KY
Shaw (Level M3)

MTE6 QUALITATIVE RESEARCH FOR THE QUANTITATIVE SCIENTIST: INCORPORATING QUALITATIVE METHODS INTO SCHOLARSHIP AND CLINICAL PRACTICE
M. Eakin, PhD, Baltimore, MD
C.T. Hough, MD, MSc, Portland, OR
S.J. Niranjani, PhD, MS, BPharm, Birmingham, AL
K. Hauschildt, PhD, Baltimore, MD
LeDroit Park (Level M3)

K1: FRAN COMI KEYNOTE LECTURE
CME Credits Available: .75

8:00 a.m. -8:45 a.m.
Walter E. Washington Convention Center
Hall E (Level 2)

The inaugural **Fran Comi Keynote Lecture**
Title: How Science Promotes Health Equity by Decreasing Disparities
Speaker: Eliseo Perez-Stable, MD, Bethesda, MD

YEAR IN REVIEW
CME Credits Available: 1.5
MOC Points Available: 1.5

A1 CLINICAL YEAR IN REVIEW 1

9:00 AM - 10:30 AM **Walter E. Washington Convention Center**
Hall E (Level 2)

Target Audience

Pulmonary, critical care and sleep providers. The program will discuss general topics of interest to a broad group of providers, inside and outside of these subspecialties. The program is relevant to not only clinicians, but also to researchers and administrators

Objectives

At the conclusion of this session, the participant will be able to.

- apply new clinical research knowledge to clinical practice
- apply new findings about key conditions in pulmonary, critical care and sleep
- learn new strategies to manage the care of common conditions in pulmonary, critical care, and sleep

Pulmonary, critical care and sleep providers. The program will discuss general topics of interest to a broad group of providers, inside and outside of these subspecialties. The program is relevant to not only clinicians, but also to researchers and administrators.

Chairing: R.J. Shah, MD, MSCE, San Francisco, CA
J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil
S. Auld, MD, MSc, Atlanta, GA

9:00 ALI/ARDS
D.W. Russell, MD, Birmingham, AL

9:22 Pulmonary Vascular Disease
G.A. Heresi, MD, MSci, Cleveland, OH

9:45 COPD
S. Christenson, MD, MS, San Francisco, CA

10:07 ILD
R.K. Putman, MD, MPH, Boston, MA

This session and the International Conference are supported by independent medical educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, AstraZeneca LP, Boehringer Ingelheim Pharmaceuticals, Inc., and Merck & Co.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BASIC • CLINICAL

CRITICAL CARE TRACK

CME Credits Available: 1.5

A2 JAMA AND THE NEW ENGLAND JOURNAL OF MEDICINE. DISCUSSION ON THE EDGE: REPORTS OF RECENTLY PUBLISHED CRITICAL CARE RESEARCH

9:00 a.m. - 10:30 a.m. **Walter E. Washington Convention Center**
Room 207 A-B (Level 2)

This session will provide a forum for attendees to interact with the authors and editors about papers published in JAMA and the New England Journal of Medicine. Papers presented will be recent publications, selected by the editors, to be of significant importance to the field of pulmonary medicine. Attendees will have the opportunity to hear presentations directly from the author and address questions to both the authors and editors. The discussion is intended to provide a unique insight into these papers, the selection process, and how the research applies directly to the field of critical care medicine.

Chairing: C. Seymour, MD, MSc, Pittsburgh
D. Taichman, MD, PhD, Boston, MA

Speakers and Talks To Be Announced

CLINICAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 1.5

A3 FELLOWS CASE CONFERENCE

Assemblies on Behavioral Science and Health Services Research; Training Committee

9:00 AM - 10:30 AM **Walter E. Washington Convention Center**
Ballroom C (Level 3)

Target Audience

Clinicians, nurses, fellows, residents, and researchers looking to broaden their clinical acumen to facilitate clinical and translational research

Objectives

At the conclusion of this session, the participant will be able to:

- recognize clinical, radiographic, and pathologic findings of rare diseases
- gain insight into clinical decision-making skills demonstrated by master clinicians, radiologists, and pathologists which will improve the quality of learners' practice and potentially improve the quality of care for the learner's patients
- develop strategies to evaluate patients with common symptoms that include uncommon/ rare diseases in the differential diagnosis when appropriate

In this session, six unknown cases will be presented by fellows to a panel of experts in a traditional Clinical Pathology Conference (CPC) format. The panel of experts includes three clinician experts, an expert radiologist, and an expert pathologist. The panel of clinician experts will discuss the key clinical elements of the history and a differential diagnosis. The expert radiologist and pathologist will interpret the imaging and pathology, respectively, which the expert clinician will then use to further the discussion and ultimately make a diagnosis.

Chairing: M.M. Lee, MD, ATSF, FCCP, FACP, Los Angeles, CA
C.M. Bojanowski, MD, MSCR, New Orleans, LA

9:00 A Tale of Two Cities: A Mass and an SVC
M. Islam, MBBS, Charlottesville, VA

9:10 Expert Clinician
A.E. Dixon, MA, BM BCH, ATSF, Burlington, VT

9:18 The Welder, the Smoker, and the Joint Acher
B. Khan, MBBS, Richmond, VA

9:28 Expert Clinician
M.P. Rivera, MD, ATSF, Rochester, NY

9:36 A Knives (Or Forceps) Out Tracheal Mystery
A. Kabadi, MD, La Jolla, CA

9:46 Expert Clinician
E. Schmidt, MD, ATSF, Boston, MA

- 9:54** **Everything, Everywhere All in the Lungs**
J. Pryor, MD, Aurora, CO
- 10:04** **Expert Radiologist**
B. Ellicker, MD, San Francisco, CA
- 10:12** **A 79-year-old Woman with Bilateral Exudative Effusions**
R. Nair, MD, Bronx, NY
- 10:22** **Expert Pathologist**
J.L. Myers, MD, Ann Arbor, MI

CLINICAL**CRITICAL CARE TRACK**

CME Credits Available: 1.5

A4 ACHIEVING HEALTH EQUITY IN GLOBAL CRITICAL CARE: CHALLENGES AND INNOVATIONS

Assembly on Critical Care; Africa Interest Group

9:00 AM - 10:30 AM Walter E. Washington Convention Center

Room 145 A-B (Street Level)

Target Audience

All critical care physicians, advance practice providers, nurses and allied health providers with an interest in healthcare equity and diversity on a global level

Objectives

At the conclusion of this session, the participant will be able to:

- better understand challenges and nuances of critical care delivery in diverse practice settings globally
- incorporate innovative solutions to best practices in critical care in lower-resourced settings around the world
- describe innovations in critical care research, education and practice in lower-resourced settings

The practice of critical care around the world varies considerably based on environment, geography, and human and material resource availability. Consequently, effective critical care delivery often requires nuance and adaptation. With an emphasis on global equity and diversity, this session provides perspective on innovations that improve outcomes in lower-resourced settings. This multidisciplinary session will cover a diversity of essential topics relevant to attendees interested in critical care delivery in strained settings around the world.

Chairing: A. Papali, MD,CM, Charlotte, NC
D.O. Obaseki, MD, ATSF, Ile-Ife, Nigeria

- 9:00** **Crisis Standard of Care Protocols in Low-Resource Settings: Ensuring Equity Amidst Scarcity**
E.D. Riviello, MD, MPH, Boston, MA

- 9:07** **Crisis Standards of Care Protocols in Low-Resource Settings: Ensuring Equity Amidst Scarcity**
T. Twagirumugabe, MD, MMed, FCCM, PhD, Butare, Rwanda
- 9:15** **Sepsis Treatment Around the World: Challenges and Innovations**
J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil
- 9:30** **Oxygen Delivery: Overcoming Supply Chain Problems During the COVID-19 Pandemic**
E. Vanderwal, PA, Sidvokodvo, Swaziland
- 9:45** **Innovations in Critical Care Education: Lessons from Kenya**
B.W. Lee, MD, Bethesda, MD
- 10:00** **Decolonizing Global Critical Care**
R. Haniffa, MD, Edinburgh, United Kingdom
- 10:15** **Essential Emergency and Critical Care**
K.Khalid, MD, Dar-es-Salaam, Tanzania

BASIC • TRANSLATIONAL**BASIC SCIENCE CORE**

CME Credits Available: 1.5

A5 QUANTIFICATION OF ENVIRONMENTAL EXPOSURES USING STATE-OF-THE-ART METHODS

9:00 a.m. - 10:30 a.m. Marriott Marquis Washington

Independence Ballroom, Salons E-H

Target Audience

Clinicians and researchers

Objectives

At the conclusion of this session, the participant will be able to:

- identify opportunities for novel investigation into understudied aspects of exposure assessment, (patho)physiological mechanisms, and cellular and molecular biology.
- apply new technologies such as functional imaging and in vitro translational models for detecting onset and progression of lung function changes to environmental exposures
- learn how advances in lung biology are revealing new mechanisms of lung homeostasis and therapeutic targets to reduce/ reverse the deleterious impacts of environmental exposures.

This is part 1 of a 2-part symposium

Part 1 focuses on quantification of environmental exposures using state-of-the-art methods.

Part 2 on Sunday, May 21, 2:15 p.m.-3:45p.m. focuses on the physiological and cellular impact of environmental exposures.

Occupational and environmental lung diseases are caused by the inhalation of chemical irritants, allergens or toxins in work or home environments. Most diseases are caused by repeated, long-term exposure, but even a one-time or indirect contact with a hazardous agent can result in lung diseases with lasting effects.

Environmental exposures related to fossil fuel and heavy metals and occupational exposures related to silica and coal mining generate oxidative stress and inflammation in the lungs. Sustained oxidative stress causes DNA damage, epigenetic instability, mitochondrial dysfunction, and cell cycle arrest in key progenitor cells in the lung.

Inhaled environmental exposures accelerate lung aging by injuring the lungs and damaging the cells responsible for wound healing. Novel exposure assessment methods, including functional imaging and -omics studies, together with mathematical models are needed to quantify environmental exposures. Interventions that minimize exposure to noxious antigens are critical to improve lung health, and novel research is required to expand our knowledge of therapies that may slow or prevent premature lung aging.

Each presentation will leave 5 minutes for questions and answers.

Chairing: I. Yang, PhD, ATSF, Aurora, CO
J. Woods, PhD, ATSF, Cincinnati, OH
L. Alexander, MD, ATS, San Diego, CA

9:00 Quantifying Vaping-Related Pulmonary Illnesses

I. Jaspers, PhD, Chapel Hill, NC

9:30 Long-Term Exposure to Ambient Air Pollution and Change in Quantitatively Assessed Emphysema and Lung Function

R. G. Barr, MD, DrPH, New York, NY

9:50 Identifying Epigenetic Modifications to Allergens and Pollution

C. Carlsten, MD, MPH, Vancouver, Canada

10:10 Visualizing Lung Destruction and Repair to Environmental Exposures

T.L. Hackett, PhD, ATSF, Vancouver, Canada

10:25 Questions and Answers

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

A6 BEYOND TRANSCRIPTOMICS: THE NEXT FRONTIER IN COPD/EMPHYSEMA

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems; Section on Genetics and Genomics

9:00 AM - 10:30 AM **Walter E. Washington Convention Center**

Room 146 A-C (Street Level)

Target Audience

Providers of lung health care, those who provide care to patients with COPD/emphysema, and basic and translational scientists with an interest in COPD/emphysema and gene x environment interactions

Objectives

At the conclusion of this session, the participant will be able to:

- apply emerging data to identify cell types and lung compartments injured in COPD to more accurately discuss disease biology and likely disease trajectories with patients to improve care quality
- understand existing gaps in the knowledge of pathobiology in COPD
- identify emerging resources and data being applied to facilitate future therapeutic development

Therapeutic discoveries have not kept pace with the significant, world-wide burden of disease associated with COPD/emphysema. No major class of drugs has introduced for COPD therapy in decades, suggesting the urgent need to delineate disease mechanisms that will facilitate drug discovery. Multiple recent publications have detailed at single-cell resolution the cellular transcriptional response to chronic smoke exposure and COPD/emphysema, particularly in the in the distal airways and alveoli. This session will explore approaches, including the integration of multi-omic datasets and the application of longitudinal cohorts and novel model systems that will extend understanding of disease mechanisms to facilitate therapeutic discovery.

Chairing: A.A. Wilson, MD, Boston, MA
A.X. Zhou, PhD, Boston, MA
M.C. Basil, MD, PhD, Philadelphia, PA

9:00 RASCs, BASCs, or TASCs? ASCing What Cells in the Respiratory Bronchioles Contribute to COPD Pathogenesis

M.C. Basil, MD, PhD, Philadelphia, PA

9:13 CAPitalizing on Single Cell RNA Sequencing to Identify Dysregulated Alveolar Endothelium in COPD

M. Sauler, MD, New Haven, CT

9:26 Integrating GWAS Signals with Omics Datasets to Identify Causal Variants in COPD

M.H. Cho, MPH, MD, Boston, MA

9:39 Application of Human iPSC Model Systems to Illuminate the Functional Contribution of COPD GWAS Genes to Cellular Phenotypes

R. Werder, PhD, Melbourne, Australia

9:52 Novel Signaling Pathways as Potential Therapeutic Targets in COPD Pathogenesis

E.R. Neptune, MD, ATSF, Baltimore, MD

10:04 Can Insights from the Pediatric Lung Teach Us About COPD?

X. Sun, PhD, San Diego, CA

10:17 Leveraging Multilevel Profiling of Longitudinal Cohort Participants to Illuminate COPD Endotypes

M.R. Faner, PhD, BSc, Barcelona, Spain

This session and the International Conference are supported by an independent medical educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BEHAVIORAL • CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

MOC Points Available: 1.5

A7 THE NEW ATS CLINICAL PRACTICE GUIDELINES FOR PULMONARY REHABILITATION

Assemblies on Pulmonary Rehabilitation; Behavioral Science and Health Services Research

9:00 AM - 10:30 AM **Walter E. Washington Convention Center**

Room 143 A-C (Street Level)

Target Audience

Clinicians and researchers working with patients with chronic respiratory disease, in particular those involved in PR, as well as patients, care givers and patient advocacy groups with an interest in PR.

Objectives

At the conclusion of this session, the participant will be able to:

- describe the current evidence underpinning the new PR clinical practice guidelines
- apply the new clinical practice guidelines into current practice
- better understanding of the evidence and implementation of clinical practice guidelines for PR will improve the quality of life/health status of this patient group

Attendees will develop an understanding of the new pulmonary rehabilitation (PR) clinical practice guidelines, recommendations across the spectrum of chronic lung disease and the evidence that underpin this guidance. The session will also give practical tips on how to implement this guidance.

Chairing: L. Houchen-Wolloff, PhD, Leicester, United Kingdom
S.P. Bhatt, MD, MSPH, Birmingham, AL

9:00 Rationale for New ATS Clinical Practice Guidelines in Pulmonary Rehabilitation

C.L. Rochester, MD, New Haven, CT

9:10 Overview of New Guidelines

A.E. Holland, PT, PhD, Melbourne, Australia

9:35 Spotlight on Post-Hospitalization Rehabilitation

P. Camp, PT, PhD, Vancouver, Canada

9:55 Patient Speaker

Speaker To Be Announced

10:00 Strategies for Implementation of the New Guidelines

N.S. Cox, PT, MSc, PhD, Melbourne, Australia

10:15 Panel and Audience Discussion

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

A8 BRONCHOPULMONARY DYSPLASIA ACROSS THE LIFESPAN

Assembly on Pediatrics

9:00 AM - 10:30 AM

Marriott Marquis Washington

Marquis Ballroom Salon 6 (Level M2)

Target Audience

Neonatologists, pediatric pulmonologists, pediatric radiologists, respiratory therapists, adult pulmonary critical care specialists, and basic science researchers interested in pulmonary development and molecular mechanisms of lung injury

Objectives

At the conclusion of this session, the participant will be able to:

- to describe new findings about pre- and postnatal molecular mechanisms of lung injury that may plausibly serve as therapeutic targets that mitigate severe respiratory disease trajectories in preterm at risk for BPD
- to integrate new guidelines into current practice related to the multidisciplinary care of children with established BPD with focus on: multidisciplinary BPD care programs, pulmonary vascular disease, and the application of advanced imaging
- to improve the quality of life/health status of patients with BPD by understanding how longitudinal pulmonary function trajectories in childhood, adolescence, and adulthood are modified by BPD

Bronchopulmonary dysplasia (BPD), the chronic lung disease of infancy, is the most common morbidity of preterm birth. Despite improvements in the respiratory care of infants born preterm, the incidence of BPD is increasing, owing to the improved survival of infants born extremely preterm. As increasing numbers of preterm infants survive to adulthood, BPD is increasingly recognized as an important contributor to morbidity and mortality throughout life even into adulthood. This session will situate current information regarding the molecular mechanisms of BPD pathogenesis within the context of longitudinal state-of-the-art, evidence-based respiratory care practices and outcomes research of individuals with established BPD.

Chairing: J.A. Wambach, MD, MS, St. Louis, MO
M.J. Kielt, MD, Columbus, OH

- 9:00 Introduction**
M.J. Kielt, MD, Columbus, OH
- 9:03 Antenatal Determinants of Bronchopulmonary Dysplasia**
S.H. Abman, MD, Aurora, CO
- 9:15 Lung Injury and Lung Developmental Programming in BPD**
E. Plosa, MD, Nashville, TN
- 9:27 Multidisciplinary BPD Care**
L.D. Nelin, MD, Columbus, OH
- 9:39 Evaluation and Management of Pulmonary Vascular Disease in BPD**
S. Bhombal, MD, Atlanta, GA
- 9:51 Advanced Imaging in Bronchopulmonary Dysplasia**
N. Higano, PhD, Cincinnati, OH
- 10:03 BPD Respiratory Trajectories in Childhood, Adolescence, and Adulthood**
S.A. Mcgrath-Morrow, MD, Philadelphia, PA
- 10:15 Panel Discussion**
J.A. Wambach, MD, MS, St. Louis, MO

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

A9 USING TECHNOLOGY TO SAVE THE BRAIN AND BODY: NOVEL INTERVENTIONS TO MANAGE PAIN, ANXIETY, DELIRIUM, AND PROMOTE MOBILITY IN ICU

Assemblies on Nursing; Critical Care

9:00 AM - 10:30 AM **Walter E. Washington Convention Center**

Room 102 A-B (Street Level)

Target Audience

Providers at all levels in critical care, as well as patients, caregivers and administrators

Objectives

At the conclusion of this session, the participant will be able to:

- describe novel non-pharmacological interventions to manage pain, anxiety, stress and delirium, and how they can be utilized to improve delirium outcomes in critically ill adults
- define strategies and pitfalls involving use of technologies to aid patient assessment in the ICU, including machine-learning technologies

- apply an understanding of the advantages and challenges of novel technologies, and how to implement these to improve outcomes in ICU delirium survivors

Delirium occurs in up to 80% of patients admitted to the Intensive Care Unit (ICU) and is a major risk factor for Post-Intensive Care Syndrome (PICS). In addition to delirium, ICU patients experience pain and anxiety secondary to procedures, invasive ventilation, forced immobilization, and inability to communicate. Our symposium presents innovative clinical care approaches leveraging technology to provide non-pharmacological interventions for management of pain, anxiety, and delirium. We will also present machine learning approaches for patient assessment, patient communication technology, music applications to manage delirium, pain and anxiety, and telehealth-based cognitive and physical training for ICU delirium survivors.

Chairing: S.H. Khan, DO, Indianapolis, IN
H.L. Lindroth, PhD, RN, Rochester, MN

- 9:00 Ready for Prime Time: Novel Technology Applications to Manage Pain, Anxiety, Sleep in ICU Patients**
L.L. Chlan, PhD, RN, ATSF, Rochester, MN
- 9:15 Revitalizing Brain Body After Critical Illness: Lessons Learned from a Remote, Video-Based Physical and Cognitive Training Program**
B.A. Khan, MD, Zionsville, IN
- 9:30 Designing and Implementing a Music Listening Intervention to Manage the Complex Needs of Patients in the ICU Environment**
A. Heiderscheit, PhD, MT-BC, LMFT, Minneapolis, MN
- 9:45 Benefits and Challenges in Implementation of a Music Intervention Application in an Academic ICU**
S.H. Khan, DO, Indianapolis, IN
- 10:00 Safer Than Skynet: Using Machine Learning to Save Patients from Delirium**
H.L. Lindroth, PhD, RN, Rochester, MN
- 10:15 We Can't Manage What We Do Not Assess: Supporting Patient Communication and Symptom Assessment in the ICU**
J. Guttormson, MS, PhD, RN, Milwaukee, WI

BEHAVIORAL • CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

A10 ASTHMA HOT TOPIC 2023: WHICH "ICS PLUS BRONCHODILATOR" RELIEVER FOR WHICH PATIENT?

Assemblies on Allergy, Immunology and Inflammation; Pediatrics

9:00 AM - 10:30 AM **Walter E Washington Convention Center**

Ballroom A (Level 3)

Target Audience

Clinicians (physicians, nurses, fellows, residents, pharmacists), researchers, administrators, regulators and policymakers, or anyone involved in delivery of care and the science of patients with asthma

Objectives

At the conclusion of this session, the participant will be able to:

- understand the evidence behind various options for asthma reliever inhalers, and their strengths and potential limitations. The audience will be able to fill their knowledge gaps about reliever inhalers for both pediatric and adult patients
- learn about the practical application of each reliever option for different populations and settings (pediatrics, adults, US, international) and gain knowledge on how to integrate the decision on the choice of reliever in asthma patient management
- improve the understanding of challenges and remaining implementation and research gaps in reliever therapy in asthma. The audience will be able to identify implementation gaps in care and begin to develop methods to address those gaps

Evidence regarding use of a reliever coupled with inhaled corticosteroids (ICS) in asthma has been mounting and there have been substantial changes in guideline-based recommendations in recent years. Currently, three reliever options are available; short-acting beta-agonist (SABA), ICS plus SABA, and ICS plus formoterol. This symposium will review the current evidence, research gaps, controversies, implementation challenges and equity around the clinical application of each reliever option in asthma in a broad range of patients and settings (mild-severe, pediatric-adults, international-US). The session will enhance understanding of how to choose and use asthma relievers in clinical practice, and identify future research needs.

Chairing: F. Holguin, MD, MPH, Aurora, CO
K. Sumino, MD, MPH, Saint Louis, MO

9:00 Introduction, Current Options for Asthma Reliever and the Guidelines

K. Sumino, MD, MPH, Saint Louis, MO

9:07 Use of ICS Plus SABA As-Needed in Asthma

J.C. Cardet, MD, MPH, Tampa, FL

9:22 Use of ICS Plus Formoterol As-Needed in Asthma

H. Reddel, MBBS, PhD, Glebe, Australia

9:39 Pediatric Perspective of Reliever Therapy in Asthma

F.D. Martinez, MD, Tucson, AZ

9:55 Challenges and Equity in US and Global Perspective Surrounding Choice of Relievers in Asthma

F. Holguin, MD, MPH, Aurora, CO

10:11 Panel Discussion/Questions: Panel 1

A. Papi, MD, Ferrara, Italy

10:15 Panel Discussion/Questions: Panel 2

E. Israel, MD, Boston, MA

10:19 Panel Discussion/Questions: Panel 3
H. Reddel, MBBS, PhD, Glebe, Australia

10:23 Panel Discussion/Questions: Panel 4
F.D. Martinez, MD, Tucson, AZ

10:27 Panel Discussion/Questions: Panel 5
F. Holguin, MD, MPH, Aurora, CO

10:29 Panel Discussion/Questions: Panel 6(Moderator)
K. Sumino, MD, MPH, Saint Louis, MO

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

A11 CARING FOR HISTORICALLY MARGINALIZED PATIENTS: ETHICAL, LEGAL AND ADVOCACY PRIMER FOR PROVIDERS

Assemblies on Critical Care; Nursing; Ethics and Conflict of Interest Committee

9:00 AM - 10:30 AM

Marriott Marquis Washington

Marquis Ballroom Salon 5 (Level M2)

Target Audience

ICU clinicians including physicians, nurses, and respiratory therapists, as well as healthcare administrators, health policy makers and patient advocates

Objectives

At the conclusion of this session, the participant will be able to:

- understand complexity around care and decision making for patients who are undocumented or crossing state lines to seek medical therapies not offered in their home state
- recognize and mitigate issues surrounding care of incarcerated patients and clinician interactions with law enforcement
- define new strategies to understand ethical issues surrounding patients' medical decision making for patients with limited health literacy or with non-traditional alternate decision making structure, or no legally authorized representative

In this symposium, we consider practical ethics involved in the care for a wide range of patients with vulnerabilities, due to lack of representation, that may be underappreciated by their providers: internally displaced people and refugees seeking asylum; individuals along the spectrum of criminalization from arrest to incarceration; patients without consistent housing; and those without legally-recognized heteronormative relationships. Additionally, we acknowledge, across all topics, of the effects of systemic racism that disproportionately disenfranchise communities of color. This session presents ethical challenges while also proposing a framework for advocacy for these patient groups from the bedside to the seats of government.

- Chairing:** E.S. Demartino, MD, Rochester, MN
K.M. Akgun, MD, MS, ATSF, West Haven, CT
S. Beesley, MD, MSc, Salt Lake City, UT
M.F. Griffith, MD, MPH, Aurora, CO
- 9:00 Intro: Practical Ethics: Caring for Underrepresented Patients in the ICU**
S. Beesley, MD, MSc, Salt Lake City, UT
- 9:05 A Patient's Perspective**
M. Henderson, Washington, D.C.
- 9:10 A Chilling Effect: Immigration Policy and Documentation Status-Related Challenges to the Delivery of Critical Care for Immigrant Populations**
M. Venkataramani, MD, MPH, Baltimore, MD
- 9:20 Serious Mental Health, Home Insecurity and Family Estrangement: Clinical Challenges in Medical Decision Making and Patients Declining Treatment**
M.F. Griffith, MD, MPH, Aurora, CO
- 9:30 Advocating for the Rights of Justice-Involved Patients**
E.S. Demartino, MD, Rochester, MN
- 9:45 Decision Making for ICU Patients Without Heteronormative Partners/Surrogates**
K.M. Akgun, MD, MS, ATSF, West Haven, CT
- 9:55 Navigating Variable Legal Access to Standard Therapies Across State Lines**
A.E. Turnbull, DVM, MPH, PhD, Baltimore, MD
- 10:10 Reducing Stigma During Home Care Transition Education Out of the ICU of Low-Literacy Parents of Children with Heart Disease**
S. Staveski, PhD, RN, CPNP-AC, OAKLAND, CA
- 10:25 Questions and Discussion**
S. Beesley, MD, MSc, Salt Lake City, UT

BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

A12 PUBLICATION TO EMPOWERMENT-TRANSITIONING SCIENCE INTO ENVIRONMENTAL JUSTICE ADVOCACY

Assemblies on Environmental, Occupational and Population Health; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Nursing; Pediatrics

9:00 AM - 10:30 AM **Walter E. Washington Convention Center**

Room 147 A-B (Street Level)

Target Audience

Providers of lung health, including basic, clinical, and translational researchers focused on disparities, environmental or occupational exposures, community engaged research or health policy

Objectives

At the conclusion of this session, the participant will be able to:

- to contrast spatial epidemiology and community participatory-based research approaches to quantifying the health impacts of environmental injustice
- to develop a framework for clinical and community-based approaches to reducing environmental injustice and improve respiratory health outcomes for individual patients and communities
- to examine the impact of policy-based initiatives to reduce environmental injustice

Environmental justice recognizes the disparities in exposure to environmental hazards borne by communities of color as a result of structural racism. These disparities have profound health impacts, from birth into adult life. Improving respiratory health for communities impacted by environmental injustice requires both high quality research, and mechanisms to move from research into action. This jointly sponsored, multi-disciplinary symposium aims to bridge this gap, highlighting both advances in research capturing the impact of environmental injustice, and the role of policy, community advocacy and clinical care in translating research into meaningful change.

Chairing: S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN
N. Thakur, MD, MPH, San Francisco, CA
A. Lee, MD, MS, New York, NY
M.G. Macmurdo, MBChB, MPH, Cleveland, OH

- 9:00 The Environmental Injustice of Childhood Asthma**
S. Lovinsky-Desir, MD, MS, New York, NY
- 9:15 Utilizing Community Based Participatory Research in Environmental Justice Research**
N. Thakur, MD, MPH, San Francisco, CA
- 9:30 Disparities in Heat Exposure: Utilizing Remote Sensing to Drive Policy Change**
T. Adeyeye, PhD, Albany, NY
- 9:45 Using Policy Interventions to Address Environmental Injustice**
G. Smith, MSPH, PhD, Baltimore, MD
- 10:00 Confronting Environmental Injustice in the Clinical Care of Asthma and COPD**
D. Belz, MD, MPH, Baltimore, MD
- 10:15 Panel Discussion on Addressing Environmental Injustice Through Inter-Professional Collaboration**
S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

A13 ASTHMA, THE NEXT FRONTIER: NEW DEVELOPMENTS IN PATHOPHYSIOLOGY AND TREATMENT

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**
Ballroom B (Level 3)

Chairing: R.D. Britt, PhD, ATSF, Columbus, OH
 F.J. Rosser, MD, MPH, Pittsburgh, PA

Oral Presentations:

- 9:00 Association of Prenatal Maternal and Infant Vitamin D Supplementation With Offspring Asthma Outcomes/L. Ramirez, Boston, MA**
- 9:12 Ontogeny of Lung Lavage Granulocyte Patterns in Children With Problematic Wheeze/Asthma Infected With Rhinovirus/W.G. Teague, Charlottesville, VA**
- 9:24 Association of Sphingolipid De-novo Synthesis With Airway Reactivity in Response to Magnesium Sulfate/A.F. Heras Barros, New York, NY**
- 9:36 Spatial Analysis of Housing Problems and Asthma Control Among Children With Asthma in an Urban Environment/P. Kaviani, Washington, DC**
- 9:48 Airway Epithelial Expression of CCL8, CXCL11, FLG2, and CXCL9 Is Associated With Violence-related Distress and Atopic Asthma in Youth/M. Yue, Pittsburgh, PA**
- 10:00 Violence Exposure and Maltreatment During Childhood and Asthma in Youth and Adults With Positive Biomarkers of T Helper 2-High Immunity/K.M. Gaietto, Pittsburgh, PA**
- 10:12 Characterization of Airway and Esophageal Inflammation in Children With Severe Uncontrolled Asthma/J. Erkman, New York, NY**
- 10:24 Effect of Early-life Household Exposure to Lipopolysaccharide on Childhood Asthma Is Modified by 17q12-q21 Genotype/S. Saxena, Nashville, TN**
- 10:36 A Randomised, Double-Blind, Parallel Group, Multicentre, Stratified Study Evaluating the Efficacy and Safety of Once-Daily Fluticasone Furoate/Vilanterol Compared With Once-Daily Fluticasone Furoate in the Treatment of Asthma in Participants Aged 5-17 Currently Uncontrolled on Inhaled Corticosteroids/P. Bareille, Stevenage, United Kingdom**
- Featured Speaker:**
- 10:48 A Breath of Fresh Air: Community Partnerships to Advance Pediatric Asthma Care/M. Trivedi, Worcester, MA**

BASIC • TRANSLATIONAL

MINI SYMPOSIUM

A14 THIS IS GETTING COMPLICATED: EPIGENETICS, -OMICS, AND CELL SIGNALING IN PULMONARY HYPERTENSION

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**
Room 152 A-B (Street Level)

Chairing: Y.C.C. Lai, PhD, Indianapolis, IN
 L. Farkas, MD, Columbus, OH
 J. Aman, MD, PhD, Amsterdam, Netherlands

Oral Presentations:

- 9:00 Pericytes Contribute to the Vascular Remodeling of Pulmonary Hypertension/T. Klouda, Boston, MA**
- 9:12 Osteoprotegerin Has Distinct Roles in Pulmonary Vascular and Cardiac Remodelling in a Mouse Model of Pulmonary Arterial Hypertension/A. Lawrie, London, United Kingdom**
- 9:24 C-Type Natriuretic Peptide Signalling Attenuates the Development of Pulmonary Hypertension and Right Ventricular Remodelling/J.P. Dignam, London, United Kingdom**
- 9:36 Multi-omic Profiling of the Pulmonary Arterial Endothelium Reveals Disturbed Cell Adhesion and Extracellular Matrix Reorganization in Chronic Thromboembolic Pulmonary Hypertension/J. Aman, Amsterdam, Netherlands**
- 9:48 Cell Type Specific Targeting of Microglial Activation in the Thoracic Spinal Cord as a Novel Therapeutic Strategy for Pulmonary Hypertension and Right Ventricular Failure/A. Razee, Los Angeles, CA**
- 10:00 Single-nucleus Transcriptome Profiling Identifies Phenotypic Shift in Capillary Endothelial Subpopulations in Pulmonary Arterial Hypertension/J. Dai, Chicago, IL**
- 10:12 Acute Pressure Overload in the Right Ventricle (RV) Changes the Tortuosity, Orientation, and Hemodynamics of the Microcirculation/I. Essafri, Aurora, CO**
- 10:24 Comprehensive Characterization of RV Function in Pulmonary Arterial Hypertension Model With Mitochondrial Dysfunction/M. Niihori, Tucson, AZ**
- 10:36 Single-cell Transcriptomics and Machine Learning Approach to Identify Novel Targets to Treat Right Ventricle Hypertrophy/A.A. Dekan, Tucson, AZ**

10:48 Breakdown of the Apical Spectrin Network Leads to Endothelial Dysfunction and Vascular Stiffening in Pulmonary Arterial Hypertension/S. Sulstarova, Toronto, Canada

BEHAVIORAL • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

A15 TAKING PULMONARY REHABILITATION TO THE NEXT LEVEL

9:00 a.m. - 11:00 a.m. Walter E. Washington Convention Center

Room 150 A-B (Street Level)

Chairing: F. Franssen, MD, PhD, Horn, Netherlands
S.J. Singh, PhD, Leicester, United Kingdom

Oral Presentations:

- 9:00 Improving Depression in COPD Patients Through Home-based Pulmonary Rehabilitation With Health Coaching/R. Benzo, Rochester, MN**
- 9:12 Pulmonary Rehabilitation With Balance Training for Fall Reduction in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial/Q. Hao, Hamilton, Canada**
- 9:24 Association Between Muscle Oxidative Capacity and Mortality in Humans With and Without COPD/A. Adami, Kingston, RI**
- 9:36 Telerehabilitation Vs. Centre-based Pulmonary Rehabilitation: An Economic Analysis/A. Burge, Melbourne, Australia**
- 9:48 High-Pressure Non-Invasive Ventilation (NIV) During Exercise Training in COPD Patients With Chronic Hypercapnic Respiratory Failure (CHRF) - Effects on Quality of Life and People's Perception. A Randomized Controlled Trial/T. Schneeberger, Schoenau am Koenigssee, Germany**
- 10:00 Screening for Clinically Relevant Thresholds of the Incremental Shuttle Walk in People With COPD Using the One-minute Sit to Stand/S. Patel, London, United Kingdom**
- 10:12 Updated Cochrane Review: Exercise-based Rehabilitation Programs for Pulmonary Hypertension/N. Morris, Gold Coast, Australia**
- 10:24 Video Telerehabilitation Versus Centre-based Pulmonary Rehabilitation: A Real-World Propensity Matched Analysis/W. Man, Harefield, United Kingdom**
- 10:36 Self-Efficacy Enhancing Intervention Increases Physical Activity in People With Chronic Obstructive Pulmonary Disease/J.L. Larson, Ann Arbor, MI**

BASIC • TRANSLATIONAL

MINI SYMPOSIUM

A16 INTERROGATING GENOMIC, TRANSCRIPTIONAL, AND EPIGENETIC MECHANISMS IN LUNG FIBROSIS

9:00 a.m. - 11:00 a.m.

Marriott Marquis Downtown

Independence Ballroom Salons A-D (Level M4)

Chairing: M. Rojas, MD, Columbus, OH
O. Eickelberg, MD, ATSF, Pittsburgh, PA
E.F. Redente, PhD, Denver, CO

Featured Speaker:

9:00 Dynamics of Fibroblast Heterogeneity in Pulmonary Fibrosis/D. Sheppard, San Francisco, CA

Oral Presentations:

- 9:12 Genome-wide Screens Identify an Intracellular Rheostat Controlling Collagen Turnover/M. Podolsky, New York, NY**
- 9:24 Profiling Chromatin Accessibility and Gene Expression From the Same Nucleus to Expose Regulators of Human Lung Cell Identity/T.E.A. Duong, San Diego, CA**
- 9:36 Using Single Nuclei Multiomics and Spatial Transcriptomics to Identify Drivers of Early Pulmonary Fibrosis/N. Banovich, Phoenix, AZ**
- 9:48 Genetically-informed Single-cell Genomic Analysis of Discordantly Affected Regions of IPF Lungs/J. Kropski, Nashville, TN**
- 10:00 Spatial Transcriptomic Analysis Allow the Identification of Abnormal Airway Niches in the Fibrotic Lung/A. Justet, New Haven, CT**
- 10:12 Multiomic Single-nucleus Sequencing Implicates RUNX Family Transcription Factors in Activated Myofibroblast Differentiation in SSc-ILD/E. Valenzi, Pittsburgh, PA**
- 10:24 Resolving Age-dependent Cellular Senescence Programs in Lung Fibrosis Using Longitudinal Single Cell Transcriptomics/M. Lehmann, Marburg, Germany**
- 10:36 Somatic Mutations of MUC5B Within Lung Tissue in Idiopathic Pulmonary Fibrosis/J.H. Yun, Boston, MA**
- 10:48 Investigating the Role of YAP/TrkB Signaling in Lung Capillary Endothelial Cell Regeneration and Fibrosis Resolution/A.A. Raslan, Boston, MA**

BASIC • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

A17 TELL ME WHAT YOU SEE: NEW STUDIES IN LUNG IMAGING

9:00 a.m. - 11:00 a.m. Walter E. Washington Convention Center

Room 204 A-C (Level 2)

Chairing: P.J. Niedbalski, PhD, Kansas City, KS
G. Parraga, PhD, London, Canada

Oral Presentations:

- 9:00 Fully Automatic Quantitative Analysis of Airway-artery Dimensions and Ratios of Normal Chest CT Scans From Infancy Into Adulthood/H.A.W.M. Tiddens, Rotterdam, Netherlands**
- 9:12 Progressive Airway Wall Thinning and Loss of Total Airway Count After Three-Years in COPD/P.V. Wyszkiwicz, London, Canada**
- 9:24 Development of a CT-based Algorithm to Link Individual Upper Airways to Downstream Parenchymal Disease: A COPDGene Study/A.J. Bell, Ann Arbor, MI**
- 9:36 Age-related Changes in Ventilation and Perfusion Ratio (V/Q') Assessed With Dual-Energy CT: The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study/E.A. Hermann, New York, NY**
- 9:48 Computational Fluid Dynamics Analysis Demonstrates Impact of Mucus Plugging on Modifying Airway Dimensions Leading to Increased Airway Resistance and Reduced Lung Deformation in Asthma/J. Choi, Kansas City, KS**
- 10:00 ^{129}Xe Gas-exchange MRI and CT Pulmonary Vascular Abnormalities in GINA 4-5 Asthma/A.M. Matheson, London, Canada**
- 10:12 Hyperpolarized ^{129}Xe MRI Visualizes Lung Function Impairment in Suspected Inflammatory Interstitial Lung Disease/E. Graumann, Kansas City, KS**
- 10:24 Validation of X-ray Velocimetry With Pneumotachograph to Assess Respiratory Physiology/A.E. Tombleson, Larchmont, NY**
- 10:36 Homothety Ratio of Airway Diameters Is Associated With Respiratory Morbidity and Mortality in Chronic Obstructive Pulmonary Disease/S. Bodduluri, Birmingham, AL**

BEHAVIORAL • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

A18 BREAKING NEWS IN OSA: NEW APPROACHES AND NEW TRIALS

9:00 a.m. - 11:00 a.m. Walter E. Washington Convention Center

Room 202 B (Level 2)

Chairing: M. Cao, DO, Stanford, CA
N.A. Shah, MD, MPH, MScI, New York, NY
S.R. Patel, MD, MS, ATSF, Pittsburgh, PA
S. Pamidi, MD, MScI, Montreal, Canada

Oral Presentations:

- 9:00 Treatment of Sleep Apnoea Early After Myocardial Infarction With Adaptive Servo-ventilation (TEAM-ASV I): A Multicentre Randomised Controlled Trial/M. Arzt, Regensburg, Germany**
- 9:12 Effects of Positive Airway Pressure on Glycemic Variability in Persons With Type 2 Diabetes and Obstructive Sleep Apnea/R.N. Aurora, New York, NY**
- 9:24 Cognition and Obstructive Sleep Apnea in Parkinson's Disease, Effect of Positive Airway Pressure Therapy (COPE-PAP Trial)/A.C. Lajoie, Québec, Canada**
- 9:36 Oral Appliance Therapy as First-line Treatment Option in Patients Diagnosed With Moderate to Severe Obstructive Sleep Apnea/M. Dieltjens, Antwerp, Belgium**
- 9:48 Optimal Dose and Efficacy of Acetazolamide as Obstructive Sleep Apnea Treatment/S. Hellemans, Wilrijk, Belgium**
- 10:00 The Oral Agent AD109 Improves Objective and Subjective Outcomes in Obstructive Sleep Apnea Patients. Results From the Mariposa Study, a Randomized, Controlled Clinical Trial/P. Schweitzer, Chesterfield, MO**
- 10:12 Sustained Therapeutic Benefits for at Least 3 Years in the THN3 Randomized, Controlled Trial of Targeted Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea/A.R. Schwartz, Philadelphia, PA**
- 10:24 Loop Gain as a Predictor of Blood Pressure Response in Patients With Obstructive Sleep Apnea: Secondary Analysis of the Heartbeat Trial/L. McGinnis, La Jolla, CA**
- 10:36 The Impact of Night-to-Night Variability in Obstructive Sleep Apnea Severity and Classification Status on the Ability of Research Trials to Detect Incident Hypertension/B. Lechat, Adelaide, Australia**

Featured Speaker:

- 10:48 Translation of Novel Approaches to OSA Care into Mainstream Clinical Practice/C.L. Chai-Coetzer, Adelaide, Australia**

CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

A19 LUNG CANCER SCREENING: WHERE THE RUBBER MEETS THE ROAD

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**
Room 202 A (Level 2)

Chairing: C.R. Sears, MD, ATSF, Indianapolis, IN
M.C. Aldrich, MPH, PhD, Nashville, TN

Oral Presentations:

- 9:00 Evaluation of Sex Differences in Lung Cancer Screening Outcomes Among Never-smokers/Y.W. Kim, Seongnam, Korea, Republic of**
- 9:12 Evaluating the Intersectionality of Race and Gender in Lung Screening Eligibility in the 2021 United States Preventive Services Task Force Lung Screening Guidelines/A. Manful, Nashville, TN**
- 9:24 What Makes Someone “Too Sick to Screen”? Factors Associated With Clinicians Deeming Patients Inappropriate for Lung Cancer Screening in the Veterans Health Administration/E.R. Nunez, Springfield, MA**
- 9:36 Recruiting and Retaining Patients for an Urban Comprehensive Lung Cancer Screening Program for Lung Nodules Coupled With Detection of Comorbid Conditions: Temple Healthy Chest Initiative (THCI)/S.E. Murphy, Philadelphia, PA**
- 9:48 Mammography and Tomography: A Tale of Two Screening Programs/J.M.C. Sweetnam, Charleston, SC**
- 10:00 Impact of Economic Hardship, Race, and Educational Attainment on Utilization of Electronic Communication Among Individuals Receiving Lung Cancer Screening/C.S. Shusted, Philadelphia, PA**
- 10:12 Quantifying the Economic Value of Reduced Health Disparities From Increased Rates of Low-Dose CT Screening for Lung Cancer/J. Shafrin, Los Angeles, CA**
- 10:24 Poor Lung Cancer Screening Outcomes Was Associated With Diabetes in a National Lung Screening Trial Subgroup (N=18,463)/R.J. Scott, Auckland, New Zealand**
- 10:36 Frequency of Radiology Non-concordance in Multi-disciplinary Review of Low-dose CTS for Lung Cancer Screening/J.A. Barta, Philadelphia, PA**
- 10:48 “What Is a Lung Nodule?” - Providers’ Answers and Analog Patients’ Preferences in the Communication of Lung Cancer Screening Results/M. Ito Fukunaga, Worcester, MA**

BASIC • TRANSLATIONAL

POSTER DISCUSSION SESSION

A21 INFECTION, LUNG INJURY, AND SEPSIS FROM MODELS TO TRANSLATION

9:00 a.m. - 11:00 a.m. **Marriott Marquis Washington**
Marquis Ballroom, Salons 1-2 (Level M2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

- Chairing:** J.A. Masso Silva, PhD, La Jolla, CA
A.N. Rizzo, MD, PhD, Boston, MA
J.A. Hippensteel, MS, MD, Aurora, CO
M. Hepokoski, MD, La Jolla, CA
- 101 Sleep Disruption Alters Cellular Immune Response to Endotoxin-mediated Sepsis/M.T.Y. Lam, La Jolla, CA**
- 102 Gasdermin-D-Dependent NETs Generation Promotes Cigarette-Smoke Induced Flu Severity/T.W. Kaminski, Pittsburgh, PA**
- 103 Cooperation of Immune Regulators Tollip and Surfactant Protein A Inhibits Influenza A Virus Infection in Mice/N. Schaanaman, Denver, CO**
- 104 The Protective Role of the Heme-scavenging Protein, Hemopexin, in Host Defense Against Invasive Pulmonary Aspergillosis/G. Qu, Gainesville, FL**
- 105 Mechanisms of Enhanced Streptococcus Pneumoniae Clearance Observed in Mertk-null Mice/M.K. Mcpeek, Chapel Hill, NC**
- 106 The Role of Peripherally-induced Regulatory T Cells in the Recovery From Influenza-induced Lung Injury/M. McCullough, Chapel Hill, NC**
- 107 A Novel Next-generation Non-catalytic P38alpha/MK2 Immunomodulator With Endothelial-Barrier-Stabilizing and Anti-inflammatory Activity Mitigates LPS-induced Acute Lung Injury (ALI)/J.D. Hasday, Baltimore, MD**
- 108 LGM1506 Protects Against Ozone-Induced Lung Injury in Rhesus Macaques/P.A. Hernandez, Davis, CA**
- 109 Novel Oxidized Phospholipid Signatures and Epithelial Cell Cytotoxicity in THC-related Vaping-associated Lung Injury/K. Lockwood, Pittsburgh, PA**
- 110 IRL201104, a Novel Immunomodulatory Peptide, Prevents Inflammatory Infiltration and Proinflammatory Cytokine Release in a New Model of ARDS Associated to Influenza Infection/J. De Alba, London, United Kingdom**
- 111 Phagocytic Role of DHX58 During the Resolution of Pneumonia-ARDS in Mice/A.F. Villabona-Rueda, Baltimore, MD**

- 112 **Piezo1 Channels Regulate Pulmonary Function, Vascular Permeability and Inflammation Following Lung Ischemia-reperfusion Injury/H.Q. Ta, Charlottesville, VA**
- 113 **Myeloid and Type II Alveolar Cell-specific Mitofusins Regulate Kidney Fibrosis-associated Lung Injury/D. Bhatia, New York, NY**
- 114 **Cupping Therapy Alleviates Acute Lung Injury Through the Adenosine/A_{2B}AR Signalling Pathway in Rats/L. Qiao, Xi'an, China**
- 115 **The Effects of the Inflammatory Injury Microenvironment on Mesenchymal Stromal Cell (MSC) Function In Vivo/L. Liu, Galway, Ireland**
- 116 **Time Course Changes in a Peripheral Blood, 50-gene Signature Are Associated With Lung Injury, Mortality, and Resolution in COVID-19/B. Tourki, Tampa, FL**
- 117 **Initiation of Extracorporeal Membrane Oxygenation (ECMO) in Patients With COVID-19 Related ARDS Does Not Increase Blood Markers of Neutrophil Extracellular Traps (NETs) or IL-8/M.F. Odish, La Jolla, CA**
- 118 **Lung Epithelium Releases GDF15 in Response to Pathogen-Mediated Injury to Modulate the Airspace Cytokine Environment/W. Bain, Pittsburgh, PA**
- 119 **Sex Differences of the Pulmonary Inflammatory Response and sRAGE Serum Levels in a Murine Model of Sustained Vitamin-e Acetate (VEA) Inhalational Exposure/M.J. Lim, Sacramento, CA**
- 120 **Deoxyribonucleic Acid Capture by Red Blood Cells Contributes to Inflammation in Sepsis/M. Lam, Philadelphia, PA**
- 121 **Disruption of Capsule Gene wcaJ in a Carbapenemase-producing Klebsiella Pneumoniae Bloodstream Clinical Isolate Enhances Complement-mediated Opsonophagocytosis/N.J. Tolman, Pittsburgh, PA**
- 122 **Elucidating Sex Differences in Host Response to Klebsiella Pneumoniae/J.E. Mccombs, New Orleans, LA**
- 123 **TRPV4 Regulates Macrophage Metabolism in Sepsis-Induced Lung Injury/E.M. Orsini, Cleveland, OH**
- 124 **Adoptive Transfer of Murine Engineered T Regulatory Cells Ameliorates Disease in a Model of Lipopolysaccharide Induced Acute Lung Injury/M. Hoover, Cambridge, MA**

BEHAVIORAL • CLINICAL

RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

A22 UNDERSTANDING THE IMPACT OF HEALTH DISPARITIES ON LUNG HEALTH9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**

Room 144 A-C (Street Level)

Viewing 9:00-9:45

Summaries/Discussion 9:45-11:00

Chairing: M. Eakin, PhD, Baltimore, MD
M. George, PhD, RN, New York, NY
M. Sharp, MD, MHS, Baltimore, MD

- 301 **Race/ethnic, Ancestral, Social, and Environmental Correlates of Lung Function Decline: The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study/A. Elmaleh-Sachs, New York, NY**
- 302 **Regional and Ethnic Disparities in Lung Cancer Screening for United States Adults, 2017 to 2020/M. Tsai, Boston, MA**
- 303 **Understanding the Social Risk Factors That Avert Equitable Lung Cancer Care/C. Green, Chicago, IL**
- 304 **Understanding Differences in Geographic Access to Care Among Patients Treated for Pulmonary Arterial Hypertension in the United States/N. Anderson, Durham, NC**
- 305 **Disparities in COVID-19 Vaccine Coverage in High-risk Adult Population/J.R. Felzer, Rochester, MN**
- 306 **A Qualitative Study on COVID-19 Vaccine Intentions Among Latinx Individuals in Northern California/E. Casillas, San Francisco, CA**
- 307 **COVID-19 Pandemic-associated Socioeconomic Vulnerability and Challenges to Isolation Across the United States/M. Ye, San Francisco, CA**
- 308 **Associations Between Food Insecurity and Assistance With Asthma and Symptomology Burden Among Children in a Safety-net Practice/M. Ye, San Francisco, CA**
- 309 **Insurance and Income Disparity in Diabetic Ketoacidosis (DKA) Readmission in Adults With Type 1 Diabetes/K.U. Lio, Philadelphia, PA**
- 310 **An Evaluation of Demographic Factors Affecting Sepsis Care Delivery/G.L. Day, Aurora, CO**
- 311 **Disparities Among Hispanic Adults With Respiratory Failure: A Systematic Review/J.A. Blank, Ann Arbor, MI**
- 312 **Telehealth Visit Preferences Among Black and Latinx Patients With Moderate-severe Asthma/I.C. Ugalde, Tampa, FL**

- 313 **Black Individuals With Sarcoidosis Have Significant Delays in Referral/O.A. Akhiwu, Baltimore, MD**
- 314 **Sleep Disparities Among Sexual Minority Early Adolescents: The Mediating Role of Sexual Identity-based Discrimination/J.-M. Bruzzese, New York, NY**

CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

A23 LEVERAGING IMAGING AND BIOSAMPLES TO IMPROVE DIAGNOSIS AND RISK PREDICTION IN ILA AND ILD

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**

Room 209 A-C (Level 2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: P.L. Molyneaux, MD, FRCP, PhD, London, United Kingdom
G.H.J. Kim, PhD, MS, Los Angeles, CA
M.L. Salisbury, MD, MS, Nashville, TN

- 801 **Plasma Metabolomics and Quantitative Interstitial Abnormalities in Ever-smokers/B. Choi, Boston, MA**
- 802 **Exploring the Causal Effects of Circulating Galectin-3 and sRAGE on Interstitial Lung Abnormalities Risk: A Mendelian Randomization Study/R. Sangani, Boston, MA**
- 803 **Proteins Associated With Interstitial Lung Abnormalities in Relatives of Patients With Pulmonary Fibrosis/J.A. Rose, Boston, MA**
- 804 **Antinuclear Antibodies and Progression of High Attenuation Areas on Chest Computed Tomography: The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study/K.F. Flack, Philadelphia, PA**
- 805 **Airway Tree Caliber and Subclinical Interstitial Lung Disease in Community-dwelling Adults: The Multi-ethnic Study of Atherosclerosis (MESA)/K. Berger, New York, NY**
- 806 **New Quantitative Metric for Identifying Fibrosis Predicts Lung Cancer Outcomes in the National Lung Screening Trial/J.M. Wang, Ann Arbor, MI**
- 807 **Endobronchial Optical Coherence Tomography to Assess Small Airway Involvement in Early IPF/S.R. Berigei, Boston, MA**
- 808 **Machine Learning of Plasma Proteomics for Differential Diagnosis of Interstitial Lung Disease/Y. Huang, Charlottesville, VA**
- 809 **Circulating Biomarkers in Patients With Progressive Pulmonary Fibrosis: Data From the INBUILD Trial/I. Noth, Charlottesville, VA**
- 810 **A Machine Learning-based Radiomics Model for Differentiating Idiopathic Pulmonary Fibrosis and Chronic Hypersensitivity Pneumonitis Thorough Pyradiomics/Y. Onodera, Yokohama, Japan**
- 811 **Lung Graph-based Machine Learning for Identification of Fibrotic Interstitial Lung Diseases/H. Sun, Beijing, China**
- 812 **Development and Validation of a CT-based Deep Learning Algorithm to Augment Non-invasive Diagnosis of Idiopathic Pulmonary Fibrosis/M. Maddali, Stanford, CA**
- 813 **Deep Learning and Artificial Intelligence Based Optical Coherence Tomography for Quantifying Microscopic Disease Burden in Interstitial Lung Disease/S. Nandy, Boston, MA**
- 814 **AI Techniques to Differentiate Between Sub-Groups of Diffuse Cystic Lung Diseases Using Phenotypic Characteristics/R.T. Hearne, Belfield, Ireland**
- 815 **Mapping of Collagen Organization in Pulmonary Fibrosis In Vivo Using Optic Axis-resolved Polarization Sensitive Optical Coherence Tomography/J. Lee, Boston, MA**
- 816 **Computed Tomography Pulmonary Fat Attenuation Volume (ctP_{fat}) as a Novel Biomarker of Idiopathic Pulmonary Fibrosis/M. O'Callaghan, Dublin, Ireland**
- 817 **The Automated E-ILD CT Algorithm Is More Prognostic Than FVC in the Serial Assessment of Patients With Non-IPF Fibrotic Interstitial Lung Disease/P.M. George, London, United Kingdom**
- 818 **Imaging Signature Idiopathic Pulmonary Fibrosis (IS-IPF): An Analytic Validation Study of Two CT Image-based Biomarkers in an Independent Cohort for Predicting Disease Progression in Idiopathic Pulmonary Fibrosis/G.H.J. Kim, Los Angeles, CA**
- 819 **Associations Between Semi-quantitative HRCT Features and Outcomes in Patients With IPF: Data From the IINPULSIS Trials/J. Jacob, London, United Kingdom**
- 820 **IgM Rheumatoid Factor Is Associated With ILD-related Hospitalization and Death in the Multi-ethnic Study of Atherosclerosis (MESA)/S. Levsky, New York, NY**
- 821 **Association of Circulating Complement Pathway Gene Expression With Progression of Idiopathic Pulmonary Fibrosis/A.C. Swaminathan, Durham, NC**
- 822 **Changes in Complement Pathway Gene Expression in the Lung Tissue of Patients With Pulmonary Fibrosis With and Without an Acute Exacerbation/A.C. Swaminathan, Durham, NC**
- 823 **Dynamic Changes in Hyperpolarized ¹²⁹Xe MRI Measures After Initiation of Therapy in Patients With Idiopathic Pulmonary Fibrosis Associate With Lung Function/A.C. Swaminathan, Durham, NC**

824 **A Proteomic Signature to Predict Rapidly Progressive Idiopathic Pulmonary Fibrosis**/J. Oldham, Ann Arbor, MI

825 **Effects of Nintedanib on Circulating Biomarkers in Patients With Progressive Pulmonary Fibrosis: Subgroup Analyses of the INBUILD Trial**/T.M. Maher, Los Angeles, CA

CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

A24 COPD PHENOTYPES: LOOKING OUTSIDE THE LUNG

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**

Room 151 A (Street Level)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: L. Vanfleteren, MD, PhD, Gothenburg, Sweden
D. Chandra, MD, Pittsburgh, PA
A. Balasubramanian, MD, MHS, Baltimore, MD

401 **Use of the Wnt/ β -catenin Activator Lithium Is Associated With Less Emphysema in Smokers**/K.O. Albright, Pittsburgh, PA

402 **Genetic Risk for Body Mass and Mortality in COPD**/J. Zhang, Boston, MA

403 **Interaction of Diabetes and Lung Diffusing Capacity With Survival in a Tobacco Exposed Cohort**/J.C. Hulbert, Pittsburgh, PA

404 **Elevated Adiponectin Levels Associate With Hip Bone Mineral Density Loss in Current and Former Smokers**/V. Babu, Pittsburgh, PA

405 **Intermuscular Adipose Tissue Mass Is Associated With Muscle Weakness in Smokers With COPD**/R.H. Zou, Pittsburgh, PA

406 **The Association Between Metformin Use and Respiratory-related Outcomes After Overlap Weighting**/Y. Li, Aurora, CO

407 **Associations of Low Skeletal Muscle Quantity With Coronary Artery Calcification and Low Bone Mineral Density on Computed Tomography in Normal Weight Patients With COPD**/S. Terada, Kyoto, Japan

408 **Frailty Is a Risk Factor for Chronic Obstructive Pulmonary Disease Hospitalization**/A.C.G. Ferreira, Goiânia, Brazil

409 **Telomere Length and Telomerase Activity Are Associated With COPD and Lung Function**

Abnormalities in Persons Living With HIV/S.
Chang-Huang, San Francisco, CA

410 **Clinical Risk Factors for Unintentional Weight Loss in Participants With COPD Are Present Five Years Before Its Onset**/J.W. Chiles, Birmingham, AL

411 **Compound Sarcopenia in Hospitalized COPD Patients Worsens Outcomes in Relation to Age**/A. Attaway, Cleveland, OH

412 **Classifying Physical Conditioning Using Remote Monitoring in Chronic Obstructive Pulmonary Disease**/A. Balasubramanian, Baltimore, MD

413 **Sleep Disordered Breathing Is Associated With Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD)**/C. Buri-Nagua, Baltimore, MD

414 **Anemia Trajectories Are Associated With Risk for Adverse Outcomes in COPD**/Y. Kunitomo, Baltimore, MD

415 **Outcomes of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Patients With Lung Cancer: A Nationwide Inpatient Analysis**/V. Deenadayalan, Chicago, IL

416 **The Burden of Atrial Fibrillation, Supraventricular and Ventricular Arrhythmias in COPD Exacerbation Hospitalizations**/A. Aboelnasr, Cincinnati, OH

417 **Cardiovascular Complications According to Inhaler Therapy in Chronic Obstructive Pulmonary Disease**/J.H. Park, Suwon, Korea, Republic of

418 **COPD Phenotypes: Out-of-Proportion Pulmonary Hypertension in Emphysema Vs. Non-emphysema COPD**/J.D. Rivera Robles, Weston, FL

419 **Right Ventricle Diastolic Diameter Can Be Used as a Predictor of Adverse Outcomes in COPD Patients**/F.P.G. Rizzatti, Sao Paulo, Brazil

420 **Individuals With the PI**MZ* and PI**MS* Genotypes Have Similar Prevalence of Liver and Lung Disease in an EHR-based Cohort Study**/V. Tejwani, Cleveland, OH

421 **Stability and Predictive Value of Persistent Airflow Limitation in Patients With Physician-diagnosed COPD and/or Asthma in the NOVELTY Study**/R.A. Del Olmo Sansone, Buenos Aires, Argentina

422 **Association Between Oral Health and Airflow Limitation: Analysis Using a Nationwide Survey in Korea**/S.-H. Kim, Cheongju-si, Korea, Republic of

423 **Chronic Bronchitis Is Associated With Pulmonary Artery Enlargement in Smokers With and Without COPD: An Analysis of the COPD Gene Study**/F.A. Laghi, Philadelphia, PA

424 **Clinical Significance of Chronic Bronchitis in Different Racial Groups**/J.Y. Choi, Incheon, Korea, Republic of

425 **Whole Genome Sequencing Analysis of Mucus Plugging in Chronic Obstructive Pulmonary Disease (COPD)/K. Kim, Boston, MA**

BEHAVIORAL • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

A25 'OMICS AND THE EXPOSOME: HIGH DIMENSIONAL METHODS IN ENVIRONMENTAL LUNG HEALTH RESEARCH

9:00 a.m. - 11:00 a.m. **Marriott Marquis Washington**

Marquis Ballroom, Salons 3-4 (Level M2)

Poster Viewing **9:00-9:45**

Discussion **9:45-11:00**

Chairing: P. Silveyra, PhD, MSc, ATSF, Bloomington, IN
S.-Y. Liao, MD, MPH, ScD, Denver, CO
D.C. Christiani, MD, MPH, MS, ATSF, Boston, MA

901 **Whole Genome Sequencing Based Metagenome Profiles in House Dust and Pulmonary Function/M. Lee, Durham, NC**

902 **Polymorphisms in Oxidative Stress-related Genes Modify Environmental Effects on Asthma Exacerbations/S. Xue, Pittsburgh, PA**

903 **A Genome Wide Association Study for Lung Function Decline in the Korean General Population/E. Bae, Seoul, Korea, Republic of**

904 **A Shared Genetic Locus Is Associated With Airway Inflammatory Response to Acute Ozone Exposure in Mice and Humans/S.N. Kelada, Chapel Hill, NC**

905 **Longitudinal DNA Methylation Analysis Reveals Pathways Influencing Lung Function/Y. Huang, Boston, MA**

906 **Exploring Epigenetic Differences in Asthma Patients Living in Western Pennsylvania: What It May Tell Us About the Consequences of Air Pollution and Socioeconomic Stress/T.V. Macedonia, Pittsburgh, PA**

907 **DNA Methylation Predicting Lung Function Trajectories Across Life Course in Multi-ethnic Childhood Cohorts/P. Kachroo, Boston, MA**

908 **Gene Expression Changes in Lung Induced by Subacute Inhalation of PM₁₀-rich Particulate Matter in Mice/S.-W. Park, Bucheon, Korea, Republic of**

909 **Similarities and Differences in the Effects of Waterpipe Smoking and Cigarette Smoking on the Small Airway Epithelium Transcriptome/Y. Strulovici-Barel, New York, NY**

910 **Sex Differences in Gene Expression in the Lung in Mice Exposed Daily to Electronic Cigarette Aerosols/J. Mcdermott, San Diego, CA**

911 **Association of Clinical Characteristics and miRNA Expression in Sarcoidosis/N. Lin, Denver, CO**

912 **Protein Biomarkers of Cigarette Smoking/M. Aggarwal, Framingham, MA**

913 **Comparison of Multiplexed Proteomics Platforms for the Detection of Biomarkers in the Nasal Epithelial Lining Fluid of Healthy Subjects/H.L. Zetlen, Boston, MA**

914 **Flavor-specific Effects on Inflammatory Pathways of the Lungs of Mice Exposed to Pod-based E-cigarettes/J.A. Masso Silva, La Jolla, CA**

915 **Inflammatory Mediators and sRAGE and Association With Nutritional Adherence: Firehouse RCT/J. Kim, New York, NY**

916 **TSLP Contributes to Ozone Induced Augmentation for Pulmonary Responses to House Dust Mite in Mice/Y. Kurihara, Saga, Japan**

917 **Prenatal Exposure to Environmental Particles Impairs the Network of Specialized Pro-resolving Mediators of Inflammation and Delays Resolution of Asthmatic Airway Inflammation Restored by Synthetic Resolvin E2 or Lipoxin A4/A.V. Fedulov, Providence, RI**

918 **Soluble Epoxide Hydrolase Inhibitors and ACE Inhibitors Ameliorate Phosgene Inhalation Injuries/S. Achanta, Durham, NC**

919 **Early-life Heavy Metal Exposure Causes Metabolic and Functional Defect in Airway Development/X. Hu, Atlanta, GA**

920 **Alcohol, Cannabis and Combined Metabolites Differentially Affect Peripheral Blood Mononuclear Cell Gene Expression in a Dose-dependent Manner/E.L. Burnham, Aurora, CO**

921 **Exposome Related Breath Volatile Organic Compounds (VOCs) in Children of the All Age Asthma Cohort (ALLIANCE)/J.M. Hohlfeld, Hannover, Germany**

922 **Investigating Induced Acute Lung Inflammation Using Breath Biopsies/A. Smolinska, Cambridge, United Kingdom**

923 **Novel Approach to Detect Effects of Complex Inhalational Exposure on Lung Function: Analysis of Civilians Exposed to the World Trade Center Environmental Disaster/Y. Wang, New York, NY**

924 **Sputum Macrophage Carbon Load as a Biomarker for Episodic Exposure to Ambient Combustion Particles in a Mountain West Area in the United States/S. Leng, Albuquerque, NM**

925 **Genome Filtering Based on Wood Smoke-Responsive Enhancer RNA Transcription Identifies Novel Functional Genetic Variants Associated With Asthma Risk/A. Gupta, Denver, CO**

BASIC • CLINICAL • TRANSLATIONAL

RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

A26 PRECISION-BASED APPROACHES TO PULMONARY VASCULAR DISEASE

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**

Room 103 A-B (Street Level)

Viewing 9:00-9:45

Summaries/Discussion 9:45-11:00

Chairing: B. Maron, MD, Boston, MA
S. Provencher, MD, Quebec City, Canada
A. Hemnes, MD, ATSF, Nashville, TN

- 201 **The Role of Long-Term Daily Activity Monitoring for the Assessment of Functional Capacity in Pulmonary Arterial Hypertension/A. Hughes, Nashville, TN**
- 202 **Heterogeneity of Treatment Effects by Predicted Risk in Pulmonary Arterial Hypertension: An Individual Participant Data Meta-analysis/H.-M. Pan, Philadelphia, PA**
- 203 **Epicardial Adipose Tissue Is Associated With Worse Survival in Pulmonary Arterial Hypertension/B.E. Mccarthy, Philadelphia, PA**
- 204 **Sex Differences in the Baseline Phenotype of Chronic Thromboembolic Pulmonary Hypertension Patients in the United States CTEPH Registry/M.M. Cirulis, Salt Lake City, UT**
- 205 **Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)/E. Bajwa, Rahway, NJ**
- 206 **Prognostic Implications of New Definitions of Pulmonary Hypertension at 5,280 Feet/A. Longino, Aurora, CO**
- 207 **AI-based Clot Burden Detection and Assessment for CTEPH Severity/P. Nardelli, Boston, MA**
- 208 **Medication Non-adherence and Health-related Outcomes in Patients With Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR)/E.W. Robbins, Providence, RI**
- 209 **Administration of KER-012, a Modified Activin Receptor IIB Ligand Trap, Led to Changes in Biomarkers of Cardiovascular Health in a Ph1 Study Conducted in Healthy Post-Menopausal Women/H. Natarajan, Lexington, MA**

210 **Topology-based Machine Learning Identifies New High-risk Phenotype of Pulmonary Arterial Hypertension Defined by Echocardiographic Parameters/A. Alexander, Bryan, TX**

211 **Comparative Effective Analysis of Treatment for Pulmonary Arterial Hypertension: An Individual Participant Data Network Meta-analysis/J. Moutchia, Philadelphia, PA**

212 **Stressed Blood Volume Changes in a Cohort of Patients With Preload Insufficiency/S. Fakhri, Pittsburgh, PA**

213 **Clinical Characteristics of Pulmonary Embolism Identified by Electrical Impedance Tomography in Patients With Suspected Chronic Thromboembolic Pulmonary Hypertension/X. Wu, Shanghai, China**

214 **Metabolomic Assessment of Preload Insufficiency Compared to Preload Insufficiency Controls During Rest and Peak Exercise/M.G. Risbano, Pittsburgh, PA**

BASIC • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

A27 WHITE PLAGUE (TUBERCULOSIS) RESEARCH

9:00 a.m. - 11:00 a.m. **Marriott Marquis Washington**

Marquis Ballroom, Salons 9-10 (Level M2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: M. Farhat, MD, Boston, MA
M. Campo Patino, MD, Minneapolis, MN
P. Escalante, MD, MSc, Rochester, MN

- 1001 **The Long-term Impact of Early-life Tuberculosis Disease on Child Health: A Prospective Birth Cohort Study/L. Martinez, Boston, MA**
- 1002 **Admissions Due to Childhood Tuberculosis at Two Referral Hospitals in Uganda/G.L. Becker, Iowa City, IA**
- 1003 **Use of a Digital Adherence Technology for TB Treatment Supervision in Adolescents/A. Schraufnagel, San Francisco, CA**
- 1004 **The Impact Study: A Cluster-randomised Clinical and Health Economic Feasibility Study of a Theory-based Manualised Intervention to Support People With Tuberculosis Disease During Treatment/M.C.I. Lipman, London, United Kingdom**
- 1005 **Impact of COVID-19 Pandemic on the Public-private Mix Tuberculosis Control Project in Korea: Analysis of the Monitoring Indicators Before and During COVID-19 Pandemic/J.S. Park, Cheonan, Korea, Republic of**

- 1006 **Impact of COVID-19 on Multi-drug Resistant Tuberculosis (MDR-TB) Registrations and Outcomes in Pakistan: The Challenging Journey Continues/M.D. Imran, Peshawar, Pakistan**
- 1007 **Unmasking Pulmonary Tuberculosis in Patients Undergoing Chest Radiography During COVID 19 Pandemic in a Tertiary Care Center in India/D. Shastri, Johnson City, TN**
- 1008 **Factors Associated With Delays at Tuberculosis Treatment Centres in South-West Nigeria: A Cross-sectional Study/O. Olayanju, Cape Town, South Africa**
- 1009 **Approaches to Addressing Positive Tuberculosis Screening in Patients Receiving Biologic Medications: An Upstate New York Cohort Analysis/M. Connolly, Rochester, NY**
- 1010 **Epidemiology and Risk Factors Associated With Osteoarticular Tuberculosis/A. Ashkin, Naples, FL**
- 1011 **Extrapulmonary Tuberculosis in Florida From 2012-2021/A. Ashkin, Naples, FL**
- 1012 **Pseudotumour Presentation of Pulmonary Tuberculosis/Z. Laklaai, Casablanca, Morocco**
- 1013 **Retrospective Review of Management of Smear-negative Pulmonary Mycobacterium Tuberculosis/M. Oudah, Washington, DC**
- 1014 **Mucous Gland Abnormalities in Latent and Active Tuberculosis: A Histological Demonstration/A.M. Hutton, Birmingham, AL**
- 1015 **An Exhaled microRNA Panel Interrogated for Sarcoidosis and Mediastinal Tuberculosis: A Pilot Study in a TB-endemic Setting/B.R. Pattnaik, New Delhi, India**
- 1016 **The Error Rate of Phenotypic Drug Susceptibility Tests According to Specimens in Patients With Tuberculosis/Y. NA, Gwangju, Korea, Republic of**
- 1017 **Baseline and Treatment Emergent Bedaquiline Resistance in Drug-resistant Tuberculosis: A Systematic Review and Meta-analysis/R. Perumal, Durban, South Africa**
- 1018 **Treatment Outcomes of Multidrug-resistant Tuberculosis With Selective Use of New Drugs Guided by an Expert Committee/Y.S. Kwon, Gwangju, Korea, Republic of**
- 1019 **Small Airway Involvement After Tuberculosis Treatment: Findings From a Post-tuberculosis Cohort Study in Georgia/W. Du, Atlanta, GA**
- 1020 **Increased Lung Cancer Risk in Tuberculosis Survivors and Its Associated Risk Factors: A Korean Population-based Study/H. Choi, Seoul, Korea, Republic of**
- 1021 **Lung Function Abnormalities Are Common After Microbiologic Cure of Drug Sensitive Tuberculosis in Southwest Uganda/E. Nuwagira, Mbarara, Uganda**

- 1022 **HIV and Tuberculosis Are Associated With Lower Diffusing Capacity for Carbon Monoxide in Ugandan Adults/K.L. Byanova, San Francisco, CA**
- 1023 **Prior Tuberculosis and Female Sex Are Major Risk Factors for Chronic Hypoxemia in Kenyan Adults/N. Navuluri, Durham, NC**
- 1024 **A Systematic Review of National Institutes of Health Funding for Tuberculosis Comorbidities/M. Carwile, Boston, MA**
- 1025 **Xpert MTB/RIF Test as the Initial Diagnostic Test in the Diagnosis of Pulmonary Tuberculosis: A Pragmatic Trial/Y.-W. Huang, Changhua, Taiwan**

BASIC • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

A28 WHAT IS TRENDY IN THE PNEUMONIA WORLD?

9:00 a.m. - 11:00 a.m. Walter E. Washington Convention Center

Room 201 (Level 2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: B.E. Jones, MD, MSc, Salt Lake City, UT
F. Sanz, MD, Valencia Spain

- 601 **The Impact of Pseudomonas Aeruginosa Isolation on Exacerbations, Hospitalizations and All-cause Mortality in Chronic Obstructive Pulmonary Disease (COPD) Patients: A Case-control Study/E. Faniadou, London, United Kingdom**
- 602 **Diagnosis and Treatment of Patients With Suspected Pneumonia in 28 Utah Urgent Care Clinics/N.C. Dean, Murray, UT**
- 603 **Association Between Bacteria Isolated From Admission Bronchoalveolar Lavage and Hospital Mortality in Inhalation Injury/T.D. Coston, Seattle, WA**
- 604 **Inhalation Injury Grade and Risk of Ventilator-associated Pneumonia/T.D. Coston, Seattle, WA**
- 605 **Integrative Microbial Cell-free DNA Sequencing and Host-response Profiling in the Lower Respiratory Tract and Systemic Circulation of Patients With Severe Pneumonia/M.K. Hensley, Pittsburgh, PA**
- 606 **Comparing the Accuracy of Mini-BAL to Bronchoscopic BAL in the Diagnosis of Pneumonia Among Ventilated Patients: A Systematic Literature Review/J. Tepper, Indianapolis, IN**

- 607 **RIG-I Is a Cytosolic Receptor of CPG Oligodeoxynucleotides That Can Be Manipulated to Protect Against Pneumonia**/Y. Wang, Houston, TX
- 608 **Prediction of Ventilator Associated Pneumonia Using a Novel Artificial Intelligence Based Decision Support System**/S.K. Raut, New Delhi, India
- 609 **Pseudomonas Aeruginosa Utilizes a Nitric Oxide Metabolic Pathway to Evade Killing by Neutrophils in the Lung**/Y. Nakatsuka, Ann Arbor, MI
- 610 **Exoenzyme Y - Generated Uridine - 3', 5'- Cyclic Monophosphate Contributes to Pulmonary Edema During Pseudomonas Aeruginosa Infection**/A. Dewever, Mobile, AL
- 611 **Single Sequential Bacteriophage Therapy Decreases Pseudomonas Virulence More Than a Cocktail Approach**/G.L. Stanley, New Haven, CT
- 612 **Chronic Alcohol Consumption and Infection With Klebsiella Pneumoniae Additively Induce Mitochondrial Derangements in Alveolar Macrophages**/S.M. Yeligar, Decatur, GA
- 613 **Lipid A Modification of Colistin-Resistant Klebsiella Pneumoniae Does Not Alter the Host Inflammatory Response**/G.L. Bhushan, Hershey, PA
- 614 **Outcome of Infection of the Lung by Highly Pathogenic Klebsiella Pneumoniae**/A. Patel, Pittsburgh, PA
- 615 **Chronic Secondhand Cigarette Smoke Exposure Enhances Susceptibility to Carbapenem-resistant Klebsiella Pneumoniae Infection in a Mouse Model**/T. Rangasamy, Baton Rouge, LA
- 616 **Pneumonia-induced Shedding of Epithelial Glycosaminoglycans Inhibit Antimicrobial Peptide Bactericidal Activity**/E. Zehr, Aurora, CO
- 617 **Impact of Dual Electronic and Conventional Cigarette Smoke on MRSA Growth**/L. Sullivan, San Diego, CA
- 618 **Investigation Into Role of Diagnostic Bronchoscopy in Management of Suspected Lung Abscess: A Retrospective Cohort Analysis**/A. Mittal, Danville, PA
- 619 **Accuracy of the Recording of Pneumonia Events in UK Electronic Healthcare Record Data in Patients With Chronic Obstructive Pulmonary Disease**/A. Adamson, London, United Kingdom
- 620 **Determinants of Health and Outcomes in Necrotizing Lung Infections**/F. Zeba, Lebanon, NH
- 621 **Diagnostic Stewardship Initiative Focusing on Appropriate Urine Legionella Pneumophila Antigen Testing in Patients With Community Acquired Pneumonia**/R.D. Isern, Omaha, NE

- 622 **Clinical Outcomes of Patients Receiving Corticosteroids Prior to Hospitalization for Community-acquired Pneumonia**/P. Shelley, Louisville, KY
- 623 **Potential Role of 20-valent Pneumococcal Conjugate Vaccine in Preventing Septic Shock in Patients Older Than 65 With Bacteremic Pneumococcal Pneumonia**/F. Sanz, Valencia, Spain
- 624 **Pre-exposure to Lipopolysaccharide Protects Mice From Lethal Infection by Pseudomonas Aeruginosa**/S. Das, Pittsburgh, PA
- 625 **Early Video Assisted Thoracoscopic Surgery (VATS) or Intrapleural Enzyme Therapy (IET) in Pleural Infection - A Feasibility Randomised Controlled Trial**/E. Bedawi, Oxford, United Kingdom

BASIC • TRANSLATIONAL

POSTER DISCUSSION SESSION

A29 EPITHELIUM: FIRST LINE OF DEFENSE

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**

Room 151 B (Street Level)

- Poster Viewing** 9:00-9:45
- Discussion** 9:45-11:00
- Chairing:** H.S. Kulkarni, MD, MSc, ATSF, Saint Louis, MO
P. Chen, MD, Los Angeles, CA
C.M. Shaver, MD, PhD, Nashville, TN
- 501 **The Mitochondrial Calcium Uniporter of Pulmonary Type 2 Cells Determines Severity of Acute Lung Injury**/M.N. Islam, New York, NY
- 502 **Micro-bronchoscopy for Targeted Airway Injury and Cell Delivery in a Mouse Model of Airway Regeneration**/A. Kohn, Boston, MA
- 503 **Long COVID Patients Show Abnormalities and Activated -inflammatory States of Airway Cells**/N. Baalbaki, Amsterdam, Netherlands
- 504 **Mechanisms of Cysteine-Mediated Polymerization and Secretion of MUC5AC and MUC5B**/A.M. Jaramillo, Aurora, CO
- 505 **Luminal ATP Stimulates Submucosal Gland Mucus Secretion Through the P2X4 Receptors**/W. Yu, Iowa City, IA
- 506 **A Genotype-faithful In Vitro Airway Epithelial Tissue Culture Platform Generated From Directed Differentiation of Induced Pluripotent Stem Cells for the Study of Asthma Susceptibility Genes**/S.D. Rollins, Boston, MA
- 507 **Impact of Aging on Alveolar Type II Cell Energetics Before and After Influenza A Virus Infection**/I.C. Davis, Columbus, OH

- 508 **IFN- γ Mediates Inhibition of Oxidative Phosphorylation in Alveolar Type II Cells After Influenza A Virus Infection**/I.C. Davis, Columbus, OH
- 509 **Imaging RSV Infection in Differentiated Primary HAE Cells With High Spatial and Temporal Resolution**/M. Mitrovich, St. Louis, MO
- 510 **Notch Drives Alveolar Barrier Repair After Staphylococcal Lung Injury**/S. Moore, New York, NY
- 511 **Highly Upregulated Lymphotoxin Beta Receptor (L β R) May Be Involved in the Repair Process Following Influenza- and SARS-CoV-2-Induced Lung Injury**/C. Malainou, Giessen, Germany
- 512 **Efficient Gene-editing of iPSC-derived Airway Basal Cells to Study Primary Ciliary Dyskinesia**/A.C. Bercal, Boston, MA
- 513 **Rev-erb α Synthetic Ligand Attenuates House Dust Mite-induced Epithelial Barrier Dysfunction in Human Bronchial Epithelial Cells**/S.K. Duraisamy, Kansas City, KS
- 514 **Epidermal Growth Factor Receptor Regulates Beclin-1 in Hyperoxia-Induced Lung Injury**/Z.M. Harris, New Haven, CT
- 515 **Influenza Reduces Ubiquitin E3 Ligase March10 to Inhibit Ciliary Function**/M.J. Tsai, Columbus, OH
- 516 **The Role of ER-phagy Pathway in Influenza Virus Infection**/D. Souza De Lima, Burlington, VT
- 517 **Amino Acid Metabolism Is Associated With Balance of mTOR and Autophagy Signaling in Airway Mucous Metaplasia**/J.D. Dickinson, Omaha, NE
- 518 **Platelets and Bronchial Epithelial Cell Crosstalk in Severe Asthma**/D. Gras, Marseille, France
- 519 **Spatio-Temporal Kinase Signaling Dynamics Reveal a Novel Phenomenon in Human Airway Epithelial Cell Biology: Cytokine-Mediated ERK Waves**/N. Decuzzi, Davis, CA
- 520 **Pneumolysin Induces Lung Epithelial Cells to Release Mitochondria-loaded Extracellular Vesicles That Cause Endothelial Barrier Disruption**/E. Letsiou, Chicago, IL
- 521 **The Novel E3-ligase F-box Only Protein 24 (fbxo24) Is Induced By Bacterial Infection And Suppresses Mitochondrial Function In Epithelial Cells**/B. Johnson, Columbus, OH
- 522 **Differential Responses to Alveolar Epithelial Type 2 Cellular Stress Distinguish COVID-19 Fibrosis and Idiopathic Pulmonary Fibrosis**/R.E. Cardenas Castillo, Houston, TX
- 523 **Maternal Asthma and C-Section Birth Associate With Nasal Microbiota and Methylation Signatures That Associate With Childhood Asthma**/K. Magnaye, San Francisco, CA

- 524 **A Redox Proteome Screen in Lungs From Patients With Idiopathic Pulmonary Fibrosis Identifies Cathepsin B as a Target for Glutathione-Dependent Protein Oxidation That Is Associated With Dysregulated Airway Epithelial Cell Proteostasis**/E. Corteselli, Burlington, VT
- 525 **Immunoglobulin Superfamily Member 3 Inhibits Epithelial Cell Proliferation and May Delay Lung Repair Following SARS-CoV-2 Infection**/N.W. Egersdorf, Denver, CO

CLINICAL

POSTER DISCUSSION SESSION

A30 ALL THINGS INTERVENTIONAL PULMONARY A LIVELY POSTER DISCUSSION

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**

Room 206 (Level 2)

- Poster Viewing** 9:00-9:45
- Discussion** 9:45-11:00
- Chairing:** D. Dibardino, MD, Philadelphia, PA
A.V. Gonzalez, MD, MSc, Montreal, Canada
- 701 **Performing Thoracoscopy With Flexible Bronchoscope. From Resource Limitation to Resource Optimization**/D.R. Mishra, Dharan, Nepal
- 702 **Brazilian Analysis of Lent Score: Predicting the Survival Rate of Malignant Pleural Effusion**/P.F.B. Colares, Sao Paulo, Brazil
- 703 **Indwelling Pleural Catheter Outcomes During the COVID-19 Pandemic**/A. Demaio, New York, NY
- 704 **Utilization of BioSentry Tract Sealant System Reduces the Rate of Post-biopsy Pneumothoraces**/F.A. Mithani, Houston, TX
- 705 **Shape-sensing Robotic-assisted Bronchoscopy for the Diagnosis of Peripheral Lung Nodules: Experience From a Large Academic Medical Center**/O. Mahmoud, Baltimore, MD
- 706 **Correlation Between the Specimen Size and Diagnostic Yield of Bronchoscopy for Malignant Lymphoma**/A. Torii, Nagoya, Japan
- 707 **Combined Endoscopic and Endobronchial Ultrasound Guided Fine Needle Aspiration for Lung Cancer Diagnosis and Staging: A Single Institutional Experience Under Interventional Pulmonary**/M. Hafiz, Oklahoma City, OK
- 708 **Is the Diagnostic Yield of Electromagnetic Navigation Bronchoscopy-guided Biopsy Improving?: A Retrospective Study at a Community Hospital**/M. Tiwari, Newark, NJ

- 709 **Risk of Bleeding Among Patients With Thrombocytopenia Undergoing Transbronchial Biopsies With Advanced Bronchoscopy**/A. Cypro, San Diego, CA
- 710 **Top 50 Most Influential Publications on Navigational Bronchoscopy**/E.M. Toloza, Tampa, FL
- 711 **Diagnostic Yield and Complication Rates From Transbronchial Biopsies of Abnormal Lung Lesions in a Tertiary Referral Centre for Lung Cancer**/D. Quigley, Dublin, Ireland
- 712 **Rigid Bronchoscopic Intervention for Airway Stenosis in Post-pneumonectomy Patients**/H. Murao, Nagoya-shi, Japan
- 713 **Contribution of Bronchial Fiberoptic in the Diagnosis of Primary Bronchopulmonary Cancers in the Bronchial Endoscopy Unit of the Pneumology Department of the National University Hospital Center (NUHC) of Fann**/K. Thiam, Dakar, Senegal
- 714 **Epidemiology of Malignant Central Airway Obstruction at a Comprehensive Cancer Center in the United States**/N.M. Ivanick, Buffalo, NY
- 715 **Diagnostic Value of Endobronchial Ultrasound Transbronchial Need Aspiration (EBUS-TBNA) in Multi-Focal Adenocarcinoma Patients With Pet Negative Hilar and Mediastinal Lymph Nodes**/F. Al-Ghoula, Rochester, MN
- 716 **Single-anesthesia for Robotic-assisted Bronchoscopy and Robotic Lobectomy in Diagnosis and Treatment of Stage I Non-small Cell Lung Cancer Reduces Time to Curative Intervention**/A. Wolf, Fort Worth, TX
- 717 **Current Trends in Prevalence of Hospitalization for Malignant Pleural Effusions**/R. Sinha, Brooklyn, NY
- 718 **Accuracy of Cytological Vs Histological Specimens for Assessment of Programmed Death-ligand 1 Expression in Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis**/P. Tajareramuang, Mueang Chiang Mai, Thailand
- 719 **A Multicenter, Prospective Trial Assessing the Diagnostic Yield of Electromagnetic Bronchoscopic and Transthoracic Navigation for Peripheral Pulmonary Nodules**/J. Thiboutot, Baltimore, MD

CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A31 GLOBAL AND ENVIRONMENTAL INFLUENCES IN ASTHMA9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area A, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session **11:30-1:15****Discussion:** **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1 Succinate Induces Parkin Expression in Airway Epithelial Cells**/D.E. Winnica, Aurora, CO
- P2 Human Lung B Cells Express the Adult-onset Asthma Associated Non-classical HLA-DQ2 Genes and Proteins**/N. Schoettler, Chicago, IL
- P3 Serum α -klotho Level and Lung Function in a Nationwide Study of U.S. Adults**/Y.-Y. Han, Pittsburgh, PA
- P4 Exogenous HSP70 Attenuates Inflammatory Response by Increasing Glucocorticoid Receptor Expression in a Cell Type-specific Manner**/L. Zhou, Basel, Switzerland
- P5 Physiologic Relationships Between Asthma and Gastroesophageal Reflux Disease**/R. Sheth, San Diego, CA
- P6 Content Validity of the Asthma Daytime Symptom Diary and Asthma Nighttime Symptom Diary in Patients With Moderate-to-Severe Asthma**/T. Keeley, Brentford, Middlesex, United Kingdom
- P7 Effect of Albuterol-budesonide As-needed on Asthma-related Systemic Corticosteroid Use in Mandala**/B.E. Chipps, Sacramento, CA
- P8 Inhaler Technique Maintenance in Patients With Uncontrolled Asthma Using a Maintenance and Reliever Digihaler System**/M.E. Wechsler, Denver, CO
- P9 SUNRISE: A Phase 3, Parallel-group Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing OCS Use in OCS-dependent Patients With Severe Asthma**/M.E. Wechsler, Denver, CO
- P10 Effects of Pulmonary Endothelial Cell Knockouts of HIF-1 α and HIF-2 α Subunits on Lung Physiology in a Murine Model of Asthma**/J. Pham, San Diego, CA
- P11 TMEM178 Inhibits Allergic Lung Inflammation in a Murine Model of Asthma**/K. Stelzig, Rochester, MN
- P12 Circulating Mirnas Associated With Both Bronchodilator Response and Airways Hyperresponsiveness in Asthma**/U. Srivastava, San Diego, CA

- P13** **Residual Dyspnea May Predict Small Airways Dysfunction and Poor Responsiveness to Single-inhaler Triple Therapy in Asthmatic Patients/K. Ito, Nagoya, Japan**
- P14** **The Effect of Long-acting Muscarinic Antagonist on Airway Inflammation Through Leukotrienes/T. Matsuyama, Kagoshima City, Japan**
- P15** **Sputum Trypsin in Patients With Moderate to Severe Asthma/M. Kjarsgaard, Hamilton, Canada**
- P16** **Characteristics of Elderly Severe Asthma: Observations From the Korean Severe Asthma Registry (KoSAR)/S.-H. Kim, Seoul, Korea, Republic of**
- P17** **Predictors of Asthma Exacerbation in a Large Retrospective Cohort and Role of Effect Modification by Female Sex and Race/M.D. Althoff, Aurora, CO**
- P18** **Tmem178 Regulates Calcium Responses in Normal Human Bronchial Epithelial Cells/A.M. Hernandez Botero, Rochester, MN**
- P19** **The Effects of Circulating and Adipocyte-derived Factors From Allergic and Non-allergic Obese Asthmatics on Airway Epithelium Following Bariatric Surgery/P. Pena Garcia, Burlington, VT**
- P20** **Clinical Trial of a Probiotic and Herbal Supplement for Lung and Gut Health/C.V. Lal, Birmingham, AL**
- P21** **Relationship Between Circulating Th2, ILC2, and Follicular Helper T Cells and Airway Obstruction in Bronchial Asthma/T.K. Tsukuda, Nankoku, Japan**
- P22** **Effects of DHEA Treatment on Normal Airway Epithelial Cell Proteins/N. Marozkina, Indianapolis, IN**
- P23** **Characterizing Asthma in Madagascar/J. Ratomaharo, Athis-Mons, France**
- P24** **The MiSTIC Study Design: Medium Strength Triple Therapy Vs High Strength ICS/LABA for Adult Patients With Asthma Uncontrolled on Medium Strength ICS/LABA/K. Kostikas, Ioannina, Greece**
- P25** **Modulating the Level of ICS in Triple ICS/LABA/LAMA FDC: Effect Against Airway Hyperresponsiveness in a Human Ex Vivo Model of Severe Eosinophilic Asthma/P. Rogliani, Rome, Italy**
- P26** **Corticosteroid Changes Mast Cell Receptor Expression and Responses to Asthma-associated Cytokines/Y. Ohne, Gaithersburg, MD**
- P27** **Baseline Characteristics of Patients With Severe Asthma Treated With Mepolizumab: An Interim Analysis of a Multi-country Real-world Cohort/R.O. Allehebi, Riyadh, Saudi Arabia**
- P28** **Demographics and Characteristics of Patients Who Initiate Biologics for Severe Asthma in Japan /J. Harvey, Collegeville, PA**
- P29** **Patterns of Use in Severe Asthmatic Patients Who Initiate Biologics in Japan /J. Harvey, Collegeville, PA**
- P30** **Corticosteroid-sparing Effect of Biologics in Patients With Allergic Bronchopulmonary Aspergillosis/K.A. Darragh, San Diego, CA**
- P31** **Predictive Factors of Favorable Outcome for Mepolizumab Treatment for Eosinophilic Granulomatosis With Polyangiitis: A Case Series/R. Tsuzuki, Sumida City, Japan**
- P32** **A Transcriptomic Signature of Mepolizumab Response in Eosinophilic Granulomatosis With Polyangiitis (EGPA)/S.H. Baek, Boston, MA**
- P33** **Tet1 Regulates Diesel Exhaust Particle (DEP)-Induced Th17 Immune Response/S. Henson, Davis, CA**
- P34** **Cholinergic System in the Exposure of Iron Particles in an Experimental Model of Chronic Allergic Inflammation/I.C. Tiberio, Sao Paulo, Brazil**
- P35** **Biological Effects of Long-term Electronic Cigarette Exposure: Studying the Lungs of Asthmatic Mice/M.-A. Song, Columbus, OH**
- P36** **Mitochondrial Dysfunction Is Enhanced by Electronic Cigarette Exposure in Combination With Established Asthma/S. Chung, Columbus, OH**
- P37** **Fourth Generation E-cigarettes Present Immunosuppressive Properties in Mouse Models of Allergic Asthma/S. Gaboyan, La Jolla, CA**
- P38** **E-cigarette Aerosols Modify the Lung Immune Response in a Murine Model of Allergic Asthma/S. Paoli, Montreal, Canada**
- P39** **Proinflammatory Activation of Lung Macrophages and Altered Bioenergetics Following Chlorine Inhalation in Mice/R. Malaviya, Piscataway, NJ**
- P40** **Efficacy of High-Dose IM Vitamin D on Unplanned Emergency Department Visits for Asthma in Asthmatic Children: Analysis of the Largest Prospective Randomized Trial/B. Davidson, Everett, WA**
- P41** **Triglyceride-Glucose Index and Risk of Asthma Exacerbation/T.D. Wu, Houston, TX**

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

**A32 CASES IN AUTOIMMUNITY,
AUTOINFLAMMATION, AND INFECTION**

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area A, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P43 Secondary PAP With PAH as the Initial Manifestation of SAVI Syndrome in an Adult Woman/R. Reddy, Gainesville, FL**
- P44 Neurologic Manifestations of Erdheim-Chester Disease Treated With Cobimetinib/R. Reddy, Gainesville, FL**
- P45 Secondary Hemophagocytic Lymphohistiocytosis After Mild Covid-19 Infection: A Case Report/K. Rai, Aurora, CO**
- P46 Cryptococcus Meningoencephalitis Associated Immune Reconstitution Inflammatory Syndrome in a Liver Transplant Recipient/B. Liang, Los Angeles, CA**
- P47 Treatment of Protracted COVID-19 Symptoms With High Titer COVID-19 Convalescent Plasma in B-cell Depleted Patients: A Single-center Case Series/D.F. Martin, Los Angeles, CA**
- P48 A Case of Secondary HLH in Setting of RMSF/P. Moku, Providence, RI**
- P49 A Consideration for Immune Reconstitution Inflammatory Syndrome in a Newly Diagnosed PCP Following Early Antiretroviral Therapy/N. Carguill, Atlantis, FL**
- P50 Rare Case of Persistent SARS-CoV 2 for 9 Months in HIV Patient/H. Mhanna, Paterson, NJ**
- P51 Recurrent Pneumonia In An Adult, Leading To Diagnosis Of Common Variable Immunodeficiency (CVID), A Rare Diagnosis In Adult Population/M. Shahzadi, Wayne, NJ**
- P52 Variable Lung Diseases in Common Variable Immunodeficiency: A Case of Pulmonary Complications in a Patient With Common Variable Immunodeficiency/Z.S. Baird, Louisville, KY**
- P53 Standing Still: A Case of Stiff-person Syndrome and Common Variable Immunodeficiency/S. Escobar, South Setauket, NY**
- P54 An Unexpected Diagnosis of a 57-year-old Woman With Migratory Pulmonary Infiltrates/E. Mor, Haifa, Israel**
- P55 Necrotizing Pneumonia in an Adult Woman Due to P40phox (NCF4) Deficiency/A.M. Estrella, New York, NY**
- P56 An Uncommon Cause Of Immunosuppression: Fatal Pneumocystis Jiroveci Pneumonia In A Patient With Cushing's Syndrome/A. Cecchini, Norfolk, VA**
- P57 Hemoptysis - Thinking Beyond the Lungs/P. Rashmi, Brooklyn, NY**
- P58 Descending Aortic Thrombus - New Onset Antiphospholipid Syndrome (APL) in a COVID-19-infected Patient/P. Rashmi, Brooklyn, NY**
- P59 Diffuse Alveolar Hemorrhage in the Setting of Systemic Lupus Erythematosus/A. Cheek, Omaha, NE**
- P60 Micro Things Can Cause Massive Damage: A Rare Presentation of Lung Hemorrhage and Nephritis Syndrome/S.R. Zaidi, Huntington, WV**
- P61 Not All Hypoxia Is The Same/E.J. Pacheco, Tampa, FL**
- P62 An Unusual Cause of Miliary Radiographic Findings/A. Duarte, Tyler, TX**
- P63 Myositis... Without the Myositis?/M.A. Dirico, Bethlehem, PA**
- P64 Pulmonary Renal Syndrome: A Rare Life-threatening Disease/F.L. Das Gracias, Richmond Hill, NY**
- P65 Not All Hoofbeats Are Horses: A Case of Antisynthetase Syndrome Masquerading as Community-Acquired Pneumonia/N. Brewer, Greenville, SC**
- P66 IgG4-Related Diseases: A Rare Cause of Epigastric Pain/K. Desai, Philadelphia, PA**
- P67 Exudative Pleural Effusion as Initial Manifestation in Rapidly Progressive Rheumatoid Arthritis Associated Interstitial Lung Disease/W.S. Sango, Farmington, CT**
- P68 Novel Onset Gpa Vasculitis and the Adjunctive Agentavacopan to Limit Glucocorticoid Exposure/M. Ellis, Rochester, MN**
- P69 Stanch The Bleeding: A Case Of Diffuse Alveolar Hemorrhage In Relapsing Granulomatosis With Polyangiitis/M. Whittaker, Lexington, KY**
- P70 Respiratory Failure and Ground Glass Opacities in the Age of COVID-19/C. Dossett, Phoenix, AZ**
- P71 Don't Breathe: It's a Trap/A. Saha, Worcester, MA**
- P72 Necrotizing Sarcoid Granulomatosis: A Rare Condition Masquerading As Infection/O. Lin, Morgantown, WV**
- P73 Granulomatosis With Polyangiitis Presenting as Diffuse Alveolar Hemorrhage/K. Muralidharan, Bridgeport, CT**
- P74 Pyoderma Gangrenosum: A Rare Case With Pulmonary Manifestation/A. Pham, Honolulu, HI**
- P75 A Case Of Anti-MPO Vasculitis: Yet Another Sequela Of Covid-19/N. Chan, Greenville, NC**

- P76 Paraneoplastic Dermatomyositis Syndrome Presenting As Pulmonary Connective Tissue Disease/E. Bak, Louisville, KY**
- P77 Pulmonary Renal Syndrome in Pauci-immune ANCA Positive Vasculitis/K. Shah, Athens, GA**
- P78 Bilateral Infiltrates On Chest X-Ray-Thinking Outside The Box/C.L. Weldrick, Galway, Ireland**
- P79 Medium Vessel Vasculitis Presenting As Progressive Pulmonary Nodules/C.M. Fiore, Worcester, MA**
- P80 IgG4-Related Lung Lesion Presenting as Lung Mass/S. Nair, Omaha, NE**
- P81 Rare Pulmonary Manifestations Of Ankylosing Spondylitis/S. Chandna, Cleveland, OH**
- P82 An Equivocal Presentation of Anti Neutrophil Cytoplasmic Antibodies (ANCA)-negative Eosinophilic Granulomatosis With Polyangiitis/A. Mathew, Stockton, CA**
- P83 First Impressions Can Be Elusive: A Case of EJ+ Idiopathic Inflammatory Myopathy Flare Mimicking Metastatic Lung Cancer/S. Shimizu, Cleveland, OH**
- P84 Atypical Presentation Of Rhinovirus Infection With Rapid Deterioration Requiring Mechanical Ventilation/T. Simpson, New York, NY**
- P85 Finding a Diagnosis in the Woods: A Case of Anti-Glomerular Basement Membrane Antibodies and Pauci-immune Glomerulonephritis With Blastomycosis/K.E. Berry, Chicago, IL**
- P86 Repeated Whole Lung Lavage With Extracorporeal Membrane Oxygenation Assistance and Multimodal Medical Therapy in Severe Pulmonary Alveolar Proteinosis/C. Provenza, Memphis, TN**
- P87 Hypoventilation Syndrome as a Scleroderma Variant With Myositis: A Novel Manifestation Attributed to COVID/A. Gubran, Brooklyn, NY**
- P88 Avoiding Diagnostic Closure: A Case Of PJP That Wasn't/S. Sasmal, Columbus, OH**
- P89 A Case of Lofgren Syndrome Incited by Covid-19 Vaccination/A.J. Pronko, New York, NY**
- P90 Whipple's Disease Diagnosed By Pulmonary Manifestations in a Young Adult With Autoimmune Disease/K. Richard, Boston, MA**

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A33 LATE BREAKING ADVANCES IN ASTHMA AND IMMUNOLOGY9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area A, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session **11:30-1:15****Discussion: 11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P92 Mitochondrial DNA-toll-like Receptor 9 Interactions Drives Fibrosis in the Adult Lung/C. Ryu, New Haven, CT**
- P93 Sphingosine 1 Phosphate Signaling Pathway Drives Female Asthma Susceptibility/E. Granato, Naples, Italy**
- P94 First-in-class Inhalable Anti-TSLP Single Domain Antibody With Therapeutic Potential in Asthma Treatment/Y. Wan, Shanghai, China**
- P95 Phase I Safety and Efficacy Evaluation of the First-in-class Inhalable Anti-IL-4R α Single Domain Antibody/Y. Wan, Shanghai, China**
- P96 First-in-class Inhalable Anti-notch2 Single Domain Antibody for the Treatment of Cystic Fibrosis Lung Disease/Y. Wan, Shanghai, China**
- P97 ETI Triple Therapy Shows Sustained, Progressive Normalisation of Airway Cytokine and Antiprotease Balance and Systemic Inflammation Over One Year of Treatment/M.P. Murphy, Dublin, Ireland**
- P98 DNA Methylation of Leucine Aminopeptidase 3 (LAP3) at Birth Mediates the Association of Maternal Gestational Metabolites to Childhood Lung Function/N. Mukherjee, Little Rock, AR**
- P99 Long-term Alteration of Alveolar Epithelial Cells After Early-life RSV Infection/W. Fonseca, Ann Arbor, MI**
- P100 Oxidized Low Density Lipoprotein Mediates NLRP3 Activation in Patients With Sleep Apnea and Early Subclinical Atherosclerosis/E. Draz, Madrid, Spain**
- P101 E-Cigarette Vape Impairs Lung Endothelial Barrier Function and Autophagy via Jun N-Terminal Kinase/T. Rivera, Denver, CO**
- P102 Protracted Pulmonary Inflammation in IFN-gamma Deficient Mice Recovering From Cytokine Release Syndrome/G. Rajagopalan, New Haven, CT**
- P103 Human $\gamma\gamma 2v\delta 2$ T Cells Attenuate Collagen Type I Expression in Lung Fibroblasts By Inhibiting Myocardin Expression/D. Okuno, Nagasaki, Japan**

- P104 Neonatal Alveolar Macrophages Undergo Metosis in an Inflammatory Model of Lung Injury/R. Higazy, Toronto, Canada**
- P105 Sepsis-Induced Immune Paralysis: Of Monocytes and Metabolites/L.K. Torres, New York, NY**
- P106 Harnessing the Immune System for Treatment of Idiopathic Pulmonary Fibrosis/A. Bhattacharyya, San Francisco, CA**
- P107 Pharmacological Activation of Cannabinoid-2 Receptor Reduces SARS-CoV-2-Spike Protein-Induced Acute Lung Injury and Inflammation/J. Lockett, Norfolk, VA**
- P108 Murine Hepatitis Virus-1 β 2-Coronavirus Pulmonary Infection and Subsequent Exposure to Fio2=0.60 but Not 0.30 Synergistically Worsen Survival and Lung Injury in a Mouse Model/X. Cui, Bethesda, MD**
- P109 Assessing the Clinico-Immunological Profile of Patients With Obesity and Chronic Rhinosinusitis/M. Chaaban, Cleveland, OH**
- P110 HAQ and AQ STING/MPYS Are Resistant to STING-Mediated T Cell Death/L. Jin, Gainesville, FL**
- P111 Insights on Interferon-Independent Induction of Interferon-Stimulated Genes in the Airway at Early Stage of SARS-CoV-2 Infection: Human and In Vivo/H.J. Kim, Seoul, Korea, Republic of**
- P112 The Role of sNASP-TRAF6 Axis in Diesel Exhaust Particles-Exacerbated Allergic Inflammation/F.-M. Yang, Taipei, Taiwan**
- P113 Identification and Verification of an Allergen-Induced Cell Surface Signature in Dendritic Cells/M. Sia, Orlando, FL**

BEHAVIORAL • CLINICAL
THEMATIC POSTER SESSION
A34 IDENTIFYING AND IMPROVING PALLIATIVE CARE NEEDS ACROSS THE CARE CONTINUUM
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area K, Hall C (Lower Level)
Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1093 Trends in Utilization of ICU for Older Adults With Cancer at the End-of-Life/S. Jain, New Haven, CT**
- P1094 How Important Is Spirometry for Identifying Patients With Chronic Obstructive Pulmonary Disease Who Are Appropriate for Palliative Care?/A.V. Lange, Aurora, CO**

- P1095 Feasibility and Acceptability of Goals of Care Elicitation in an Emergency Department Setting/S.R. Yapalater, Philadelphia, PA**
- P1096 Listen Don't Reload: Discussing Racism and Healthcare With Racially Marginalized Patients With Serious Illness/C.E. Brown, Seattle, WA**
- P1097 Palliative Care Ad-hoc and Largely Unknown in Rural Chronic Disease - a Cross Sectional Service-Level Survey/R. Disler, Melbourne, Australia**
- P1098 Palliative Approach Remains Lacking in Terminal Admissions for Chronic Disease: A Five Site Retrospective Medical Record Audit/R. Disler, Melbourne, Australia**
- P1099 The "Heart" of CHART: A Qualitative Analysis of an Informed Assent Approach to Discussing CPR With Inpatients With Advanced Medical Comorbidities/S. Sexauer, Charleston, SC**
- P1100 How Much Do Patient Preferences Really Matter When Predicting Their Risk for Invasive Mechanical Ventilation in the ICU?/G.E. Weissman, Philadelphia, PA**
- P1101 The Utility of Triggers to Prompt Specialty Palliative Care Consultation in the Intensive Care Unit/J. Treadway Nomitch, Seattle, WA**
- P1102 Using Human-Centered Design to Refine and Target an ICU Communication Intervention/M. Modes, Los Angeles, CA**
- P1103 Stakeholder Perspectives on Family Caregiving After Critical Illness: A Qualitative Content Analysis/A.C. Moale, Pittsburgh, PA**
- P1104 Evaluation of Morphine and Oxygen Use in Terminally Ill Adult Patients With Dyspnea in Two Public Hospitals in Brazil: A Cross-sectional Study/L. Stanzani, Brasilia, Brazil**
- P1105 Surrogate Trust in the Intensive Care Unit: An Evaluation of Trust Levels in Physicians and the Healthcare System/A. Kazi, Philadelphia, PA**

BEHAVIORAL • CLINICAL
THEMATIC POSTER SESSION
A35 LEVERAGING USE OF INFORMATICS AND TECHNOLOGY
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area E, Hall C (Lower Level)
Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P477** **Real-world Evidence: Correlates of the Differential Documentation of Incident Childhood Asthma Diagnoses in Electronic Health Records/A.H. Owora, Bloomington, IN**
- P478** **Development and Validation of Case-finding Algorithms for Use in Secondary Electronic Health Databases to Identify Patients With Fibrotic Interstitial Lung Disease/P. Pimple, Ridgefield, CT**
- P479** **Machine-learning Model Identifies Patients With Alpha-1 Antitrypsin Deficiency (AATD): Expert Validation and Comparison of Journeys for Patients With AATD Versus Chronic Obstructive Pulmonary Disease/J. Hinson, Lexington, MA**
- P480** **A Novel Electronic Health Records Algorithm to Identify COPD Exacerbations in Real Time/M.G. Rydberg, Chapel Hill, NC**
- P481** **Classifying Asthma Health Deterioration Using Synthetic Patient Data Generation and Associated Machine-learning Predictions Derived From Global Clinical Characteristic Data/S. Iyer, Austin, TX**
- P482** **Characterizing Communication and Reminder Preferences Among Individuals Eligible for Annual Lung Cancer Screening: Targeting Opportunities in the Digital Age/E. Hirsch, Aurora, CO**
- P483** **Continuous Respiratory Monitoring and Analysis by an Integrated Pressure Sensing Backrest of the Seat/Y.-J. Cheng, Seattle, WA**
- P484** **Community Use of Digital Auscultation to Improve Diagnosis of Childhood Pneumonia in Sylhet, Bangladesh/S. Ahmed, Dhaka, Bangladesh**
- P485** **Patient Satisfaction With Wireless Handheld Home Spirometers: Identifying Barriers to Use in the Cystic Fibrosis Population/M. Artov, New Orleans, LA**
- P486** **Telemedicine in Pulmonary Clinics and Associated Resource Utilization Patterns/R. Puthumana, Miami, FL**
- P487** **External Validation of the Proprietary Epic No-Show Prediction Model at a Single Academic Medical Center/J.C. Rojas, Chicago, IL**
- P488** **“We Haven’t Even Gotten Through This Horror Show, and Now There’s Another Horror Show:” The Simultaneous Impact of COVID-19 and an Electronic Health Record Transition/J.M. Rucci, Boston, MA**

BEHAVIORAL • CLINICAL
THEMATIC POSTER SESSION
A36 SLEEP-RELATED HEALTH SERVICES RESEARCH
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area E, Hall C (Lower Level)
Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P490** **Effects of Expiratory Muscle Strength Training on Oropharyngeal Swallow Physiology in Persons With Obstructive Sleep Apnea (OSA): A Pilot Study/A.M. Bhutada, Mobile, AL**
- P491** **Trajectory of Bicarbonate With CPAP Usage Across the Spectrum of Obesity Related Hypoventilation/A. Taylor, Salt Lake City, UT**
- P492** **BiPAP as a Mode of Ventilation in Moderate to Severe OSA/S. Patil, Dhule, India**
- P493** **Diagnostic Accuracy of Three Screening Questionnaires for Predicting Moderate to Severe Obstructive Sleep Apnea in Patients With Morbid Obesity/N. Saiphoklang, PathumThani, Thailand**
- P494** **Prevalence of Obstructive Sleep Apnea During the Lifetime in Colombia According to the National Health Registry 2017-2021/A.R. Waich, Bogotá, Colombia**
- P495** **Long-Term Maintenance of Efficacy and Safety of Pitolisant in the Treatment of Residual Sleepiness in Patients With Obstructive Sleep Apnoea/C. Caussé, Paris, France**
- P496** **Healthy User Effect: Medication Adherence as a Proxy Measure in Obstructive Sleep Apnea/W. Mcconnell, San Diego, CA**
- P497** **Prevalence of Insomnia in Patients With Hypertension in a Tertiary University Center/A.V.V. Martins, Sao Paulo, Brazil**
- P498** **Prevalence, Risk and Subsequent In-hospital Outcomes of Secondary Pulmonary Hypertension in Obese OSA Admissions With Vs. Without Prior Bariatric Surgery/Z.J. Gandhi, Wilkes-Barre, PA**
- P499** **Longitudinal Sleep Instability and Depression: Finding From the Seattle Longitudinal Study/Y. Cho, Seattle, WA**
- P500** **The Association Between Sleep Hygiene and Cessation of Cigarette Smoking/D.M. Moore, Miami, FL**
- P501** **Neuropsychiatric Problems in Primary Ciliary Dyskinesia? First, Go to Sleep/R.A. Cardona Quinones, San Juan, PR**

P502 Sleep Well and Live Well: Impact of Micro Behavior Changes in a Rural Community (the Swell Study)/E. Rojas, Morgantown, WV

CLINICAL

THEMATIC POSTER SESSION

A37 CASE REPORTS: AUTOIMMUNITY, COVID, AND LUNG DISEASE, OH MY!

**9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area G, Hall C (Lower Level)**

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

P679 Evolving Cavitory Lung Nodules/Z. Zhang, Rochester, MN

P680 Calcified Pulmonary Nodules And Cysts In A Patient With Sjögren's Syndrome/V.P. Trelles, Gainesville, FL

P681 Nodular Pulmonary Amyloidosis as a Manifestation of Sjögren's Syndrome: Report of Two Cases/P.A. Navarrete Sosa, Bogota, Colombia

P682 Baltoma, An Unconventional Complication Of Sjögren's Syndrome/D.S. Bustamante-Soliz, Cuenca, Ecuador

P683 The Airway of Refractory Ulcerative Colitis/N. Sahu, Bethlehem, PA

P684 Interstitial Lung Disease In A Patient With Ulcerative Colitis And Chronic Use Of Mesalazine. A Case Report/J.L. Galindo Pedraza, BOGOTA D.C., Colombia

P685 Interstitial Lung Disease in a Patient With Ulcerative Colitis/D. Shyu, Minnesota, MN

P686 Extensive Arterial and Venous Pulmonary Vasculopathy in the Setting of Crohn's Disease/W.T. Smith, Rochester, MN

P687 Antisynthetase Syndrome in the American Southwest/E. Biringen, Phoenix, AZ

P688 COVID-19 Leading To Accelerated Rapidly Progressive Interstitial Lung Disease in Anti-MDA5 Dermatomyositis/S. Dandu, Neptune, NJ

P689 Rapidly Progressive Interstitial Lung Disease In The Setting Of Anti-Melanoma Differentiation-Associated Gene 5 Positive Clinically Amyopathic Dermatomyositis/D.L. Winter, Richmond, VA

P690 Rare Case of Non-j1 Anti-synthetase Syndrome in a 30-year-old Female Presenting With Subacute Dyspnea/V. Reyes Pinzon, Chicago, IL

P691 A Case of Anti-synthetase Syndrome Presenting as Fever of Unknown Origin/K. Yaseen, Cleveland, OH

P692 Dermatomyositis Associated With Rapidly Progressive Interstitial Lung Disease Requiring Lung Transplant/A. Mahmood, Lafayette, LA

P693 Severe Gangrene in a Patient With Anti-U1RNP and PL-7 Antibodies Associated With Polymyositis and Mixed Connective Tissue Disorder/A.A. Bukiej, Chicago, IL

P694 Unmasking of Autoimmune Diseases After COVID-19 Infection/M. Shahzadi, Wayne, NJ

P695 Rare Autoimmune Disease Caused By Not-So Rare Virus/T. Marchewka, Farmington Hills, MI

P696 A Case of COVID-19 Infection in a Patient With Advanced Rheumatic Lung Disease/J. Livingston, New Jersey, NJ

P697 Lymphoid Interstitial Pneumonia as the Presenting Manifestation of Rheumatoid Arthritis/S. Alsakarneh, Kansas, MO

P698 Interstitial Lung Disease as Primary Presentation of Rheumatoid Arthritis/O. Akinboboye, Athens, GA

P699 Acute Exacerbation of Interstitial Lung Disease in the Setting of COVID-19/S. Avera, Knoxville, TN

P700 An Underestimated Risk? When Long Covid Becomes Life Threatening! Massive and Rapidly Progressing Pulmonary Fibrosis With a Pattern of Systemic Sclerosis Following Mildly Symptomatic COVID-19 Infections/M. Stahl, Ulm, Germany

P701 A Case Of Initially Misdiagnosed Antisynthetase Syndrome With Characteristic Nonspecific Interstitial Pneumonia/Organizing Pneumonia Overlap/E.N. Haber, Washington, DC

P702 An Atypical Case of ILD With CADM/V. Geedigunta, Bronx, NY

P703 Interstitial Lung Disease: Don't Forget the Skin/U. Khan, Fort Smith, AR

P704 Anti-MDA 5 Antibody Positive Rapidly Progressive Interstitial Lung Disease in a Woman With Porphyria Cutanea Tarda, SLE, and Dermatomyositis/P. Rath, Akron, OH

P705 A Case of Granulomatous Lymphadenitis Due to COVID-19/D. Sung, Stockton, CA

P706 Successful Treatment of Steroid-refractory COVID-19-associated Organizing Pneumonia With Intravenous Immunoglobulin (IVIG)/A. Jbeli, Minneapolis, MN

P707 Hidden Dangers: A Case of Progressive Lung Disease in an Immunocompromised Patient, Found to Have Persistent COVID Positivity on Bronchoscopy/S.A. Raia, Denver, CO

P708 Indeterminate Pattern for Usual Interstitial Pneumonia as a Manifestation of ANCA-MPO Vasculitis/N. Remolina, Bogota, Colombia

- P709 An Unusual Case Of Pneumonia And Hemoptysis/A.** Khodadadi, St. Louis, MO
- P710 EGPA - Takes My Breath Away/R.** Patel, Norwalk, CT
- P711 A Rare Presentation Of Atypical Anti-Glomerular Basement Membrane Disease/C.J.** Fernandez, Buffalo, NY
- P712 Another Case of the Sniffles: Chronic Sinusitis and Recurrent Otitis Media in Granulomatosis With Polyangiitis/E.M.P.** Almazan, Lexington, KY
- P713 Diffuse Alveolar Hemorrhage Associated With Anti-synthetase Syndrome and COVID-19/P.** Shah, West Reading, PA
- P714 ANCA Negative Granulomatosis With Polyangiitis With Associated Progressive and Extensive Emphysema/C.J.** Merino Gualan, Norwalk, CT
- P715 All That Glitters Is Not Gold - A Curious Case of Granulomatosis With Polyangiitis With Predominant Pulmonary Involvement/P.** Shekar, Hartford, CT
- P716 Rapid Onset of Diffuse Alveolar Hemorrhage in Newly Diagnosed Granulomatosis With Polyangiitis: A Case Report/S.** Shah, Abington, PA
- P717 A Bloody Affair - IgA Vasculitis Presenting As Diffuse Alveolar Hemorrhage Post COVID-19/J.** Alunilkummannil, Cleveland, OH
- P718 Diffuse Alveolar Hemorrhage - A Commonly Encountered But Often Missed Diagnosis/A.** Makadia, Corpus Christi, TX
- P723 Insights on the Management and Outcomes of Patients With Progressive Fibrosing Interstitial Lung Disease in Clinical Practice: INSIGHTS-ILD Registry/J.** Behr, Munchen, Germany
- P724 Spectrum and Profile of Patients With Interstitial Lung Diseases Presenting at a Tertiary Care Centre in North India/I.** Shekh, New Delhi, India
- P725 The Spectrum of Presentations Associated With Myositis-Related Interstitial Lung Disease (ILD) - a Single Centre Series/C.M.** Gill, Dublin, Ireland
- P726 Interstitial Lung Disease in Anti-synthetase Syndrome: A Single Center Experience/M.** Khasawneh, Gainesville, FL
- P727 Anti-Nuclear Matrix Protein-2 (NXP-2) Antibodies in Interstitial Lung Disease: A Rare Manifestation of a Rare Disease/B.** Flashner, Boston, MA
- P728 Multifaceted Analysis of Interstitial Pneumonias With Autoimmune Features: A Prospective Multicenter Cohort Study/N.** Enomoto, Hamamatsu, Japan
- P729 Clinical and Radiographic Characterization of Non-specific Interstitial Pneumonia on High-resolution CT Chest Imaging/V.** Marcoux, Saskatoon, Canada
- P730 Description of Chest CT Patterns in Patients With Connective Tissue Diseases Related Interstitial Lung Diseases (ILD) in an ILD Clinic in Canada: A Quasi Population-based Study/S.** Gunn, Kingston, Canada
- P731 Prevalence, Computed Tomography Patterns, and Risk Factors for Development of Connective Tissue Disease Associated Interstitial Lung Disease: A Systematic Review and Meta-analysis/G.M.** Joy, Vancouver, Canada
- P732 Comparative Study of the Clinical Features and Prognosis Between Idiopathic Pulmonary Fibrosis and Unclassifiable Interstitial Pneumonia/K.** Koda, Hamamatsu, Japan
- P733 Intrafamilial Correlation and Variability in the Clinical Evolution of Pulmonary Fibrosis/T.** Goos, Leuven, Belgium
- P734 Prevalence and Mortality of Idiopathic Pulmonary Fibrosis in Brazil/R.** Rufino, Rio de Janeiro, Brazil
- P735 Hospitalisation Patterns in Interstitial Lung Disease - Data From the Exciting-ILD Registry/M.** Kreuter, Heidelberg, Germany
- P736 Risk Assessment for Acute Exacerbations of Interstitial Lung Disease/R.** Dinparastisaleh, Jacksonville, FL
- P737 Histological Predictors of Progression and Mortality in Fibrotic Interstitial Lung Diseases/V.** El Mir Arida, Sao Paulo, Brazil
- P738 Risk Factors for Progressive Pulmonary Fibrosis in Primary Sjögren Interstitial Lung Disease/S.J.** Auteri, Buenos Aires, Argentina

CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A38 ADVANCING OUR UNDERSTANDING AND TREATMENT OF ILD

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area G, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P720 Association Between Statin Use and the Risk for Idiopathic Pulmonary Fibrosis and Its Prognosis/J.** Park, Seoul, Korea, Republic of
- P721 Cigarette Smoking and Risk of Interstitial Lung Disease Diagnosis: A Systematic Review and Meta-Analysis/C.** Lee, Chicago, IL
- P722 Non-Tobacco Exposures in Combined Pulmonary Fibrosis and Emphysema Across ILDs: A Case-Control Analysis/C.** Lee, Chicago, IL

- P739** Sex Differences in Progression of Rheumatoid Arthritis-associated Interstitial Lung Disease by Pattern/Y. Sugawara, Aurora, CO
- P740** Association Between Smoking and Clinical Outcome in Patients With Idiopathic Pulmonary Fibrosis: A Nationwide Population-based Study/H.-Y. Yoon, Seoul, Korea, Republic of
- P741** Progression in Fibrotic Interstitial Lung Diseases - Prevalence and Indicators in the Initial Evaluation in a Brazilian Multicentric Cohort/C.L. Resende, Sao Paulo, Brazil
- P742** Current Definitions of Progressive Pulmonary Fibrosis Might Be Inaccurate: Data From a Cohort of Patients With Rheumatoid Arthritis Associated Interstitial Lung Disease/M. Vermant, Leuven, Belgium
- P743** Clustering Analysis of HRCT Parameters Measured Using a Texture-based Automated System: Relationship With Clinical Outcomes of IPF Patients/J.S. Park, Bucheon, Korea, Republic of
- P744** Biomarkers Extracted by Fully Automated Body Composition Analysis From Chest CT Correlate With Survival in Idiopathic Pulmonary Fibrosis (IPF)/F. Bonella, Essen, Germany
- P745** Circulating Urokinase-Type Plasminogen Activator Receptor Protein Highly Correlates With the Severity of Idiopathic Pulmonary Fibrosis (IPF): Data From the IPF-PRO Registry/J.L. Todd, Durham, NC
- P746** Bronchoalveolar Lavage (BAL) Fluid Cytokine and Chemokine Analysis in Interstitial Lung Disease (ILD)- Can It Predict Progressive Fibrotic Phenotype?/N. Iannazzo, Indianapolis, IN
- P747** Neutrophil Extracellular Trap Associated Proteins in Bronchoalveolar Lavage Fluid Are Associated With Worse Baseline Lung Function and Worse Survival in Patients With Idiopathic Pulmonary Fibrosis/S. Matson, Kansas City, KS
- P748** Clinical Features and Outcomes of Patients With Myositis Associated-Interstitial Lung Disease/T. Karampitsakos, Patras, Greece
- P749** Identification of Molecular Profiles Predictive of Outcome by RNA-Sequencing of Formalin-Fixed, Paraffin-Embedded (FFPE) Lung Tissue From Patients With Idiopathic Pulmonary Fibrosis/T. Karampitsakos, Tampa, FL
- P750** Quantitative High-Resolution Computed Tomography Predicts Progressive Pulmonary Fibrosis/M. Koslow, Denver, CO

- P751** A Model to Predict Idiopathic Pulmonary Fibrosis Outcomes Using Artificial Intelligence/K. Ussavarungsi, Cleveland, OH

CLINICAL • TRANSLATIONAL
THEMATIC POSTER SESSION
A39 MANAGEMENT OF INTERSTITIAL LUNG DISEASE AND ITS CO-MORBIDITIES
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area G, Hall C (Lower Level)

- Viewing:** Posters will be on display for entire session **11:30-1:15**
- Discussion:** **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.
- P753** Burden and Trends in Secondary Pulmonary Hypertension and Associated Inpatient Outcomes in Elderly Patients Hospitalized With Autoimmune Disorders: A Nationwide Analysis, 2016-2019/J. Jasti, Sioux Falls, SD
- P754** Pulmonary Hypertension Was Associated With Increased Risk of Mortality in Patients With Combined Pulmonary Fibrosis and Emphysema/A.S. Sadigov, Baku, Azerbaijan
- P755** Survival After Secondary Spontaneous Pneumothorax in Interstitial Lung Disease/A. Coolidge, Boston, MA
- P756** The Prognostic Value of Gastroesophageal Reflux Disorder in Interstitial Lung Disease Related Hospitalizations: Insight From National Inpatient Sample/S. Alqalyoobi, Greenville, NC
- P757** Esophageal-gastric Sphincter Weakness in Chronic Lung Disease/J.K. Joshua, San Diego, CA
- P758** Prevalence of Interstitial Lung Abnormalities in Patients With Achalasia Requiring Peroral Endoscopic Myotomy Procedure/D.R. Kramer, Philadelphia, PA
- P759** Health-related Quality of Life in Patients With Rheumatoid Arthritis (RA) Vs RA-associated Interstitial Lung Disease/Y. Sugawara, Aurora, CO
- P760** Dyspnea During Sexual Activity in Patients With Fibrotic Interstitial Lung Disease/N. Avitzur, Calgary, Canada
- P761** Laryngology Evaluation and Management of Chronic Cough in Interstitial Lung Disease Patients/S.K. Mathai, Dallas, TX
- P762** Pregabalin for Interstitial Lung Disease-related Cough: A Single-center Experience/M.D. Saint-Pierre, Ottawa, Canada

- P763 Feasibility of Smartphone Application-based Cough Frequency Monitoring in Patients With Interstitial Lung Disease/B.S. Kwon, Seongnam-si, Korea, Republic of**
- P764 Clinical Characteristics of Progressive Pulmonary Fibrosis of Idiopathic Pulmonary Fibrosis Patients Who Receive Anti-fibrotic Agent/T. Kishaba, Uruma, Japan**
- P765 Variation in Treatment Efficacy of Nintedanib for Idiopathic Pulmonary Fibrosis (IPF) Over 2 Years/N. Arai, Naka-gun, Japan**
- P766 Preliminary Baseline Data From the Teton Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis/S.D. Nathan, Falls Church, VA**
- P767 Tolerability and Overall Mortality in Patients With Non-idiopathic Pulmonary Fibrosis Progressive Fibrosing Interstitial Lung Disease Treated With Nintedanib: Real-world Evidence From a Single Specialist Centre/P. Rivera Ortega, Manchester, United Kingdom**
- P768 Rituximab Improves Lung Function Decline in Patients With Idiopathic Inflammatory Myopathy-associated Interstitial Lung Disease/Y. Jang, Seoul, Korea, Republic of**
- P769 Short Term Outcomes and Factors Associated Treatment Response in Fibrotic Hypersensitivity Pneumonitis/T. Petnak, Bangkok, Thailand**
- P378 Is Endoscopic Bronchial Occlusion an Effective Treatment for Hemoptysis? A Case Series and Literature Review/R. Yoneoka, Chiba, Japan**
- P379 Histoplasma to Loss of Plasma: A Case of Massive Hemoptysis in the Setting of Fibrosing Mediastinitis/B. Hackett, Kansas City, KS**
- P380 Left Upper Lobe Pulmonary Sequestration Presenting as Persistent Hemoptysis/D. Khalil, Sherbrooke, Canada**
- P381 Stop Being So Extra...in the Lung: A Case of Pulmonary Sequestration/K. Patel, Smyrna, TN**
- P382 Endobronchial Chondrolipoma: An Uncommon Cause of Obstructive Pneumonia/I. Ortiz Velez, San Juan, Puerto Rico**
- P383 This Rare Cause Of Variable Intrathoracic Obstruction Has A Nice Ring To It/R. Sheth, San Diego, CA**
- P384 Unusual Culprit for Chronic Cough. A Case of Relapsing Polychondritis/O. Idubor, Lawrenceville, GA**
- P385 Tracheobronchopathia Osteochondroplastica: A Disregarded Incidental Finding?/R. Cordeiro, Torres Vedras, Portugal**
- P386 Life In Plastic: Not So Fantastic/H. Channa, Shreveport, LA**
- P387 The Plot Thickens When the Trachea is Thickened/S. Falde, Rochester, MN**
- P388 Unusual Etiology of Spontaneous Pneumomediastinum/M. Cheema, Port Jefferson, NY**
- P389 Tension Pneumothorax and Subcutaneous Emphysema - A Rare Cause of Dysphagia in a Patient With Marfan Syndrome/A. Kainat, McKeesport, PA**
- P390 Bochdalek Hernia Induced Restrictive Lung Disease/M. Siebert, Indianapolis, IN**
- P391 Acute Airway Compromise: Angioedema Versus Subcutaneous Emphysema of Boerhaaves Syndrome/R. Hendry, Las Vegas, NV**
- P392 Severe Airway Obstruction as a Complication of Nasogastric Tube Placement/A.C. Prandecki, Las Vegas, NV**
- P393 Foreign Body Aspiration Presenting as Tracheal Stenosis From Granulation Tissue Formation/A.C. Prandecki, Las Vegas, NV**
- P394 Spontaneous Regression of Initially Proliferating Endobronchial Squamous Metaplasia of Unknown Cause/A.L. Mora Carpio, New Haven, CT**
- P395 A Case of Primary Tracheal Schwannoma as an Unrecognized Cause of Cardiac Arrest/M. Hafiz, Oklahoma City, OK**
- P396 Incidental Finding of Massive Tracheal Diverticulum After Inhalation Burn Injury and Review of Management Options/E.L. Amaechi, Bronx, NY**

CLINICAL

THEMATIC POSTER SESSION

A40 AIRWAY CASE REPORTS: HEMOPTYSIS, ANOMALIES, AND MORE

**9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area D, Hall C (Lower Level)**

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P374 Recurrent Hemoptysis: A Diagnostic Conundrum/J. Medina, Miami, FL**
- P375 A Case of Massive Hemoptysis Requiring Venovenous Extracorporeal Membrane Oxygenation (VV ECMO) in a Patient With Kartagener's Syndrome and Pulmonary Arteriovenous Malformations (AVMs)/A. Yalamanchi, Houston, TX**
- P376 A Rare Case of Kartagener Syndrome Presenting With Massive Hemoptysis/D. Avila, Kingwood, TX**
- P377 A Rare Case Of Hemoptysis/K. Ramirez Gorbea, Mayaguez, Puerto Rico**

- P397** **Obstructive Fibrinous Tracheal Pseudomembrane Managed By Flexible Bronchoscopy With Cryoprobe**/M.M. Kimble, Plantation, FL
- P398** **An Aberrant Tree-cheal Branch: A Case Of Tracheal Bronchus**/B. Amir-Kabirian, Charleston, WV
- P399** **Mediastinal Mass: Recurrent Pulmonary Infections Caused By Tracheal Bronchus**/C. Yurosko, Cleveland, OH
- P400** **Tracheal Bronchus: Lobar Collapse Revealing Swine Anatomy**/F. Chesta, Honolulu, HI

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A41 EMERGING CLINICAL AND TRANSLATIONAL RESEARCH IN COPD AND ALPHA-1-ANTITRYPSIN

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area D, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P402** **Using Multi-omics Factor Analysis to Determine the Major Axes of Heterogeneity in Chronic Obstructive Pulmonary Disease**/A. Halu, Boston, MA
- P403** **Associations Between a Bilirubin-associated Single Nucleotide Polymorphism (SNP) and Respiratory Health Outcomes: A Mendelian Randomization Study Within COPD Gene**/D.M. Macdonald, Minneapolis, MN
- P404** **Associations Between Biomarkers of Inflammation and Longitudinal Measures of Lung Function and Physical Activity: A Secondary Analysis in CASCADE**/D.M. Macdonald, Minneapolis, MN
- P405** **Accuracy and Reproducibility of Plethysmographic Thoracic Gas Volume Measurements in Healthy Subjects**/T. Siddharthan, Miami, FL
- P406** **Small Airways Deposition of Two Fixed-dose Triple Therapy Combinations Assessed With Functional Respiratory Imaging (FRI)**/J. Marshall, Cambridge, United Kingdom
- P407** **COPD Phenotypes: Pulmonary Artery:Aorta Ratio and Its Correlation to Pulmonary Vascular Resistance in Emphysema Vs. Non-emphysema COPD**/J.D. Rivera Robles, Weston, FL
- P408** **COPD Phenotypes: Pulmonary Vascular Resistance/FEV1 Ratio, Normalizing Hemodynamics to Degree of Airflow Obstruction**/J.D. Rivera Robles, Weston, FL
- P409** **Persistent Hypereosinophilia: An Unveil Case of Chronic Lymphocytic Leukemia**/R.E. Vazquez Nieves, San Juan, PR
- P410** **Relationship Between Lung Hyperinflation and Prognosis in Patients With Chronic Obstructive Pulmonary Disease: Analysis From Prospective Kocoss Cohort**/Y. Kim, Seoul, Korea, Republic of
- P411** **Changes of Usual Practice According to Annual Adequacy Evaluation in Patients With Chronic Obstructive Pulmonary Disease (COPD) From Nationwide Population-based Cohort Study**/Y. Kim, Seoul, Korea, Republic of
- P412** **Cat Score Changes and the Outcomes of Chronic Obstructive Pulmonary Disease**/Y. Kim, Seoul, Korea, Republic of
- P413** **Mortality and Hospital Outcomes in Patients for Asthma and COPD Exacerbations in Thailand During 2017-2021; a Population-based Study**/N. Nakwan, Songkhla, Thailand
- P414** **The Life-sustaining Treatment Decision of Patients With Terminal Stage of Chronic Pulmonary Disease in Tertiary Care Hospital**/H. Lee, Busan, Korea, Republic of
- P415** **Prospective Evaluation of Pneumonia Incidence in COPD Patients With or Without Esophageal Hiatus Hernia and GERD**/Y. Iwata, Tokyo, Japan
- P416** **Patients With History of Non-alcoholic Fatty Liver Disease Admitted for COPD Exacerbation Have Higher Mortality and Worse Outcomes**/A. Aboelnasr, Cincinnati, OH
- P417** **Long-term Stability of SGRQ Total Score in Individuals With AATD-associated Lung Disease Participating in Alphanet's Disease Management Program**/R. Choate, Lexington, KY
- P418** **Characteristics Associated With SGRQ in Alpha-1 Antitrypsin Deficiency-associated Lung Disease: A Cross-sectional Analysis**/R. Choate, Lexington, KY
- P419** **PiSS Alpha-1 Antitrypsin Deficiency: A Clinical Risk Variant?**/D. Fraughen, Dublin, Ireland
- P420** **Alpha-1-antitrypsin Genotyping in Underserved Patients at Risk for Alpha-1-antitrypsin Deficiency in Chicago, Illinois**/Z. Elfessi, Chicago, IL
- P421** **Family Screening in Severe Alpha-1 Antitrypsin Deficiency - Too Little, Too Late? An Argument for Newborn Screening**/S. Roche, Dublin, Ireland
- P422** **Is Genetic Discrimination a Problem in AATD? An Irish Perspective**/S. Roche, Dublin, Ireland
- P423** **Machine-learning Model Identifies Patients With High Probability of Alpha-1 Antitrypsin Deficiency Across the United States**/J. Hinson, Lexington, MA

- P424** Establishment of the Alpha-1 Research Registry Analyzing Demographic and Participant Specific Characteristics/M.P. Goldklang, New York, NY
- P425** Alpha-1 Antitrypsin Deficiency With Cutaneous Manifestation/A. Shahid, St. Louis, MO
- P426** Impact of SARS-CoV2 Pandemic on Pragmatic Study Outcomes/B.P. Yawn, Blaine, MN
- P427** Impact of One Vs. Two Walks on Responsiveness of the Incremental Shuttle Walk Test to Determine Functional Decline in a Tobacco Exposed Cohort/C.A. Rapoza, Pittsburgh, PA
- P428** Association of Small Airway Dysfunction Parameters by Impulse Oscillometry With Lung Function Decline: A Based on E COPD Cohort Study/L. Lu, Guangzhou, China
- P429** PUMA Questionnaire in Combination With Peak Expiratory Flow Rate to Identify at-Risk COPD Subjects/T.-H. Jeng, Taipei, Taiwan
- P430** Clinical, Radiologist-reported, and Quantitative Imaging Analysis-assessed Respiratory Disease in a Veteran Lung Cancer Screening Population/G.H. Frobel, Boston, MA
- P431** Gender Bias in the Diagnosis of COPD in Smokers in a Community Setting/I. Aiyer, Blairstown, NJ
- P432** Survey Results Among COPD Patients About Advanced Care Planning and Lung Disease Education Priorities/D. Many, Charlottesville, VA
- P433** Never-smoker COPD: Does It Have a Different Clinical Course?/S. Jo, Seoul, Korea, Republic of
- P434** A Social Media Listening Study to Understand the Key Focus Areas and Unmet Needs of Healthcare Professionals Around COPD/A. Bhanja, London, United Kingdom
- P435** Sex and Age Related Differences in Clinical Profile and Outcomes in a Cohort of African Adults With COPD/G.A. Amusa, Jos, Nigeria
- P436** Effectiveness of Lung Cancer Screening for Never Smoker COPD/Y.J. Lee, Seongnam-Si, Korea, Republic of
- P438** All That Coughs Is Not Corona: A Challenging Case Of Chronic Cough/S. Biswas Roy, Phoenix, AZ
- P439** Is It Asthma?: A Rare Case of an Endobronchial Hamartoma/K. Dhaliwal, Peoria, IL
- P440** Something in Your Lung: A Cough Caused by Hodgkin Lymphoma/M. Heritage, Columbia, SC
- P441** Diffuse Large B Cell Lymphoma Masquerading As Chronic Cough In Pulmonary Clinic/I. Budnick, Aurora, CO
- P442** Esophageal Rupture Secondary to Aggressive Coughing - Does It Happen?/V.A. Persaud, Corpus Christi, TX
- P443** A Rigorous Persistent Cough Is Not to Be Ignored: A Case of Cough Induced Rib Fracture and Hemothorax in a 57 Year Old Male/A.H.M. Aiken, Paterson, NJ
- P444** Impact of Productive and Dry Chronic Cough on Mortality in the Canadian Longitudinal Study on Aging (CLSA)/I. Satia, Hamilton, Canada
- P445** Laryngeal Hypersensitivity Associated With Chronic Cough in Patients With Underlying Pulmonary Disease/A. Taylor, Salt Lake City, UT
- P446** Nighttime Cough Frequency in Patients With Severe Asthma/S. Nemala, Santa Clara, CA
- P447** No Such Thing as a COVID Cough/M. Glass, Philadelphia, PA
- P448** A Novel Deep Learning Algorithm to Detect Cough and Throat Clearing Events Using Computer Aided Auscultation (cough-caae)/H.A.H. Albitar, Rochester, MN
- P449** Development and Validation of the Mayo Clinic Cough Hypersensitivity Questionnaire (MACHS-Q)/H.A.H. Albitar, Rochester, MN
- P450** A Randomized, Double-blind, Placebo Controlled, Dose Escalation Phase 2 Study Evaluating the Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough/H.A.H. Albitar, Rochester, MN
- P451** Unexplained Chronic Cough: Review of Clinical Characteristics and Response to Pregabalin Therapy/M.D. Saint-Pierre, Ottawa, Canada
- P452** A Phase 3b Trial of Gefapixant, A P2X3-receptor Antagonist, in Women With Chronic Cough and Stress Urinary Incontinence/S.S. Birring, London, United Kingdom
- P453** Remote Monitoring of Pulmonary Patients: A Comparative Analysis of Cough Counts, SpO2, and Patient-Reported Symptoms in Clinical Management/G. Fann, Santa Clara, CA

CLINICAL

THEMATIC POSTER SESSION

A42 CHRONIC COUGH: CUTTING EDGE CLINICAL STUDIES AND CASE REPORTS

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area D, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

BEHAVIORAL • CLINICAL

THEMATIC POSTER SESSION

A43 CLINICAL STUDIES IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area D, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session **11:30-1:15****Discussion:** 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P455 Pleural Complications in Patients Undergoing Percutaneous Renal Cryoablation: A Retrospective Study/I. Albaba, Albany, NY**
- P456 Optimal Interventional Management for Iatrogenic Pneumothorax; Survey of Patients' Perspective on Treatment Options/B. Iqbal, Oxford, United Kingdom**
- P457 Validation of the RAPID Score for Complicated Pleural Infection Treated With Intrapleural Enzyme Therapy/M. Diddams, Chapel Hill, NC**
- P458 Stick It Where It Doesn't Belong: Indwelling Pleural Catheters for Malignant and Non-malignant Pleural Effusions - 5 Years Experience at a Single Academic Center/R. Rakocevic, Los Angeles, CA**
- P459 Burden of Pleural Effusion at Minia Cardiothoracic University Hospital; One Year Study/A. Abdelaziz, Minia, Egypt**
- P460 Endobronchial Ultrasound Guided Intranodal Forcep Biopsy in Mediastinal and Hilar Lymphadenopathy/B. Delprete, Washington, DC**
- P461 A Case Series of Adult Patients With Isolated Tuberculous Mediastinal Lymphadenopathy Diagnosed Via EBUS TBNA/P. Pintac, Manila City, Philippines**
- P462 Cone-beam Computed Tomography, Augmented Fluoroscopy and Radial EBUS Guided Robotic Bronchoscopy Is a Safe and Effective Method of Sampling Pulmonary Nodules in Patients With Severe Lung Disease/B.H. Lashari, Philadelphia, PA**
- P463 Safety And Efficacy Of A Systematic Approach To Evaluation And Treatment Of Airway Malacia: A Single Center, Retrospective Analysis/H. Singh, Milwaukee, WI**
- P464 Discrepancies in Endobronchial Valve Candidacy Between Quantitative Software Platforms/M. Wayne, St. Louis, MO**
- P465 Characteristics of Pleural Effusions Following Bronchoscopic Lung Volume Reduction/S. Dachert, Philadelphia, PA**

- P466 Improving Pulmonary Procedural Anticoagulation Management Via a Quality Improvement Initiative/K. Kolbe, Ann Arbor, MI**
- P467 Timing of Tracheostomy in SARS-CoV-2: Impact in Anatomical Abnormalities of the Airway/O.M. Garcia Morales, Bogota, Colombia**
- P468 Outcomes of Tracheostomy in Critically Ill COVID 19 Patients in North West Texas/M.H. Sarwar, Lubbock, TX**
- P469 Tracheostomy in COVID-19 ARDS Patients on Venovenous Extracorporeal Membrane Oxygenation (VV-ECMO) Support: A Single Center Retrospective Study/B.S. Bhandari, Houston, TX**

CLINICAL

THEMATIC POSTER SESSION

A44 COVID AND ITS CONSEQUENCES: PART I9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area H, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session **11:30-1:15****Discussion:** 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P771 Pathogenetic and Prognostic Significance of Elevated Plasma Levels of the Receptor for Advanced End Glycation Products (RAGE) as a Biomarker of Alveolar Epithelial Injury in Hospitalized COVID-19 Patients/H. Zhuo, San Francisco, CA**
- P772 Vaccination Status During Acute COVID-19 Infection as a Predictor for Post-acute Sequelae of COVID-19 (PASC) Symptoms/A. Witzl, New York, NY**
- P773 Efficacy and Safety of Antiplatelet Agents (or Therapies) in COVID-19 Patients: A Metanalysis of Randomized Controlled Trials/A. Wahab, Mankato, MN**
- P774 The Sound of COVID: Measuring Sound Pressure Levels in COVID ICU Rooms/N. Qureshi, New Brunswick, NJ**
- P775 Confocal Laser Endomicroscopic Findings in Critically Ill COVID-19 Patients/A. Averyanov, Moscow, Russian Federation**
- P776 Accuracy of Intensivist Prognostication on the Development of Late-onset Organ Failure Among Patients With COVID-19: A Prospective Cohort Study/A. Thenappan, Ann Arbor, MI**
- P777 Descriptive Analysis of Impact of COVID-19 Pandemic on Central-line-associated Bloodstream Infections (CLABSIS) Using National Inpatient Sample/U. Bhagat, Cleveland, OH**

- P778 Trends in Outgoing Transfers From Caseload Surge-strained U.S. Hospitals During the COVID-19 Pandemic/S. Sarzynski, Bethesda, MD**
- P779 Implementing Best Practices for COVID-19 Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) in an Intermediate Care Unit Turned to Intensive Care Unit/A.S. Case, Baltimore, MD**
- P780 A Contemporaneous Comparison of Functional Recovery in COVID-19 Extracorporeal Membrane Oxygenation (ECMO) and COVID-19 Non-ECMO Survivors of Acute Respiratory Failure/M.P. Snyder, Baltimore, MD**
- P781 Validation of the Age- Neutrophil to Lymphocyte Ratio-C-reactive Protein Score (ARC) in a National, Multi-site Cohort Across SARS-CoV-2 Variants/B. Sines, Chapel Hill, NC**
- P782 Age Moderates the Effect of Obesity on Mortality Risk in Critically Ill Patients With COVID-19: A Nationwide Observational Cohort Study/C. Den Uil, Rotterdam, Netherlands**
- P783 Do Not Resuscitate Order Prevalence by COVID-19 Status Throughout the First Year of the COVID-19 Pandemic/G. Piscitello, Chicago, IL**
- P784 Estimating Oxygen Demand by Patients Hospitalized With SARS-CoV-2 Infection at a Large Safety-Net Hospital/S. Vanderburg, San Francisco, CA**
- P785 Inhaled Nitric Oxide Administration Does Not Improve Hypoxemia in Critically Ill Patients With COVID-19/T. Ramaswamy, Boston, MA**
- P786 Effects of Inhaled Nitric Oxide in Acute Respiratory Distress Syndrome Due to COVID-19/J. Lee, Dallas, TX**
- P787 Ventilatory Dead Space Fraction Is Not Associated With Markers of Hypercoagulability by Thromboelastography in COVID-19 Acute Respiratory Distress Syndrome/I.S. Jaffe, New York, NY**
- P788 Association Between Severity Scores and Neutrophil to Lymphocyte Ratio in Coronavirus Disease 2019 (COVID-19) Hospitalized Patients/A.R. Mian, Willemstad, Curaçao**
- P789 Procalcitonin as a Proxy for Culture Positive Ventilator-associated Pneumonia in COVID-19/A.I. Kim, Weston, FL**
- P790 A Case-Control Study of Critically Ill Incarcerated Individuals With COVID-19 at a Tertiary Care Center/M. Gillespie, Columbus, OH**
- P791 Examining Heterogeneity of Treatment Effect in Hospitalized Veterans With COVID-19/H. Naiditch, Pittsburgh, PA**
- P792 Cytomegalovirus Infection Is Associated With Poor Clinical Outcomes and Prolonged Duration of SARS-CoV-2 Shedding in Intensive Care Unit Patients With COVID-19 Pneumonia/H.-C. Shen, Taipei, Taiwan**
- P793 Association of Procalcitonin Level With Superimposed Infection and Early Antibiotic Discontinuation in COVID-19 Patients/S. Isha, Jacksonville, FL**
- P794 Assessing Critical Resources: Early Estimation of Mechanical Ventilation and Extracorporeal Mechanical Oxygenation in COVID-19 Patients Based on Early Immune WBC Differential Profiles/S. Isha, Jacksonville, FL**
- P795 Persistently High IL-6 Plasma Levels Associated With Mortality and Receipt of Renal Replacement Therapy in Patients Admitted to Intensive Care Unit With SARS-CoV-2/A. Mostaghim, Bethesda, MD**
- P796 Prolonged Viral Replication Defined by Minus Strand PCR or Positive Strand Cycle Threshold Is Associated With Worse Outcomes in COVID-19 Patients Admitted to ICU/A.R. Moore, Stanford, CA**
- P797 Pulmonary Embolism in COVID-19 Patients With Invasive Mechanical Ventilation in Intensive Care Unit/J. Fuentes, Santiago, Chile**
- P798 The Incidence Rate of Coinfection in COVID-19 Intubated Patients/B. Khiatah, Auburn, WA**
- P799 Use of Finasteride and Spironolactone in Hospitalized COVID-19 Patients and Their Effect on Severity Outcomes/F. Loyola-Nieto, Mexico City, Mexico**
- P800 ABO Blood Group and Rhesus Factor Association With COVID-19 Mortality and Severity: A Two-year Retrospective Review/A.T. Phan, Colton, CA**
- P801 Efficacy and Safety of Zilucoplan for the Treatment of COVID-19 in Hospitalized Patients: Part of the COMMUNITY Platform Trial/A. Ako, Slough, United Kingdom**
- P802 Respiratory Rate-oxygenation Index Score in Corona Virus Disease 2019 (COVID-19) Patients Undergoing Non-invasive Mechanical Ventilation or High Flow Oxygen Supplementation/M. Ziad-M. Said, Willemstad, Curaçao**
- P803 Machine Learning Based Model to Predict COVID-19 Mortality Using Clinical Data and Serum Cytokine Levels/A. Hashemi Shahraki, Jacksonville, FL**
- P804 Palliative Care Needs in Patients Admitted With Severe COVID-19 in Brazil: A Descriptive Study/L. Stanzani, Brasilia, Brazil**
- P805 Serial Metabolomic Analyses Identify Distinct Clinical Implications of Biomarkers in Severe COVID-19 Patients/R. Uchimido, Tokyo, Japan**

P806 Progressive Decline in Serum Albumin Portends Poor Prognosis in ARDS Associated With COVID-19/F.
Nasrawi, Fresno, CA

CLINICAL

THEMATIC POSTER SESSION

A45 ICU PRACTICES, QUALITY IMPROVEMENT, AND MEDICAL EDUCATION

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area K, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

P1107 The Impact of Fluid Dosing on Lactate Clearance and Outcomes in Mild Lactatemia/M. Cabrera, Washington, DC

P1108 Removing Central Lines: Safe Administration of Peripheral Vasopressors/A. Hukku, Chicago, IL

P1109 Infusion Pumps and Their Labeling: A Potential Cause of Error/Z.A. Suchal, Karachi, Pakistan

P1110 Trend Analysis of CLABSI During COVID-19 Pandemic/U. Bhagat, Cleveland, OH

P1111 Set the Standard: Clinical Course and Outcomes for Septic Shock Patients Directly Admitted to the Intensive Care Unit of a Five-Star Medicare Hospital/J. Fiorica, Sarasota, FL

P1112 The Effect of Multidisciplinary Daily Rounding in Intensive Care Unit on Clinical Outcomes/A.A. Chohan, Corpus Christi, TX

P1113 Diagnostic Accuracy of Point-of-Care Ultrasound (POCUS) in Patients With Respiratory Tract Disorders - A Systematic Review and Meta-analysis/F.A. Malik, New Orleans, LA

P1114 Sepsis R Us: Augmenting Inpatient Sepsis Recognition and Management/L. Sankari, Cleveland, OH

P1115 A Multidisciplinary QI Project to Improve SAT/SBT Compliance/A. Vojtek, Allentown, PA

P1116 Improving Intravenous Fluid Resuscitation and Documentation for Sepsis Rapid Response in a Metropolitan Veterans Affairs Hospital/C.N. Neme, Chicago, IL

P1117 Implementation of Antimicrobial Stewardship Rounds in the ICU: Assessing the Utility of a New Intervention/A. Beliavsky, Kingston, Canada

P1118 Single Center Analysis of Spontaneous Awakening Trial Safety Screen Results in the Medical Intensive Care Unit/M. Weiss, Chicago, IL

P1119 Measurable Outcomes in a Quality Improvement Focused Approach for ICU Checklist Implementation and Adherence in a Tertiary Care Center/N. Guirguis, Peoria, IL

P1120 Identifying Barriers to Performing Spontaneous Awakening and Breathing Trials in Mechanically Ventilated Patients in the Intensive Care Unit/M. Murphy, Bronx, NY

P1121 Real World Challenges in Quality Improvement: Implementation of a Respiratory Therapist Driven Spontaneous Breathing Trial Protocol/C. Linke, Minneapolis, MN

P1122 CLABSI Who? Eradication of CLABSI in the ICU Via a Team Approach/H. Channa, Shreveport, LA

P1123 Perception of Challenges and Barriers of Implementing Point of Care Lung Ultrasound Among Respiratory Therapists in California/K.I. Ireland, Loma Linda, CA

P1124 Mortality Rounds: Fellow-Led Multidisciplinary Intensive Care Unit Rounds Discussing End-of-Life Care/K. Bruening, Cleveland, OH

P1125 Arterial Line Placement Practice and Outcomes in Pediatric ICU Patients Requiring Vasoactive Therapy/B. Johnston, New Hyde Park, NY

P1126 Impact of a Low Cost Chest Tube Simulator Model on Procedural Competency/M. Younis, Gainesville, FL

P1127 Bedside Examination? A Forgotten Art in Modern Day ICU/S. Patil, Dhule, India

P1128 Ultrasound Guided Pleural Biopsy: Description of a Model and Trainee Preferences With Respect to Technique/V. Sharma, Aurora, CO

P1129 Virtual Reality Simulation Versus Low-fidelity Text-based Simulations to Teach Medical Students Clinical Emergency Management/D. Argueso, Philadelphia, PA

P1130 Introduction of RUSH (Rapid Ultrasound in Shock and Hypotension) Protocol to the Existing Ultrasound Curriculum for IM Residents/A.D. Patel, Little Rock, AR

P1131 Predictors of Early Readmission After Septic Shock Management: A Pilot Study to Launch Performance Improvement Initiative for Better Sepsis Care/F. Ahmad, Omaha, NE

P1132 Reduction in Intensive Care Unit Length of Stay, Ventilator Days, Central Line Associated Blood Stream Infections, Catheter Associated Urinary Tract Infections, Hospital Associated Venous Thromboembolisms and Mortality Through Implementation of an Intensivist Program in a Non-Academic Community Hospital/I/M.A. Wilson, Mobile, AL

- P1133** **Characterizing In-Hospital Clinical Deterioration From Conditions Present on Admission Versus Hospital-Acquired Conditions/E. Murnin, Madison, WI**
- P1134** **Use of a Digital Twin Virtual Patient Simulator in Critical Care Education: A Pilot Study/P.J. Gary, Rochester, MN**
- P1135** **Decreased Incidence of Hospital- Acquired Infections After Implementation of Real-Time Visualization of Nursing Observations/C.L. Debolt, Charlottesville, VA**
- P1136** **Using Machine Learning to Predict the Diagnosis Causing Clinical Deterioration in Hospitalized Patients/R. Ingebritsen, Madison, WI**
- P1137** **Improving Trainee Performance in the Intensive Care Unit With a Multidisciplinary Rounds Checklist: A Pilot Study/N. Khan, Houston, TX**

CLINICAL

THEMATIC POSTER SESSION

A46 ECMO, ARDS, AND ACUTE RESPIRATORY FAILURE

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area K, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1139** **Drivers of Prognosis Differ in COVID and Non-COVID Patients With Acute Respiratory Failure/S. Pienkos, Stanford, CA**
- P1140** **Potential Value of the Radiographic Assessment of Lung Edema (RALE) Score to Assess Resolution of Pulmonary Edema in a Clinical Trial in ARDS/M. Jabaudon, Clermont-Ferrand, France**
- P1141** **COVID-19 Is Not Associated With Differences in the Frequency or Severity of Ventilator Dyssynchrony/P.D. Sottile, Aurora, CO**
- P1142** **Diaphragm Thickness and Respiratory Drive in Mechanically Ventilated Patients/K. Luoma, La Jolla, CA**
- P1143** **A Retrospective Safety Analysis of Intubations on Patients With COVID-19 by Video Vs. Direct Laryngoscopy/H.J. Young, Fairborn, OH**
- P1144** **Trend of ROX Index Predicts Failure of High Flow Nasal Cannula/V. Kusupati, Tucson, AZ**
- P1145** **The “Secret Sauce”: Key Primary Care Practices for Hospital Survivors of Acute Respiratory Illness/K. Hauschildt, Baltimore, MD**

- P1146** **Impact of PEEP on Surfactant Replacement Therapy in Acute Respiratory Distress Syndrome/R.D. Hite, Cincinnati, OH**
- P1147** **Asymmetrical Elements of a Cannula Interface to Increase Airway Pressure and Improve Dead Space Clearance and During Nasal High Flow/S. Tatkov, Auckland, New Zealand**
- P1148** **Risk Factors for Ventilator-induced Lung Injury Developed Three-to Five-times Faster Post a Single Episode of Lung Injury Compared to Healthy Lungs/E. Rohrs, New Westminster, Canada**
- P1149** **Physician- and Machine-learning of Radiographic Assessment of Lung Edema (RALE) Scores in Acute Hypoxemic Respiratory Failure/K. Golubykh, Harrisburg, PA**
- P1150** **Intracycle Power Distribution Among Anatomic Compartments in a Biologic Lung Model/L.T. Thornton, Minneapolis, MN**
- P1151** **A Comparison Between Sensitivity Analysis of Oxygenation Severity and Acute Respiratory Distress Syndrome (ARDS) of a Machine Learning Algorithm to Predict Hypoxic Respiratory Failure by Utilizing Features Derived From Electrocardiogram (ECG) and Routine Clerical Data/C.E. Marshall, Champaign, IL**
- P1152** **Novel Normoglycemic Human RBC Storage: Post-transfusion Respiratory Sequelae in Nude Mice/B. Hoehn, Durham, NC**
- P1153** **Evaluation of a Novel High Oxygenation Mask System Using Artificial Lung and Simulation/C.-C.A. Hsu, Taipei, Taiwan**
- P1154** **Study of Respiratory Distress Among Neonates in Developing Countries: Unique Insights Into Factors Shaping Early Origin of Adult Lung Diseases/N.K. Bhatta, Dharan, Nepal**
- P1155** **Is Excursion-time Index Measured by Ultrasound of the Diaphragm a Valid Surrogate of Inspiratory Effort?/S. Pini, Milan, Italy**
- P1156** **Investigating the Effect of Mechanical Ventilation on Diaphragmatic Thickness and Contractility in Pediatric Patients Under Neuromuscular Blockade Without Spontaneous Respiratory Effort/C.E. Naber, Boston, MA**
- P1157** **Measuring Central Venous Oxygen Saturation in Severe Hypoxemia/C. Castillo Zambrano, Rochester, MN**
- P1158** **The Deadspace Fraction in Spontaneously Breathing, Healthy Individuals Is Lower in the Prone Position Among Patients With Obesity/W.C. Mcquire, La Jolla, CA**
- P1159** **The Effect of Hospital-wide Use of Oscillating Lung Expansion Systems on Postoperative Respiratory Failure Rates: A Retrospective Study of More Than 2000 US Hospitals From 2013 to 2019/B.C. Becker, St. Paul, MN**

- P1160** Tidal Volume and Volume Targeted Pressure Control in Acute Respiratory Distress Syndrome (ARDS)/A.K. Pearce, La Jolla, CA
- P1161** Dyspnea Is Associated With a Higher Intubation Rate and Mortality in De Novo Acute Hypoxemic Respiratory Failure - A Secondary Analysis of a Randomized Trial/A. Demoule, Paris, France
- P1162** Right Ventricular Systolic Dysfunction Is Associated With the Short-term Mortality in Patients With Pulmonary Acute Respiratory Distress Syndrome/J.-W. Yoo, Jinju, Korea, Republic of
- P1163** Intraerythrocytic Transport of a Respiratory Stimulant: LC-MS Analysis/B. Gaston, Indianapolis, IN
- P1164** Point-of-care Ultrasound Evaluation of Diaphragm as a Predictor of Extubation Failure in Mechanically Ventilated, Valnourished, End-stage Liver Disease Transplant Candidates/I. Barjaktarevic, Los Angeles, CA
- P1165** Association Between Mortality and Gas Exchange in a Mixed Effects Logistical Model of Patients With Severe COVID-19-associated ARDS Undergoing VV-ECMO Support/A.J.O. Davis, Madison, WI
- P1166** A Contemporaneous Comparison of Lung Function Recovery in Extracorporeal Membrane Oxygenation (ECMO) and Non-ECMO Survivors of Acute Respiratory Failure/M.P. Snyder, Baltimore, MD
- P1167** Early Extracorporeal Membranous Oxygenation (ECMO) Referral Leads to Less ECMO Use/G. Manek, Cleveland, OH
- P1168** Prevalence of Delirium by Confusion Assessment Method-Intensive Care Unit (CAM-ICU) Criteria in an Extracorporeal Life Support Population of a Large Tertiary Medical Center/J.G. Hanks, Cleveland, OH
- P1169** Reasons for Death in Patients Cannulated for Extracorporeal Membrane Oxygenation/R.P. Lerner, Bronx, NY
- P1170** Comparing Types of Extracorporeal Membrane Oxygenation (ECMO) in COVID Patients/M. Al Khateeb, Bronx, NY
- P1171** Pulmonary Arterial Cannulation in Venopulmonary-arterial ECMO Compared to Protek Duo With an Oxygenator in Patients With Acute Right Ventricular Failure Requiring Mechanical Circulatory Support/M. Haj Bakri, Washington, DC
- P1172** Safe Administration of Novel Allogeneic iNKT Cell Infusion to Four Patients With Severe COVID-19 Respiratory Failure (CARDS) Receiving Venovenous Extracorporeal Membrane Oxygenation (VV-ECMO) Support/T.C. Hammond, Santa Monica, CA
- P1173** Clinical Characteristics and Outcomes of Pneumothorax in COVID-19 Patients Receiving Venovenous Extracorporeal Membrane Oxygenation/B.V. Garimella, New York, NY
- P1174** Extracorporeal Membrane Oxygenation Practice Changes in Australian Adult Intensive Care Units From 2018 to 2022/C. Hodgson, Melbourne, Australia
- P1175** The Pattern and Distribution of Ventilatory Defects After Extracorporeal Membrane Oxygenation in Leptospirosis With Acute Respiratory Distress Syndrome Survivors: A Single Center Cross-sectional Study/B.L.M. Quizon, Quezon City, Philippines
- P1176** Derivation and Validation of Three Non-Critical COVID-19 Acute Lung Injury Subphenotypes/W.S. Stringer, New York, NY
- P1177** Prolonged Neuromuscular Blockade Administration and Mortality in Patients With Acute Respiratory Distress Syndrome/D. Pan, New York, NY
- P1178** SPA4 Peptide Treatment Reduces the Lipopolysaccharide (LPS)-stimulated CXCL1/KC and Lactate in Primary Mouse Lung Alveolar Epithelial Cells/A.A. Chowdhury, Oklahoma City, OK
- P1179** Noninvasive Host Response Markers for Lower Respiratory Tract Infection Diagnosis in Critical Care/D. Chen, Sykesville, MD
- P1180** Machine Learning Algorithms Predict Successful Weaning From Mechanical Ventilation Before Intubation/H.-J. Kim, Seongnam, Korea, Republic of
- P1181** Observational Versus Experimental Studies on Salvage Therapies in Critical Care Exhibit Profound Selection Bias/E. Landzberg, Philadelphia, PA

CLINICAL

THEMATIC POSTER SESSION

A47 AUTOIMMUNITY, RHEUMATOLOGY, AND THERMOREGULATION: CASE REPORTS

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area C, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

P249 Intractable Pain and Digital Ulceration From Severe Digital Ischemia With Raynauds- How to 'Cut It'?/A. Sinha Ray, Omaha, NE

P250 An Autoimmune Diagnostic Dilemma in the ICU/T. Boyd, Columbia, MO

- P251 A Case of Suspected Mitochondrial Dysfunction Presenting in an Adult/J.A. Blank, Ann Arbor, MI**
- P252 Difficult-to-PinPoint Fatal Hyperammonemia Possibly Secondary to Mutation in PNPT1 Gene/K.A. Darragh, San Diego, CA**
- P253 Rare Fatal Cardiac Tamponade in Systemic Sclerosis/K.L. Burgess, Atlanta, GA**
- P254 Recurrent Manifestation Of Hypothermia, Hyperhidrosis, And Hypotension/A.S. Labar, Pittsburgh, PA**
- P255 Hypothermia And Rescue Collapse In The Sunshine State/R. Puthumana, Miami, FL**
- P256 Beat The Heat: Managing Heat Stroke With An External Cooling Device/A. Proto, Aurora, CO**
- P257 Moderate Hypothermia Without Arrhythmias/D. Alleyne-Agard, Bronx, NY**
- P266 Starvation Ketoacidosis in a Patient With Duchenne's Muscular Dystrophy/D. Prajapati, La Jolla, CA**
- P267 Catastrophic Intracranial Hemorrhage In A Patient With Choriocarcinoma Syndrome/M. Veers, Aurora, CO**
- P268 Post-hypoxic Myoclonus: A Tale Of Two Minds/A. Asghar, Springfield, MA**
- P269 Etomidate Drip For Treatment Of Progressive Proximal Myopathy Due To Severe Cushing's Syndrome/E. Zehr, Aurora, CO**
- P270 Status Epilepticus in Myxedema Coma, A Rare Entity/W. Ali, McKeesport, PA**
- P271 New Onset Refractory Status Epilepticus Shaking Up the Intensive Care Unit/G. Ang, Forest Hills, NY**
- P272 Mind Over Matter: NMDA-Encephalitis Misabeled as Psychosis/A. Wasim, Brighton, MA**
- P273 Consumptive Meningoencephalitis in an Immunocompetent Patient/K. Leonard, Flushing, NY**
- P274 An Unusual Cause of Psychosis in a 69-year-old Man/H. Alaws, Gainesville, GA**
- P275 Hidden With Clues, A Case of Cerebral Amyloid Angiopathy With Recurrent ICH/A. Amirian, Harrisburg, PA**
- P276 A Case of Valproate Encephalopathy Treated With Levocarnitine/K. Seeli, Dover, DE**
- P277 A Unique Case Of A Single Cranial Nerve Deficit And Bilateral Lentiform Nuclei Involvement With Uremic Encephalopathy/G.C. Sun, Bronx, NY**
- P278 Subarachnoid Hemorrhage Presentation May Mimic Acute Myocardial Infarction Due To Diffuse St Elevations/S. Geris, Paterson, NJ**
- P279 Hemodynamic Instability and Refractory Bradycardia in a Patient With Huntington Disease: A Case Report/T.D. Zerpa, Bronx, NY**
- P280 Embolic Stroke Secondary to Massive Stress-induced Apical Thrombosis: A Clinical Conundrum Relating to Anticoagulation Initiation/S.N.S. Yarrarapu, Long Branch, NJ**
- P281 Catastrophic Cerebral Malaria as a Cause for Refractory Distributive Shock/J. Bilodeau, Tampa, FL**
- P282 Creutzfeldt-Jakob Disease: A Rare But Detrimental Cause Of Altered Mental Status/T. Rizvi, Oak Lawn, IL**
- P283 Don't Forget PRES When Evaluating a Patient With Acute Encephalopathy/M. Zopey, Torrance, CA**

CLINICAL

THEMATIC POSTER SESSION

A48 NEUROCRITICAL CARE CASE REPORTS

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area C, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P259 A Case of Ethical Heuristic in Organ Donation During Brain Death Testing Due to a Rare Complication of Apnea Test/F. Dollar, San Antonio, TX**
- P260 A Case of a 67 Year Old Female With Neurological Manifestation of Fat Embolism Syndrome Without Acute Cardiopulmonary Involvement/M. Mashayekhi, Farmington, CT**
- P261 Locked-In Syndrome: A Case Report And Review Of Literature/S. Usman, East Setauket, NY**
- P262 Amyotrophic Lateral Sclerosis as the Initial Manifestation of Chronic Lymphocytic Leukemia: A Rare Possibility/A. Ashraf, Port Jefferson, NY**
- P263 Neurological Devastation: An Interesting Case of Neuroborreliosis Complicated by Cerebral Venous Sinus Thrombosis/C. Tejera Quesada, Atlantis, FL**
- P264 Diffuse Disseminated Demyelination: A Detrimental Outcome/S. Schambach, Saginaw, MI**
- P265 Herpes Simplex Virus 1 Meningitis Presenting as Status Epilepticus/A. Chittal, Baltimore, MD**

CLINICAL

THEMATIC POSTER SESSION

A49 CARDIAC AND VASCULAR CRITICAL CARE CASES9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area C, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session **11:30-1:15****Discussion:** 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.**P285 Free Floating Thrombus of Aortic Arch Due to Essential Thrombocythemia/J. Yang, Springfield, MA****P286 Cardiac Tamponade From a Blood Pressure Pill: An Unusual Presentation of Hydralazine Induced Lupus/P. Ayat, Brooklyn, NY****P287 BRASH Syndrome: A Vicious Cycle/S. Thakur, Wynnewood, PA****P288 Ischemic Mitral Regurgitation Presenting as Unilateral Pulmonary Edema/J.S. Psomiadis, Macon, GA****P289 Protective Effect Of Left Ventricular Hypertrophy In Pulmonary Embolism Of Significant Thrombotic Burden/A. Adam, New York, NY****P290 A Rare Case of Double-valve Streptococcus Mutans Infective Endocarditis in an Immunocompetent Man/A. Adam, New York, NY****P291 A Rare Case: Seizure From Defecation With Severe Aortic Stenosis/Z. Idrees, Bronx, NY****P292 Iatrogenic Takotsubo Cardiomyopathy During Abdominoplasty/R. Cacdac, Rancho Mirage, CA****P293 Acute Heart Failure Due to Multisystem Inflammatory Syndrome in Adults (MIS-A) Requiring Extracorporeal Membrane Oxygenation (ECMO)/S. Sompalli, Springfield, IL****P294 Isolated Pulmonic Valve Endocarditis With Septic Pulmonary Embolism/M. Monk, Kingwood, TX****P295 Successful Treatment With Hydroxycobalamin For Post-arrest Vasoplegic Shock/A. Cecchini, Norfolk, VA****P296 Intra-myocardial Dissecting Hematoma: Late Complication of Cocaine-induced Myocardial Infarction/F.F. Costa Filho, Kalamazoo, MI****P297 Mitral Regurgitation: A Common But Complex Cause of Flash Pulmonary Edema/S. Rodrigues, Farmington, CT****P298 Hiding in Plain Hindsight - A Case of Cardiac Amyloidosis/L. Sangha, Harrisburg, PA****P299 Pericardial Angiosarcoma Presenting as Recurrent Pericardial Effusions/R.N. Abbasi, Grand Rapids, MI****P300 Post-operative R-on-T Phenomenon-induced Cardiac Arrest Due to Temporary Pacemaker Undersensing Requiring Extracorporeal Membrane Oxygenation Support/C. Provenza, Memphis, TN****P301 Uncommon Pathogen Causing Left-sided Endocarditis/M. Henien, Peoria, IL****P302 Large Adhesive Pericardial Effusion: Infrequent Complication of Acute Pericarditis in Young Patients/M. Tayyeb, Long Branch, NJ****P303 Chordae Tendineae Vegetation in the Setting of Strep Mitis: A Case Report/A. Soutar, Wilmington, NC****P304 Use of Intra-aortic Balloon Pump to Augment Treatment of No Reflow Phenomenon After Percutaneous Coronary Intervention of Non St Segment Elevation Myocardial Infarction/V. Garber, Jonesboro, AR****P305 Pacemaker Nearly Turns Into a Widow-maker/M.I. Islam, Charlottesville, VA****P306 A Diagnostic Subterfuge: Stress Induced Cardiomyopathy Following Direct Current Cardioversion/C. Beavers, Wichita, KS****P307 Cardiogenic Shock and Spontaneous Coronary Artery Dissection Successfully Treated With Intravascular Ultrasound Guided Percutaneous Intervention/L.C. Beltran, Berwyn, IL****P308 Evidence Based Management of Right Heart Failure in Intensive Care Unit: A Case Report/S. Usman, Port Jefferson, NY****P309 Balance Between Thrombosis and Major Bleeding Events in a Specific Subset of Patients With Out of Hospital Cardiac Arrest/S.R. Mekala, Kalamazoo, MI**

CLINICAL

THEMATIC POSTER SESSION

A50 CRITICAL CARE CASE REPORTS: CARDIAC AND VASCULAR DISEASE9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area C, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session **11:30-1:15****Discussion:** 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.**P311 A Unique Case Presentation Of Takotsubo Cardiomyopathy After Cardiac Arrest And Resuscitation Without Cpr/M. Gwiazdowski, Poughkeepsie, NY****P312 Calcified Amorphous Tumor of the Heart/H. Alrahamneh, Las Cruces, NM**

- P313** How Worse Can Endocarditis Get? An Unfortunate Case of Subacute Endocarditis Complicated by Elevated INR Secondary to Cefazolin/J. Ravilla, Long Branch, NJ
- P314** A Heart-aching Presentation of Chest Pain: Diagnosis of Pericardial Tamponade in a Middle-aged Woman/S. Price, Olympia Fields, IL
- P315** Wet Beriberi in a Patient Consuming a Restrictive, Gluten-free Diet/M. Jensen, Joint Base Lewis-McChord, WA
- P316** CABG as the Initial Revascularization Therapy for SCAD in a Postpartum Female/H.A. Nayef, Detroit, MI
- P317** An Unusual Presentation of Pericardial Empyema/J. Gala, Urbana, IL
- P318** Point-of-care Ultrasound in the Diagnosis of Cardiac Tamponade in Advanced HIV Infection/M. Freeze, Brooklyn, NY
- P319** In-flight Arrest- A Case of Sudden Cardiac Death/K.L. Burgess, Atlanta, GA
- P320** "Drugs Bug the Heart": A Case of Multiloculated Purulent Pericardial Effusions From IV Drug Use/L. Jain, San Bernardino, CA
- P321** The Implantable Cardioverter Defibrillator- Twiddler's Syndrome - A Seizure Mimic?/K. Rajak, Harrisburg, PA
- P322** Lone Atrial Septal Aneurysm: "Steaming Teapot" - Is Long-term Anticoagulation and Surveillance Warranted?/K. Rajak, Harrisburg, PA
- P323** Trust But Verify: Torsades With a Normal QTc/K. Roman, Birmingham, AL
- P324** Takotsubo Cardiomyopathy Following Viral Gastroenteritis: A Case Report/W. Karam, Wichita, KS
- P325** A Tale Of Broken Hearts: Cardiac Aspergillosis In An Immunocompromised Patient/T. Malik, New York City, NY
- P326** A Case of Uncontrolled Atrial Flutter in a Patient With Known Mac Requiring Prophylactic Intubation and Mechanical Ventilation for Rate Control/S. Avera, Knoxville, TN
- P327** Cardiac Arrest From Superior Mesenteric Artery Syndrome/G. Guzman, Minneapolis, MN
- P328** Cardiac Tamponade After Thrombectomy/A. Gorantla, Brooklyn, NY
- P329** Purulent Tamponade: A Management Dilemma/H. Hussain, Peoria, IL
- P330** I Can't Breathe: A Case of Primary Chylopericardium/D. Font Rivera, San Juan, PR
- P331** Lightning Strikes Twice. A. Defectiva Causing Tri-valvular Infective Endocarditis (ie) in a Patient With Ventricular Septal Defect/J. Dallarosa, Cleveland, OH
- P332** Symptomatic Ruptured Thoracic Aortic Aneurysm Treated By Thoracic Endovascular Aneurysm Repair/S. Chandna, Cleveland, OH
- P333** Aortic Dissection: Rare Complication Of Fibromuscular Dysplasia/M. Malik, Harrisburg, PA
- P334** How Big Is Too Big? A Case of Ruptured Abdominal Aortic Aneurysm/K. Golubykh, Harrisburg, PA
- P335** Alerted by the Wrong Electrogram: A Case of Cardiac Arrest Post Succinylcholine Administration During an Electroencephalogram/P. Adderley, Atlantis, FL
- P336** Pseudoephedrine Induced Chest Pain With Stuttering Ischemic Priapism/M. Eid, New York, NY

BEHAVIORAL • CLINICAL • TRANSLATIONAL
THEMATIC POSTER SESSION
A51 MANAGEMENT AND IMPACT OF THE COVID-19 PANDEMIC ON RESPIRATORY HEALTH
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area H, Hall C (Lower Level)
Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P808** COVID-19 Antibody Testing in Healthcare Workers/P. Saluja, Little Rock, AR
- P809** Healthcare Workers' Disinfection Practices for Elastomeric Half-mask Respirators/P. Thurman, Baltimore, MD
- P810** Healthcare Worker Reusable Respirator Disinfection Practices and Notice of Odor and Residue/A. Shah, Baltimore, MD
- P811** Assessing the Effectiveness of Surface Cleaning Methods in the Medical Intensive Care Unit/R. Zhang, Portland, OR
- P812** Prevalence of Respiratory Symptoms Among Janitors, Custodians, and Maids and Associations With Changes in COVID-19 Cleaning Protocols/A.M. Wilson, Tucson, AZ
- P813** Mental Health and Smoking Cessation Trends During the First Year of the COVID-19 Pandemic/J. Schuster, Rochester, NY
- P814** Trends in COPD Exacerbations Through the COVID-19 Pandemic/A. Balavenkataraman, Jacksonville, FL

- P815** Real-world Retrospective Claims Database Analysis (REACT) of the COVID-19 Pandemic Impact on COPD Exacerbations in the USA/S. Pironi, Parma, Italy
- P816** Hospitalization and Post COVID-19 Symptoms Among Patients With Asthma/A.M. Aldhahir, Jazan, Saudi Arabia
- P817** Mortality and Intubation Risk Factors in Patients With Interstitial Lung Disease Infected With COVID-19 in the United States in 2020/S. Ehteshami-Afshar, Stanford, CA
- P818** The Impact of COVID-19 Pandemic Isolation Measures on Pediatric Bronchiolitis Admissions/S. Raja, Wilmington, DE
- P819** Impact of Air Quality on COVID-19 Outcomes in Ohio/A. Monoson, Columbus, OH
- P820** Impact of Socioeconomic Status on Mortality in Patients With COVID-19 at a Safety-net Hospital/M. Fernandes, Brooklyn, NY
- P821** Typical Clinical Profile of Patients With Suspected COVID-19 Infection Managed in Primary Care and in Emergency Department During the Two Epidemic Peaks of the SARS-CoV2 Pandemic in 2020/O. Taheri, Besançon, France
- P822** Trust in Biomedical Research and Workplace COVID-19 Surveillance Test and Vaccine Uptake Among Miners: A Mixed Methods Study/S. Assaf, Albuquerque, NM
- P823** Veterans Diagnosed With COVID19 With Preexisting COPD Did Not Have an Increased Mortality Compared to Those With Other Comorbid Conditions/J. Suder, San Antonio, TX
- P824** Gender Disparities in All-cause Mortality Among U.S. Veterans Diagnosed With COVID-19 With Prior Chronic Pulmonary Disease/Y. Khairandish, San Antonio, TX
- P825** Quick Resolution of COVID-19 Symptoms Among Vaccinated Major League Baseball Players/J. Rossiello, South Setauket, NY
- P826** Understanding Long COVID in Australia: Shaping Policy and Health Services to Support Long COVID Patients/L. Hatte, Milton, Australia
- P827** Supplemental Oxygen Prescriptions After Hospitalization for Coronavirus Disease 2019/D.A. Puebla Neira, Phoenix, AZ
- P828** Glycemic Control in Post-COVID-19 Patients: A Retrospective Study/K. Golubykh, Harrisburg, PA
- P829** Dynamic Breathing Zone Dose Monitoring of Room Occupants: A New Approach to Demonstrating Safe and Effective Germicidal UV (GUV) Air Disinfection/E.A. Nardell, Boston, MA
- P830** The Convergence of the E-Cigarette or Vaping Associated Lung Injury (EVALI) Epidemic With the COVID-19 Pandemic: A Systematic Review/V.M. Patel, Birmingham, AL

BEHAVIORAL • CLINICAL

THEMATIC POSTER SESSION

A52 STUDIES AND CASE REPORTS IN OCCUPATIONAL LUNG DISEASE9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area D, Hall C (Lower Level)**

- Viewing:** Posters will be on display for entire session **11:30-1:15**
- Discussion:** **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.
- P351** Prevalence of Alpha-1 Antitrypsin Deficiency Among Veterans With Confirmed Chronic Obstructive Pulmonary Disease/G. Rozenbaum Lerner, Miami, FL
- P352** Long-term Outcomes in Veterans Previously Diagnosed With Constrictive Bronchiolitis/T.K. Boyle, Nashville, TN
- P353** Establishing a Specialty Pulmonary Clinic for Veterans With Suspected Deployment-Related Respiratory Disease/A. Rabin, Ann Arbor, MI
- P354** Quantitative Ct Analysis With Functional Respiratory Imaging Detects Objective Pulmonary Abnormalities In Subject With History Of Exposure To Military Burn Pits/J. De Backer, New York, NY
- P355** Bronchial Anthracofibrosis From Burn Pit Exposure/H.V. Tran, New Orleans, LA
- P356** Aerodigestive Disease Overlap: Defining the Cohort for an Observational Non-invasive Biomarker Study in World Trade Center Exposed First Responders/U. Javed, New York, NY
- P357** Association of Post-WTC-mortality With Normal Pre-exposure FEV1/M.D. Weiden, New York, NY
- P358** Occupational Lung Function Decline: A Systematic Review and Network Meta-analysis/A. Moinuddin, Hamilton, Canada
- P359** Occupational Exposure in Non-smokers COPD Patients/E. Fireman Klein, Haifa, Israel
- P360** Patient and Radiological Characteristics Associated With Malignant Lung Nodules in Smokers With Coal Workers' Pneumoconiosis/S. Sarkar, Morgantown, WV
- P361** Coal Workers Pneumoconiosis Complicated With Progressive Massive Fibrosis/A. Vangara, Harlan, KY
- P362** Rapidly Progressive Fixed Airways Obstruction Characterized by Obliterative Bronchiolitis and Coal Macules in an Underground Coal Miner/J.T. Hua, Denver, CO
- P363** The Growing Burden Of Silicosis In Australia - The Case For Prevention/E. Early, Milton, Australia

- P364 A Doll-maker's Lung: Pneumoconiosis Secondary to Long Term Exposure to Silica and Sanding During Doll Production/G. De Allie, Los Angeles, CA**
- P365 Treatment of Acute Silicoproteinosis With Whole Lung Lavage: A Case Report/A. Mittal, Danville, PA**
- P366 Plumber With Pulmonary Nodular Lymphoid Hyperplasia Possibly By Silicosis/V. Dong, New York, NY**
- P367 Inhalation Without Ignition: A Case of Severe Asthma Exacerbation From Occupational Cannabis Exposure/R. Patel, Saint Louis, MO**
- P368 Mesothelioma in Former Nevada Test Site Employee/M. Kapetanios-Fountoulakis, Las Vegas, NV**
- P369 Top Lung: A Case of Intralobar Pulmonary Sequestration in an Active-duty Fighter Pilot/T. Reed, Portsmouth, VA**
- P370 Association of Preserved Ratio Impaired Spirometry With Airflow Obstruction and Mortality Among Silicotic Patients: A Cohort Study/S. Yang, Shatin, Hong Kong**
- P371 Quantitative CT Analysis Identifies Comparable Phenotypes Amongst Gulf War and Post 9/11 Veterans With Suspected Deployment Related Respiratory Disease/J.J. Osterholzer, Ann Arbor, MI**
- P372 Comparison of Lung Clearance Index and Forced Oscillation Testing in Southwest Asia-Deployed Military Veterans With Deployment Lung Disease/S. Kamineni, Aurora, CO**
- P597 Non-invasive Carbon Dioxide Measurement in Ventilator-dependent Children in the Outpatient Setting Increases Likelihood of Ventilator Setting Adjustments/A.S. Montgomery, Washington, DC**
- P598 Scoliosis in Patients With Spinal Muscular Atrophy After Treatment/C. Leon Astudillo, Gainesville, FL**
- P599 Outcomes of Tracheostomy Decannulation Protocol at Texas Children's Hospital/T. Isaacs, Houston, TX**
- P600 Respiratory-Related Investigations Following Pediatric Decannulation/J. Henningfeld, Milwaukee, WI**
- P601 Outpatient Utilization of RAM Cannula for Nasal Non-invasive Ventilation in Children/B. Truitt, Atlanta, GA**
- P602 Evaluating Aerosol Drug Delivery With Continuous Nebulization During Paediatric Mechanical Ventilation/J. Robertson, Chicago, IL**
- P603 BiPAP as a Bridge to Breathing Better: A Novel Approach to Persistent Hypoxemia in a Child With Sickle Cell Disease/S.H. Rizvi, Dallas, TX**
- P604 Case Study: Use Of An Hemadsorption Device During An Infant VA-ECMO/C.N. Immanuel, Austin, TX**
- P605 New Models Of Care For Children At Home With Respiratory Technology Dependence In Washington State/L. Elder, Seattle, WA**
- P606 Dynamic Airway Computed Tomography and Flexible Bronchoscopy for Diagnosis of Tracheomalacia - a Comparison Study/A. Corcoran, Philadelphia, PA**
- P607 Flexible Bronchoscopy in Critically Ill Children and Impact of a High-risk Bronchoscopy Team (HRBT) in a High-volume Center/D. Bullard Elias, Cincinnati, OH**
- P608 Pediatric Nodular Tracheobronchitis: An Institutional Cross-Sectional Review/L.M.C. Grant, Philadelphia, PA**
- P609 Airway Findings in Trisomy 13 and Trisomy 18; A Ten-year Retrospective Review/C. Dress, Cincinnati, OH**
- P610 CT Airway and Bronchoscopy: Do They Correlate?/E. Stokolchik, Wilmington, DE**
- P611 Heterogeneity of Pharyngeal Dysphagia Phenotype to Thin Liquid in a Cohort of Young Children From a Specific Arab Tribe Without Apparent Risk Factors/A. Abdulwahab, Doha, Qatar**
- P612 Smartphone-Based Acoustic Waveform Airway and Respiratory Examination/X. Yin, Pittsburgh, PA**
- P613 Use of Ultrasound for Outpatient Monitoring of Bronchopulmonary Dysplasia/N. Stephenson, Chapel Hill, NC**
- P614 Sham Bilevel Positive Airway Pressure (BPAP) For a Prospective, Randomized, Double Blind, Controlled Trial Evaluating the Role of BPAP in Pediatric Acute Asthma Exacerbations/P. Wilson, Denver, CO**

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A53 CUTTING EDGE: ADVANCES IN PEDIATRIC TECHNOLOGY AND AIRWAY MONITORING

**9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area F, Hall C (Lower Level)**

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P595 Development of Remote Data Collection for Chronic Management of Pediatric Home Mechanical Ventilation/C.C. Foster, Chicago, IL**
- P596 The Correlation of Respiratory Support to Ventilator Weaning in the Pediatric Long-term Mechanical Ventilator Dependent Population/L. Kanbar, Cincinnati, OH**

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A54 PEDIATRIC PULMONARY VASCULAR DISEASE9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area F, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P616 Myocardin-related Transcription Factor A Plays a Key Role in Right Ventricular Pro-fibrotic Signaling and Dysfunction in Response to Right Ventricular Pressure-loading/M. Rzepka, Toronto, Canada**
- P617 Accelerometer-measured Physical Activity Is Associated With Longer 6-minute Walk Distance and Better Handgrip Muscle Strength in Children With Pulmonary Hypertension/C. Avitabile, Philadelphia, PA**
- P618 Dynamic Vital Sign Changes Are Associated With Six-minute Walk Work Performed by Children With Chronic Cardiopulmonary Disease/J.V. Russo, Charlottesville, VA**
- P619 Prevalence of Pulmonary Hypertension in Children With Severe Obstructive Sleep Apnea- a Single Center Study/M. Feeley, New York, NY**
- P620 Factors Associated With Chylothorax Among Children Who Underwent Congenital Cardiac Surgery/E.A.R. Sumayod, Quezon City, Philippines**
- P621 Concurrent Pulmonary Hypertension And Diffuse Alveolar Hemorrhage In A Child With Scurvy/K.M. Gaietto, Pittsburgh, PA**
- P622 Case Report Of Pulmonary Hypertension In A Child As A Sequela Of COVID-19/R.T. Huq, Shreveport, LA**
- P623 Diagnosis of Scimitar Syndrome in an Asymptomatic 10-year-old Patient With Previous History of Pulmonary Hypertension in Infancy: A Case Report/B. Marburger, Pittsburgh, PA**
- P624 Severe Heritable Pulmonary Arterial Hypertension Due To A Pathologic SOX17 Variant Treated With A Reverse Potts Shunt/K. Hendra, Palo Alto, CA**
- P625 An Atypical Cause Of An Acute Exacerbation Of Bronchopulmonary Dysplasia Associated Pulmonary Hypertension/K.A. Carr, Nashville, TN**
- P626 Anomalous Systemic Venous Return: A Rare Cause of Hypoxemia Identified in a Neonate/H. Schmidt, Chicago, IL**

- P627 Unusual Pulmonary Manifestation in a Child With Congenital Mitral Stenosis/O. Alhalabi, Doha, Qatar**
- P628 The Role of Type I Interferon on Trisomy 21 Endothelial Angiogenesis/A. Frauenpreis, Torrance, CA**
- P629 Long-Standing Alterations in Pulmonary Vascular Cell Phenotype and Cell-Cell Communication Upon Recovery From Acute Hyperoxia Defined at Single-Cell Resolution/C. Knutsen, Palo Alto, CA**

CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A55 ZEBRAS FOR \$800: RARE PEDIATRIC LUNG DISEASE CASES9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area F, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P631 Negative Pressure Pulmonary Hemorrhage Following Upper Airway Obstruction In A Toddler/S.J. Rose, Cincinnati, OH**
- P632 Pediatric Pulmonary Rehab: A New Frontier/K. Ruff, Cincinnati, OH**
- P633 Diffuse Alveolar Hemorrhage as Initial Presentation of Childhood Systemic Lupus Erythematosus/K. Ruff, Cincinnati, OH**
- P634 Pulmonary Manifestations of Pediatric Microscopic Polyangiitis: A 12 Year Case Series From a Tertiary Care Facility/S. Sridhar, Columbus, OH**
- P635 The Bleeding Dilemma: Idiopathic Pulmonary Hemosiderosis or Capillaritis? When Tissue Is Not Diagnostic/L. Lee, Palo Alto, CA**
- P636 A Rare Case of Sjogren's Syndrome Following Steven Johnson Syndrome and Bronchiolitis Obliterans in a 15-year-old Female/A. Pant, Gainesville, FL**
- P637 So Many Eos - A Toddler With Eosinophilic Granulomatosis With Polyangiitis/T.A. Curry, Aurora, CO**
- P638 Chronic Cough, Wheezing, And Eosinophilia In A Preschool-aged Boy/C.W. Wynn, Cincinnati, OH**
- P639 Autologous Stem Cell Transplant in a Patient With Severe Restrictive Lung Disease From Juvenile Systemic Sclerosis/Dermatomyositis Overlap Syndrome Refractory to Disease-modifying Antirheumatic Drugs/A. Zaveri, Pittsburgh, PA**

- P640** Post-transplant Lymphoproliferative Disease Presenting as a Chronic Cough and Necrotic Palatal Ulcer/A. Zaveri, Pittsburgh, PA
- P641** Immunologic Mediated Lung Disease In An Adolescent Male/D. Saad, Little Rock, AR
- P642** An Unusual Case of Aspiration Pneumonitis Due to CSF Aspiration/S. Hendricks, Chapel Hill, NC
- P643** Mek-in Chylothorax Go Away: Ras/mitogen-activated Protein Kinase-extracellular Signal-regulated Kinase Inhibitor (mek-in) Treatment of Diffuse Pulmonary Lymphatic Disease/R. Wong, San Diego, CA
- P644** An 11-year-old Boy With Dyspnea, Desaturation And A Rash/S.A. Cabrera Guerrero, Washington, DC
- P645** A Case Of Seizure-induced Hemoptysis In A Pediatric Patient/M. Kahwaty, Baltimore, MD
- P646** Chest Pain And Angioedema In A Child With Neurofibromatosis Type 1/I. St. Onge, Worcester, MA
- P647** Rare Cause Of Bullous Emphysema In An Adolescent Female/K. Capusan, Lake Success, NY
- P648** Membranous Obliterative Bronchitis in a Pediatric Patient With Congenital Neutropenia/S. Chun, Los Angeles, CA
- P649** Dyspnea With Normal Chest CT Findings/A. Dodson, Los Angeles, CA
- P650** An Imaging Conundrum in Ataxia Telangiectasia/T.D. Hicks, Los Angeles, CA
- P651** A Unique Presentation Of Dyskeratosis Congenita And Enormous Lung Cysts/J.A. Palomares, Los Angeles, CA
- P652** Spontaneous Pneumothorax as an Initial Presentation of Marfan Syndrome in a Teenager With Intermittent Chest Pain: A Case Report/J.B. Ancheta, Quezon City, Philippines
- P653** The Return of the Rachitic Lungs: A Case Report of Respiratory Failure/L.E. Lezama, Dallas, TX
- P654** Acute Liver Failure Following Lamotrigine Use: Drug Reaction, Hemophagocytic Syndrome, or Both?/K. Roman, Birmingham, AL
- P655** New-onset Dyspnea and Stridor in a Patient With Urbach-wiethe Disease/J. Kimpo, Brooklyn, NY
- P656** Joubert Syndrome: A Rare Cause of Progressive Chronic Respiratory Failure/N. Kharode, New York, NY
- P657** Alveolar Proteinosis Following Covid-19 Infection: Cause Or Confounder?/M. Middendorf, Gaithersburg, MD

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A56 PEDIATRIC BRONCHIECTASIS CASES

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area F, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P659** Primary Ciliary Dyskinesia in Premature Neonates/L. Mapala, Montreal, Canada
- P660** Persistence Pays Off: Expanding Genetic Analyses to Identify Variants in Recently Discovered Genes Associated With Primary Ciliary Dyskinesia/R.A. Gardner, Chapel Hill, NC
- P661** KCNQ1 Gene Defect in a Child With Severe Multi-lobar Bronchiectasis/A. Han, Seattle, WA
- P662** An Uncommon Bacteria And A Rare Disease: Burkholderia Cepacia And Primary Ciliary Dyskinesia/J. Muñoz, Cayey, Puerto Rico
- P663** Total Lung Consolidation/Collapse as a Rare Presentation of Primary Ciliary Dyskinesia/O. Alhalabi, Doha, Qatar
- P664** Concomitant Ciliopathies: Trio-genetic-analysis of a Rare Case With Bardet Biedl Syndrome and Overlapping Primary Ciliary Dyskinesia Phenotype/A.J. Santos-Lopez, Ponce, Puerto Rico
- P665** Persistent Pneumonia And Worsening Bronchiectasis In A Patient With MIRAGE Syndrome : A Case Report/P.E. Mishra, Pittsburgh, PA
- P666** Meconium Aspiration Syndrome As A Novel Etiology Of Pediatric Bronchiectasis/E.G. Lorton, Aurora, CO
- P667** Could Malacia of the Tracheobronchial Tree Cause Bronchiectasis in Pediatric Patients?/M. Siegert Ospina, Gainesville, FL
- P668** Hemoptysis In The Time Of Covid/T. Kockar Kizilirmak, New Haven, CT
- P669** When Less Is More: Reversion to Pancreatic Insufficiency Due to Switch From Ivacaftor to Elexacaftor/Tezacaftor/Ivacaftor in a Cystic Fibrosis Patient Heterozygous for F508del and G551D/R. Wong, San Diego, CA
- P670** To Do or Not to Do: Extracorporeal Membrane Oxygenation (ECMO) In a Cystic Fibrosis With Septic Shock Due to Methicillin Resistant Staph Aureus (MRSA)/M. Rehman, Morgantown, WV

- P671** Acute Respiratory Failure Requiring VV ECMO in a Toddler With Cystic Fibrosis/C. Giles, Denver, CO
- P672** Worsening Anxiety With Elexacaftor-Tezacaftor-Ivacaftor: Navigating the Mental Health and Pulmonary Implications in an Adolescent Patient With Cystic Fibrosis/A. Hughes, Nashville, TN
- P673** Lightning Never Strikes in One Place Twice? Not for My Patient With Both HPS and CF/W. De Jesus-Rojas, Ponce, PR
- P674** Management of Rash in the Setting of a Triple Combination Cystic Fibrosis Transmembrane Regulator Modulator/M. Pertzborn, Little Rock, AR
- P675** Continuing Positive Sweat Test Despite Trikafta Therapy: A Case Report/A.G. Beshish, Madison, WI

CLINICAL

THEMATIC POSTER SESSION

A57 GREAT CASE! INTERESTING CASES IN PULMONARY VASCULAR DISEASE

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P115** Not Just For Pirates: A Young Woman Presenting With Severe Pulmonary Hypertension Secondary To Scurvy/L. Benes, New York, NY
- P116** Novel 3D Electrical Impedance Tomography Evaluating Perfusion Recovery in Chronic Thromboembolic Pulmonary Hypertension Patient After Balloon Pulmonary Angioplasty/L. Wang, Shanghai, China
- P117** A Novel 3D EIT Imaging Measurement for Pulmonary Perfusion Without Saline Injection at the Bedside/L. Wang, Shanghai, China
- P118** An Antemortem Diagnosis Of Pulmonary Tumor Thrombotic Microangiopathy Via Right Heart Catheter Wedged Blood Sampling /C. Ambrogi, Camden, NJ
- P119** Decompensated Right Heart Failure Secondary to Systemic Lupus Erythematosus Flare and Pulmonary Arterial Hypertension Managed With Aggressive Immunosuppression: A Case Series/J.F. Jaber, Gainesville, FL
- P120** Successful Treatment Of A Rapidly Expanding Life-Threatening Pulmonary Artery Aneurysm With An Amplatzer Vascular Plug In A Patient With Behçet's Disease/N.B. Ghaleb, Holy Makkah, Saudi Arabia
- P121** Pulmonary Vascular Remodeling May Precede Pulmonary Arterial Pressure Elevation In Pulmonary Veno-occlusive Disease- A Report Of Three Cases/V. Foris, Graz, Austria
- P122** A Rare Case of Hepatopulmonary Syndrome Due to Hepatic Sarcoidosis Without Cirrhosis/J.R. De La Fuente, New Brunswick, NJ
- P123** Fatal Pulmonary Arteriovenous Malformation Rupture/K. Lai, Taipei, Taiwan
- P124** Haemodynamic and Clinical Improvement After Endovascular Embolization in a Patient With Pulmonary Hypertension Secondary to a Traumatic Hepatic Arteriportal Fistula/A. Reis Guimaraes, Porto Alegre, Brazil
- P125** Chronic Pancreatitis: A Rare Cause of Hemoptysis by the Inferior Phrenic Artery/M.M. Kattula, Detroit, MI
- P126** Here Today, Gone Tomorrow: A Case Of Transient Pulmonary Hypertension In Sickle Cell Crisis/A.P. Marmaro, Camden, NJ
- P127** Gastric Adenocarcinoma Presenting as Pulmonary Hypertension in a Young Female/N. Street, Knoxville, TN
- P128** It's Complicated: Dyspnea and Hypoxemia in a Patient With Portal Hypertension/K.T. Del Valle, Rochester, MN
- P129** A Case Report of Pulmonary Arterial Hypertension Caused By TBX4 Mutation With Suspected Impaired Hepatic Synthesis/D. Liu, Beijing, China
- P130** When We Ignore the Obvious: A Case of Respiratory Failure Secondary to Pectus Excavatum/R. Ali, Harrisburg, PA
- P131** Flail Posterior Mitral Leaflet From Infective Endocarditis: An Unusual Case of Diffuse Alveolar Hemorrhage/M. Tsai, Boston, MA
- P132** Wall Eclipsing Sign: Pulmonary Artery Intimal Sarcoma (PAIS) Mimicking PE/D.E. Espinoza Barrera, New Orleans, LA
- P133** A Great Red Herring: A Rare Case of Primary Pulmonary Artery Sarcoma/G.F.U. Salacup, Baltimore, MD
- P134** Time for Teamwork: An Interdisciplinary Approach to Pulmonary Arteriovenous Malformations in Pregnancy/J. Grincer, Orange, CA
- P135** Double Jeopardy: An Unusual Case of Pulmonary Venous Varix With Associated Embolic Stroke and Alveolar Adenoma/R.S. Simmons-Beck, Providence, RI
- P136** A Rare Case of Pulmonary Venous Thrombosis (PVT)/A. Jain, Valhalla, NY
- P137** A Case of Cardiac and Pulmonary Cement Embolism (CPCE) After Percutaneous Vertebroplasty/A. Jain, Valhalla, NY

- P138** An Unusual Complication of Fibrosing Mediastinitis Presenting as Dyspnea on Exertion/A. Nadkarni, Urbana, IL
- P139** VA ECMO as a Bridge to Pulmonary Thromboendarterectomy in a Patient With Cardiogenic Shock Due to CTEPH/C.A. Thomas, Falls Church, VA
- P140** Large Pulmonary Artery Aneurysm: A Case of Congenital Malformation Diagnosed in Adulthood/G. Ivashchuk, Houston, TX
- P141** Acute Hypoxic Respiratory Failure Due to CTEPH Managed With Awake Venovenous ECMO/M. Naser, Springfield, MA
- P142** Acute Right Heart Failure in a Patient With a Massive Pulmonary Artery Aneurysm During a Long-haul Flight/A. Jin, San Jose, CA
- P143** In the Shadow of MEN; A Case Report on Chronic Thromboembolic Disease Associated With Multiple Endocrine Neoplasia, Type 1/Y. Abouleish, Norfolk, VA
- P144** An Unexpected Cause of Shortness of Breath/A. Weyer, Tyler, TX
- P145** Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia in Adults/S. Hon, Boston, MA
- P146** "Inside The Web": Hemodynamic Measurements In Unexpandable Lung/D. Kulkarni, Tampa, FL
- P147** Hemoptysis in a Patient With Double-Inlet Left Ventricle/M.A. Pascoe, Lexington, KY
- P547** Pulmonary Arterial Hypertension in Patients With Pulmonary Fibrosis Undergoing Lung Transplantation Is Associated With CT Evidence of Arterial Pruning/F.N. Rahaghi, Boston, MA
- P548** Novel Electrical Impedance Tomography for Diagnosis of Pulmonary Embolism: A Diagnostic Trial/L. Wang, Shanghai, China
- P549** Clot Ratio, a New Clot Burden Marker Correlating With the Risk Stratification of Patients With Acute Pulmonary Embolism/L. Xi, Beijing, China
- P550** Right Ventricular Free Wall Longitudinal Strain Varies Significantly by Pulmonary Arterial Hypertension Etiology/A. Meservey, Philadelphia, PA
- P551** Cardiac MRI Stroke Volume Correlates With Cardiac Effort But Not Activity/D. Lachant, Rochester, NY
- P552** Relationship Between Right and Left Ventricular Strain in Systemic Sclerosis-related Pulmonary Hypertension/J.K. Lui, Boston, MA
- P553** Relationship Between Quantitative CT Metrics of Pulmonary Vascular Volume Distribution and Pulmonary Hemodynamics in Pulmonary Arterial Hypertension/B.R. Lavon, New York, NY
- P554** Factors Associated With Overutilization of Transthoracic Echocardiography in Pulmonary Embolism and Its Outcomes/J.M. Martinez Manzano, Philadelphia, PA
- P555** Increased CT-derived Left Atrial Measurements Are Associated With Elevated Pulmonary Capillary Wedge Pressure in Patients With Idiopathic Pulmonary Fibrosis/T. Shirahata, Boston, MA
- P556** Hemorrhagic Complications of Percutaneous CT-Guided Lung Biopsy in Patients With Pulmonary Hypertension: A Systematic Review and Meta-Analysis/D. Jang, Providence, RI
- P557** Transthoracic Echocardiogram Findings in Patients With Enlarged Pulmonary Arteries and Increased Pulmonary Artery to Ascending Aorta Ratios on CT Pulmonary Angiography in an Emergency Department Cohort/B. Scarpato, Salt Lake City, UT
- P558** Subcutaneous Fat Volume at T8 Level (SFV-T8) Is Associated With High Intrathoracic Pressure in Obese Patients Undergoing Right Heart Catheterization/G. Manek, Cleveland, OH
- P559** Incidence of Venous Thromboembolism in Motor Neuron Disease: A Retrospective Analysis/F. Pyarali, Los Angeles, CA
- P560** Study of a Novel 3D-printed Hypoxia System to Evaluate Endothelial Cell Dysfunction in Chronic Thromboembolic Pulmonary Hypertension/Y. Roger Valle, Barcelona, Spain

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A58 VISUALIZING THE FUTURE: IMAGING IN PULMONARY HYPERTENSION

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area E, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P545** Systematic Use of Chest Imaging and Spirometry to Distinguish Phenotypes of Pulmonary Hypertension in Patients With Connective Tissue Disease-related Interstitial Lung Disease/S.L. Khan, Baltimore, MD
- P546** CT Vascular Findings in PAH Associated With Schistosomiasis, Portopulmonary Hypertension and Group 1 Pulmonary Hypertension: A Comparison/F.N. Rahaghi, Boston, MA

CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

**A59 CLOTS, CLOTS, AND MORE CLOTS:
VENOUS THROMBOEMBOLIC DISEASE**

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P149 Hemodynamic and Exercise Limitation of Chronic Pulmonary Embolism Compared to Patients With Resolved Pulmonary Embolism/A. Kelder, Pittsburgh, PA**
- P150 Association Between Nutritional Status and Hospital Readmission in Acute Pulmonary Embolism/K.U. Lio, Philadelphia, PA**
- P151 Impact of Reperfusion Therapies in the Late Outcomes of Acute Pulmonary Embolism/K.U. Lio, Philadelphia, PA**
- P152 Diagnostic and Prognostic Value of Plasminogen Activator Inhibitor -1 in Acute Pulmonary Embolism/A. Abdelaziz, Minia, Egypt**
- P153 End Tidal Carbon Dioxide Reflects Pulmonary Embolism Risk Severity/P. Ho, Wynnewood, PA**
- P154 Cellular Indices May Be Predictive of In-hospital Mortality in Patients With Acute Pulmonary Embolism/J. Moore, Philadelphia, PA**
- P155 Transthoracic Echocardiography Can Help to Predict Venous Thromboembolism and Mortality in Sickle Cell Disease/M. Spring, Boston, MA**
- P156 Acute Kidney Injury as a Surrogate for Right Ventricular Strain in Acute Pulmonary Embolism/N. Van Der Rijst, Philadelphia, PA**
- P157 The Impact of Varying Interventions on Rate of Renal Recovery in Acute Pulmonary Embolism/N. Van Der Rijst, Philadelphia, PA**
- P158 Impact of Obesity on Outcomes in Intermediate-high Risk Pulmonary Embolism/S. Ansari, Philadelphia, PA**
- P159 Impact of Deep Vein Thrombosis on Outcomes in Obesity and Intermediate Risk Pulmonary Embolism/S. Ansari, Philadelphia, PA**
- P160 Creatinine at Presentation and Length of Stay in Intermediate and High Risk Pulmonary Embolism Presenting at an Academic Tertiary Care Center/A. Singh, Farmington, CT**
- P161 Prevalence of Uterine Fibroids Amongst Women Hospitalized for Acute PE in a Single Tertiary Center/O. Ahmed, Baltimore, MD**
- P162 Uric Acid (UA) as a Potential Novel Biomarker to Improve Risk Stratification of Acute Intermediate High-risk Pulmonary Embolism (IHRPE)/H. Subba, Portland, ME**
- P163 Description of a Cohort of Patients Diagnosed With High and Intermediate-high Risk Acute Pulmonary Embolism Presented in the PERT Group Between 2019 and 2022 at Hospital Universitario San Ignacio (HUSI) in Bogota-Colombia/C. Villaquirán-Torres, Bogotá, Colombia**
- P164 Reasons to Rebuild a Multidisciplinary Pulmonary Embolism Response Team Post-COVID/J. Moore, Norwalk, CT**
- P165 Predicting Presence of Massive Pulmonary Embolism (PE)/M. Samant, Saint Louis, MO**
- P166 The Impact of Catheter-based Therapy Approach and Timing on Survival in Patients With Pulmonary Embolism. Nationwide Analysis/R. Ahmad, Toledo, OH**
- P167 Assessment of Prehospital Aspirin Use and Outcomes of Pulmonary Embolism in Non-surgical Patients/H. Shanmugavel Geetha, Worcester, MA**
- P168 Outcomes of Patients With COPD and ILD Admitted With Pulmonary Embolism/R. Dalbah, Johnson City, TN**
- P169 4-year Clinical Impact of Pulmonary Embolism Response Team at a Single Tertiary Care Center/A. Longino, Aurora, CO**
- P170 Trend, Prevalence, and Outcomes of Pulmonary Embolism Amongst Us Hospitalizations - National Estimate/H. Regassa, Addis Ababa, Ethiopia**
- P171 Anticoagulation Practices in Intermediate Risk Pulmonary Embolisms After Advanced Therapy/A.B. Karanam, Philadelphia, PA**
- P172 Comparison of Events Across Bleeding Scales in Patients Who Underwent CDT and Systemic Thrombolysis- A Single Center Retrospective Review/S. Pettigrew, Philadelphia, PA**
- P173 Analysis of Outcomes of Acute Pulmonary Embolism Patients Receiving Inter-hospital Transfer Managed by the Pulmonary Embolism Response Team/P. Sridhar, New York, NY**
- P174 Prevalence and Impact of Chronic Obstructive Pulmonary Disease in Pulmonary Embolism/M.H. Yusuf, Bronx, NY**
- P175 Multidisciplinary Evaluation and Early Surgical Outcomes for Chronic Thromboembolic Pulmonary Hypertension in an Emerging Comprehensive Management Center/A. Cruse, Atlanta, GA**

- P176** **Diagnosis of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) by Cardiologists and Pulmonologists - a Global Cross-Sectional Scientific Survey (CLARITY)/P.R. Forfia, Philadelphia, PA**
- P177** **Real Life Epidemiology of Adverse Drug Events Under Oral Anticoagulant Treatment in the Emergency Department/O. Taheri, Besançon, France**

BASIC • TRANSLATIONAL
THEMATIC POSTER SESSION
A60 LET'S MEET AT DUPONT CIRCLE: NEW MOLECULAR TRAFFIC PATTERNS IN PULMONARY HYPERTENSION

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**
Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P179** **A Novel Mechanism Regulating Apoptosis Resistance in Pulmonary Artery Smooth Muscle Cells/S. Niedermeyer, Baltimore, MD**
- P180** **Renin Angiotensin Aldosterone Pathway in Group 1 and 2 Pulmonary Hypertension (PH)/D. Padmanabhan Menon, Boston, MA**
- P181** **Resistin Like Molecule and RAGE Pathways for the Responses of the Pulmonary Vasculature to Challenge With Ambient Urban Particulates/S. Kwon, New York, NY**
- P182** **Bone Marrow-derived Stem Cells From Mice With Pulmonary Hypertension Exhibit Differential Expression of Genes That Modulate Lymphoid Differentiation and Myeloid Recruitment/R.S. Simmons-Beck, Providence, RI**
- P183** **Non-canonical Role of Caspase-3 in Promoting Migration and Proliferation in Endothelial Cells/N. Skandan, Baltimore, MD**
- P184** **RNA Binding Protein, ZFP36 Regulates Cell Cycle and DNA Repair in PAH-PASMC/G. Ruffenach, Los Angeles, CA**
- P185** **Expression and Purification of the Human Phosphatase PPM1B/R.P. Stevens, Mobile, AL**
- P186** **PFKFB3 Inhibits Fructose Metabolism in Pulmonary Microvascular Endothelial Cells/R.P. Stevens, Mobile, AL**
- P187** **Characterizing Endostatin-induced Changes in Endothelial Gene Expression: The Important Role of MicroRNA/N.R. Klauer, Baltimore, MD**
- P188** **Savi Mice Spontaneously Develop Pulmonary Hypertension in a Sex-specific Manner/A. Pham, Gainesville, FL**
- P189** **Intrinsic Bone Morphogenetic Protein Antagonist Gremlin 1 as a Potential Biomarker for Therapy Efficacy in a Rat Model of Pulmonary Arterial Hypertension/S. Cantoni, Parma, Italy**
- P190** **NAMPT Overexpression Decreases Sirt 3 Deacetylase Activity in Human Pulmonary Artery Endothelial Cells/P.E. Adogamhe, Indianapolis, IN**
- P191** **miR-637/COL18a1 Expression in the Sugem-hypoxic Rat Model of Pulmonary Hypertension/A.S. Ambade, Baltimore, MD**
- P192** **Estriol: Effects on Control Rat and Human Pulmonary Arterial Smooth Muscle Cells and Markers of Fibrosis in Mice/S. Sharma, Glasgow, United Kingdom**
- P193** **Circadian Immunity in Pulmonary Hypertension/E. Ebrahimi, Gainesville, FL**
- P194** **The Mitochondrial Protein Mitoneet and Its Involvement With Iron Homeostasis and Metabolic Regulation in Pulmonary Hypertension/M.R. Smith, Atlanta, GA**
- P195** **Loss of Vascular EC-SOD Is Protective Against PH in the Sugem Hypoxia Model of Pulmonary Hypertension Through Changes in Mitochondrial Respiration Mediated by p-AMPK/D. Colon Hidalgo, Aurora, CO**
- P196** **MiRNA-133-a as a Mediator of Endostatin-dependent Gene Expression in Pulmonary Arterial Hypertension/M. Naranjo Tovar, Baltimore, MD**
- P197** **Complement C3/C3a Loaded Small Extracellular Vesicles Generated by Pulmonary Hypertensive Fibroblasts Cause Metabolic Reprogramming and Proinflammatory Activation of Macrophage/S. Kumar, Aurora, CO**

BASIC • CLINICAL • TRANSLATIONAL
THEMATIC POSTER SESSION
A61 TUBERCULOSIS

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**
Area I, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P851** **An Unusual Presentation of Extrapulmonary Tuberculosis/A. Gogokhia, Telford, United Kingdom**
- P852** **The Many Faces Of Tuberculosis: A Case Of Pulmonary Tuberculosis Mimicking Granulomatosis With Polyangiitis/B. Wong, Boston, MA**

- P853 Tuberculoma Brainstorm: A Case of Concurrent Intra-cranial and Intra-medullary Tuberculomas Presenting as Ascending Paralysis/S. Toor, Grand Rapids, MI**
- P854 Successful Treatment of Both Tuberculosis and Hepatitis C Virus Co-infected Patients With the Utilization of Therapeutic Drug Monitoring/A. Alexis, Miami, FL**
- P855 Comprehensive Analysis of Short Non-coding RNAs Accumulated in the Plasma of Patients Infected With Mycobacterium Tuberculosis/J. Gumas, Philadelphia, PA**
- P856 Tuberculosis Unraveled: A Rare Complication of Coil Embolization for Rasmussen's Aneurysm in Pulmonary TB/M. Weingart, San Francisco, CA**
- P857 Tuberculous Empyema in a Patient With Lymphangioma/O. Salamo, Houston, TX**
- P858 Granulomatous Reaction Not Otherwise Specified: Culture-Negative Tuberculosis vs Sarcoidosis in a Patient With Pericarditis. Easier Said Than Done/F. Aldaghlawi, Cleveland, OH**
- P859 When Great Mimickers Mimic Each Other: TB Under The Veil Of Sarcoid/J. Bell, Washington, DC**
- P860 Consider The Patient: A Case Of Clinical Correlation Versus Laboratory Proof In Miliary Tuberculosis/R. Teich-Mcgoldrick, Farmington, CT**
- P861 A Case of Miliary Tuberculosis Presenting With Neurologic Symptoms/C. Walker, Washington, DC**
- P862 Tb Or Not Tb: A Unique Presentation Of Pleural And Peritoneal Tuberculosis/M. Zemel, Worcester, MA**
- P863 Pulmonary Cavitation Found to Be Coinfected With Mycobacterium Tuberculosis and Coccidioides Immitis/A.Z. Kiani, Rancho Mirage, CA**
- P864 Asymptomatic Tb Bacteremia And Complication In A Immunocompetent Host/M. Sharfi, Queens, NY**
- P865 Tuberculosis Septic Shock In An Immunocompetent Patient/M.K. Gill, Brooklyn, NY**
- P866 Poncet's Disease: Reactive Arthritis in a Patient With Tuberculosis/M. Qaiser, Stamford, CT**
- P867 Presumed Miliary Tuberculosis in an Immunocompetent Patient/M. Qaiser, Stamford, CT**
- P868 Incidental Discovery of Endobronchial Tuberculosis in an Elderly Man/C.H. Yee, Hershey, PA**
- P869 A Rare Presentation of Extrapulmonary Tuberculosis/S.M. Hussain, Rochester, MI**
- P870 Tuberculous Pleural Effusion Diagnosed by History and Polymerase Chain Reaction Alone/R. Singh, New York, NY**
- P871 A Case of Endobronchial Tuberculosis (EBTB)/J.R. Israel, Sacramento, CA**
- P872 A Rare And Misleading Presentation Of Pulmonary Tuberculosis Complicated With Alveolar-pleural Fistula/A.R. Reihani, Rancho Mirage, CA**
- P873 Black Bronchoscopy in Healed and Active Pulmonary Tuberculosis/M. Agustin, Dededo, Guam**
- P874 A Unique Case of Tuberculosis Induced Acute Respiratory Distress Syndrome/S. Price, Olympia Fields, IL**
- P875 Extrapulmonary Tuberculosis Presenting As Hepatic Granulomas In An Immunocompetent Female Patient/A.J. Dunham, Tampa, FL**
- P876 Tuberculosis Presenting as Diffuse Alveolar Hemorrhage/M. Jayamani, Chennai, India**
- P877 Bilateral Tuberculosis Pleural Effusion Requiring Medical Thoracoscopy/R. Chauhan, Brooklyn, NY**
- P878 Tuberculous- And Nontuberculous-mycobacterial Coinfection In A Young Man Presenting With Hemoptysis/S. Srivastava, Flushing, NY**
- P879 A Rare Case Of Tuberculosis-induced Hemopericardium In A Young Patient/A. Uts, Oceanside, NY**
- P880 Tuberculosis: The Great Masquerader/N.S. Khakoo, Miami, FL**
- P881 Mycobacterium Tuberculosis Versus Sarcoidosis: The Diagnostic Dilemma/N.S. Khakoo, Miami, FL**
- P882 TB or Not TB: A Mysterious Case of Altered Mental Status/J. Tepper, Indianapolis, IN**
- P883 Subacute Presentation of Miliary Pulmonary Tuberculosis: A Rare Diagnosis in the Developed World/D. Ramanujam, Pittsburgh, PA**
- P884 Active Mycobacterium Tuberculosis Diagnosed By Surgical Resection With Post Surgical Recurrence/M.L. Mccrary, Saint Louis, MO**
- P885 A Microcosting Analysis of Nutritional Support for Persons Living With Tuberculosis and Their Families in India/G. Buonomo, Boston, MA**
- P886 Changes in Treatment Regimens and Drug Susceptibility of Multidrug or Rifampicin Resistance Tuberculosis Over 20 Years at a Highly Specialized TB Facility in Japan/K. Kamada, Kiyose, Japan**
- P887 An Unexpected Rapid Progression Presentation of Miliary Tuberculosis/J. Torrens Olan, San Juan, PR**
- P888 Two Cases of Reactivated Tuberculosis Developed in Patients With Outpatient Treatment for COVID-19 Infection/J. Kang, Jeju, Korea, Republic of**
- P889 Rifampicin-resistant Disseminated Tuberculosis Presenting as a Mass Lesion in an 18-year Old Female/P.N.G. Abella, Cebu City, Philippines**

- P890 Tuberculous Lymphadenitis - A Challenging Case/A.** Ribeiro, Barreiro, Portugal
- P891 Early Medical Thoracoscopy For The Diagnosis Of Pleural Tuberculosis/A.** Sahi, Farmington, CT
- P892 Tuberculous Pleural Effusion Without Respiratory Symptoms/Z.** Idrees, Bronx, NY
- P893 The Great Mimicker Strikes Again: A Rare Case of Isolated Prosthetic Knee Joint Tuberculosis/A.** Nunes, Torres Vedras, Portugal
- P894 How Mycobacterium Tuberculosis Builds Its House: ESX-1 Drives the Heterogeneous Mononuclear Phagocyte Recruitment After Infection/B.S.** Zha, San Francisco, CA
- P895 Tuberculin Skin Test and Quantiferon-gold Test Discordance in HIV Infected Population- a Retrospective Cohort Study/K.** Ghosh, Valhalla, NY
- P896 Prevalence of Latent TB Infection in Patients With Metabolic Syndrome/B.** Soto-Moncivais, Monterrey, Mexico
- P897 Epidemiological Situation of Tuberculosis in Djibouti/I.A.** Awaleh, Dakar, Senegal
- P898 Adverse Drug Reactions and Missed Doses of Anti-Tuberculosis Therapy, a Scoping Review/E.** Dixon, Edinburgh, United Kingdom
- P899 Pulmonary Pseudotumor Tuberculosis/M.** Colamonic, Aoura, CO
- P900 Delay in Diagnosis of Tuberculosis Can Be Serious Community Health Issue/M.** Shahzadi, Wayne, NJ
- P901 Chest Radiological Predictors of Treatment Failure in Rifampicin-susceptible Pulmonary Tuberculosis/M.** Ghanem, Boston, MA
- P902 Association of Systemic Inflammatory Markers With Anti-Tuberculous Drug-Induced Liver Injury/Q.** Liu, Chengdu, China
- P905 Exacerbation of Oral Streptococci-induced Pneumonia by Prevotella Intermedia Depends on the Type IX Secretion System/H.** Ashizawa, Nagasaki, Japan
- P906 Regulation of the Lung Epithelial Inflammatory Response to Streptococcus Pneumoniae by the DNA Repair Enzyme, 8-Oxoguanine DNA Glycosylase (OGG1)/N.M.** Maurice, Decatur, GA
- P907 Isolation of Lytic Phages Against Multi-drug Resistant Pseudomonas Aeruginosa From Respiratory Secretions/A.** Hashemi Shahraki, Jacksonville, FL
- P908 UF Phage Center: A Center to Combat Multidrug- and Pandrug-resistant Bacteria/A.** Hashemi Shahraki, Jacksonville, FL
- P909 The Application of Educational Interventions to Influence the Use of Urinary Antigens in the Diagnosis of Community Acquired Pneumonia/A.** Go, St. Louis, MO
- P910 Antiseptic Irrigation for Adult Pleural Infection: A Case Series/M.H.** Fayed, Alexandria, Egypt
- P911 Bronchoalveolar Lavage Diagnostic Yield and Pathogen Profile in Hospitalized Patients With Cancer/E.** Arnold, Saint Louis, MO
- P912 RESP® in Patients Hospitalized With Exacerbations of Chronic Lung Diseases/M.** Glass, Philadelphia, PA
- P913 IL-1R-signaling in Pulmonary Immune Defense/L.** Wu, Philadelphia, PA
- P914 Hiding Amidst the Pus: A Rare Case of Pulmonary Artery Pseudoaneurysm/R.** Winters, Aurora, CO
- P915 A Rare Case Of Transdiaphragmatic Extension Of A Lung Abscess Into The Liver/M.** Oudah, Washington, DC
- P916 A Rare Case Of Infected Bronchogenic Cyst Growing Salmonella Enterica/J.** Torres, Kingwood, TX
- P917 Alveolar Neutrophilia Is Temporally Correlated With Staphylococcal Outgrowth, Not Pulmonary Injury, Following Hyperoxia Exposure/B.** Mayoras, Ann Arbor, MI
- P918 A Complex Case of Necrotizing Pneumonia in the Context of Fusarium Infection/A.** Akkawi, Wichita, KS
- P919 Lemierre's Syndrome: Eyes See What the Brain Knows/S.** Bhasin, New Brunswick, NJ
- P920 Right Sided Infective Endocarditis Mimicking Appendicitis: Diagnostic Error Involving A Covert Cavitation/A.** Gubran, Brooklyn, NY
- P921 Bilateral Empyema as a Complication of Viral Pneumonia/K.K.** Solanki, Johnson City, TN
- P922 Critical Airway Obstruction Secondary to Acute Necrotizing Tracheitis/V.A.** Persaud, Corpus Christi, TX

BASIC • CLINICAL • TRANSLATIONAL
THEMATIC POSTER SESSION
A62 B-A-C-T-E-R-I-A, FIND OUT WHAT IT MEANS TO ME
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area I, Hall C (Lower Level)
Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P904 Assessing Bias in Treatment of Empyema/Y.** Ishisaka, New York, NY

- P923** **Persistent Ochrobactrum Anthropi Bacteremia in a Lung Transplant Recipient With Devastating COVID-19 Disease and Prolonged ECMO Cannulation: Be Aware of Rare!**/D. Razia, Phoenix, AZ
- P924** **Ochrobactrum Anthropi: A Curious Case of Pneumonia!**/S. Ghosh, San Bernardino, CA
- P925** **Clostridium Perfringens Pleural Effusion as First Presentation for Malignant Mesothelioma!**A.M. Shadid, Detroit, MI
- P926** **Empyema Thoracis Caused by Candida Lusitanae: A Rare but Emerging Pathogen!**S. Ashfaq, Queens, NY
- P927** **A Case Of Non-communicative Lung And Splenic Abscesses Caused By Escherichia Coli From An Unknown Origin!**Q. Meng, Evanston, IL
- P928** **Empyema Therapy: Is There a Difference?!**A. Elshikh, Maywood, IL
- P929** **Double Trouble: Escherichia Coli Bilateral Empyema!**C. Tanba, Baltimore, MD
- P930** **Pasteurella Multocida Empyema in a Patient With Oropharyngeal Cancer!**J. Sugarman, Toronto, Canada
- P931** **MSSA Burst (MSSA Causing Refractory Bilateral Tension Pneumothorax)!**E. Kareem, Huntington, WV
- P932** **Organizing Pneumonia From Chronic Aspiration: A Lung Tumor Mimiker!**J.A.S. Cordero, Taguig, Philippines
- P933** **A Pain In The Neck: Fusobacterium Infection During Acute COVID-19!**J. Huston, New Haven, CT
- P934** **Bilateral Empyema From Recreational Use Of Dialysis Line!**A. Pingili, Baltimore, MD
- P935** **Breath Taking: An Unusual Case Of Pasteurella Multocida Empyema!**L. Pitts, Winston Salem, NC
- P936** **Persistent Pulmonary Cavitation Induced by Inverted Jejunostomy Tube!**A. Abrahamian, Toledo, OH
- P937** **Pseudomonas Pneumonia With Pneumothorax: A Case of an Uncommon Pathogen With a Common Risk Factor!**N.C. Parker, Springfield, IL
- P938** **True Pneumonia or Not!**A. Mckenna, Worcester, MA
- P939** **Bleeding Bronchial Artery: To Embolize or Not?!**K. Singh, Mobile, AL
- P940** **The Significance of Biofire Filmarray Pneumonia Panel on Pneumonia Treatment!**M.K. Ameduite, Danville, VA
- P941** **Recurrent Pneumonia: Don't Miss a Pulmonary Sequestration!**G.M. Gonzalez Santiago, San Juan, PR
- P942** **Inhibiting Pyoverdine Biosynthesis Attenuates the Virulence of Pseudomonas Aeruginosa Exoenzyme Y During Infection!**A. Deweever, Mobile, AL
- P943** **Pseudomonas Aeruginosa Infection Induces a Lung Endothelial Cell Antiviral Gene Response: Role of a Novel tRNA Mir Residing in the Gamma Secretase Activating Protein Gene!**M.S. Gwin, Mobile, AL
- P944** **Ex Vivo Models for Predictive Testing of Inhalable Anti-infectives in Early Pre-clinical Development!**K. Schwarz, Hannover, Germany
- P945** **Leukemia Inhibitor Factor (LIF) Interacts With Lung Hippo Signaling During Pneumonia!**M. Perez Vazquez, Worcester, MA
- P946** **Establishment of an Isolated Perfused Lung Model for Analysis of Local Induced Immune Response of the Immuno-modulating Agent OM-85!**H. Obernolte, Hannover, Germany
- P947** **64-year-old: A Case of Cough and Cavities!**P. Ghai, Bridgeport, CT
- P948** **Clinical Spectrum of Community-Acquired Pneumonia in Elderly With Comorbid Type 2 Diabetes Mellitus in a Developing Country: Exploring the Not-so-sweet Relationship!**K. Bhandari, Dharan, Nepal
- P949** **Harvesting Septations: Loculated MSSE Empyema in a 70-Year-Old Agricultural Worker!**Z. Ali, Longview, TX
- P950** **Drawing Attention to Signs: Diagnoses Other Than Pulmonary Tuberculosis!**F.F. Fernandes, Brasília, Brazil
- P951** **A Case Of Pasteurella Multocida In Adult Female Pet Owner In Outpatient Clinic!**A.S. Adebola, Corvallis, OR
- P952** **Hide and Seek: A Fatal Case of Streptococcus Constellatus Empyema and COVID-19 Infection in Elderly Patient!**K. Andrade, Forest Hills, NY
- P953** **Microbiome Dynamics of Lower Airway Challenges With Established Microbial Concentrations!**Y. Kyeremateng, New York, NY
- P954** **Diffuse Infection Mimicking Metastatic Colonic Cancer!**A. Medani, Rancho Mirage, CA
- P955** **Aspiration Pneumonia Complicated by Transdiaphragmatic Empyema Necessitans!**A.M. Bischin, Lebanon, NH

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A63 NTM AND BRONCHIECTASIS, STILL TOGETHER

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area I, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion

12:15-1:15 authors will be present for discussion with assigned facilitators.

- P957** **Mycobacterium Nebraskense as a Rare Cause of Non-tuberculous Mycobacterial Disease**/M. Assaad, Sayre, PA
- P958** **Clinical And Radiological Improvement In Adult Non - Cystic Fibrosis Bronchiectasis Following Robotic Toupet Fundoplication**/C. Iskandar, New York, NY
- P959** **Multifocal Cavitory Lung Lesions In A Patient With Granulomatosis With Polyangiitis And Mycobacterium Avium Complex Infection**/M. Mayer, Aurora, CO
- P960** **Vaping-Induced Non-Tuberculous Mycobacterium Disease**/J. Rha, Boston, MA
- P961** **A Window Into the Past: Use of Clagett Window/Eloesser Flap for the Management of Chronic Nontuberculous Mycobacterial Pleural Space Infection With Bronchopleural Fistula**/J.B. Mullholand, Hershey, PA
- P962** **Non-Tuberculous Mycobacterial Disease and Lung Adenocarcinoma: Birds of a Feather Flock Together. A Case Report of Increasing Lung Mass Despite Non Tuberculous Mycobacterial Treatment**/J. Bercier, New Orleans, LA
- P963** **When Immune Reconstitution Inflammatory Syndrome Manifests as Endobronchial Mycobacterium Avium Complex Infection With Concomitant Actinomycosis. Could This Be Prevented?**/M. Azhar, Houston, TX
- P964** **Subclinical Mycobacterium Avium Intercellulare Infection - A Diagnostic Challenge**/A. Shahid, St. Louis, MO
- P965** **Mycobacterium Abscessus Bacteremia With Disseminated Infection to the Lungs vs. Colonizer, a Complex Case in an Immunocompetent Hemodialysis Patient**/G.K. Rai, New York, NY
- P966** **A Case of Recurrent Mycobacterium Avium Complex in a Patient With Igg4 Related Disease**/Y. Ishisaka, New York, NY
- P967** **Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease in Korea: Individual Participants Data Meta-analysis**/Y. Park, Seoul, Korea, Republic of
- P968** **Multidrug Therapy Does Not Affect Prognosis of Pulmonary MAC Disease**/A. Ushiki, Matsumoto, Japan
- P969** **Mycobacteria Simulans, Second Identification Worldwide and First Identification in Djibouti**/I.A. Awaleh, Dakar, Senegal
- P970** **A 49 Year Old Woman With Shortness of Breath and Diffuse Lung Opacities**/H. Johnson, Houston, TX
- P971** **Miliary Pulmonary Nodules Secondary to Non-tuberculous Mycobacterium Infection in an Immunocompetent Adult**/R. Chapman, Harlow, United Kingdom
- P972** **When a Quiescent Beast Creeps Out and Unlocks Pandora's Box: A Case of a Young Man With a Relentless Cough in Massachusetts**/A. Mughrabi, Boston, MA

- P973** **Detecting Clusters of High Nontuberculous Mycobacteria Infection Risk for Persons With Cystic Fibrosis - an Analysis of U.S. Counties**/R. Mercaldo, Bethesda, MD
- P974** **Bronchiectasis in Patients With Chronic Lymphocytic Leukemia**/O. Wand, Ashkelon, Israel

BEHAVIORAL • CLINICAL • TRANSLATIONAL
THEMATIC POSTER SESSION
A64 POST-COVID19 REHABILITATION

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area H, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P832** **Clinical Outcome of Supervised Pulmonary Telerehabilitation Program Among Adult Patients With Post-acute COVID-19 Symptoms in a Developing Country**/N.J.A. Dalisay, Quezon City, Philippines
- P833** **Hyperventilation in Long COVID Patients Is Part of the Clinical Picture**/K. Ides, Kontich, Belgium
- P834** **Myoreflex Therapy - A Novel Therapeutic Option as a Solution for Non-Specific Post-COVID Complaints?**/J.C. Baudrexl, Ulm, Germany
- P835** **A Six-month Analysis of Inpatient Pulmonary Rehabilitation in Tallaght University Hospital Following COVID-19 Infection**/C. Ottewill, Dublin, Ireland
- P836** **Changes in Lung Function Following Personalized Pulmonary Rehabilitation Programs in Patients With Post-Acute Sequelae of COVID-19 (PASC)**/W. Dierckx, Kontich, Belgium
- P837** **Effect of Pulmonary Rehabilitation After Lung Transplantation in Patients With COVID-19 Associated Fibrotic Lung Disease: A Single-Center Retrospective Review**/D.F. Martin, Los Angeles, CA
- P838** **Effects of Cranial Electrical Stimulation in Patients With Post-Covid Syndrome With and Without Anxiety Symptoms- a Pilot Randomized Controlled Trial**/D. Leiti, Marburg, Germany
- P839** **A Cohort Analysis Comparing Pulmonary Rehabilitation Outcomes in Post COVID-19, Chronic Obstructive Pulmonary Disease (COPD), and Interstitial Lung Disease (ILD) Patients**/T. Truong, Los Angeles, CA

- P840** **Effect of Inspiratory Muscle Training Along With Graded Aerobic Exercise on Pulmonary Function and Functional Status in Patients With Long COVID/A. Kaur, Nashik, India**
- P841** **Assessment of Short- and Long-term Quality of Life in Patients With Post-acute COVID-19 Syndrome and Its Association With Functionality/L. Braga Monnerat, Rio de Janeiro, Brazil**
- P842** **Outcomes of Pulmonary Rehabilitation for Patients With COVID-19/J. Aljazeera, Harrisburg, PA**
- P843** **The Effect of a Personalized Rehab Program in Long COVID on Physical Fitness, Dyspnea and Quality of Life/Y. De Meyer, Kontich, Belgium**
- P844** **Rehabilitation Needs of Adult British Columbians With Long COVID/D.M. Petry Moecke, Vancouver, Canada**
- P845** **An Exploratory Survey of Maintenance Option Preferences for Post-COVID Patients Following a Rehabilitation Programme/L. Houchen-Wolloff, Leicester, United Kingdom**
- P846** **A Home-based, Remotely Monitored Program to Improve Physical Activity in Patients With Long COVID/C. Jelinek, Hines, IL**
- P847** **Pulmonary Rehabilitation Outcomes in Treatment of Post-COVID Dyspnea/B.N. Hance, Kansas City, KS**
- P848** **Characterizing Long COVID in Patients With Respiratory Symptoms Referred to a Multidisciplinary Long COVID Clinic/T.D. Litchman, Boston, MA**
- P849** **Pulmonary Rehabilitation Use Post-discharge From Coronavirus Disease 2019 Hospitalization /D.A. Puebla Neira, Phoenix, AZ**
- P980** **Regulated IRE1 α -Dependent Decay Unlocks Alveolar Type 2 Cell Plasticity After Injury/V.C. Auyeung, San Francisco, CA**
- P981** **The Porcupine Inhibitor AZD5055 Inhibits Wnt Palmitoylation and Release, and Has Potential to Repair Damaged Alveoli Through Increasing Type 1 Alveolar Epithelial Cell Numbers/C. Overed-Sayer, Cambridge, United Kingdom**
- P982** **Epithelial Cell Specific Deletion of Focal Adhesion Kinase Decreases Epithelial Cell Senescence and Lung Fibrosis/P. Che, Birmingham, AL**
- P983** **Exploring the Mutational Landscape of Alveolar Type II Cells Using Alveolar Organoids/A. Ammar, London, United Kingdom**
- P984** **Functional Screening in Lung Epithelial Cells and Fibroblast of Novel and Known Genetic Associations With Idiopathic Pulmonary Fibrosis/E.L. Lopez Jimenez, London, United Kingdom**
- P985** **Rise of the Resistance: Cannabis Is Cytoprotective of Lymphangiomyomatosis (LAM) Cells but Fuels Lung Epithelium Dysregulation to Drive Stress-induced Premature Senescence/M. Ho, Toronto, Canada**
- P986** **Genotypic and Phenotypic Correction of Surfactant Protein C Trafficking Defect After Cas9-mediated Cytosine Base Editing/V. Luks, Philadelphia, PA**
- P987** **Identification of Unfolded Protein Response Related Proteins in Lungs From Hypersensitivity Pneumonitis Patients/S. Cabrera, Mexico DF, Mexico**
- P988** **Single Cell Analysis of Gene Variation Across Multiple Datasets Identifies Erratic S100A2 Expression as a Feature of the IPF Distal Lung Epithelium/J. Wellmerling, Rochester, MN**
- P989** **PIC-seq Identified Signals Promoting Direct Cell-cell Communications Between AT2 and Fibroblasts/X. Liu, Los Angeles, CA**
- P990** **Construction of Alveolar Niche Environment Using Human Induced Pluripotent Stem Cell-derived Mesenchymal Cells/K. Tamai, Kyoto, Japan**
- P991** **Elastin Degradation Products Cause Epithelial to Mesenchymal Transition/D. Nagel, Rochester, NY**
- P992** **Consensus Network Analysis Identifies Core Transcriptional Pathways That Prevent Disruption of the Human Airway Epithelial Barrier/A. Devries, Tucson, AZ**
- P993** **Dysregulated Sox9 Overexpression in Multiple Lung Cells Contributes to Severe Fibrotic Lung Disease/P. Singh, Cincinnati, OH**

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A65 THE ALVEOLAR NICHE IN THE SPOTLIGHT OF LUNG FIBROSIS

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area J, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P977** **Indole Metabolites as Novel Danger Signals to Lung Epithelial Cells/J. Evankovich, Pittsburgh, PA**
- P978** **Regulation of AT2 Progenitor Renewal by LPCAT1 in IPF/A. Rabata, Los Angeles, CA**
- P979** **Adipogenesis in Lung Fibroblasts Supports AT2 Cell Renewal in Lung Fibrosis/X. Zhang, Los Angeles, CA**

P994 Low Vascular Endothelial Growth Factor Levels and Increasing Environmental Stiffness Potentiate Vascular Hyper-remodeling in Computational Model of Idiopathic Pulmonary Fibrosis/J. Leonard-Duke, Charlottesville, VA

P995 Transcriptomic Signatures of Lung Stretch/P. Martín, Oviedo, Spain

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A66 DISSECTING THE MATRIX AND MESENCHYMAL CELLS IN FIBROSIS

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area J, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

P997 Matricellular Protein CCN3 as a Target to Promote Lung Endothelial Homeostasis and Repair in the Fibrotic Lung/K.R. Betageri, Rochester, MN

P998 Effects of Stiffness, Matrix, and Culture Conditions on the DNA Methylation Patterns of Normal and IPF Lung Fibroblasts/A.M. Scruggs, Ann Arbor, MI

P999 Transglutaminase Type II (TGM2) Secretion Contributes to Changes in Extracellular Matrix (ECM) in Idiopathic Pulmonary Fibrosis (IPF) In Vivo and Lung Fibroblast Ex Vivo/A. Estrada-Bernal, Pittsburgh, PA

P1000 Oxidative Stress Drives Cytokine Expression and Inhibits Contractility of IPF Fibroblasts in Fibrotic Tissue Hydrogels/J. Fernandez Davila, Manassas, VA

P1001 Identification and Characterization of Fibroblast Subpopulations Using Redox in Fibrosis/P. Link, Rochester, MN

P1002 Proteomic Analysis of Mitochondria of Healthy Pulmonary Fibroblasts and Fibrotic Fibroblasts Exposed to Hypoxia/A. Aquino-Galvez, Ciudad de México, Mexico

P1003 Tollip Deficiency Enhances the Transcriptomic Response of TGF β -treated Primary Mouse Lung Fibroblasts/C. López-Martínez, Oviedo, Spain

P1004 Histone Lactylation Contributes to Human Lung Myofibroblast Differentiation in Response to TGF- β /E. Reed, Chicago, IL

P1005 Targeting Repressive Histone H3K27me3 Medicated Lung Fibroblast Activation/J. Zhou, Birmingham, AL

P1006 Upregulation of MOXD1 Is Associated With Changes in the Expression of Copper Transporters ATP7a and Ctr1 in IPF Fibroblasts/L. Rosas, Columbus, OH

P1007 Increased IL-25 Expression in Idiopathic Pulmonary Fibrosis and Role in Fibroblast Proliferation and Activation/A. Kanwal, Newcastle, Australia

P1008 CXCL6 Upregulates COL1A1 and COL1A2 mRNAs in IPF Fibroblasts by a Post-transcriptional Mechanism/H. Bahudhanapati, Pittsburgh, PA

P1009 Bax Inhibitor-1 (BI-1) Is a Multifaceted Inhibitor of ER Stress Induced Apoptosis in IPF Derived Fibroblasts/D.W. Moore, Manassas, VA

P1010 March8 Is a Novel Regulator of Lung Myofibroblast Differentiation/G. Qian, Tyler, TX

P1011 Distinct Roles of Canonical and Non-canonical WNT Signaling on Myofibroblast Differentiation/T. Liu, Ann Arbor, MI

P1012 Zip Kinase Is Involved in Progression of Myofibroblast Differentiation of Human Pleural Mesothelial Cells/Y. Choo, Tyler, TX

P1013 Loss of cIAP1 Inhibits Mitochondrial Function in Fibroblasts and Diminishes Myofibroblast Differentiation/J.C. Horowitz, Columbus, OH

P1014 Deregulated Lactate Expression by the Alteration of LDHA and LDHB in IPF Fibroblasts Promotes Myofibroblast Differentiation/R. Nho, Columbus, OH

P1015 REV-ERB α Role in TGF β 1-induced Fibroblast to Myofibroblast Differentiation in Human Lung Fibroblasts: Implications for the Pathogenesis of Pulmonary Fibrosis/C. Prasad, Kansas City, KS

P1016 Profibrotic Behavior of Lung Fibroblasts Derived From MMP8-MMP13 Double Knockout Mice Is Associated With a Delayed Fibrosis Resolution/A. Garcia, Mexico City, Mexico

P1017 Inhibition of the Epigenetic Regulator CBX5 Promotes Fibroblast Metabolic Reprogramming and Attenuates Lung Fibrosis/J. Hong, Boston, MA

P1018 miR-133a Mediated Regulation of Transgelin Via TGF- β /Smad3 Signaling Pathway in Pulmonary Fibrosis/F. Muneesa M, Mangalore, India

P1019 Characterising the Contribution of Casein Kinase 1 Delta (CK1 δ) in TGF- β -induced Fibrogenesis/S.S. Zhang, Parkville, Australia

P1020 Anastellin, a Bioactive Fragment of Fibronectin, Is Increased in Idiopathic Pulmonary Fibrosis/A.H. Hansen, Herlev, Denmark

- P1021** Mesenchymal Stem Cell-derived Humoral Factor **STC-1** Suppresses **Il-6** Auto-amplification in **Bleomycin-induced Pulmonary Fibrosis Model/S.** Ohkouchi, Sendai, Japan
- P1022** Involvement of **Ten-eleven Translocation Gene** in the Pathology of **Pulmonary Fibrosis/K.** Takagi, Kagoshima, Japan
- P1023** **UPARAP: What Is It Doing in the Lung?/B.** Simon, Madison, WI
- P1024** Role of **ALDH2** in Fibroproliferation After Acute Lung Injury/**Y.** Aschner, Aurora, CO
- P1025** Characterization Of The Pericyte Transcriptome In Systemic Sclerosis-associated Interstitial Lung Disease/**C.L.** Wilson, Madison, WI
- P1026** Skin Transcriptomes Are Associated With Lung Function Impairment in Systemic Sclerosis Related Interstitial Lung Disease/**J.** Zielonka, New Haven, CT
- P1027** The Relationship Between MicroRNA Expression Profiles in Animal Models for Lung Fibrosis and Idiopathic Pulmonary Fibrosis/**K.U.E.** Perera, Melbourne, Australia
- P1028** Online Cell Atlases Improve Interrogation of Lung Transcriptomic Data/**J.** Flint, New Haven, CT
- P1029** A Multi-omics Approach Identifies That Human R Antigen (HuR) Controls Multiple Cellular Pathways in Idiopathic Pulmonary Fibrosis (IPF) Pathogenesis/**Q.S.** Islam, Montreal, Canada
- P1030** Characterization of an Inducible Tensin1 Deficient Transgenic Murine Model by RNA Sequencing Analysis/**K.** Holbert, Madison, WI
- P1031** G-Protein Coupled Receptor-Mediated Camp Activation Within Lung Fibroblasts Is Essential for Spontaneous Fibrosis Resolution Following Bleomycin-Induced Lung Injury/**S.M.** Fortier, Ann Arbor, MI
- P1032** In Vivo Intra-airway Epigenetic Editing in the Promoter of **CXCL11/A.V.** Fedulov, Providence, RI
- P1033** Oxidative Processes in the Endoplasmic Reticulum Contribute to Enhanced Oxidation of Collagen 1 and Promote Aberrant Activation of Lung Fibroblasts/**Y.M.W.** Janssen-Heininger, Burlington, VT
- P1034** Mitogen Activated Protein Kinase Phosphatase 1 Induction Leads to **P38** Inhibition and Myofibroblast De-differentiation/**N.M.** Walker, Ann Arbor, MI
- P1035** Role of Myocardin on the Expression of Fibronectin 1 in Human Pleural Mesothelial Cells/**T.** Sakai, Tyler, TX
- P1036** **S100A3** Regulates the Expression of Telomerase Reverse Transcriptase (**TERT**)/**S.** Al Qattan, Riyadh, Saudi Arabia

- P1037** Interaction of **S100A13** With Vimentin in Pulmonary Fibrosis/**V.V.** Raveendran, Riyadh, Saudi Arabia
- P1038** **Oncostatin M, A Key Player in Fibrosis/V.** Kumar, Gaithersburg, MD

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A67 BIOMARKERS, MEDIATORS, AND TRANSLATIONAL MODELS FOR ILD

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area J, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1040** The Pulmonary Fibrosis Drug Connectome/**J.** Flint, New Haven, CT
- P1041** The Therapeutic Gap in Idiopathic Pulmonary Fibrosis: Insights From Single Cell Transcriptional Profiling/**N.** Mckenna, Houston, TX
- P1042** Functional Roles for **CD26/DPP4** in Mouse Bleomycin-induced Pulmonary Fibrosis/**K.** Yu, Chiba, Japan
- P1043** Inhaled Therapeutic for Idiopathic Pulmonary Fibrosis Reduces Fibrotic Biomarkers in Mouse Model/**A.** Chang, Provo, UT
- P1044** Lactobacillus Based Live Biotherapeutic Product Downregulates Profibrotic Markers in Models of Pulmonary Fibrosis/**C.V.** Lal, Birmingham, AL
- P1045** Combining Dual $\alpha v \beta 6 / \alpha v \beta 1$ Integrin Inhibitor, **PLN-74809**, With Standard-of-Care Therapies Has a Synergistic Effect on Reducing Fibrogenic Gene Expression in Fibrotic Human Lung Slices/**J.** Schaub, South San Francisco, CA
- P1046** Lead Compound Development of Antifibrotic **N23Ps** and Molecular Target Identification/**X.** Wei, Munich, Germany
- P1047** Anti-fibrotic Loaded Drug Delivery Vesicles Survive in Surfactant, Dramatically Improve Lung Pharmacokinetics, and Reach Multiple Alveolar Cell Types/**L.** Ferguson, Philadelphia, PA
- P1048** Serum Collagen Neoepitopes Are Associated With Multi-organ Disease in the Access and **GRADS** Sarcoidosis Cohorts/**C.** Ryu, New Haven, CT

- P1049 Assessing Challenges and Opportunities for Biomarker, Device, and Pre-clinical Drug Development/Commercialization in the Pulmonary Arena/L. Hecker, Atlanta, GA**
- P1050 Mtor Signalling and More in Dipnech/M. O'Callaghan, Dublin, Ireland**
- P1051 Programmed Cell Death Protein 1 (PD-1) Is an Effective Inducer of IL-6 Expression in Sarcoidosis CD4+ T Cells/O.S. Chioma, Nashville, TN**
- P1052 Preclinical Profile of PRS-220, a Novel Inhaled Inhibitor of CTGF/CCN2 in Clinical Development for Idiopathic Pulmonary Fibrosis/V. Neiens, Hallbergmoos, Germany**
- P1053 Novel Small Molecule Rock Inhibitor GNS-3595 Attenuates Idiopathic Pulmonary Fibrosis Progression in Preclinical Models/S. Hwang, Billerica, MA**
- P1054 The Anti-fibrotic Effect OFGB0139, a Small Molecule Galectin-3 Inhibitor, in Precision Cut Lung Slices From Idiopathic Pulmonary Fibrosis Tissue/A.C. Mackinnon, Edinburgh, United Kingdom**
- P1055 Anti-fibrotic Potential of a Novel Long-acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of Idiopathic Pulmonary Fibrosis/J.A. Kim, Hwaseong-si, Korea, Republic of**
- P1056 Pathogenic Role of Extracellular Heat Shock Protein 90 α (HSP90 α) in Interstitial Lung Diseases Through Macrophages Programming/T. Isshiki, Hamilton, Canada**
- P1057 Analysis of the Anti-fibrotic Potential of JAK Inhibitors in a Bleomycin-induced Pulmonary Fibrosis Model/K. Murakami, Tokushima, Japan**
- P1058 Chemical Activation of Protein Phosphatase 2A Counters Bleomycin-induced Fibrosis in Mice/M. Pillai, Brooklyn, NY**
- P1059 Structure Based Discovery and Anti-fibrotic Activity of Novel Antagonists of Lysophosphatidic Acid Receptor 1 (LPAR1)/C. Tan, South San Francisco, CA**
- P1060 Type VI Collagen Formation Is Induced in a Scar-in-a-Jar Fibroblast Model Stimulated With a Combination of TGF- β and PDGF/F.B. Simoes, Herlev, Denmark**
- P1061 Evaluation of Rodent PRO-C6, a Biomarker of Type VI Collagen Formation, in a Bleomycin Induced IPF Mouse Model/M. Skarsfeldt, Herlev, Denmark**
- P1062 Inhaled Alpha1 Adrenoreceptor Antagonism Does Not Affect Experimentally Induced Lung Fibrosis in Animal Models/A. Ghincea, New Haven, CT**
- P1063 Inhaled Alpha2 Adrenoreceptor Agonism Does Not Affect Experimentally Induced Lung Fibrosis in Animal Models/J. McGovern, New Haven, CT**
- P1064 Lactobacillus Rhamnosus Supernatant Insufficient in Limiting the Adverse Effects of Bleomycin Induced Lung Fibrosis/A. Lancaster, Nashville, TN**
- P1065 The Effect of Quercetin on Human Lung Fibroblasts and Regulation of Collagen Production/Z. Wiggins, Nashville, TN**
- P1066 A Biomarker of Club Cell Secretory Protein 16 Degraded by Human Neutrophil Elastase (CC16-HNE) Is Elevated in Patients With Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease/H.W. Breisnes, Herlev, Denmark**
- P1067 An Unbiased Proteomic Screen of Bronchoalveolar Lavage Fluid in the Sftpc Mouse Identifies Potential Biomarkers for Idiopathic Pulmonary Fibrosis/K. Chavez, Philadelphia, PA**
- P1068 CXCL1 Is Highly Expressed in Secretory Cells and Correlates With Poor Outcomes in Patients With Idiopathic Pulmonary Fibrosis/H. Bahudhanapati, Pittsburgh, PA**
- P1069 Sodium Alginate Hydrogels as an Alternate to Agarose for Lung Inflation/J.A. Mereness, Rochester, NY**
- P1070 Impact of Enzymatic Digestion on Single Cell Suspension Yield From Human Lungs/A. Bondonese, Pittsburgh, PA**
- P1071 Soft Microenvironment Engenders 'Afibrogenic' Phenotype in Pulmonary Fibroblasts/A. Gunatilaka, Parkville, Australia**
- P1072 Micro-Computed Tomography Visualization and Quantitation of the Aging Pulmonary Microvascular Tree in Chronic Lung Disease/B. Schneider, Denver, CO**
- P1073 The Utility of Transbronchial Cryobiopsy as Precision Medicine for Interstitial Pneumonia/H. Kitamura, Yokohama, Japan**
- P1074 Novel Echogenic Liposomal Carriers Loaded With Tissue Plasminogen Activator and Urokinase Plasminogen Activator for Preclinical Studies/M. Ranjpour, Tyler, TX**
- P1075 Plasminogen Activators Encapsulated Into Microfiber Carriers to Deliver and Support Sustainable Plasminogen Activation/M. Ranjpour, Tyler, TX**
- P1076 Fresh Biospecimen Distribution to Enhance Pulmonary Research Via Human Tissue Biobanking/S.D. Stacey, Columbus, OH**
- P1077 Rapid Low-ischemic Time Lung Explant Tissue Collection at the University of California San Diego/K. Afshar, La Jolla, CA**
- P1078 Inhalational Delivery of MRI-1867 (Zevaquenabant) as a Novel Therapeutic Modality in Pulmonary Fibrosis/A. Basu, Rockville, MD**

- P1079** Why Is Peripheral CB1R Antagonism a Rational Therapeutic Strategy for Pulmonary Fibrosis? Evidence From Multi-omics Approach for Establishing a Translational Link/M. Arif, Rockville, MD
- P1080** The Potential Role of Fibulin-5 in Pulmonary Fibrosis/S. Saito, New Orleans, LA

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A68 MITOCHONDRIAL AND METABOLOMIC ALTERATIONS IN THE PATHOGENESIS OF ILDs

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area J, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1082** Plasma Mitochondrial DNA Is Associated With Patient-related Outcome Measures in Sarcoidosis/V. Fiorini, New Haven, CT
- P1083** Metabolomic Analysis Identifies Differences in Energy Metabolism in Exhaled Breath Condensate From Patients With Radiation-induced Lung Fibrosis/J. Pierre-Louis, Richmond, VA
- P1084** The Hedgehog (Hh) Pathway Induced Metabolic Reprogramming of Macrophages in Idiopathic Pulmonary Fibrosis (IPF)/R. Joshi, Birmingham, AL
- P1085** Pirfenidone Blunts Transforming Growth Factor β -mediated Increase in Enzymes of Amino Acid Metabolism/J. Szafran, Chicago, IL
- P1086** Elevated Levels of Mitochondrial DNA and CGAS Ligands Are Found in Scleroderma Associated Interstitial Lung Disease and Mediate Fibroblast Activation/S. Yu, New Haven, CT
- P1087** Therapeutic Potential of an Indole Derivative in Fatal Environmental Compound-induced Lung Injury/J.S. Jeong, Jeonju, Korea, Republic of
- P1088** Novel Lipid Mediators in Pulmonary Fibrosis/M. O'Callaghan, Dublin, Ireland
- P1089** Transcriptional Downregulation of Mitochondrial Proteins as an Adaptive Response in the Aging Lung/L. Coyne, Syracuse, NY
- P1090** The Role of Macrophage Lipid Metabolism in Pulmonary Fibrosis/R.L. Watson, Los Angeles, CA

- P1091** Spatially-Resolved Lipidomic Analysis of Normal and Idiopathic Pulmonary Fibrosis (IPF) Human Lungs Using Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging (MALDI-MSI)/T. Khaliullin, Columbus, OH
- P1092** Mitochondrial Fission Contributes to Diaphragmatic Weakness Induced by Mechanical Ventilation/S. Matecki, Montpellier, France

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A69 AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area E, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P504** Prospective Description of High Resolution Computed Tomography Evidence of Airways Disease in Rheumatoid Arthritis Patients/S. Matson, Kansas City, KS
- P505** Using Lateral Decubitus Computed Tomography (CT) to Monitor Structural Lung Disease in Young Children With Cystic Fibrosis/R.M. Sandvik, Copenhagen, Denmark
- P506** Association of Change in Upper Lung Zone Radiologic Pleuroparenchymal Fibroelastosis (PPFE) With Mortality in a Lung Cancer Screening Cohort/R. Chapman, London, United Kingdom
- P507** Learning Models of Chest X-rays Accurately Segment Lung Parenchyma Independent of Datasets and Disease States/D.J. Conrad, La Jolla, CA
- P508** Dynamic ^{129}Xe -Hyperpolarized MRI for Non-invasive Evaluation of Regional Lung Ventilation in Thoracic Insufficiency Syndrome/M.K. Ismail, Philadelphia, PA
- P509** Non-invasive Assessment of Post-transplant Alterations in Pulmonary Ventilation Using Dynamic 4DCT/M.K. Ismail, Philadelphia, PA
- P510** Improved Dynamic Micro-CT Imaging Binning for Optimized Image Reconstruction/M.K. Ismail, Philadelphia, PA
- P511** Retrospective Cardiopulmonary Gating of Free-breathing Hyperpolarized Xenon-129 Spectroscopy/F. Amzajerjian, Philadelphia, PA

- P512 Assessing Unilateral Lung Transplantation With Dynamic Hyperpolarized Xenon-129/F. Amzajerdian, Philadelphia, PA**
- P513 Uneven Respiratory Function Observed With Dynamic Hyperpolarized Xenon-129 MRI in a Pig Thoracic Insufficiency Syndrome Model/H. Hamedani, Philadelphia, PA**
- P514 Spatial-temporal Dynamics of Pulmonary Blood Flow in Interstitial Lung Disease/P. Patel, La Jolla, CA**
- P515 A Deep Learning Algorithm to Predict Lung Density in Healthy Subjects Based on Tracheal Shape/X. Huang, Coralville, IA**
- P516 Regional Correlation of Pulmonary Gas Exchange and Perfusion in IPF Using MRI/S.B. Fain, Iowa City, IA**
- P517 Optimization of Photon Counting CT for Quantitative Airway and Lung Density Measures/S.B. Fain, Iowa City, IA**
- P518 In-silico/In-Vitro Assessment of Deposition Patterns of Two Dry Powder Inhalers in Cystic Fibrosis and Healthy Subjects/I. Rossi, Cwmbran, United Kingdom**
- P519 Digital Dynamic Radiography Imaging Detects Acute Phase of Hypoxic Pulmonary Vasoconstriction in Humans/S. Yamamoto, Madison, WI**
- P520 Harmonization of Reconstructed Field of View Improves Accuracy of Lung CT Measurements/J. Tschirren, Coralville, IA**
- P521 Regional Ventilation-perfusion in Non-smoking Adults Using DECT and Image Registration/S.E. Gerard, Iowa City, IA**
- P522 Performance of CT:V Quantitative Ventilation Imaging Against PET Ventilation Imaging/N. Eikelis, Melbourne, Australia**
- P523 Quantitative Analysis of High-resolution Computed Tomography Scans in Subclinical Rheumatoid Arthritis Airways Disease/S. Khan, Kansas City, KS**
- P524 On the Influence of Realistic Upper Airway on Lung Deposition; a Numerical Study/H. Sadafi, Kontich, Belgium**
- P525 Airflow and Particle Transport Simulations for Subjects With Cement Dust Exposure/J. Hwang, Daegu, Korea, Republic of**
- P526 Active Ratio Curve Reconciling Spatial and Temporal Features of Pulmonary Ventilation Assessed by Three-dimensional Electrical Impedance Tomography/X. Wu, Shanghai, China**
- P527 Feasibility of 3D Dynamic Gas- and Dissolved-Phase Imaging of the Rodent Lung Using Hyperpolarized ¹²⁹Xe Magnetic Resonance Imaging/L. Loza, Philadelphia, PA**
- P528 Lung Structure-function in Pediatric Survivors of Congenital Diaphragmatic Hernia/R.L. Eddy, Vancouver, Canada**
- P529 Measuring Lung Function With Inversion Instead of Saturation Recovery Hyperpolarized Xenon-129 MR Spectroscopy/K. Ruppert, Philadelphia, PA**
- P530 Impact of Inspired Volume in Patients With Systemic Sclerosis-associated Interstitial Lung Disease on Quantitative Computed Tomography Parameters/A. Campbell, Vancouver, Canada**
- P531 Radiographic Assessment of Lung Edema (RALE) Score in COVID-19 Associated Pneumothorax and Pneumomediastinum/S. Syaj, Irbid, Jordan**
- P532 A Novel Approach for Computer Aided Lung Sound Analysis in Relation to Imaging Biomarkers in Cystic Fibrosis/E. Lauwers, Wilrijk, Belgium**
- P533 Novel Method for Quantifying Liquid Thickness in Flooded Alveoli of Optically-Cleared Lungs/C. Singh, Hoboken, NJ**
- P534 Automatic and Manual Quantification of Small Airways Disease on Chest CT of Children With Severe Asthma/H. Tiddens, Rotterdam, Netherlands**
- P535 Deep-masker: A Deep Learning Based Fully Automated Tool to Assess Chord Length From Murine Lungs Images/A.S. Leme, Pittsburgh, PA**
- P536 Distribution of UIP Fibrosis Is Accentuated Around Lymphatics - Analysis by a Deep Learning Model/Y. Nei, Ichihara, Japan**
- P537 X-ray Velocimetry in Veterans With Constrictive Bronchiolitis/M.G. Lester, Nashville, TN**
- P538 Minimal Clinically Important Difference for ¹²⁹Xe MRI Ventilation Defect Percent in Patients With Asthma/A. Biancaniello, London, Canada**
- P539 Hyperpolarized ¹²⁹Xe Ventilation and Gas Exchange MRI in Young Adults With Cystic Fibrosis/P.J. Niedbalski, Kansas City, KS**
- P540 Bronchopulmonary Dysplasia Was Associated With Both Functional and Structural Pulmonary Abnormalities in School-aged Children/K.W. Kim, Seoul, Korea, Republic of**
- P541 Abnormal CT Findings in Upper and Lower Airways of Newborn Pigs With Primary Ciliary Dyskinesia/M. Rector, Iowa City, IA**
- P542 The Impact of Different Valved Holding Chambers (VHCS) on Lung Drug Delivery: Using Functional Respiratory Imaging (FRI) and an Asthma Patient/J. Suggett, London, Canada**

P543 Validation of a Computational Fluid Dynamics Model for Airway Deposition Using Single-photon Emission Computed Tomography (SPECT)/H. Sadafi, Kontich, Belgium

BASIC • TRANSLATIONAL

THEMATIC POSTER SESSION

A70 RELAX ALREADY! MECHANISTIC INSIGHTS INTO AIRWAY SMOOTH MUSCLE BIOLOGY

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

P199 Activation of Aryl Hydrocarbon Receptor Inhibits Airway Smooth Muscle Proliferation/M.I. Reza, Fargo, ND

P200 Succinate Receptor GPR91 (G Protein-coupled Receptor 91) Modulates Excitation-contraction Coupling in Human Airway Smooth Muscle (HASM)/J. Antony Jude, New Brunswick, NJ

P201 Ginger Metabolites and Metabolite-inspired Synthetic Derivatives Modulate Cytoskeletal Regulatory Proteins Controlling Airway Smooth Muscle Tone/E. Lukovic, New York, NY

P202 Role of the LINC Protein Nesprin-1 in Airway Smooth Muscle Contractility/Y. Wu, Albany, NY

P203 Selective Ligands of the Mitochondrial Translocator Protein (TSPO) Regulate Airway Smooth Muscle Contraction/D. Villalba, Philadelphia, PA

P204 TNF α Mediates Mitophagy in Human Airway Smooth Muscle Cells/O.A. Ramirez Ramirez, Rochester, MN

P205 Estrogen Metabolites Regulate Airway Contractility by Modulating Airway Smooth Muscle Intracellular Calcium/P. Balraj, Fargo, ND

P206 ABCC1 Efflux of Camp From HASMc Is a Negative Regulator of cAMP Signaling Controlled by PKA/G. Cao, New Brunswick, NJ

P207 Role of Bronchial Hyperresponsiveness in Patients With Obstructive Sleep Apnea With Asthma-like Symptoms/A. Sano, Osaka-sayama, Japan

P208 Aging Affects Expression but Not Activity of β 2-adrenoreceptors in Equine Bronchial and Tracheal Smooth Muscle/S. Ceriotti, Auburn, AL

P209 Mitigation of TNF α Mediated ER Stress in Human Airway Smooth Muscle Cells/P. Delmotte, Rochester, MN

P210 Calcium Oscillations and Contraction in Peripheral Airway Smooth Muscle Are Modulated by Mitochondria/J.F. Perez-Zoghbi, New York, NY

P211 Calcium Dynamics by Translocator Protein (TSPO) in Airway Smooth Muscle Cells/G. Peruggia, Philadelphia, PA

P212 Nicotine Affects Mitochondrial Dynamics in Human Airway Smooth Muscle Cells/N.A. Borkar, Rochester, MN

P213 Role of Estrogen Metabolites in Regulating Airway Smooth Muscle Cell Extracellular-matrix Deposition/A. Kumar, Fargo, ND

P214 Beta-Hydroxybutyrate Attenuates Aeroallergen-induced Responses by Bronchial Smooth Muscle/V.A. Fastiggi, Burlington, VT

P215 SDHB-knockdown Reduces the Maximum Respiratory Capacity of Mitochondria in Human Airway Smooth Muscle Cells/S. Mahadev Bhat, Rochester, MN

P216 miR-106b-5p Overexpression Increases Maximal Contractile Force Output of Airway Smooth Muscle Cells 3D-printed Into Airway Rings/J.M. Evasovic, Reno, NV

P217 Transforming Growth Factor Beta Abrogates Interleukin-17A-induced Increase in Krüppel-like Factor 4 Expression and Proliferation in Asthmatic Airway Smooth Muscle Cells/J.M. Evasovic, Reno, NV

P218 A Force-induced Force-generation Mechanism in the Airway Smooth Muscle/H. Parameswaran, Boston, MA

P219 A Novel Platform to Study Airway Constriction and Cilia Beating in Mouse Precision-cut Lung Slices/L. Fereydoonzad, Montréal, Canada

P220 19-HETE Promotes Airway Smooth Muscle Relaxation and Reduces DNA Synthesis Through the Prostacyclin Receptor/C.D. Pascoe, Winnipeg, Canada

P221 Non-genetic Insights Into the Functional Efficacy of β 2-adrenoreceptors in Human Airway Smooth Muscle Cells Through the Lens of Bitter Taste Receptors/J.M. Lee, New Brunswick, NJ

P222 Epigenetic Modulation of Airway Smooth Muscle Cell Function Via Glutamate Metabolism/Y. Sun, Pittsburgh, PA

P223 IL-33, but Not TSLP, Augments Carbachol-induced Bronchoconstriction and Attenuates Formoterol- and Forskolin-induced Bronchodilation of Human Small Airways in a Precision-cut Lung Slice Model/C.J. Koziol-White, New Brunswick, NJ

P224 SS-31 Mitigates Allergic Airway Hyperresponsiveness/W.W.-Y. Tang, Pittsburgh, PA

P225 Airway Smooth Muscle Relaxation Via Opsin 3 Activation With Beta-carotene Metabolites/S. Uribe, New York, NY

- P226** Diacylglycerol Kinase Inhibition Attenuates Airway Smooth Muscle Cell Proliferation Via Activation of Protein Kinase A/M.A. Hernandez, Philadelphia, PA
- P227** TNF α Induced Activation of Phospho CREB-PGC1 α Axis Promotes Mitochondrial Biogenesis/D. Dasgupta, Rochester, MN
- P228** Volume-regulating Anion Channel, LRRC8, Modulates Excitation-contraction Coupling and Agonist-induced Shortening in Human Airway Smooth Muscle Cells (HASM/C)/J. Woo, Piscataway, NJ
- P229** Glucose Bioenergetics Regulate Extracellular Matrix Hyaluronan in Human Airway Smooth Muscle Cells/A. Mulya, Cleveland, OH
- P230** Comparing Response of Obese and Lean Human Airway Smooth Muscle Cells to Insulin/S.A. Cabrera Guerrero, Washington, DC

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A71 MATTERS OF THE HEART...AND LUNGS: STUDIES ON CARDIOPULMONARY VASCULAR DISEASE

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P232** Aerobic Training Decreases Cardiorespiratory Morphological and Functional Changes in Experimental Pulmonary Arterial Hypertension/C.C. Araujo, Rio de Janeiro, Brazil
- P233** Tertiary Lymphoid Follicles Associate With Lung Neointima Lesions/A.M. Andruska, Palo Alto, CA
- P234** HS135, a Novel Activin and GDF Trap, Is Efficacious in Models of Pulmonary Hypertension (PH) and Heart Failure (HF)/G. Schang, Montreal, Canada
- P235** Regional Pulmonary Vascular Resistance (PVR) Beyond the Lungs' Total: A Proof-of-Concept PET Imaging Study of Regional PVR in Pulmonary Arterial Hypertension (PAH) at Baseline and During Inhaled NO/T. Winkler, Boston, MA
- P236** Predicting Real-world Modifiers for Drugs Inducing Pulmonary Arterial Hypertension/M. Sarangdhar, Cincinnati, OH

- P237** Evaluation of Frailty in Patients With Pulmonary Hypertension/R. Momen, Toronto, Canada
- P238** GLUT1 Expression and Right Ventricular Adaptation to Pressure Overload in Experimental Pulmonary Hypertension/S. Wang, Giessen, Germany
- P239** Respiratory Symptom Perception During Exercise in Patients With Heart Failure With Preserved Ejection Fraction: Impact of Phenotype/J. Goh, Dallas, TX
- P240** A Study on the Effects of Cheyne-stokes Breathing on the Prognosis of Acute Congestive Heart Failure in Maputo, Mozambique/E. Gruenberg, La Jolla, CA
- P241** Nitrofen/Bisdiamine Congenital Diaphragmatic Hernia Murine Model Induces Pulmonary Vascular Changes Consistent With Pulmonary Hypertension/C.R. Gonyea, Newark, DE
- P242** Modeling Neonatal Pulmonary Vascular Flows and Wall Shear Stress in Congenital Diaphragmatic Hernia Using a Stochastic Computational Framework/C. Gonyea, Newark, DE
- P243** Hypoxia-preconditioning of Bone Marrow Derived Mesenchymal Stromal Cells and Their Extracellular Vesicles in Experimental Pulmonary Arterial Hypertension: Proteomic Profile and Therapeutic Effects/P.L. Silva, Rio De Janeiro, Brazil
- P244** RKER-012, a Novel Modified Actrii Ligand Trap, Attenuated Cardiac Remodeling and Fibrosis in a Transverse Aortic Constriction Model of Heart Failure/C. Materna, Lexington, MA
- P245** Effects of Oxygen Supplementation on Exercise Physiology in Patients With Pulmonary Vascular Disease/M.J. Segel, Ramat Gan, Israel
- P246** Accuracy of Disposable Adhesive Pulse Oximeter Finger Probes Used on Ear Lobes and Fingers in Measuring Oxygen Saturations as Compared to Oxygen Saturations Measured on Arterial Blood Gases/W.S. Bagol, Cebu City, Philippines

BEHAVIORAL • CLINICAL

THEMATIC POSTER SESSION

A72 NEW INSIGHTS INTO PAP EFFECTIVENESS

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area E, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P575** The Impact of CPAP Refusal on Rates of Medical Emergency Team Activation During Hospitalization/K. Sheehan, Winston-Salem, NC
- P576** Usefulness of Nocturnal Oximetry in Patients Treated With Positive Airway Pressure for Obstructive Sleep Apnea/C. Bianquis, Paris, France
- P577** Associations Between Chronic Medication and Positive Airway Pressure Adherence/A.M. May, Cleveland, OH
- P578** Does Sleep Apnea Severity Matter? The Correlation of AHI and RDI With CPAP/B. Bass, Valhalla, NY
- P579** Enhanced Recovery Pathways and Management of Patients With Obstructive Sleep Apnea: A Survey of Perioperative Practice Patterns/M. Yilmaz, Chicago, IL
- P580** Hypoxic Burden and Continuous Positive Airway Pressure Requirements in Patients With Obstructive Sleep Apnea/I. Kaplan, Valhalla, NY
- P581** Obesity Hypoventilation Syndrome (OHS): Does Compliant Use of Non-invasive Ventilation (NIV) Improve Capillary Carbon Dioxide (CO₂) Levels and Provide Symptomatic Relief/E. Livingston, Glasgow, United Kingdom
- P582** Assessing Adherence to Positive Airway Pressure Therapy in Patients With Down Syndrome Using Cloud-based Data/R. Bhattacharjee, San Diego, CA
- P583** The Tolerance of Non Invasive Positive Pressure Ventilation in Patients with Myotonic Dystrophy/E. Hamada, Kashihara, Japan
- P584** Treatment of Sleep-Disordered Breathing With Adaptive Servo-Ventilation (READ-ASV) - Effects on Quality of Life and Symptoms in a European Registry/M. Arzt, Regensburg, Germany
- P564** Oral Breathing Among Obstructive Sleep Apnea Patients Is Associated With Minute Ventilation and Ventilatory Drive/E. Finnsson, Reykjavik, Iceland
- P565** App-Mediated Signaling Affects Sleep and Memory in an Alzheimer's Disease Mouse Model/C. Puech, Columbia, MO
- P566** The Effect of Continuous Positive Airway Pressure on Neuromuscular Control of the Upper Airway in Pediatric Subjects With Obstructive Sleep Apnea/Q. Xiao, Cincinnati, OH
- P567** Ventilatory Instability During Non-Rapid Eye Movement Sleep in Opioid-Associated Sleep Disordered Breathing/D. Greig, Detroit, MI
- P568** Study of the Upper Airway Anatomy Using Magnetic Resonance Imaging in Asian Obese Patients With and Without Severe Obstructive Sleep Apnea/S. Sinha, New Delhi, India
- P569** Fractional Exhaled Nitric Oxide and Its Correlation With Polysomnography Parameters in Healthy Children With Obstructive Sleep Apnea and Asthma/O. Pantoja-Gomez, Bogota, Colombia
- P570** Impaired Left Ventricular Relaxation May Be Associated With Ventilatory Control Instability in Obstructive Sleep Apnea/A. Adawi, New York, NY
- P571** Comparison of the Watchpat Device With Home Limited Sleep Studies for the Diagnosis of Obstructive Sleep Apnoea/C.D. Campbell, Dublin, Ireland
- P572** An Overview of Percutaneous Endoscopic Gastrostomy (PEG) Insertion Under Non-invasive Ventilation (NIV) Cover for Patients Living With Motor Neuron Disease (MND)/A. Mowat, Stoke-on-Trent, United Kingdom
- P573** Cerebrovascular CO₂ Responsiveness in Opioid-Associated Sleep Disordered Breathing/R. Rastogi, Detroit, MI

CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

A73 DISPATCH FROM THE SLEEP LAB: UNCOVERING OSA PATHOPHYSIOLOGY

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area E, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P562** Difference in Obstructive Sleep Apnea Measures Between In-lab Vs. Home in Patients With Atrial Fibrillation/Y. Cho, Seattle, WA
- P563** Airway Occlusion Pressure in Spontaneously Breathing, Healthy Individuals Is Mediated by Increasing Body Mass Index Irrespective of Body Position/W.C. McGuire, La Jolla, CA

CLINICAL

THEMATIC POSTER SESSION

A74 RARE CASES IN THORACIC ONCOLOGY

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area L, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1201** Rare Case of Bronchial Carcinoid Tumor Presenting as Hemoptysis in a Healthy Young Male/E.K. Hourigan, Portsmouth, VA

- P1202 Sole Symptom of Constipation Leading to Diagnosis of Bronchial Carcinoid Tumor/M. Shahzadi, Wayne, NJ**
- P1203 A Rare Case of Neuroendocrine Breast Carcinoma With Lung Metastasis/J.W. Burgei, Sayre, PA**
- P1204 A Rare Case of Invasive Thymoma Presenting as a Pleural-Based Mass/S. Sathitratanaheewin, Bangkok, Thailand**
- P1205 A Rare Case of Superior Vena Cava Syndrome Secondary to Occluded Right-Sided Internal Jugular Vein Port Catheter/K.M. Ruiz Gonzalez, Wilmington, NC**
- P1206 A Rare Case of Embryonal Carcinoma Presenting With Chest Discomfort/S.R. Mekala, Kalamazoo, MI**
- P1207 A Rare Case of Lung Adenocarcinoma With Oligometastasis to the Right Thigh/A.F. Beirat, Muncie, IN**
- P1208 A Rare Case Of Primary Lung Squamous Cell Carcinoma Presenting As Solitary Part-solid Nodule With Lepidic Like Growth/D. Condit, Farmington, CT**
- P1209 A Rare Case of Pulmonary Glomus Tumor With Malignant Transformation and Widespread Metastasis/S. Sapkota, Baltimore, MD**
- P1210 A Rare Case Of Primary Pulmonary Endotracheal Diffuse Large B-cell Lymphoma/K. Gharaibeh, Baltimore, MD**
- P1211 A Rare Case of Isolated Pulmonary Melanoma/K. Lin, Danbury, CT**
- P1212 A Rare Case Of Small Cell Lung Cancer With Metachronous Metastatic Breast Cancer/P. Sharma, Cleveland, OH**
- P1213 A Rare Case of Fungal Mediastinitis Associated With Metastatic Malignant Thymoma/J.Y. Chang, Stanford, CA**
- P1214 A Rare Case of Metastatic Adenocarcinoma of Unknown Primary Site With Aortic Aneurysm and Chemo-radiation: A Real Management Challenge/R. Kashyap, Florence, AL**
- P1215 A Rare Case of Pulmonary Carcinosarcoma Obstructing the Lingular Bronchus/M. Al-Momani, Johnson City, TN**
- P1216 A Rare Case of Immune Checkpoint Inhibitor Induced Tracheitis/N. Agrawal, Houston, TX**
- P1217 A Rare Case of Endobronchial Pulmonary Hamartoma/D. Shyu, Minnesota, MN**
- P1218 Fish Out of Water: A Rare Case of Metastatic Disease Presenting as Endobronchial Obstruction/C. Shah, Gainesville, GA**
- P1219 A Rare Case of Right Mainstem Bronchus Obstruction Secondary to Breast Cancer Metastasis/C. Shah, Gainesville, GA**
- P1220 A Rare Case of Non-small Cell Lung Cancer Metastases to Skeletal Muscles Presenting as Groin Pain/U. Ekin, Paterson, NJ**
- P1221 A Rare Case of Mediastinal Chordoma/H.A. Albitar, Rochester, MN**
- P1222 A Rare Case Of Laryngeal And Cardiac Synovial Sarcoma/S. Salman, New York, NY**
- P1223 Rare Case of Pleomorphic Plasmacytoid Lung Adenocarcinoma/D.R. Logan, Atlanta, GA**
- P1224 Sclerosing Thymoma: A Rare Subtype/A.S. Cuerdo, Las Pinas City, Philippines**
- P1225 Necrotic Cystic Lymphadenopathy: A Rare Presentation of Small Cell Lung Cancer/N.W. Bethuel, Indianapolis, IN**
- P1226 Presentation of Adenoid Cystic Carcinoma of Lung With Widespread Metastasis: A Rare Occurrence/M. Parmar, Oklahoma city, OK**
- P1227 Advanced Small Cell Lung Cancer Without Intrathoracic Involvement/H. Singh, Jackson, MI**
- P1228 A Rare Presentation Of Pulmonary Extranodal NK/T-cell Lymphoma/K. Capp, Minneapolis, MN**
- P1229 Bilateral Optic Retinopathy: An Unusual Presentation of Small Cell Carcinoma/E. Fellows, Minneapolis, MN**
- P1230 Pleomorphic Dermal Sarcoma- Rare Cancer With An Affinity For The Lungs/H. Safdar, Columbia, MO**
- P1231 Salivary Gland Tumor of the Lungs: A Rare Presentation/R. Khanam, Urbana, IL**
- P1232 A Rare Complication: Spontaneous Tumor Lysis Syndrome In Newly Diagnosed Small Cell Lung Cancer/S. Rijal, West Reading, PA**
- P1233 Recurrent Hypoglycemia: A Rare Paraneoplastic Syndrome of Squamous Cell Carcinoma of the Lung/S.R. Menakuru, Muncie, IN**
- P1234 Hide and Seek Carcinoma: A Case of Extrapulmonary Small Cell Carcinoma Without Primary Source or Widespread Disease/B. Hackett, Kansas City, KS**
- P1235 Primary Cardiac Sarcoma: A Rare Occurrence/N. Aimalla, Marshfield, WI**
- P1236 EBV-positive Diffuse Large Cell Lymphoma: A Rare Cause of Life Threatening Diffuse Extrinsic Airway Compression/H. Li, Jamaica, NY**
- P1237 Middle Lobe Syndrome: A Rare Presentation of Endobronchial Mantle Cell Lymphoma/A. Yarema, Jonesboro, AR**
- P1238 Fast Mass: Rapidly Progressive Non-Small Cell Lung Cancer in a Young Patient/V. Dong, New York, NY**

- P1239 High Grade Undifferentiated Pleomorphic Sarcoma of the Aorta: A Rare Clinical Entity/R.A. Memon, Abington, PA**
- P1240 Primary Pulmonary Chronic Lymphocytic Leukemia: A Rare Cause Of Intermittent Hemoptysis/S.S. Wu, Miami, FL**
- P1241 A Case of a Rare Benign Myofibroblastic Tumor of the Lung/M. Alsaggaf, Washington, DC**
- P1242 Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) A Rare Paraneoplastic Phenomenon/Á. Connerton, Dublin, Ireland**
- P1243 Tracheoinnominate Fistula As A Rare Complication Of Bevacizumab Therapy In The Management Of Metastatic Rectal Adenocarcinoma/K. Alsheimer, Sayre, PA**
- P1244 A Rare Presentation of a Rare Non-Langerhans Cell Histiocytosis/A. Velthottam Rathinam, Urbana, IL**
- P1245 Tumoral Pulmonary Hypertension; A Rare But Severe Cause Of Pulmonary Hypertension/S. Shireen Kanamgode, Worcester, MA**
- P1254 Spinal Leptomeningeal Carcinomatosis With Brain Metastasis From Lung Adenocarcinoma/M. Agustin, Dededo, Guam**
- P1255 Pleomorphic Adenoma of the Trachea/M. Agustin, Dededo, Guam**
- P1256 Pulmonary Granular Cell Tumor and Allergic Bronchopulmonary Aspergillosis: Any Association Relevance?/J. Scudiero, Kingman, AZ**
- P1257 Recurrent Respiratory Papillomatosis With Parenchymal Involvement and Malignant Transformation/T. Wang, Chapel Hill, NC**
- P1258 Right Middle Lobe Torsion Secondary to Video-assisted Thoracoscopic Surgery/J.G. Liu, Wichita, KS**
- P1259 A Case of Obstructive Squamous Cell Carcinoma Improvement With Early Aggressive Bronchoscopic and Oncologic Interventions/E. Lam, Newark, NJ**
- P1260 Squamous Cell Carcinoma Of Lung Complicated By Chronic Empyema/R. Dua, Long Branch, NJ**
- P1261 Incidental Finding Of Acquired Tracheoesophageal Fistula In A Mechanically-ventilated Patient With Non-small Cell Lung Cancer Treated With Radiation And Immunotherapy/J. Vellore, Stratford, NJ**
- P1262 Multiple Non-diagnostic Biopsies For High-risk Pulmonary Lesions In Coal Workers Do Not Rule Out Malignancy/H.T. Khan, Morgantown, WV**
- P1263 Double Trouble! Utilizing Precision Medicine to Enhance Lung Cancer Care/R. Lakra, Shreveport, LA**
- P1264 A Lifetime Malignant Transformation: Recurrent Respiratory Papillomatosis to Squamous Cell Carcinoma of the Lung/R. Lakra, Shreveport, LA**
- P1265 The Preoperative Challenges For Management Of A Giant Benign Thoracic Schwannoma In A 39-year-old Woman/K. Andersen, Burlington, MA**
- P1266 Necrotizing Skin And Soft Tissue Infections In Patients Suspected To Have Cutaneous Manifestations Of Underlying Malignancy/R. Patel, Toledo, OH**
- P1267 An Unusual Presentation of Bronchial Squamous Cell Carcinoma in Situ/A. Thomas, Knoxville, TN**
- P1268 Quadruple Primary Malignant Neoplasm in a 40 Year Old Male: A Case Report/V.C. Yap, Iloilo City, Philippines**
- P1269 Occult Adenocarcinoma Stage 4 With Liver, Lung, and Ovarian Metastasis in a 56 Year-old Female/J.F. Gonzaga, Iloilo City, Philippines**
- P1270 Kidneys in the Lungs: A Pulmonary Manifestation of Renal Cell Carcinoma Fifteen Years After Nephrectomy and Renal Transplant/J.P. Im, Red Bank, NJ**

CLINICAL

THEMATIC POSTER SESSION

A75 A MEDLEY OF INTERESTING LUNG CANCER CASES

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area L, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1247 An Unusual Product Of Squamous Cell Carcinoma/B. Hyun, Portland, OR**
- P1248 Does the Lung Reporting and Data System Need to Be Redefined?: A Case of Missed Opportunities in Lung Cancer Screening/T. Nagar, Rochester, MI**
- P1249 Immune Checkpoint Inhibitor-Induced Bronchiolitis Treated With Inhaler Therapy/S. Vedachalam, Indianapolis, IN**
- P1250 A Pain In The Neck: An Unusual Presentation Of Metastatic Lung Cancer/H. Choi, Bronx, NY**
- P1251 Weaving a Sad Tale: A Case of Spindle Cell Carcinoma of the Lung/A. Fatima, Smyrna, TN**
- P1252 A Case Of Mucoepidermoid Carcinoma Presenting As Primary Lung Cancer/J. Torres, Kingwood, TX**
- P1253 Right Bronchus Obstruction Due To Malignancy - Medical And Surgical Management/J. Yang, Springfield, MA**

- P1271 You Can't Escape From Your Past! Papillary Thyroid Cancer With Lung Metastasis After 35 Years: A Case Report/S.** Alrasheed, Riyadh, Saudi Arabia
- P1272 Paraneoplastic Myositis Associated With Lung Adenocarcinoma, An Unusual Presentation/M.** Nees Van Baalen, Jackson, MI
- P1273 Lumper or Splitter, What Is the Balance?/T.** Moore, Roanoke, VA
- P1274 A Case of Solitary Endobronchial Squamous Papilloma/J.** Frederickson, Omaha, NE
- P1275 Respiratory Papillomatosis: Raising the Question on Post-procedure Surveillance/J.G.** Rodriguez Velez, San Juan, Puerto Rico
- P1276 Bilateral Mainstem Obstruction Due to Mycobacterial Spindle Cell Pseudotumor/R.** Katragadda, Las Vegas, NV

MEDICAL EDUCATION SEMINAR

CME Credits Available: 1

ME101 BUILDING BLOCKS TO CRAFTING A SUCCESSFUL CLINICIAN-EDUCATOR CAREER

Assembly on Behavioral Science and Health Services Research

10:15 a.m. - 11:15 a.m.

Target Audience

Trainees, junior and mid career faculty pursuing careers as clinician educators although all clinician educators are likely to benefit from this session

Objectives

At the conclusion of this session, the participant will be able to:

- understand how to create an educational portfolio and identify mentors early in ones career
- describe opportunities for production of scholarly work as a clinician educator
- identify opportunities for leadership in medical education locally, regionally and nationally

During this interactive session, participants will have the opportunity to hear from successful, nationally recognized clinician educators in pulmonary & critical care medicine regarding career advancement as clinician educators. Topics will include developing an educational portfolio, fostering successful mentoring relationships, scholarly productivity, leadership, and networking locally, regionally and nationally through organizations such as the ATS. Discussants will provide attendees with practical tips and focused suggestions as well as ample opportunity for discussion and questions regarding how to best achieve success in each of the content domains being presented

Faculty

S.M. Kassutto, MD, Philadelphia, PA
 L. Santhosh, MD, MEd, San Francisco, CA
 B. Coruh, MD, ATSF, FCCP, Seattle, WA
 W.G. Carlos, MD, MSCR, ATSF, Indianapolis, IN

.11:45 a.m. - 1:15 p.m.

SECTION ON MEDICAL EDUCATION

Renaissance Washington Downtown
 Rock Creek Ballroom A (Ballroom Level)



The Section meetings are open to all ATS members and other interested individuals.

Items to be discussed include the Section's current projects and future directions.

Items to be discussed include the Section's current projects and future directions.



**ATS
2023**

**INTERNATIONAL
CONFERENCE**
WASHINGTON, DC
conference.thoracic.org

Sunday Mid-day, May 21

11:45 a.m. - 1:15 p.m.

DIVERSITY FORUM



The annual ATS Diversity Forum focuses on diversity within the fields of pulmonary, critical care, and sleep medicine and research. All ATS Members are invited to attend this event to find inspiration and valuable career insights.

The Underrepresented Trainee Development Scholarship will be presented at this forum. The scholarship was created to increase representation of underrepresented racial and ethnic groups as defined by the National Institutes of Health (NIH) (African American, Hispanic or Latinx, American Indian, Alaskan Native and Pacific Islander) in pulmonary, critical care, and sleep medicine research by providing an opportunity for trainees in U.S. based programs to attend the ATS International Conference

The 2023 Diversity Fellowship recipients will also be presented during the forum. These fellowships are designed to support the efforts of senior fellows, post-doctoral students, or junior faculty with research, clinical and policy endeavors to advance health equity for patients with respiratory disease, critical care illness or injury, and sleep disordered breathing.

The Diversity Forum is organized and presented by the ATS Membership Committee and will be hosted by its **Chair Meshell Johnson, MD** and Vice Chair **Alexandra Noel, PhD**. The Underrepresented Trainee Development Scholarship are supported by the American Thoracic Society.

**Pre-registration and an additional fee are required.
\$30 members/non-members**

*Many thanks to Actelion Pharmaceuticals US, Inc.,
a Janssen Pharmaceutical Company of Johnson & Johnson
for support of the Diversity Forum*

CLINICAL

ADULT CLINICAL CORE CURRICULUM

CME Credits Available: 1.5

MOC Points Available: 1.5

CC1 SLEEP CLINICAL CORE CURRICULUM

Education Committee

11:30 AM - 1:00 PM

Walter E. Washington Convention Center

Hall E (Level 2)

Target Audience

Clinicians who are engaged in maintenance of certification activities

Objectives

At the conclusion of this session, the participant will be able to:

- explain the relationship between sleep disordered breathing and obstructive lung disease
- characterize common manifestations of sleep disordered breathing in patients with neuromuscular disease
- understand the risks of obesity hypoventilation and application of best guidelines for management

Chairing: S. Shafazand, MD, Miami, FL
K. Dudley, MD, Boston, MA

11:30 Wheezing and Snoring: The Intersection of Obstructive Lung Disease and Sleep Disordered Breathing
M. Lowery, MD, Gainesville, FL

11:55 Weak Muscles and Restless Sleep: Neuromuscular Disease and Sleep Disordered Breathing
J. Contreras, MD, Cleveland, OH

12:20 Shallow Breathing into the Night: Obesity Hypoventilation Syndrome
K. Dupuy-McCauley, MD, Rochester, MN

12:45 Questions and Answers

ASSEMBLY MEMBERSHIP MEETINGS

**Marriott Marquis Washington &
Renaissance Washington Downtown**



The Assembly Membership Meetings provide an update on the Assembly's activities via the Assembly's Leadership and provide Assembly members the chance to have input on future directions, information on how to get involved and networking opportunities. Voting results for the Assembly's future leaders will also be announced.

CME Credits Available: 1

SPS1 THE AMERICAN THORACIC SOCIETY AND AMERICAN COLLEGE OF CHEST PHYSICIANS JOINT SESSION ON BRONCHIECTASIS

12:00 p.m. - 1:00 p.m. **Walter E. Washington Convention Center**
Room 207 A-B (Level 2)

Objectives

At the conclusion of this session, the participant will be able to:

- be able to recognize bronchiectasis is related to a diverse group of lung conditions. Key components of the history, physical exam and imaging will assist the learner in the evaluation of underlying etiologies of bronchiectasis.
- appreciate the recent progress in understanding genotypes and endotypes, the process of defining groups of patients by pathobiology with use of biomarkers
- be able to employ strategies to improve management of complex infections including inhaled, oral and parenteral antimicrobial therapy

This is part 1 of a joint session between ATS and CHEST. Part 2 will be presented at the CHEST 2023 conference. Bronchiectasis is characterized by pathologic airway dilation and bronchial wall thickening. Affected individuals complain of a chronic cough and frequent episodes of bronchitis and pneumonia. Bronchiectasis was once described as an orphan disease. Several studies show it is increasing in prevalence. Bronchiectasis affects an estimated 500,000 adults in the US and the prevalence increases with age. A Medicare survey from 2018 reported an annual prevalence of 701/100,000 persons over the age of 65. The COVID pandemic is likely to significantly impact the prevalence of bronchiectasis globally. This session on bronchiectasis will include expert presentations on the diagnostic evaluation, phenotyping, therapeutics targeting bronchiectasis and the management of multi-drug resistant infections.

Chairing: S. Kasperbauer, MD, Denver, CO
D. Addrizzo-Harris, MD, New York, NY

12:00 The Diagnostic Evaluation of Bronchiectasis
P. Mcshane, MD, Tyler, TX

12:15 Phenotyping Bronchiectasis
J. Chalmers, MBChB, PhD, Dundee, United Kingdom

12:30 Therapeutics in Bronchiectasis
C. Daley, MD, Denver, CO

12:45 Management of MDR Infections
M. Restrepo, MD, MSc, PhD, San Antonio, TX

NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES

OUTSIDE ORGANIZATION SESSION

L1 OPPORTUNITIES IN SLEEP AND RESPIRATORY HEALTH DISPARITIES RESEARCH FUNDED BY NIMHD

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**
Room 202 B (Level 2)

Target Audience

Providers serving patients that experience health disparities, including racial and ethnic minority, low SES, rural, and sex and gender minority populations; and members engaged in sleep and respiratory health research

Objectives

At the conclusion of this session, the participant will be able to:

- describe NIH/NIMHD programs and funding opportunities for research on the causes and consequences of sleep and respiratory health disparities in the US
- examine how social determinants of health may impact sleep and respiratory health disparities
- integrate an understanding of the multilevel causes and consequences of sleep and respiratory health disparities into current practice

Racial and ethnic minority and socioeconomically disadvantaged populations in the US face sleep and respiratory health inequalities. The National Institute on Minority Health and Health Disparities (NIMHD), in collaboration with other NIH institutes, promotes and funds research to understand how social, cultural, and environmental factors contribute to sleep and respiratory health and health disparities. This session will highlight NIMHD programs and funding opportunities of interest to ATS members and showcase the work of NIMHD grantees, including those studying biobehavioral, structural, environmental, and social determinants of sleep and respiratory health and health disparities. Research gaps, future directions, and NIH funding opportunities will be discussed.

Chairing: R. Das, PhD, Bethesda, MD

12:00 Director's Introduction to NIMHD
E. Perez-Stable, MD, Bethesda, MD

12:05 Programs and Funding Opportunities in Sleep and Respiratory Health Disparities: Community Health and Population Sciences
N. Jones, PhD, Bethesda, MD

12:15 Programs and Funding Opportunities in Sleep and Respiratory Health Disparities: Integrative Biological and Behavioral Sciences
A.S. Gillman, PhD, MPH, Bethesda, MD

- 12:25 Programs and Funding Opportunities in Sleep and Respiratory Health Disparities: Clinical and Health Services Research**
L. Aviles-Santa, MD, MPH, Bethesda, MD
- 12:35 Exposure to Violence, Epigenetic Variation, and Asthma in Puerto Rican Children**
J.C. Celedon, MD, DrPH, ATSF, Pittsburgh, PA
- 12:50 Panel Discussion**
R. Das, PhD, Bethesda, MD

CENTERS FOR DISEASE CONTROL

OUTSIDE ORGANIZATION SESSION

L2 UPDATES FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION: TOOLS FOR CLINICIANS

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**

Room 152 A-B (Street Level)

Target Audience

Clinicians, academics, and public health practitioners interested in chronic and acute lung disease

Objectives

At the conclusion of this session, the participant will be able to:

- Identify local geographic areas where chronic pulmonary disease burden is highest and better understand demographic differences within their state.
- improve communication and education with patients at risk for acute and chronic disease by using evidence-based, culturally- and linguistically-appropriate resources to explain tuberculosis risk, recommended testing, and treatment options.
- Incorporate updated recommendations and describe the current evidence, operational challenges, and need to address patient preferences for the use of directly observed therapy during treatment and management of medication adherence.

New tools from the U.S. Centers for Disease Control presented will help clinical providers and researchers to identify local populations among whom tuberculosis and chronic pulmonary disease risk is highest, to better understand demographic differences in risk within their local area, to communicate effectively with patients, and to use an updated approach to monitoring medication adherence. These tools and resources will enhance health screenings and patient outcomes.

Chairing: C. Winston, PhD, Atlanta, GA

- 12:00 Data Tools for State and Local Estimates for Chronic Obstructive Pulmonary Disease - part 1**
S.A. Carlson, PhD, MPH, Atlanta, GA

- 12:10 Data Tools for State and Local Estimates for Chronic Obstructive Pulmonary Disease - part 2**
K. Watson, PhD, Atlanta, GA
- 12:20 Think. Test. Treat TB. Starting the Conversation**
N. DeLuca, PhD, MA, Atlanta, GA
- 12:35 Directly Observed Therapy Updates and Recommendations**
J.M.C. Mangan, PhD, ATLANTA, GA
- 12:50 Panel Discussion and Audience Questions**
C. Winston, PhD, Atlanta, GA

DIVISION OF LUNG DISEASES, NHLBI/NIH

OUTSIDE ORGANIZATION SESSION

L3 RECENT CLINICAL AND OMICS FINDINGS IN PATIENTS WITH PULMONARY HYPERTENSION FROM THE NHLBI PVDOMICS PROGRAM

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**

Room 202 A (Level 2)

Target Audience

Healthcare providers, researchers, and trainees with an interest in pulmonary hypertension

Objectives

At the conclusion of this session, the participant will be able to:

- learn about new genomic findings including rare variant analysis and mRNA transcriptomic profiles in the peripheral blood of patients with pulmonary hypertension
- learn about metabolic changes that precede a diagnosis of PAH in scleroderma patients.
- learn about the effect of pollution on pulmonary vascular disease, right ventricular function and HRQL in the PVDOMICS cohort.

This session will cover new research discoveries stemming from the NHLBI "Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS)" program that seeks to better understand clinical and molecular aspects of pulmonary hypertension (PH), a complex disease with high mortality. This national observational clinical study co-sponsored by NHLBI and the Pulmonary Hypertension Association is performing extensive phenotyping in a large cohort of 1200 participants, which includes the prospective collection and analysis of biomarker, genetic, genomic, and phenotypic clinical data from subjects with PH for the purpose of identifying subpopulations and intermediate outcome measures.

Chairing: L. Xiao, MD, PhD, Bethesda, MD
N.S. Hill, MD, Boston, MA

- 12:00 Rare Variant Analysis in Non-Group 1 Pulmonary Hypertension**
M. Aldred, PhD, ATSF, Indianapolis, IN
- 12:15 The Effect of Pollution on Pulmonary Vascular Disease, Right Ventricular Function and HRQL in the PVDOMICS Cohort**
C. Lim, PhD, Tucson, United States
- 12:30 Metabolic Evolution Precedes PAH Diagnosis in Scleroderma: Insights from PVDOMICS and the Johns Hopkins Scleroderma Centerr**
C. Simpson, MD, Baltimore, MD
- 12:45 Genomics Analysis of mRNA in Peripheral Venous Blood Leukocytes for Identification of Clusters Across WSPH Groups and Associations with Severe or Mild**
G. Grunig, DVM, PhD, New York, NY

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

OUTSIDE ORGANIZATION SESSION

L4 ADVANTAGES OF NASA SATELLITE DATA IN AIR QUALITY AND RESPIRATORY HEALTH APPLICATIONS

12:00 PM - 1:00 PM Walter E. Washington Convention Center

Room 147 A-B (Street Level)

Target Audience

Physicians; nurses; allied health professionals; public health practitioners; community health educators; researchers who are interested in using Earth observation data for environmental and occupational health research applications

Objectives

At the conclusion of this session, the participant will be able to:

- provide an overview of the NASA Health and Air Quality Program activities that are of interest to clinicians and researchers.
- analyze at least three cross-cutting applications where NASA satellite data can strengthen scientific understanding of the global health risk of air pollution.
- inform clinicians and researchers about the PAHO/WHO experiences fostering integrative air quality monitoring as well as training opportunities in applying satellite data for health and air quality topics.

NASA Earth-observing satellites offer real-time data about natural and anthropogenic processes within atmospheric, aquatic, and terrestrial ecosystems. These data, which complement ongoing epidemiological surveillance programs, provide health leaders with valuable insight on the spatial and temporal variation of health risks attributed to harmful exposure to poor air quality. In this session, panelists will demonstrate how NASA satellite data can strengthen health applications related to air quality and respiratory health with community decision-makers.

Panelists will share ongoing NASA projects that apply satellite data to quantify health risks associated with exposure to urban ambient pollution to enhance clinical practice and policy decision-making.

Chairing: H. Chapman, MD, PhD, MPH, Washington, DC
L. Judd, PhD, Hampton, VA

- 12:00 NASA Health and Air Quality Applications: Applying Satellite Data to Respiratory Health**
J. Haynes, MS, WASHINGTON, DC
- 12:15 Advancing Air Quality Monitoring and Health Surveillance in the Americas**
J. Castillo, MSc, Washington, DC
- 12:30 The Impacts of Drought on Respiratory Health: Using NASA Data Products to Understand these Connections**
J. Bell, PhD, Omaha, NE
- 12:45 NASA Applied Remote Sensing Training (ARSET) for Health and Air Quality Applications**
M. Follette Cook, PhD, Greenbelt, MD

DIVISION OF LUNG DISEASES, NHLBI/NIH

OUTSIDE ORGANIZATION SESSION

L5 CUTTING EDGE IN TRANSLATION - NHLBI CATALYZE PROGRAM

12:00 PM - 1:00 PM Walter E. Washington Convention Center

Room 204 A-C (Level 2)

Target Audience

Providers of lung health, investigators in lung physiology and pathophysiology, specific patient group or multiple groups

Objectives

At the conclusion of this session, the participant will be able to:

- to learn about the NHLBI Catalyze Program and Objectives
- improve NHLBI catalyze program pipeline and success rate
- learn emerging technologies and therapeutics for the treatment/management of respiratory diseases

The NHLBI Catalyze Program provides a comprehensive suite of support and services to facilitate the translation of basic scientific discoveries into viable therapeutics, devices, and diagnostics ready for human testing. Currently, the Catalyze Program supports five funding opportunities with different funding mechanisms, budget limits, cost sharing requirements, application materials, and project periods. The Catalyze program have funded 14 awards in lung or lung related research areas, ranging from device, imaging technique, small molecules to biologics on a variety of lung diseases, acute or chronic. ATS noon session will be a good opportunity to highlight/showcase catalyze program and to advocate the cutting edge translational effort in NHLBI/DLD mission space.

Chairing: G. Zhou, PhD, Bethesda, MD
M. Pieck, PHD, Bethesda, MD

12:00 Introduction to the Catalyze Program

M. Pieck, PhD, Bethesda, MD

12:10 Optimization of PET Probe for Imaging Lung Fibrogenesis

P.D. Caravan, PhD, Charlestown,, MA

12:20 Bedside Tomosynthesis Imaging for ICU Patients

O. Zhou, PhD, Chapel Hill, NC

12:30 Therapeutic Targeting a Ubiquitin E3 Ligase to Control Pulmonary Inflammation

R.K. Mallampalli, MD, Columbus, OH

12:40 Panel Discussion

G. Zhou, PhD, Bethesda, MD

DIVISION OF LUNG DISEASES, NHLBI/NIH

OUTSIDE ORGANIZATION SESSION

L6 COMMUNITY RESULTS FROM ASTHMA EMPOWERMENT COLLABORATIONS TO REDUCE CHILDHOOD ASTHMA DISPARITIES

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**

Room 145 A-B (Street Level)

Target Audience

stakeholders engaged with children with asthma (e.g., health care providers, public health officials, municipal leaders, care givers)

Objectives

At the conclusion of this session, the participant will be able to:

- to assess which interventions affected asthma outcomes in communities with children at high risk for poor outcomes.
- to understand why an evidence based intervention may need to be tailored for a specific community.
- to consider how asthma care for children can be coordinated among a variety of providers.

In 2017, NHLBI funded 4 groups of investigators to conduct multi-level clinical trials to provide comprehensive asthma care within communities where children were at high risk for poor asthma outcomes. The trials were designed with evidence based interventions targeted to address findings from a formal needs assessment in each community. Key aspects of these trials included the integration of asthma care for the children and their families as well as efforts to facilitate the sustainability of the programs after the conclusion of the trials. Investigators will briefly review the protocols conducted in each community and provide the available results as most of these multi-year trials were recently completed. The assessment of the sustainability of the programs will be conducted in the future.

Chairing: M.M. Freemer, MD, MPH, Bethesda, MD

12:00 Asthma among Dine children living on the Navajo Nation
B.G. Bender, PhD, Denver, CO

12:15 Asthma among West Philadelphia Asthma Care Collaborative (WePACC) participants

T. Bryant-Stephens, MD, Philadelphia, PA

12:30 Asthma among RVA Breathes participants

R.S. Everhart, PhD, Richmond, VA

12:45 Asthma among Rhode Island Asthma Integrated Care (RI AIR) participants

D. Koinis-Mitchell, PhD, Providence, RI

MEET THE EXPERT SEMINARS

CME Credits Available: 1

R Pre-registration and additional fees required. Attendance is limited.

\$100 Member/Non-Members

\$70 LMIC Member/LMIC Non-Members

12:00 p.m. - 1:00 p.m

Marriott Marquis Washington

MTE7 INTERSTITIAL LUNG DISEASE IN ANCA VASCULITIS

M. Baqir, MBBS, Rochester, MN

R. Krishna, MBBS, Charleston, SC

University of DC/Catholic University (Level M1)

MTE8 MITIGATING DISPARITIES IN THE LUNG CANCER SCREENING PIPELINE

F.C. Duncan, MD, MS, Indianapolis, IN

S.B. Ogake, MD, Plain City, OH

E.R. Nunez, MD, Boston, MA

Howard University (Level M1)

MTE9 PEDIATRIC INVASIVE VENTILATION: MANAGEMENT AND RESOURCE CONUNDRUMS

F. Afolabi, MD, Dallas, TX

C.D. Baker, MD, Aurora, CO

A.S. Gelfand, MD, Dallas, TX

D. Liptzin, MD, MS, Missoula, MT

Georgetown University (Level M1)

MTE11 SMALL AIRWAYS DISEASE: WHEN IT'S NOT ASTHMA

S.J. Callahan, MD, Salt Lake City, UT

M. Koslow, MD, Denver, CO

R. De Oliveira Duarte Achcar, MD, Denver, CO

B. Elicker, MD, Novato, CA

Chinatown (Level M3)

MTE13 MEDIA & ME: HOW TO COMMUNICATE SCIENCE AND HEALTH THROUGH DIFFERENT MEDIA SOURCES

S.C. Sadreameli, MD, MHS, Baltimore, MD

P. Galiatsatos, MD, Baltimore, MD

LeDroit Park (Level M3)

MTE14 PERSONALIZING SELECTION OF INHALER DELIVERY SYSTEMS IN COPD

D.A. Mahler, MD, Claremont, NH
 D.M.G. Halpin, PhD, Exeter, United Kingdom
Mount Vernon Square (Level M3)

MTE15 CYSTIC FIBROSIS PULMONARY EXACERBATIONS: BASICS FOR THE GENERAL PULMONOLOGIST

G.R. Winter, MD, Birmingham, AL
Gallaudet University (Level M1)



BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

YEAR IN REVIEW

CME Credits Available: 1.5

MOC Points Available: 1.5

A81 PEDIATRIC YEAR IN REVIEW

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems; Environmental, Occupational and Population Health

2:15 PM - 3:45 PM

Walter E Washington Convention Center

Ballroom A (Level 3)

Target Audience

Any provider of lung health care for children, as well as clinical and translational researchers who study pediatric respiratory problems

Objectives

At the conclusion of this session, the participant will be able to:

- learn about the latest science and advocacy related to the impact of climate change on global respiratory health
- determine local environmental factors that influence respiratory health (exposome) with a focus on health equity
- learn about the long-term impact of viral pandemics on pediatric health

This session will provide up-to-date and state-of-the-art information on four topics: (1) global respiratory health during climate change (2) pediatric exposome, (3) pandemic science (4) well-being and resilience

Chairing: E. Forno, MD, MPH, ATSF, Pittsburgh, PA
 B.T. Kopp, MD, MPH, ATSF, Atlanta, GA

2:15 Pediatric Exposome

S. Lovinsky-Desir, MD, MS, New York, NY

2:38 Epidemic and Pandemic Viruses — Long-term Impact on Respiratory Health

C. Rosas-Salazar, MD, MPH, ATSF, Nashville, TN

3:00 Wellness and Resilience

H.H. De Keyser, MD, MSCR, Aurora, CO

3:23 Global Respiratory Health in the Setting of Climate Change

D. Vilcins, PhD, Brisbane, Australia

CLINICAL**CLINICAL TOPICS IN PULMONARY MEDICINE**

CME Credits Available: 1.5

A82 RACE AND PFTs: USE, CONTROVERSIES, AND ALTERNATIVES**Assembly on Clinical Problems; Pulmonary Function Testing Committee****2:15 PM - 3:45 PM****Marriott Marquis Washington****Marquis Ballroom Salon 5 (Level M2)****Target Audience**

Clinicians that use PFTs to diagnose or assess patients with respiratory disease, and/or clinical researchers with an interest in race or health equity

Objectives

At the conclusion of this session, the participant will be able to:

- understand the scientific justification for, potential benefits of, and potential harms from the use of race-specific equations
- improve interpretation and clinical application of PFT reports via understanding of how race-specific equations impact percent-predicted PFT values
- describe potential alternatives to current interpretation strategies and race-specific GVI equations, and their impact on patient care

Currently, ATS/ERS guidelines recommend the use of race-specific equations for the interpretation of spirometry. However, their use has recently been the subject of intense debate due to concerns that the equations may inappropriately normalize lower average lung function observed in Black and Asian populations. The session will present research related to why race-specific equations are used and what the potential harms and benefits of their use may be. Additionally, the session will highlight proposed alternatives to race-specific equations from the literature and discuss pros and cons of their use.

Chairing: N. Thakur, MD, MPH, San Francisco, CA
J.H. Brems, MD, MBE, Baltimore, MD
S. Lovinsky-Desir, MD, MS, New York, NY

2:15 Race-Specific Equations: Why We Use Them, What We Know, and What We Don't

S. Stanojevic, PhD, Halifax, Canada

2:33 Prediction of Clinical Outcomes with Race-Specific Versus Race-Neutral Equations

A.D. Baugh, MD, San Francisco, CA

2:51 Implications for Care and Impact on Health Disparities

R. Adamson, MBBS, ATSF, Seattle, WA

3:09 Proposed Alternatives to Race-specific Equations: Possibilities, Pros and Cons

M.C. McCormack, MHS, MD, Baltimore, MD

3:27 Panel Discussion with Q+A

N.R. Bhakta, MD, PhD, San Francisco, CA

This session and the International Conference are supported by an independent medical educational grant from AstraZeneca LP, Boehringer Ingelheim Pharmaceuticals, Inc., Insmid Incorporated, and United Therapeutics Corporation.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL**CLINICAL TOPICS IN PULMONARY MEDICINE**

CME Credits Available: 1.5

A83 GREAT CASES: CLINICAL, RADIOLOGIC, AND PATHOLOGIC CORRELATIONS BY MASTER CLINICIANS**Council of Chapter Representatives****2:15 PM - 3:45 PM****Walter E. Washington Convention Center****Ballroom C (Level 3)****Target Audience**

Clinicians in adult and pediatric PCCM

Objectives

At the conclusion of this session, the participant will be able to:

- describe findings based on observing master clinicians describe clinical, radiologic, and pathologic findings to challenging patient cases
- describe clinical reasoning used to reach a differential diagnosis based on a multidisciplinary team model
- learners will garner knowledge about treatment & management approaches to different pathologies presented at the conference

Junior physicians (trainees) present interesting cases to a multidisciplinary panel to demonstrate a team approach to diagnosing and managing challenging clinical cases. It will enhance medical knowledge, and diagnostic and management skills.

Chairing: M.J. Mammen, FACP, ATSF, Rochester, NY
N.-C. Liang, MD, Encinitas, CA

- 2:15 The Case of the Labored Breaths.**
Gorvetzian, MD, Aurora, CO
- 2:27 When You Hear Hoofbeats**
L. Power, MBCh, MRCPI, Galway, Ireland
- 2:39 A Zebra Walks into the ICU**
M. Richert, MD, Bethesda, MD
- 2:51 What if It's Not Just Air in There?**
P. Sekhon, MBBS, MD, Brooklyn, NY
- 3:03 Master Clinician**
A.E. O'Donnell, MD, Washington, DC
- 3:10 Master Clinician**
M. Kreider, MD, Philadelphia, NY
- 3:17 Master Clinician**
P.C. Stillwell, MD, Aurora, CO
- 3:24 Master Clinician**
J.B. Taylor, MD, MSCR, Pittsburgh, PA
- 3:31 Pathology Findings**
J.L. Myers, MD, Ann Arbor, MI
- 3:38 Radiological Findings**

P. Bergquist, Washington, DC BASIC • CLINICAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 1.5

A84 NEW ENGLAND JOURNAL OF MEDICINE AND JAMA. DISCUSSION ON THE EDGE: REPORTS OF RECENTLY PUBLISHED PULMONARY RESEARCH

2:15-3:45 PM **Walter E. Washington Convention Center**
Room 207 A-B (Level 2)

This session will provide a forum for attendees to interact with the authors and editors about papers published in the New England Journal of Medicine and JAMA. Papers presented will be recent publications, selected by the editors, to be of significant importance to the field of pulmonary medicine. Attendees will have the opportunity to hear presentations directly from the author and address questions to both the authors and editors. The discussion is intended to provide a unique insight into these papers, the selection process, and how the research applies directly to the field of pulmonary medicine.

Chairing: D. Taichman, MD, Boston, MA
G. O'Connor, MD, Boston, MA

Speakers and Talks To Be Announced

BASIC • TRANSLATIONAL

BASIC SCIENCE CORE

CME Credits Available: 1.5

A85 PHYSIOLOGICAL AND CELLULAR IMPACT OF ENVIRONMENTAL EXPOSURES

2:15-3:45pm **Location: Marriott Marquis Washington**
Independence Ballroom, Salons E-H

Target Audience
Researchers and clinicians

Objectives
At the conclusion of this session, the participant will be able to:

- identify opportunities for novel investigation into understudied aspects of the impact of environmental exposure of cellular and biological pathways relevant to lung disease.
- learn how advances in epidemiological studies are revealing new knowledge on health effects of environmental exposures.
- learn how advances in lung biology are revealing how environmental exposures can alter the pulmonary immune response and disease susceptibility.

This is part 2 of a 2-part symposium.

Part 1 is on Sunday, May 21, 9:00 a.m. -10:30 a.m. focuses on quantification of environmental exposures using state-of-the-art methods.

Part 2 focuses on the physiological and cellular impact of environmental exposures.

Occupational and environmental lung diseases are caused by the inhalation of chemical irritants, allergens or toxins in work or home environments. Most diseases are caused by repeated, long-term exposure, but even a one-time or indirect contact with a hazardous agent can result in lung diseases with lasting effects.

Environmental exposures related to fossil fuel and heavy metals and occupational exposures related to silica and coal mining generate oxidative stress and inflammation in the lungs. Sustained oxidative stress causes DNA damage, epigenetic instability, mitochondrial dysfunction, and cell cycle arrest in key progenitor cells in the lung.

Inhaled environmental exposures accelerate lung aging by injuring the lungs and damaging the cells responsible for wound healing. Novel exposure assessment methods, including functional imaging and -omics studies, together with mathematical models are needed to quantify environmental exposures. Interventions that minimize exposure to noxious antigens are critical to improve lung health, and novel research is required to expand our knowledge of therapies that may slow or prevent premature lung aging.

Each presentation will leave 5 minutes for questions and answers.

- Chairing:** G. Mutlu, MD, ATSF, Chicago, IL
D. Kamp, MD, Chicago, IL
A. Mora, MD, Columbus, OH
- 2:15 Air Pollution, Oxidative Stress, and Cardiopulmonary Diseases: A Life Course Epidemiologic Perspective**
G. Thurston, DSc, New York, NY
- 2:45 Environmental Toxins and Macrophages in Progression of Chronic Lung Disease**
J. Larson-Casey, PhD, Birmingham, AL
- 3:00 Role of Innate Immune System in Environmental Lung Diseases**
R. Tighe, MD, ATSF, Durham, NC
- 3:20 Understanding the Molecular Mechanisms of How Air Pollution Increases Susceptibility to Pulmonary Infections**
K. Gowdy, BS, MS, PhD, Columbus, OH
- 3:40 Questions and Answers**

<p>BASIC • BEHAVIORAL • CLINICAL</p> <p>SCIENTIFIC SYMPOSIUM</p> <p>CME Credits Available: 1.5</p>
--

A86 PHYSICAL FITNESS AND LUNG HEALTH

ATS Public Advisory Roundtable

2:15 PM - 3:45 PM **Walter E. Washington Convention Center**
Room 204 A-C (Level 2)

Target Audience

Providers of lung health and allied services

Objectives

At the conclusion of this session, the participant will be able to:

- Describe current ‘state of the art’ evidence supporting the role of physical activity in maintaining lung health
- Improve the quality of life/health status of patients by assessing technologies that may encourage patient engagement in physical fitness initiatives.
- Describe new findings related to the role of pulmonary rehabilitation in preserving lung function and improving quality of life for individuals with lung disease

This session will focus on the critical role of physical activity and conditioning in supporting respiratory health and improving patient quality of life. It will explore the current science on exercise and cardiorespiratory health, technologies to engage patients in physical activity, and the critical role of pulmonary rehabilitation in preserving respiratory health.

Chairing: M. Manion, BS, Minneapolis, MN
L.M. Schnapp, MD, ATSF, Madison, WI

- 2:15 Session Introduction**
L.M. Schnapp, MD, ATSF, Madison, WI
- 2:30 Every Mile Changes You: A Patient’s Perspective**
K. O’Grady, Patient Speaker, Hudson, MA
- 2:45 The Role of Physical Conditioning in Respiratory Health**
D.M. Mannino, MD, Lexington, KY
- 3:00 Pulmonary Rehab to Support Physical Conditioning**
C.L. Rochester, MD, New Haven, CT
- 3:15 Monitoring and Tracking Physical Activity: The Role of Wearable Tech**
A. Chesnutt, MD, Cupertino, CA
- 3:30 Exercise for Chronic Lung Conditions: What is the Evidence?**
M.B. Brown, PT, PhD, Seattle, WA

<p>CLINICAL • TRANSLATIONAL</p> <p>SCIENTIFIC SYMPOSIUM</p> <p>CME Credits Available: 1.5 MOC Points Available: 1.5</p>

A87 NEW TREATMENT APPROACHES FOR BRONCHIECTASIS

Assemblies on Pulmonary Infections and Tuberculosis; Allergy, Immunology and Inflammation; Clinical Problems

2:15 PM - 3:45 PM **Walter E. Washington Convention Center**
Hall E (Level 2)

Target Audience

Clinicians and scientists engaged in clinical care and research for bronchiectasis and related conditions

Objectives

At the conclusion of this session, the participant will be able to:

- describe new findings about the epidemiology and unmet need in patients with bronchiectasis
- improve the treatment of bronchiectasis patients by better applying the evidence for long term inhaled and oral antibiotics in clinical practice
- improve the treatment of bronchiectasis patients by better applying the evidence for mucus clearance treatments including airway clearance/physiotherapy and mucus targeting treatments

This symposium will review the emerging evidence in the field of bronchiectasis including new data from randomized controlled trials of inhaled antibiotics, cutting edge science around endotyping, and the application of personalized medicine as well as evidence for emerging therapies targeting inflammation.

Chairing: S.H. Kasperbauer, MD, Denver, CO
A.E. O’Donnell, MD, WASHINGTON, DC

- 2:15 A Patient's Perspective**
J. Torrence, Henderson, NV
- 2:20 Epidemiological Approaches to Investigating Treatment Effects and Unmet Need**
E. Henkle, PhD, MPH, Portland, OR
- 2:40 New Data for Airway Clearance and Mucoactive Approaches in Bronchiectasis**
A. Basavaraj, MD, FCCP, ATSF, New York, NY
- 3:00 The Role of Long Term Antibiotic Treatments in Bronchiectasis**
T.R. Aksamit, MD, Rochester, MN
- 3:20 Neutrophils, Eosinophils and Endotyping Bronchiectasis**
J.D. Chalmers, MD, PhD, Dundee, United Kingdom
- 3:40 Wrap Up and Panel Discussion**
S.H. Kasperbauer, MD, Denver, CO

This session and the International Conference are supported by an independent medical educational grant from Insmad Incorporated.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BASIC • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

A88 NEURO-IMMUNE INTERACTIONS IN LUNG DEVELOPMENT AND DISEASE

Assemblies on Respiratory Structure and Function; Respiratory Cell and Molecular Biology; Sleep and Respiratory Neurobiology

2:15 PM - 3:45 PM Marriott Marquis Washington

Marquis Ballroom Salon 6 (Level M2)

Target Audience

Those with clinical and/or research responsibilities

Objectives

At the conclusion of this session, the participant will be able to:

- understand the anatomy and function of the airway neural network in development and physiology
- understand how the airway neural network is altered in chronic lung disease
- integrate this knowledge to better understand how current and prospective pharmacological and nonpharmacological treatments modifying the airway neural network, improve symptoms in patients with chronic lung disease

The vagal nerve integrates afferent and efferent peripheral nerve fibers that control the functions of a large number of internal organs including

the respiratory tract. Chronic inflammation drives plasticity of those neurons, contributing to increased neuronal density in a variety of pathological conditions including asthma and chronic cough. In addition, evidence is building for a role of the nervous system in guiding immunological responses. In fact, neuro-immune interactions are recognized to play key roles in inflammation and remodeling in a variety of chronic lung diseases. As a consequence, there is a need to review current concepts surrounding neuronal development, neuroplasticity and neuro-immune interactions in chronic lung disease.

Chairing: N. Jendzjowsky, PhD, Torrance, CA
R. Gosens, PhD, Groningen, Netherlands

- 2:15 In Utero Development of the Pulmonary Nervous System**
X. Ai, PhD, Boston, MA
- 2:33 Dissection of Neuroimmune Control of Lung Function in Animal Models of Disease**
X. Sun, PhD, San Diego, CA
- 2:51 Airway Neuroplasticity in Asthma**
M.G. Drake, MD, Portland, OR
- 3:09 Macrophage Derived Netrin in Fibrosis**
E. Herzog, MD, PhD, New Haven, CT
- 3:27 Targeted Lung Denervation for COPD**
D.-J. Slebos, MD, PhD, Groningen, Netherlands

BEHAVIORAL • CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

A89 CAN ENVIRONMENTAL INTERVENTIONS CHANGE THE SOCIAL DETERMINANTS OF HEALTH?

Assemblies on Environmental, Occupational and Population Health; Behavioral Science and Health Services Research; International Health Committee

2:15 PM - 3:45 PM Walter E. Washington Convention Center

Room 147 A-B (Street Level)

Target Audience

Trainees, clinicians, researchers, allied health personnel

Objectives

At the conclusion of this session, the participant will be able to:

- describe approaches to quantifying SDOH in the context of high income and low income settings
- define how global factors such as climate change influences the relationship between household energy insecurity and SDOH
- define new strategies for changing the SDOH through environmental interventions

Social determinants of health (SDOH) are the conditions where people live, learn, work, and play. SDOH drive disparities in health outcomes, but most studies have focused on documenting the role of the SDOH rather than on identifying interventions that directly influence the SDOH. Environmental factors are both a component of and also a potential target for intervention on the SDOH. This session, which will include examples from both high income and low and middle income countries, will discuss how environmental factors are a core component of the SDOH and show that environmental interventions can change the SDOH and address health disparities.

Chairing: P.S. Lai, MPH, MD, ATSF, Boston, MA
R. Bascom, MD, MPH, Hershey, PA
O.B. Ozoh, MBBS, ATSF, MSc, Lagos, Nigeria

- 2:15 How Do We Quantify the Social Determinants of Health?**
J.R. Balmes, MD, ATSF, San Francisco, CA
- 2:30 Environmental Context and Barriers to Asthma Inhaler Use in High Income vs. Low and Middle Income Countries**
I.L. Riley, MD, MPH, Durham, NC
- 2:45 Household Energy Use in Low and Middle Income Countries Affects Lung Health and Perpetuates Poverty**
O.B. Ozoh, MBBS, ATSF, MSc, Lagos, Nigeria
- 3:00 Climate Change Exacerbates Health Inequalities Due to Household Energy Insecurity**
D. Hernandez, PhD, New York, NY
- 3:15 Should I Pay for Food, Rent, or Inhalers? Community Linkage Resource Programs and Pediatric Asthma Exacerbations in the United States**
A. Martinez, MD, MPH, San Francisco, CA
- 3:30 Can a Household Energy Intervention Change the Social Determinants of Health? Solar Lighting in Rural Uganda**
P.S. Lai, MPH, MD, ATSF, Boston, MA

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

A90 MYTHS OR TRUTHS: CONTROVERSIES IN RESPIRATORY MEDICINE, THE NEW FRONTIER

Assemblies on Sleep and Respiratory Neurobiology; Allergy, Immunology and Inflammation; Critical Care; Respiratory Cell and Molecular Biology

2:15 PM - 3:45 PM **Walter E. Washington Convention Center**
Ballroom B (Level 3)

Target Audience

Clinicians and researchers working in the fields of critical care, fibrotic and inflammatory lung disease, asthma, allergy and sleep medicine

Objectives

At the conclusion of this session, the participant will be able to:

- inform the clinicians and researchers about specific areas of debate in management of common and burdensome respiratory conditions: 1) Asthma; 2) OSA; 3) Fibrotic lung disease and 4) ARDS
- apply state of the science to help the audience decide on appropriate 1) management of severe Asthma with biologics; 2) use of the AHI in OSA patients; 3) therapeutics in lung fibrosis and 4) treatment of ARDS for their patients
- identify key gaps for conditions mentioned in objectives 1 and 2 that should inform future research

The pulmonary, critical care, and sleep communities have made progress toward evidence-based care and developing novel therapies for “incurable” diseases. However, recent data challenge current approaches and create uncertainty about the research and management approaches to highly burdensome respiratory conditions. These controversies include 1) management of severe asthma, 2) apnea-hypopnea index as a prognostic marker in OSA, 3) correcting cellular aging in fibrotic and inflammatory diseases, and 4) targeting oxygenation during ventilation of acute respiratory distress syndrome. This session will address the state of the science and evidence for aspects of managing these conditions to inform clinical decision-making and future research.

Chairing: A. Zinchuk, MD, MHS, BS, New Haven, CT
A.M. Esper, MD, MS, ATSF, Atlanta, GA
M. Rojas, MD, Columbus, OH
M. Wechsler, MD, Denver, CO
N.A. Shah, MD, MPH, MSci, New York, NY

- 2:15 Introduction to Debate 1: Biologics Overlap in Asthma**
M. Wechsler, MD, MSc, Denver, CO
- 2:18 Truth: Biologics Can Be Combined and Overlapped in Severe Asthma**
M. Kraft, MD, ATSF, New York, NY
- 2:27 Myth: Biologics Can Be Combined and Overlapped in Severe Asthma**
P. Akuthota, MD, ATSF, La Jolla, CA
- 2:36 Summary and Audience Response Results (Debate 1)**
M. Wechsler, MD, MSc, Denver, CO
- 2:38 Introduction to Debate 2: Utility of the AHI**
N.A. Shah, MD, MPH, MSci, New York, NY
- 2:40 Truth: The AHI Should Be Used in Prognostication and Treatment of OSA**
A. Malhotra, MD, ATSF, La Jolla, CA
- 2:49 Myth: The AHI Should Be Used in Prognostication and Treatment of OSA**
S.S. Redline, MD, MPH, Boston, MA
- 2:58 Summary and Audience Response Results (Debate 2)**
A. Zinchuk, MD, MHS, BS, New Haven, CT

- 3:00 Introduction to Debate 3: Senolytics in Respiratory Diseases**
M. Rojas, MD, Columbus, OH
- 3:02 Truth: Senolytics Can Be Effective in Fibroproliferative and Other Respiratory Diseases**
A.M. Nambiar, MD, MSCR, San Antonio, TX
- 3:11 Myth: Senolytics Can Be Effective in Fibroproliferative and Other Respiratory Diseases**
B. Crestani, MD, PhD, Paris, France
- 3:20 Summary and Audience Response Results (Debate 3)**
M. Rojas, MD, Columbus, OH
- 3:22 Introduction to Debate 4: PEEP and Oxygenation in ARDS**
A.M. Esper, MD, MS, ATSF, Atlanta, GA
- 3:24 Truth: PEEP Titration in ARDS Should Prioritize Arterial Oxygenation**
S. Sahetya, MD, MHS, Baltimore, MD
- 3:33 Myth: PEEP Titration in ARDS Should Prioritize Arterial Oxygenation**
J. Beitler, MD, MPH, New York, NY
- 3:42 Summary and Audience Response Results (Debate 4 and Overall Session)**
A.M. Esper, MD, MS, ATSF, Atlanta, GA

This session and the International Conference are supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BASIC • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

A93 MECHANISTIC INSIGHTS AND NOVEL THERAPEUTICS IN ACUTE LUNG INJURY

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 143 A-C (Street Level)

Chairing: F.T. Korkmaz, PhD, Worcester, MA
C. Mikacenic, MD, Seattle, WA
J.M. Sturek, MD, PhD, Charlottesville, VA
H.S. Kulkarni, MD, MSc, ATSF, Saint Louis, MO

Oral Presentations:

- 2:15 CD177+ Neutrophils Produce Neutrophil Extracellular Traps to Promote Lung Ischemia Reperfusion Injury/C.**
Li, Shanghai, China

- 2:27 Distinct Plasma and Lower Respiratory Tract Biomarker Profiles During Acute Respiratory Failure/C.** Caglayan, Pittsburgh, PA
- 2:39 Macrophage TRPV4 Protects Against Bacterial Pneumonia-induced Lung Injury Through the NF- κ B Pathway/R.G.** Scheraga, Cleveland, OH
- 2:51 Aerosolized aCT1 Peptide Reduces SARS-CoV-2 Induced Lung Injury in the Syrian Hamster/M.** Bowler, Mount Pleasant, SC
- 3:03 Myeloid STAT1 Regulates Injury Response During Hemorrhagic Alveolar Damage/A.P.** Gheware, Pittsburgh, PA
- 3:15 A Lysine Demethylase, Kdm6b, Contributes to Treg Function During Influenza-induced Lung Injury/J.R.** Mock, Chapel Hill, NC
- 3:27 Small Extracellular Vesicles From MSC-NTF Cells Induce Significant Improvement in Inflammatory Lung Disease Models/H.** Kaspi, Petach Tikva, Israel
- 3:39 The Role of Overdistension and Recruitment/Derecruitment on Alveolar Inflammation and Injury/S.** Blair, Syracuse, NY
- 3:51 A Novel Non-catalytic p38alpha/MK2 Pathway Modulator Mitigates Acute Lung Injury and Improves Survival in a Mouse Influenza Model/J.D.** Hasday, Baltimore, MD
- 4:03 Alveolar Macrophage Subsets Are Dynamic and Associated With Mortality in the Acutely Injured Lung/E.D.** Morrell, Seattle, WA

BEHAVIORAL • CLINICAL

MINI SYMPOSIUM

A94 ADVANCES IN HEALTH SERVICES RESEARCH FOCUSED ON INTERSTITIAL LUNG DISEASE AND CYSTIC FIBROSIS

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 152 A-B (Street Level)

Chairing: M. Sharp, MD, MHS, Baltimore, MD
K.J. Ramos, MD, MS, Seattle, WA
L. Fidler, MD, MSci, Toronto, Canada

Oral Presentations:

- 2:15 Prescribing Patterns of Antifibrotics in Patients Diagnosed With Idiopathic Pulmonary Fibrosis/D.**
Shankar, Boston, MA
- 2:27 Comparative Effectiveness of Nintedanib and Pirfenidone in Patients Diagnosed With Idiopathic Pulmonary Fibrosis/D.** Shankar, Boston, MA

- 2:39 Association Between Nintedanib Adherence Trajectories and Healthcare Use Among Idiopathic Pulmonary Fibrosis Patients/M. Nili, Ridgefield, CT**
- 2:51 Barriers and Facilitators to Care for Rural Populations With Interstitial Lung Disease: Perspectives From Pulmonary Fibrosis Foundation Care Center Network Providers/A.M. Dedent, San Francisco, CA**
- 3:03 Exploring Patient Perspectives to Develop a Stakeholder Curriculum for Scleroderma-related Interstitial Lung Disease/T.A. Di Vitantonio, New York, NY**
- 3:15 Delay in Referral for Sarcoidosis Care Is Associated With Racial Disparities and Lung Function Decline/R. Strykowski, Chicago, IL**
- 3:27 Racial and Ethnic Representation in Clinical Trials in the CF Therapeutics Development Network/T. Milinic, Seattle, WA**
- 3:39 The Impact of Lung Allocation Score Exceptions on Outcomes in Persons With Cystic Fibrosis/O. Bayomy, Seattle, WA**
- 3:51 “I Eat Chocolate Milk for Dinner Because We Just Have Nothing in Our Fridge”: The Invisible Burden and Dire Consequences of Food Insecurity for People With Cystic Fibrosis in the United States/G.R. Oates, Birmingham, AL**
- 4:03 Feasibility Testing of a Web-based Reproductive Decision Support Tool for Cystic Fibrosis/T.M. Kazmerski, Pittsburgh, PA**

CLINICAL

MINI SYMPOSIUM

A95 THIS IS YOUR BRAIN ON (ICU) DRUGS: SEDATION, DELIRIUM, AND LONG-TERM COGNITIVE IMPAIRMENT

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 146 A-C (Street Level)

Chairing: T.D. Girard, MD, MSci, ATSF, Pittsburgh, PA
E. Wilcox, MD, PhD, FRCPC, Toronto, Canada
J.A. Palakshappa, MD, MSci, Winston-Salem, NC

Oral Presentations:

- 2:15 Tackling Delirium: An Educational Tool to Improve Nursing-level Identification and Treatment of Delirium in the Intensive Care Unit/E. Balaban, Pittsburgh, PA**
- 2:27 Development and Implementation of Standardized Metrics for Sedation and Delirium Assessment Across a Large Health System/B.J. Anderson, Philadelphia, PA**

- 2:39 Validation of a Predictive Tool for Sedative-associated Delirium During Respiratory Failure/N. Prendergast, Pittsburgh, PA**
- 2:51 Distribution of Data-Driven Delirium Subtypes Within Prior Knowledge-based Delirium Phenotypes/K. Potter, Pittsburgh, PA**
- 3:03 Novel Sampling Methodology to Identify Metabolites Associated With Delirium in a Sepsis Cohort/C.A. Onyemekwu, Pittsburgh, PA**
- 3:15 Association of Plasma Brain Injury Markers With Delirium and Delirium/Coma Free Days in Critically Ill Septic Patients/T.G. Boyce, Philadelphia, PA**
- 3:27 Outcomes Among Data-Driven Delirium Subtypes During Critical Illness/K. Potter, Pittsburgh, PA**
- 3:39 Association of New Sedatives Prescription With Falls and Fractures Among Older Adults After Critical Illness/L.D. Burry, Toronto, Canada**
- 3:51 Development and Validation of a Prediction Model for Cognitive Impairment in Older Adults Following Critical Illness/A.E. Eisner, Winston Salem, NC**
- 4:03 Sedation Practices for Intubated Non-COVID Patients Have Worsened in the Post-COVID Era/A. Barker, Ann Arbor, MI**

BEHAVIORAL • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

A96 ENHANCING SUPPORT FOR PATIENTS AND FAMILIES EXPERIENCING SERIOUS ILLNESS

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 145 A-B (Street Level)

Chairing: J. Choi, PhD, RN, Seoul, Korea, Republic of
T.L. Eaton, PhD, MSc, RN, FNP-BC, ACHPN, Ann Arbor, MI

Oral Presentations:

- 2:15 Improving Homecare for Children With Technology Dependence Through Web-based Education/J. Henningfeld, Milwaukee, WI**
- 2:27 The Use of a Therapeutic Robotic Seal to Facilitate Rehabilitation in the Pediatric Intensive Care Unit/B.D. Hetland, Omaha, NE**
- 2:39 Patient and Caregiver Decision-making in Advanced Lung Disease: Qualitative Content and Dyadic Interview Analyses/M. George, New York, NY**

- 2:51 **End-of-Life Decision Making and Symptoms After a Loved One's Cardiac Arrest: A Qualitative Descriptive Study**/C.E. Deforge, New York, NY
- 3:03 **Development of a Digital ICU Diary Intervention Prototype for Survivors of Critical Illness Requiring Extracorporeal Membrane Oxygenation (ECMO)**/K. Knudson, Milwaukee, WI
- 3:15 **Navigating the Transfer of Cystic Fibrosis Self-management Responsibility During Healthcare Transition**/K. South, New York, NY
- 3:27 **Effects of a Web-based Multiple Component Mindfulness Meditation for Pulmonary Hypertension (MMPH) Program on Symptoms and Health-related Quality of Life: A Pilot Randomized Controlled Trial**/T.T. Von Visger, Buffalo, NY
- 3:39 **A Randomized Clinical Trial to Test a Mobile Application That Supports Family Caregiver Participation in Patient Care in the Intensive Care Unit**/B.D. Hetland, Omaha, NE
- 3:51 **A Pilot Randomized Trial of a Videoconferencing-based Communication Training Program With Group Coaching for Intensive Care Unit Nurses**/J. Choi, Seoul, Korea, Republic of

CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

A97 RISE OF THE MACHINES: -OMICS AND COMPUTATIONAL BIOLOGY IN PULMONARY HYPERTENSION

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 150 A-B (Street Level)

Chairing: C.J. Rhodes, PhD, London, United Kingdom
D. Valdez-Jasso, PhD, La Jolla, CA
F.N. Rahaghi, MD, PhD, Boston, MA
C. Simpson, MD, Baltimore, MD

Oral Presentations:

- 2:15 **Fatty Acid Dysregulation Identifies Right Ventricular Dysfunction in Chronic Obstructive Pulmonary Disease (COPD) Patients: A Metabolomic Analysis in the Pulmonary Vascular Disease Phenomics (PVDOMICS) Cohort**/S. Chung, New York, NY
- 2:27 **Using an Unsupervised Learning Ensemble to Identify and Evaluate PAH Immune Phenotypes Longitudinally During Disease Progression**/A. Sweatt, Stanford, CA
- 2:39 **Distinct Proteomic Signatures Are Associated With Right Ventricular Vulnerability and Outcomes in Pulmonary Arterial Hypertension**/H. Pi, Seattle, WA

- 2:51 **A Supervised Machine-learned Algorithm to IDENTIFY PH in Patients With New Onset Symptoms**/C.R. Bridges, Washington, DC
- 3:03 **Cytokines as Prognostic Biomarkers in Pulmonary Arterial Hypertension**/A. Boucly, London, United Kingdom
- 3:15 **Complement Cascade Peptide Levels in the Peripheral Circulation of PAH Patients Are Related to Hemodynamic Measures of Vascular Function**/V.O. Kheyfets, Aurora, CO
- 3:27 **Mitochondrial Dysfunction Across Pulmonary Vascular Diseases**/S.Y. Farha, Cleveland, OH
- 3:39 **Compartment-specific Remodeling of End-stage Chronic Obstructive Pulmonary Disease Patients With Severe Pulmonary Hypertension Based on Histological Lung Tissue Samples**/K. Zeder, Graz, Austria
- 3:51 **Metabolites of the Kynurenine Pathway Are Significantly Altered in Systemic Sclerosis Associated PAH Compared to Other Subgroups of PAH**/N. Wallace, San Diego, CA
- 4:03 **Pulmonary Vascular Pruning in Severe Pulmonary Hypertension Associated With Chronic Lung Diseases**/A.R. Garcia, Barcelona, Spain

BASIC • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

A98 HOST VS. BUG

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 202 A (Level 2)

Chairing: J. Keane, MD, Dublin, Ireland
K. Traber, MD, PhD, ATSF, Boston, MA
J. Pantaleon-Garcia, MD, Houston, TX

Oral Presentations:

- 2:15 **Pulmonary Surfactant Phospholipids Antagonize Infection and Replication of SARS-CoV-2 and Its Variants**/J. Loeffler, Denver, CO
- 2:27 **The Anti-inflammatory Club Cell Protein 16 Is Decreased in Human Airways After Intrabronchial Lipopolysaccharide (LPS) Exposure**/E.I. Cardenas, Stockholm, Sweden
- 2:39 **Murine Host Response to Typical and Atypical Pneumonia**/M.S. Mccravy, Durham, NC
- 2:51 **A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Bronchiectasis Patient Neutrophil-Mediated Killing of Pseudomonas Aeruginosa**/M.B. Long, Dundee, United Kingdom

- 3:03 Unique Local Immune Gene Expression Signatures in Recall Responses of Individuals With Latent Tuberculosis Infection Following Bronchoscopic Challenge With Purified Protein Derivative (PPD)/** R.F. Silver, Cleveland, OH
- 3:15 Global Cell Free DNA Methylation in Pulmonary Tuberculosis Versus Latent Tuberculosis Infection/** C. Chang, Taipei, Taiwan
- 3:27 Disruption of 3 β -hydroxysteroid Dehydrogenase in Mycobacterium Tuberculosis Leads to Increased Virulence and Altered Inflammatory Response/**A.T. Roth, St. Louis, MO
- 3:39 Inhibiting PD-1 Restores Mycobacterium Tuberculosis Specific Poly-functional T Cells: Impact on Therapy of Drug Resistant Tuberculosis Patients/**D.K. Mitra, Delhi, India
- 3:51 Intradermal Immunization With Double Mutant Labile Toxin- Adjuvanted Antigen 85 Complex Promotes Mucosal Immunity Against Tuberculosis/**A. Meyer, New Orleans, LA

Featured Speaker:

- 4:03 Host Directed Therapies for TB: Old and New/**W.R. Bishai, Baltimore, MD

- 2:51 An Updated Interim Analysis of the Air Trial; an Open-label, Single-arm, 36-week, Phase 2 Trial of an Angiotensin Type 2 Receptor Agonist, C21, in Individuals With IPF/R.** Batta, Stockholm, Sweden
- 3:03 Randomized Proof-of-concept Study of AX-8, a TRPM8 Agonist, in Refractory or Unexplained Chronic Cough/**J. Smith, Manchester, United Kingdom
- 3:15 Response in Patient-reported Cough Severity in Soothe, a Phase 2b Trial of Camlipixant in Refractory Chronic Cough/**L. Mcgarvey, Belfast, United Kingdom
- 3:27 A Pilot Study Using a Novel Respiratory Wearable for Identifying Exacerbation Periods Remotely in High-risk Patients With Chronic Respiratory Diseases/**M.L. Chiu, Boston, MA
- 3:39 Predicting the Clinical Phenotype of COPD Patients Who May Benefit From Selective Pulmonary Vasodilator Therapy During Exercise: A Placebo-controlled Randomized Double-blind Cross-over Trial/**S.É. Collins, Edmonton, Canada
- 3:51 Data-Driven Clustering Identifies Idiopathic Pulmonary Fibrosis Endotypes With Prognostic Implications Using Tissue Turnover Biomarkers/**L. Egerod, Herlev, Denmark

BASIC • CLINICAL • TRANSLATIONAL**MINI SYMPOSIUM****A99 CLINICAL TRIALS IN CHRONIC LUNG DISEASE**

2:15 p.m. - 4:15 p.m. **Marriott Marquis Downtown**
Independence Ballroom Salons A-D (Level M4)

Chairing: M.G. Drake, MD, ATSF, Portland, OR
V. Mock, MD, New York, NY
K. Melamed, MD, Los Angeles, CA

Oral Presentations:

- 2:15 Dupilumab Reduces Sputum Eosinophils, Mucus Plugging and Improves Ventilation in Patients With Moderate-to-Severe Asthma/**S. Svenningsen, Hamilton, Canada
- 2:27 Pulmonary Vascular Redistribution Following 2.5-years Anti-IL5-R α Treatment in Eosinophilic Asthma/**M. Mcintosh, London, Canada
- 2:39 Associations of a Plant Centered Diet and Lung Function Decline Across Early to Mid-adulthood: The Cardia Lung Study/**R. Wharton, New York, NY

BASIC • TRANSLATIONAL**POSTER DISCUSSION SESSION****A101 LINKING BIOLOGY TO THE REAL WORLD IN ASTHMA AND ALLERGIC INFLAMMATION**

2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center**
Room 201 (Level 2)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: J.G. Krings, MD, MSci, Saint Louis, MO
M. Curtiss, MD, PhD, Birmingham, AL
B.D. Medoff, MD, Boston, MA
L. Rogers, MD, New York, NY

- 601 Mice Deficient in Glp1r Exhibit Increased Airway Resistance in a Model of Chronic Allergen-induced Airways Disease With Obesity/**M.D. Ihrle, Durham, NC
- 602 Targeting Reprogrammed Glycolysis in Aspergillus Fumigatus-activated Lung Eosinophils and Alveolar Macrophages for the Treatment of Severe Asthma/**P.X.L. Gan, Singapore, Singapore
- 603 Aspergillus Fumigatus Alkaline Protease 1 (Alp1) Controls Airway Smooth Muscle Functions in Asthma/**N.L. Pereira, Bethesda, MD

- 604 **Relative Abundance of Gram-negative Airway Microbiota Is Associated With Airway Eosinophilia and Obesity in Allergic Asthma/V. Mcquade, Durham, NC**
- 605 **Role of Eosinophil Mitochondrial Function in Severe Eosinophilic Asthma/J.B. Koranteng, London, United Kingdom**
- 606 **Dysregulation of Complement Pathways in the U-BIOPRED Severe Asthma Cohort/I.M. Adcock, London, United Kingdom**
- 607 **Mouse Model of Neutrophilic Asthma Reveals an Epithelium-Lymphocyte-Neutrophil Communication Circuit Underlying Destructive Allergic Airway Neutrophilia/A.T. Shenoy, Boston, MA**
- 608 **Neutrophilic Responses in a Subacute and Chronic Mouse Model of Pollutant-aggravated Allergic Asthma/J. De Volder, Ghent, Belgium**
- 609 **Impact of Rhinovirus Infection and Th17 Cell Conditioning on Airway Epithelial Expression of IL-1 β , TNF- α , IL-17C and GCSF and Neutrophil Activation in T2-low Vs T2-high Asthma/E.R. Vanderwall, Seattle, WA**
- 610 **Epithelial Immunomodulation by Aerosolized Toll-like Agonists Prevents Allergic Lung Inflammation by Reducing Th2 Polarization/M. Ntita, Houston, TX**
- 611 **IL-13 Regulated Airway Epithelial Genes Correlate to Lung Function and Markers of T2 Asthma in Sarpilii Participants/J.S. Boomer, St. Louis, MO**
- 612 **Rev-erb α Knockout Mice Show Exaggerated Lung Inflammation Following Acute House Dust Mite-induced Allergic Asthma/S.K. Duraisamy, Kansas City, KS**
- 613 **Lower CC16 Expression in the Airway Is Associated With an Asthma Phenotype and Local and Systemic Type 2 Inflammatory Traits/H. Kimura, New York, NY**
- 614 **Airway IL-1 Family Signaling Is Increased in Allergic Controls Compared to Allergic Asthmatics in Response to Allergen Challenge/A. Haring, Charlestown, MA**
- 615 **Preventive Effects of Inhibition of Thymic Stromal Lymphopoietin on Bronchial Hyperresponsiveness and Inflammatory Cellular Pattern in an Experimental Model of Chronic Allergic Pulmonary Inflammation Exacerbated by Lipopolysaccharide/E.A. Grencheski, Sao Paulo, Brazil**
- 616 **Serum TSLP Levels in Asthma - Relationship to Type 2 and Non-Type 2 Biomarkers/K. Khanna, San Francisco, CA**
- 617 **Epigenetic Training of the Interleukin 6 Gene in Airway Epithelial Cells Is Central to Asthma Exacerbations/L. Lunding, Borstel, Germany**
- 618 **Circulating Natural Killer Cell Immunophenotypes Correlate With Severe Asthma Clinical Traits/M.G. Duvall, Boston, MA**
- 619 **Pattern of Allergic Sensitization in Lagos, Nigeria: Informing Cost Effective Testing for a Low Resource Setting/S.K. Dede, Lagos, Nigeria**
- 620 **The Conundrum of Early Childhood Asthma Treatment: Evidence From the Canadian Asthma Primary Prevention Study/R. Li, Bloomington, IN**
- 621 **Characteristics of Patients With Moderate-to-Severe Asthma and High Healthcare Costs in the United States/J. Hwee, Mississauga, Canada**
- 622 **Heterogeneity of Elderly Asthmatics Unveiled by Phenotyping/Endotyping of a Brazilian Sample/M. Menezes, Ribeirao Preto, Brazil**
- 623 **Real World Investigation of Eosinophilic-associated Disease Overlap (REVEAL): Persistent Asthma Healthcare Resource Utilization and Associated Cost Sub-study/J. Kwiatek, Wilmington, PA**
- 624 **Airway Efficacy and Systemic Activity With Different Inhaled Corticosteroid-containing Dosing Regimens in Patients With Persistent Asthma: A Structured Literature Review and Modeling Analysis/D. Singh, Manchester, United Kingdom**
- 625 **Quality of Life in Patients With Asthma Using Oral or Inhaled Corticosteroids - a Qualitative Study/P.N. Persaud, Cleveland, OH**

CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

A102 THE DEVELOPMENT, PROGRESSION, AND TREATMENT OF ILD

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 209 A-C (Level 2)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: G.M. Hunninghake, MPH, MD, Boston, MA
A. Podolanczuk, MD, ATSF, New York, NY
Y.H. Khor, BMedSci, MBBS, FRACP, PhD, Heidelberg, Australia

801 **Adult Lung Function Trajectories and Future Interstitial Features/G.Y. Liu, Chicago, IL**

802 **Nocturnal Hypoxemia Is Associated With Increased Risk of Disease Progression and All-cause Mortality at One and Two Year Follow Up in Patients With Fibrotic Interstitial Lung Disease/K.J. Myall, London, United Kingdom**

803 **The Clinical Frailty Scale Is Associated With Mortality in Patients With Fibrotic Interstitial Lung Disease - A Multicenter Cohort Study/S.A. Guler, Bern, Switzerland**

- 804 **Relationship of Sarcopenia and Frailty in Patients With Outcomes in Idiopathic Pulmonary Fibrosis**/M. Sridhar, Birmingham, AL
- 805 **Body Mass Index Is Associated With Clinical Outcome in Patients With Idiopathic Pulmonary Fibrosis: A Nationwide Population-based Study**/H.-Y. Yoon, Seoul, Korea, Republic of
- 806 **Clinical Impact of Weight Loss on Mortality in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Cohort Study**/J.K. Lee, Seoul, Korea, Republic of
- 807 **Associations Between L-PF Questionnaire Dyspnea Scores and Outcomes in Patients With Progressive Fibrosing ILDs: Data From the INBUILD Trial**/M. Wijsenbeek, Rotterdam, Netherlands
- 808 **External Validation and Longitudinal Application of a Multidimensional Index to Individualize Survival Prediction in Idiopathic Pulmonary Fibrosis**/A. Chandel, Bethesda, MD
- 809 **New Prognostic Scoring System for Mortality in Idiopathic Pulmonary Fibrosis by Modifying the Gender, Age, and Physiology Model With Desaturation During the Six-minute Walk Test**/J.H. Jang, Busan, Korea, Republic of
- 810 **Derivation of Multidimensional Index for Predicting Progression in Fibrotic Interstitial Lung Diseases and Comparison With Criteria Suggested by INBUILD and ATS/ERS-2022**/S.A. Cordero Da Silva, Sao Paulo, Brazil
- 811 **Clinical and Epidemiological Characteristics of Patients Admitted With Idiopathic Pulmonary Fibrosis Exacerbation, a Nationwide Study**/M. El Labban, Mankato, MN
- 812 **Identification of Factors Associated With Acute Respiratory Failure in Patients With Interstitial Lung Disease**/T. Ozlu, Trabzon, Turkey
- 813 **Monocyte Count and Transplant-free Survival in Patients With Fibrotic Interstitial Lung Disease**/B. Min, Calgary, Canada
- 814 **Differences in Serum Protein Expression by Sex in Patients With Systemic Sclerosis Associated Interstitial Lung Disease**/G.C. Cerro Chiang, Los Angeles, CA
- 815 **Factors Associated With Persistence With Antifibrotic Therapy in Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Pulmonary Fibrosis Foundation Patient Registry**/T. Kulkarni, Birmingham, AL
- 816 **Real World Outcomes of Progressive Fibrosing Interstitial Lung Disease: Validity of Definition and the Efficacies of Antifibrotics**/T. Niitsu, Suita, Japan
- 817 **Effect of Nintedanib on Decline in Forced Vital Capacity (FVC) in Patients With Combined Pulmonary Fibrosis and Emphysema: Data From the INBUILD Trial**/V. Cottin, Lyon, France
- 818 **Effect of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis and Differing Extents of Emphysema on HRCT**/V. Cottin, Lyon, France
- 819 **Immunosuppressive Treatment in Interstitial Lung Disease Secondary to Antisynthetase Syndrome and Systemic Sclerosis - a Multicenter Observational Study**/O. Freund, Tel Aviv, Israel
- 820 **Steroid Therapy in Acute Exacerbations of Fibrotic Interstitial Lung Disease**/K. Koshy, Melbourne, Australia
- 821 **Conventional Hypersensitivity Pneumonitis Management Vs the Addition of Antifibrotic Therapy: Does It Slow Disease Progression?**/S. Shah, Maywood, IL
- 822 **Genomic Classifier for Usual Interstitial Pneumonia Predicts Progression in Fibrotic Lung Disease Across a Range of Clinical Diagnoses**/L.H. Lancaster, Nashville, TN
- 823 **Endobronchial Optical Coherence Tomography Imaging as a Novel Method to Detect and Monitor Microscopic Disease Progression in IPF**/L.P. Hariri, Boston, MA

CLINICAL

POSTER DISCUSSION SESSION

A103 TOWARDS IMPROVING ICU PRACTICE

2:15 p.m. - 4:15 p.m.

Marriott Marquis Washington

Marquis Ballroom, Salons 9-10 (Level M2)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: H.B. Gershengorn, MD, FCCM, ATSF, Miami, FL
S.M. Bagshaw, MD, MSc, Edmonton, Canada
A.J. Admon, MD, MPH, MS, Ann Arbor, MI

1001 **Lactation Practices and Breastfeeding in the Critically Ill Adult Patient**/K. Kolbe, Ann Arbor, MI

1002 **Restrictive Versus Liberal Oxygen Targets in Post Cardiac Arrest Patients - Meta Analysis of Randomized Controlled Trials**/S. Singh, Baltimore, MD

1003 **A Systematic Review and Meta-analysis Comparing the Mortality in Aggressive Versus Moderate Fluid Hydration for Acute Pancreatitis: A Paradigm Shift?**/R. Ali, Harrisburg, PA

1004 **Extracorporeal Membrane Oxygenation (ECMO) Utilization in the Emergency Cardio-pulmonary Disorders - An Estimate of Pre-COVID-19 Era**/N. Abdi, Beijing, China

- 1005 **Comparison of Eight Versus Fifteen Days of Antimicrobial Therapy for Ventilator Associated Pneumonia: A Systematic Review and Meta-analysis of Randomized Controlled Trials/R. Reddy, Austin, TX**
- 1006 **The Temperature Battle: A Systematic Review and Meta-analysis Comparing Normothermia and Hypothermia After Cardiac Arrest/T.M. Mirza, Harrisburg, PA**
- 1007 **Frequency, Duration, and Risk Factors for Diagnostic Delays Associated With Bacterial Meningitis/R.D. Struble, Iowa City, IA**
- 1008 **Hospitalization Outcomes in Patients With Central Line Associated Bloodstream Infections: A Nationwide Study From 2011-2018/A.R. Patel, Nashville, TN**
- 1009 **A Cost Effectiveness Analysis of a Quality Improvement Intervention to Increase Preferential Balanced Fluid Prescribing/M.C. Spiegel, Charleston, SC**
- 1010 **Chest Compressions During Cardiopulmonary Resuscitation Produce Oscillations in Capnography Associated With Return of Spontaneous Circulation/S. Bhandari, Seattle, WA**
- 1011 **Phenobarbital Can Reduce Intensive Care Unit Length of Stay in Patients With Alcohol/Benzodiazepine Withdrawal as Compared to Benzodiazepines/S. Gayen, Philadelphia, PA**
- 1012 **Dexmedetomidine as an Alternative Therapy for the Treatment of Alcohol Withdrawal Syndrome: A Systematic Review and Metanalysis/Z. Umar, Queens, NY**
- 1013 **Normative Statistical Analysis of Continuous Artificial Intelligence/Computer Vision Monitoring of Patient Activity and Clinical Attention in a Medical Intensive Care Unit/G. Krishnan, Durham, NC**
- 1014 **Racial Differences in Early Warning Scores at Time of Hospital Admission Versus ICU Transfer/I. Ganapathiraju, Winston-Salem, NC**
- 1015 **Randomized Trial of Normosol-R Vs Lactated Ringer's for Critically Ill Adults/E.T. Qian, Nashville, TN**
- 1016 **Patients Who Trigger Rapid Response Immediately Upon Hospital Admission Have Higher Mortality Than Equivalent Patients Without Rapid Responses/M.T. Freedman, Richmond, VA**
- 1017 **Intraoperative Factors Associated With Impaired Postoperative Oxygenation After Lung Resection With Protective Ventilation and Restrictive Intravenous Fluid Administration/A. Nagrebetsky, Boston, MA**
- 1018 **Duration of the Presumably Unnecessary and Harmful Preprocedural Fasting in Patients Who Receive Tube Feeding and Have a Secure Airway/A. Khoudary, Boston, MA**
- 1019 **Improving Goals of Care Discussion Documentation in the Medical Intensive Care Unit: A Quality Improvement Project/S.A. Mahmood, Winston-Salem, NC**
- 1020 **A Ten-year, Single-Center Retrospective Analysis of Adult Patients With Sickle Cell Disease Admitted to the Intensive Care Unit at an Urban Tertiary Care Center/A. O'Laughlin, Richmond, VA**
- 1021 **Risk of Bleeding and Thrombotic Events in CAR T-cell Therapy Recipients With Cytokine Release Syndrome: A Retrospective Analysis From the Trinetx U.S. Collaborative Network/C. Fowler, New York, NY**
- 1022 **Relationship Between Resuscitation Teams' Confidence and Competence During In-hospital Cardiac Arrest/G. Hooper, Salt Lake City, UT**
- 1023 **Validation of a Deep Learning Tool for Automatic Pulmonary Embolism Detection/J. Schlossman, Irvine, CA**
- 1024 **Cost Analysis of Phenobarbital Versus Lorazepam for the Management of Alcohol Withdrawal Syndrome (AWS) in Hospitalized Patients/S. Prabhu, Worcester, MA**

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
POSTER DISCUSSION SESSION
A104 NOVEL INSIGHTS ON CANNABIS, TOBACCO, AND E-CIGARETTE USE
2:15 p.m. - 4:15 p.m.
Marriott Marquis Washington
Marquis Ballroom, Salons 1-2 (Level M2)
Poster Viewing 2:15-3:00
Discussion 3:00-4:15
Chairing: M.E. Rebuli, PhD, Chapel Hill, NC
 S.E. Jordt, PhD, Durham, NC
 H. Kathuria, MD, ATSF, Boston, MA

- 101 **Age Started Smoking Regularly and Risk of COPD/L.M. Paulin, Lebanon, NH**
- 102 **Respiratory Symptoms as a Predictor of Future Smoking Patterns: The Cardia Lung Study/D. Kidd, Chicago, IL**
- 103 **The Nature and Extent of Vaping and Tobacco Use Amongst South African High School Learners/G.K. Soin, Cape Town, South Africa**
- 104 **Current Patterns of Single, Dual and Triple Use of Conventional Tobacco, E-cigarettes and Marijuana/A. Singh, La Jolla, CA**
- 105 **Respiratory and Non-Respiratory Clinical Manifestations Are Associated With Current Nicotine, Marijuana, and Dual E-cigarette Use in Young Adults in North Texas/D.R. Rao, Dallas, TX**

- 106 **Comparison of Respiratory Symptoms Among Adults With Versus Without Vaping, Smoking, and Dual-use: a Cross-sectional Study in a Call Center in Quezon City**/C.J.R. Tubig, Quezon City, Philippines
- 107 **Respiratory Symptoms and Alcohol Usage in Nicotine and THC E-cigarette Users**/D. Roy, La Jolla, CA
- 108 **Use of Social Media to Recruit Nicotine and THC E-cigarette Vapers in San Diego County**/D. Roy, La Jolla, CA
- 109 **Acute Vaping Cessation Improves Markers of Lung Function Impairment**/T. Afshar, Vancouver, Canada
- 110 **Electronic Cigarette Menthol Flavoring Is Associated Worse Lung Function and Increased Inhaled Particle Count**/K. Hajjipouran Benam, Pittsburgh, PA
- 111 **Impact of Nicotine and THC E-cigarette Use on Circulating Immune Cells**/I.N. Advani, La Jolla, CA
- 112 **Associations of Cigarette Smoking With Plasma Extracellular Vesicle-encapsulated MicroRNA Expression**/C. Eckhardt, New York, NY
- 113 **Non-cigarette Tobacco Products, AHRR Methylation, and All-cause Mortality in US Adults**/C. Eckhardt, New York, NY
- 114 **Effects of Vaping of Nicotine and THC E-cigarettes on Airway Resistance, Saliva, and Sputum Production**/N. Kasaraneni, La Jolla, CA
- 115 **Chemical Characterization of Currently Available Vaping Liquids Via Gas Chromatography-mass Spectroscopy (GC-MS)**/M. Zhang, Pittsburgh, PA
- 116 **Sex-Based Differences in Lung Injury Produced by E-cigarette Humectant Aerosols in Mice**/A. Noel, Baton Rouge, LA
- 117 **Disposable Mint Flavored FLUM E-cigarette Exposure Decreases Lung Immune Cell Recruitment in a Murine Model of Asthma**/B. Ma, La Jolla, CA
- 118 **Long-term Exposure to E-cigarette Vapour In Vivo Induced Inflammation and Structural Alterations in the Lungs**/O. Pak, Giessen, Germany
- 119 **Impacts of Aerosolized Nicotine (Vaping) on Lung Inflammation**/T.J. Moraes, Toronto, Canada
- 120 **Exposing EVALI - Developing Severity Grading Criteria to Inform Timely and Appropriate Treatment of Patients Diagnosed With EVALI**/J.M. Hendel, San Diego, CA
- 121 **Elevated Levels of Inflammatory Cells in Sputum and Nasal Cytology of Nicotine and Tetrahydrocannabinol (THC) E-cigarette Vapers**/C. Truong, La Jolla, CA
- 122 **The Impact of Cannabis Use on Patients Admitted With Acute Chronic Obstructive Pulmonary Disease Exacerbation: Results From the National Inpatient Sample**/A. Nathani, Cleveland, OH

- 123 **The Impact of Cannabis Use on Patients Admitted With Acute Asthma Exacerbation: Results From the National Inpatient Sample**/J.L. Reinoso Abreu, Gainesville, FL
- 124 **High Toxicity of Cinnamon-flavored Electronic Cigarette Liquids: A Lesson Not Learned**/S.E. Jordt, Durham, NC
- 125 **Synthetic Cooling Agents in California-Marketed "Non-menthol" Cigarette Brands Introduced After the State's Menthol Ban**/S.E. Jordt, Durham, NC

CLINICAL

POSTER DISCUSSION SESSION

A105 I NEED A HERO: PEDIATRIC INTERVENTIONAL BRONCHOSCOPY CASES

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 206 (Level 2)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: C. Spencer Grant, MD, New York, NY
J.C. Piccione, MS, DO, ATSF, Philadelphia, PA
G. Burg, MD, Cincinnati, OH

- 701 **Management of Refractory Type 1 Plastic Bronchitis Airway Cast With Selective Lymphatic Embolization**/M. Yoo, Atlanta, GA
- 702 **Bronchoscopic Balloon Dilation Of Bronchial Atresia**/R. Wong, San Diego, CA
- 703 **A Teenage Girl With Henoch- Schoenlein Purpura and a Mediastinal Mass, Assessment With Novel Bronchoscopy Technique in Pediatrics**/A. Wannes Daou, Cincinnati, OH
- 704 **Pulmonary Mucormycosis in a Child With Acute Lymphoblastic Leukemia and Hemophagocytic Lympho-Histiocytosis: Bronchoscopic Approach**/A. Wannes Daou, Cincinnati, OH
- 705 **Endobronchial Blocker Technique And Added Safety Measures In Whole Lung And Lobar Lavages In A Small Child With Pulmonary Alveolar Proteinosis**/V.S. Wang, Houston, TX
- 706 **Persistent Air Leak Treated With Endobronchial Valve in an Adolescent With Hyper-IgE Syndrome**/C.W. Wynn, Cincinnati, OH
- 707 **A Case of Near Complete Tracheal Obstruction by Salivary Mucinous Adenocarcinoma in an Adolescent**/E. Osei-Kuffuor, Brooklyn, NY

- 708 **Diagnosis of Pulmonary Aspergilloma in a Patient With Lymphoblastic Lymphoma by Radial Bronchial Endoscopic Ultrasound/O. Pantoja-Gomez, Bogota, Colombia**
- 709 **The Role of Flexible Bronchoscopy and Intrabronchial Valve Placement in a 2-year-old Pediatric Patient With Persistent Air Leak/R. Shah, New York, NY**
- 710 **A Difficult Case Of A Pediatric Foreign Body/M.S. Fracchia, Boston, MA**
- 711 **A Large Lung Abscess: A Foreign Body or an Unusual Bronchoscopy Complication?/M. Hernandez Rodriguez, Durham, NC**
- 712 **Disseminated Aspergillosis With Ulcerative Tracheitis and Tracheo-pleural Fistula: A Case Report/E.C. Santillana, Birmingham, AL**
- 713 **Persistent Lobar Opacities: The Straw That Broke the Airway's Back/K.J. Kokesh, Gainesville, FL**
- 714 **Foreign Body Aspiration in a Patient With Chronic Respiratory Failure Requiring Tracheostomy/S.H. Averill, Indianapolis, IN**
- 715 **Development Of Airway Collapse Over Six-Month Period In Adolescent With Sickle Cell Disease And Systemic Lupus Erythematosus/M.G. Gayoso Liviach, Washington, DC**
- 204 **Topological Data Analysis Reveals Antimicrobial Resistotypes Associated to the Microbiome in Bronchiectasis: An International Multi-centre Study/J.K. Narayana, Singapore, Singapore**
- 205 **The Airway Microbiome in Chronic Bronchitis Is Intermediate Between Health and Chronic Obstructive Pulmonary Disease/Z. Wang, Guangzhou City, China**
- 206 **Characterizing the Oral and Gut Microbiome in a COPD Cohort/D.G. Dunlap, Pittsburgh, PA**
- 207 **Lung Microbiota and Neutrophilic Inflammation Associated With Clinical Outcomes in Bronchiectasis and Chronic Obstructive Pulmonary Disease Overlap/Y.-F. Chen, Douliou City, Taiwan**
- 208 **Complexities of the Lower Airway Microbiome in Bronchiectasis and NTM Lung Disease/S. Singh, New York, NY**
- 209 **Lung Graft Microbiological Patterns Before and After Ex Vivo Lung Perfusion in Lung Transplant Recipients/P. Balasubramanian, Jacksonville, FL**
- 210 **The Gut Microbiome Regulates Sepsis-Induced Skeletal Muscle Atrophy/K.S. Bongers, Ann Arbor, MI**
- 211 **Spatiotemporal Analysis of Oral, Lung and Gut Microbiota and Their Impact on Outcomes of Mechanically Ventilated Patients With Acute Respiratory Failure/G. Kitsios, Pittsburgh, PA**
- 212 **The Altered Microbial Ecology of Acutely Injured Lungs Is Characterized by Increased Metabolite Concentrations and Bacterial Growth Promotion/J.M. Baker, Ann Arbor, MI**

BASIC • CLINICAL • TRANSLATIONAL

RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

A106 MICROBIOME RESEARCH

2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Room 103 A-B (Street Level)

Viewing **2:15-3:00**

Summaries/Discussion **3:00-4:15**

Chairing: R.P. Dickson, MD, Ann Arbor, MI
L.N. Segal, MD, New York, NY
G. Kitsios, MD, PhD, Pittsburgh, PA

- 201 **Nitrate Air Pollution Alters the Diversity and Composition of the Gut Microbiome in a Clinically Diverse Cohort/J. Radder, Pittsburgh, PA**
- 202 **Lung Microbiome Correlates With Lung Adenocarcinoma and Self-reported Dental Cleaning/A.A. Pragman, Minneapolis, MN**
- 203 **Long-term Doxycycline Demonstrates Microbial Perturbation and Altered Interactomes in COPD: Exploratory Analysis From a Randomized, Double-blind, Placebo-controlled Trial/J.K. Narayana, Singapore, Singapore**

BASIC • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

A107 AGING AND LUNG DISEASES COMING TO AGE

2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Room 151 A (Street Level)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: V. Thannickal, MD, New Orleans, LA
I. Rahman, PhD, ATSF, Rochester, NY
M. Bueno, PhD, Pittsburgh, PA

- 401 **Lung Cellular Senescence Atlas by Single Cell RNA Sequencing and Other Biomarkers in Patients With COPD/G. Kaur, Rochester, NY**
- 402 **Lungaging Score: Single Cell Transcriptomic Signatures in the Aging Lung/M. Jia, Pittsburgh, PA**

- 403 **Cellular Ageing and Senescence Transcriptional Modules in the Aged Human Lung**/R. De Man, New Haven, CT
- 404 **Mitochondrial Response to Telomere Dysfunction-induced Cellular Senescence**/D.I. Sullivan, Pittsburgh, PA
- 405 **Regulation of Senescence and Mitochondrial Function by CD148 in Idiopathic Pulmonary Fibrosis Alveolar Epithelial Cells**/B.J. Moss, Houston, TX
- 406 **Loss of ANT1 Increases Fibrosis and Senescence in Idiopathic Pulmonary Fibrosis**/J. Sui, Pittsburgh, PA
- 407 **Chronic WNT/ β -catenin Signaling Impairs Mitochondrial Function in Lung Epithelial Cells**/Q. Hu, Pittsburgh, PA
- 408 **Age-dependent Loss of Alveolar Type II Cells and Impaired Proliferation in a Murine Model of Hermansky-Pudlak Syndrome-related Pulmonary Fibrosis**/J. Wang, Philadelphia, PA
- 409 **Lipid Deficiency Contributes to Impaired Alveolar Progenitor Cell Function in Aging and Idiopathic Pulmonary Fibrosis**/C.J. Liang, Los Angeles, CA
- 410 **HDAC9 Deficiency Drives Impaired Lipid Metabolism During Chronic Inflammation in the Aged Lung**/E. Avci, Bad Nauheim, Germany
- 411 **Non-canonical Pathways Involving the Glycolytic Enzyme PGK1 Mediate Myofibroblast Differentiation in Age-related Lung Fibrosis**/G. Roda, Aurora, CO
- 412 **Transitional Alveolar Type 2 Cells Acquire Senescent Features in Association With Proteostasis Defects**/B. Deskin, New Orleans, LA
- 413 **XBP1 Is a Key Regulator of the Cellular Stress Response and Senescence in AT2 Progenitor Cells Promoting Resilience to Lung Injury**/J. Calyeca, Columbus, OH
- 414 **Senescence or Autophagy, Divergent Mechanisms Driving Alveolar Regeneration in Accelerated Aging Mice**/Y. Romero, Mexico City, Mexico
- 415 **Syndecan-1 Regulates Alveolar Type 2 Epithelial Cell Senescence Through Autophagy During Lung Fibrosis**/Z. Ortega, Los Angeles, CA
- 416 **Hermansky Pudlak Syndrome-1 (HPS-1) Lung Fibroblasts Show a Profibrotic Phenotype Characterized by Decreased Slc7a11, a Phenotype Shared by Aging and IPF Lungs**/J. Roman, Philadelphia, PA
- 417 **IL-17A Augments Cellular Senescence in Fibrotic Pulmonary Disease**/S.B. Shaikh, Rochester, NY
- 418 **Senolysis by Targeting Metabolic Reprogramming in Senescent Lung Fibroblasts**/G. Liu, Birmingham, AL
- 419 **Identification and Analysis of Secretome of IPF Senescent Human Lung Fibroblasts Using ER-BioID2 Revealed Profibrotic Proteins Profile Involved Extracellular Matrix Remodeling**/N.D. Vanegas, Columbus, OH
- 420 **The Extracellular Matrix of the Human Proximal Pulmonary Artery Regulates Gene Expression of Resident Cells Responsible for Remodeling During Aging**/Y. Yuan, New Haven, CT
- 421 **Cellular Senescence Is Associated With Extracellular Matrix Dysregulation in COPD**/C.-A. Brandsma, Groningen, Netherlands
- 422 **Senescent Cells Suppress Macrophage-mediated Corpse Removal Via Upregulation of the CD47-QPCT/I Axis**/D. Schloesser, Biberach an der Riss, Germany
- 423 **AMPK Stimulates Recovery From Aging-impaired Efferocytosis and Promotes Lung Fibrosis Resolution in Aged Mice**/J.W. Zmijewski, Birmingham, AL
- 424 **Lung-Targeted Delivery of Nrf2 Activators Promotes the Reversal of Age-Dependent Established Lung Fibrosis**/K. Kato, Atlanta, GA
- 425 **Bleomycin Induces Chronic Progressive Pulmonary Fibrosis in Premature Aging *Erc1^{ΔL}* Mice**/T. Koudstaal, Rotterdam, Netherlands

BASIC • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

A108 NEW INSIGHTS INTO CHRONIC OBSTRUCTIVE PULMONARY DISEASE

2:15 p.m. - 4:15 p.m.

Marriott Marquis Washington

Marquis Ballroom, Salons 3-4 (Level M2)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: F. Polverino, MD, PhD, Houston, TX
R. Zakarya, BSc(Hons), PhD, Sydney, Australia

901 **CRISPR Interference (CRISPRi) of Chronic Obstructive Pulmonary Disease (COPD) GWAS Genes in iPSC Derived Alveolar Type 2 (iPSC-AT2) Cells Reveals Similar Transcriptomic Aberrations in DSP and ADGRG6 Knockdown**/V. Malik, Boston, MA

902 **The Gycopolymer PAAG Improves MCT in Trachea Derived From a Ferret Model of COPD and Bronchitis**/S.S. Hussain, Birmingham, AL

- 903 **Linking Pathophysiology to Lung Pathology in Spiromics Using Respiratory Oscillometry (OSC) and High-resolution Computed Tomography (HRCT)/C.B. Cooper, Los Angeles, CA**
- 904 **Relationships Between Clock Gene Expression and Inflammation in Bronchial Brushes of Severe COPD Patients/X. Li, Groningen, Netherlands**
- 905 **Pathobiology of Airway and Arterial Vascular Remodeling in Chronic Obstructive Pulmonary Disease/K. Wu, Vancouver, Canada**
- 906 **Proteomics of COPD-Related Phenotypes in the General Population. The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study/D.E. Guzman, New York, NY**
- 907 **Multiscale Stiffness of Emphysematous Human Precision-cut Lung Slices/R. Krishnan, Boston, MA**
- 908 **Automated Measures of Airway-Artery Ratios Across Different GOLD Classes: A COPD Gene Pilot Study/H.A. Tiddens, Rotterdam, Netherlands**
- 909 **The Effect of Extra Fine Medium-dose Inhaled Corticosteroid/Long-Acting Beta-2 Agonist/Long-Acting Muscarinic Antagonist (ICS/LABA/LAMA) on Distal Airway Indices Using Functional Respiratory Imaging in Patients With Symptomatic COPD on ICS/LABA/B.R. Lavon, Kontich, Belgium**
- 910 **Circadian Clock Signaling Regulates Pulmonary Microvascular Endothelial Repair in Response to Cigarette Smoke and Air Pollution/X. Wu, Groningen, Netherlands**
- 911 **Sweat and Serum CRP Concentration in Humans With and Without Chronic Obstructive Pulmonary Disease: Implications for Wearable Biosensors/J. Moore, Torrance, CA**
- 912 **Extracellular Vesicles and Soluble Factors Secreted by Lung Fibroblasts Have a Protective Effect on Elastase-induced Emphysema in Precision-cut Lung Slices/L. Van Der Koog, Groningen, Netherlands**
- 913 **Identifying Responder Subgroups for Exacerbations Using Machine Learning in the Impact Trial/K. Verstraete, Leuven, Belgium**
- 914 **Assessment of Regional Lung Ventilation Using Computer Tomography (CT) Lung Ventilation Analysis in Chronic Obstructive Pulmonary Disease (COPD)/D. Karmali, Miami, FL**
- 915 **Analysis of Lung Shape Improves Quantitative Computed Tomography Assessments of Chronic Obstructive Pulmonary Disease/S.M. Humphries, Denver, CO**
- 916 **Changes in Lung Function With Diaphragm Morphometry Following Bronchoscopic Lung Volume Reduction in Advanced Emphysema and Severe Hyperinflation/J.S. Kim, Philadelphia, PA**
- 917 **Severity and Heterogeneity of Emphysema as Predictors of Success in Bronchoscopic Lung Volume Reduction/J.S. Kim, Philadelphia, PA**
- 918 **Effect of Total Lung Capacity on the Pulmonary Vasculature in COPD Patients/W. Dierckx, Kontich, Belgium**
- 919 **Factors Contributing to Exercise Induced CO₂ Retention in COPD Patients/W. Dierckx, Kontich, Belgium**
- 920 **Topological CT Analyses of Interstitial Lung Abnormalities in Chronic Obstructive Pulmonary Disease (COPD) Patients and Non-COPD Subjects Using Persistent Homology/Y. Shiraishi, Kyoto, Japan**
- 921 **Assessment of Ventilation Heterogeneity in COPD Using Subsegmental Quantification With Single Photon Emission Computed Tomography/M. Dalzell, Miami, FL**

BASIC • CLINICAL • TRANSLATIONAL

RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

A109 MICE TO HUMANS: MECHANISTIC DISCOVERIES IN SLEEP APNEA

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 144 A-C (Street Level)

Viewing 2:15-3:00

Summaries/Discussion 3:00-4:15

Chairing: P.V. Borker, MD, Pittsburgh, PA
V.Y. Polotsky, MD, PhD, Baltimore, MD
A. Laposky, PhD, Bethesda, MD
R. Cortese, PhD, Columbia, MO

301 **The Association Between Obstructive Sleep Apnea, Circulating Cytokines, and Incident Cancer/A.M. Hirsch Allen, Vancouver, Canada**

302 **Senolytic Adjuvant Treatment Improves Metabolic Function in a Murine Model of Obstructive Sleep Apnea/A. Khalyfa, Columbia, MO**

303 **Pinocembrin Ameliorates Intermittent Hypoxia-induced Neuroinflammation Through BNIP3-dependent Mitophagy in a Murine Model of Sleep Apnea/L. Gong, Chengdu, China**

304 **Epigenetic Signatures in Circulating DNA in Patients With Obstructive Sleep Apnea Predict Atherosclerosis and Response to CPAP/R. Cortese, Columbia, MO**

305 **Senolytic Treatment Combined With Reduction of Intermittent Hypoxia (IH) Exposure Duration Mimicking "Good" CPAP Adherence Improves Coronary Artery Function in a Murine Model of OSA/M. Badran, Columbia, MO**

- 306 **CPAP Therapy Tempers Monocytosis and Hematopoietic Activation Among Newly-diagnosed OSA/O.** Cohen, New York, NY
- 307 **Senolytic Adjuvant Treatment Ameliorates Sleep Propensity and Explicit Memory in a Murine Model of OSA Receiving “Adherent” CPAP Therapy/C.** Puech, Columbia, MO
- 308 **Association of TNF- α (-308 G/A) Gene Polymorphism With the Changes in Circulating TNF- α Levels Over 12 Months in Response to CPAP Treatment in the RICCADSA Cohort/Y.** Peker, Istanbul, Turkey
- 309 **Assessing Vascular Inflammation and Atherosclerosis Heterogeneity in Sleep Apnea Using Machine Learning Approaches and Multimodal Imaging Before and After CPAP/V.** Kundel, New York, NY
- 310 **Effects of HIF-1 α Inhibition on the Metabolic Effects of Intermittent Hypoxia in a Rodent Model of Diabetes Mellitus/U.J.** Magalang, Columbus, OH
- 311 **Obstructive Sleep Apnea (OSA)-related Intermittent Hypoxia (IH) Induces Hepatic Senescence in a Mouse Model/Y.** Wang, Changsha, China
- 312 **Intermittent Hypoxia Is Associated With Increased Mortality in a Mouse Model of COVID-19/L.** Barnes, La Jolla, CA
- 313 **Impaired Endothelial Cell Cholesterol Trafficking in Obstructive Sleep Apnea/A.** Chang, New York, NY
- 314 **Effect of Intermittent Hypoxia on Genes Associated With Cardiac Muscle Contraction/R.** Cetin-Atalay, Chicago, IL
- 315 **Pre-treatment With VEGF Alleviates Some of the Metabolic Impairments in a Murine Model of Sleep Apnea/O.** Yajuk, Jerusalem, Israel
- 502 **Lung Cancer Risk Assessment Among People Exposed to Secondhand Tobacco/R.** Yip, New York, NY
- 503 **The Prediction Model “Stress Test:” Comparison of Lung Cancer Prediction Models’ Performance on a Challenging Peripheral Pulmonary Lesion Registry/**B.E. Heideman, Nashville, TN
- 504 **Lung Cancer in Asian Indian Females: Identification of Disease-specific Characteristics and Outcome Measures Over a 12-year Period/A.** Mohan, New Delhi, India
- 505 **Pneumonitis in Stage III Non-small Cell Lung Cancer: Who Is at Risk?/D.** Dustin, Providence, RI
- 506 **Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors for Treatment of Malignant Pleural Effusion in EGFR-Mutant Lung Adenocarcinoma Patients/K.L.** Lee, Taipei, Taiwan
- 507 **The Effectiveness of Local Consolidative Therapy for Advanced Lung Adenocarcinoma Harboring EGFR Mutation Treated With First-line Afatinib/Y.-C.** Tsai, Kaohsiung, Taiwan
- 508 **Association Between the Distressed Community Index and Outcomes Among Patients With Lung Cancer/S.O.** Okoli, New Orleans, LA
- 509 **The Trajectory of Lung Cancer Diagnosis and Management During the COVID Pandemic in the Veteran Population/S.O.** Okoli, New Orleans, LA
- 510 **Timeliness of Care Among Patients With Small Cell Lung Cancer Evaluated by a Multi-disciplinary Team/M.** Block, Grand Rapids, MI
- 511 **Multiple Annual Low Dose CT Scans Needed to Detect Malignancy: Number Needed to Scan ≥ 4 /E.L.** Bernstein, New Haven, CT
- 512 **Disparities in Lung Cancer Screening in a Sample of Veterans/E.L.** Bernstein, New Haven, CT
- 513 **Time to Diagnosis and Treatment of Non-small Cell Lung Cancer in Patients Undergoing Lung Cancer Screening/E.L.** Bernstein, New Haven, CT
- 514 **The Presence of Targetable Mutations in Metastatic Non-Small Cell Lung Cancer Patients With Malignant Pleural Disease Is Not Associated With Improved Survival/C.** Gilbert, Charleston, SC
- 515 **USPSTF-eligible Asian-Americans Receiving Lung Cancer Screening Have Lower Rates of Tobacco Cessation, Annual Adherence, and Screen-detected Lung Cancer/B.** Tasevac, Philadelphia, PA
- 516 **Screening Beyond the Nodule: Annual LDCT as a Screening Tool for Other Comorbid Conditions/A.** Herring, Baltimore, MD

BEHAVIORAL • CLINICAL

POSTER DISCUSSION SESSION

A110 LUNG CANCER RISK, SCREENING, TREATMENT, AND OUTCOMES

2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Room 151 B (Street Level)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: L.T. Tanoue, MD, New Haven, CT
J. Thompson, MD, MS, Philadelphia, PA

- 501 **Effect of Removing Race and Ethnicity From Lung Cancer Prediction Models on Disparities in Eligibility for Lung Cancer Screening/H.** Katki, Rockville, MD

- | | | | |
|-----|--|-----|--|
| 517 | Poor Lung Cancer Screening Outcomes Was Associated With Chronic Bronchitis in a National Lung Screening Trial Subgroup (n=18,463)/R.J. Scott, Auckland, New Zealand | 521 | Improving Lung Cancer Service Delivery - Virtual Lung Nodule Clinics Are Feasible and Cost-effective/S. Proctor, Bedford Park, Australia |
| 518 | Incidental Thyroid Findings in Low-dose Computed Tomographic Scans for Lung Cancer Screening: Prevalence and Subsequent Evaluation/A. Meng, Philadelphia, PA | 522 | Lung Cancer in Nonsmokers- a Risk Factor Analysis/ D. Albano, Stony Brook, NY |
| 519 | Increasing Lung Cancer Screening Awareness in a High-risk Population/C. Kapp, Chicago, IL | 523 | Biases in Lung Cancer Screening: Demographic Characteristics of Databases Used in Construction of Lung Cancer Risk Models/M. Shen, Boston, MA |
| 520 | Retrospective Cohort Assessing Incidence of Pneumonitis Among Patients With COPD Treated With an Immune Checkpoint Inhibitor at a Single Institution/L.M. Khoury, Winston-Salem, NC | 524 | Correlation Between Lung Cancer Type and Histopathological Grade With the Likelihood of Metastasis: A SEER Analysis/S. M Fahmawi, Johnson City, TN |
| | | 525 | Correlation Between Lung Cancer Subtypes and the Primary Tumor Location With the Likelihood of Metastasis: A SEER Analysis/S. M Fahmawi, Johnson City, TN |

4:30 p.m. - 5:30 p.m.

SUNDAY AWARDS SESSION

Walter E. Washington Convention Center
Hall E (Level 2)



Amberson Lecture

The Amberson Lecture recognizes major lifetime contributions to clinical or basic research that have advanced our fundamental understanding of the basic, translational, or clinical approaches to respiratory disease, critical illness, or sleep disorders. This award also recognizes exemplary professionalism, collegiality and citizenship through mentorship and leadership in the ATS community. The Lecture is given in honor of James Burns Amberson, an international authority on chest disease and tuberculosis.

Lecturer: Zea Borok, MBChB, ATSF, Del Mar, CA

Lecturer Title: Type I, Type II and Everything in Between: Unlocking the Plasticity of Alveolar Epithelial Cells

Trudeau Medal

The Trudeau Medalist is an individual with lifelong major contributions to the prevention, diagnosis and treatment of lung disease, critical illness, or sleep disorders through leadership in research, education, or clinical care. The Trudeau Medal is the highest honor bestowed by the ATS and is given in honor of Edward Livingston Trudeau, a founder and the first president of the American Lung Association.

Awardee: J. Randall Curtis, MD, MPH, Seattle, WA

Distinguished Achievement Award

The Distinguished Achievement Award is given to individuals who have made outstanding major contributions that advance the missions of the American Thoracic Society. The Award recognizes the substantial contributions to prevention, diagnosis and treatment of lung disease, critical illness, or sleep disorders through advocacy, training, and mentorship. This award recognizes one major accomplishment or cumulative impact on the field.

Awardees: Jennifer L. Taylor-Cousar, MD, MSc, ATSF, Denver, CO
Sharron J. Crowder, PhD, RN, ATSF, Fishers, IN

7:15 p.m. - 8:45 p.m.

SECTION ON TERRORISM AND INHALATION DISASTERS

Marriott Marquis Washington

Congress (Level M4)



The Section meetings are open to all
ATS members and other interested individuals.

Items to be discussed include the
Section's current projects and future directions.

ASSEMBLY MEMBERSHIP MEETINGS

Marriott Marquis Washington

The Sunday and Monday Assembly Membership Meetings will be held in the Marriott Marquis Washington.

Please click the bar below to access the date, time and
room location for each Assembly meeting.



The Assembly Membership Meetings provide an update
on the Assembly's activities via the Assembly's Leadership and provide Assembly members the chance to have input on future directions,
information on how to get involved and networking opportunities. Voting results for the Assembly's future leaders will also be announced.



ATS
2023

INTERNATIONAL
CONFERENCE
WASHINGTON, DC
conference.thoracic.org

Monday Morning, May 22

[Click Here to Access the Program Itinerary and Add Monday Sessions and Presentations to Your Calendar](#)

MEET THE EXPERT SEMINARS

CME Credits Available: 1

R Pre-registration and additional fees required. Attendance is limited.
\$100 Member/Non-Members
\$70 LMIC Member/LMIC Non-Members

10:15 a.m. - 11:15 a.m. **Marriott Marquis Washington**

MTE16 IT TAKES A VILLAGE: INTEGRATING ILD SUPPORT GROUPS INTO COMMUNITY MEDICAL CENTERS

J. Wescoe, EdM, Coopersburg, PA
D. Corwin, MD, Fountain Hill, PA
Gallaudet University (Level M1)

MTE17 SEVERE CHILDHOOD ASTHMA: WHEN TO USE BIOLOGICS AND WHAT TO DO IF THEY FAIL

C. Rosas-Salazar, MD, MPH, ATSF, Nashville, TN
L.B. Bacharier, MD, Nashville, TN
Chinatown (Level M3)

MTE18 BIOLOGICS AND BEYOND: UNDERSTANDING AND MANAGING SEVERE ASTHMA

G.S. Skloot, MD, ATSF, Cary, NC
M.G. Drake, MD, Portland, OR
University of DC/Catholic University (Level M1)

CME credit isn't available for this seminar

MTE19 DECENTRALIZED CLINICAL TRIALS IN INTERSTITIAL LUNG DISEASE

R. Aggarwal, MD, Pittsburgh, PA
D.I. Sullivan, MD, Pittsburgh, PA
Judiciary Square (Level M3)

MTE20 DYSPNEA DURING MECHANICAL VENTILATION

R.M. Schwartzstein, MD, Boston, MA
Shaw (Level M3)

MTE21 NEW APPROACHES FOR NON-INVASIVE ACCESS TO THE LUNG

S.D. Spivack, MD, MPH, Bronx, NY
LeDroit Park (Level M3)

K2: KEYNOTE LECTURE

CME Credits Available: .75

YEAR IN REVIEW

CME Credits Available: 1.5

MOC Points Available: 1.5

8:00 a.m. - 8:45 a.m.

Walter E. Washington Convention Center
West Salon G-I (Street Level)

Title: The Air That I Breathe: Climate Change and Health: A Conversation with EPA Administrator Michael Regan

Presenters: Michael S. Regan, BS, MPA, Washington, DC
Greg Downey, MD, FRCP(C), ATSF., Denver, CO

B1 CLINICAL YEAR IN REVIEW 2

9:00 AM - 10:30 AM **Walter E. Washington Convention Center**

Hall E (Level 2)

Target Audience

Pulmonary, critical care and sleep providers. The program will discuss general topics of interest to a broad group of providers, inside and outside of these subspecialties. The program is relevant to not only clinicians, but also to researchers and admini

Objectives

At the conclusion of this session, the participant will be able to:

- apply new clinical research knowledge to clinical practice.
- apply new findings about key conditions in pulmonary, critical care and sleep.
- learn new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

Pulmonary, critical care and sleep providers. The program will discuss general topics of interest to a broad group of providers, inside and outside of these subspecialties. The program is relevant to not only clinicians, but also to researchers and administrators.

Chairing: R.J. Shah, MD, MSCE, San Francisco, CA
 J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil
 S. Auld, MD, MSc, Atlanta, GA

9:00 Lung Cancer
 A.C. Melzer, MD, MS, Minneapolis, MN

9:23 COVID-19
 S.E. Jolley, MD, MSc, Aurora, CO

9:45 Palliative Care
 A.L. Jennerich, MD, MS, ATSF, Seattle, WA

10:08 Critical Care
 Tiffanie Jones, MD, MPH, MSCE, Philadelphia, PA

This session and the International Conference are supported by an independent medical educational grant from Merck & Co.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL
CLINICAL TOPICS IN PULMONARY MEDICINE
CME Credits Available: 1.5

B2 PRO CON DEBATES ON PLEURAL CONTROVERSIES: WHAT PULMONOLOGISTS NEED TO KNOW

Assemblies on Clinical Problems; Thoracic Oncology

9:00 AM - 10:30 AM Walter E Washington Convention Center

Ballroom A (Level 3)

Target Audience

Clinicians, nurses, allied health staff and researchers in respiratory diseases, including chest physicians, interventional pulmonologists, thoracic/general surgeons, oncologists, general/emergency physicians, junior staff and scientists

Objectives

At the conclusion of this session, the participant will be able to:

- learn about advances in spontaneous pneumothorax care. Understand the pros and cons of conservative management versus traditional drainage approach, and new ambulatory drainage devices
- learn about advances in pleural infection care. Understand the pros and cons of intrapleural tPA/DNase therapy versus traditional surgical drainage, and areas of knowledge gaps
- learn about advances in malignant pleural effusion management. Understand the pros and cons of indwelling pleural catheter (with talc instillation) versus video assisted thoracoscopic surgery

The past decade saw an unprecedented number of randomized trials published on pleural medicine. These advances bring new questions

and controversies confronting pulmonologists on clinical care. This session highlights topical issues on which opinions are polarized and management heterogeneous worldwide. Leaders in the field debate the evidence that support (or not) common practice. In particular, [1] conservative (non-drainage) approach for spontaneous pneumothorax challenges conventional drainage algorithm (PSP trial NEJM 2020); [2] intrapleural tPA/DNase therapy questions need for surgical drainage of empyema; and [3] indwelling pleural catheter pleurodesis presents an alternative to VAT surgical pleurodesis for malignant pleural effusions.

Chairing: D.J. Feller-Kopman, MD, Lebanon, NH
 C.R. Lamb, MD, Burlington, MA
 C. Broaddus, MD, San Francisco, CA

9:00 Safety First: Primary Spontaneous Pneumothorax Should Be Drained - the Pros
 J. Akulian, MD, MPH, MBA, FACP, ATSF, Chapel Hill, NC

9:15 Safety First: Primary Spontaneous Pneumothorax Should Be Drained - the Cons
 Y.C.G. Lee, MBChB, PhD, Perth, Australia

9:30 Surgical Decortication Should Be Default First Choice for Pleural Infection, Not Intrapleural tPA/DNase Therapy - the Pros
 N. Maskell, DM, Bristol, United Kingdom

9:45 Surgical Decortication Should Be Default First Choice for Pleural Infection, Not Intrapleural tPA/DNase Therapy - the Cons
 K. Yasufuku, MD, Toronto, Canada

10:00 Video-Assisted Thoracoscopic Talc Poudrage Is Preferred Over Indwelling Pleural Catheter for Malignant Effusion Management - the Pros
 E. Gillaspie, MD, MPH, FACS, Nashville, TN

10:15 Video-Assisted Thoracoscopic Talc Poudrage Is Preferred Over Indwelling Pleural Catheter for Malignant Effusion Management - the Cons
 D. Fitzgerald, MBChB, Tallaght, Ireland

BASIC • CLINICAL • TRANSLATIONAL
CLINICAL TOPICS IN PULMONARY MEDICINE
CME Credits Available: 1.5

B3 TARGETING MUCUS ACROSS LUNG DISEASES: FROM PATHOGENESIS AND IMAGING TO THERAPY

Assemblies on Clinical Problems; Pediatrics; Respiratory Cell and Molecular Biology

9:00 AM - 10:30 AM Marriott Marquis Washington

Independence Ballroom Salons A-D (Level M4)

Target Audience

Fellows, junior professionals, clinicians, researchers

Objectives

At the conclusion of this session, the participant will be able to:

- describe new findings on the pathogenesis of mucus dysfunction
- recognize imaging features of mucus dysfunction readily to be applicable
- describe the new therapies targeting mucus dysfunction

Mucus dysfunction plays a significant role in COPD, asthma, and cystic fibrosis. It has been stimulating progress in understanding the pathogenesis and imaging of mucus dysfunction. This progress includes the role of mucus mucins in disease pathogenesis and the use of imaging modalities, such as computed tomography, to evaluate this process. This significant progress has been combined with developing targeted therapeutics for mucus dysfunction in cystic fibrosis, furthering studies for therapies for other airway diseases. This session will present the advances in mucus dysfunction from pathogenesis and imaging to therapy.

Chairing: A.A. Diaz, MD, MPH, Boston, MA
A.M. Jaramillo, PhD, Aurora, CO
J.V. Fahy, MD, San Francisco, CA
J.A. Wedzicha, MD, ATSF, London, United Kingdom

- 9:00 Patient's Perspective**
J. Conroy, MSc, Baltimore, United States
- 9:10 Mucus, Mucins, and Mucociliary Dysfunction: A Sticky Problem**
R.C. Boucher, MD, Chapel Hill, NC
- 9:26 Mucus Dysfunction in Cystic Fibrosis**
S.E. Birket, PharmD, PhD, Birmingham, AL
- 9:42 Seeing Is Believing: Imaging of Mucus Plugs in Asthma and COPD 1**
E. Dunican, BM BCH, Dublin, Ireland
- 9:50 Seeing Is Believing: Imaging of Mucus Plugs in Asthma and COPD 2**
A.A. Diaz, MD, Boston, MA
- 9:58 The Dawn of a New Era: Therapies Targeting Mucus**
R. Jain, MD, MSci, ATSF, Dallas, TX
- 10:14 Panel Discussion and Q & A**

This session and the International Conference are supported by an independent medical educational grant from Vertex Pharmaceuticals.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BEHAVIORAL**CRITICAL CARE TRACK**

CME Credits Available: 1.5

**B4 FAIL SMARTER AND LEARN FASTER:
MOVING BEYOND BYSTANDER TRAINING
TO ORGANIZATIONAL STRATEGIES TO
REINFORCE THE DEI PIPELINE IN
PULMONARY AND CRITICAL CARE**

Assemblies on Critical Care; Behavioral Science and Health Services Research; Clinical Problems; Nursing; Pediatrics

9:00 AM - 10:30 AM Walter E. Washington Convention Center

Room 207 A-B (Level 2)

Target Audience

All levels, all practicing healthcare providers

Objectives

At the conclusion of this session, the participant will be able to:

- describe successfully implemented institutional and organizational system solutions which can be applied to the participants respective institutions and organizations
- highlight new NIH strategies to support the pipeline of women and URiM into pulmonary and critical care
- develop a deeper understanding of the challenges of implementing policies, the unforeseen issues, and how to overcome the challenges

Significant attention has focused on identifying strategies to retain and recruit women and underrepresented minorities in pulmonary and critical care medicine. Despite this, the COVID-19 pandemic resulted in women and underrepresented in medicine (URiM) clinicians leaving pulmonary and critical care medicine not only because of the continued racism and sexism that exist but because of the additional challenges imposed by the pandemic. New solutions beyond bystander trainings and implicit bias tests are needed to address the challenges of the past two years. This session will highlight current system solutions that are being implemented and disseminated in academia at a systems level.

Chairing: E.M. Viglianti, MD, MPH, MSc, Ann Arbor, MI
D. Colon Hidalgo, MD, MPH, aurora, CO
J.C. Celedon, MD, DrPH, ATSF, Pittsburgh, PA

- 9:00 The Diversity Bonus: Not Just a URiM Issue**
J. Reede, MD, MS, MPH, MBA, Boston, MA
- 9:15 You Want Us to Stay in Academics? Here Is How You Keep Us**
D. Montoya-Williams, MD, Philadelphia, PA
- 9:25 "Passing the Harasser": How to Stop the Game and Change the Culture**
K. Spear, MPH, Washington, DC

- 9:40** **Actions Speak Out Louder Than Policies: Institutional Variation in Holding Patients Accountable for Inappropriate Behaviors**
E.M. Viglianti, MD, MPH, MSc, Ann Arbor, MI
- 9:50** **Pay to Stay: How Do Funding Agencies Support DEI Faculty?**
.A. Bernard, MD, Washington, DC
- 10:05** **When Color Blindness Is Not an Option - What Institutions Can Do to Recruit, Promote and Retain URIM**
V. Asare, MD, New Haven, CT
- 10:15** **Panel Discussion**
J.C. Celedon, MD, DrPH, ATSF, Pittsburgh, PA

BASIC • TRANSLATIONAL**BASIC SCIENCE CORE**

CME Credits Available: 1.5

B5 BACK TO BASICS: HARNESSING THE POWER OF MOUSE MODELS TO UNDERSTAND HUMAN SEPSIS

Assemblies on Allergy, Immunology and Inflammation; Critical Care; Pulmonary Circulation; Respiratory Cell and Molecular Biology

9:00 a.m. - 10:30 a.m.

Target Audience

Basic, translational, and clinical scientists

Objectives

At the conclusion of this session, the participant will be able to:

- describe new mechanistic insights into human sepsis derived from pre-clinical mouse models
- understand and identify perceived and actual barriers to translating pre-clinical findings to the clinic
- identify new strategies to limit infection-induced inflammation

Sepsis, the dysregulated host response to infection, is a life-threatening clinical syndrome affecting all cells, tissues, and organs. While no pre-clinical model can recapitulate the myriad complexities of organ dysfunction and tissue injury in human sepsis, animal models are essential to developing a mechanistic understanding of sepsis and identifying novel targets for intervention. This symposium will provide attendees with a basic overview of commonly used mouse models of sepsis, with an emphasis on how these models provided new insights directly relevant to human sepsis.

Chairing: J.A. Bastarache, MD, Nashville, TN
N.S. Mangalmurti, MD, Philadelphia, PA
E.P. Schmidt, MD, ATSF, Boston, MA

- 9:00** **Utilizing Complementary Murine Models of Experimental Sepsis to Determine How Age Increases the Virulence of Gut-Derived Pathogens**
J. Colbert, MD, Aurora, CO
- 9:20** **Preserved Alternative Complement Function is Associated with Improved Survival During ARDS: A Translational Perspective**
W. Bain, MD, Pittsburgh, PA
- 9:40** **A Clinically Relevant Mouse Model of Sepsis-Induced Delirium**
J.A. Bastarache, MD, Nashville, TN
- 10:00** **Red Cell-DNA Delivery Contributes to the Heterogeneous Host Response in Sepsis**
N.S. Mangalmurti, MD, Philadelphia, PA
- 10:20** **Cytokine Networks That Limit Infection-Induced Inflammation**
C. Hunter, PhD, Philadelphia, PA

CLINICAL • TRANSLATIONAL**SCIENTIFIC SYMPOSIUM**

CME Credits Available: 1.5

B6 NON-PAP ALTERNATIVES FOR OSA: FROM ACCEPTED TO REVOLUTIONARY

Assembly on Sleep and Respiratory Neurobiology

9:00 a.m. - 10:30 a.m.

Target Audience

Clinicians and researchers interested in Obstructive Sleep Apnea (OSA) therapies

Objectives

At the conclusion of this session, the participant will be able to:

- understand better current and future approaches to optimal patient selection for available OSA therapies
- describe recent progress and challenges in the (pre)clinical development of new drug/device therapies
- describe regulatory requirements to translate interventions into FDA-approved clinical therapies

While CPAP can have transformative effects for some patients with obstructive sleep apnea (OSA), many patients are unable to tolerate PAP therapy long-term and due to limited alternatives remain untreated. Based on recent publications and conference sessions, there is a clear need for novel, personalized treatment options.

Through state-of-the-art reviews and an in-depth panel discussion, we will provide the audience with current best practices for more established therapies (e.g. oral appliances, hypoglossal nerve stimulation) and speak to critical issues including regulatory considerations for the development of novel, personalized alternative therapies (e.g. ansa cervicale stimulation, endotype-targeted drug therapy, DREADD).

Chairing: N. Ayas, MPH, MD, Vancouver, Canada
 F.R. Almeida, PhD, DDS, Vancouver, Canada
 V.Y. Polotsky, MD, PhD, Baltimore, MD
 A. Parekh, PhD, New York, NY
 S.S. Redline, MD, MPH, Boston, MA

- 9:00 Introduction**
 N. Ayas, MPH, MD, Vancouver, Canada
- 9:02 Patient Perspective**
Speaker To Be Announced
- 9:07 What's New with Weight Loss, Oral Appliances, and Upper Airway Surgery?**
 B.A. Edwards, PhD, Melbourne, Australia
- 9:21 Electrical Stimulation: Hypoglossal Nerve Stimulation, Ansa Cervicale Stimulation, and Transoral Daytime Neurostimulation**
 D. Kent, MD, Nashville, TN
- 9:35 Clinical Drug Discovery Based on Endotypes**
 C.N. Schmickl, MD, PhD, San Diego, CA
- 9:49 Preclinical Drug Discovery: Cannabimimetics, Intranasal Leptin, DREADD, and Beyond**
 B. Prasad, MD, ATSF, Chicago, IL
- 10:03 FDA Perspective: Regulatory Considerations for the Development of New OSA Therapies 1**
 L. Kim, MD, Silver Spring, MD
- 10:10 FDA Perspective: Regulatory Considerations for the Development of New OSA Therapies 2**
 N.A. Weir, MD, Silver Spring, MD
- 10:17 Panel Discussion Plus Q&A**
 S.S. Redline, MD, MPH, Boston, MA

CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

MOC Points Available: 1.5

B7 SICKLE CELL LUNG DISEASE ACROSS THE LIFESPAN: WHERE ARE WE NOW?

Assemblies on Pediatrics; Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Nursing; Pulmonary Circulation; Sleep and Respiratory Neurobiology

9:00 a.m. - 10:30 a.m.

Target Audience

Pediatric and adult pulmonary, critical care, and sleep trainees, and clinicians and researchers interested in the pulmonary complications of sickle cell disease (SCD) across the lifespan

Objectives

At the conclusion of this session, the participant will be able to:

- define the current state-of-the-art management of the acute and chronic pulmonary complications of sickle cell disease and identify knowledge gaps that exist
- understand the impact of abnormalities throughout the pulmonary system (airway, gas exchange/sleep, and vascular) as disease modifiers on SCD outcomes throughout the lifespan
- gain an understanding of the mechanisms of new SCD disease-modifying therapies including hematopoietic stem cell transplantation and gene therapy on overall disease progression and potential impacts on cardiopulmonary dysfunction

SCD affects approximately 100,000 US individuals, and 300,000 births annually worldwide, largely on the African continent. While it is a genetic hemoglobinopathy, SCD is a systemic disorder. In the lungs, nearly every cell type and structure are affected, and cardiopulmonary complications are a leading cause of morbidity and accelerated mortality. The goal of this scientific symposium is to present recent findings and evidence-based interventions for acute and chronic pulmonary complications of SCD across the lifespan. We will actively engage pediatric and adult clinicians and researchers to promote collaborative investigation and implementation of evidence-based clinical care for patients living with SCD.

Chairing: R.T. Cohen, MD, MPH, Boston, MA
 A.P. Ruhl, MD, MHS, Bethesda, MD
 E.S. Klings, MD, Boston, MA
 S.C. Sadreameli, MD, MHS, Baltimore, MD

- 9:00 Introduction**
 R.T. Cohen, MD, MPH, Boston, MA
- 9:03 Patient Speaker**
 T. Woolford, Owings Mills, MD
- 9:08 A Pulmonary Perspective of Sickle Cell Disease and Disease-Modifying Therapies**
 A. Campbell, MD, Washington, DC
- 9:21 Airway Function in SCD: Impact on Morbidity and Mortality Across the Lifespan**
 S.M. Willen, MD, Sacramento, CA
- 9:34 Sleep Disordered Breathing in SCD - What Have We Learned?**
 O. Afolabi-Brown, MD, Philadelphia, PA
- 9:47 Pulmonary Hypertension Beyond the ATS Guidelines: New Concepts in Pathophysiology, Diagnosis and Treatment**
 R.F. Machado, MD, Indianapolis, IN
- 10:00 Acute Chest Syndrome and Venous Thromboembolism in SCD: When the Acute Becomes Chronic**
 E.S. Klings, MD, Boston, MA
- 10:13 Curative Therapies for Sickle Cell Disease: Potential Cures for SCD but What About the Lung?**
 C. Fitzhugh, MD, Bethesda, MD
- 10:26 Conclusion**
 A.P. Ruhl, MD, MHS, Bethesda, MD

BASIC • CLINICAL • TRANSLATIONAL**SCIENTIFIC SYMPOSIUM**

CME Credits Available: 1.5

MOC Points Available: 1.5

**B8 BEYOND THE LUNGS:
EXTRAPULMONARY MANIFESTATIONS
OF PULMONARY VASCULAR DISEASE****Assembly on Pulmonary Circulation****9:00 a.m. - 10:30 a.m. Marriott Marquis Washington****Liberty Ballroom Salons I-L (Level M4)****Target Audience**

Providers caring for those with pulmonary vascular disease, and those with clinical or research responsibilities related to pulmonary vascular disease or lung diseases with similar extrapulmonary manifestations

Objectives

At the conclusion of this session, the participant will be able to:

- describe new findings about extrapulmonary manifestations in PAH within the CNS, skeletal musculature, gut microbiome and changes in systemic inflammation, endocrine and metabolic function
- define new strategies to manage the care of PAH including the role that pulmonary rehabilitation may play and how novel therapeutic targets addressing inflammation and metabolism may prove to improve clinical outcomes
- apply new findings toward novel research questions and continue investigation of how these systemic effects of PAH may play a role in disease development and outcomes

This session will provide a comprehensive review of extrapulmonary manifestations of pulmonary arterial hypertension (PAH). Several systems will be reviewed including the central nervous system, skeletal musculature, endocrinological manifestations and the immune system. Presenters will provide a review of the literature from bench to bedside observations and proposed pathophysiological mechanisms. Therapeutic implications and knowledge gaps will also be highlighted. By the conclusion of this session, learners will understand how PAH may affect multiple extrapulmonary systems and how the multi-system interplay in the development of this complex disease may contribute to clinical outcomes.

Chairing: S. Umar, MD, PhD, Los Angeles, CA
A. Hemnes, MD, ATSF, Nashville, TN
N. Singh, MD, MBA, Providence, RI

9:00 Welcome and Introductions**9:05 Patient Speaker**
*Speaker To Be Announced***9:10 Spinal Cord Neuroinflammation in PAH**
S. Umar, MD, PhD, Los Angeles, CA**9:22 Questions/Discussion****9:26 Retinal Involvement in PAH**
T. Lahm, MD, ATSF, Denver, CO**9:38 Questions/Discussion****9:42 Gut Microbiome and Systemic Inflammation in PAH**
T. Thenappan, MD, Minneapolis, MN**9:54 Questions/Discussion****9:58 Obesity and Metabolic Dysfunction in PAH**
N. Al-Naamani, MD, MS, Philadelphia, PA**10:10 Questions/Discussion****10:14 Skeletal Muscle and Exercise in PAH**
E. Brittain, MD, Nashville, TN**10:26 Questions/Discussion**

This session and the International Conference are supported by an independent medical educational grant from Merck & Co.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BASIC • TRANSLATIONAL**SCIENTIFIC SYMPOSIUM**

CME Credits Available: 1.5

**B9 SEX-SPECIFIC MECHANISMS OF LUNG
DISEASE PATHOGENESIS THROUGH THE
LENS OF SINGLE CELL RNA SEQUENCING****Assemblies on Respiratory Cell and Molecular Biology; Allergy,
Immunology and Inflammation; Respiratory Structure and
Function****9:00 AM - 10:30 AM Marriott Marquis Washington****Marquis Ballroom Salon 5 (Level M2)****Target Audience**

Health professionals and life scientists interested in lung disease pathogenesis, and trainees in biomedical research interested in single cell profiling studies, bioinformatics, and the role of sex on lung disease pathogenesis

Objectives

At the conclusion of this session, the participant will be able to:

- describe recent findings from scRNAseq analyses that improved our understanding of sex-based lung disease pathogenesis
- understand the role and limitations of single cell profiling in the future of clinical pulmonary medicine with an emphasis on sexually dimorphic clinical features
- define emerging single-cell technologies and analytic techniques for the study of lung disease and outline a pathway to properly sample, process, and analyze samples for sex-specific studies

There are well-documented examples of sex-specific clinical features of many lung diseases. Yet, our understanding of how a patient's sex influences lung disease pathogenesis remains limited. This symposium will cover recent breakthroughs in our understanding of lung disease enabled by the application of single-cell profiling technologies. This session reviews the current landscape of ARDS, cystic fibrosis, asthma, and COPD pathophysiology discoveries through the lens of single-cell profiling and the role of sex-specific contributions. As we review these recent breakthroughs, we will highlight the strengths and limitations of this approach and discuss emerging technologies that will shape the future of this field.

Chairing: C.J. Britto-Leon, MD, ATSF, New Haven, CT
J. Kropski, MD, Nashville, TN
V. Krymskaya, PhD, MBA, Philadelphia, PA

9:00 Sex-Based Differences in Macrophage Transcriptional Heterogeneity in Acute Lung Injury

K. Mould, MD, MPH, Denver, CO

9:15 Using Transcriptome Metanalysis to Uncover Sex-Specific Mechanisms of Asthma Pathogenesis

S. Kay, MD, MS, New Haven, CT

9:30 The Sex-Specific Connectome of Airway Immune Cells in Cystic Fibrosis as a Determinant of Its Dimorphic Clinical Course

C.J. Britto-Leon, MD, ATSF, New Haven, CT

9:45 Sex-Specific Pathogenic Cell Populations in the Fibrotic Lung

J. Kropski, MD, Nashville, TN

10:00 Lung Spatial Profiling Reveals a Sex-Specific T Cell Signature in COPD Patients with Fatal SARS-CoV-2 Infection

F. Polverino, MD, PhD, Houston, TX

10:15 Using the Human Cell Atlas' discovAIR Project to Uncover Sex-Based Differences That Drive Lung Disease on a Large-Scale

Speaker To Be Announced

CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

**B10 REIGNITING THE CANCER MOONSHOT:
ATS = MISSION CONTROL FOR LUNG
CANCER**

Assembly on Thoracic Oncology; Tobacco Action Committee

9:00 AM - 10:30 AM

Marriott Marquis Washington

Marquis Ballroom Salon 6 (Level M2)

Target Audience

Providers of lung health, clinicians and researchers

Objectives

At the conclusion of this session, the participant will be able to:

- identify the critical role the NCI Moonshot will play in cancer detection and treatment research for years to come
- Recognize research gaps in detecting and treating lung cancer
- identify ongoing efforts in tobacco control and early detection including screening and biomarkers to improve outcomes from lung cancer

The ATS is a vital partner in NCI's Cancer Moonshot. Lung cancer care and research will focus on efforts to reduce deaths from this deadliest of cancers through early detection and new molecularly driven diagnoses and targeted treatment. Taken directly from Moonshot version 2.0 the overarching themes of this symposium will focus on Expanding Use of Proven Cancer Prevention and Early Detection Strategies and Developing new enabling cancer technologies. Each speaker will discuss LC specific topics related to these themes including reducing disparities, increasing early detection and primary prevention, and the role of biomarkers along the continuum of care.

Chairing: N.T. Tanner, MD, MSCR, Charleston, SC
R.S. Wiener, MD, MPH, ATSF, Boston, MA
M.P. Rivera, MD, ATSF, Rochester, NY

9:00 Introduction to the 2022 Reignition of the Cancer Moonshot

S. Elnahal, MD, MBA, Washington, DC

9:15 Reducing Disparities Across the Lung Cancer Continuum: Expanding Use of Proven Early Detection Strategies

M.C. Aldrich, MPH, PhD, Nashville, TN

9:33 Lung Cancer Screening: Harnessing the VA Enterprise to Expand Proven Early Detection Strategies

C.G. Slatore, MD, Portland, OR

9:52 Tobacco Control and Treatment: A Major Key to Cancer Prevention

A.C. Melzer, MD, MS, Minneapolis, MN

10:11 Precision Oncology for Lung Cancer: Developing New Enabling Cancer Technologies

P. Nana-Sinkam, MD, Richmond, VA

This session and the International Conference are supported by an independent medical educational grant from Merck & Co.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

B11 GLOBAL INSIGHTS ON THE LONG-TERM SEQUELAE OF INFECTIONS: BEYOND COVID

Assemblies on Pulmonary Infections and Tuberculosis; Allergy, Immunology and Inflammation

9:00 AM - 10:30 AM Walter E. Washington Convention Center

Room 147 A-B (Street Level)

Target Audience

Providers caring for patients with current and/or prior lung infections, and researchers interested in lung immunology, pneumonia, HIV, and/or cognitive impairment

Objectives

At the conclusion of this session, the participant will be able to:

- gain understanding of the range and frequency of long-term pulmonary and extra-pulmonary sequelae of bacterial and viral infections
- describe commonalities of mechanisms of impairment from pulmonary infections
- apply knowledge of mechanisms of impairment to improve research into the long-term sequelae of pulmonary infections

Acute pneumonia has long been known to be a significant and persistent etiology of mortality worldwide. Acute bacterial and viral pulmonary infections can also lead to persistent morbidity and long-term pulmonary and extrapulmonary complications. This has recently been highlighted by the emergence of post-acute sequelae of SARS-CoV-2 infection (PASC). In this seminar, we aim to explore the long-term complications of other viral and bacterial pulmonary infections, highlighting the mechanisms of disease, and allowing the audience to understand differences and commonalities among these sequelae.

Chairing: K. Traber, MD, PhD, ATSF, Boston, MA
J.S. Zifodya, MD, MPH, New Orleans, LA
N. Navuluri, MD, MPH, Durham, NC

9:00 Post Infectious Lung Disease: A Global Perspective

A. Ddungu, MBChB, MMed, Kampala, Uganda

9:20 HIV's Pulmonary Long Game

E.F. Attia, MD, MPH, Seattle, WA

9:40 Long Term Cognitive Impact of Pneumonia: Burden and Mechanisms

B.H. Singer, MD, PhD, Ann Arbor, MI

10:00 Mechanisms of Post-Acute Infection Syndromes

J. Sun, PhD, Charlottesville, VA

10:20 Moderated Q&A

N. Navuluri, MD, MPH, Durham, NC

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

MOC Points Available: 1.5

B12 ATS CLINICAL PRACTICE GUIDELINES: CLINICAL PRACTICE ON THE CUTTING EDGE

Assemblies on Behavioral Science and Health Services Research; Clinical Problems; Pulmonary Infections and Tuberculosis; Sleep and Respiratory Neurobiology; This is jointly sponsored by the PRS and QIIC chairs; Documents Development and Implementation Committee

9:00 AM - 10:30 AM Walter E. Washington Convention Center

Room 143 A-C (Street Level)

Target Audience

Physicians, nurses, respiratory therapists and trainees who care for adults with idiopathic pulmonary fibrosis, post-prematurity respiratory lung disease, asthma, pneumonia and COPD and sarcoidosis

Objectives

At the conclusion of this session, the participant will be able to:

- understand how evidence is used to inform diagnostic and treatment recommendations
- apply clinical recommendations from recently published guidelines in clinical practice, improving patient outcomes
- obtain new strategies to approach: pulmonary fibrosis, pulmonary rehabilitation and measurements of lung volumes as well as late-breaking guidelines

This session is proposed as the 8th annual scientific symposium highlighting ATS Clinical Practice Guidelines (CPGs) as requested by the ATS Executive Committee. We will highlight CPGs published over the last year, including: the updated IPF guidelines, the workshop report defining pulmonary rehabilitation, the technical statement on measurement of lung volumes as well as late approved guidelines.

Chairing: D.J. Feller-Kopman, MD, Lebanon, NH
M.L. Metersky, MD, Farmington, CT
J.M. Liebler, MD, ATSF, Los Angeles, CA

9:00 Welcome

M. Metersky, MD, Farmington, CT

9:02 Clinical Practice Guideline Methodology

K.C. Wilson, MD, ATSF, Boston, MA

9:12 Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

G. Raghu, MD, Seattle, WA

9:27 Pulmonary Rehabilitation

A.E. Holland, PT, PhD, Melbourne, Australia

- 9:42** **ATS Statement on Race and Ethnicity in Pulmonary Function Test Interpretation**
N. Bhakta, MD, San Francisco, CA
- 9:57** **ATS Statement on Priorities for Interventions to Address Health Disparities in Lung Nodule Management**
K. Steiling, MD, MSc, Boston, MA
- 10:12** **Guideline Implementation**
J. Ruminjo, MD, New York, NY
- 10:20** **Panel discussion**

CLINICAL

SCIENTIFIC SYMPOSIUM

B13 **BREAKING NEWS: CLINICAL TRIAL RESULTS IN PULMONARY MEDICINE**9:00-11:00 am **Walter E. Washington Convention Center****Ballroom C (Level 3)****Target Audience**

Clinicians, research scientists, and other allied health professionals

Objectives

At the conclusion of this session, the participant will be able to:

- gain new findings about emerging inhaled therapy for pulmonary arterial hypertension
- learn new findings about the effects new drugs and new biologics to treat COPD symptoms and exacerbation frequency
- learn new findings about novel dual target biologic formulations for treating asthma

This session will provide late-breaking information on leading clinical trials affecting the pulmonary community.

Chairing: P. Lai, MD, MPH, ATSF, Boston, MA
J. Lee, MD, ATSF, Aurora, CO

- 9:00** **Welcome and Introduction**
- 9:04** **Seralutinib Treatment in Adult Subjects with Pulmonary Arterial Hypertension: Results from the TORREY Study**
R.P. Frantz, MD, Rochester, MN
- 9:24** **Questions and Answers**
- 9:32** **Effect of Ensifentrine, a Novel PDE3 and PDE4 Inhibitor, on Lung Function, Symptoms and Exacerbations in Patients With COPD: The Enhance Trials**
A. Anzueto, MD, San Antonio, TX
- 9:52** **Questions and Answers**
- 9:59** **Targeting of TSLP and IL-13 by the Novel Nanobody® Molecule SAR443765 Reduces FeNO in Asthma Following Single Dose Exposure**
B.T. Suratt, MD, Cambridge, MA

- 10:19** **Questions and Answers**
- 10:27** **Efficacy and Safety of Dupilumab in Chronic Obstructive Pulmonary Disease With Type 2 Inflammation**
S.Bhatt, MD, Birmingham, AL, USA
- 10:47** **Questions and Answers**
- 10:55** **Wrap Up**

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

LATE BREAKING MINI SYMPOSIUM

B14 **COVID SEVERITY, OUTCOMES, AND DISPARITIES: FROM MOLECULE TO COMMUNITY**9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center****Room 202 A (Level 2)****Chairing:** C.H. Weiss, MD, Evanston, IL
K.M. Potter, PhD, RN, CNE, Pittsburgh, PA**Oral Presentations:**

- 9:00** **Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation/E. Alfaro, Madrid, Spain**
- 9:12** **Natural Anti-ACE2 IgM Levels Are Associated With Protection From Severe COVID-19/E.L. Mitchell, Charlottesville, VA**
- 9:24** **Dual Energy CT (DECT)-derived Ventilation/perfusion (V/Q') Mismatch Following COVID-19 Infection: Preliminary Results From the Lung Microvascular and Parenchymal Sequelae (Lung-MaPS) of COVID-19 Study/E. Oelsner, New York, NY**
- 9:36** **Longitudinal Evaluation of Quantitative Computed Tomography Measurements and Diffusion Capacity of the Lung in Recovered COVID-19 Patients With Normal Chest Computed Tomography Scans/S. Lee, Bethesda, MD**
- 9:48** **Development and External Validation of a National Veterans COVID-19 Machine Learning Model/S. Govindan, Kansas City, MO**
- 10:00** **Association of Smoking History With COVID-19 Infection, Hospitalization and Death in the C4R Study/P. Balte, New York, NY**
- 10:12** **Living Life in the Fast Lane: Sinus Tachycardia Following COVID-19 and It's Implications/B. Amir-Kabirian, Charleston, WV**
- 10:24** **Association of Delirium With Functional and Cognitive Outcomes Among Older Survivors of a COVID-19 Hospitalization/R. Kaushik, New Haven, CT**

- 10:36 **Use of a Multi-Center Weighted Lottery to Promote Equity in the Allocation of Scarce COVID Medications/D.B. White, Pittsburgh, PA**
- 10:48 **Severe Neighborhood Deprivation and Symptom Burden Among Older Adults Following COVID-19 Infection/J. Falvey, Baltimore, MD**

BASIC • CLINICAL • TRANSLATIONAL**MINI SYMPOSIUM****B15 ASTHMA: HOT OFF THE PRESS FROM THE BENCH TO THE CLINIC**9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center****West Salon G-I (Street Level)**

Chairing: P. Lamothe, MD, PhD, Atlanta, GA
M.L. Manni, PhD, Pittsburgh, PA
C.R. Morris, PhD, Burlington, VT

Oral Presentations:

- 9:00 **Placebo Rates Confound Asthma Exacerbation Rate Reductions: A Meta-regression Analysis of Pivotal Trials of Three Anti-IL5 Biologics/D.B. Khatri, Rockville, MD**
- 9:12 **Androgen Receptor (AR) Signaling Decreases Glutamine Metabolism in Th17 Cells to Decrease House Dust Mite-Induced Airway Inflammation/N.U. Chowdhury, Nashville, TN**
- 9:24 **Cannabinoid Receptor 1 Inverse Agonist, INV-202, Induces Weight Loss and Reduces Airway Hyperreactivity in a Mouse Model of Obese Asthma/C.R. Morris, Burlington, VT**
- 9:36 **Airway Epithelial Circular RNA Expression Is Altered in Asthma/C. Huang, Wuhan, China**
- 9:48 **FeNO, Biomarkers of High Th2 Immunity, and Response to Inhaled Corticosteroids in African American Children With Asthma/Y.-Y. Han, Pittsburgh, PA**
- 10:00 **Increased Numbers of Group 3 Innate Lymphoid Cells and C-kit-positive ILC2s Expressing IL-17A in Sputum From Severe Asthmatics With Neutrophilic or Mixed Granulocytic Bronchitis/X. Ju, Hamilton, Canada**
- 10:12 **Pathologic CD8+ Effector Memory T Cells Re-expressing CD45RA in Severe Asthma/R.P. Ramonell, Pittsburgh, PA**
- 10:24 **Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Prior Omalizumab Use: A Post Hoc Analysis of the Phase 3 Navigator Study/A. Menzies-Gow, London, United Kingdom**

- 10:36 **Distinct Epithelial-Innate Immune Cell Transcriptional Circuits Underlie Airway Hyperresponsiveness in Asthma/R.C. Murphy, Seattle, WA**

- 10:48 **Fractional Exhaled Nitric Oxide Is a Stable Longitudinal Biomarker in Severe Asthma and Correlates With Markers of Systemic Inflammation/E.A. Townsend, Madison, WI**

BEHAVIORAL • CLINICAL**MINI SYMPOSIUM****B16 THE CURRENT STATE OF CRITICAL CARE: ROLE OF SYSTEMS AND HEALTH DISPARITIES**9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center****Room 204 A-C (Level 2)**

Chairing: M.F. Griffith, MD, MPH, Aurora, CO
R. Kohn, MD, MSCE, Philadelphia, PA
K.R. Gillmeyer, MD, Boston, MA

Oral Presentations:

- 9:00 **The Earlier the Better: Timing of Transfer Is Associated With Improved Outcomes in Patients With Acute Respiratory Failure/A. Ludwig, Chicago, IL**
- 9:12 **Implementing an Interdisciplinary Triage Huddle to Reduce ED to Medical ICU Wait Times/S.M. Hyder, Chicago, IL**
- 9:24 **Admission to a TeleICU Hospital Is Associated With Similar Rates of Inter-Hospital Transfer but Improved 30-Day Mortality: A Patient-Level Instrumental Variable Analysis/B. Deshpande, Ann Arbor, MI**
- 9:36 **One Versus Two Weeks of Physician Continuity in the Intensive Care Unit and Subsequent Outcomes: A Target Trial Emulation/A.J. Admon, Ann Arbor, MI**
- 9:48 **Keeping Tabs on Sepsis: A Modified CDC Adult Sepsis Event (CDC-ASE) Definition/K.J. Karlic, Ann Arbor, MI**
- 10:00 **Illness Presentation Characteristics Associated With Antimicrobial Timing and In-hospital Mortality Among Patients With Hospital-onset Sepsis/J.C. Ginestra, Philadelphia, PA**
- 10:12 **An Intersectional Analysis of Sociodemographic Disparities in Hospital Mortality After Mechanical Ventilation for Pneumonia and Sepsis/G.L. Day, Aurora, CO**
- 10:24 **A Retrospective Analysis of Differences in Sedation Practice by Race During Mechanical Ventilation/D. Ramadurai, Philadelphia, PA**

- 10:36 **Disparities in Hospital Length of Stay Among Severely Ill Patients With Community Acquired Sepsis and Acute Respiratory Failure Across 27 Hospitals/C.F. Chesley, Philadelphia, PA**
- 10:48 **Operationalizing the Social Determinants of Critical Care/D. Ramadurai, Philadelphia, PA**

CLINICAL

MINI SYMPOSIUM

B17 EMERGING DATA ON DISEASE AND SYMPTOM BASED THERAPEUTICS FOR PATIENTS WITH IPF

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**
Ballroom B (Level 3)

Chairing: M. Kreuter, MD, Heidelberg, Germany
S.B. Montesi, MD, Boston, MA
J.S. Lee, MD, ATSF, Aurora, CO

Featured Speaker:

9:00 **Treating Pulmonary Fibrosis: The Future Is Bright/L. Richeldi, Rome, Italy**

Oral Presentations:

- 9:12 **PLN-74809 Shows Favorable Safety and Tolerability and Indicates Antifibrotic Activity in a Phase 2a Study for the Treatment of Idiopathic Pulmonary Fibrosis/L.H. Lancaster, Nashville, TN**
- 9:24 **Long-term Safety Data of Inhaled Pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis (IPF) and Non-IPF Interstitial Lung Disease (ILD) Patients/F.A. Woodhead, Seattle, WA**
- 9:36 **The Impact of Switching to a Second Antifibrotic Therapy on Outcomes in Patients With IPF in the Empire Registry Treated With Pirfenidone or Nintedanib/M.K. Vasakova, Praha, Czech Republic**
- 9:48 **Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: Preliminary Results of a Systematic Review and Meta-analysis/A.K.Y. Teoh, Camperdown, Australia**
- 10:00 **Efficacy of Oral Nalbuphine Extended Release in Patients With Idiopathic-Pulmonary-Fibrosis-related Chronic Cough: A Phase 2 Study/T.M. Maher, Los Angeles, CA**
- 10:12 **The Effect of Oral Nalbuphine Extended Release on Patient-reported Outcome Measures in Patients With Idiopathic-Pulmonary-Fibrosis-related Chronic Cough/T.M. Maher, Los Angeles, CA**

- 10:24 **A Digital Therapeutic For Anxiety Symptoms In Patients With Idiopathic Pulmonary Fibrosis: An Open-label Pilot Clinical Investigation/M.R. Horton, Baltimore, MD**
- 10:36 **Generalizability of Pharmaceutical Randomized Controlled Trials for Idiopathic Pulmonary Fibrosis/Y. Khor, Heidelberg, Australia**
- 10:48 **BMS-986278, an Oral Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist, for Patients With Idiopathic Pulmonary Fibrosis: Results From a Phase 2 Randomized Trial/T.J. Corte, Sydney, Australia**

BEHAVIORAL • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

B18 TIME TO ACT: INTERVENTIONS TO REDUCE RESPIRATORY HEALTH EFFECTS OF POLLUTANTS

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**
Room 102 A-B (Street Level)

Chairing: N.N. Hansel, MD, MPH, Baltimore, MD
G.D. Thurston, DSc, New York, NY
J.G. Wang, MD, Columbus, OH

Oral Presentations:

- 9:00 **Effects of a Liquefied Petroleum Gas, Continuous Fuel Delivery and Behavioral Messaging Intervention on Linear Growth in Children With Exposure to Household Air Pollution: A Multi-country Randomized Controlled Trial/W. Checkley, Baltimore, MD**
- 9:12 **Antioxidant Intake Modifies Susceptibility to Indoor Air Pollution in Children With Asthma/R.N. Shade, Baltimore, MD**
- 9:24 **Omega-3 Fatty Acids Attenuate Air Pollution Particulate Matter Induced Inflammation and Oxidative Stress in Airway Epithelial Cells/R.D. Huff, Vancouver, Canada**
- 9:36 **Impact of 20 Years of Tobacco Policy, Strategy, and Programs on Chicago's Adult and Youth Tobacco Use/A. Patel, Chicago, IL**
- 9:48 **AIRWEIGHS: A Randomized Clinical Trial of Indoor Air Cleaners Among Normal and Overweight/Obese Children With Asthma/A.Y. Qiu, Baltimore, MD**
- 10:00 **Reduction in Coking-operation-related Particulate Matter and Pediatric Asthma Emergency Department Visits After Plant Closure - An Interrupted Time Series Analysis/W. Yu, New York, NY**
- 10:12 **Change in Rate of Healthcare Encounters for Respiratory Infection From Air Pollution Exposure After Improved Vehicle Emissions Standards in New York State/D. Croft, Rochester, NY**

- 10:24 **Real-world Effectiveness of Portable Air Cleaners in Reducing Home Particulate Matter Concentrations**/F.T. Lu, Piscataway, NJ
- 10:36 **Effectiveness of WeChat-Based Smoking Cessation Intervention Among Chinese Male Workers Exposed to Dust: A Randomized Controlled Trial**/R. Li, Kunming, China

Featured Speaker:

- 10:48 **Closing Remarks: Multi-pronged Approaches to Reduce Harmful Impacts of Pollutants**/N.N. Hansel, Baltimore, MD

BASIC • CLINICAL • TRANSLATIONAL**MINI SYMPOSIUM****B19 PLAYING THE TIKI-TAKA: THE CELL CROSSTALK GAME IN LUNG REPAIR**

9:00 a.m. - 11:00 a.m. Walter E. Washington Convention Center

Room 202 B (Level 2)

Chairing: A.L. Mora, MD, Columbus, OH
J.L. Larson-Casey, PhD, Birmingham, AL
D. Lagares, PhD, MSc, Boston, MA

Featured Speaker:

- 9:00 **Role of Transitional AECs in Pulmonary Fibrosis**/R.L. Zemans, Ann Arbor, MI

Oral Presentations:

- 9:12 **GPR87 Regulates Epithelial Repair During Pulmonary Fibrosis**/F.J. Kamga Gninzeko, Nashville, TN
- 9:24 **IL11 Causes Alveolar Type 2 Pneumocyte Dysfunction and Inhibits Alveolar Regeneration in the Damaged Lung**/B. Ng, Singapore, Singapore
- 9:36 **Epithelial HIF Inhibition Enables Adaptive Repair and Alveolar Regeneration in Chronic Lung Injury**/A.S. McCall, Nashville, TN
- 9:48 **Disrupted Alveolar Epithelial Proteostasis Drives AT2 Cell Phenotype Changes in Murine and Human Preclinical SP-C Mutation Models of Pulmonary Fibrosis**/J. Katzen, Philadelphia, PA
- 10:00 **Immune Checkpoint Blockade Is Associated With Improved Alveolar Epithelial Repair Responses in a Humanized CTLA4 Murine Model**/S. Yadav, New Orleans, LA
- 10:12 **Ectopic MUC5B Expression in SFTPC-Positive Alveolar Epithelial Cells in Subjects Without Lung Fibrosis**/T. Kato, Chapel Hill, NC

- 10:24 **Wnt Signaling in Mesenchymal Vascular Progenitor (MVPC) Drives Adaptive Angiogenesis During Fibrosis and Regulates Pulmonary Tissue Repair**/E. Mason, Denver, CO

- 10:36 **Single Nuclear RNAseq of Differentially Affected IPF Lung Uncovers Potential Cellular Origins of Aberrant Basaloid Cells**/T.S. Adams, New Haven, CT

- 10:48 **Sex-dependent Susceptibility to Pulmonary Fibrosis Is Associated With Reduction in ASK1 Activation and Autophagy in Aged Mice**/S. Dos Santos Valenca, Lexington, KY

BASIC • CLINICAL • TRANSLATIONAL**MINI SYMPOSIUM****B20 THE ONLY CONSTANT IS CHANGE: NEW INSIGHTS INTO AIRWAY REMODELING**

9:00 a.m. - 11:00 a.m. Walter E. Washington Convention Center

Room 150 A-B (Street Level)

Chairing: R. Gosens, PhD, Groningen, Netherlands
J.R. Johnson, PhD, Birmingham, United Kingdom

Oral Presentations:

- 9:00 **Development of Airway Sensory Hyperinnervation and Reflex Hyperresponsiveness in Offspring of Obese Mothers**/K. Williams, Portland, OR
- 9:12 **Oxidized Phosphatidylcholine Promotes Protein Kinase C-mediated B₂ Adrenoceptor Dysfunction to Induce Bronchodilator Insensitivity**/J.M. Vaghasiya, Winnipeg, Canada
- 9:24 **Recruited Lung Macrophages Contribute to Airway Remodeling and Airway Hyperresponsiveness in a Mouse Model of Severe Allergic Airway Inflammation**/B.W. Lewis, Columbus, OH
- 9:36 **Senescence Induction in Aging Asthmatic Airway Cells**/A. Aghali, Rochester, MN
- 9:48 **Hyperoxia Induces Senescence in Developing Human Airway Smooth Muscle Cells**/A. Aghali, Rochester, MN
- 10:00 **Defining the Prostanoid Component in Mast Cell-dependent Constriction of Isolated Human Small Airways**/J. Säfholm, Stockholm, Sweden
- 10:12 **CD38 Promotes Th17 Inflammation in Aged Mice With Severe Allergic Airway Inflammation**/M.L. Ford, Columbus, OH
- 10:24 **The Phenotypic Effect of Sex Chromosomes Versus Sex Hormones in a Mouse Model of Allergic Asthma**/C.D. Ekpruke, Bloomington, IN

- 10:36 **Opto-Electrical Quantification of Airway Epithelial Injury**/J. Kim, Hoboken, NJ
- 10:48 **Probing Lung Function at High Spatiotemporal Resolution Using a Novel Crystal Ribcage**/H. Nia, Boston, MA

BEHAVIORAL • CLINICAL
POSTER DISCUSSION SESSION
B21 SUPPORTING PATIENTS AND FAMILIES THROUGH SERIOUS ILLNESS AND RECOVERY

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**

Room 206 (Level 2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: A.S. Iyer, MD, MSPH, Birmingham, AL
C.E. Brown, MD, MA, Seattle, WA
J.M. Kruser, MD, MS, Madison, WI

- 701 **Changes in End-of-Life Treatment Intensity Between Urban and Rural Patients in the U.S. Between 2010 and 2019**/E. Harlan, Ann Arbor, MI
- 702 **Factors Associated With Costly and Potentially Burdensome Care Among Patients With Dementia and Respiratory Failure**/L.R. Pollack, Seattle, WA
- 703 **Predictors of Documented Goals-of-Care Discussions for Hospitalized Patients With Chronic Illness**/A.M. Uyeda, Seattle, WA
- 704 **Timing and Predictors of Documented Goals-of-Care Discussions for Patients With Acute Respiratory Failure Requiring Mechanical Ventilation**/R.Y.-F. Lee, Seattle, WA
- 705 **Prevalence and Variation in Goals of Care Assessment During Hospitalization for Sepsis**/L.M. Cagino, Ann Arbor, MI
- 706 **Goals of Care in Chronic Critical Illness: A Mental Model of Physician Decision Making**/S.K. Andersen, Pittsburgh, PA
- 707 **Inpatient Palliative Care and Acute Healthcare Utilization Among Hospitalized Patients With Impaired Functional Status**/L. Xu, New York, NY
- 708 **Medical Mistrust and Communication Among Black Patients With Serious Illnesses**/K. Cueva, Seattle, WA
- 709 **Medical Mistrust Among Surrogate Decision Makers of High-risk ICU Patients and Associations With Patient Outcomes - a Pilot Study**/S.T. Vasher, Chapel Hill, NC
- 710 **Social Support Mediates the 6-Month Mental Health Related Quality of Life of ICU Caregivers With Depressive Symptoms**/S.T. Vasher, Chapel Hill, NC
- 711 **Towards a Trauma-informed Intensive Care Unit (ICU): Trauma Among Family Members of ICU Patients and Family-clinician Interpersonal Outcomes**/D.C. Ashana, Durham, NC
- 712 **Individuals Experiencing ICU Surrogacy Demonstrate Greater Optimism Than Future Surrogates When Interpreting Prognostic Statements**/I.M. Oppenheim, Washington, DC
- 713 **Fatigue Is Often Associated With Severe Headache, Dyspnea, and Insomnia in Adult Patients With Post-acute Sequelae of SARS-CoV-2 (PASC)**/A. Panda, Portland, OR
- 714 **The Role of Peer Support in Addressing Epistemic Injustice Among Individuals With Post-COVID Syndrome: A Qualitative Study**/N. Sarma, Portland, OR
- 715 **Patient Experiences of Recovery Following Hospitalization for Severe COVID-19: A Qualitative Multi-center Study**/N. Sarma, Portland, OR
- 716 **Financial Toxicity Is Associated With Impaired Recovery After Severe COVID-19: Results From the BLUE-CORAL Study**/J. Womer, Baltimore, MD
- 717 **Empowering Patients: Implementing a Peer Health Coaching Program Following Hospital Discharge**/R. Tal-Singer, Miami, FL
- 718 **Understanding US Health Insurance Experiences During Critical Illness Recovery: A Qualitative Study of Intensive Care Unit (ICU) Recovery Visits**/T.L. Eaton, Ann Arbor, MI
- 719 **Impact of a Multidisciplinary Post-Covid-19 Clinic on Healthcare Utilization**/S.R. Levan, San Francisco, CA
- 720 **A Multi-Hospital Survey of Current Practices for Supporting Recovery From Sepsis**/R.K. Hechtman, Ann Arbor, MI
- 721 **Unpacking Core Components of an Effective Sepsis Transition and Recovery Program**/S.P. Taylor, Charlotte, NC
- 722 **Primary Care Clinicians Identify Barriers and Facilitators to High-quality Follow-up After Acute Respiratory Failure**/K. Hauschildt, Baltimore, MD
- 723 **A Pragmatic Randomized Trial of the Jumpstart Intervention to Promote Communication About Goals of Care for Hospitalized Patients With Serious Illness**/E.K. Kross, Seattle, WA
- 724 **The Racial Empathy Gap in Healthcare: A Mixed-Methods Analysis of Family-Clinician Communication in the Intensive Care Unit**/M. Modes, Los Angeles, CA

CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

B22 NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-19:00 a.m. - 11:00 a.m. **Marriott Marquis Washington****Marquis Ballroom, Salons 1-2 (Level M2)****Poster Viewing** 9:00-9:45**Discussion** 9:45-11:00**Chairing:** D.L. Demeo, MD, Boston, MA
J.M. Wells, MD, MSPH, Birmingham, AL
S. Raju, MD, MPH, Baltimore, MD

- 101** **Twice-daily, Nebulized Ensifentrine Produced Significant Improvement in Week 12 Lung Function: Sub-group Analysis in the Phase 3 Trial Enhance-2/K. Rickard, Raleigh, NC**
- 102** **Ensifentrine Reduced Healthcare Resource Utilization in Subjects With COPD: Results From Enhance-2, a Phase 3 Trial of Ensifentrine, a Dual PDE3/4 Inhibitor/I. Barjaktarevic, Los Angeles, CA**
- 103** **Longitudinal Analysis of Clinical Outcomes in PiMZ Alpha-1 Antitrypsin Smokers From the Spiromics Cohort/I. Barjaktarevic, Los Angeles, CA**
- 104** **Budesonide/Glycopyrrolate/Formoterol Fumarate Effects on Exacerbations of Chronic Obstructive Pulmonary Disease Based on Airflow Limitation: A Post-hoc Analysis of the KRONOS Study/F.J. Martinez, New York, NY**
- 105** **Community Health Worker-supported Self-management Action Plan for Chronic Obstructive Pulmonary Disease Exacerbations: A Feasibility Intervention Trial/W. Checkley, Baltimore, MD**
- 106** **The Feasibility and Efficacy of Heated Humidified Air Via Nasal Cannula for COPD Patients Post Exacerbation: An Open-label, Non-randomized Pilot Study/T. Ho, Hamilton, Canada**
- 107** **Analysis From Phase II Clinical Trial, Alvelestat, NE (Neutrophil Elastase) Inhibitor in AATD-LD: Correlation Between Biomarker Response (Desmosine and Aa-val³⁶⁰) and Clinical Outcome (SGRQ)/J. Parkin, London, United Kingdom**
- 108** **The Protease-Antiprotease Balance in Alpha-1 Antitrypsin Deficiency/M. Herron, Dublin, Ireland**
- 109** **Isoflavone Intake Associated With Decreased Chronic Obstructive Pulmonary Disease Morbidity/E. Quiroz, Baltimore, MD**
- 110** **Persistent Hypercapnia After Acute Exacerbation of Chronic Obstructive Pulmonary Disease: An Indicator for Long-term Non-invasive Ventilation/Z.J. Gandhi, Wilkes-Barre, PA**
- 111** **Flow Profiles Uncover and Correct Suboptimal Metered Dose Inhaler Technique/S. King, Olten, Switzerland**
- 112** **Inhalation Technique Maintenance in COPD Patients Using the Albuterol Digihaler/T. Wang, Chapel Hill, NC**
- 113** **Factors Influencing Correctness of the Inhalation Technique/I. Domagala, Poland, Poland**
- 114** **App-Based Symptom Assessment Is Triggered by Inhaler Use Changes Preceding COPD Exacerbations/M.B. Drummond, Chapel Hill, NC**
- 115** **Inhalation Parameter and Inhaler Usage Thresholds Preceding COPD Exacerbations in Patients Using the Albuterol Digihaler/G.T. Ferguson, Farmington Hills, MI**
- 116** **Variable Obstruction Is Associated With Chronic Obstructive Pulmonary Disease Development and Faster Lung Function Decline: Finding From ECPD Cohort Study/F. Wu, Guangzhou, China**
- 117** **Bronchodilator Responsiveness, Small Airway Disease, and Spirometric Pattern Variability/S. Fortis, Iowa City, IA**
- 118** **Estimating Rate of Lung Function Change Using Clinical Spirometry Data/A. Balasubramanian, Baltimore, MD**
- 119** **Prediction of Exacerbations in Chronic Obstructive Pulmonary Disease Using Race-specific Versus Race-neutral Reference Equations/J.H. Brems, Baltimore, MD**
- 120** **Persistent Airway Mucus Plugs and Changes in Lung Function in COPD/S. Mettler, Boston, MA**
- 121** **Airway Mucus Plugs and Chronic Obstructive Pulmonary Disease Exacerbations/V. Kim, Philadelphia, PA**
- 122** **Mortality Risk Reduction With Budesonide/Glycopyrrolate/Formoterol Fumarate Versus Fluticasone Furoate/Umeclidinium/Vilanterol in COPD: A Matching-Adjusted Indirect Comparison of Ethos and Impact/D. Stolz, Freiburg, Germany**
- 123** **Plasma Omega-3 Fatty Acid Levels Associated With Reduced COPD Morbidity/T. Kemper, Waco, TX**

CLINICAL

POSTER DISCUSSION SESSION

B23 ADVANCING THE SCIENCE OF ACUTE RESPIRATORY FAILURE

9:00 a.m. - 11:00 a.m. Walter E. Washington Convention Center

Room 209 A-C (Level 2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: H.E. Faust, MD, MS, Madison, WI
 B. Rochweg, MD, MSCE, FRCPC, Hamilton, Canada
 R.G. Khemani, MD, MSCR, Los Angeles, CA

- 801 Predicting Extubation Success in the Intensive Care Unit/D. Rose, Saint Louis, MO**
- 802 Laryngoscopy and Tracheal Intubation: Does Use of a Video Laryngoscope Facilitate Both Steps of the Procedure?/A. Lofrano, Minneapolis, MN**
- 803 Sphingosine-1-phosphate Mediates the Effect of Apolipoprotein M on Respiratory Failure in Viral Pneumonia/C.V. Cosgriff, Boston, MA**
- 804 Sleep Architecture Measured With the Odds Ratio Product in Mechanically Ventilated Patients With Acute Hypoxemic Respiratory Failure/A. Rodrigues, Toronto, Canada**
- 805 Severity of Lung Injury and Positive End-expiratory Pressure Are Associated With Respiratory Drive in Intubated Hypoxemic Patients/E. Spinelli, Milan, Italy**
- 806 Heart Rate Variability (HRV) Based Interpretable Machine Learning Algorithm for Prediction of All-cause Acute Respiratory Failure (ARF) Among ICU Patients/P. Krishnan, Atlanta, GA**
- 807 The Use of Analgesedation in Patients With Acute Respiratory Failure Requiring Non-invasive Positive Pressure Ventilation Is Associated With an Increased Risk of Intubation and Mortality/P.J. Dunbar, Aurora, CO**
- 808 Associations Between Substance Use Disorders and Sedative Exposure During Acute Respiratory Failure/P. Tiberio, Pittsburgh, PA**
- 809 Pressure-support Compared to Pressure-controlled Ventilation Improves Cardiorespiratory Function and Mitigates Brain Endothelial Cell Damage in Experimental Acute Ischemic Stroke/A.L. Silva, Rio de Janeiro, Brazil**
- 810 Outcomes of Acute Respiratory Failure in Patients With Cancer in the United States/K. Heybati, Rochester, MN**
- 811 Continuous Positive Airway Pressure Versus High-flow Nasal Cannula Oxygen Therapy for Acute Hypoxemic Respiratory Failure/T. Yokoyama, Seto, Japan**
- 812 Assessment of Negative Inspiratory Force in Determining Need for Positive Pressure Ventilation/L. Cooper, Chicago, IL**
- 813 Time-Limited Trials of Critical Care in Acute Respiratory Failure: A Prospective Observational Study/M. Peliska, Madison, WI**
- 814 Oxygen Supply and Demand During the COVID-19 Pandemic: An Integrated Health System Perspective/H.D. White, Temple, TX**
- 815 An Asymmetric High Flow Nasal Cannula Interface Reduces Work of Breathing in Patients With Hypoxemic Respiratory Failure/D. Slobod, Montreal, Canada**
- 816 Neutrophil-derived Microvesicles Directly Enhance Endothelial Permeability Independent of Monocytes/Y. Iki, London, United Kingdom**
- 817 Accuracy of Nasal Pressure Swing to Predict Failure of High Flow Nasal Oxygen in Patients With Acute Hypoxemic Respiratory Failure/G. Bruzzi, Modena, Italy**
- 818 Association of Endotracheal Tube Outer Diameter With Reintubation Rates/A. Sutaria, Miami, FL**
- 819 Presence of Heart Failure With Preserved Ejection Fraction Is Associated With Increased Rates of Failure of High Flow Nasal Cannula in Patients Presenting With Acute Hypoxemic Respiratory Failure/V. Kusupati, Tucson, AZ**
- 820 Assessing Safety in Patients on Pressure Support Ventilation: Preliminary Results From the ASOP Study/E.H. Pratt, Durham, NC**
- 821 Compatibility and Interoperability of the Ventilator Waveform Data for Clinical Research: The Mechanical Ventilator as an Internet of Things (IOT) Device/A. Tlilat, Birmingham, AL**
- 822 The Metabolic Cost of Inspiratory Muscle Training in Mechanically Ventilated Patients/T. Jenkins, London, United Kingdom**
- 823 The Development of a Comprehensive Inspiratory Muscle Strength Training (IMST) Weaning Protocol for Patients on Prolonged Mechanical Ventilation/J.C.G. Feliciano, Manila, Philippines**
- 824 Performance Gaps in Ventilator Liberation Protocols - an Observational Study/M. Sameed, Cleveland, OH**
- 825 Use of a Negative Pressure Trigger to Assess Successful Extubation/P. Ratanawatkul, Khon Kaen, Thailand**

CLINICAL

POSTER DISCUSSION SESSION

**B24 NOT YET OUT OF THE WOODS:
LONG-TERM OUTCOMES AFTER THE ICU**9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**

Room 201 (Level 2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: C.M. Sevin, MD, Nashville, TN
K.J. Haines, PhD, BHS, Melbourne, Australia
J.M. Mcpeake, PhD, MSc, Glasgow, United Kingdom

- 601 **Creative Arts Therapy for Healthcare Professionals Is Associated With Long Term Improvements in Psychological Distress/R. Avallone Mantelli, Aurora, CO**
- 602 **Using Age as a Prognostic Factor for Short-term Survival Improves Life Support Allocation Under Crisis Standards of Care/M. Hermsen, Chicago, IL**
- 603 **Distressing Symptoms and Disability After Critical Illness Among Older Adults/S. Jain, New Haven, CT**
- 604 **Social Vulnerability and Delivery of In-hospital Rehabilitation Services to Older Adults With Critical Illness/S. Jain, New Haven, CT**
- 605 **Early Deep Sedation May Be Associated With Long-term Post-hospital Mortality in Critically Ill Surgical Patients/C. Wen-Cheng, Taichung, Taiwan**
- 606 **ICU Delirium in the Development of Post-ICU Cognitive Impairment and Dementia/R. Chi, Indianapolis, IN**
- 607 **Associations Between COVID-19, Unexpectedness of Death, and Symptoms of PTSD Among Bereaved ICU Surrogates/K.R. White, Chicago, IL**
- 608 **Platelet Distribution Width Is an Independent Predictor of All-cause and Cardiac Mortality Among Healthy Us Adults/L. Botros, Norfolk, VA**
- 609 **Onset of Chronic Critical Illness Varies Based on the Outcome Being Evaluated/N.E. Ingraham, Minneapolis, MN**
- 610 **"From the Moment I Started Standing Again I Was Worried About Falls": Mixed Methods 12-month Observational Study Exploring the Fear of Falls in Intensive Care Unit Survivors/S.M. Parry, Parkville, Australia**
- 611 **Long-term Health Related Quality of Life and Mortality in Children With Pediatric Acute Respiratory Distress Syndrome/Z.O. Zayed, Los Angeles, CA**
- 612 **Racial Differences in Health Care Outcomes Among Patients Admitted With COVID-19 Infection in 2020/P. Patel, Las Vegas, NV**

- 613 **Differences in Health Care Outcomes Among Patients With Various Payers Sources Diagnosed With COVID-19 Infection in 2020/P. Patel, Las Vegas, NV**
- 614 **Exposure to IL-6 Inhibitors in Critically Ill COVID Patients Is Associated With Worsening Depression, Anxiety and Quality of Life at Post-ICU Clinic Follow Up/M.S. Aboodi, New York, NY**
- 615 **Long-term Cognitive Outcomes in Mechanically Ventilated Patients With and Without COVID-19 Pneumonia/A. Clark, Nashville, TN**
- 616 **Prevalence of Long-term Cognitive Impairment Following Hospitalization With COVID-19/A.P. Turner, Philadelphia, PA**
- 617 **Dyspnea and Health-related Quality of Life Among Survivors of COVID-19 Hospitalization: A Prospective Cohort Study/R.S. Agyekum, Philadelphia, PA**
- 618 **Reconceptualizing Patient Safety After Critical Illness: A Secondary Qualitative Analysis of Stakeholder Perspectives/L.P. Scheunemann, Pittsburgh, PA**
- 619 **Comparison of Skeletal Muscle Wasting in Mechanically Ventilated Patients With Early Mobilization Versus Usual Care: A Substudy of a Randomized Clinical Trial/S. Panchamukhi, Chicago, IL**
- 620 **One-Year Pulmonary Recovery in Patients Hospitalized for COVID-19/S.E. Jolley, Aurora, CO**

CLINICAL

POSTER DISCUSSION SESSION

**B25 TOP HEMATOLOGY/ONCOLOGY
CRITICAL CARE CASE REPORTS**9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**

Room 151 A (Street Level)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

- Chairing:** R.S. Stephens, MD, ATSF, Baltimore, MD
S.M. Pastores, MD, New York, NY
C. McEvoy, MD, St. Louis, MO
- 401 **A Confounding Consolidation in a Man With Relapsed Acute Lymphoblastic Leukemia/J. Loso Girard, Birmingham, AL**
- 402 **Intravascular Lymphoma: When Tissue Is The Issue/D.E. Loy, Aurora, CO**
- 403 **Adult Supraglottitis With Hematological Malignancy/M.B. Shaikh, Lexington, KY**

- 404 **An Ace In The Hole: Use Of Sutimlimab In Secondary Cold Agglutinin Disease Causing Hemodynamic Collapse**/D. Saxena, Houston, TX
- 405 **Pembrolizumab-Induced Rhabdomyolysis: A Tale of Two Patients**/S. Kumar, New York, NY
- 406 **Confusion, Clotting, and Bilateral Adrenal Hemorrhage: A Catastrophic Outcome**/R. Esteitie, Saginaw, MI
- 407 **Cytomegalovirus Retinitis With Combination Therapy Of Bendamustine And Rituximab For Waldenstrom Macroglobulinemia**/S.X. Lee, Morgantown, WV
- 408 **Sepsis and Cold Agglutinin Hemolytic Anemia - An Innovative Approach to the Management of Refractory Hemolysis in Critical Illness**/M. Ingemi, Springfield, MA
- 409 **A Case of Methemoglobinemia: How Visiting an Adult Shop Can Turn Your Blood Brown**/D.Y. Wang, Newark, DE
- 410 **The Elusive Imitator: A Case Of Respiratory Failure And Septic Shock Caused By Nocardia Cyriaciageorgica In A Patient With Squamous Cell Carcinoma Of The Lung**/R. Abubakar, Rancho Mirage, CA
- 411 **Unclear Etiology for Seizures in a Lung Transplant Recipient**/M.T. Olson, Phoenix, AZ
- 412 **A Rare Case of Spindle Cell Carcinoma With Unknown Primary in a Lung Transplant Recipient**/J. Jacob, Phoenix, AZ
- 413 **Heparin: A Cause and Cure for Clots**/S. Natarajan, Scranton, PA
- 414 **Profound Thrombocytopenia in a Young Healthy Woman With Urosepsis Complicated by Acute Respiratory Distress Syndrome**/Y. Huang, Chicago, IL
- 415 **Lepidic Adenocarcinoma Presenting as Acute Hypoxemic Respiratory Failure**/P. Jain, Pittsburgh, PA
- 416 **Management of a Thrombus in Transit in a Patient With Gastric Cancer and Hepatic Abscess in a Resource-Poor Setting**/M. Bermudez, The Bronx, NY
- 417 **Primary Mediastinal B-Cell Lymphoma Presenting as Cardiac Tamponade**/A.T. Phan, Colton, CA
- 418 **Cross My Heart and Hope to Live: Complicated Shock From an Invasive Lung Tumor and Pembrolizumab**/P. Singh, Philadelphia, PA
- 419 **Advanced and Refractory Evan's Syndrome: A Case Report**/C. Suh, La Jolla, CA
- 420 **Thrombotic Thrombocytopenic Purpura in a Post Cardiac Surgery Patient**/J.M. Chowdhury, Falls Church, VA
- 421 **Obstructive Shock In Malignant Central Airway Obstruction**/P. Sharma, Cleveland, OH
- 422 **Not Too Hot, Not Too Cold: The Goldilocks of Hemolysis**/M. Brandorff, New York, NY

- 423 **TTP With Positive Coombs, A Mere Coincidence or Underlying Relationship Coexists?**/A. Mahmoud, Paterson, NJ
- 424 **Shock and Spontaneity: A Deadly Combo Spontaneous Tumor Lysis Syndrome in a Patient With Metastatic Colorectal Cancer**/Z.M. Baig, Easton, PA
- 425 **A Rare Case: Life-Threatening Fulminant Evan's Syndrome**/Z.M. Htet, Bronx, NY

BEHAVIORAL • CLINICAL • TRANSLATIONAL
POSTER DISCUSSION SESSION
B26 IT'S TIME TO ADVANCE THE CARE OF PATIENTS WITH COPD, PULMONARY HYPERTENSION, AND OTHER LUNG CONDITIONS

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**

Room 151 B (Street Level)

- Poster Viewing** 9:00-9:45
- Discussion** 9:45-11:00
- Chairing:** K.O. Lindell, PhD, RN, ATSF, Charleston, SC
T.T. Von Visger, APRN, PhD, CCNS, PCCN, ATSF, Buffalo, NY
- 501 **The Experience of Chronic Obstructive Pulmonary Disease During COVID-19: A Qualitative Study**/L.A. Clark, Philadelphia, PA
- 502 **The Effect of Screening for Obstructive Sleep Apnea in Severe and Very Severe COPD - an Exploratory Clinical Study**/O. Hilberg, Vejle, Denmark
- 503 **Cognitive Impairment in Patients With COPD: Prevalence and Correlation With Disease Severity**/O. Hilberg, Vejle, Denmark
- 504 **Validity and Reliability of the Chronic Obstructive Pulmonary Disease-related Stigma Scale Using Confirmatory Factor Analysis**/S. Woo, Wilmington, NC
- 505 **The Association of Oxygen Use and Symptoms, Health Status and Mood in Pulmonary Hypertension**/L.A. Matura, Philadelphia, PA
- 506 **Exploring the Unmet Care Needs of Women With Advanced Chronic Obstructive Lung Disease (COPD)**/J. Madiraca, Charleston, SC

BASIC • CLINICAL • TRANSLATIONAL

RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

B27 EVOLVING CONCEPTS IN LUNG FUNCTION TESTING AND MONITORING

9:00 a.m. - 11:00 a.m. Walter E. Washington Convention Center

Room 103 A-B (Street Level)

Viewing 9:00-9:45

Summaries/Discussion 9:45-11:00

Chairing: J.H. Rayment, MD, MSc, Vancouver, Canada
 P.D. Robinson, MD, MRCPCH, FRACP, PhD, ATSF,
 Sydney, Australia
 L.G. Gochicoa-Rangel, PhD, MSci, México City, Mexico

- 201 **Longitudinal Multiple Breath Washout Testing to Monitor Lung Function After Paediatric Haematopoietic Stem Cell Transplantation/B.X.-M. Ha, Vancouver, Canada**
- 202 **A Single Center Experience of a Pulmonary Surveillance Program in Pediatric Patients With Allogeneic Hematopoietic Stem Cell Transplantation/P.C. Cheng, Indianapolis, IN**
- 203 **Lung Function in Patients With Fanconi Anemia/S.J. Rose, Cincinnati, OH**
- 204 **Airway and Impulse Oscillometry in Healthy Children: Is All Respiratory Oscillometry the Same?/H. Boas, Philadelphia, PA**
- 205 **Effect of Nusinersen on Respiratory Function in Paediatric Spinal Muscular Atrophy: 3 Year Follow-up/A. Chacko, Brisbane, Australia**
- 206 **Hyperpolarized ¹²⁹Xenon Magnetic Resonance Imaging (MRI) Ventilation Mapping in Pediatric COVID-19 Survivors/S. Munidasa, Toronto, Canada**
- 207 **Pulmonary Function and Cardiopulmonary Exercise Testing in Children and Young People With Post-COVID Persistent Dyspnoea/I. Makariou, London, United Kingdom**
- 208 **Diaphragmatic Dysfunction in Pediatric Patients After Lung Transplantation/J. Reyes Angel, Pittsburgh, PA**
- 209 **Relationship Between Intermediate Sweat Chloride Values and Pulmonary Function in Children and Adolescents/S.S. Krishnan, Valhalla, NY**
- 210 **Long Term Pulmonary Outcomes in Children With Congenital Lung Malformations/S. Shanmugarajan, Randwick, Australia**
- 211 **Full Infant Pulmonary Function Assessment Reveals a Predominantly Obstructive Phenotype in Former Premature Infants in the First Year of Life/A. Gileles-Hillel, Jerusalem, Israel**

- 212 **Lung Function in Multi-ethnic Cohort of Adolescents and Adults With History of Prematurity/N.J. Sanchez Solano, Dallas, TX**
- 213 **Comparison of Pneumotachometer and Digital Turbine Spirometry for Field-based Assessment in Children With Bronchopulmonary Dysplasia Participating in the AERO-BPD Study/L. Mukharesh, Boston, MA**
- 214 **Shepherd's Hook: Changes in Relative Growth of Airways Versus Lungs in Children With Asthma/A. Ahmed, Valhalla, NY**
- 215 **Electronic Stethoscope Lung Sounds Analysis Versus Spirometry to Detect Change With Bronchodilator Use in Pediatric Asthma Patients/A. Dodson, Los Angeles, CA**

BASIC • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

B28 SOLVING THE PUZZLE OF BRONCHIECTASIS AND NONTUBERCULOUS MYCOBACTERIA

9:00 a.m. - 11:00 a.m. Marriott Marquis Washington

Marquis Ballroom, Salons 3-4 (Level M2)

- Poster Viewing 9:00-9:45
- Discussion 9:45-11:00
- Chairing:** R. Thomson, MBBS, PhD, FRACP, Greenslopes, Australia
 C. Haworth, MD, Cambridge, United Kingdom
 A.J. Losier, MD, New Haven, CT
- 901 **Evolution of Antimicrobial Resistance in Mycobacterium Abscessus Isolated From Drinking Water/K. Patterson-Fahy, Brisbane, Australia**
- 902 **Water-quality Constituents Associated With Pulmonary NTM Infection Risk Among persons With CF: A Case-control Study Across the Coterminal U.S./E. Lipner, Rockville, MD**
- 903 **Characterising Pulmonary Microbial Communities in Mycobacterium Avium Complex Pulmonary Disease and Mycobacterium Abscessus Pulmonary Disease/K. Kumar, London, United Kingdom**
- 904 **Nontuberculous Mycobacteria Testing and Culture Positivity in the United States Based on Labcorp Data/J. Marshall, Rockville, MD**
- 905 **Characteristics of Bronchiectasis Patients Who Tested Positive for Coronavirus Disease 2019 - Data From the United States Bronchiectasis and Nontuberculous Mycobacterial Pulmonary Disease Research Registry/P.J. Mcshane, Tyler, TX**

- 906 **Prevalence of Non-tuberculous Mycobacterial Infection in Chronic Obstructive Lung Disease Patients With Abnormal Alpha-1 Antitrypsin Genotypes/R. Werne, Miami, FL**
- 907 **Radiological Pleuroparenchymal Fibroelastosis Pattern in Nontuberculous Mycobacterial Pulmonary Disease: A Multicenter Retrospective Study/H. Tanaka, Tokyo, Japan**
- 908 **Computer-aided Detection Chest X-ray Findings in People With Culture-confirmed Pulmonary Tuberculosis Versus Non-tuberculous Mycobacteria Infection in a Low-TB Incidence Setting/C. Geric, Montreal, Canada**
- 909 **Diagnosis of Mycobacterium Avium-intracellulare Complex (MAC) by Bronchial Lavage Fluid Combined With the Titers of Anti-glycopeptidolipid-core IgA Antibodies in the Sera of the Patients Suspected Pulmonary MAC Diseases/M. Seki, Hidaka City, Japan**
- 910 **Identification by Lipid Finger-print-based MALDI-TOF Method Using Biotyper Sirius for the Diagnosis of Mycobacterium Abscessus Complex/Y. Hoshino, Tokyo, Japan**
- 911 **Development of Subspecies-level Identification and Drug Resistance Prediction System for Mycobacterium Abscessus Species Using Multi-locus Sequence Typing/W. Arakaki, Nishihara, Japan**
- 912 **Development of an Nontuberculous Mycobacteria (NTM) Chest CT Score to Improve NTM-pulmonary Disease Diagnosis in Cystic Fibrosis/S.L. Martiniano, Aurora, CO**
- 913 **Clinical Features of Dominant Circulating Clones of Mycobacterium Abscessus Species in Non-cystic Fibrosis Patients in Japan and Taiwan/T. Kinjo, Nishihara, Japan**
- 914 **Clinical Features of Bronchiectasis Patients With Rheumatoid Arthritis: An Analysis of the Bronchiectasis Research Registry/L. Sullivan, San Diego, CA**
- 915 **Hypertonic Saline Use in Patients With Bronchiectasis: Analysis From the United States Bronchiectasis and NTM Research Registry/A. Basavaraj, New York, NY**
- 916 **Sarecycline Pharmacokinetics-pharmacodynamics in the Hollow Fiber Model of M. Avium Complex/S. Singh, Tyler, TX**
- 917 **In Vitro Susceptibility Testing of Imipenem- Relebactam and Tedizolid Against Australian Mycobacterium Abscessus Isolates/A.J. Burke, Brisbane, Australia**
- 918 **Variables Associated With Antibiotic Treatment Tolerance in Patients With Mycobacterium Avium Complex Lung Disease: A Retrospective Chart Review/M. Marmor, Stanford, CA**
- 919 **The Clinical Course of Mycobacterium Avium Complex Pulmonary Disease With Bacterial Co-infection at Diagnosis/M. Ito, Kiyose, Tokyo, Japan**
- 920 **A Qualitative Interview Study to Explore the Use of Adverse Event Mitigation Strategies Among Adults Receiving Amikacin Liposome Inhalation Suspension (ALIS) in Real World Settings/J. Ali, New Orleans, LA**
- 921 **Validating the BACES Mortality Score in Canadian Patients With Nontuberculous Mycobacterial Pulmonary Disease/M. Yan, Toronto, Canada**
- 922 **Mycobacterium Gordoniae in People With Bronchiectasis: More Than Just Contamination?/D. Condit, Farmington, CT**
- 923 **Peroxisome Proliferator Activated Receptor γ Coactivator-1 α (PGC-1 α) Activation to Enhance Macrophage Immune Function in Nontuberculous Mycobacteria (NTM) Infections/J.R. Frandsen, Omaha, NE**
- 924 **Pseudomonas Aeruginosa and Bronchiectasis: Pathogenicity and Immune Response in Patients Exacerbated and Not Exacerbated/C. Cabrera, Barcelona, Spain**

BEHAVIORAL • CLINICAL • TRANSLATIONAL
RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION
B29 EXCITING DEVELOPMENTS IN PULMONARY REHABILITATION
9:00 a.m. - 11:00 a.m. Walter E. Washington Convention Center
Room 144 A-C (Street Level)
Viewing 9:00-9:45
Summaries/Discussion 9:45-11:00
Chairing: R.A. Evans, MBChB, FRCP, PhD, Leicester, United Kingdom
A.W. Jones, PhD, Melbourne, Australia

- 301 **A Synchronous, Virtual Pulmonary Rehabilitation Program Is Safe and Efficacious, and Expands Geographic Catchment/E.S. Wan, Boston, MA**
- 302 **Assessment of Airway Clearance Therapy Usage and Outcomes in Post-operative Care - A Real World Evidence Study/J. Suggett, London, Canada**
- 303 **Outpatient Pulmonary Rehabilitation in Lung Transplant Candidates With Pulmonary Arterial Hypertension/M. Munawar, Toronto, Canada**
- 304 **Regular Exercise Interventions Support Cognitive Function Gain and Maintenance in Older Individuals With Stable COPD: A Scoping Review/D.E. Baez, Kingston, RI**
- 305 **Performance of Pulmonary Rehabilitation in a National Severe Asthma Cohort/I. Jarosch, Schoenau am Koenigssee, Germany**

- 306 **Feasibility and Efficacy of a Software Enabled Virtual Pulmonary Rehab With Remote Therapeutic Monitoring - Preliminary Findings/S.** Flynn, Altadena, CA
- 307 **NiwH Yizt'lyh Hilht'Iz Nets'Eelh'lyh - Strengthening Our Bodies: The Values of and Barriers to Physical Activity in Rural and Remote First Nations Communities in Northern British Columbia, Canada/S.** Chopra, Vancouver, Canada
- 308 **Lung Cancer Survivors View Telerehabilitation Following Curative Intent Therapy Both as a Convenience and Challenge: A Qualitative Study/D.** Ha, Aurora, CO
- 309 **Pulse Oximetry Integrated Into Smartphone With Global Distribution Meets Full FDA/ISO Standards for Clinical Use in Patient Assessment/S.** Browne, La Jolla, CA
- 310 **Aerobic Exercise Training Attenuates Cigarette Smoking Induced Harmful Effects on Skeletal Muscle in Animal Model/T.**K.H. Fung, Hong Kong, Hong Kong

CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

B30 BREATHE (IN THE AIR): STUDIES IN PULMONARY FUNCTION

9:00 a.m. - 11:00 a.m. **Marriott Marquis Washington**

Marquis Ballroom, Salons 9-10 (Level M2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: J.H.T. Bates, PhD, DSc, ATSF, Burlington, VT
A.A. Zeki, MD, Davis, CA
J.E. Pittman, MD, MPH, Saint Louis, MO

- 1001 **Volume-dependence of Reactance as a Measure of Ventilation Inhomogeneity in Cystic Fibrosis/T.**L. Blake, South Brisbane, Australia
- 1002 **Spectral and Intra-breath Oscillometry in Relation to Spirometric Impairment in Adult Cystic Fibrosis/P.**F. Medina, Montreal, Canada
- 1003 **The Effects of Obesity on Dynamic Hyperinflation and Expiratory Flow Limitation During a Cardiopulmonary Exercise Test in Children/C.**W. Nusekabel, Columbus, OH
- 1004 **Pulmonary Function Tests in Neonates With Congenital Heart Disease, a Pilot Study/H.**S. Leeds, Portland, OR
- 1005 **Investigating the Inspired Sinewave Test for the Assessment of Chronic Obstructive Pulmonary Disease/R.** Bruce, London, United Kingdom
- 1006 **Measuring the Effective Lung Volume, Dead-space Volume and Ventilatory Heterogeneity at the Bedside Using the Inspired Sinewave Technique in ARDS Animal Model/M.** Tran, Oxford, United Kingdom
- 1007 **Impulse Oscillometry in the Evaluation of Airway Hyperresponsiveness in Patients With Asthma/D.** Ge, Piscataway, NJ
- 1008 **Impact of the ERS/ATS 2021 Guidelines for Lung Function Interpretation/M.** Topalovic, Leuven, Belgium
- 1009 **Development and Validation of an Automated Algorithm for the Interpretation of Pulmonary Function Test/Y.**-C.T. Huang, Durham, NC
- 1010 **Sex Differences in Hemodynamic Response to Exercise in Patients With Myalgic Encephalomyelitis: Insights From Invasive Cardiopulmonary Exercise Testing/K.** Wichmann Madsen, Boston, MA
- 1011 **ME/CFS Pathophysiology Investigated by Invasive Cardiopulmonary Exercise Testing and Autonomic Function Testing/J.** Squires, Boston, MA
- 1012 **Predicting Exacerbation in the Adult Patient With Cystic Fibrosis Using a 1-minute Sit to Stand Test/G.**L. Stanley, New Haven, CT
- 1013 **Congruence Between Remote and In-person Spirometry in the Tucson Children's Respiratory Study/J.** Jarczyk, Tucson, AZ
- 1014 **Impact of Global Lung Function Initiative (GLI) Reference Equations on Total Lung Capacity (TLC) Interpretation in Patients of Different Ancestral Origins/T.** Herzog, Rochester, MN
- 1015 **The Global Lung Index: A More Accurate Representation of Disease Severity in Underrepresented Pulmonary Diseases/E.** Lynn, Dublin, Ireland
- 1016 **Improving Quality Control in Oscillometry: Repeatability, Efficiency and Accuracy/A.** Abufardeh, Halifax, Canada
- 1017 **Normalizing Spirometric Bronchodilator Responses/A.** Alexis, Miami, FL
- 1018 **Effect of Twice Daily Inhaled Albuterol on Cardiopulmonary Exercise Outcomes, Dynamic Hyperinflation, and Symptoms in Tobacco-exposed Persons With Preserved Spirometry and Air Trapping/M.** Arjomandi, San Francisco, CA
- 1019 **Postural Respiratory Mechanics in Children With Obesity/T.** Olojo, Columbus, OH
- 1020 **Assessing Ventilation Heterogeneity From Measurement of D_LCo Using Rapid Gas Analysis/D.**A. Kaminsky, Burlington, VT

- 1021 **Comparison of the Old (2005) and New (2021) ATS/ERS Methods for Assessing Bronchodilator Response (BDR) by FEV1 in a Clinical Trial for Asthma/K. Mccarthy, Matthews, NC**
- 1022 **Feasibility of Achieving the 2019 ATS-ERS Spirometry FIVC Acceptability Standard Among Patients With Nonspecific Pattern of Lung Dysfunction/R. Eggleston, Rochester, MN**
- 1023 **Application of GLI Global Spirometry Reference Equations to a Large Population Across a Multi-site Academic Healthcare System/A. Kanj, Rochester, MN**
- 1024 **Proportional Tidal Volume Variation During Cardio-pulmonary Exercise Testing to Diagnose Dysfunctional Breathing in Patients With Exertional Dyspnoea/M.H. Brutsche, St. Gallen, Switzerland**
- P686 **Circadian Clock Rev-erβ Role in the Recruitment of Immune Cells Into the Lung During Chronic House Dust Mite-induced Allergic Asthma/S.K. Duraisamy, Kansas City, KS**
- P687 **Pulmonary Hypertension Is Associated With Higher Mortality and Worse Outcomes in Asthma Exacerbation Related Hospitalizations/A. Aboelnasr, Cincinnati, OH**
- P688 **Atrial Fibrillation, Supraventricular Tachyarrhythmias and Ventricular Arrhythmias Are Associated With Higher Mortality and Worse Outcomes in Asthma Exacerbation Hospitalizations/A.A. Aboelnasr, Cincinnati, OH**
- P689 **Increased Platelet Counts Are Associated With Female Sex and Asthma Severity/N. Solanki, Cleveland, OH**
- P690 **Associations Between Asthma Control, Adherence and Short-Acting Beta₂-Agonist (SABA) Use in Patients With Uncontrolled Asthma Using a Maintenance and Reliever Digital System (MRDS)/G. Mosnaim, Evanston, IL**
- P691 **The Effect of Chronic Allergic Lung Inflammation on Gut Microbiota and Depression in Mice/A. Kanaya, New York, NY**
- P692 **Gasdermin B Is an RNA Sensor That Promotes Interferon Response and Airway Inflammation/T. Liu, Boston, MA**
- P693 **BNT162b2 mRNA Covid-19 Vaccine Increases the Sensitivity to Histamine in a Human Ex Vivo Model of Severe Eosinophilic Asthma/L. Calzetta, Parma, Italy**
- P694 **BNT162b2 mRNA Covid-19 Vaccine Increases the Contractility to Parasympathetic Activation in a Human Ex Vivo Model of Severe Eosinophilic Asthma/L. Calzetta, Parma, Italy**
- P695 **Particulate Matter Induces Lung Inflammation in Healthy Mice and Exacerbates Experimental Asthma Model Animals/I.C. Tiberio, Sao Paulo, Brazil**
- P696 **Rhinovirus Infection Induces Endothelin-1 Secretion From Human Bronchial Epithelial Cells and in Mouse Models of Allergic Airway Disease/A.B.C. Dy, Boston, MA**
- P697 **Phenotyping Nasal Epithelial Cells in Severe Eosinophilic Asthma Patients/K.L. Raby, London, United Kingdom**
- P698 **Modulating the Level of ICS in Triple ICS/LABA/LAMA FDC: Effect Against Inflammation in a Human Ex Vivo Model of Severe Eosinophilic Asthma/P. Rogliani, Roma, Italy**
- P699 **Periostin Induction by MicroRNAs Associated With Neutrophilic Airway Inflammation in Asthma/V. Dubovik, New Haven, CT**
- P700 **The Role of Myeloid-derived Suppressor Cells in a Murine Model of Influenza Virus-induced Asthma Exacerbation/S. Kolahian, Marburg, Germany**
- P701 **Long-term Metformin Use Is Not Associated With Lower Risk of Asthma Exacerbations/P. Zhang, Cleveland, OH**

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

B31 ASTHMA: FROM MICE TO MEN, AND BACK AGAIN

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area G, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P679 **Precision Medicine for Asthma and Eosinophilic Inflammation in Exacerbations/E. Scott, Baltimore, MD**
- P680 **Role of Type 2 Immunity in the Context of IFN-γ^{High}/Type 1^{High} Severe Asthma/S.L. Kale, Pittsburgh, PA**
- P681 **Glucagon Like Peptide-1 Receptor Signaling Suppresses Pulmonary Macrophage Migration Inhibitory Factor and CD74 Expression/J.T. Womble, Durham, NC**
- P682 **A Phase 1 First-in-Human Single Ascending-dose Study With a Novel Antibody to the Human Thymic Stromal Lymphopoietin Receptor/A. Deykin, Waltham, MA**
- P683 **Novel Machine Learning Identifies Five Asthma Phenotypes Using Cluster Analysis of Real-world Data/C. Wu, Cleveland, OH**
- P684 **Chronic Allergic Lung Inflammation Induced by Intranasal House Dust Mite Antigen Causes Suppression of Neuronal Activity in Mice/M. Trichas, New York, NY**
- P685 **Functional Analysis of Sputum Eosinophil Subpopulations in Children With Asthma/G. Wilson, New Haven, CT**

- P702** The Validity of the Asthma Daytime Symptoms Diary (ADSD) and the Asthma Nighttime Symptoms Diary (ANSD) As Measures of Symptoms in Patients With Moderate-to-Severe Asthma/T. Keeley, Brentford, Middlesex, United Kingdom
- P703** The Use of Depot Formulation Systemic Steroid Injections in Young Adults With Asthma - a Nationwide Study/K.E.J. Håkansson, Hvidovre, Denmark
- P704** MiRNAs and Baseline Asthma Daytime Symptoms in Two Pediatric Cohorts/B. Desai, La Jolla, CA
- P705** Enhanced Blocking toward TSLP Variants at Lung Barrier Protects against Experimental Asthma/C. Guo, Hangzhou, China
- P706** Plant Protease Inhibitors in Mice ACO Model: Comparison With Corticosteroid/J. Joao, Sao Paulo, Brazil
- P707** Comparison of Extrafine Beclomethasone Dipropionate/formoterol Fumarate (BDP/FF) Dry Powder Inhaler (DPI) and Pressurized Metered-dose Inhaler pMDI in Chinese Patients With Asthma: The FORTUNE Study/J. Zheng, Guangzhou, China
- P708** Assessment of Rescue Medication Use According to the Asthma Control Questionnaire 6-items (ACQ-6) Vs Daily E-diaries: A Pooled Analysis of the Trimaran and Trigger Studies/D. Singh, Manchester, United Kingdom
- P709** Anti-alarmins for Severe Asthma: A Systematic Review and Meta-analysis/T. Ho, Hamilton, Canada
- P710** α and β Tryptase Is Released From Mast Cells by IgE Cross-linking and Increased α/β Ratio Is Associated With Diminished PAR-2 Activity/N. Rathore, South San Francisco, CA
- P711** Cross-Sectional Associations Between the Chronic Airways Assessment Test and Clinical Characteristics in Asthma and/or COPD in the NOVELTY Study/P.W. Jones, Brentford, United Kingdom
- P712** Associations Between the Chronic Airways Assessment Test and History of Physician-Reported Exacerbations in Asthma and/or COPD in the NOVELTY Study/P.W. Jones, Brentford, United Kingdom
- P713** Characterization of OCS Use Among Patients With Physician-Assigned Asthma and/or COPD in NOVELTY/C. Janson, Uppsala, Sweden
- P714** Blocking Either the IL-33 or IL-4R α Pathway Attenuates Inflammatory Mediators of Airway Disease/S. Asrat, Tarrytown, NY
- P715** The Role of TRPA1 Channel in Cold Air-Induced Aggravation of Airway Inflammation/Y. Dotake, Kagoshima-shi, Japan
- P716** Early Outcomes and Comparisons of Biologic Therapy for Severe Asthma in a Pediatric Cohort/N. Koka, Little Rock, AR
- P717** Reduced Peripheral CD5⁺Regulatory B Cells Are Associated With Sputum Autoantibodies in Eosinophilic Asthma/N.S. Tan, Hamilton, Canada
- P718** Diet Regulation of Immunometabolism in Asthma/S.A.A. Comhair, Cleveland, OH
- P719** Different Airway Mucus Plug Phenotypes in Fatal and Non-Fatal Asthma/M. Liegeois, San Francisco, CA
- P720** Mitochondrial Hydrogen Peroxide Is Required for Preventing Allergic Airway Disease in Early Life/H. Yuan, Pittsburgh, PA
- P721** Risk of COVID-19 Incidence and Severity Among Patients With Severe Asthma Receiving Therapy With Monoclonal Antibodies/R. Dhand, Knoxville, TN
- P722** Genetic Risk Profiling for Indoor and Outdoor Aeroallergens Sensitization in a French-Canadian Family Asthma Cohort/M.-P. Bouchard, Saguenay, Canada
- P723** Paradoxical Bronchodilator Response Is Associated With Increased Risk of Asthma Exacerbations/B.F. Fakhry, Cleveland, OH
- P724** Efficacy of As-needed Use of Albuterol-Budesonide in Patients With Moderate-to-Severe Asthma Who Are Adherent to Maintenance Therapy/A. Papi, Ferrara, Italy

CLINICAL

THEMATIC POSTER SESSION

B32 WHEEZES, HIVES, AND THERAPIES GONE AWRY

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area G, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion

12:15-1:15 authors will be present for discussion with assigned facilitators.

P726 Beginning With An Ace Of Spades And Ending With A Clot Of Hearts- Hypereosinophilic Syndrome With Left Ventricular Thrombus/B. Amir-Kabirian, Charleston, WV**P727** When Addiction Medicine and Pulmonary Medicine Intersect: Two Cases of Eosinophilic Pneumonia Secondary to Intramuscular Naltrexone/A.G. Ryden, Salt Lake City, UT**P728** A Case of Successful Use of Benralizumab in a Patient With Chronic Eosinophilic Pneumonia (CEP)/A. Jain, Valhalla, NY

- P729 Severe Cutaneous Adverse Reactions In Pirfenidone-treated Patients: A Case Series/S.** Janiczak, Silver Spring, MD
- P730 An Unusual Case of Hymenoptera Venom-induced Angioedema/H.** Sajjad, Lafayette, LA
- P731 What Is Next? - The Role Of Fresh Frozen Plasma In Refractory Angioedema/L.** Sangha, Harrisburg, PA
- P732 A Rare Case Of Samter's Triad Due To Acetaminophen/A.S.** Shaik, Darby, PA
- P733 Desensitization Protocol To Fam-trastuzumab Deruxtec-an-nxki (Enhertu)/S.** Budhan, East Setauket, NY
- P734 Anaphylaxis to Intravenous Methylprednisolone in Status Asthmaticus- A Case Report/S.** Sharma, New York, NY
- P735 Drug Reaction With Eosinophilia And Systemic Symptoms (dress) Syndrome With Shock In The Setting Of Nitrofurantoin/S.S.** Rijal, West Reading, PA
- P736 A Rare Case of Dalbavancin Induced Anaphylaxis/M.I.** Bilal, Pittsburgh, PA
- P737 Immune Sensitization and Subsequent Anaphylaxis to an Ultrasound Enhancing Agent in Echocardiography/E.S.** Mikhail, Flint, MI
- P738 A Case of Severe Lactic Acidosis in Nut-Induced Anaphylaxis/A.** Zviman, Stanford, CA
- P739 Anaphylactic Shock With Ketorolac-rare Case/S.T.** Kollu, Bronx, NY
- P740 Melatonin: Harmless Supplement? A Case Of Angioedema And Anaphylaxis/N.** Kumar, Miami, FL
- P741 Hypersensitivity Pneumonitis With Elevated IgE- A Rare Subtype/A.** Chakraborti, Newark, NJ
- P742 An Atypical Presentation Of Allergic Bronchopulmonary Aspergillosis After COVID-19 Infection/R.** Diaz Lankenau, Miami, FL
- P743 Dupilumab as a Last Resort for Allergic Bronchopulmonary Aspergillosis, Effective Even After Other Biologics Have Failed/P.** Lamothe, Atlanta, GA
- P744 Dual Anti-IgE and Anti-IL5 Therapy in Treatment-Resistant Allergic Bronchopulmonary Aspergillosis: A Case Series/A.** Yenepalli, San Jose, CA
- P745 Stop Blaming The Chickens: A Case Report on the Overlap and Differentiation Between Asthma and Hypersensitivity Pneumonitis/Y.** Abouleish, Norfolk, VA
- P746 Unconventional Diagnosis of Asthma By Bronchoscopy/A.A.** Rodriguez, Philadelphia, PA
- P747 Steroid-sparing Effects of Dual Biologic Therapy in Refractory ABPA/M.L.** Curtiss, Birmingham, AL
- P748 Airway B-Lymphoma in a Woman With Difficult-to-Control Allergic Asthma/P.M.** Cavalcante Neto, Sao Paulo, Brazil
- P749 Theophylline: Bad for the Heart, the Brain, the Gastrointestinal Tract, and Modern-Day Medicine/S.S.** Kommineni, Harlan, KY
- P750 A Case of Albuterol-induced Lactic Acidosis in Asthma Exacerbation/K.** Kumar, Baltimore, MD
- P751 A Rare Case Of Congenital Defects In The Newborn Of A Patient With Uncontrolled Asthma On Dual Omalizumab-dupilumab Biological Therapy/P.-A.** Reed, Sherbrooke, Canada
- P752 Diffuse Panbronchiolitis in a Patient With Ulcerative Colitis Treated With Ustekinumab/M.** Marmor, Stanford, CA
- P753 Phenotypic Alterations Causing Delayed Diagnosis in Hyper IgE Syndromes: A Case of a Novel IL6ST Heterozygous Mutation Associated With Allergic Bronchopulmonary Aspergillosis/T.** Andersen, Los Angeles, CA
- P754 Trying It All: A Case of Chronic Eosinophilic Pneumonia and Chronic Spontaneous Urticaria/V.** Khazar, South Setauket, NY
- P755 Scratching The Surface: Eosinophilic Granulomatous Polyangiitis Successfully Managed With Mepolizumab/M.** Sridhar, Birmingham, AL
- P756 A Manifestation of Pericardial Effusion in Seronegative Antinuclear Antibody Hydralazine Induced Lupus Syndrome/C.** Burke, Olympia Fields, IL
- P757 Gift of the Anemio: Belimumab and Mycophenolate Mofetil for Management of Shrinking Lung Syndrome/M.J.** Hamblin, Kansas City, KS

BEHAVIORAL • CLINICAL

THEMATIC POSTER SESSION

B33 TOPICS IN QUALITY IMPROVEMENT AND IMPLEMENTATION SCIENCE

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area K, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

P1093 Effect of Intensive Training and Education of Healthcare Workers on the Maintenance of Venous Access Devices in Critically Ill Patients- a Quality Improvement Project/R. Sharma, Chandigarh, India

- P1094** **Creation and Expansion of an Intermediate Care Unit to Improve ICU Capacity: A Quality Improvement Study and Retrospective Review/E.A. Kistler, Boston, MA**
- P1095** **Impact of Pulmonary Embolism Response Team Consultation on Patient Outcomes at a Single Tertiary Care Center/A.N. Fuher, Aurora, CO**
- P1096** **Clinical Profile of Patients Included in the Hospital Readmissions Reduction Program: A Quality Improvement Study/C.X. Huang, Boston, MA**
- P1097** **Diagnostic Woes: The Challenge of Spotting Sepsis/T. Clouse, Ann Arbor, MI**
- P1098** **COPD Educator Program Improves Escalation to Triple Therapy at Discharge for Patients Hospitalized With COPD Exacerbation/D. Witt, Chapel Hill, NC**
- P1099** **Higher Electronic COPD Assessment Test (eCAT) Scores Are Associated With an Increased Number of Acute Exacerbations Observed Among Individuals With COPD Receiving Care at M Health Fairview (MHF)/N. Gaeckle, Minneapolis, MN**
- P1100** **Inspiring Health Advances in Lung Care (INHALE): New State-wide Quality Improvement Infrastructure to Improve Asthma and COPD Care in Michigan/N.L. Lugogo, Ann Arbor, MI**
- P1101** **Alpha-1 Antitrypsin Inpatient Ordering Practices: A Quality Improvement Project/B. Ratakonda, Augusta, GA**
- P1102** **Clinical Audit of Asthma Management Based on Standardised Asthma Proforma Use/D. Ganesan, Galway, Ireland**
- P1103** **Effectiveness of Community Health Worker Intervention at Dayton Children's Hospital at Decreasing Emergency Department Visits and Hospitalization Rates for Pediatric Asthma Patients/G. Evans, Dayton, OH**
- P1104** **Designing a Decision Support System to Screen for Glucocorticoid Induced Osteoporosis in Outpatient Clinic a Quality Improvement Project/Z. Zia, Cleveland, OH**
- P1105** **Institutional Support Required to Operate an Urban Comprehensive Lung Cancer Screening Program for Lung Nodules Coupled With Detection of Comorbid Conditions: Temple Healthy Chest Initiative (THCI)/Z.B. Pino, Philadelphia, PA**
- P1106** **Inpatient Capture: Inpatient Lung Cancer and Tobacco Screening in an Urban Community: A Quality Improvement Project to Improve Lung Cancer Screening Utilization and Smoking Cessation Referral Rates in Vulnerable Populations/K. Ghosh, New York, NY**
- P1107** **Promoting Lung Cancer Screening in High-Risk Populations/N. Khouzam, Chicago, IL**
- P1108** **Use of a Reminder System to Improve Lung Cancer Screening in an Urban Veterans Hospital/E. Pacheco, Chicago, IL**
- P1109** **Utilizing Non-invasive Open Ventilation and Non-invasive Ventilators in Advanced Lung Disease/F. Zeba, Lebanon, NH**
- P1110** **Improving the Complication Rate and Follow-up for Patients With Airway Stenting, a QI Project/J.D. Duke, Rochester, MN**
- P1111** **How Can We Meet the Needs of People Living With HIV/AIDS in a Low- and Middle Country for Tobacco Smoking Cessation? Steps Taken Through a Feasibility Study in Brazil/M. Ribeiro, Londrina, Brazil**
- P1112** **Optimizing Wildfire Smoke Messaging in British Columbia Through Community Feedback/E. Shellington, Vancouver, Canada**
- P1113** **Using Program Websites to Assess Diversity, Equity and Inclusion Curricula Within Pulmonary and Critical Care Programs in the United States/D.N. Lapoint, Buffalo, NY**
- P1114** **Improving Pneumococcal Vaccination Rates in a Fellow Run General Pulmonary Clinic/S. Murphy, New York, NY**
- P1115** **Scaling Up the ICU-pause: A Multi-center Qualitative Study of Intensivists Regarding Implementation of a Structured ICU Transitions Framework/E.G. Cornell, San Francisco, CA**
- P1116** **Views of Proactive Outreach for Tobacco Cessation Among Patients With Chronic Obstructive Pulmonary Disease Who Smoke: A Mixed Methods Study/A.C. Melzer, Minneapolis, MN**
- P1117** **Sustainment of Prone Positioning in ICU Practice for COVID-19 Acute Respiratory Distress Syndrome (ARDS)/C.H. Hochberg, Baltimore, MD**
- P1118** **Adaptations and Uncertainties: Clinicians' Experiences With Prone Positioning for COVID-19 Acute Respiratory Distress Syndrome (ARDS)/C.H. Hochberg, Baltimore, MD**
- P1119** **Using a Dissemination and Implementation Approach to Understand and Adapt a Multi-sector, Evidenced-based Community Asthma Program on the Navajo Nation/A.A. Lowe, Tucson, AZ**
- P1120** **Findings From the Process Evaluation of the Community Asthma Program on the Navajo Nation/P. Ravi, Tucson, AZ**
- P1121** **Decision-Making Among Laypeople and Healthcare Workers in Scarce Resource Allocation Policy Development/C. Yumori, Los Angeles, CA**
- P1122** **Brazilians' Perspectives on Adopting Measures to Prevent and Control Respiratory Infectious Diseases: A Qualitative Study Using In-depth Interviews and Theoretical Frameworks/T.A. Santino, Campina Grande, Brazil**

- P1123 **Implementation of a Pleural Pathway**/G.C. Michaud, Tampa, FL
- P1124 **Implementation Considerations Identified by Community Partners Prior to Initiation of a Randomized Clinical Trial in Federally Qualified Health Centers**/M. George, New York, NY

BEHAVIORAL • CLINICAL
THEMATIC POSTER SESSION
B34 HEALTH SERVICES AND EPIDEMIOLOGY RESEARCH IN OBSTRUCTIVE LUNG DISEASE

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area K, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1126 **Improved Inhaler Handling After Repeated Inhalation Guidance for Elderly Patients With Bronchial Asthma and Chronic Obstructive Pulmonary Disease**/O. Usami, Kurihara, Japan
- P1127 **Adherence to Controller Therapy Among Patients With Severe Asthma Enrolled in a 6-month Digital Intervention**/L. Elsey, Manchester, United Kingdom
- P1128 **Asthma Outcome: Functional Medicine in Asthma Study in Relationship to Standard Asthma Care**/P.S. Wnek, Cleveland, OH
- P1129 **The Association of Asthma Symptom Perception With Inhaled Corticosteroid Dosing in Older Adults With Asthma**/N. Agrawal, New York, NY
- P1130 **Use of Oral Corticosteroids in Asthma: A Cross-sectional Survey**/A.W. Jones, Melbourne, Australia
- P1131 **Regional Differences in Prescribing Benralizumab for Asthma Treatment in Japan**/N. Kobayashi, Yokohama, Japan
- P1132 **Outcomes of Patients With Severe Asthma Not Meeting Criteria for a Biologic Prescription in a Multispecialty Clinic**/P. Palmon, Madison, WI
- P1133 **A Novel Approach to Integrated Asthma Care in the Community: Asthma MDT Clinic**/R. Gill, London, United Kingdom
- P1134 **Impact of Obesity on Spirometry Values in Patients With Asthma**/A.A. Alqarni, Jeddah, Saudi Arabia
- P1135 **Sepsis Increases Rates of Mortality and Mechanical Intubations in Patients Admitted With Status Asthmaticus, a Nationwide Study**/M. El Labban, Mankato, MN
- P1136 **Improving Children's Access to Unassigned Albuterol at School by Establishing a Multi-city, Multi-disciplinary Collaboration to Align Texas Policy With National Recommendations**/L.C. Allsopp, Fort Worth, TX
- P1137 **Cost Effectiveness of Portable Hepa Filter Air Cleaners on Asthma Exacerbations: Engaging Stakeholders in Model Development**/E. Shellington, Vancouver, Canada
- P1138 **Integrated Knowledge Translation to Enable Coordinated Action for Improved Asthma and Chronic Obstructive Pulmonary Disease Prevention and Care**/A. Collins-Fairclough, Vancouver, Canada
- P1139 **Comparing the Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) and Interstitial Lung Disease (ILD) in England and Wales (2004-2019) Using a Harmonised Approach in the Clinical Practice Research Datalink (CPRD) and Secure Anonymised Information**/S. Cook, London, United Kingdom
- P1140 **Survey-identified Experiences of Pre-diagnosis and Diagnosis Processes Amongst Patients With COPD, Asthma, Interstitial Lung Disease and Bronchiectasis**/X. Zhang, London, United Kingdom
- P1141 **Identifying COPD Exacerbations Using Administrative Claims Database: A Review of Current Literature**/P. Veeranki, Eden Prairie, MN
- P1142 **Barriers to Treatment Optimization in COPD: A Physician Survey**/K. Wroblewski, Philadelphia, PA
- P1143 **Integrating the COPD Action Plan Into the Clinic**/J.R. Dahl, Tallahassee, FL
- P1144 **Clinical Outcomes After Multi-Disciplinary Evaluation for Lung Volume Reduction Surgery for Patients With Chronic Obstructive Pulmonary Disease**/A. Nathani, Cleveland, OH
- P1145 **Referral Pattern for Bronchoscopic Lung Volume Reduction in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation**/G. Habib, Staten Island, NY
- P1146 **The Association Between Oxygen Use and SGRQ Scores Over Time in COPD**/Gene/J.J. Swigris, Denver, CO
- P1147 **Development of a Stoicism and Cautiousness Questionnaire for COPD and Its Associations With Care-seeking, Social Support and Psychological Symptoms**/V.S. Fan, Seattle, WA
- P1148 **The Impact of Treated and Untreated Chronic Obstructive Pulmonary Disease Exacerbations on Health-related Quality of Life**/N. Wang, Seattle, WA
- P1149 **Analysis of Factors Associated With Reduction of Sedentary Time After Treatment With Bronchodilators in Treatment-naïve COPD Patients**/K. Takahashi, Saga, Japan

- P1150 **Perceptions of Clinical Team Members Regarding a Web-based Physical Activity Intervention for COPD: A Mixed Methods Study**/S.A. Robinson, Bedford, MA
- P1151 **Provider Behaviors in Addressing Physical Inactivity in Adults With Asthma**/A. Bag, Englewood, NJ
- P1152 **Challenges and Opportunities in Conducting Real-world Chronic Obstructive Pulmonary Disease Studies in a US Healthcare Network: A Qualitative Feasibility Assessment**/A. Rabe, Cambridge, United Kingdom
- P1153 **Challenges and Opportunities With Recruiting and Enrolling Diverse Us Hospitals for a Cluster Randomized Trial of COPD Transition of Care Programs**/V.G. Press, Chicago, IL
- P1154 **Dupilumab Real-world Effectiveness (RWE) in Reducing Healthcare Resource Utilization Among Moderate-to-Severe Asthma Patients**/B.D. Modena, La Jolla, CA
- P1155 **Reducing Potential Carbon Footprint by Maximizing the Benefits of the Inhaler**/M. Nagel, London, Canada
- P1156 **Sociodemographic Predictors of Digital Health Data Sharing and Concern With Remote Care in Asthma and COPD Patients**/D. Tellez, San Diego, CA
- P1157 **External Validation of a Machine Learning Tool to Predict 90-day Readmission for Patients With Chronic Obstructive Pulmonary Disease**/S. Chokkara, Chicago, IL
- P1158 **Prevalence of Airflow Limitation in a Community-based Spirometry Screening Initiative**/W. Chan, Singapore, Singapore

- P1162 **Financial Wellness Education in U.S. Pulmonary and Critical Care Medicine Fellowship Programs**/D. Krutsinger, Omaha, NE
- P1163 **Effectiveness of Training in Renal Pocus for Acute Kidney Injury: A Novel Curriculum for Internal Medicine Residents**/Y. Ishisaka, New York, NY
- P1164 **Abdominal Point-of-care Ultrasound: A Multimodal Approach**/S. Shah, New York, NY
- P1165 **End of Life Conversations in the Intensive Care Unit: Improving Resident Comfort**/B. Fitzgerald, Aurora, CO
- P1166 **Experiential Model of Near-Peer Debriefing**/J. Chandler, Kansas City, KS
- P1167 **Self-directed Learning Strategy for a Pulmonary and Critical Care Medicine Program**/M.U. Syed, Houston, TX
- P1168 **Design and Implementation of a Year-long Curriculum to Train the Next Generation of Anti-tobacco Advocates and Tobacco Researchers**/S. Perera, La Jolla, CA
- P1169 **Burnout Among Non-internal Medicine Residents Compared to Internal Medicine Residents Within the Tertiary Care Medical Intensive Care Unit**/A.N. Michaels, Chapel Hill, NC
- P1170 **The Impact of a Medical Intensive Care Unit Point of Care Ultrasound Curriculum for Internal Medicine Residents**/M. Horn, St. Louis, MO
- P1171 **Pulmonary Fellows Need More Sleep: A Sleep Disordered Breathing Curriculum for Pulmonary Fellows**/B. Stone, Pittsburgh, PA

BEHAVIORAL • CLINICAL

THEMATIC POSTER SESSION

B35 IMPROVING MEDICAL EDUCATION IN PULMONARY, CRITICAL CARE, AND SLEEP

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**
Area K, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1160 **Survey of Smoking Behavior, Perception and General Knowledge Regarding E-cigarette Among Medical Students in Thailand**/A. Vajirakaphan, Bangkok, Thailand
- P1161 **Evolving Attitudes Towards Self-care and a Wellness Curriculum in a Pulmonary and Critical Care Medicine Fellowship Training Program Pre and Post-COVID-19 Pandemic**/R. Potter, New York, NY

CLINICAL

THEMATIC POSTER SESSION

B36 THE GOOD, THE BAD, AND THE UGLY: DRUG TOXICITY CASE REPORTS

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**
Area E, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P477 **An Unusual Case of Acute Eosinophilic Lung Disease in the Setting of Adalimumab Use**/A. Patel, Springfield, MA
- P478 **A Case of Steroid Unresponsive Bortezomib-induced Pneumonitis**/N. Moallem, Farmington, CT
- P479 **Damned if You Do, Damned if You Don't: PD-1 Inhibitor Induced Pulmonary Plight**/S. Kakulavarapu, Atlantis, FL

- P480 An Unusual Case Of Pulmonary Opacities Following Cryoablation/R. Gendron, Sherbrooke, Canada**
- P481 Cyclosporine Induced Organizing Pneumonia: When the Immunosuppressant Causes Inflammation/H. Singh, Jackson, MI**
- P482 Cytarabine Induced Lung Toxicity/I. Khatim, Albany, NY**
- P483 Interstitial Pneumonitis From Gemcitabine and Oxaliplatin Combination/A. Farrukh, St. Louis, MO**
- P484 Seeing Through the Haze: A Rare Case of Nucleoside Analog-Induced Granulomatous Interstitial Lung Disease/B.A. Bagley, Indianapolis, IN**
- P485 Association of Imatinib and Diffuse Alveolar Hemorrhage/J.H.J. Jun, San Diego, CA**
- P486 Lenalidomide Induced Pneumonitis- A Rare Etiology/A. Tameez Ud Din, Buffalo, NY**
- P487 Lenalidomide Induced Lung Injury; A Rare But Debilitating Medication Side Effect/S. Sultan, Philadelphia, PA**
- P488 A COVID-19 Mimic: Palbociclib-Induced Pneumonitis/C. Asuzu, Bronx, NY**
- P489 Rapidly Developing Radiation Pneumonitis: A Case of Caution/T.M. Mirza, Harrisburg, PA**
- P490 A Rare Case of Trabectedin Associated Pulmonary Edema/K. Lin, Danbury, CT**
- P491 Pulmonary Eosinophilic Wildfire - A Complication of Amiodarone Toxicity/S. Chaparala, Athens, GA**
- P492 Not Your Typical Amiodarone Toxicity Presentation/A. Schwegman, Minneapolis, MN**
- P493 A Diagnostic Dilemma: COVID-19 Infection Versus Interstitial Lung Disease/M.A. Amjad, Scranton, PA**
- P494 A Case Of Recurrent Pulmonary Toxicity Due To Amiodarone/J. Torres, Kingwood, TX**
- P495 Black Bronchoscopy: Finding a Common Answer/R. Ahmed, Lahore, Pakistan**
- P496 A Case Of Daptomycin Induced Acute Eosinophilic Pneumonia/D. Patel, Brooklyn, NY**
- P497 Daptomycin-Induced Acute Eosinophilic Pneumonia in Context of Osteomyelitis and Discitis Treatment/B. Liu, Saint Joseph, MI**
- P498 A Daptomycin Dilemma/B. Ravichander, Harrisburg, PA**
- P499 A Tale of a Drug That Killed a Bug but Caused Pneumonia: A Case Report of Daptomycin Induced Eosinophilic Pneumonia/R. Sharma, Detroit, MI**
- P500 Daptomycin Induced Acute Eosinophilic Pneumonia/J.R. Israel, Sacramento, CA**
- P501 Doxycycline Alert! A Rare Case of Respiratory Failure Following Chemical Pleurodesis/M. Rehan, Atlantis, FL**
- P502 Bloody Hydra-LA-Zones/S. Kumar, Mobile, AL**
- P503 Hydralazine-induced ANCA Associated Vasculitis Presenting With Hemoptysis/J.W. Burgei, Sayre, PA**
- P504 Medications Are Not Always Innocent: A Case of Hydralazine Induced Pneumonitis/R. Ali, Harrisburg, PA**
- P505 Hydralazine Induced Pleural and Pericardial Effusion/A. Mahmoud, Paterson, NJ**
- P506 Methimazole Induced Eosinophil Predominant Exudative Pleural Effusion: A Rare Complication of the Thionamides/T. Rahman, St Louis, MO**
- P507 Minocycline-induced Pleuropericarditis/J. Bahgat, Farmington, CT**
- P508 Methotrexate-Induced Hypersensitivity Pneumonitis/F. Heis, Long branch, NJ**
- P509 Methotrexate-Induced Interstitial Pneumonitis In A Patient With Ulcerative Colitis/C. Espinosa, Miami Beach, FL**
- P510 Why Is This 70-year-old Drug Still Being Prescribed For Urinary Tract Infections? A Case Of Nitrofurantoin-induced Interstitial Lung Disease/C. Park, Honolulu, HI**
- P511 Giant Cell Interstitial Pneumonitis As A Rare Manifestation Of Chronic Nitrofurantoin Lung Toxicity/M. Zane, Pontiac, MI**
- P512 Rotten Rituximab: Rituximab Related ILD/B.S.K.R. Sabbula, East meadow, NY**
- P513 Rituximab-Induced Lung Injury and a Possible Cause of Hypoglycemia/Z.K. Ng, Lafayette, LA**
- P514 Pain Intolerance Versus Respiratory Distress: A Case of Suboxone Induced Pulmonary Edema/O.S. Bawa, Harlan, KY**
- P515 Non Thrombotic Pulmonary Embolism Improved With Direct Oral Anticoagulant/M. Dufour, Montreal, Canada**
- P516 Acute Eosinophilic Pneumonia Attributed to Experimental "Personalized Immunotherapy"/I.D. Bentley, Columbus, OH**
- P517 Non-ARDS Chloramine Induced Lung Injury Managed By Venovenous Extracorporeal Membrane Oxygenation (ECMO): A Novel Approach/U. Hochfeld, Hackensack, NJ**
- P518 A Crack in the Lungs Keep Extending/C.R. Phang, Salisbury, MD**
- P519 A Case of a Ferrous Sulphate Tablet Aspiration Leading to Bronchial Stenosis/S. Okamori, Tochigi, Japan**
- P520 Transfusion Related Acute Lung Injury (TRALI) Induced By Intravenous Immunoglobulins (IVIG)/R. Mehreen, Abington, PA**
- P521 A Case of Sclerosing Mesenteritis and Treatment-Induced Pneumonia Complicated by Post-infectious Pulmonary Fibrosis/A. Alam, Everett, WA**

CLINICAL

THEMATIC POSTER SESSION

B37 **ILD CASE REPORTS: THE SPECTRUM FROM DIAGNOSIS TO TREATMENT**9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area E, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session **11:30-1:15****Discussion:** **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P523** "scar"cinoma: When A Scar Begets More Than Just A Scar/A. Mittal, Danville, PA
- P524** Pirfenidone-induced Phototoxic Cutaneous Reaction/M. Agustin, Dededo, Guam
- P525** Acute Exacerbation Of Idiopathic Pulmonary Fibrosis In A Patient With Lung Cancer On Immunotherapy And After Video-assisted Thoracoscopic Surgery/C. Irons, Cleveland, OH
- P526** When Aspergillus Hits a Rare Diagnosis: Refractory Hemoptysis in a Patient With Asymmetric Pleuroparenchymal Fibroelastosis/R. Jha, Youngstown, OH
- P527** Incidentally Identified Early Pleuroparenchymal Fibroelastosis in a Patient Planned for Stem Cell Transplant/C. Christian, Chicago, IL
- P528** Pleuroparenchymal Fibrosis in the Setting of Mycobacterial Infection/T.G. Dyster, San Francisco, CA
- P529** Subcutaneous Emphysema As A Life Threatening Presentation Of Fibrosing Interstitial Lung Disease/A. Makadia, Corpus Christi, TX
- P530** Pneumothorax With Extensive Subcutaneous Emphysema In Combined Pulmonary Fibrosis Emphysema (CPFE) Syndrome/H. Singh, Jackson, MI
- P531** Persistent Bilateral Spontaneous Pneumothorax in Combined Pulmonary Fibrosis and Emphysema/S. Natarajan, Scranton, PA
- P532** Acute Exacerbation After Mini-cryobiopsy of a Lung Nodule in a Patient With Chronic Fibrosing Lung Disease/C. Salmon, Nashville, TN
- P533** Trans-Bronchial Lung Cryobiopsy: Weighing Up Risks And Benefits/V.P. Trelles, Gainesville, FL
- P534** A Unique Dynamic Duo Case of Genomic Classifier Testing and Unusual UIP/J. Lum, Kailua, HI
- P535** Recurrent Hemoptysis Associated With Humidifier Lung/A.M.A.A. Eltarras, Indianapolis, IN
- P536** Why So Sensitive? The Value of Exposure History Taking in a Case of Shortness of Breath/K. Eid, Miami, FL
- P537** Nsrip/op Overlap: An Unknown In Modern Era./M.G. Suresh, Worcester, MA
- P538** Recurrent Flash Pulmonary Edema Due To Unmasking Of Mitral Regurgitation Following Bilateral Lung Transplantation For Pulmonary Arterial Hypertension/P. Modi, Philadelphia, PA
- P539** A Case of Gastrointestinal Post-transplant Lymphoproliferative Disorder in the Early Post-lung Transplant Period/K. Kommaraju, Rochester, MN
- P540** Aseptic Cavitory Lesion Associated With Cryogenic Ablation In Lung Transplant Recipient/D.F. Martin, Los Angeles, CA
- P541** Left Main Coronary Disease and Lung Transplantation Survival/P. Patil, Philadelphia, PA
- P542** Chronic Eosinophilic Pneumonia Relapse/H. Alrahamneh, las cruces, NM
- P543** Recurrent Bronchopneumonia in a Long-lived Elderly With Myelodysplastic Syndrome/P.M. Cavalcante Neto, Sao Paulo, Brazil
- P544** A Case of Cryptogenic Organizing Pneumonia - A Delayed Diagnosis?/K. Quinn, Los Angeles, CA
- P545** Organized Pneumonia, Unusual Etiology: A Case of Organizing Pneumonia Due to Mycobacterium Avium Complex/M. Dondarski, Philadelphia, PA
- P546** Diagnosing Cryptogenic Organizing Pneumonia in a Resource Limited Setting: A Case Report/G. Ayele, Washington, DC
- P547** Chronic Cough, Sometimes There Is Something to Find: A Case of Organizing Pneumonia Secondary to Infectious Etiology With Actinomyces Species/N. Abu Hussein, New Haven, CT
- P548** Intravenous Immunoglobulin Treatment Of Steroid-dependent Organizing Pneumonia In A Patient With Secondary Hypogammaglobulinemia/H. Decarvalho, Richmond, VA
- P549** Acute Fibrinous and Organizing Pneumonia (AFOP) With Spontaneous Recovery Following Resolution of Neutropenia in a Young Adult Patient With Acute Myelogenous Leukemia (AML)/S. Shimizu, Cleveland, OH
- P550** Acute Fibrosing And Organizing Pneumonia:The Great Masquerader And What Lies Beneath./A. Devarajan, Phoenix, AZ
- P551** Macrolide Therapy In Acute Fibrinous Organizing Pneumonia: A Case Report./A. Devarajan, Phoenix, AZ

- P552** It Doesn't Have To End That Way: A Case Of Acute Fibrinous And Organizing Pneumonia With Spontaneous Resolution/D.G. Thomas, New York, NY
- P553** Acute Fibrinous Organizing Pneumonia in an Immunocompromised 66 Year Old Female With a Posterior Mediastinal Mass and Rectal Adenocarcinoma/A.H.M. Aiken, Paterson, NJ
- P554** It Can Desquamative Interstitial Pneumonia (DIP) Without Tobacco/T.N. Hamdani, Huntington, WV

CLINICAL

THEMATIC POSTER SESSION

B38 SARCROID IS ALWAYS IN THE DIFFERENTIAL: CASE REPORTS IN SARCROIDOSIS

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area E, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P556** A Case Of Multisystem Sarcoidosis Diagnosed Incidentally During Surveillance Colonoscopy/G. Stone, Los Angeles, CA
- P557** A Case of Neurosarcoidosis Presenting as an Isolated Cranial Nerve 4 and 6 Palsy in a Patient With Otherwise Asymptomatic and Inactive Pulmonary Sarcoidosis/J. Kent, Dallas, TX
- P558** A Rare Case of Concomitant Extrapulmonary Sarcoidosis and Auto-immune Hepatitis/A. Yun, Louisville, KY
- P559** Sarcoidosis Associated Pleural Effusion - Uncommon Presentation of Sarcoidosis/S. Ali, Albany, NY
- P560** A Unique Presentation Of Neurosarcoidosis/V. Dhillon, Muncie, IN
- P561** Sarcoidosis: A Hard Diagnosis to Swallow/A. Sharma, Pittsburgh, PA
- P562** Bullous Emphysema in a Young Female With Sarcoidosis: From Suspicion to Diagnosis/T. Chowdhury, Brooklyn, NY
- P563** A Common Presentation of an Uncommon Disease- Pulmonary and Cardiac Sarcoidosis/G. Primera, Springfield, MA
- P564** Challenges In Diagnosis And Management Of Sarcoidosis With Rheumatoid Arthritis Overlap/H.A. Nayef, Detroit, MI
- P565** Fibrocystic Sarcoidosis: Should Patients Be on Prophylaxis for Opportunistic Infections?/I. Riestra, Rochester, MN
- P566** The Granuloma You Cannot Seem to Scratch/S. Johnson, Indianapolis, IN
- P567** A Case Of Pulmonary Sarcoidosis Following Diagnosis And Treatment Of Follicular Lymphoma In An Individual With Crohn's Disease/A.B. Mathew, Aurora, CO
- P568** Ascites in Sarcoidosis/M. Wajid, Indianapolis, IN
- P569** A Diagnosis of Sarcoidosis Masquerading as Pulmonary Silicosis/A. Go, St. Louis, MO
- P570** Dropping Anchor: A Case of Premature Closure on Sarcoidosis/R. Patel, Saint Louis, MO
- P571** A Unique Case of Non-pulmonary Sarcoidosis With Chylothorax/T. Al-Bermani, Valhalla, NY
- P572** Sarcoidosis Associated Immune Thrombocytopenia With Spontaneous Intracranial Hemorrhage/C. Tseng, Danbury, CT
- P573** Sarcoidosis Masquerading as Severe Emphysema/J. Ioanimescu, Dallas, TX
- P574** Not All Non-Caseating Granuloma is Sarcoidosis; Reading between the Granuloma/G. Sikka, Houston, TX
- P575** Candida in Sarcoid Lungs: A Trick to Ignore or Treat?/R. Jha, Youngstown, OH
- P576** Multiple Pulmonary Nodules: Is It Cancer?/C. Barrows, Albuquerque, NM
- P577** Unusual Behavior in an Otherwise Healthy 26-year-old Male With Newly Found Pulmonary Cavitory Lesion/N. Tangella, Newark, NJ
- P578** Sarcoidosis Associated With COVID-19 Infection in a Patient With Chronic Renal Failure/M. Al-Momani, Johnson City, TN
- P579** The Fulminant Version of Undiagnosed Systemic Sarcoidosis/S. Singh, Durgapur, India
- P580** Usefulness of Lung Ultrasound in the Study of Pulmonary Sarcoidosis/C. Villaquirán-Torres, Bogotá, Colombia
- P581** Is Not Lung Cancer, Is Sarcoidosis/K. Ramirez Gorbea, Mayaguez, Puerto Rico

CLINICAL

THEMATIC POSTER SESSION

B39 ADVANCES IN LUNG TRANSPLANTATION

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area E, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P583** Technical Aspects of Bronchoscopic Balloon Dilatation in Patients With Bronchial Stenosis After Lung Transplantation/M.S. Ki, Seoul, Korea, Republic of
- P584** Increased Airway Dehiscence in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients/R. Koshy, Pittsburgh, PA
- P585** Evaluation of Indications, Contra-Indications and Willingness for Lung Transplant in Patients With Chronic Respiratory Illness at a Tertiary Care Centre in India/A. Mohan, New Delhi, India
- P586** Post-transplant Native Lung and Allograft Volumes in Single Lung Recipients/M. Zulty, Philadelphia, PA
- P587** High-altitude Does Not Modify the Outcomes After Lung Transplantation/F.A. Varon, Bogota, Colombia
- P588** The Effect of Fluid Balance on Post-operative Outcomes in Lung Transplant Patients: A Retrospective Cohort Study/T. Thompson, Maywood, IL
- P589** Transfusion Requirements During Lung Transplantation: A Single Center, Retrospective Cohort Analysis/B. Gordon, New York, NY
- P590** Patient Engagement With a Bespoke Remote Monitoring Program For Follow-up Care Post-lung Transplantation/R. Borton, Dublin, Ireland
- P591** Evolution of Allograft Function in Lung Transplant Recipients With and Without Aspiration/J. Gagermeier, Maywood, IL

CLINICAL

THEMATIC POSTER SESSION

B40 POTPOURRI IN ILD: SPANNING THE SPECTRUM FROM RARE TO COMMON LUNG DISEASES

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area F, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P595** Steroids in Post COVID-19 Interstitial Lung Disease/P. Ntiamoah, Cleveland, OH
- P596** Effects of Amiodarone on COVID-19 Pneumonia Outcomes/A.K. Rahman, Bethlehem, PA
- P597** De Novo Eosinophilic Granulomatous With Polyangiitis (EGPA) Following COVID-19 Infection or Vaccination/G. Alrehaili, Rochester, MN
- P598** Mortality of SARS-CoV-2 Infection in Patients With Fibrotic Interstitial Lung Disease/K. Donohoe, Cincinnati, OH
- P599** Acceptance and Adherence to Coronavirus Disease 2019 Vaccination Among Interstitial Lung Disease Patients/R. Dinparastisaleh, Jacksonville, FL
- P600** Effect of COVID-19 Disease on Lung Functions in Idiopathic Pulmonary Fibrosis Patients/M. Sterclova, Prague, Czech Republic
- P601** Multiorgan Involvement Is a Risk Factor for COVID-19 Infection in Sarcoidosis Patients/A.V. Pulapaka, Baltimore, MD
- P602** In the Era of COVID-19: Outcomes in Rituximab Therapy in Interstitial Lung Disease/R. Strykowski, Chicago, IL
- P603** SouthEastern SArcoiDosis Registry (SESAR): Variation in Clinical Characteristics and Prescribing Patterns in Sarcoidosis Across Academic Medical Centers/D.J. Dennis, Charleston, SC
- P604** Analysis of Cardiac MRI With T2 Mapping in Cardiac Sarcoidosis/D.J. Dennis, Charleston, SC
- P605** Prevalence, Incidence, and Patients' Characteristics of Cardiac Sarcoidosis in Patients With Biopsy-proven Pulmonary Sarcoidosis/T. Sato, Sapporo, Japan
- P606** Role of Screening for Uveitis in Subjects With Sarcoidosis/M.L. Wilsher, Auckland, New Zealand
- P607** Prevalence and Epidemiology of Pulmonary Hypertension Amongst Patients With Sarcoidosis/J.R. Shah, Ahmedabad, India
- P608** Airborne Fungal Antigen Exposure Is Associated With Disease Severity and Lung Fibrosis in Patients With Sarcoidosis/M. Shlossman, Iowa City, IA
- P609** Lofgren's Syndrome: Prognostically as Good as We Think?/B. Karakaya, Nieuwegein, Netherlands
- P610** Comparison Between Complete Versus Limited Granulomatous Inflammation in Thoracic Lymph Nodes on the Clinical Course of Sarcoidosis/M. Kassirer, Beer Sheeva, Israel
- P611** Pulmonary Rehabilitation in Sarcoidosis: A Systematic Review and Meta-analysis/J. Sellares Torres, Barcelona, Spain

- P612** **Characteristic Chest Computed Tomography Findings for Birt-Hogg-Dube Syndrome Indicating Requirement for Genetic Evaluation**/Y.J. Choi, Seoul, Korea, Republic of
- P613** **Correlation of Clinical Features, Pulmonary Function, Cyst Scores and Genetic Mutations in Patients With Birt-Hogg-Dube Syndrome**/J. Khan, Dublin, Ireland
- P614** **Outstanding Characteristics of Birt-Hogg-Dube Syndrome in Korea: Including Systematic Review**/M. Byun, Seoul, Korea, Republic of
- P615** **Diagnostic Utility of Quantitative 3D HRCT Analysis to in Diffuse Cystic Lung Diseases**/Y. Sekimoto, Dublin, Ireland
- P616** **Prevalence and Clinical Characteristics of Lymphangioleiomyomatosis; Less Rare Than Previously Reported?**/E. Lynn, Dublin, Ireland
- P617** **Clinical Background of Pregnant Cases of Lymphangioleiomyomatosis**/M. Hirose, Sakai, Japan
- P618** **Insufficient Medical Assessment for Lung Involvements in Patients With Tuberous Sclerosis Complex in Clinical Setting in Japan**/A. Masunaga, Kumamoto, Japan
- P619** **Evaluation of Chest Radiographic Changes Visualized by Computed Tomography in Patients With the Pulmonary Langerhans Cell Histiocytosis**/E. Radzikowska, Warsaw, Poland
- P620** **A Phase I Trial of Inhaled GM-CSF in Patients With Autoimmune Pulmonary Alveolar Proteinosis Evaluating Immunologic Responses in the Lower Respiratory Tract**/B.C. Carey, Cincinnati, OH
- P621** **Autoimmune Pulmonary Alveolar Proteinosis: Update From the US National PAP Registry**/B.C. Carey, Cincinnati, OH
- P622** **Cytokine Profiles Associated With Disease Severity and Prognosis of Autoimmune Pulmonary Alveolar Proteinosis**/T. Takada, Niigata, Japan
- P623** **Spirometry in ANCA Vasculitis**/J. Clark, Chapel Hill, NC
- P624** **Clinical Manifestations and Health Care Resource Utilization of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in China: A Multi-center Retrospective Cohort Study in China (Interim Analysis)**/L. Xue, Guangzhou, China
- P625** **Investigating Risk Factors for Immune Checkpoint Inhibitor-induced Pneumonitis in Lung Cancer Patients**/C. Zhou, Lebanon, NH
- P626** **Investigating Pneumonitis in Cancer Patients Receiving Immune Checkpoint Inhibitors**/M. Moodabagil, Columbus, OH
- P627** **Pharmacotherapy and Pulmonary Fibrosis Risk After SARS-CoV-2 Infection: A Prospective Nationwide Cohort Study**/R. Baccile, Chicago, IL

- P628** **Association of Pre-pandemic CT Interstitial Lung Abnormalities and High Attenuation Areas With COVID-19 Hospitalization: The C4R Study**/J. Kim, Charlottesville, VA
- P629** **Biomarkers of Inflammation and Aging Are Not Associated With Fibrotic-Like Pulmonary Radiographic Patterns in Severe COVID-19 Survivors**/A. Jones, New York, NY
- P630** **Longitudinal Consistency of CT-Based Evaluation of the Volumetric Percentage of Cystic Regions in the Lungs of Patients With Lymphangioleiomyomatosis**/B.P. Matthew, Bethesda, MD
- P631** **Oxygenation Kinetics of Patients With Pulmonary Alveolar Proteinosis During Whole Lung Lavage**/C. Yoshida, Kumamoto, Japan

CLINICAL

THEMATIC POSTER SESSION

B41 **RISK FACTORS AND OUTCOMES FOR COPD EXACERBATIONS**

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area H, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P771** **Self-report Underestimates COPD Exacerbation Frequency but Is Associated With BAL Neutrophilia and Lymphocytosis**/Y.D. Abrahm, San Francisco, CA
- P772** **Redefining Cut-points for High Symptom Burden of the Gold Classification Assists Better Prediction of Future Acute Exacerbation and Mortality Than the Conventional ABCD Classification in Patients With Chronic Obstructive Pulmonary Disease**/S. Teramoto, Hachioji-shi, Japan
- P773** **Subtypes of Early Chronic Obstructive Pulmonary Disease Could Predict COPD Exacerbation**/N. Kim, Seoul, Korea, Republic of
- P774** **An Analysis of the Prognosis of Chronic Obstructive Pulmonary Disease Patients With Acute Exacerbations Based on Types of Acute Respiratory Failure**/J.K. Lee, Gwangju, Korea, Republic of
- P775** **Deep Residual Convolutional Network Predicts Future Severe Exacerbations of COPD in SPIROMICS**/H.A. Awan, Iowa City, IA
- P776** **Saliva as a Non-invasive Specimen for COPD Evaluation**/V.J. Rangrej, Vadodara, India

- P777** Exacerbation and Lung Function Change According to the Longitudinal Variability of Bronchodilator Response in Patients With COPD/J.-K. Lee, Seoul, Korea, Republic of
- P778** Lung Function and Drinking Habits in People With and Without COPD in a Danish Rural Population/L.B. Nielsen, Aalborg, Denmark
- P779** The Difficulty With Treating Alcohol Withdrawal in Severe Chronic Obstructive Pulmonary Disease/D.J. Brown, Bronx, NY
- P780** Alcohol Abuse as Emerging Modifiable Risk Factor for Acute Exacerbations of COPD (AECOPD) in Developing Countries: Placing New Evidence in Context/N. Bhatta, Dharan, Nepal
- P781** Management of Acute COPD Exacerbations in the Internal Medicine Departments - The COPDIS National Israeli Audit/A. Bar-Shai, Tel Aviv, Israel
- P782** Comorbid HIV Infection in Patients Hospitalized With Acute Exacerbation of COPD/R. Sinha, Brooklyn, NY
- P783** Nocturnal Dislodgement of Nasal Cannula in Patients With Chronic Obstructive Pulmonary Disease Treated With Continuous Supplemental Oxygen: A Life-threatening, Unmet Medical Need/Z. Elfessi, Chicago, IL
- P784** Characteristic of Hypercapnic Chronic Obstructive Pulmonary Disease Readmissions: A 6-year Analysis/Z.J. Gandhi, Wilkes-Barre, PA
- P785** Changing Patient Compliance After Hospitalization With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease/O. Freund, Tel Aviv, Israel
- P786** Takotsubo Syndrome as a Manifestation of COPD Exacerbation in a 6 Case Series/C. Kirchenchtejn, Sao Paulo - SP, Brazil
- P787** Stressed Lungs Leading to a Stressed Heart?/S.K. Kommineni, Johnson City, TN
- P788** Incidence of Severe Cardiovascular Events Following Acute Exacerbation of Chronic Obstructive Pulmonary Disease in a Large Claims Database/K. Daniels, Wilmington, DE
- P789** Serum Proteomics Identify Potential Biomarkers in Frequent Exacerbation of COPD/L. Wang, Xinxiang, China
- P790** Safety and Efficacy of COVID-19 Vaccination in Severe Alpha-1 Antitrypsin Deficiency/O. Mcelvaney, Dublin, Ireland

CLINICAL

THEMATIC POSTER SESSION

B42 DIAGNOSTIC TESTING AND CASE REPORTS IN DYSPNEA AND LUNG DISEASE9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area F, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session**11:30-1:15****Discussion:** 11:30-12:15 authors will be present for individual discussion

12:15-1:15 authors will be present for discussion with assigned facilitators.

- P633** Pulmonary Eosinophilia and Chronic Aspiration/V. Kang, Burlington, MA
- P634** Unusual Cause of Dry Cough and Shortness of Breath Tricked Admission Team/H. Azeez, Port Jefferson, NY
- P635** Acute Hypoxic Respiratory Failure: Here Is the Gist/G. Mohan, Long Branch, NJ
- P636** Muscle or Junction: A Clinical Case of Respiratory Failure and Muscle Weakness/T. Nguyen, Lexington, KY
- P637** Ipsilateral Hemi-diaphragmatic Paralysis After Intra-scalene Nerve Block - A Rare But Reported Entity/V.A. Persaud, Corpus Christi, TX
- P638** Electromyograms And Diaphragms: Two Unexpected Cases Of Diaphragmatic Weakness Driving Hypoxia/C. Chou, New York, NY
- P639** Diaphragmatic Eventration Masquerading as Recurrent Eructation: The Importance of Proper Diagnosis/E. Fischer, Kailua, HI
- P640** Awareness for Surgical Reconstruction of Phrenic Nerve Injury for Hemidiaphragm Paralysis/C. Mccalmon, Grand Rapids, MI
- P641** Platypnea Orthodeoxia Syndrome: Is It Really Rare or Just an Easily Overlooked Conundrum?/J. Lum, Kailua, HI
- P642** Expect the Unexpected: Recognizing a Case of Non-cardiogenic Pulmonary Edema Following an Elective Surgery/C. Oprysko, New Britain, CT
- P643** Acute Right-to-Left Intracardiac Shunting/C.E. Durant, Los Angeles, CA
- P644** When Exercise Becomes Dangerous: A Case of Exercised Induced Mobitz Type II Heart Block/J.M. Levy, Mullica Hill, NJ
- P645** Reverting Back To The Basics, Thorough History And Physical Examination In Evaluating Patients With Pulmonary Complaints/A. Alkhatib, Long Branch, NJ

- P646** Neck Deep In Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): A Rare Cause Of Dyspnea/I.A. Pearce, Dayton, OH
- P647** Cystic Lung Disease Misdiagnosed as Chronic Obstructive Pulmonary Disease (COPD)/M. Shahzadi, Wayne, NJ
- P648** A Comparison of Visually Measured Respiratory Rate and Continuous Monitoring With an Electronic Device in a Tertiary Centre - A Retrospective Cohort Study/L. Piggott, Dublin, Ireland
- P649** Strados Labs RESP Provides Early and Clinically Significant Pre-symptomatic Signs of Changes in Cardiorespiratory Status/M. Glass, Philadelphia, PA
- P650** Dyspnea Among Mechanically Ventilated Patients: A Systematic Review/K. Grush, Aurora, CO
- P651** Use of Opioids to Relieve Chronic Dyspnea in Advanced COPD/M. Jamil, Oklahoma City, OK

CLINICAL

THEMATIC POSTER SESSION

B43 UNCOMMON TYPES AND CAUSES OF PLEURAL EFFUSION: CASE REPORTS IN PLEURAL DISEASE

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area D, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P351** Recurrent Uremic Pleural Effusion: An Unwelcomed Regular/W. Meng, San Francisco, CA
- P352** The Rapid Evolution Of Urinothorax/B.M. Dolan, New York, NY
- P353** Rare Presentation Of Urinothorax In A Patient With Nash (nonalcoholic Steatohepatitis) Liver Cirrhosis: Importance Of Reestablishing A Diagnosis/U. Ahmad, Poughkeepsie, NY
- P354** A Case of Imaging-confirmed Sweet Hydrothorax/N. Hubbell, Detroit, MI
- P355** Hepatic Hydrothorax As A Presentation Of Recurrent Thrombotic Event In A Patient With Triple Positive Antiphospholipid Syndrome (APS) While On Direct Oral Anticoagulant (DOAC)/R. Seno, Poughkeepsie, NY
- P356** Rare Cause Of Massive Pancreatic Pleural Effusion/A. Mohammed, Hackensack, NJ
- P357** My Sympathies To The Spleen: An Unusual Case Of Pleural Effusion/A. Bundy, Indianapolis, IN
- P358** An Unusual Cause of Loculated Pleural Effusion/R. Dalbah, Johnson City, TN
- P359** Development of Malignant Pleural Effusions Following Acute Resuscitation for Septic Shock/J.E. Fesen, New Orleans, LA
- P360** Presentation Of Multiple Myeloma As Bilateral Pleural Effusions-significance Of Obtaining Pleural Fluid Cytology/H. Singh, Jackson, MI
- P361** Recurrent Idiopathic Chylothorax: A Therapeutic Challenge/H. Singh, Jackson, MI
- P362** Neoplastic Fevers in a Case of Malignant Pleural Mesothelioma/H.K. Boppana, Rochester, NY
- P363** An Unusual Case of Non-Clear Renal Cell Carcinoma Camouflaging as Pleural Effusions/B.D. Vadhar, Greenville, NC
- P364** A Novel Case of Spontaneous Pulmonary Hematoma and Hemothorax in a Patient With Glanzmann Thrombasthenia/S. Jothi, Tucson, AZ
- P365** Unusual Cause Of Massive Hemothorax: Spontaneous Rupture Of Lymphangioma/O.M. Garcia Morales, Bogota, Colombia
- P366** A Rare Case of Cough-Induced Chylothorax/J. Frederickson, Omaha, NE
- P367** Post-surgical Bilateral Chylothorax Resulting in Acute Hypoxic Respiratory Failure/E.M.P. Almazan, Lexington, KY
- P368** An Unexpected Cause of Malignant Pleural Effusion: Metastatic Thyroid Carcinoma/K.C. Padilla Rodriguez, san juan, Puerto Rico
- P369** An Unusual Case Of Bilateral Transudative Chylothorax/B. Amir-Kabirian, Charleston, WV
- P370** The Green Pleural Effusion: An Unusual Case of Right Sided Bilothorax/S. Aprilia, Jakarta, Indonesia
- P371** Transudative Hepatic Chylothorax as the Presenting Manifestation of a New Diagnosis of Cirrhosis/R. Sheth, San Diego, CA
- P372** Yellow Nail Syndrome Presenting After Hip Arthroplasty With Titanium Implants/A. Nassereddin, Gainesville, FL
- P373** Thoracic Aortic Dissection Complicated With Left Hemothorax and Possible Right Reactive Effusion/P. Schroff, Greenville, NC
- P374** A Rare Presentation of Primary Pleural Mantle Cell Lymphoma/M.J. Obregon, Springfield, IL
- P375** Pulmonary Infarction With Non-Traumatic Hemothorax: Less Is More/J.E. Munoz, Houston, TX

- P376** **Bilateral Pleural Effusions: Not Always Heart Failure!**/M. Gleeson, Dublin, Ireland
- P377** **Hyperimmune Response to COVID-19 Vaccination**/R. Hoerner, Louisville, KY
- P378** **Bloody Mess! A Case of a Spontaneous Hemothorax in a Patient on Therapeutic Warfarin**/P. Gandhi, Newark, DE
- P379** **A Tell-Tale Chylothorax**/G. Boghdadi, Washington, VA
- P380** **Chylothorax As The Initial Presentation Of Follicular Lymphoma**/K. Kaur, Johnson City, TN
- P381** **A Mysterious Case Of Chylous Effusion**/T. Iqbal, Morristown, NJ
- P382** **Bilateral Chylothorax From Amyloid Light Chain (AL) Amyloidosis**/V. Chun, Los Angeles, CA
- P383** **A Case of Incidental Finding of Left Sided Chylothorax During Elective Thoracic Discectomy and Spinal Fusion**/M. Alrjoob, Long Branch, NJ
- P384** **A Case of Left-sided Hepatic Transudative Chylothorax in a Patient With Liver Cirrhosis**/P. Haririan, Los Angeles, CA
- P385** **Chylothorax Secondary to Spontaneous Idiopathic Thoracic Duct Leak**/E. Teplitsky, Omaha, NE
- P386** **Rare Case of Spontaneous Idiopathic Chylothorax in an Adult With Noonan Syndrome**/P. Shah, West Reading, PA
- P854** **Thrombosis in Critical Illness in COVID-19 Is Associated With Impaired Mobility Related Quality of Life at Hospital Follow Up**/E. Nielsen, New York, NY
- P855** **Reported Penicillin Allergy and ICU Outcomes**/S. Khadka, Jacksonville, FL
- P856** **Impact of Long-Term COVID-19 Symptoms on Patients' Health-Related Quality-of-Life Indicators After Discharge From the ICU**/D.M. Bernhard, Honolulu, HI
- P857** **A Study to Investigate COVID-19 Patients' Caregivers Perceived Burden**/A. Kewalramani, Port Jefferson, NY
- P858** **Frailty in Transcatheter Aortic Valve Repair (TAVR) Patients Predicts Higher Mortality and Morbidity**/N. Dasu, Voorhees, NJ
- P859** **Protein Malnutrition as a Predictor of Mortality and Morbidity in Critically Ill TAVR Patients: A National Cohort Study**/N. Dasu, Voorhees, NJ
- P860** **Could Impatience Be a Virtue? Early Versus Late Parenteral Nutrition in Critically Ill Adult Patients**/M. Imperio, Loma Linda, CA
- P861** **Frailty in Patients Requiring Venous-arterial Extracorporeal Membrane Oxygenation After Cardiac Surgery**/A. Gongola, Washington, DC
- P862** **Clinical Outcomes of Tracheostomized Patients: COVID-19 Vs Non-COVID-19**/J. Bahk, New York, NY
- P863** **Predictors of Length of Stay, Ventilator Wean, Decannulation, and Mortality in Tracheostomized Patients**/J. Bahk, New York, NY
- P864** **Characteristics of Tracheostomized Patients: COVID-19 Vs Non-COVID-19**/J. Bahk, New York, NY
- P865** **Complications of Tracheostomies in the COVID-19 Era**/V. Sharma, New York, NY
- P866** **Validation of the Modified NUTRIC Score to Predict Mortality Between Tracheostomized and Non-tracheostomized Ventilated Patients**/K. Lee, Busan, Korea, Republic of
- P867** **A Protocolized Approach to Ventilator Weaning in Prolonged Mechanical Ventilated Patients**/M.R. Jordan, Birmingham, AL
- P868** **Clinician, Family and Patient Factors Driving Interhospital Transfer to a Tertiary Care Center: A Qualitative Study**/R. Hadler, Iowa City, IA
- P869** **Telehealth in Sepsis Care: A Scoping Review and Meta-analysis**/K.J. Tu, College Park, MD
- P870** **Convalescent Plasma Administration Worsens Respiratory Failure in Hospitalized Seronegative COVID 19 Patients**/S. Pannu, Columbus, OH

CLINICAL

THEMATIC POSTER SESSION

B44 FRAILITY, NUTRITION, AND PROLONGED MECHANICAL VENTILATION9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area I, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session **11:30-1:15****Discussion:** **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P851** **Evaluating the Prevalence of Post Intensive Care Syndrome in an Urban Population**/V. Dronamraju, Philadelphia, PA
- P852** **Prolonged Use of Neuromuscular Blocking Agents May Associate With Long-term Outcome in Critically Ill Ventilated Patients**/C. Lin, Taichung, Taiwan
- P853** **Longitudinal Generalized Anxiety Disorder 7-Item (GAD-7) Scale Outcomes as Compared to Other Post-acute Sequelae SARS-CoV-2 (PASC) Symptoms in a Post-COVID Patient Population**/I.R. Young, New York, NY

- P871** Point of Care Lactate as a Predictor of 7day Morbidity and Mortality in Critically Ill Patients Presenting to the Emergency Department in Kenyatta National Hospital/P.M. Mutuku, Nairobi, Kenya
- P872** Survival Predictions Among Physicians and Surrogates of Mechanically Ventilated Patients at Two ICU Time Points/B. Dufour, Chicago, IL
- P873** Outcomes of Virtual Intensive Care Consults for an Academic Tertiary Care Center During COVID-19/D. Decicco, Morgantown, WV
- P874** Incidence and Risk Factors of 30 Days Readmissions Following Hospitalization for Pneumonia in a Large Academic Medical Center/K.Z. Abbas, Cleveland, OH
- P875** Linking Sepsis With Chronic Non-communicable Diseases and Socioeconomic Factors: A Systematic Review/C.D. Ahlberg, Baltimore, MD
- P876** Outcomes With Early Rehabilitation in Post-Intensive Care Syndrome (PICS): A Systematic Review and Meta-Analysis/R. Sharma, Wilkes-Barre, PA
- P1207** A Comparison of a Host-response Test and an Electronic Health Record Model as Diagnostic Aids and Risk Stratification Tools for Sepsis/J.D. Bradford, Baton Rouge, LA
- P1208** Diagnostic Criteria and Inflammatory Markers for Sepsis as Predictors of Clinical Outcome: A Retrospective Study/H. Lee, Brooklyn, NY
- P1209** The Effect of Empirical Treatment With Meropenem and Vancomycin in Sepsis Patients: A Retrospective Study/H. Lee, Brooklyn, NY
- P1210** Comparison of Systemic Inflammatory Response Syndrome Criteria (SIRS) and Sepsis 3 Criteria for Assessing Outcomes in Sepsis: A Prospective Observational Study/M.K. Daga, Delhi, India
- P1211** Outcomes After Early Hypotension in Sepsis: A Retrospective Cohort Study/C. Chessare, Charlottesville, VA
- P1212** Multiomic, Mass Spectrometry-based Analysis of Dried Blood: Toward Deep Phenotyping of Sepsis/M.W. Foster, Durham, NC
- P1213** Got MAP 65mm Hg, What Next?: Increased Inhospital Mortality With Elevated Central Venous Pressure/J. Ninan, Rochester, MN
- P1214** Weight Based Fluid Resuscitation in Obese Patients With Sepsis and Septic Shock/A. Saha, Worcester, MA
- P1215** Determining the Association Between the Origin of Sepsis and Severity of Sepsis in ICU Patients Using Apache IV Score/A.J. Arumairaj, New York, NY
- P1216** ABO Blood Type Is Not Associated With Increased Risk of Septic Shock in Intensive Care Unit Patients With Sepsis/V. Bansal, Jacksonville, FL
- P1217** Clinical Context From the Medical Record Improves Artificial Intelligence Models for Sepsis Prediction/A. Holder, Atlanta, GA
- P1218** Association of Blood Culture-positive Pathogens With Outcomes in Community Onset Sepsis in the Intensive Care Unit/T. Ohnuma, Durham, NC
- P1219** C-type Natriuretic Peptide Attenuates Endothelial and Cardiac Dysfunction During Endotoxemia and Polymicrobial Sepsis/A. Moyes, London, United Kingdom
- P1220** Use of Beta-lactam Antibiotics in the Management of Sepsis in the Intensive Care Unit/M. Horn, St. Louis, MO
- P1221** Are Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Associated With Improved Outcomes in Diabetic Patients Admitted to Intensive Care Unit (ICU) With Septic Shock?/N. Ashcherkin, Scottsdale, AZ
- P1222** White Blood Cell Population Data Improves Identification of Sepsis in Hospitalized Adults: A Retrospective Cohort Study/A. Barros, Charlottesville, VA

CLINICAL

THEMATIC POSTER SESSION

B45 NEW STUDIES IN SEPSIS AND INFECTIOUS DISEASES

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area L, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1201** Treatment and Outcomes of Sepsis Among Patients With Versus Without Comorbid Heart Failure/J. King, Ann Arbor, MI
- P1202** Sepsis-induced Increases in Blood Acetylcarnitine Reflect Organ-level Energy Disruption That Is Improved by Supplemental L-carnitine/K.A. Stringer, Ann Arbor, MI
- P1203** The Impact of Aging on Sepsis-related Endothelial Glycocalyx Degradation/R. Sullivan, Aurora, CO
- P1204** Impact of Positive Fluid Balance on Each Day of the First Three Days of ICU in Patients With Sepsis/D.-G. Hyun, Seoul, Korea, Republic of
- P1205** Creation and Validation of Novel Actionable Sepsis Phenotypes Using Clinical Data/G. Wardi, San Diego, CA
- P1206** Association of Estimated Plasma Volume Status With Clinical Outcomes in Patients With Sepsis/S. Isha, Jacksonville, FL

- P1223** Systemic TGF-Beta and Lower IFN-Gamma Drive Kidney, Lung, and Brain Damage in Sepsis/P. Yang, Atlanta, GA
- P1224** Prospective Look on the Utility of Point of Care Ultrasound During Cardiac Arrest's/K.H. Patel, Brooklyn, NY
- P1225** Increased Alveolar Epithelial Damage Markers and Inflammasome-regulated IL-18 Are Associated With Superinfection in Human ARDS/K. Peukert, Bonn, Germany
- P1226** Outbreak of *Ralstonia Pickettii* Bacteremia in Critically Ill Patient of a City in Colombia: Find the Source/A. Triana, Miami, FL
- P1227** Urinary IL-18 as an Early Marker for Acute Kidney Injury in Snake Bite/A. Polasa, Hyderabad, India
- P1228** Time of Herpes Simplex-1 Virus Detection Among Critical-ill With COVID-19 Pneumonia Patients/E. Magira, Athens, Greece
- P1229** Profiles of Microbiomes in Multiuse Closed Suction System Catheters/R. Dhand, Knoxville, TN
- P1230** Phenotyping Sepsis in Hospitalized Patients According to Infection Site/A.R. Schertz, Winston Salem, NC
- P1231** Immunomodulators Did Not Increase Secondary Bacterial Infections in Critically Ill Mechanically Ventilated COVID-19 Patients/A. Kakkad, Bangor, ME
- P1232** The Prevalence, Microbiological Profile, and Clinical Impact of Nosocomial Infections in Patients Requiring Venous-arterial Extra Corporeal Membrane Oxygenation Support/Y. Sawalha, Leonardtown, MD
- P1233** Clinical Profile Analysis and Nomogram for Predicting In-hospital Mortality Among Elderly Severe Community-acquired Pneumonia Patients With Comorbid Cardiovascular Disease: A Retrospective Cohort Study/L. Gong, Chengdu, China
- P1234** Sufficiency of the Maintenance DNA Methylation Protein UHRF1 in Promoting Regulatory T Cell-mediated Recovery Following Viral Pneumonia/C.P. Reyes Flores, Chicago, IL
- P1235** Multicenter Development and External Validation of a Machine Learning Model to Identify Hospitalized Patients With Untreated Infection/K.G. Buell, Chicago, IL
- P1236** Impact of Gender on Mortality Following Intensive Care Unit Admission/K. Lewis, Jacksonville, FL
- P1237** Leveraging Machine Learning and MDW to Enhance Early Sepsis Detection Among Hospitalized Patients/E.D. Crouser, Columbus, OH
- P1238** Validation of a Rapid Sepsis Diagnostic for Use in Patients Presenting to the Emergency Department With Signs or Suspicion of Infection/H.R. O'Neal, Baton Rouge, LA

- P1239** Loss of Phosphorylated Tyrosine-33 WW Domain-Containing Oxidoreductase (Wwox) Is Associated With Sickness Behavior in a Sepsis Model/P. De La Cruz, Indianapolis, IN
- P1240** Enteral Therapy to Reverse the Inflammatory Dyslipidemia of Sepsis/J.H. Boyd, Vancouver, Canada

CLINICAL

THEMATIC POSTER SESSION

B46 OTHER SPECIALTIES IN THE ICU: TOPICS IN NEPHROLOGY, HEMATOLOGY/ONCOLOGY, AND MORE

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area I, Hall C (Lower Level)

- Viewing:** Posters will be on display for entire session **11:30-1:15**
- Discussion:** **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.
- P878** Pre-hospital Use of Direct Oral Anticoagulants Agents Is Associated With Lower Risk of Major Bleeding Events in Critically Ill Patients: A Single Academic Center Experience/A. Lal, Rochester, MN
- P879** The Microbiological Flora, Complications, Therapeutic Interventions and Outcomes After Bronchoalveolar Lavage (BAL) in Critically Ill Patients With Haematological Malignancy and Stem Cell Transplants. A Tertiary Care Experience Over 4 Years/A.M. Khan, Riyadh, Saudi Arabia
- P880** Outcomes of Immunocompromised and Non-immunocompromised Patients With COVID in the ICU Are Similar in the Pre-vaccine Era/C. Parmer-Chow, Stanford, CA
- P881** Evaluation of Left Ventricular Function in Patients With Pulmonary Embolism and Right Ventricular Failure/L. Phan, New York, NY
- P882** Neutrophil to Lymphocyte Ratio Is Associated With Mortality in Patients Undergoing Treatment for Hemato-oncologic Malignancies and Admitted for COVID 19/C.J. Wakefield, Fort Sam Houston, TX
- P883** Relative Performance of the Systemic Inflammatory Response Syndrome Criteria, the Quick Sequential Organ Failure Assessment, and Early Warning Scores in Oncology Patients Outside the ICU/Y. Raka, St. Louis, MO
- P884** Does Thromboelastography in Non-trauma Critical Care Patients Promote the Judicious Use of Blood Products?/S. Yu, Morgantown, WV

- P885** **An Assessment of Current Practice Patterns of Tissue Plasminogen Activator Versus Video Assisted Thoracoscopic Surgery for Retained Hemothorax in Trauma Patients at a Level 1 Trauma Center/M. Burger, New Orleans, LA**
- P886** **Incidence and Risk Factors of Acute CVA Associated With ARDS Secondary to SARS-CoV-2/K. Krolikowski, New York, NY**
- P887** **Neuropathological Findings in COVID-19 Vs Non-COVID-19 Acute Respiratory Distress Syndrome - a Matched Case Control Study/M. Humayun, Baltimore, MD**
- P888** **Volumetric Patterns and Prognosis of Neurogenic Pulmonary Edema After Subarachnoid Hemorrhage/T. Mutoh, Akita, Japan**
- P889** **Measurement of Heart and Lung Function in Neurocritical Care Using the Inspired Sinewave Technique/A.G.P. Joseph, Oxford, United Kingdom**
- P890** **In Patients With Suspected Sepsis, Early Anti-anaerobic Antibiotic Exposure Increases Risk of Acute Kidney Injury/K. Winner, Ann Arbor, MI**
- P891** **Association Between End of Life Care and Discordance About Prognosis Between Physician and Surrogate Decision Maker of Critically Ills With Severe AKI/S. Sathitratanaheewin, Bangkok, Thailand**
- P892** **The Incidence and Clinical Profile of Acute Kidney Injury in Intensive Care Unit Admitted Patients With COVID-19 at Eka Kotebe Hospital, Addis Ababa, Ethiopia/D.K. Huluka, Addis Ababa, Ethiopia**
- P893** **Utilizing Renal Micropuncture to Understand Ventilator Induced Kidney Injury/A.J. Kumar, La Jolla, CA**
- P894** **Multi-omics Analyses Reveal the Mechanisms of Ultra-early Stage Kidney Toxicity by Diquat/H. Zhang, Nanjing, China**
- P895** **Early Use of Vasopressors in the Resuscitation of Hemorrhagic Shock Due to Gastrointestinal Bleeding/J. Bahk, New York, NY**
- P896** **Effectiveness of Intravenous Fluids (IV) in Diabetic Ketoacidosis (DKA) Resolution for Adults in the Emergency Department/C. Peralta, Harlingen, TX**
- P897** **Increased Alpha Power in the Frontal Lobes With Diaphragm Neurostimulation in ARDS Patients/T. Bassi, Vancouver, Canada**
- P898** **Increased Parasympathetic Activity in the Brain Vessels With Diaphragm Neurostimulation/T. Bassi, Vancouver, Canada**
- P899** **Prospective Validation of the Venous Excess Ultrasound Score (VExUS)/A. Longino, Aurora, CO**

- P900** **Measuring Changes in Respiratory Effort Using Central Venous Pressure in Patients on Non-invasive Ventilation After Extubation/P.J. Biselli, Sao Paulo, Brazil**
- P901** **Risk Factors for Stroke Development After Thoracic Aortic Surgery/S.R. Pothapragada, Washington, DC**

CLINICAL

THEMATIC POSTER SESSION

B47 **CRITICAL CARE NEPHROLOGY: CASE REPORTS**

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area I, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P903** **Don't Always Blame the Chemo: Spontaneous Tumor Lysis Syndrome in a Patient With Non-hematological Malignancy/A. Jain, Johnstown, PA**
- P904** **A Curious Case Of Hyponatremia/S. Selvakumar, Davie, FL**
- P905** **Anti-glomerular Basement Membrane Disease Presenting With Renal Failure And Extensive Deep Venous Thrombosis/A. Rhodes, Kingwood, TX**
- P906** **A Unique Approach to Management of Hyperosmolar Hyponatremia in the Setting of End Stage Renal Disease/D. Mcfarland, Springfield, MA**
- P907** **Supine Obstructive Shock Exacerbated By Adult Polycystic Kidney Disease/A.L. Mora Carpio, New Haven, CT**
- P908** **Renal Tubular Acidosis Associated With Topamax Use Exacerbated by Sepsis Secondary to Pneumonia and Acute Respiratory Failure/J.D. Hennig, Lafayette, LA**
- P909** **Mind The Gap: Recognizing The Lactate Gap In Ethylene Glycol Toxicity/K. Ebeid, Paterson, NJ**
- P910** **A Rare Cause of Postrenal Acute Kidney Injury Secondary to Complete Bladder Herniation to the Inguinal Canal/P. Ayat, Brooklyn, NY**
- P911** **Cefepime-induced Neurotoxicity in the Setting of Acute Renal Failure Requiring Hemodialysis/N. Baghdasaryan, Los Angeles, CA**
- P912** **Too Little, Too Late: Case of Systemic Serum A Amyloidosis Associated With Metastatic Renal Cell Carcinoma/F. Yazdi, Shreveport, LA**
- P913** **A Case of Hyponatremia Precipitated By Discontinuing of Empagliflozin/T.M. Mirza, Harrisburg, PA**

- P914** A Strange Pathogen Causing Peritoneal Dialysis-Associated Peritonitis in a Dog Owner/B. Wu, Morgantown, WV
- P915** Renal Replacement Therapy to Correct Refractory Hypokalemia From Hydroxychloroquine Toxicity/D.D. Ying, Manhasset, NY
- P916** Acute Kidney Injury as an Unexpected Etiology of Carvedilol Toxicity/L.A. Wulff, Tampa, FL
- P917** Xigduo and Metformin an Acidotic Cocktail for the Kidney/S.M. Rosa Santiago, San Juan, Puerto Rico
- P918** Dialysate Discoloration Following Vitamin B12 Infusion Resulted in a False Blood Leak Alarm/A.R. Akkawi, Wichita, KS
- P919** Rare Association of Life-threatening Hypokalemia Secondary to Rituximab Infusion/C.D. Miks, Norfolk, VA
- P920** Back to the Basics: A Case of Sodium Bicarbonate Toxicity/J.M. Habibullah, New Hyde Park, NY
- P929** Vancomycin Induced Acute Interstitial Nephritis Causing Renal Failure/K. Dekitani, Los Angeles, CA
- P930** Acetaminophen Induced Liver Injury Precipitating Neuroleptic Malignant Syndrome Due to Depot Formulation of Haloperidol/N.J. Flores, Springfield, MA
- P931** Shock Due to Minoxidil Toxicity Related to Medication Dispensing Error/N. Siddiqui, Queens, NY
- P932** Intralipids for Refractory Shock in a Case of Unknown Toxin/B.H. Screws, Springfield, MA
- P933** Nose Necrosis in Septic Shock: Cocaine Use With Confounding Factors/M.U.Z. Mirza, Lahore, Pakistan
- P934** When Fevers and Chills Aren't Run of the Mill: A Case Study in Serotonin Syndrome/M. Neinast, Springfield, IL
- P935** Suspected Trimethoprim-sulfamethoxazole Induced Lung Injury in a Healthy Adult Female/T. Muradashvili, Waterbury, CT
- P936** Dranoderone Induced Pneumonitis in Liver Transplant Recipient on Immunosuppression/S.T. Virk, Pittsburgh, PA
- P937** A Case of Nifedipine Overdose Due to Drug Interaction With Paxlovid/J. Kepfinger, Charleston, WV
- P938** Remdesivir Related QT Prolongation Resulting in Cardiac Arrest/A. Krishnaiah, Scranton, PA
- P939** An Overdose Overload - A Unique Case Of Ibuprofen Overdose/S. Shah, Stratford, NJ
- P940** Calcium Channel Induced Thrombocytopenia: An Unfortunate Complication Secondary To Overdose/G. Habib, Syracuse, NY
- P941** A Critical Case of Metformin Associated Lactic Acidosis/A. Rueschhoff, Kansas City, KS
- P942** Trazodone Toxicity Leading to Severely Prolonged QTc Interval and Hypotension Requiring Intensive Care/G. Mohan, Long Branch, NJ
- P943** Fatal Case of Methotrexate Toxicity Presenting With Severe Myelosuppression and Punctate Cutaneous Eruption of the Skin Flexures/R.L. Imel, Toledo, OH
- P944** Dramatic Presentation Of Inhalational Heroin Use Refractory To Mechanical Ventilation Requiring Venovenous Extra Corporeal Membrane Oxygenation: A Case Report /A. Mittal, Danville, PA
- P945** A Toxic Ingestion Of Mr. Clean/A. Chajkowski, Toms River, NJ
- P946** Fentanyl Chest Syndrome: Where Time Is Not on Your Side/A. AL Ani, Galveston, TX
- P947** Methotrexate Toxicity in CNS Lymphoma/T. Haque, Glendale, AZ
- P948** From Transdermal Patches to Hypoxia: A Rare Complication of Lidocaine/C. Barrows, Albuquerque, NM

CLINICAL

THEMATIC POSTER SESSION

B48 TOXICOLOGY AND OTHER MEDICATIONS IN THE ICU: CASE REPORTS

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area I, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P922** Neuroleptic Malignant Syndrome Secondary to Olanzapine Use/A.J. Arumairaj, New York, NY
- P923** An Ophtha-MALA-gic Anomaly: Metformin Associated Lactic Acidosis Causing Transient Blindness/C. Fling, Seattle, WA
- P924** An Uncommon Presentation of Multi-organ Failure in the Setting of Kratom Overdose/M. Manzo, Augusta, GA
- P925** Unexpected Case Of Sacubitril-Valsartan Induced Brash Syndrome/J. Maurer, Flushing, NY
- P926** Immunotherapy Related New-onset Type 1 Diabetes Mellitus and DKA/M.T. Tun, Easton, PA
- P927** Urea Cycle Disorders - A Rare Cause Of Metabolic Encephalopathy In The Intensive Care Unit/B. Bangash, Grand Rapids, MI
- P928** Captive African Gaboon Viper (Bitis Gabonica) Envenomation: Complications of Toxins and Treatment/K.H. Libby, Richmond, VA

CLINICAL

THEMATIC POSTER SESSION

B49 CASE REPORTS IN NEUROCRITICAL CARE9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area I, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P950 Acute Pontine Infarct Due to Neurosyphilis/J. Swankutty, San Bernardino, CA**
- P951 Medical Management of Stroke-related Hemichorea/M. Haley, Portland, OR**
- P952 Refractory Seizures in Sturge Weber/T. Haque, Glendale, AZ**
- P953 A Case of Stiff Person Syndrome Complicated By Acute Interstitial Pneumonia: Successful Treatment With IVIG and Glucocorticoids/K. Kumar, Baltimore, MD**
- P954 A Rare Case of West Nile Virus Associated Subarachnoid Hemorrhage/N. Tangella, Newark, NJ**
- P955 Psychogenic Nonepileptic Seizure Concealed A Focal Epileptic Seizure/M. Sedaghati, Bronx, NY**
- P956 The Silent Migrants: Bilateral Septic Embolic Strokes Caused by Mitral Valve Endocarditis/H. Naveed, Kingwood, TX**
- P957 The Contrast Between Stroke and Stroke Mimics/S. Natarajan, Scranton, PA**
- P958 Paradoxical Improvement of Intraventricular Hemorrhage and Associated Hydrocephalus After Antithrombotics/A. Subedi, Sioux Falls, SD**
- P959 Intracranial and Visceral Arterial Embolization of an Undifferentiated Cardiac Sarcoma Treated With Embolectomy/L.C. Beltran, Berwyn, IL**
- P960 Not a Stroke of Luck!/P. Korpole, Southfield, MI**
- P961 It's All in Her Head: A Case of Extensive Dural Venous Sinus Thrombosis/L. Pavlik, Indianapolis, IN**
- P962 Acute Flaccid Quadriplegia of Unclear Etiology With Fatal Outcome in a Critically Ill Patient: A Case Report/S. Chetana Shanmukhappa, Rochester, NY**
- P963 Viral Reactivation: An Insidious Cause of Flaccid Paralysis/S.G. Chulani, Stony Brook, NY**
- P964 Foggy Thoughts: The Mystery Behind a Large Arachnoid Cyst and Cryptococcus Meningitis in an Immunocompetent Male/K. Andrade, Forest Hills, NY**

- P965 Double Trouble: Dual Pathogen Bacterial Meningitis/R. Mendpara, Lexington, KY**
- P966 Post-Vaccination Acute Disseminated Encephalomyelitis (ADEM): A Case Report/A. Mehta, Rancho Mirage, CA**
- P967 A Rare Case Of Vzv And Neurosyphilis Co-infection In A Hiv Patient/M. Morgan, Providence, RI**
- P968 Post-hypoxic Myoclonus: A Case of Lance Adams Syndrome/K. Anis, Springfield, MA**
- P969 Rare Case Of Ischemic Stroke, Pulmonary Embolism, Patent Foramen Ovale And Congenital Inferior Vena Cava Stenosis In A Patient/R. Garg, Wilkes-Barre, PA**
- P970 Fahr's Disease: An Incidental Finding/M. Qaiser, Stamford, CT**
- P971 Revisiting The Dragon: An Uncommon Case of Heroin Induced Toxic Leukoencephalopathy With Cerebellar Sparing/S.G. Barraqueta, Brooklyn, NY**
- P972 Chasing the Dragon a Rare Case of Heroin Induced Leukoencephalopathy/A. Mujahid Ali, Queens, NY**
- P973 Streptococcus Intermedius Brain Abscesses in an Otherwise Healthy Young Man/M. Cheema, Port Jefferson, NY**
- P974 Pyogenic Ventriculitis Secondary to Streptococcus Pneumoniae Pneumonia/A.N. Qadri, Olympia Fields, IL**

CLINICAL

THEMATIC POSTER SESSION

B50 CASES IN PULMONARY CRITICAL CARE9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area F, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P653 Leukemic Pulmonary Infiltrates in a Neutropenic Patient/L. Al Bizri, Cleveland, OH**
- P654 The Curious Case of a Rare Cancer and an Endless Hemothorax/K. Pitka, San Antonio, TX**
- P655 Butane Hash Oil-induced Spontaneous Pneumomediastinum and Acute Respiratory Distress Syndrome Necessitating Extra Corporeal Membrane Oxygenation/A. Jain, Johnstown, PA**
- P656 Hypereosinophilic Syndrome: A Case of Hypoxic Respiratory Failure/R. Geringer, Omaha, NE**
- P657 Thoracentesis Leading to Intercostal Artery Laceration in a Postoperative Coronary Artery Bypass Graft Patient/A. Othman, Johnson City, TN**

- P658 Malice in the Mediastinum: A Case of Fibrosing Mediastinitis and Hemoptysis**/J.L. Peng, Maywood, IL
- P659 PALs Are Challenging to Mechanically Ventilate: Chronic Tracheopleurocutaneous Fistula**/J. Ninan, Rochester, MN
- P660 A Rare Case of Acute Fulminant Cryptogenic Organizing Pneumonia**/A. Nasrullah, Pittsburgh, PA
- P661 Diffuse Alveolar Hemorrhage Without The Hemoptysis- A Case Report**/G. Primera, Springfield, MA
- P662 Sail Sign: Why Recognizing Radiographic Patterns On Chest X-ray Is Important**/A. Krebs, Danville, VA
- P663 Massive Hemoptysis Years After Lung Resection: A Rare Case Where Distorted Lung Architecture Eroded Surrounding Blood Vessels Due to Chronic Cough**/P. Weeraddana, Danbury, CT
- P664 A Unique Case of Respiratory Arrest in the Intensive Care Unit**/H. Bakalli, Los Angeles, CA
- P665 Nodular Consolidations as a Manifestation of Chronic Rejection Physiology in a Lung Transplant Recipient**/M.T. Olson, Phoenix, AZ
- P666 Suspected Solitary Pulmonary Nodule Later Diagnosed as Post-transbronchial Biopsy Hematoma**/M.T. Olson, Phoenix, AZ
- P667 Diffuse Alveolar Hemorrhage In A Patient With End-Stage Liver Disease**/I. Joshi, Washington, DC
- P668 A Case of Idiopathic Multicentric Castleman Disease in Which High-Flow Nasal Cannula/Non-Invasive Positive Pressure Ventilation With the Same Devices Was Useful in Severe Type 2 Respiratory Failure and Pulmonary Hypertension**/M. Okuda, Kawachinagano, Japan
- P669 Central Sleep Apnea in a Patient With Submassive Pulmonary Embolism and Underlying Obstructive Sleep Apnea and Obesity Hypoventilation Syndrome**/M. Hirsh, Portland, OR
- P670 Hypoxic Respiratory Failure in a Patient With AIDS: PJP, Kaposi or Both? A Diagnostic Dilemma**/C. Cajuste, New York, NY
- P671 Bronchopleural Fistula as an Unexpected Complication of Routine Dental Care**/L.S.M. Tremblay, Cleveland, OH
- P672 Adult Respiratory Syncytial Virus Infection and Non-invasive Ventilation in Respiratory Failure**/G.C. Sun, Bronx, NY
- P673 Hepatopulmonary Syndrome: A Frequently Overlooked Diagnosis**/T.-A. Smith, Atlantis, FL
- P674 Platypnea-orthodeoxia Syndrome in a Patient - What Caused the Shunt**/J. Rutowski, Buffalo, NY
- P675 Parapharyngeal Abscess; A Rare Complication Of Endotracheal Intubation**/M. Qaiser, Stamford, CT
- P676 A 41-year-old Woman With Cyanosis and Nitrituria**/J. Fox, Boston, MA

BEHAVIORAL • CLINICAL • TRANSLATIONAL
THEMATIC POSTER SESSION
B51 ENVIRONMENTAL AND CLINICAL EPIDEMIOLOGY OF AIRWAY DISEASE, ASTHMA, AND COPD
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area H, Hall C (Lower Level)
Viewing: Posters will be on display for entire session

11:30-1:15
Discussion: 11:30-12:15 authors will be present for individual discussion

12:15-1:15 authors will be present for discussion with assigned facilitators.

- P792 Adult Patients Diagnosed With Obesity Have an Increased Likelihood of Having a Concomitant Diagnosis of Dyspnea**/J. Granados, Dallas, TX
- P793 Patient Satisfaction With the Management of Chronic Cough in Canada: Results From a National Patients' Survey**/T. Abraham, Kirkland, Canada
- P794 The Impact of Insomnia and Depression on Asthma Control**/S. Rhoads, Aurora, CO
- P795 Association Between Educational Level and Asthma: Potential Mediation by Lifestyle Profiles in the French Nutrinet-santé Cohort**/A. Bédard, Villejuif, France
- P796 Feasibility of Multi-dimensional Remote Monitoring of Indoor Air Quality and Asthma Control Among High-risk Urban Pregnant Women**/A. Wang, New York, NY
- P797 The Effect of Classroom Temperature and Relative Humidity on Self-reported Upper Respiratory Infections in Elementary School Children With Asthma**/M.S. Kelly, Boston, MA
- P798 Sex Differences in Asthma Readmissions, a Population Health Study**/A. Hills, Aurora, CO
- P799 The Cost of Asthma Exacerbations in Denmark**/A.H. Røvsing, Hvidovre, Denmark
- P800 Cognitive Interview Validation of a Novel Household Hazard Vulnerability Assessment**/J.P. Castner, Grand Island, NY
- P801 Visual Scale of Frailty (VS-frailty) as a Diagnostic Tool for Frailty Risk Assessment in Elderly Patients With Moderate to Severe Asthma**/R.G. Figueiredo, Feira De Santana, Brazil
- P802 Assessment of the Validity of the University of California San Diego Inhalant Use Questionnaire**/N. Bhango, La Jolla, CA
- P803 Predictors of Mortality in Admissions for Status Asthmaticus**/G. Mohan, Long Branch, NJ

- P804** The Prevalence of Allergic Rhinitis in Asthmatic Patients and Association Between Allergic Rhinitis and Asthma Control in Thailand/T. Sriprasart, Bangkok, Thailand
- P805** Air Pollution Exposure Among Adult Chronic Airway Disease Patients in the Gambia: A Pilot Case-control Study/B.I. Awokola, Fajara, Gambia
- P806** Particulate Air Pollution Increased Severity in Chronic Obstructive Pulmonary Disease With Eosinophil Inflammation/H.-C. Chuang, Taipei, Taiwan
- P807** Population Management of Chronic Obstructive Pulmonary Disease: Coupling Hospital Metrics With 30-to-90-day Patient Outcome/A.L. Bui, Scranton, PA
- P808** Airway Predominant Copd Is Associated With Elevated Risk for Cognitive Impairment in Tobacco Exposed Older Adults/G.L. Kinney, Aurora, CO
- P809** The Usage and Impact of Race-based Correction in Pulmonary Function Testing Within Randomized Controlled Trials in COPD: A Systematic Review/J.Z. Wang, Ottawa, Canada
- P810** Racial Disparities Affecting Mortality Rates In Patients With Chronic Obstructive Pulmonary Disease/S. Singireddy, Athens, GA
- P811** Association of Childhood Socioeconomic Status With Dysanapsis Among Older Adults: The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study/B.M. Smith, Montreal, Canada
- P812** The Economic and Health Burden of COPD in North America: Forecasting Through 2050/E. Boers, Halifax, Canada
- P979** Impact of Moderate Ambient PM 2.5 Levels on Pulmonary Function in a Nonhuman Primate Model of Nonatopic Asthma/C.M. Royer, Davis, CA
- P980** The Role of Carbonic Anhydrase in Particulate Matter-Induced Inflammation in Macrophages/K. Sun, Chicago, IL
- P981** Plasma Sterols and Vitamin D Are Correlates and Predictors of Ozone-induced Responses in the Lung/A. Perryman, La Jolla, CA
- P982** Prolonged Inflammation Following Ozone Exposure in Endotoxemic Mice Is Associated With Reduced Resident Lung Macrophage Efferocytosis of Apoptotic Neutrophils/J.M. Radbel, New Brunswick, NJ
- P983** Pulmonary Effects of Silver Nanoparticle Preparations by Size, Shape and Chemical Composition/P. Chan, Davis, CA
- P984** Clinical Significance of Cadmium-Induced Endoplasmic-resident Protein 57 in Idiopathic Pulmonary Fibrosis/F.J. Li, Birmingham, AL
- P985** Molecular Features of Immune Cell Phenotypes in Sarcoidosis Granuloma Cells/S.-Y. Liao, Denver, CO
- P986** Autoimmunity Associated Pathology of Constrictive Bronchiolitis in Cutaneously Lewisite Exposed Mice/R. Surolia, Birmingham, AL
- P987** Sex Influences on Nuclear Receptor Expression in Electronic Cigarette Induced Lung Inflammation/S. Sharma, Bloomington, IN
- P988** HSP70 Is a Critical Regulator of HSP90 Inhibitor Effectiveness in Preventing HCl-induced Chronic Lung Injury and Pulmonary Fibrosis In Vivo and Alveolo-Capillary Barrier Dysfunction In Vitro/R.M.L. Colunga Biancatelli, Norfolk, VA
- P989** SERCA2 Protects Against Cardiac Damage and Dysfunction From Inhaled Halogens/S. Ahmad, Birmingham, AL

BEHAVIORAL • TRANSLATIONAL

THEMATIC POSTER SESSION

B52 MECHANISMS OF PULMONARY TOXICITY

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area J, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P977** A Method for the Isolation of Environmental Mycobacterium Species From Soil and House Dust/R.M. Carter, Brisbane, Australia
- P978** Bioactive Lipids Enhance Lung Macrophage IL-22 Signaling in a Mouse Model of Organic Dust Exposure/T.M. Nordgren, Fort Collins, CO

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

B53 PEDIATRIC ASTHMA BENCH TO BEDSIDE

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area C, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P249** **Viral Presence Associated With Decreased Nasal Microbiome Alpha Diversity and Differential Relative Abundance in Infancy**/Y.C. Qian, Toronto, Canada
- P250** **A Novel Study of Collective Effects of DNA Methylation and SNPs on Gene Expression in Nasal Epithelium of Youth With and Without Asthma**/S. Kim, Pittsburgh, PA
- P251** **Micrnas and Short-Acting Beta-2 Agonist Usage in Asthma**/R. Wong, San Diego, CA
- P252** **Symptom Control and Lung Function in Children With Asthma After COVID-19 Infection**/K.M. Gaietto, Pittsburgh, PA
- P253** **Association of Caregiver Depression With Childhood Asthma - a Nationwide Study**/S.A. Cabrera Guerrero, Washington, DC
- P254** **Parental Numeracy and Severe Asthma Exacerbations in a Prospective Study of Puerto Rican Youth**/A.B. Gutwein, Pittsburgh, PA
- P255** **Risk of Incident Asthma Among Asian American and Pacific Islander Children in a U.S. Integrated Healthcare System**/A.C. Arroyo, Stanford, CA
- P256** **Association Between Race and Obesity and Outcomes for Critical Asthma in Children**/P.A. Ross, Los Angeles, CA
- P257** **Long-term Ambient PM_{2.5} Exposure and Change in Lung Function Measures in Children With Asthma Receiving Low-dose Inhaled Corticosteroids**/F.J. Rosser, Pittsburgh, PA
- P258** **Proximity to Fast-food Restaurants and Pediatric Asthma Outcomes**/F.J. Rosser, Pittsburgh, PA
- P259** **Solar and Geomagnetic Activity Impacts Pulmonary Health Outcomes in Children With Asthma**/J.X. Lee, Boston, MA
- P260** **Effects of Ambient PM_{2.5} Pollution on High School Aged Children in Mobile, Alabama**/M. Cage, Mobile, AL
- P261** **Relationship of Lung Function to Allergic Sensitization in Children: Findings From the Urban Environmental and Childhood Asthma Birth Cohort**/A. Konno-Yamamoto, Madison, WI
- P262** **Feasibility and Acceptability of Point-of-Care Blood Eosinophil Count Together With Lung Function in Wheezy Preschool Children**/K.T. Lajunen, Turku, Finland
- P263** **Validation of a Revised Criteria for Defining Post Bronchodilator Spirometry Changes in Children With Asthma**/R. Alfouzan, Toronto, Canada
- P264** **Machine-learning for Automated Wheeze Detection in Children**/J.C. Schroeder, Washington, DC
- P265** **Safety, Accuracy and Performance of a Novel Wearable Sensor Device in Children With Asthma**/J.C. Sanchez, Aurora, CO
- P266** **8-Bromo-cAMP Attenuates Human Airway Epithelial Barrier Disruption Caused by Titanium Dioxide Fine and Nanoparticles**/C. Lee, Cleveland, OH
- P267** **Trainable Laminins Genes in Asthma Development**/M. Abu Risha, Borstel, Germany
- P268** **Omega-3 Fatty Acids Interact With DPP10 Region Genotype in Association With Childhood Atopy**/K. Lee-Sarwar, Boston, MA
- P269** **Real-world Evidence: Early Diagnosis of Childhood Asthma That Progresses to Severe Disease**/Y. Du, Bloomington, IN
- P270** **Effects of Environmental Exposures on Sickle Cell Disease Respiratory Events and Pain Crises in New York City**/A. De, New York, NY
- P271** **Investigating the Effect of Early Life Antibiotic Use on Asthma and Allergy Incidence in Over 600,000 Canadian Children: A Retrospective Cohort Study in British Columbia and Manitoba**/H. Lishman, Vancouver, Canada
- P272** **Household and Neighborhood Risk Factors Associated With Indoor Endotoxin Levels in an Urban Neighborhood**/S. Gueye-Ndiaye, Boston, MA
- P273** **Factors Affecting Recovery Time of Pulmonary Function in Children With Acute Asthma Exacerbation**/S. Ozdogan, Madera, CA
- P274** **Association of Viral Respiratory Illness With Asthma Hospitalizations and ED Visits**/E.E. Mchugh, Houston, TX
- P275** **Timing of Albuterol and Transfer to the Pediatric Intensive Care Unit in Patients Admitted for Status Asthmaticus: A Matched Case-control Study**/Z. Ahmed, St Petersburg, FL
- P276** **Factors With Negative Impact on Adherence to Controller Therapy in Asthmatic Children**/C.C. Gheonea, Craiova, Romania
- P277** **The Impact of the COVID-19 Pandemic on Pediatric Emergency Department Visits for Asthma: A Scoping Review**/P. Law, Columbia, SC
- P278** **Effect of Acute COVID-19 Infection on Control, Quality of Life and Pulmonary Function in Children With Asthma**/L. Tan, Queens, NY
- P279** **Healthcare Quality Project: Evaluating Asthma In-person Educational Model Feasibility Among Patients Admitted With Asthma Exacerbation**/S. Al Qatarneh, Morgantown, WV
- P280** **An Early SYK Stop: Novel Frameshift Mutation in a Case of Neutrophilic Asthma**/C. Cruz Rivera, Ponce, PR
- P281** **Acute Pulmonary Edema After Extubation For Status Asthmaticus**/S. Chickmagalur, Houston, TX

- P282 Lungs on Lockdown - Three Children Requiring Extracorporeal Life Support for Status Asthmaticus After Pandemic-related Social Distancing/B.D. Sharon, Sacramento, CA**
- P283 Extensive Subcutaneous Emphysema and Pneumo Mediastinum Complicating an Acute Exacerbation of Bronchial Asthma in a Nigerian Adolescent/C.I. Ndukwu, Awka, Nigeria**
- P284 Allergic Broncho Pulmonary Aspergillosis (ABPA) As A Mass/S. Mariappan, Tirunelveli, India**
- P285 Bird Fancier's Lung in an Adolescent Male: A Case Report/K. Zahradin, Doha, Qatar**
- P286 Urinary Metabolite Signatures Are Associated With Low Cortisol Levels in Children Taking Inhaled Corticosteroids/D.T. Tran, Boston, MA**
- P287 Nasal Fluid Sphingolipids as a Marker for Asthma in Children/Z. Solomon, New York, NY**
- P288 Metformin Use Is Associated With Decreased Asthma Exacerbations in Adolescents and Young Adults/E. Ararat, Little Rock, AR**
- P289 Differences in Features of Built Environments at School vs. Home: A Pilot Study/S. Beshah, New York, NY**
- P290 Real-World Evidence: Effects of Inhaled Corticosteroids on Asthma Control and Lung Function Among Children With Severe Asthma/A.H. Owora, Bloomington, IN**
- P295 C. Elegans as a Model Organism for Studying Human Disease-associated ABCA3 Variants/J.A. Wambach, St. Louis, MO**
- P296 In Vitro Anti-sense Oligonucleotide (ASO) Correction and Population-based Frequency of a Pathogenic ABCA3 Splicing Variant Associated With Lethal Neonatal RDS/D.J. Wegner, St. Louis, MO**
- P297 Developmental Impact of Perinatal Exposure to Environmental Tobacco Smoke on Infant Rhesus Monkey Lungs/J. Seo, Davis, CA**
- P298 Maternal Exposure to Polycyclic Aromatic Hydrocarbons (PAH)s Causes Lung Microbiome Dysbiosis in Mice Lacking the CYP1A2 Gene - A Potential Protective Role/B. Moorthy, Houston, TX**
- P299 Genetic Foundation for Responsiveness to Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Extremely Low Birth Weight (ELBW) Infants/H.J. Sampath, Valhalla, NY**
- P300 Frequency of Inhaled Corticosteroid Use and Diagnosis of Asthma in Formerly Preterm Children With a History of Bronchopulmonary Dysplasia/C. Leon, Philadelphia, PA**
- P301 Long-term Survival After Chronic Respiratory Failure of Infancy in Ellis-Van Creveld Syndrome (EVC)/M. Olsakowski, Wilmington, DE**
- P302 Congenital Hybrid Lung Lesions- Factors Associated With Severe Clinical Presentation/D. Gatt, Toronto, Canada**
- P303 Recurrent Bronchiolitis: A Bridge To Diagnosis/D. Gatt, Toronto, Canada**
- P304 Histologic Features And Decreased Lung Foxf1 Gene Expression In Severe Bronchopulmonary Dysplasia Without A Genetic Diagnosis Of Alveolar Capillary Dysplasia/C. Galambos, Aurora, CO**
- P305 When the Gut Communicates Directly to the Lung. A Case of Congenital Esophageal Lung/J. Lee, Palo Alto, CA**
- P306 Undiagnosed H-type Tracheoesophageal Fistula In A Toddler Contributing To Chronic Lung Disease Following Neonatal Severe Covid-19 Infection/A.F. Brown, Birmingham, AL**
- P307 Esophageal Bronchus/H. Ahmad, Seattle, WA**
- P308 Two Different Courses in Children With Tracheal Cartilaginous Sleeve/S. Gannarapu, Brooklyn, NY**
- P309 Recurrent Apneic Episodes and Stridor Secondary to Innominate Artery Compression Syndrome/S.J. Deskins, Morgantown, WV**
- P310 Congenital Lobar Emphysema: A Rare Cause of Respiratory Failure in Neonates/S.J. Deskins, Morgantown, WV**

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

B54 EARLY ORIGINS OF PEDIATRIC LUNG DISEASE

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area C, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P292 Sex-specific Differences in Cell-cell Communication Patterns and Receptor-ligand Interactions in the Developing Lung: Implications for Bronchopulmonary Dysplasia/K. Lingappan, Philadelphia, PA**
- P293 Morphomolecular Pathobiology of the Capillary Network in Alveolar Capillary Dysplasia/J.C. Kamp, Hannover, Germany**
- P294 Impaired Myofibroblast Proliferation Drives Pathologic Alveolar Simplification/I.S. Khan, San Francisco, CA**

- P311** **A Case of Hemoptysis Due to Unilateral Pulmonary Vein Atresia**/C. Mertens, Birmingham, AL
- P312** **A Pulmonary Perspective of De Novo Pathogenic Variant in the Gene SAMD9 Causing Mirage Syndrome**/J. Valencia, Norfolk, VA
- P313** **Late Presenting Congenital Diaphragmatic Hernia Initially Diagnosed as a Splenule on CT Imaging**/Y. Sun, Boston, MA
- P314** **Recurrent Congenital Diaphragmatic Hernia Presenting as Pleural Effusion: An Unusual Presentation of a Common Complication**/T.G. Allen, Charlotte, NC
- P315** **Congenital Diaphragmatic Hernia Presenting As Lower Lobe Pneumonia**/S. Shajimon, Philadelphia, PA
- P316** **A Winding Path to a Diagnosis: A Case of Alveolar Capillary Dysplasia With Misalignment of the Pulmonary Veins**/F.A. Almulhim, Edmonton, Canada
- P317** **Pulmonary Interstitial Glycogenosis in a Neonate With Hypoplastic Left Heart Syndrome**/Y.A. Yu, Los Angeles, CA
- P318** **Pulmonary Interstitial Glycogenosis In A Neonate With Congenital Diaphragmatic Hernia**/H.J. Choi, Los Angeles, CA
- P319** **A Rare Case of Cleidocranial Dysplasia Causing Lung Herniation in the Setting of an Acute Viral Infection**/M. Rehman, Morgantown, WV
- P320** **A Case of a Hybrid Congenital Lung Abnormality in an Asymptomatic Teenager**/N.M. Bulang, El Paso, TX
- P321** **Rare Case of Hypoxia in a Toddler**/E. Stekolchik, Wilmington, DE
- P322** **Incidental Finding of a Very Rare Congenital Lung Disorder**/H. Mirzan, Jacksonville, FL
- P323** **Extremely Preterm With One Pathogenic Variant CCDC39 and Chronic Hypoxemic Respiratory Failure**/S. Zuleta, Houston, TX
- P324** **Management of Pulmonary Complications of Pregnancy in a Patient With Spondylocostal Dysostosis**/L. Bolden, Minneapolis, MN
- P325** **Lung Resiliency Following Lung Perforation in a Neonate**/A. Jostes, Los Angeles, CA
- P326** **The Effects of Childhood Opportunity on Home Oxygen Therapy (HOT) Duration in Preterm Infants**/K. Richard, Boston, MA
- P327** **Predictive Value of Early Salivary MiRNAs in Preterm Infants With Bronchopulmonary Dysplasia**/R. Siddaiah, Hershey, PA
- P328** **Alveolar Cell Pathology in Pompe Disease**/L. El Haddad, Durham, NC
- P329** **Cellular Senescence Is Associated With Trisomies During Lung Development**/R. Belgacemi, Torrance, CA

CLINICAL

THEMATIC POSTER SESSION

B55 GETTING TO THE HEART OF CARDIOPULMONARY ANOMALIES AND DIAGNOSTIC DILEMMAS IN PH

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion

12:15-1:15 authors will be present for discussion with assigned facilitators.

- P115** **Double Negative Is Positive - Anomalous Aortic Origin of the Left Coronary Artery Saved by a Bicuspid Aortic Valve**/G. Mohan, Long Branch, NJ
- P116** **Pulmonary Arteriovenous Malformation Leading to Embolic Stroke**/G. Mohan, Long Branch, NJ
- P117** **A Rare Complication Encountered During Cardiac Catheterization: Pulmonary Arteriovenous Malformation**/N. Yosry, Toms River, NJ
- P118** **Cavitation Carving a Forbidden Communication: A Case of Transdiaphragmatic Systemic-Pulmonary Artery Fistula**/S.T. Virk, Pittsburgh, PA
- P119** **A Ticking Time Bomb: Untreated Pulmonary Arteriovenous Malformation Leading to Brain Abscess**/S.C. Liu, Portland, OR
- P120** **Rare Diagnosis of Incidental Partial Anomalous Pulmonary Venous Return by Chest X-Ray**/K.R. Mcleod, Aurora, CO
- P121** **Hole-y Hypoxia! A Case of Profound Hypoxia and Platypnea-orthodeoxia Secondary to PFO/C.** Quartermaine, Columbus, OH
- P122** **Pulmonary Hypertension in a Patient With Left-Sided Partial Anomalous Pulmonary Venous Return**/K. Pope, Aurora, CO
- P123** **Follow The Bubbles! An Unexpected Cause of Right-to-left Shunting**/N. Sharma, Knoxville, TN
- P124** **The Road Less Travelled By: A Presentation of Pulmonary Arterial Hypertension in Association With Partial Anomalous Pulmonary Venous Return**/V. Williams, Weston, FL
- P125** **Unilateral Pulmonary Artery Atresia - A Rare Case of Pulmonary Hypertension**/R. Iverson, Portland, OR
- P126** **Chronic Thromboembolic Pulmonary Hypertension in a Patient With Hereditary Hemorrhagic Telangiectasia**/C. Eagan, Gainesville, FL

- P127 Refractory Bronchospasm Due to Inhaled Veletri in a Patient With Acute COVID-19 Associated Respiratory Failure/T.C. Hammond, Santa Monica, CA**
- P128 Rare Presentation In A Rare Disease/A.M. Al-Dobyany, Mecca, Saudi Arabia**
- P129 DAH In PAH: Vaping Associated Lung Injury In A PAH Patient/D. Zusin, Norfolk, VA**
- P130 An Unusual Cause of Shortness of Breath in an Underserved Patient: Hepatopulmonary Syndrome/J.R. Flores Gonzalez, Harlingen, TX**
- P131 A Case Of Severe Pulmonary Arterial Hypertension And Cardiac Tamponade: A Clinical Dilemma/S. Toth, Omaha, NE**
- P132 Successful Transition From Oral Selexipag To Treprostinil/A. Pham, Honolulu, HI**
- P133 Unilateral Ground Glass Opacity After Left Ventricular Assist Device Implant/C. Benson, Hershey, PA**
- P134 Acute Nitroglycerine Induced Hypoxemia/K.H. Patel, Brooklyn, NY**
- P135 Lung Reperfusion Injury Following Pericardiocentesis for Cardiac Tamponade/J. Fagg, Springfield, IL**
- P136 Cardiopulmonary Powder Keg: Rapid Hemodynamic Decompensation in Previously Undiagnosed Pulmonary Hypertension Due to Myelofibrosis/A. Gazda, New York, NY**
- P137 Birth History: An Often Missed Clue For The Differential Diagnosis/Z.W. Blair, Dallas, TX**
- P138 An Unusual Cause of Pulmonary Artery Hypertension in Adult/S. Subramaniam, Thanjavur, India**
- P139 Babesiosis Associated Pericarditis/R. Dua, Long Branch, NJ**
- P140 It's Not Pneumonia! A Case Of Unilateral Pulmonary Edema With Acute Respiratory Distress Syndrome (ARDS)/A. Ketkar, Long Branch, NJ**
- P141 Posterior St Elevation Myocardial Infarction. Is It Truly?/S.K. Kommineni, Johnson City, TN**
- P142 Bedside PHOCUS (Pulmonary Hypertension On Cardiac Ultrasound) - A Resident's Evil/J.B. Nudanu, Fresno, CA**
- P143 Friday Leukemia? When a Patient With Acute Myelocytic Leukemia Present With Pneumonia on a Friday/J.J. Adams Chahin, San Juan, Puerto Rico**
- P144 A Walking Cardiac Tamponade/A. Mahmoud, Paterson, NJ**
- P145 An Accidental Finding of Brugada Pattern in an Asymptomatic Woman/M. Alam, Hialeah, FL**
- P146 Concomitant Myocardial Infarction, Pulmonary Embolism And Anoxic Encephalopathy In A Patient With Paradoxical Embolism Due To Patent Foramen Ovale/S.R. Mekala, Kalamazoo, MI**
- P147 Perspectives Of Hepatopulmonary Syndrome: Presentation, Pathophysiology And Palliation/J.K. Khosa, Loma Linda, CA**
- P148 A Curious Case Of Platypnea-Orthodeoxia Syndrome/A. Singh, Farmington, CT**
- P149 Lung Loses to Liver: When to Suspect Hepatopulmonary Syndrome?/F. Ghazal, Farmington, CT**
- P150 "High-Risk" Hepatopulmonary Syndrome! A New Concern?/P. Arun Kumar, Worcester, MA**

CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

B56 -OMICS, MACHINES, AND DEVICES IN PULMONARY HYPERTENSION

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P152 High-throughput, Automated Analysis of Blood Vessel Histomorphometry in Two Rat Models of Pulmonary Arterial Hypertension/C. Serdjebi, Marseille, France**
- P153 Artificial Intelligence-Based Analysis Differentiates PAH From PH Using Non-Contrast Chest CT Scans/Q. Maloir, Liège, Belgium**
- P154 A Step Towards Early Detection of Pulmonary Hypertension on Non-Contrast Chest CT Scans Using Artificial Intelligence/Q. Maloir, Liege, Belgium**
- P155 Spatial Transcriptomics Reveal Altered Gene Expression in Lungs of Rats With Sugen/Hypoxia-Induced Pulmonary Hypertension/J.R. Klinger, Providence, RI**
- P156 Transcriptomic Analysis of Peripheral Blood Mononuclear Cells to Dissect Smoking-related Molecular Abnormalities in Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension/I. Zhyvlylo, Davis, CA**
- P157 The Peripheral Blood Transcriptome and Right Ventricular Dysfunction in Acute Pulmonary Embolism/M.M. Cirulis, Salt Lake City, UT**
- P158 Single-nuclei Transcriptomics Reveal Cell Type-specific Transcriptional Programs and Cell Status Change in Right Heart Failure Due to Pulmonary Hypertension/B. Liu, Phoenix, AZ**
- P159 Single-cell Transcriptomics Analysis Affirms Phenotypic Changes and Altered Cellular Communication in Pulmonary Arteries From Hypoxia-induced PH Calves/C.-J. Hu, Aurora, CO**

CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

B57 INTERMEDIATES, CORRELATES, AND SURROGATES, OH MY!: NOVEL END POINTS AND ASSESSMENTS IN PVD

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P161 Win Ratio Analysis of the FREEDOM-EV Trial - a Hierarchical Approach to Multiple Clinical Endpoints/R.J. White, Rochester, NY**
- P162 Impact of Body Position on Hemodynamic Measurements During Exercise: A Tale of Two Bikes/P. Kirupaharan, Philadelphia, PA**
- P163 Worth “Weighting”: A Single-center Cohort Study of Current and Historical Weight in Pulmonary Arterial Hypertension/L.J. Oppedgaard, Portland, OR**
- P164 D-dimer and Angiotensin-2 Are Markers of Hospitalization-free Survival and Treatment Response in Pulmonary Hypertension/H. Clark, Rochester, NY**
- P165 Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH (REPEAT-PAH)/C. Durrington, Sheffield, United Kingdom**
- P166 Changes in Human Neutrophil Elastase May Impact Pulmonary Vascular Reactivity in People With PAH/C.J. Dennis, Stanford, CA**
- P167 Frailty and Body Composition in Patients With Pulmonary Arterial Hypertension/M. Prakash, Philadelphia, PA**
- P168 Assessing the Correlation Between Actigraphy Data and Clinical Measures: Insights From the Adapt Registry/J. Gagermeier, Maywood, IL**
- P169 Pilot Study of a Novel Biosensor Device in Pulmonary Arterial Hypertension/J. Hsieh, Philadelphia, PA**
- P170 Association of Cerebrovascular Remodeling With Chronic Pulmonary Vascular Remodeling; Is Uric Acid the Missing Link?/M.A. Fini, Aurora, CO**
- P171 Relationship Between Hepatic Fat Content and Pulmonary Vascular Disease Severity in a Subset of the Pvdomics Cohort/B.E. Funke, Nashville, TN**
- P172 Role of Genetic Testing in Pulmonary Arterial Hypertension Evaluation: A Patient and Clinician Survey/J. Rice, Denver, CO**
- P173 Six-minute Walk Test Heart Rate Variability in Pulmonary Arterial Hypertension/S. Rusnak, Rochester, NY**
- P174 Hemodynamic Predictors of Mortality in Pulmonary Hypertension, a Secondary Data Analysis/A.G. Shepherd, Atlanta, GA**
- P175 Correlation of WHO Functional Class and Patient-Reported Outcome Measures in Adults With Pulmonary Arterial Hypertension/K. El-Kersh, Omaha, NE**
- P176 Home 6-Minute Walk Using Wearable Sensors/D. Lachant, Rochester, NY**
- P177 Activity Does Not Increase After Adding Vasodilators in Pulmonary Arterial Hypertension/D. Lachant, Rochester, NY**
- P178 Physical Activity Characteristics in Pulmonary Arterial Hypertension (PAH): The Pulmonary Hypertension Association Registry (PHAR)/M. Batson, Philadelphia, PA**
- P179 Older Patients With Pulmonary Hypertension Have Comparable Transplant-free Survival to Younger Patients at a Tertiary Referral Academic Pulmonary Hypertension Center/R.A. Estrada, San Antonio, TX**
- P180 Patients With Hispanic Ethnicity Have Similar Transplant-free Survival Compared to Non-Hispanics at a Tertiary Referral Academic Pulmonary Hypertension Center in South Texas/R.A. Estrada, San Antonio, TX**
- P181 Biopsychosocial and Economic Impact in Patients With Pulmonary Arterial Hypertension: Treatable Traits/B. Esper Baptista Da Costa, Goiânia, Brazil**
- P182 Vasodilator Therapy Does Not Change Heart Rate Variability in Pulmonary Arterial Hypertension/B. Gyawali, Rochester, NY**
- P183 Pulmonary Artery Pulsatility Index Is Associated With Pericardial Effusion in Patients With Systemic Sclerosis-related Pulmonary Hypertension/J. Vakhshoorzadeh, Boston, MA**
- P184 Non-invasive Evaluation of Oxygen Deficit in Pulmonary Vascular Disease/N. Patel, Los Angeles, CA**
- P185 Candidemia as a Risk Factor for Pulmonary Hemorrhage in Adults: A Preliminary Observation/N. Khouzam, Chicago, IL**
- P186 Gender Difference in Pulmonary Arterial Hypertension/J. Gatuz, Shreveport, LA**
- P187 Determinants of Right Ventricular Failure in Pulmonary Hypertension Type 1/K. El Gharib, New York, NY**
- P188 Cardiac Output Assessment by Thoracic Bio-reactance for the Follow-up of Patients With Pulmonary Hypertension Phreact Study/S. Turquier, Bron, France**

- P189** Predictors of Earlier PAH Combination Therapy: Findings From the Real-world in the US, Europe, and Japan/D. Lautsch, North Wales, PA
- P190** PHederation - The Federated Network of Real-World Data Assets in Pulmonary Hypertension/R.T. Zamanian, Stanford, CA
- P191** Long-term Ablation Outcomes of Atrial Flutter in Patients With Pulmonary Hypertension/H. Zhang, Beijing, China

BASIC • CLINICAL • TRANSLATIONAL
THEMATIC POSTER SESSION
B58 DON'T FORGET ABOUT THE BLOOD VESSELS! PULMONARY VASCULAR FUNCTION IN ACUTE LUNG INJURY
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area B, Hall C (Lower Level)
Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P193** Sod2 Is a Key Mechanistic Player in WWOX-mediated ARDS Resilience/W. Chen, Chicago, IL
- P194** Metabolic Acidosis Does Not Increase Lung Permeability in Carbonic Anhydrase IX Knockout Mice/R.P. Stevens, Mobile, AL
- P195** Sleep Fragmentation Results in Increased Vascular Permeability and Lung Injury Following Pneumonia/L. Zheng, Baltimore, MD
- P196** UCHL1, a Deubiquitinating Enzyme, Augments Endothelial Cell Barrier Function in Radiation-induced Lung Injury/Y. Epshtein, Chicago, IL
- P197** Functional Roles for CD26/DPP4 in LPS-induced Lung Injury in Mice/S. Sato, Chiba, Japan
- P198** Smoking and Outcomes in Candidates for Liver Transplantation: PVCLD2/C. Cecil, Philadelphia, PA
- P199** Pulmonary Embolism Induces Pneumonia-Like Lung Injury Beyond Pulmonary Infarction/L. Zhao, Shenyang, China
- P200** Developmental Expression of Paternally Expressed Gene-3 Promotes Angiogenic Function in General Capillary Endothelial Cells From the Early Alveolar Lung/M. Liu, Stanford, CA
- P201** Endothelial S-nitrosothiol Import via LAT1 Modulates Red Blood Cell Adhesion in the Mouse Lung/H. Zhu, Durham, NC

BASIC • CLINICAL • TRANSLATIONAL
THEMATIC POSTER SESSION
B59 BREAKING BAD: NEW DRUGS AND FORMULATIONS FOR PULMONARY HYPERTENSION AND RV FAILURE
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area B, Hall C (Lower Level)
Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P203** Longitudinal Use of Midodrine to Optimize Pulmonary Hypertension Therapies/Z. Safdar, Houston, TX
- P204** Endothelin Receptor Antagonists (ERA) and Integrase Inhibitors: Competition or Cooperation?/J.P.D. Silva Filho, Sao Paulo, Brazil
- P205** Use of Long-term Oxygen Therapy in Patients With Pulmonary Hypertension in Spain/I. Blanco, Barcelona, Spain
- P206** Tolerability of Treprostinil Dry-powdered Inhaler in Patients With Pulmonary Hypertension Related to Fibrosing Interstitial Lung Disease at a Large Respiratory Referral Center/M. Dalabih, Denver, CO
- P207** A First-in-Human Single/Multiple Ascending Dose Study of ANPA-0073, a Novel Small Molecule G-protein Biased Apelin Receptor Agonist, in Healthy Volunteers/M. Bach, South San Francisco, CA
- P208** Inhaled Milrinone in Pulmonary Hypertension: A Systematic Review and Meta-analysis/K. El Gharib, New York, NY
- P209** Study Design of the Decentralized EVOLVE Study Evaluating Real-world Use of Next Generation Infusion Pumps to Deliver Parenteral Treprostinil in Patients With Pulmonary Arterial Hypertension/M.R. Sketch, Durham, NC
- P210** Right Ventricle Specific Therapies in Acute Respiratory Distress Syndrome: A Scoping Review/S. Ganeriwal, Cleveland, OH
- P211** Therapeutic Potential Of ACE2-Ang-(1-7)-MAS Axis on Right Ventricular Remodeling in Pulmonary Hypertension/Z.-K. Dai, Kaohsiung, Taiwan
- P212** A Phase I Clinical Trial Assessing the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of NTP42:KVA4, a Novel Thromboxane Receptor Antagonist, in Healthy Subjects/B.T. Kinsella, Dublin, Ireland

- P213** **ELEVATE 2: Baseline Demographic Characteristics From the Phase IIB Study of the Efficacy and Safety of Two Doses of Rodatristat Ethyl When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension/A.** Skride, Riga, Latvia
- P214** **Extended Pulmonary Retention of Inhaled Liposomal Treprostinil (I606) Correlated With Pharmacodynamics and Plasma Pharmacokinetics/P.** Kan, Taipei, Taiwan
- P215** **Dose-response Analyses of Treprostinil Inhalation Powder in PAH and Its Effect on 6MWD/K.** El-Kersh, Omaha, NE
- P216** **Real-world Use of Upfront Combination Therapy in Pulmonary Arterial Hypertension (PAH) Patients/C.** Paoli, Titusville, NJ
- P217** **Effectiveness and Safety of Riociguat as First-line or Combination Therapy in Pulmonary Arterial Hypertension (PAH): A Riociguat Users (ROAR) Registry Analysis/R.J.** White, Rochester, NY
- P218** **Treprostinil Palmitil Hydrolysis Is Facilitated by Lung Esterases/T.L.** Nguyen, Bridgewater, NJ
- P219** **RKER-012, a Novel Activin Receptor Type IIB (ActRIIB) Ligand Trap, Inhibited Mediators of Dysregulated Vascular Remodeling in Pulmonary Endothelial and Smooth Muscle Cells/A.** Gudelsky, Lexington, MA
- P220** **The Influence of Route and Formulation on the Pulmonary Pharmacokinetics of Imatinib in Nonclinical Species/R.** Niven, Waltham, MA
- P221** **ACE2 Treatment of Pulmonary Hypertension Requires the Mas1 Receptor, But Ang(1-7) Is Not the Ligand/J.D.** West, Nashville, TN
- P224** **17 β -estradiol Prevents NLRP3 Activation and Contractile Dysfunction in Right Ventricles and Right Ventricle Cardiomyocytes From Rats With Pulmonary Hypertension/R.** Sobrano Fais, Denver, CO
- P225** **The Critical Role of High Mobility Group Box1 (HMGB1) in Regulating the Sex-Specific P53 Signaling in Pulmonary Arterial Hypertension/O.S.** Lawal, Tucson, AZ
- P226** **Genome-wide Association Analyses Identified Novel Susceptibility Loci for Pulmonary Embolism Among Han Chinese Population/Z.** Zhang, Beijing, China
- P227** **Early Non-invasive Predictors of Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia in Preterm Infants/R.** Siddaiah, Hershey, PA
- P228** **Quantitative Computed Tomography Lung Parenchymal Features Can Aid in Phenotyping of Group 1 and Group 3 Pulmonary Hypertension/K.** Dwivedi, Sheffield, United Kingdom
- P229** **Response to Inhaled Iloprost Better Predicts Long-Term Survival Than Nitric Oxide in Patients With Pulmonary Hypertension: Results From the Prospective Ovation Study (nct03044314)/R.A.** Krasuski, Durham, NC
- P230** **Associations Between Serum Activin A and Follistatin-Like 3 Levels and Outcomes in Pulmonary Arterial Hypertension/C.** Guignabert, Le Kremlin-Bicêtre, France
- P231** **Extracellular Vesicles From in Vitro and in Vivo Models of Acute Lung Injury Induce Endothelial Dysfunction in Naïve Pulmonary Endothelial Cells/B.** Guarino, Providence, RI
- P232** **Practices Affecting Opsumit® and Uptravir® atient Persistence Rates Utilizing Pulmonary Arterial Hypertension Clinical Site and Patient Perspectives: A US Qualitative Research Analysis (PERSIST)/C.** Mcevoy, St Louis, MO
- P233** **Loss of GATA6 in Lung Endothelial Cells Leads to ER Stress/UPR and Contributes to PAH Pathogenesis/V.** Dambal, boston, MA
- P234** **Coronavirus Disease Vaccination In Patients With Pulmonary Hypertension: A National Prospective Cohort Study/X.-H.** Wu, Beijing, China
- P235** **Assessment of Thermodilution Versus Direct Fick Cardiac Output Among Patients With Pulmonary Hypertension/A.J.** Brownstein, Los Angeles, CA
- P236** **Persistence and Predictors of Persistency for Pulmonary Arterial Hypertension (PAH) Patients on Selexipag in Canada: A Retrospective Claims Database Study/E.** Ibrahim, Toronto, Canada
- P237** **Assessment of Right Ventricular Work in Precapillary Pulmonary Hypertension/G.** Csósza, Budapest, Hungary

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

B60 LIFE MOVES FAST! LATE BREAKERS IN PULMONARY HYPERTENSION

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P223** **Circulating Stem, Progenitor and Endothelial Cells and Their Relationship to Disease Severity in Pulmonary Arterial Hypertension (PAH)/C.** Johnson, Bethesda, MD

- P238** Low Cholesterol and Right Ventricular Function in Pulmonary Hypertension/B.F. Fakhry, Cleveland, OH
- P239** Evaluating the Impact of a Pulmonary Hypertension Task Force at a Single Urban Center/A.S. Saini, New York, NY
- P240** Single Cell RNA Sequencing Reveals Novel Endothelial and Mesenchymal Cellular Interactions and Cellstate Transitions in TNF-mediated Pulmonary Arterial Hypertension/S. Bhattacharya, Rochester, NY
- P241** The Impact of COVID-19 Extracellular Vesicles on Pulmonary Vascular Dysfunction in Diabetic Rats/A. Kumar, Kansas City, KS

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

B61 MORE OF COVID-19

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area A, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1** A Retrospective Study of the Effect of Ronapreve (Casirivimab and Imdevimab) Treatment on the Outcomes of Hospitalised COVID-19 Patients in a UK District General Hospital/E. Mahon, Telford, United Kingdom
- P2** Compared to the Wuhan Variant, Infection With Omicron and Delta Variants of SARS-CoV-2 Are Associated With Decreased Odds of Developing Post-Acute Sequelae of COVID-19/J. Bailey, Chicago, IL
- P3** Evidence That N95 Respirators Should Become the Standard for Source Control of SARS-CoV-2 and Other Respiratory Pathogens/D.K. Milton, College Park, MD
- P4** DOCK2 Is Involved in the Host Genetics and Biology of Severe COVID-19/H. Namkoong, Tokyo, Japan
- P5** Sequential Analysis of Bronchoalveolar Lavage Proteins Associated With Coagulation in Patients With SARS-CoV2 Infection/Z.M. Htun, Baltimore, MD
- P6** Male Gender Is Independently Associated With Poor Outcomes in COVID-19 Hospitalizations: A National Inpatient Sample Study/Z. Abdalla, Sharjah, United Arab Emirates
- P7** Radiographic and Clinical Corelations in Survivors With Post -ARDS Related to COVID-19 Two Years After Discharge From Hospitals/A.S. Sadigov, Baku, Azerbaijan
- P8** C Reactive Protein and Frailty in COVID-19/J.K. Graham, San Diego, CA
- P9** Associations of Institutional COVID-19 Mortality and Bacillus Calmette Guerin in Tikur Anbessa Specialized Hospital COVID-19 Treatment Center, Addis Ababa, Ethiopia/B.W. Haile, Addis Ababa, Ethiopia
- P10** Hyperoxemia as an Additional Source of Systemic Injury in Coronavirus Disease 2019 (COVID-19) Patients/I.Y. Valencia, Houston, TX
- P11** Relation Between Baseline Asthma Treatment and COVID-19: Evaluating the Data in National Medical Center in Japan/A. Tsukada, Tokyo, Japan
- P12** Does Remdesivir Increase the Risk of Pneumothorax in COVID-19 Infected Patients/R. Smidy, Brooksville, FL
- P13** Demographics and Outcomes of Young Adults Admitted With Coronavirus Disease 2019 (COVID-19)/C. Villarreal-Carrillo, Houston, TX
- P14** Radiological and Pulmonary Function Abnormalities in Post COVID Patients- a Prospective Cohort Study/A. Krishnan, Varanasi, India
- P15** Impact of Positive Sputum Cultures on Outcomes in Mechanically Ventilated Coronavirus Disease 2019 (COVID-19) Patients/V. Gomez, Houston, TX
- P16** Association of Clinical and Imaging Characteristics With Pulmonary Function Testing in Patients With Long-COVID/A.C. Lancaster, Baltimore, MD
- P17** Outcomes in Patients Who Received Tocilizumab for SARS-CoV-2 Acute Respiratory Distress Syndrome/P. Bergin, Dublin, Ireland
- P18** Acute Cerebrovascular Events Associated With COVID-19 Infection in Multi-ethnic Population in Hawaii/P. Shah, Honolulu, HI
- P19** Magnitude and Characteristics of COVID 19 Among Patients With Hematologic Malignancy at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia/A.Y. Ashamo, Addis Ababa, Ethiopia
- P20** The Impact of COVID-19 Vaccination on Disease Severity at a Teaching Hospital in Depok, Indonesia/N. Salsabila, Jakarta, Indonesia
- P21** Could Thromboelastography (TEG) Improve Outcomes for Critically Ill COVID-19 Patients: An Exploratory Observational Study/S.M. Duenas, Manhasset, NY
- P22** Combination Treatment of Molnupiravir With Sotrovimab for COVID-19 Patients in Japan/M. Seki, Hidaka City, Japan
- P23** Impact of Aspergillus Infection on Prognosis in Severe COVID-19 Patients/S. Kamimoto, Tochigi, Japan
- P24** Elucidating a Potential Relationship Between a Preexisting History of Asthma and Longitudinal Pulmonary Symptoms After COVID-19 Infection/J.E. Dobbs, Washington, DC

- P25 Mortality and Hospitalization Outcomes Among Vaccinated Compared to Unvaccinated COVID-19 Patients/M. Ghaly, Dothan, AL**
- P26 The Ontario Multi-Regional Hospital Coronavirus Registry (COREG)-Lung Recovery Trajectory Sub-study/J. Kapralik, Hamilton, Canada**
- P27 Fatal COVID 19 Infection in an Adult Patient With Previous Miliary Tuberculosis: A Case Report/P. Pintac, Manila City, Philippines**
- P28 Improved Survival in Highly Religious Patients Hospitalized for COVID-19/S.M. Frent, Timisoara, Romania**
- P29 COVID: The Cranberry of Viral Illnesses/T.A. D'Amico, Norwalk, CT**
- P30 Sars_Cov2 Infection and Its Impact on Cystic Fibrosis Patients - An Indian Study/V. Kizhikkilot, Chennai Tamil Nadu, India**
- P31 Defining Predicting Factors for In Hospital Mortality of COVID-19 Patients/D. Handayani, Jakarta Timur, Indonesia**
- P32 Comparison of the Clinical and Virological Characteristics of SARS-COV-2 Omicron BA.1/BA.2 and Omicron BA.5 Variants: A Prospective Cohort Study/S.-W. Kang, Seoul, Korea, Republic of**
- P33 Airway Epithelial Repair and SARS-CoV-2 Spike S1 Protein Treatment/T. Guo, Vancouver, Canada**
- P34 Successful Use of Monoclonal and Antiviral Therapy in Immunocompromised Patients With Persistent and/or Relapsing COVID-19/L. Gori, Florence, Italy**
- P35 Autoantibody Profiles Differ in Immunocompromised Hospitalized COVID-19 Patients, But Are Not Associated With Mortality/H.D. Morin, Stanford, CA**
- P36 Diverse Gene Mutations by Molnupiravir After B-Cell Depletion Therapy: Report of 2 COVID-19 Cases/T. Masuda, Shizuoka, Japan**
- P37 Prolonged COVID-19 Infection in B-cell Impairment and Treatment With Intravenous Immunoglobulin (IVIG)/S. Mehta, Saint Louis, MO**
- P38 COVID-19 Vaccination Is Not Associated With Abnormal Patient Reported Outcome Measures in Patients With Long-COVID: A Prospective Cohort Study/S.-E.-D. El-Akkad, Vancouver, Canada**
- P39 SARS-CoV-2: Playing by the Ear/N.R. Perkit, Worcester, MA**
- P40 Clinical Development of Inhaled Interferon Beta-1a (SNG001) for the Treatment of Patients With COVID-19 in the Home and Hospital Settings/P.D. Monk, Southampton, United Kingdom**
- P41 When Humoral Immunity Fails Due to Rituximab in COVID-19 Pneumonia/P. Ho, Wynnewood, PA**

- P42 Large Pneumatocele as a Rare Complication in COVID-19 (Delta Variant) Pneumonia/A. Gillissen, Reutlingen, Germany**
- P43 A Case of Immune Thrombocytopenic Purpura Secondary to COVID-19 Infection/A. Acharya, Kathmandu, Nepal**
- P44 Modulation of Sphingolipid Metabolism and SARS-CoV-2 Infection in Lung/S.L. Single, Birmingham, AL**
- P45 Remdesivir and Survival Outcomes in Critically Ill Patients With COVID-19: A Multicentre Observational Cohort Study/C. Cilloniz Campos, Barcelona, Spain**
- P46 Evaluation of a Point of Care Rapid Antibody Test for the Diagnosis of Corona Virus Disease-19 (COVID-19) Infection in Indian Population/A. Mohan, New Delhi, India**
- P47 Assessing the Efficacy and Safety of Selective Serotonin Reuptake Inhibitors for Managing COVID-19 Patients: A Systematic Review and Meta-Analysis/F. Zhou, Hamilton, Canada**
- P48 Long-term Mortality in COVID-19 and Community-Acquired Pneumonia: A One-year Follow-up Study/R. Méndez Ocaña, Valencia, Spain**
- P49 Cardiopulmonary Changes in Patients Recovering From Acute COVID-19 Disease: A Prospective Observational Study/L.P.V. Kattamuri, New Delhi, India**
- P50 Thymic Hyperplasia After Severe SARS-CoV-2 Pneumonia/M.J. Cavaco, Torres Vedras, Portugal**

CLINICAL
THEMATIC POSTER SESSION

B62 FUNGI EVERYWHERE!

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area A, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P52 Precision Cut Lung Slices (PCLS) as an Ex Vivo Model to Study Pneumocystis Murina Survival/Growth/F.T. Munyonho, New Orleans, LA**
- P53 Characteristics of Pleural Coccidioidomycosis, a Single Center Experience/A.A. Abdalla, Phoenix, AZ**
- P54 Lung Cavity - A Mystery/T.H. Rahmlow, Harlan, KY**
- P55 Pulmonary Mucormycosis Requiring Cryoextraction: A Case Report and Literature Review/A. Jahangir, Oklahoma City, OK**

- P56 All That Glitters Is Not Gold: An Unexpected Case of Plastic Bronchitis/C.** Chou, New York, NY
- P57 Recurrent Pneumothorax Secondary To Blastomycosis: An Atypical Presentation/D.** Azim, Karachi, Pakistan
- P58 Aspergillus Emphyema Thoracis - A Diagnostic and Therapeutic Challenge/V.** Reyes Pinzon, Chicago, IL
- P59 Angio-Invasive Pulmonary Mucormycosis Causing Pulmonary Artery Occlusion/D.** Lamorte, San Diego, CA
- P60 Fatal Massive Hemoptysis After Rapidly Progressive Invasive Aspergillosis/S.** Meredith, New York, NY
- P61 Lethal Invasive Aspergillosis In Context Of Metastatic Small Cell Carcinoma/C.** Tanba, Baltimore, MD
- P62 Two In One: Blastomycosis And Scar Carcinoma/S.** Quon, Sacramento, CA
- P63 Blastomycosis And Multiple Concurrent Pulmonary Infections In A Benralizumab-Treated Asthmatic/A.** Fortin, Sherbrooke, Canada
- P64 Isolated Aspergillus Tracheobronchitis: A Rare Cause of Airway Compromise in an Immunocompetent Host/A.** Cruse, Atlanta, GA
- P65 Chronic Cavitory Pulmonary Histoplasmosis: A Rare Manifestation Of Histoplasmosis In A Non Endemic Area/I.** Khatim, Albany, NY
- P66 Invasive Pulmonary Aspergillosis in the Setting of Undiagnosed Cushing's Disease/J.B.** Nudanu, Fresno, CA
- P67 Allergic Bronchopulmonary Aspergillosis Presenting as an Endobronchial Mass/C.F.** Kreisel, Washington, DC
- P68 Cerebral Abscess Caused by Microascus Cirrosus in a Lung Transplant Recipient/C.** Yurosko, Cleveland, OH
- P69 Endobronchial Aspergilloma: A Rare Presentation of Pulmonary Aspergillosis/M.** Sutherland, Kankakee, IL
- P70 Blastomycosis Induced Circumferential Tracheobronchial Thickening: A Case Report/R.S.** Samrah, Irbid, Jordan
- P71 Mycetoma In Honeycomb Cysts. A Case Report In Rheumatoid Arthritis-interstitial Lung Disease/J.L.** Galindo Pedraza, Bogota D.C., Colombia
- P72 Pneumocystis Jirovecii Pneumonia in an Adult Patient With Hyper IgE Syndrome/K.** Hamid, Sioux Falls, SD
- P73 Pulmonary Coccidioidomycosis in a 57-year-old Female: A Case Report and Review of the Literature/D.** Ashley, Houston, TX
- P74 Deceptive Deaminase: Coccidioides Emphyema With Elevated Adenosine Deaminase/N.J.** Schlund, San Antonio, TX
- P75 A Tale From the Crypt: A Case of Cryptococcus Gattii in an Immunocompetent Individual/N.** Chan, Greenville, NC
- P76 Chronic Cavitory Pulmonary Aspergillosis Mimicking as Malignancy/J.W.** Burgei, Sayre, PA
- P77 It Gets Tough When It Gets Cloudy, a Case of Pulmonary Alveolar Proteinosis (PAP)/G.** Thiab, Huntington, WV
- P78 Aspergillus Fumigatus Expresses a Structural CD47 Mimic, Which May Be Used to Evade Host Defense/E.** Matthaiou, Palo Alto, CA

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

B63 IMMUNOCOMPROMISED HOST PROBLEMS AND COMPLICATIONS

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area A, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P80 Steroid-Related Pneumocystis Pneumonia: A Devastating Toll/S.** Rhoads, Aurora, CO
- P81 Diagnostic Challenges Posed by Invasive Pulmonary Fungal Infections in Patients With Hematological Malignancies/S.Y.** Park, Redwood City, CA
- P82 Immunotherapy With Pam2+ODN Improves Morbidity and Mortality Against Influenza-associated Pulmonary Aspergillosis in a Corticosteroid-immunosuppressed Murine Model/J.** Pantaleón García, Houston, TX
- P83 Determine the Extent and Type of Tissue Injury Caused by Mucorales in Lungs Using Pneumonia Mouse Model/E.** Youssef, Torrance, CA
- P84 Type I Interferon Receptor 2 (IFNAR2) Is Required to Regulate TNF α -mediated Damaging Inflammation During Aspergillus Pulmonary Infection/K.M.** Shepardson, Merced, CA
- P85 Outcomes of Solid and Hematopoietic Stem Cell Transplant Recipients With Cytomegalovirus Pneumonia: A Retrospective Cohort Study/J.** Anwar, Morgantown, WV
- P86 Nocardiosis in Lung Transplants Recipients: Incidence and Case Descriptions Form a High-volume Center/D.C.** Fleitas Sosa, Philadelphia, PA
- P87 Mediastinal Tuberculosis Leading To The Development Of An Esophagomediastinal Fistula In An HIV/AIDS Patient On RIPE Therapy/A.J.** Duval, Newark, NJ

- P88 Erosion of Mediastinal Lymph Node Into the Esophagus - A Case of HIV-TB Co-infection Complicated by Esophago-Mediastinal Fistula Managed With Adjunctive Endoscopic Intervention/D. Kim, Newark, NJ**
- P89 Clinical Characteristics and Outcomes in Transplant Recipients With Community Acquired Pneumonia/S. Khurana, Louisville, KY**
- P90 Atypical Acute Hypoxemic Respiratory Failure in a Lung Recipient: The Power of Doxycycline/D. Razia, Phoenix, AZ**
- P91 An Unusual Diffused Tuberculosis Infection Associated With Tuberculosis-Immune Reconstitution Inflammatory Syndrome In A Non-hiv Patient/Y.B. Moreno, Fort Lauderdale, FL**
- P92 AIDS in 2022: Not a Forgotten Diagnosis/K. Golubykh, Harrisburg, PA**
- P93 Herpes Simplex Virus-1 Endobronchial Pseudotumor in an HIV Patient Presenting With Hypoxemic Respiratory Failure/T.J. Martinez, Los Angeles, CA**
- P94 Subacute Invasive Pulmonary Aspergillosis 11 Years Post Radiotherapy for Breast Cancer/P. Ozueh, Longview, TX**
- P95 Isolated Reduction in Diffusing Capacity (isoDLco) Is a Reversible Lung Function Phenotype in a Longitudinal Cohort of People Living With HIV/J.R. Branchini, San Francisco, CA**
- P96 A Routine Colonoscopy With an Unexpected Finding: Reactivation of Histoplasmosis in a Patient on Tocilizumab/N. Abdelwahab, Minneapolis, MN**
- P97 Pulmonary Histoplasmosis in a Patient With Inflammatory Bowel Disease (IBD) on Infliximab/J.E. Verdone, Baltimore, MD**
- P98 The Challenge of Multi-organism Lung Infection With Human Immunodeficiency Virus/I. Ortiz Velez, San Juan, PR**
- P99 Lung Cavitation as a Window to Unlocking the Diagnosis of Disseminated Cryptococcal Disease in an HIV-positive Patient/J.M. Ramakrishna, Rochester, MI**
- P100 Evolution of a Mass-like Lesion in a Lung Transplant Recipient/M.T. Olson, Phoenix, AZ**
- P101 Refractory Hypercalcemia Secondary to Pneumocystis Jirovecii Pneumonia in the Setting of Renal Transplant: A Case Report/L. Sangha, Harrisburg, PA**
- P102 Rapidly Progressive Rhino-orbital Mucormycosis in a Lung Transplant Recipient/D. Sindu, Phoenix, AZ**
- P103 Extensive Cystic Bronchiectasis Due to Histoplasma in a Patient With Human Immunodeficiency Virus (HIV) - Acquired Immunodeficiency Syndrome (AIDS)/G. Urdaneta, Miami Beach, FL**
- P104 Disseminated Blastomycosis With Miliary Pattern After Steroids/S. Ali, Albany, NY**
- P105 Disseminated Histoplasmosis In A Patient With Acquired Immunodeficiency Syndrome In A Non-Endemic Region (California)/A.T. Phan, Colton, CA**
- P106 A Case of Pneumocystis Jirovecii Pneumonia in a Patient With Mantle Cell Lymphoma on Rituximab/U. Ishtiaq, Poughkeepsie, NY**
- P107 Disseminated Nocardial Infection With Bacteremia and Brain Involvement in Lung Transplant Recipient/A.M. Shadid, Detroit, MI**
- P108 Pleuro-pulmonary Nocardiosis in a Patient With Monoclonal Gammopathy of Undetermined Significance (MGUS)/D. Ravi, Rochester, NY**
- P109 An Unusual Cause of Cavitory Lung Lesions in an Immunocompromised Patient/K. Brown, Philadelphia, PA**
- P110 A Propensity Score Matched Comparison of COVID-19 in Patients Living With Human Immunodeficiency Virus/R.J. Vender, Philadelphia, PA**
- P111 A Compromised Airway Due to Disseminated Mucocutaneous Monkeypox Infection/N. Gras, Chicago, IL**

BEHAVIORAL • CLINICAL • TRANSLATIONAL
THEMATIC POSTER SESSION
B64 THE MULTIPLE COMPONENTS OF PULMONARY REHABILITATION
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area J, Hall C (Lower Level)
Viewing: Posters will be on display for entire session 11:30-1:15
**Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.**

- P991 Impact of Surgery on Functional and Patient-reported Outcomes in Patients With Early-stage Non-small Cell Lung Cancer/K. Quadflieg, Hasselt, Belgium**
- P992 Functional and Patient-reported Outcomes at Diagnosis of Non-small Cell Lung Cancer/K. Quadflieg, Hasselt, Belgium**
- P993 Tracheal Phrenic Nerve Stimulation for the Induction of Diaphragm Contractions in Mechanically Ventilated Animals/E. Jaworski, Newark, NJ**
- P994 Measurement Properties of Functionality Performance-based Outcome Measures for Hospitalized Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Cosmin Systematic Review/N.T. Leonardi, Sao Carlos, Brazil**

- P995** Enrichment of Immune System Related Proteins in Circulating Extracellular Vesicles by Acute Exercise in Humans With and Without COPD/A. Abbasi, Torrance, CA
- P996** Metabolic Changes in Donor Lung During Ischemia as a Function of Time and Temperature/L. Loza, Philadelphia, PA
- P997** Current Status of Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease in South Korea/H. Joo, Uijeongbu, Korea, Republic of
- P998** Pulmonary Hypertension Patient Perspectives Towards Pulmonary Rehabilitation/M. Bailey, Rochester, MN
- P999** Patients With Acute Guillain-Barre Syndrome in Long-Term Acute Care/K. Weil, Syracuse, NY
- P1000** Pilot Clinical Study on the Safety, Tolerance and Comfort of Thoracicvibratory Therapy by Electrostimulation. Phase 1. The Electrovest Study/M.D.P. Cejudo Ramos, Seville, Spain
- P1001** Exploratory Efficacy Analysis of INSPIRE Open Label Extension Study With Inhaled Treprostinil (Yutrepia™)/C.D. Burger, Jacksonville, FL
- P1002** High Levels of Comorbidity Are Strongly Associated With Mortality in Patients Enrolled in Pulmonary Rehabilitation/A.J. Portillo, North Haven, CT
- P1003** Respiratory Symptoms, Health-Related Quality of Life, and Symptom Management in Ehlers-Danlos Syndrome and Generalized Hypermobility Spectrum Disorders/N. Al Kaabi, Toronto, Canada
- P1004** Reference Equation ??for the Six-minute Walk Test in the Ecuadorian Population/M.B. Noboa-Sevilla, Barcelona, Spain
- P1005** Home-based Pulmonary Rehabilitation and Health Coaching in Bronchiectasis/C. Batzloff, Rochester, MN
- P1006** Home Based Pulmonary Rehabilitation Delivered by a Newly Established Program Improves Dyspnea and Health Related Quality of Life in a Veteran Population/D.A. Breiburg, Palo Alto, CA
- P1007** A Quality Improvement Process to Optimize Hybrid Rehabilitation Delivery for Lung Transplant Candidates/L. Wickerson, Toronto, Canada
- P1008** Pleural Based Small Cell Carcinoma With Massive Pleural Effusion- A Rare Presentation/R. Meenakshisundaram, Sayre, PA
- P1009** A Unique Course: A Case Report Of Anomalous Pulmonary Artery In An Adult With Asthma Exacerbation/M. Owolabi, Newark, NJ
- P1010** Satisfaction With Virtual Pulmonary Rehabilitation for COPD Patients Using Peer Coaches/A.C. Singh, Pittsburgh, PA
- P1011** Feasibility of Respiratory Therapy Device Three-dimensional Printing in Clinician Offices/H.S. Sagoo, Willemstad, Curaçao
- P1012** Correlation of Subjective Perceived Activity and Weakness Score (PAWS) With Maximum Inspiratory Pressure (MIP), Maximum Expiratory Pressure (MEP) and Peak Inspiratory Flow Rate (PIFR)/M.A. Valdes, Knoxville, TN
- P1013** Early COPD Diagnosis: Age, Smoking, and Ethnicity Factors/J. Park, Corpus Christi, TX
- P1014** Validation of Body Composition by Bioelectrical Impedance Analysis for Chronic Respiratory Disease/T. Muraoka, Yokohama, Japan
- P1015** The Changing Face of Community Respiratory Care/M.C. Apps, Billericay, United Kingdom
- P1016** How Is the Endothelial Function Response to Non Invasive Ventilation in Hospitalised Patients With Chronic Obstructive Pulmonary Disease and Heart Failure Exacerbation/E.Z. Kabbach, Sao Carlos, Brazil
- P1017** Post-ICU Syndrome in Extracorporeal Membrane Oxygenation Survivors Treated at a Long-Term Acute Care Hospital/D.H. Tran, Baltimore, MD
- P1018** Use and Clinical Value of Whole Exam Sequencing in Patients With Severe Asthma/K. Spaulding, New Haven, CT
- P1019** Trajectories of Quality of Life Following Home-based Pulmonary Rehabilitation in COPD Patients/R. Benzo, Rochester, MN
- P1020** The Efficacy of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis/J.H. Lee, Busan, Korea, Republic of

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

B65 IMMUNE AND ENDOTHELIAL CELLS HIT BACK AT LUNG REPAIR

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area L, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

P1242 Common and Distinct Bronchoalveolar Lavage and Lung Immune Signatures in Fibrotic Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis/A.Y.-T. Zhao, New Haven, CT

P1243 ScRNAseq Analysis of Lung Macrophage-fibroblast Crosstalk/P. Yadav, San Francisco, CA

- P1244** SLC7A11 Inhibits Macrophage Efferocytosis and Promotes Pro-fibrotic Macrophage Phenotype in Fibrotic Remodeling of the Lung/M. Patil, Birmingham, AL
- P1245** Reprogramming Rogue Macrophages: Yeast Beta-glucan Microparticles as a Macrophage Modulator for Lung Fibrosis/S. Nael, Hamilton, Canada
- P1246** Mechanosignaling Modulates Macrophage Profibrotic Polarization Epigenetically/C. He, Birmingham, AL
- P1247** Peripheral Immune Cell Profiling Reveals Distinct Immune Hallmarks in Progressive Pulmonary Fibrosis/F. Hernandez-Gonzalez, Barcelona, Spain
- P1248** Unbiased Identification of Serum Response Factor as a Central Profibrotic Mechanism in Idiopathic Pulmonary Fibrosis/H. Olsson, Gothenburg, Sweden
- P1249** Mast Cell-expressed Membrane Protein 1 (MCEMP1) Deficient Mice May Be Protected Against Bleomycin-induced Pulmonary Fibrosis In Vivo/C.Y. Perrot, Tampa, FL
- P1250** Expression of PD-1/PD-L1 Axis and CD4/CD8 Ratio in Mediastinal Lymph Nodes of Human and Experimental Lung Fibrosis Indicates a Potential Therapeutic Target for Idiopathic Pulmonary Fibrosis/T. Karampitsakos, Patras, Greece
- P1251** Growth and Differentiation Factor-15 (GDF15) Is Associated With Vascular Remodeling in Pulmonary Fibrotic Disease/K. Raffensperger, Pittsburgh, PA
- P1252** The mTOR Strikes Back: Vaping Liquid Induced mTOR Hyperactivation in Lymphangioliomyomatosis (LAM) Exacerbates Endothelial Cell Apoptosis and Impairment of Network Formation Via Senescence Associated Secretory Phenotype (SASP) Factors/M. Ho, Toronto, Canada
- P1253** Circulating Extracellular Vesicles Isolated From Young Mice Protect Endothelial Cells and Exert Anti-fibrotic Effects In Vivo and Ex Vivo/F. Giani, Rochester, MN
- P1254** Myeloid-Dependent Immunosuppressive Features Drive IPF Progression/I.E. Fernandez, Munich, Germany
- P1257** Activation of Large Conductance K⁺ (BK) Channels Protects Against LPS-induced Pneumonia/T. Zyrianova, Los Angeles, CA
- P1258** Moderate Hypoxia Does Not Worsen Lung Injury in a Mouse Model of COVID-19/Y. Xu, La Jolla, CA
- P1259** Adaptation of Human Lung Endothelial Organotypic Model to Investigate Human Sepsis Patient Plasma/H.E. Faust, Madison, WI
- P1260** Role of Apoptosis Signal-regulating Kinase-1 (ASK1) in Influenza A Virus-induced Lung Injury/E.M. Gordon, Lexington, KY
- P1261** Neutrophil Heterogeneity Underlies Differential Susceptibility to Pulmonary Vascular Leakage During Murine Hepatitis Virus Strain 1 Infection of A/J and C57BL/6 Mouse Strains/H.H. Gong, Ann Arbor, MI
- P1262** Surfactant Protein-D (SP-D) Binding Against the SARS-CoV-2 Spike (S) Protein Using Quantum- and Classical In-silico Modeling: Role of Glycosylation/A. Haczku, Davis, CA
- P1263** Effects of Exposure to Environmental Pollution From Iron Ore Pellets on Elastase-induced Lung Inflammation: Evaluation of the Effect of Reduced Acetylcholine Transporter Expression in Mice/I.C. Tiberio, Sao Paulo, Brazil
- P1264** Understanding the Impact of Asthma on the Severe Form of COVID-19 Using Genomics/O. Amri, Saguenay, Canada
- P1265** Inhibition of Sphingolipid Synthesis Decreases SARS-CoV-2 Infection in Human Airway Epithelial Cells/R. Gomi, New York, NY
- P1266** Neutrophil Reduction Attenuates the Severity of Acute Lung Injury in the Early Phase of Pneumococcal Pneumonia in Mice/H. Taenaka, San Francisco, CA
- P1267** Lung Interstitial Macrophage Dynamics and Phenotypes After Pneumococcal Respiratory Infection/E.M.R. Armstrong, Boston, MA
- P1268** The Role of the IL-1 β Pathway in Severe Acute Respiratory Syndrome Coronavirus 2 Infection of Human Airway Epithelia/A. Singh, Chapel Hill, NC
- P1269** Age-specific Responses of Yes-associated Protein to Pneumonia-induced Acute Lung Injury/R.F. Hough, New York, NY
- P1270** Long Noncoding RNA Lncenc1 Deficiency Protects Mice From Bacteria-induced Acute Lung Injury/Y. Zhu, Augusta, GA
- P1271** Role of A4-containing Nicotinic Acetylcholine Receptors (a4 nAChRs) in Lipopolysaccharide-induced Lung Injury/J. Roman, Philadelphia, PA

BASIC • TRANSLATIONAL

THEMATIC POSTER SESSION

B66 BUG'S LIFE: FROM PNEUMONIA TO SEPSIS

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area L, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1272** **Suppression by Clarithromycin of IL-8 Production From Human Airway Epithelial Cells Treated With Prevotella Intermedia Supernatants/N.** Iwanaga, Nagasaki, Japan
- P1273** **Chemical Induction of Type I Diabetes Renders Mice More Susceptible to SARS-CoV-2-induced Lung Injury/S.** Kass-Gergi, Philadelphia, PA
- P1274** **Effects of Hypercapnia on Alveolar Epithelial Cells and Macrophages Infected With Pneumonia-causing Bacteria/E.** Campaña Duel, Sabadell, Spain
- P1275** **Functional Phenotype of Recruited Monocytes in the Subacute Phase of Mice Peritoneal Sepsis; Possible Association With the Immunosuppressive Phenotype/Q.** Meng, Bunkyo-ku, Japan
- P1276** **Carbon Monoxide Improves Human Mesenchymal Stromal Cell Function During Polymicrobial Sepsis by Induction of Autophagy/N.** Hwang, Boston, MA
- P1277** **Hox5 Expression in Acute Lung Injury/C.** Hauser, Madison, WI
- P1278** **Redox Regulation of Influenza Neuraminidase by Protein Disulfide Isomerase A3/M.** Ruban, Burlington, VT
- P1279** **GS-441524 Parent Nucleoside to Remdesivir Can Effectively Inhibits Sars-Cov-2 Omicron Infections in Human Lung Organoids/J.** Liang, Toronto, Canada
- P1280** **Tissue Pathologic Role of Cd8⁺ T Cells During Influenza/N.** Khan, Gainesville, FL
- P1281** **The PTP4A3 Inhibitor, KVX-053, Ameliorates Alcohol-exacerbated SARS-CoV-2-induced ARDS/P.A.** Solopov, Norfolk, VA
- P1284** **CNI-103, a Cell Permeable Peptide Inhibitor of the Calcineurin, Alters the Composition and Function of Extracellular Vesicles in Mouse Bronchoalveolar Lavage Fluid During Acute Lung Injury/M.** Karpurapu, Columbus, OH
- P1285** **Endothelial Cell Targeted Nanoparticles Concentrate in Pulmonary Marginated Neutrophils During Acute Respiratory Distress Syndrome/E.-O.** Essien, Philadelphia, PA
- P1286** **Neutrophil-like Ly6C^{hi} Monocytes Enhance the Lung Injury Response in Sepsis Survivor Mice/S.J.** Denstaedt, Ann Arbor, MI
- P1287** **A Single-cell RNA Sequencing Comparison of Pulmonary Macrophages From LPS- and Bleomycin-treated Mice Reveals a Novel Macrophage Subset Associated With Prolonged Inflammation and Fibrosis/E.** King, Denver, CO
- P1288** **Lung Innate Immune Response in the Subacute Phase of Gut Ischemia/Reperfusion; Mouse Model/F.** Seto, Bunkyo-ku, Japan
- P1289** **Acid Sphingomyelinase Induces the Release of Alveolar Macrophage-derived Microvesicles During Acute Lung Injury/X.** Cheng, London, United Kingdom
- P1290** **Endothelial Derived IL33 Induces Fibrogenesis and Is Associated With CLAD/M.** Banday, Boston, MA
- P1291** **Intra-alveolar Neutrophil-derived Microvesicles After One-lung Ventilation Are Associated With Post-operative Pulmonary Complications in Patients Undergoing Esophagectomy/J.** Stephens, London, United Kingdom
- P1292** **Impaired Lung Functioning Following Chronic Ozone Exposure Is Associated With Inflammatory Macrophage Activation and Altered Bioenergetics/V.** Sunil, Piscataway, NJ
- P1293** **Factor XIII Limits Recruitment and Activation of Alveolar Macrophages After Lipopolysaccharide/P.K.** Moore, Aurora, CO
- P1294** **Steroid Induced Modulation of Myeloid Derived Suppressor Cells Results in Increased Suppressor Activity/M.** Berlinger, Baltimore, MD
- P1295** **Vitamin E Acetate Aerosol Induces Hemeoxygenase-1 and Cytochrome P4501A1 mRNA Expression in Human U937 Macrophages/X.** Li, Davis, CA
- P1296** **Sex Differences in Immune Response to Extracellular Matrix Nanoparticle Treatment of Endotoxin-induced Lung Injury/C.** Slaybaugh, Richmond, VA
- P1297** **Early Sphingolipid Changes in the Development of Niemann-Pick Disease (NPD) in Mice and the Impact on Acute Lung Inflammation/J.M.** Poczobutt, Denver, CO

BASIC • TRANSLATIONAL

THEMATIC POSTER SESSION

B67 ALL THE LUNG'S A STAGE: IMMUNE CELLS ARE THE PLAYERS

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area L, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1283** **Upregulation of Key Inflammatory Mediators in Broncho-alveolar Lavage Fluids From Lung Transplant Recipients With Chronic Lung Allograft Dysfunction/F.** Fattahi, Ann Arbor, MI

- P1298** The Role of Kinase Activation in Cell-free Hemoglobin Dependent Reactive Oxygen Species Production/C.M. Shaver, Nashville, TN
- P1299** Phospholipid Transfer Protein Deficiency Enhances Lung Inflammation in Mice/P. Lafortune, Brooklyn, NY

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

B68 A DIFFERENT POINT OF VIEW: LUNG IMAGING IN COPD

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area H, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P814** Imaging Disparities in Emphysema Assessment by CT/E.A. Regan, Denver, CO
- P815** Machine Learning Predicts Computed Tomography (CT)-based Normal Regional Lung Function Distribution in Asthma and Chronic Obstructive Pulmonary Disease (COPD)/Y. Lee, Seoul, Korea, Republic of
- P816** Assessing the Relationship Between Changes in Clinical Standard of Care Assessments and Alterations in Lung Density Associated With the Progression of COPD/R. Baron, Philadelphia, PA
- P817** Association Between Altered Upper Airway Dimensions and Regional Lung Structure and Function in COPD: Quantitative CT Analysis/A. Abdolijomoor, Kansas City, KS
- P818** Computed Tomography (CT)/Single-photon Emission Computerized Tomography (SPECT) Based Assessment of Chronic Obstructive Pulmonary Disease (COPD) Progression/F. Li, Iowa City, IA
- P819** Quantitative CT Parameters in Chronic Bronchitis Without Airflow Limitation, COPD and Healthy Controls/P.W. Jones, Brentford, United Kingdom
- P820** Effect of Lung Volume on Airway and Artery Analysis on Chest Computed Tomography in Chronic Obstructive Pulmonary Disease/H. Tiddens, Rotterdam, Netherlands
- P821** Volume, Noise and Bias Correction for Gas Trapping: A Mosaic Attenuation Study Case/G. Vegas-Sanchez-Ferrero, Boston, MA
- P822** Relationship Between Spirometric Measurements With %LAA in an Urban Comprehensive Lung Cancer Screening Program for Lung Nodules Coupled With Detection of Comorbid Conditions: Temple Healthy Chest Initiative (THCI)/S. Dachert, Philadelphia, PA
- P823** Relationship Between Artificial Intelligence-Calculated Airway Wall Thickness and Symptoms in an Urban Comprehensive Lung Cancer Screening Program for Lung Nodules Coupled With Detection of Comorbid Conditions: Temple Healthy Chest Initiative (THCI)/S. Dachert, Philadelphia, PA
- P824** Development of a Quantitative CT-Based Diaphragm Tool in Severe COPD Patients Treated With One-Way Endobronchial Valves/J.T. Bakker, Groningen, Netherlands
- P825** Inspiration-Expiration CT Texture-Based Delta Radiomics: A New Biomarker Associated With COPD Symptoms?/M. Koo, Toronto, Canada
- P826** Measuring Metronome-paced Tachypnea Induced Dynamic Hyperinflation Quantified by Pulmonary Cine MRI Through Transfer Learning: The Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) Heart Failure (HF) Study/X. Zhang, New York, NY
- P827** Ventilation Phenotyping Using X-ray Velocimetry Demonstrates Reproducibility During Pre and Post-bronchodilator Spirometry in COPD Patients/A. Khan, Portland, OR
- P828** Quantitative Lung Ventilation Single-photon Emission Computed Tomography With Computed Tomography Scan (SPECT/CT) Using Technegas to Assess Early Small Airway Disease in Smokers: A Pilot Study/B.-P. Dubé, Montréal, Canada
- P829** Advanced Lung Disease Assessed Using Novel Regional Lung Ventilation Analysis/P. Pirakalathanan, Carlton, Australia
- P830** Quantitative Computed Tomography Features for Classification of Stable PRISM Using Machine Learning/L. Lukhumaidze, Toronto, Canada
- P831** Reduction in Targeted Lobe Perfusion/Volume Predicts Physiologic and Functional Success With Bronchoscopic Lung Volume Reduction/J.S. Kim, Philadelphia, PA
- P832** Emphysema Score in CT for COPD Quantifications Using Artificial Intelligence Informed by Virtual Imaging Datasets/S. Sotoudeh-Paima, Durham, NC
- P833** Effects of Intra-patient End-inspiration Variability in Emphysema Quantification: A Virtual Imaging Study/A. Kavuri, Durham, NC

P834 Unbiased Estimator of Lung Density for Emphysema Detection/R. San Jose Estepar, Boston, MA

P835 3-Dimensional Simulation of Unsteady Airflow in a Realistic Airway Model of a Severe COPD Patient/M. Behnia, Apopka, FL

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

B69 AIRWAY INJURY AND REPAIR: MECHANISMS AND TREATMENT

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area J, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

P1022 Role of MicroRNAs in the Regulation of CD151 Expression in Asthma/W.L. Sim, Singapore, Singapore

P1023 Synthetic Double-stranded RNA Aggravates Allergen-induced Airway Inflammation and Remodelling While Suppressing the Expression of T Helper 2 Cytokines in the Sensitized Rats/R. Sun, Montreal, Canada

P1024 Assessment of Lung Injury in Mice Following Chronic Intermittent Hypoxia and World Trade Center Dust Exposure/J. Hua, Piscataway, NJ

P1025 The Short Chain Fatty Acid Butyrate May Decrease Matrix Remodeling Capacity of Monocyte-derived Macrophages/A. Bohnhorst, Luebeck, Germany

P1026 MicroRNA-155 Delays Bronchial Epithelial Cells Repair by Differentially Modulating IL-13R α 1 and IL-13R α 2 Pathways in Severe Asthma/M. Klein, Québec, Canada

P1027 Exploring Murine Lung Alveolarization Using an Ex Vivo Isolated, Perfused and Ventilated Lung Model in Neonates/R. Jamal, Bad Nauheim, Germany

P1028 Antagonism of the TMEM16A Calcium-activated Chloride Channel Attenuates Inflammatory Cytokine Release From CD4+ Lymphocytes/J. Danielsson, New York, NY

P1029 Characteristics of Type-2 High and Low Asthma in the U-biopred Cohort/K. Yevdokimova, New York, NY

P1030 Iron-dependent Neutrophilic Inflammation in Lungs of Mice/V. Laiman, Taipei, Taiwan

P1031 The Effects of Hyperoxia on Mucus Transport and Airway Hyperreactivity/K. Helmkamp, Iowa City, IA

P1032 E-cigarette Use in Young Adults Reduces Abundance of Transcripts Related to Collagen Organization in the Lung/C.D. Pascoe, Winnipeg, Canada

P1033 Impact of Diet-induced Obesity and G Protein-coupled Receptor 1 Deficiency on Ozone-induced Lung Injury and Lung Inflammation/R.A. Johnston, Morgantown, WV

P1034 Mechanical Forces Accelerate Enzymatic Digestion of Bovine Lung Collagen Fibers/Y. Deng, Boston, MA

P1035 Features of a Clinically Relevant Large Animal Model of Chronic Obstructive Pulmonary Disease (COPD)/R. Bischof, Berwick, Australia

P1036 Cigarette Smoke and Air Pollution Induce Human Pericyte Dysfunction/X. Wu, Groningen, Netherlands

P1037 Targeting SLC7A11/GPX4 Signaling Induces Ferroptosis in Lymphangiomyomatosis (LAM) Cells/J. Tesch, Fargo, ND

P1038 Rheological Characterization of Sputum From Patients With Primary Ciliary Dyskinesia/P.A. Rojas-Gutierrez, Montreal, Canada

P1039 Non-hepatotoxic Acetaminophen Exposure Causes Acute Injury and Chronic Changes in Lung Function in Young Mice/A.M. Sosa, Aurora, CO

P1040 Single Cell Analysis of the Human Neonatal Infant Airway Epithelium Reveals Age Related Changes in Cellular Composition and Transcriptional Programming/S. Bhattacharya, Washington, DC

P1041 Differential Modulation of Rhinovirus-Induced Expression of MUC5AC and NOS2 in Airway Epithelial Cells by Prostaglandin-E2 and Protectin-D1/E.A. Townsend, Madison, WI

P1042 Effect of Sex-specific MicroRNA Signatures on Asthma Pathogenesis/M.A. Ba, Reno, NV

P1043 Genetic Susceptibility to Fatty Airway Remodeling Through the Kiss1/Kiss1r Signaling Pathway/C. Wang, Crawley, Australia

P1044 Release of ATP in the Lung Evoked by Inhalation Exposure to Irritant Gases in Rats/N.-J. Chan, Lexington, KY

P1045 Aberrant KRas Activation in HRas/NRas-devoid Mice Distorts Lung Alveologenesis/R. Fuentes Mateos, Groningen, Netherlands

P1046 Genetic Susceptibility to Fibrogenesis in Pulmonary Alveolar Proteinosis (PAP)/I. Campo, Pavia, Italy

P1047 Introducing Breath Biopsy VOC Atlas: A List of Known Breath VOCS for Breath-based Biomarker Discovery/A. Hatch, Cambridge, United Kingdom

- P1048** Analysis of Serum Rheumatoid Arthritis Related Antibodies in Subjects With Cystic Fibrosis During Acute Exacerbation and in Recovery States/A. Rueschhoff, Kansas City, KS
- P1049** An Alkane Promotes Rapid Adsorption by the Surfactant Lipids/S.B. Hall, Portland, OR
- P1050** Stability of Exhaled Breath Condensate pH in Frozen Storage/S. De, Raipur, India
- P1051** Phase I Characterization of the Novel Cathepsin C Inhibitor BI 1291583 in Healthy Japanese Subjects/Y. Tadayasu, Kobe, Japan
- P1052** Once Daily Versus Twice Daily Inhaled Corticosteroids Plus Long Acting Beta2-agonists in Patients With Moderate-to-severe Asthma - a Meta-analysis and Systematic Review/M. Frent, Timisoara, Romania
- P1053** Nebulized Saline Delivered With High Flow of Humidified Air Hydrates the Airway Surface Liquid and Accelerates Mucociliary Transport/S. Tatkov, Auckland, New Zealand
- P1054** Distribution of Nebulized Particles in Rat Lung Characterized by High-spatial-resolution Confocal Microscopy/J.P. Battikha, Hoboken, NJ
- P1055** Model-based Dose Selection for Phase 3 Trials of the Selective P2X3 Antagonist Camlipixant in Refractory Chronic Cough/N. Chauret, Laval, Canada
- P1056** Dietary Long-chain Omega 3 Fatty Acids Modify Sphingolipid Metabolism to Facilitate Airway Hyperreactivity/S. Worgall, New York, NY
- P1057** Vaping-Induced Proteolysis Causes Airway Dehydration/A. Ghosh, Chapel Hill, NC
- P1061** Association Between Lung Function Decline and Renal Function Change in Healthy Individuals: A Longitudinal Observation Study/H.-W. Park, Seoul, Korea, Republic of
- P1062** AI Over-reading Based on ATS/ERS 2019 Criteria Is a Reliable Option for Instant Spirometry Quality Control in Clinical Trials/B. Cuyvers, Leuven, Belgium
- P1063** Impact of Artificial Intelligence Over-Reading for Instant Feedback on Quality of Home Spirometry/B. Cuyvers, Leuven, Belgium
- P1064** Comparison of Time to Peak Flow With Rise Time From 10 to 90% of Peak Expiratory Flow/J. Ramos, Philadelphia, PA
- P1065** A Study of Oscillometry in Inducible Laryngeal Obstruction and Asthma/P.A. Donohue, Rochester, NY
- P1066** Relationship Between Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function, and Pulmonary Function in Young Adults/S.S. Krishnan, Valhalla, NY
- P1067** Work of Breathing in the Prone Versus Supine Position in Healthy Adults/S. Afanador Castiblanco, Miami, FL
- P1068** Comparison of Forced Oscillation Results Using 1-hand Versus 2-hand Technique in Sedated Infants/J.S. Samuel, Indianapolis, IN
- P1069** Correspondence Between Audible Crackles and Lung Function Test Results/S. Gogaert, Leuven, Belgium
- P1070** Differences in Exertional Ventilatory Response in Normoxic V. Acute Hypoxic Conditions in Healthy Humans/L.M. Forbes, Aurora, CO
- P1071** Small Airway Dysfunction in Asthma Based on Oscillometry/T. Shirai, Shizuoka, Japan
- P1072** How Many Lung Function Interpretations Can an Expert Make in One Hour Based on the 2021 ERS/ATS Guidelines?/M. Topalovic, Leuven, Belgium
- P1073** The Impact of Learning Effect on Patient Burden for ATS/ERS 2019 Compliant Forced Spirometry Within a Clinical Trial Setting/P. Lake, Monmouth, United Kingdom
- P1074** Obesity Involves Decreasing of Pulmonary Function in Patients With Asthma, but Not Those Without Asthma/H. Tashiro, Saga, Japan
- P1075** Exercise Oximetry and Pulmonary Complication Risk in Stem Cell Transplant Recipients/Z. Zhang, Rochester, MN
- P1076** Baseline Cardiopulmonary Exercise Test Characteristics of PH-ILD Patients Receiving Inhaled Treprostinil/B. Claxton, Philadelphia, PA
- P1077** Effects of Oxygen Supplementation on Exercise Physiology in Patients With Interstitial Lung Disease/M.J. Segel, Ramat Gan, Israel

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

B70 INHALE THE FUTURE: NEW FINDINGS IN PULMONARY FUNCTION

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area J, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15**Discussion:** 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1059** Measures of Ventilation Inhomogeneity in Children With Cystic Fibrosis: Intra-breath Oscillometry Vs. MBW/T.L. Blake, South Brisbane, Australia
- P1060** Using Impulse Oscillometry to Evaluate Static Lung Hyperinflation and Treatment Response in Patients With Severe Asthma/Y.H. Hsiao, Taipei, Taiwan

- P1078** Physiologic Phenotyping of Those at Risk for Recurrent Chronic Obstructive Pulmonary Disease (COPD) Exacerbation/M. Simon, Providence, RI
- P1079** Effects of Bronchoscopic Lung Volume Reduction on Oxygen Pulse and Pulse Pressure During Cardiopulmonary Exercise Testing/J. Ayyoub, Philadelphia, PA
- P1080** Effects of Bronchoscopic Lung Volume Reduction on Ventilatory Efficiency in Patients With Advanced Emphysema and Severe Hyperinflation/J. Ayyoub, Philadelphia, PA
- P1081** Effects of Bronchoscopic Lung Volume Reduction on Diaphragm Morphometric Parameters in Patients With Advanced Emphysema and Severe Hyperinflation/J. Ayyoub, Philadelphia, PA
- P1082** Pulmonary Function Test: Part of the Puzzle/D.M. Shah, New York, NY
- P1083** Changes in Dyspnea Associated With Pulmonary Function Testing Following Bronchoscopic Lung Volume Reduction/J.S. Kim, Philadelphia, PA
- P1084** Changes in Dyspnea Associated With Diaphragm Morphometric Parameters Following Bronchoscopic Lung Volume Reduction/J.S. Kim, Philadelphia, PA
- P1085** Ultrasonic Personal Spirometer Appears Accurate and Feasible for Remote Monitoring/A.L. Crawford, Perth, Australia
- P1086** Prediction of Carbon Monoxide Diffusing Capacity (DLCO) Using Flow-volume Curve Image in Idiopathic Pulmonary Fibrosis (IPF): An Early Fusion Deep Learning Approach/W. Chung, Seoul, Korea, Republic of
- P1087** Bronchodilator Response in Children With Primary Ciliary Dyskinesia/E.L.A. Seidl, Toronto, Canada
- P1088** Characterizing the Statistical Properties of Cough Recordings/B. Suki, Boston, MA
- P1089** Approximating Spatial Deposition in a Full Volume 3D-Printed Model of the Human Lung Under Physiological Breathing Profiles/C. Fromen, Newark, DE
- P1090** Respiratory Function 34 Years After Sulfur Mustard Exposure in Survivors and Controls in Sweden/F.F. Moradi, Gothenburg, Sweden
- P1091** Predictive Value of Spirometry Z-Scores for the Development of Pulmonary Complications After Hematopoietic Stem Cell Transplantation/B.A. White, Rochester, MN

BEHAVIORAL • CLINICAL • TRANSLATIONAL
THEMATIC POSTER SESSION
B71 BEYOND CPAP: THERAPIES FOR SLEEP APNEA
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area K, Hall C (Lower Level)
Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion

12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1173** The Effect of Supplemental Oxygen on Hemoglobin Levels in Obstructive Sleep Apnea/C.D. Turnbull, Oxford, United Kingdom
- P1174** A Systematic Review and Meta-analysis of the Effects of Nocturnal Oxygen Therapy in Obstructive Sleep Apnea/S.L. Phyu, Oxford, United Kingdom
- P1175** Patterns of Adherence to Continuous Positive Airway Pressure (CPAP) and Mandibular Advancement Splints (MAS) in Pregnant Individuals With Sleep-disordered Breathing/J. Smocot, Montreal, Canada
- P1176** Objectively-Monitored Adherence to Daytime Neuromuscular Electrical Stimulation for Treatment of Obstructive Sleep Apnea/J.P. Bakker, Needham, MA
- P1177** An Observational Study Assessing the Safety Profile of Daytime Neuromuscular Electrical Stimulation for Treatment of Obstructive Sleep Apnea/J.P. Bakker, Needham, MA
- P1178** Nocturnal Oxygen Therapy for Obstructive Sleep Apnea and Its Effects on Blood Pressure/S. Ercan, Izmir, Turkey
- P1179** Transoral Neuromuscular Stimulation for OSA in Veterans/B. Nokes, La Jolla, CA
- P1180** A Randomised Controlled Trial Examining the Combined Impact of Acetazolamide and Dronabinol for the Treatment of Obstructive Sleep Apnoea/L.D.J. Thomson, Melbourne, Australia
- P1181** Assessing Precision Oral Appliance Efficacy Using Frequency-Based and Risk-Based Indices/E. Mosca, Pleasanton, CA

CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

B72 EXCITING CASES IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area D, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session **11:30-1:15****Discussion:** 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P388** **Rapidly Progressive Mesothelioma in the Absence of Asbestos Exposure Masked by Post-COVID ILD/A.**
Dursun, Roanoke, VA
- P389** **What Is Your Cough Hiding? A Malignant Pleural Mesothelioma in a Young Male/J.W. Torres, Ponce, Puerto Rico**
- P390** **Gambling With Asbestos - A Case Report of Malignant Pleural Mesothelioma/C. Chen, Las Vegas, NV**
- P391** **When Mold Masks Mesothelioma/S. Kumar, Tucson, AZ**
- P392** **Ultrasound-Guided Pleural Cutting Needle Biopsy For Diagnosis Of Mesothelioma In A Non-Surgical Patient/W. Sessions, Memphis, TN**
- P393** **Absence of a Red Herring: Mesothelioma Without Asbestos Exposure/V. Jain, Washington, DC**
- P394** **Why Is The Pleural Fluid Green? A Review of Pleural Fluid Characterization and Analysis/U. Shrestha, Morgantown, WV**
- P395** **It's Not Always an Effusion: Relapse of Follicular Lymphoma Presenting as Pleural Thickening/M.A. Faruqi, Lexington, KY**
- P396** **Unique Presentation of Small Cell Lung Cancer As Isolated Malignant Pleural Effusion/Z. Noori, Toledo, OH**
- P397** **Unique Case Of Urinothorax With Superimposed Malignant Pleural Effusion/E.M.P. Almazan, Lexington, KY**
- P398** **Flow Cytometry In Persistent Exudative Lymphocytic Pleural Effusions/A. Tey, Singapore, Singapore**
- P399** **One Pleura, Two Pictures/M. Gleeson, Dublin, Ireland**
- P400** **Pleural Metastases of Her2-negative Salivary Duct Carcinoma/R.L. Imel, Toledo, OH**
- P401** **Burkitt Lymphoma Presenting With Pleural Effusion/V.V. Woodard, Seattle, WA**
- P402** **Large B Cell Lymphoma Presenting as Primary Pleural Effusion/L. Yadukumar, Scranton, PA**
- P403** **Hide In The Light: Case Of Transudative Malignant Pleural Effusion/A. Medani, Rancho Mirage, CA**
- P404** **Catheter Tract Metastasis: A Rare Complication of Indwelling Pleural Catheter in a Patient With Metastatic Renal Cell Carcinoma/M. Parmar, Oklahoma city, OK**
- P405** **Silent Gastro-pleural Fistula: A Chronic Empyema After Esophagectomy/H.C. Sagin, New Orleans, LA**
- P406** **Recurrent Pneumothoraces and Lung Cancer: Positive or Negative?/C. Tejera Quesada, Atlantis, FL**
- P407** **Recurrent Inflammatory Pseudotumor Ten Years After Primary Resection: FDG-PET/CT Scan Imaging and Response to Treatment/J. Fanous, Phoenix, AZ**
- P408** **Primary Pleural Tumor Of Uncertain Immunophenotype/K. Lutchi, Memphis, TN**
- P409** **An Unusual Case of Contarini's Syndrome After 5 Years of Treatment of Left Ca Breast/D. Muthreja, Nagpur, India**
- P410** **Diagnosing Primary Mediastinal Large B-Cell Lymphoma With Ebus-Guided Cryobiopsy: A Case Report/L. Hoover, Seattle, WA**
- P411** **Endobronchial Tumor Invasion Following Endobronchial Ultrasound Guided Cautery-Assisted Transbronchial Forceps Biopsy: A Novel Occurrence/E.S. Tarras, New Haven, CT**
- P412** **Endobronchial Mucoepidermoid Carcinoma Masquerading as Uncontrolled Asthma/M.I. Khan, Lexington, KY**
- P413** **Mismatched Endobronchial Ball Valve Metastasis in a Patient With DNA Mismatch Repair: Lynch Syndrome/H.A. Mengiste, Buffalo, NY**
- P414** **Targeting the Invisible Tumor - Endobronchial Ultrasound Guided Fiducial Markers Placement for Radiographically Occult Endobronchial Squamous Cell Carcinoma/N. Keer, Memphis, TN**
- P415** **Bronchial Artery Embolization Before Endobronchial Tumor Debulking/D. Pfeifle, Indianapolis, IN**
- P416** **Endobronchial Fibroepithelial Polyp Diagnosed and Treated With Electrocautery Snare/S. Tosonian, Knoxville, TN**
- P417** **What Is Blocking The Bronchus? A Case Of Pulmonary Extramedullary Plasmacytoma Presenting As Right Mainstem Bronchial Obstruction/A. Anderson, Hershey, PA**
- P418** **Synchronous Multiple Primary Cancers of the Lung Diagnosed With Robotic-Assisted Bronchoscopy/S. Simeone, Farmington, CT**
- P419** **A Double Bullseye: Robotic Navigation Assisted Diagnosis of Bilateral Synchronous Lung Cancer/N. Sharma, Knoxville, TN**

- P420** **Bronchoscopy to the Rescue: An Unusual Culprit in a Case of Massive Hemoptysis**/F. Yazdi, Shreveport, LA
- P421** **A Mass and a Lymph Node**/E.J. Pacheco, Tampa, FL
- P422** **A Confusing Case of Bloody Cough: Not Everything is TB**/A. Johnson, Tucson, AZ
- P423** **Pulmonary Hemorrhage as a Presentation of Kasabach-Merritt Syndrome in an Adult-Onset Multifocal Epithelioid Hemangioendothelioma: A Case Report and Review of Available Literature**/N. Bangasan-Pizarro, Baguio City, Philippines
- P424** **Lung Abscess - A Rare Complication of Bronchoscopy**/M.I. Islam, Charlottesville, VA
- P425** **Uncharted Territory for the Bronchoscopist: Navigating Unimpeded Within a Large Bulla**/C. Salmon, Nashville, TN
- P426** **Carcinoid and Adenocarcinoma Diagnosed With Robotic-assisted Bronchoscopy**/J.W. Burgei, Sayre, PA
- P427** **Photodynamic Therapy in a Case of Pulmonary Adenoid Cystic Carcinoma**/M. Irandost, Phoenix, AZ
- P428** **Aggressive vs Conservative Management of a Solitary Fibrous Tumor (SFT) of Pleura With Atypia**/J. Lenka, Tucson, AZ
- P429** **Giant Solitary Fibrous Tumour Of The Pleura With Severe Hypokalemia And Respiratory Failure**/M. Moumkine, Tangier, Morocco
- P430** **"Milky Lungs": A Rare Case of Transudative Chylothorax in Small Cell Lung Cancer**/M. Wang, Worcester, MA
- P431** **A Unique Case of No Respiratory Symptoms With Osteolytic Lesions, Pleural Effusions and Lung Opacities With Kaposi Sarcoma**/W. Xiao, Bronx, NY
- P432** **Viscous Pleural Effusion Provides Instrumental Clue Leading to the Diagnosis of Advanced Mucinous Adenocarcinoma Masquerading as Organizing Pneumonia**/S. Jothi, Tucson, AZ
- P433** **Pleural Solitary Fibrous Tumor Masquerading As A Pericardial Cystic Mass**/J. Huang, Sioux Falls, SD
- P434** **Primary Cardiac Epithelioid Angiosarcoma: An Infrequent Cause of Recurrent Pericardial and Pleural Effusion**/M.A. Khan, Long Branch, NJ
- P435** **What's in the Mediastinum?: Nets With Mets**/J. Fouad, Baltimore, MD

CLINICAL

THEMATIC POSTER SESSION

B73 **TRULY SYMPTOMATIC OR JUST MIMICKING? LUNG CANCER CASES**9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area D, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session **11:30-1:15****Discussion:** **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P437** **Cardiac Tamponade in the Setting of Thymic Carcinoma**/M. Antic, Southfield, MI
- P438** **Lung Adenocarcinoma Presenting as Cardiac Tamponade**/S. Nagpal, Johnson, TN
- P439** **Invasive Mucinous Adenocarcinoma Manifesting as a Non-resolving Pneumonia**/A. Kainat, McKeesport, PA
- P440** **Is Pulmonary Venous Hemorrhage a Blessing?**/M. B, Hyderabad, India
- P441** **An Unusual Guest in the Heart**/R. Ali, East Norriton, PA
- P442** **A Rapidly Progressive Spindle Cell Neoplasm Causing Subacute Dyspnea**/N. Ramesh, Oakland, CA
- P443** **An Uncommon Case: Pembrolizumab Induced Pneumonitis With Bilateral Multifocal Pneumonia**/M. Sedaghati, Bronx, NY
- P444** **A Red Herring: Testicular Cancer Concealed By Dyspnea**/V. Dhillon, Muncie, IN
- P445** **Cunning Consolidations - Adenocarcinoma Masquerading As A Dense Inflammatory Infiltrate**/O. Haider, Springfield, MA
- P446** **Right Ventricular Mass Found To Be Metastatic Non-small Cell Lung Carcinoma**/S.H. Karass, Queens, NY
- P447** **Not Your Typical Tamponade: A Unique Presentation And Management Of Hodgkin's Lymphoma**/J. Weido, Parma, OH
- P448** **Lung Primary Marching to the Heart**/R. Meenakshisundaram, Sayre, PA
- P449** **Never Stop Believing That There Is Another Disease**/J.D. Duke, Rochester, MN
- P450** **The Malevolent Mimicker: Pneumonic-Type Lung Adenocarcinoma**/A. Verma, Queens, NY
- P451** **COPD: A Confounding Factor for Dyspnea on Exertion in Atrial Myxoma**/A. Mahmoud, Paterson, NJ
- P452** **Not Your Average Ground Glass Opacity**/N. Klimberg, Tucson, AZ

- P453 Primary Lung Mucinous Adenocarcinoma in a 38-year-old Male: A Case Report**/F.N.G. Salinas, Iloilo City, Philippines
- P454 Bilateral Hemorrhaging Adrenal Metastasis as the Presenting Symptom of Lung Cancer: A Review of Literature**/S. Shimizu, Cleveland, OH
- P455 Recurrent Squamous Cell Lung Cancer Presenting as Dyspnea Secondary to Distal Tracheal Mass**/T. Czech, Honolulu, HI
- P456 A Catastrophic Cause of Chronic Cough: A Case of Embryonal Choriocarcinoma With Metastasis to the Lung**/J.R. Flores Gonzalez, Harlingen, TX
- P457 Recurrent Pneumonia in a Young Woman**/L.V. Daley, Birmingham, AL
- P458 Diffuse Alveolar Hemorrhage After Everolimus Chemotherapy: A Case Report**/V. Walker, Atlanta, GA
- P459 Carcinoma Masquerading as Immune Checkpoint Inhibitor Pneumonitis**/A. Saeed, Danville, VA
- P460 Uterine Leiomyosarcoma Presenting as Hemoptysis Secondary to Pulmonary Metastases**/N. Baghdasaryan, Los Angeles, CA
- P461 A Radiation Recall Pneumonitis From Immune Checkpoint Inhibitors After Extra Pulmonary Radiation**/L.E. Kao, New York, NY
- P462 Hemoptysis and Mucus Production Secondary to Tracheal Mucoepidermoid Tumor**/R. Grant, Providence, RI
- P463 Not Every Snoring is Obstructive Sleep Apnea (OSA): Plasma Cell Neoplasm Masquerading as OSA**/M. Shrestha, Reading, PA
- P464 Lung Opacity in a Patient With Prostate Cancer**/G. Ivashchuk, Houston, TX
- P465 Cardiac Invasion of Pulmonary Squamous Cell Carcinoma**/P.M. Cavalcante Neto, Sao Paulo, Brazil
- P466 Taxotere-induced Pneumonitis**/M. Antoine, Philadelphia, PA
- P467 Kommerell's Diverticulum: A Mediastinal Mimicker of Lung Malignancy**/M. Ghose, Long Branch, NJ
- P468 Persistent Fluorodeoxyglucose (FDG) Avid Lung Mass on Positron Emission Tomography (PET): Pulmonary Sequestration as a Mimic of Parenchymal Malignancy**/S.S. Wu, Miami, FL
- P469 NSCLC With Neoplastic Epidural Spinal Cord Compression of Thoracic Vertebrae Causing Cauda Equina Syndrome**/J. Renz, Pueblo, CO
- P470 An Atypical Case of Squamous Cell Carcinoma of the Lung Presenting as Multifocal Consolidations on Imaging**/A.J. Wilson, Los Angeles, CA
- P471 Epithelioid Hemangioendothelioma Mimicking Disseminated Metastatic Lung Carcinoma: A Case Report**/I. Kovalenko, Harrisburg, PA

- P472 Hidden in Plain Sight: Malignant Pericardial Effusion in a Patient With Metastatic Lung Adenocarcinoma**/I. Kovalenko, Harrisburg, PA
- P473 When Cancer Lives in Anthracotic Shadows**/A. Wasim, Brighton, MA
- P474 Lobar Consolidation Or Infiltration: A Clinical Radiological Pathological Dilemma**/H. Grewal, New Orleans, LA
- P475 Refractory Hemoptysis Due To Migration Of Bronchial Artery Coil Into Mainstem Bronchus**/A. Deengar, Farmington, CT

MEDICAL EDUCATION SEMINAR

CME Credits Available: 1

ME102 DISCUSSING AND TEACHING ABOUT HEALTHCARE DISPARITIES

Assembly on Behavioral Science and Health Services Research

10:15 a.m. - 11:15 a.m.

Target Audience

Clinicians and providers interested in learning more about health-care disparities in pulmonary medicine and how to discuss and teach this topic to learners in different clinical environments

Objectives

At the conclusion of this session, the participant will be able to:

- participants will be more comfortable incorporating discussions about health disparities, race, and racism into their teaching.
- participants will be able to define key terms for discussions about health disparities, such as equality and equity, social determinants of health, disparity, and race.
- participants will be able to describe at least one example of a health disparity in pulmonary and critical care medicine.

Many medical educators want to teach about health disparities, race, and racism but often find it difficult due to either a lack of familiarity with the subject or a lack of strategy for how to address these issues after raising them. In this workshop, we seek to allay some of the fears and empower attendees to feel comfortable discussing and teaching about health disparities, race, and racism. We will provide an overview of important terminology used in the field of healthcare disparities and strategies to encourage and stimulate discussions among medical teams with learners in different clinical environments.

Faculty: A. Kannappan, MD, Denver, CO
G.B. Tatem, MD, Detroit, MI
E.K. Batchelor, MD, MEd, Phoenix, AZ
R. Adamson, MBBS, ATSF, Seattle, WA



**ATS
2023**

**INTERNATIONAL
CONFERENCE**
WASHINGTON, DC
conference.thoracic.org

Monday Mid-day, May 22

11:45 a.m. - 1:15 p.m.

ATS WOMEN'S FORUM

The annual ATS Women's Forum recognizes the achievements and supports the advancement of women in pulmonary, critical care, and sleep medicine and research. The forum provides a valuable opportunity for women to find value in the inspirational messages and career insights the speakers share. This year both Refiloe Masekela, MD and Margareth Dalcolmo, MD will discuss their experiences during the forum.

We will also recognize and hear remarks from the 2023 recipient of the Elizabeth A. Rich Award Lorraine Ware, MD. The Elizabeth Rich Award is presented to an outstanding woman in ATS who has made significant contributions in the fields of pulmonary, critical care and sleep medicine.

The forum is organized and presented by the ATS Membership Committee and will be hosted by its Chair **Meshell Johnson, MD** and Vice Chair **Alexandra Noel, PhD**. The Minority Trainee Development Scholarships are supported by the American Thoracic Society.

Pre-registration and an additional fee are required. \$30 members/non-members

Many thanks to United Therapeutics for support of the Women's Forum

11:45 a.m. - 1:15 p.m.

SECTION ON GENETICS AND GENOMICS MEMBERSHIP MEETING

Renaissance Washington Downtown
Rock Creek Ballroom A (Ballroom Level)



The Section meetings are open to all ATS members and other interested individuals.

Items to be discussed include the Section's current projects and future directions.

CME Credits Available: 1

SPS2 ATS ADVANCING ADULT IMMUNIZATION INITIATIVE: IMMUNE BOOST! ADDRESSING VACCINE HESITANCY AND THE LANDSCAPE OF VACCINE-PREVENTABLE DISEASES

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**
Room 207 A-B (Level 2)

Target Audience

All healthcare providers and researchers focused on infectious diseases, vaccines, vaccine hesitancy, and those interested in scientific communication

Objectives

At the conclusion of this session, the participant will be able to:

- learn new strategies used by clinicians to improve adult vaccination in their own communities
- gain an understanding of emerging strategies to support vaccine uptake and knowledge about new respiratory infectious disease prevention products.
- apply strategies to enhance patient uptake of vaccines in one's home institution or practice environment

This session will build upon the existing literature and learnings from the CDC/CMSS grant awarded to ATS in 2021. Presenters will provide real-world examples about how clinicians and patients from diverse communities approach vaccine confidence, hesitancy, and misinformation.

This novel session will provide conceptual and real-world recommendations about addressing vaccine hesitancy and misinformation to meet the needs of clinicians seeking tools to help their patients feel more confident about vaccines and provide

cutting edge information on emerging vaccines for chronic lung disease.

Chairing: T. Hartert, MD, MPH, ATSF, Nashville, TN
J. Ortiz, MD, MS, Baltimore, MD

12:00 Introduction: Overview of Importance of Vaccines and Immunization to Respiratory Health, Discuss the CMSS Initiative, and Discuss Vaccines on the Horizon

J. Ortiz, MD, MS, Baltimore, MD

12:10 Patient Perspective: Making a Shared Decision: "How Addressing My Concerns Moved Me to Vaccine Action."

T. Woolford, Owings Mills, MD

12:20 Clinician's Perspective: "What I Hear When I Urge My Patients to Get Vaccinated."

I. Riley, MD, MPH, Durham, NC

12:35 Clinician's Perspective: Addressing Hesitancy and Misinformation to Increase Vaccine Coverage Among Diverse Populations with Chronic Lung Disease

K. Fisher, MD, MSc, Worcester, MA

12:50 **Q&A**

Chairing: S. Ahmed, MD, Albuquerque, NM
D. Kelm, MD, Rochester, MN
E. Kilb, MD, Charleston, SC

11:30. Bacterial Pneumonia in the ICU: From Guidelines to Practice

Y. Odeyemi, MD, MSc, Rochester, MN

11:55 Reviving the "Other" Respiratory Viruses: Moving Beyond COVID-19

C. Sriaroon, MD, Tampa, FL

12:20 CAUTI and CLABSI and HAPI Oh MY!: Prevention and Management of Hospital-Acquired Infections

S. Giovanni, MD, MSCE, Portland, OR

12:45 Questions and Answers

CLINICAL

PEDIATRIC CLINICAL CORE CURRICULUM

CME Credits Available: 1.5

MOC Points Available: 1

PCC1 PEDIATRIC CLINICAL CORE CURRICULUM

Education Committee

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**

West Salon G-I (Street Level)

Target Audience

Clinicians who are engaged in maintenance of certification activities

Objectives

At the conclusion of this session, the participant will be able to:

- describe diagnosis and management of central and obstructive sleep disorders in infants
- identify best practices for management and treatment of pulmonary hypertension in infants
- describe best practices and standards of care for management of bronchopulmonary dysplasia in the neonatal intensive care unit and the post NICU period

Chairing: J. Gross, MD, PhD, Denver, CO
C. Okorie, MD, Paulo Alto, CA
M. McCown, MD, Bethesda, MD

12:00 Bronchopulmonary Dysplasia in the NICU
D. Chhabra, MD, Rochester, NY

12:25 Post NICU Management of BPD
M. Bansal, MD, Los Angeles, CA

12:50 Questions and Answers

CLINICAL

ADULT CLINICAL CORE CURRICULUM

CME Credits Available: 1.5

MOC Points Available: 1.5

CC2 CRITICAL CARE CLINICAL CORE CURRICULUM

Education Committee

11:30 AM - 1:00 PM **Walter E. Washington Convention Center**

Hall E (Level 2)

Target Audience

Clinicians who are engaged in maintenance of certification activities

Objectives

At the conclusion of this session, the participant will be able to:

- describe updates in the diagnosis and management of bacterial and viral respiratory infections
- identify best practices for treating infections in critically ill immunosuppressed patients
- describe diagnosis and management of hospital acquired infections in the intensive care unit

DIVISION OF LUNG DISEASES, NHLBI/NIH
OUTSIDE ORGANIZATION SESSION
L7 CIRCADIAN RHYTHMS IN PULMONARY AND CRITICAL CARE: IMPLICATIONS FOR HEALTH AND DISEASE

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**
Room 202 B (Level 2)

Target Audience

providers of lung health, pulmonologist, sleep medicine and critical care physicians and clinician-scientist, nurses, basic, translational, and clinical lung researchers

Objectives

At the conclusion of this session, the participant will be able to:

- to educate the audience about the connections between circadian rhythms and lung health and disease.
- to better understand how the consideration of circadian rhythms is relevant to critical care clinical practice.
- to identify research opportunities in chronomedicine.

Circadian rhythms help regulate many biological processes, including metabolism, immunity, and sleep. A growing body of evidence has linked circadian misalignment to several disease states, including clock-gene-related lung diseases (i.e., asthma, COPD, pulmonary fibrosis), renewing scientific interest in this space. In the ICU, where continuous patient monitoring, constant light exposure, and 24-hour feeding schedules are standard practice, circadian disruption may impact patient outcomes and even exacerbate disease. During this session, speakers will highlight recent findings, and describe the scientific gaps and opportunities for circadian research in the context of ICU management, and overall lung health and disease.

Chairing: R. Mehra, MD, MSCR, ATSF, Cleveland, United States
 M.K. Brown, PhD, Bethesda, United States
 A.D. Laposky, PhD, Bethesda, United States

12:00 ATS-SRN Perspective

R. Mehra, MD, MSCR, ATSF, Cleveland, United States

12:02 Circadian Rhythms in Health and Disease

J. Hogenesch, PhD, Cincinnati, United States

12:12 Circadian Rhythms in Development and Pediatric Pulmonary function

S. Sengupta, MPH, Philadelphia, PA

12:24 Circadian Rhythms and Immune Function in the Lung

J.A. Haspel, MD, PhD, St. Louis, MO

12:36 Sleep and Circadian Rhythms in the ICU Environment

M.P. Knauer, PhD, MD, New Haven, CT

12:48 Circadian Disruption in Pediatric OSA

D.F. Smith, MD, PhD, Cincinnati, OH

VARIOUS ORGANIZATIONS
OUTSIDE ORGANIZATION SESSION
L8 PURSUING THE RIGHT FUNDING SOURCE: INSTITUTES, ORGANIZATIONS AND FOUNDATIONS SHARE THEIR FUNDING PRIORITIES

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**
Room 102 A-B (street level)

Target Audience

Researchers whose work focuses on pulmonary, critical care, and sleep health as well as health services and quality. Information provided could also enhance career development strategies for students and early career professionals.

Objectives

At the conclusion of this session, the participant will be able to:

- describe the research priorities and mechanisms of each funding agency represented on the panel.
- identify specific criteria required for various mechanisms presented by each agency on the panel
- identify a funding agency whose priorities and mechanisms are most closely aligned with the attendee's interest and program of research.

This session will introduce programs and research funding opportunities offered through various government and non-government agencies. Speakers will present current research priorities and mechanisms of funding available within their respective agencies. Time will be provided for audience members to ask questions of the panel of speakers.

Chairing: S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN
 J.B. Seaman, PhD, RN, CHPN, Pittsburgh, PA

12:00 Introductions

J.B. Seaman, PhD, RN, CHPN, Pittsburgh, PA

12:05 National Institute of Nursing Research

K. Huss, PhD, Bethesda, MD

12:13 National Heart Lung Blood Institute

S. Shenoy, PhD, Bethesda, MD

12:21 ATS Research Program

E.M. Nebel, MS, New York, NY

12:29 Agency for Healthcare Research and Quality

M.A. Miller, MD, MS, Rockville, MD

12:37 American Lung Association

A.E. Dixon, MA, BM BCH, ATSF, Burlington, VT

12:45 Questions and Answers

S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN

**U.S. FOOD AND DRUG ADMINISTRATION/FDA/CENTER
FOR DRUG EVALUATION & RESEARCH (FDA/CDER)**

OUTSIDE ORGANIZATION SESSION

**L9 GENERIC DRUG DEVELOPMENT FOR
RESPIRATORY PRODUCTS, US FOOD
AND DRUG ADMINISTRATION UPDATE**

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**
Room 152 A-B (Street Level)

Target Audience

Clinicians in practice, researchers, pharmaceutical industry representatives, international drug regulators

Objectives

At the conclusion of this session, the participant will be able to:

- recognize key aspects of the generic drug regulatory approval process, and how the Office of Generic Drugs (OGD) evaluates comparative clinical information to support bioequivalence for complex inhaled generic drug products.
- describe product-specific guidances for generic drug products recently posted by the Office of Generic Drugs (OGD), with a focus on how these can inform complex orally inhaled and nasal generic drug development
- articulate how emerging technologies and innovative approaches are being utilized for FDA-funded research, FDA guidance development, and regulatory decision-making

This session will describe respiratory product development of generic drugs within the US, focusing on paths forward to bring safe and effective generic respiratory products to the American public. A general overview will summarize the generic drug approval process, including demonstration of bioequivalence and therapeutic equivalence utilizing comparative clinical information. Discussion of recent generic product approvals and posted regulatory guidance will provide the audience a greater understanding of the generic approval process, and how the use of emerging technologies and outcomes of research projects contribute to scientific understanding for these complex orally inhaled and nasal drug products to inform regulatory actions.

Chairing: K. Witzmann, MD, Silver Spring, MD

- 12:00 Update for Generic Orally Inhaled and Nasal Drug Products**
K. Witzmann, MD, Silver Spring, MD
- 12:20 Comparative Clinical Considerations in the Determination of Bioequivalence**
D. Santos Conti, PhD, Silver Spring, MD
- 12:37 Emerging Concepts and New Technologies for Bioequivalence of Orally Inhaled and Nasal Drug Products**
E. Bielski, PhD, Silver Spring, MD
- 12:54 Question and Answer**
K. Witzmann, MD, Silver Spring, MD

**NATIONAL INSTITUTE OF ALLERGY
AND INFECTIOUS DISEASES, NIH**

OUTSIDE ORGANIZATION SESSION

**L10 NEW FINDINGS ON ASTHMA AND
ALLERGIC DISEASE IN URBAN
ENVIRONMENTS**

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**
Room 150 A-B (Street Level)

Target Audience

Healthcare providers, clinical researchers, individuals working with disadvantaged populations

Objectives

At the conclusion of this session, the participant will be able to:

- be able to describe early life lung function interacts with allergic sensitization to influence the risk for recurrent wheezing episodes in children and be able to apply this knowledge to improve his/her practice
- describe the utility of airway transcriptome profiling in defining inflammatory pathways driving alterations in lung function at baseline and during respiratory illnesses in exacerbation-prone urban children
- understand the role of DNA methylation in mediating environmental effects of risk for asthma and allergic sensitization in children

This session will provide the listener insights into mechanisms of lung function development, lung function trajectories over childhood, and responses to respiratory infections among urban inner-city children and adolescents. The first talk will utilize the repeated pulmonary function measurements taken during the longitudinal follow-up of the URECA birth cohort to demonstrate how atopy and environmental factors influence lung function trajectories and the development of asthma. The second talk will elucidate transcriptomic pathways which are activate or suppressed during a viral respiratory infection and the impact on lung function. The third talk will present data on epigenetics role in asthma and allergic sensitizations.

Chairing: A. Coleman, MD, Bethesda, MD

- 12:00 Interactions Between Allergic Sensitization and Lung Function on Wheezing Illnesses in Urban Children**
J.E. Gern, MD, Madison, WI
- 12:20 Airway Transcriptome Patterns Relate to Lung Function in Urban Children with Exacerbation-Prone Asthma**
M.C. Altman, MD, MPhil, Seattle, WA
- 12:40 Epigenetic Contributions to Understanding Asthma and Allergic Sensitization in Urban Children**
C. Ober, PhD, Chicago, IL

**NATIONAL INSTITUTE FOR
OCCUPATIONAL SAFETY AND HEALTH**

OUTSIDE ORGANIZATION SESSION

**L11 DISPARITIES IN WORK-RELATED
RESPIRATORY DISEASE**

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**

Room 147 A-B (Street Level)

Target Audience

Providers of lung health; those interested in prevention of occupational respiratory disease.

Objectives

At the conclusion of this session, the participant will be able to:

- better identify common pitfalls in race and ethnicity reporting in the occupational respiratory health literature and describe approaches to race and ethnicity data collection and analysis that can improve understanding of health disparities.
- learn updated findings about work-related disparities in COVID-19.
- understand considerations in selecting the appropriate sex to use in spirometry reference equations for interpreting results from transgender and gender-diverse people.

The session will provide an update on current issues in work-related respiratory disease disparities. It will address the status of race and ethnicity reporting in occupational respiratory health and considerations for approaches to data collection and reporting to improve our understanding of racial or ethnic disparities and to better contextualize findings. It will also address disparities in occupations at risk for work-related COVID-19 and considerations in selecting appropriate spirometry test reference sex for transgender and gender-diverse people.

Chairing: D.N. Weissman, MD, ATSF, Morgantown, WV

12:00 Introduction to Session

D.N. Weissman, MD, ATSF, Morgantown, WV

12:03 Status of Race and Ethnicity Reporting in Occupational Respiratory Health

A.M. Foreman, PhD, Morgantown, WV

12:22 Work-Related COVID-19 Disparities

J.M. Cox-Ganser, PhD, Morgantown, WV

12:41 Selecting Appropriate Spirometry Reference Sex for Gender-Diverse People

E. Fechter-Leggett, DVM, MPVM, Morgantown, WV

DIVISION OF LUNG DISEASES, NHLBI/NIH

OUTSIDE ORGANIZATION SESSION

**L12 THE MOLECULAR ATLAS OF LUNG
DEVELOPMENT (LUNGMAP), PHASE 2**

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**

Room 204 A-C (Level 2)

Target Audience

Providers of lung health, medical fellows in training, and basic and clinical researchers interested in lung biology, developmental biology, pediatric lung disease pathogenesis, bioinformatics, and systems biology

Objectives

At the conclusion of this session, the participant will be able to:

- learn the newest datasets of LungMAP that could inform lung research
- learn the innovative technologies for molecular profiling, imaging, and data analysis of the developing lung.
- learn how to access and use the LungMAP resources

Molecular Atlas of Lung Development (LungMAP) is an NHLBI-sponsored program. The overall goal of this program is to establish an open-access reference resource by creating a comprehensive molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Speakers will demonstrate how systems biology and bioinformatic approaches can be used to inform processes in development that are recapitulated in disease and repair. The session will illustrate the LungMAP data pipeline which integrates high resolution multi-omics and imaging data.

Chairing: S. Lin, PhD, Bethesda, MD
N. Salomonis, PhD, Cincinnati, United States

12:00 Post-Natal Development of Human Lung Cell Niches
M.C. Basil, MD, PhD, Philadelphia, PA

12:12 Applying Single Nuclear Transcriptomics for Study of Rare Pulmonary Disorders in Infants and Children
K.A. Wikenheiser-Brokamp, MD, PhD, Cincinnati, OH

12:24 Single Cell Profiling of Human Bronchopulmonary Dysplasia
X. Sun, PhD, San Diego, CA

12:36 Multi-Omics Spatial Molecular Profiling of the Human Lung
G.C.D. Clair, PhD, Richland, WA

12:48 LungMAP Consortium Assay Breadth in Coordinated Use of Human Tissue Core Biorepository Samples
R. Misra, PhD, Rochester, NY

VETERANS HEALTH ADMINISTRATION (VA)

OUTSIDE ORGANIZATION SESSION

L13 GENOMICS ANALYSES FROM MILLION VETERAN PROGRAM IMPROVE LUNG CANCER DETECTION AND CARE12:00 PM - 1:00 PM **Walter E. Washington Convention Center****Room 145 A-B (Street Level)****Target Audience**

Those interested in lung cancer research and care, in VA's Million Veteran Program, in lung cancer screening, or in treatment of those with advanced stage lung cancer with immune checkpoint inhibitors.

Objectives

At the conclusion of this session, the participant will be able to:

- describe new findings from the Million Veteran Program and the ways that research in this large cohort could benefit the quality of life for patients with, or at risk for, lung cancer.
- describe new findings about how the generation of new knowledge at the population level may be used to benefit individual patients.
- describe new findings about how patients can be selected more efficiently for lung cancer screening through integrating genomics, clinical, and imaging data from individual patients.

In its Million Veteran Program (MVP), VA has collected blood for genomic analysis from over 900,000 Veterans integrated with associated longitudinal clinical data. Within MVP, VA now also has conducted the largest genome-wide association study of lung cancer, identifying novel risk loci, tumor-specific signals previously masked by smoking, and polygenic risk scores for risk stratification. This work will be described along with two related applications: (1) a multiomics dashboard integrating clinical, genetic, and imaging data to improve the efficiency of selecting high-risk Veterans for screening; (2) use of genomic and phenotypic characterization to stratify those with advanced lung cancer for immunotherapy.

Chairing: J.K. Brown, MD, San Francisco, CA
C. Clancy, MD, Washington, D.C.

- 12:00 Update on the Million Veteran Program**
S. Muralidhar, PhD, Washington, DC
- 12:15 Genome-Wide Association Study of Lung Cancer in MV**
S. Pyarajan, PhD, Jamaica Plains, MA
- 12:30 Multiomic Predictive Model of Lung Cancer Risk**
S. Aguayo, MD, Phoenix, AZ
- 12:45 Predictive Model for Lung Cancer Treatment with Immune Checkpoint Inhibitors**
M. Green, MD, PhD, Ann Arbor, MI

DIVISION OF LUNG DISEASES, NHLBI/NIH

OUTSIDE ORGANIZATION SESSION

L14 UPDATE ON PRECLINICAL MODELS OF IPF - AN NHLBI CONSORTIUM12:00 PM - 1:00 PM **Walter E. Washington Convention Center****Room 143 A-C (Street Level)****Target Audience**

Those with research interests involving the study of idiopathic pulmonary fibrosis and other fibrotic lung diseases.

Objectives

At the conclusion of this session, the participant will be able to:

- learn new findings regarding the pathogenesis of IPF from its onset through disease progression.
- increase awareness among the broader IPF research community of the availability of new and improved model systems to study IPF.
- to inform the design of research studies involving IPF by leveraging model systems uniquely suited to uncover specific types of disease mechanisms, as well as improve model selection for screening and testing new drugs/biologics that target IPF

This session highlights the recent scientific advances and collaborative research achievements of an NHLBI-sponsored U01 consortium funded through RFA-HL-20-007: Advancing Novel Research Models to Study Idiopathic Pulmonary Fibrosis. The goal of this initiative is to establish a set of complementary model systems that reproduce essential disease-defining features of human idiopathic pulmonary fibrosis (IPF) in order to develop more effective therapies.

Chairing: M. Craig, PhD, Bethesda, MD

- 12:00 From Mice to iPSC-AT2 and Back**
M.F. Beers, MD, Philadelphia, PA
- 12:20 Team Mesenchyme: Integrating iPSC, Matrix Biology, PCLS, and Organoids**
B. Gomperts, MD, Los Angeles, CA
- 12:40 A Novel Ferret Model of Idiopathic Pulmonary Fibrosis**
S.M. Rowe, MD, Birmingham, AL

MEET THE EXPERT SEMINARS

CME Credits Available: 1

 Pre-registration and additional fees required. Attendance is limited.

\$100 Member/Non-Members

\$70 LMIC Member/LMIC Non-Members.

12:00 p.m. - 1:00 p.m. Marriott Marquis Washington

MTE22 COMMUNICATING SCIENCE TO THE PRESS

V. Gupta, MD, Seattle, WA

P. Silveyra, PhD, MSc, ATSF, Bloomington, IN

LeDroit Park (Level M3)

MTE23 BRONCHIECTASIS: CASE-BASED UPDATE ON GUIDELINES AND NEW TREATMENT OPTIONS

G. Tino, MD, ATSF, Philadelphia, PA

A.E. O'Donnell, MD, WASHINGTON, DC

Chinatown (Level M3)

MTE27 SMART THERAPY AND ALLERGIC IMMUNOTHERAPY IN NEW ASTHMA GUIDELINES: PROS AND CONS

M. Cataletto, MD, New Rochelle, NY

R. Ramonell, MD, Pittsburgh, PA

Judiciary Square (Level M3)

MTE28 PROGRESS IN PROGRESSIVE PULMONARY FIBROSIS: AN UPDATE IN DEFINITION AND MANAGEMENT

J.V. Pugashetti, MD, Ann Arbor, MI

T. Kulkarni, MD, MPH, Birmingham, AL

University of DC/Catholic University (Level M1)

MTE29 BEYOND THE LUNG: TAKING A MULTI-DISCIPLINARY APPROACH TO SARCOIDOSIS

M. Sharp, MD, MHS, Baltimore, MD

N. Gilotra, MD, Baltimore, MD

B. Stern, MD, Baltimore, MD

Mount Vernon Square (Level M3)

MTE30 OBESITY HYPOVENTILATION SYNDROME: CLINICAL APPROACH

B.Y. Sunwoo, MBBS, San Diego, CA

C. Won, MD, MS, New Haven, CT

Shaw (Level M3)



ATS
2023

**INTERNATIONAL
CONFERENCE**
WASHINGTON, DC
conference.thoracic.org

Monday Afternoon, May 22

PRESENTATION OF THE RECOGNITION AWARDS FOR SCIENTIFIC ACCOMPLISHMENTS

2:15 a.m. - 3:45 p.m. Walter E. Washington Convention Center

Room 202A

As part of the ATS Respiratory Health Awards, the Recognition Awards for Scientific Accomplishments recognizes outstanding scientific contributions in basic or clinical arenas to enhance the understanding, prevention and treatment of respiratory disease, critical illness, or sleep disorders and recognizes exemplary professionalism, collegiality and citizenship through mentorship and scientific involvement in the ATS community. Awardees are selected based on contributions made throughout their careers or for major contributions made at a particular point in their careers. Awardees will make a 20-minute presentation on their research.

Chairing: Gregory P. Downey, MD, FRCP(C), ATSF, Denver, Co
Lorraine B. Ware, MD, ATSF, Nashville, TN

Awardees:

2:30 Aging and Mitochondrial Dysfunction at the Spotlight of Lung Fibrosis

A. Mora, MD, Columbus, OH

2:50 Pushing Boundary: Consider the Lung as a Sensory Organ

X. Sun, PhD, La Jolla, CA

3:10 Liberating Critically Ill Adults from Invasive Mechanical Ventilation

K. Burns, MD, MSCR, FRCPC, MSc, Toronto, ON

3:30 Lung Immunity Responsible for Pneumonia Susceptibility and Outcome

J. Mizgerd, ScD, ATSF, Boston, MA.

CLINICAL
ADULT CLINICAL CORE CURRICULUM
CME Credits Available: 1.5
MOC Points Available: 1.5

CC3 SLEEP CLINICAL CORE CURRICULUM

Education Committee

2:15 p.m. - 3:45 p.m.

Target Audience

Clinicians who are engaged in maintenance of certification activities

Objectives

At the conclusion of this session, the participant will be able to:

- characterize various NIV modes and appreciate when to apply them
- describe NIV use with heart failure and patients with different types of sleep disordered breathing
- identify best practices for diagnosis and management of sleep disorders in patients with long COVID

Chairing: S. Shafazand, MD, Miami, FL
K. Dudley, MD, Boston, MA

2:15 The Nuts and Bolts of Non-Invasive Ventilation: An Update for Providers in 2023
M. Soffler, MD, Valhalla, NY

2:40 To PAP or not to PAP: Heart Failure and Sleep Disordered Breathing
V. Kundel, NYC, NY

3:05 Long Haul COVID and Sleep Disorders
O. Rojanapairat, MD, Los Angeles, CA

3:30 Questions and Answers

CLINICAL
YEAR IN REVIEW
CME Credits Available: 1.5

B81 NURSING YEAR IN REVIEW - WE CAN'T WAIT: ASSURING A PULMONARY, CRITICAL CARE, AND SLEEP NURSING WORKFORCE

Assembly on Nursing

2:15 PM - 3:45 PM **Walter E. Washington Convention Center**
Room 102 A-B (Street Level)

Target Audience

Conference participants with concerns about the availability of pulmonary, critical care, and sleep clinicians, faculty, and researchers

Objectives

At the conclusion of this session, the participant will be able to:

- apply new clinical research knowledge to clinical practice and nursing workforce
- gain new findings about strategies to address nursing staffing through health policies; use of innovative models for well-being, burnout, safety; and recruitment and retention of nurses
- identify effective approaches to recruit and retain nurses at various stages of the career including early, mid, and senior stages

The current nursing shortage influences the availability of healthcare and research conducted in ATS specialties of pulmonary, clinical care, and sleep. To increase audience awareness of the current status, speakers will provide overviews and review the literature about policies related to nurse staffing, interprofessional models for nurses' well-being and safety, and recruitment and retention of the nursing workforce at various stages of careers. The audience will benefit from a panel discussion of staffing policies, innovative models to address professional role issues, and approaches that positively influence the recruitment and retention of nurses. The panel will focus on these issues through the lens of the early, mid, and senior career nursing workforce.

Chairing: S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN
J.B. Seaman, PhD, RN, CHPN, Pittsburgh, PA

2:15 Introduction
J.B. Seaman, PhD, RN, CHPN, Pittsburgh, PA

2:20 Supporting Nurse Staffing Through Policy Initiatives
D.K. Costa, PhD, RN, Orange, CT

2:35 Well-Being, Safety, and Burnout: Interprofessional Teams and the Roles They Play
T.L. Eaton, PhD, RN, FNP-BC, ACHPN, Ann Arbor, MI

2:50 Models and Strategies for the Recruitment and Retention of Nurses
E.G. Collins, PhD, ATSF, Chicago, IL

3:05 Brief Applicable Highlights from the Future of Nursing 2020-2030 Report
S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN

3:10 Panel Discussion
D.K. Costa, PhD, RN, Orange, CT

3:13 Panel Discussion
T.L. Eaton, PhD, MSc, RN, FNP-BC, ACHPN, Ann Arbor, MI

3:16 Panel Discussion
E.G. Collins, PhD, ATSF, Chicago, IL

3:19 Panel Discussion
L.L. Chlan, PhD, RN, ATSF, Rochester, MN

3:22 Panel Discussion
K.O. Lindell, PhD, RN, ATSF, Charleston, SC

3:25 Panel Discussion
M.M. Lyons, PhD, MSN, ACNP-BC, Columbus, OH

3:28 Q & A
S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 1.5

B82 THE GENETICS OF INTERSTITIAL LUNG DISEASE: CURRENT STATE AND FUTURE PROMISE**Assembly on Clinical Problems****2:15 PM - 3:45 PM** **Walter E Washington Convention Center****Ballroom A (Level 3)****Target Audience**

ILD clinicians, geneticists, physician-scientists

Objectives

At the conclusion of this session, the participant will be able to:

- understand how rare genetic variants and telomere length relate to interstitial lung disease risk, progression, and survival
- describe the current approaches to genetic testing and telomere length testing in ILD and how to counsel patients
- define future strategies for applying clinical genetics in the diagnosis and management of ILD

Significant progress has been made in our understanding of the genetic susceptibility underlying pulmonary fibrosis, including elucidating the associations of rare variants in more than 12 genes including genes involved with surfactant metabolism and telomere maintenance.

Researchers are beginning to understand how the presence of such variants informs clinical management and are incorporating genetic testing into their practice. This includes informing prognosis and treatment strategies for patients affected with ILD and characterizing risk for unaffected relatives. This session will review the state of research related to genetic variants and telomere length in ILD and provide a roadmap for how future clinical genetics will advance us towards precision medicine in ILD.

Chairing: E.D. Farrand, MD, San Francisco, CA
P.J. Wolters, MD, San Francisco, CA
L.V. Wain, PhD, Leicester, United Kingdom

2:15 Overview
P.J. Wolters, MD, San Francisco, CA

2:20 Genetic Variants and ILD
B. Crestani, MD, PhD, Paris, France

2:30 Question and Answer

2:35 Telomere Length and ILD
C. Newton, MD, Dallas, TX

2:45 Question and Answer

2:50 The Here and Now of ILD Genetics
J. Talbert, MS, Nashville, TN

3:00 Question and Answer

3:05 The Future of Genetics in ILD: Diagnostic Applications
C.K. Garcia, MD, PhD, New York, NY

3:20 Question and Answer

3:25 The Future of Genetics in ILD: Therapeutic Applications
J. Morisset, MD, Montreal, Canada

3:40 Question and Answer

This session and the International Conference are supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 1.5

B83 WHY YES, YOU CAN SKI WITH YOUR VENTILATOR! USING TECHNOLOGY TO KEEP NIV/IMV VENTILATOR DEPENDENT PATIENTS ACTIVE AND ENGAGED IN THEIR COMMUNITIES**Assemblies on Clinical Problems; Pediatrics; Sleep and Respiratory Neurobiology****2:15 PM - 3:45 PM** **Marriott Marquis Washington****Independence Ballroom Salons A-D (Level M4)****Target Audience**

Adult pulmonologists, pediatric pulmonologists, respiratory therapists, mid-level providers, and nurses who care for patients with ventilator (NIV or invasive) dependent respiratory failure

Objectives

At the conclusion of this session, the participant will be able to:

- develop competency in guideline based implementation of assisted NIV and IMV in advanced lung disease
- develop competency in airway clearance modalities in advanced lung disease
- adapt above competencies to multiple different community engagement models (school participation, sports, travel and camping). Review of environment specific needs/adaptations for effective device function

Session will provide state of the art, evidence based guidance on the optimal management of patients with ventilator dependent respiratory disorders. Objectives are to ensure understanding of the evidence based use of NIV, IMV, cough augmentation and sputum mobilization options in advanced lung disease to maintain quality of life, with a focus

on maintaining community participation. Optimizing evidence based respiratory assistive device adaptations to continue appropriate ventilation and airway clearance while out of the home. Specific situations that will be addressed will be sports participation (skiing, hockey), camping and day and multi-day travel. Patient and family panelists will provide expert experiential guidance.

Chairing: K.A. Provost, DO, PhD, FCCP, Buffalo, NY
 M. Cao, DO, STANFORD, CA
 J.H. Hansen-Flaschen, MD, ATSF, Wynnewood, PA

- 2:15 Why Am I Carrying All of This STUFF?**
K.A. Provost, DO, PhD, FCCP, Buffalo, NY
- 2:30 You Are Going to School Today!**
R. Amin, MD, Toronto, Canada
- 2:45 Ventilators in the Wild! Skiing, Camping and Other Sports**
J.P. Brown, MD, PhD, Salt Lake City, UT
- 3:00 London/Disneyworld/Laguna Beach Here We Come!**
L.F. Wolfe, MD, Chicago, IL
- 3:15 No Really, You Really Can Do All This!**
M. Lindquist, L. Lindquist, Buffalo, NY
- 3:25 Speaker Panel**

CLINICAL
CRITICAL CARE TRACK
CME Credits Available: 1.5

B84 NEXT GENERATION CRITICAL CARE TRIALS: FROM PRAGMATIC TRIALS TO PRECISION MEDICINE

Assemblies on Critical Care; Behavioral Science and Health Services Research; Nursing

2:15 PM - 3:45 PM **Walter E. Washington Convention Center**
West Salon G-I (Street Level)

Target Audience

Clinicians of any discipline who care for critically ill adults or children, and clinical and translational critical care researchers

Objectives

- At the conclusion of this session, the participant will be able to:
- researchers who attend the session will be able to apply knowledge acquired about novel trial designs to interpret and critique the results of future platform, adaptive, pragmatic, and personalized clinical trials
 - clinicians will be able to assess the strengths and limitations of novel trial designs in order to facilitate the implementation of results from future trials into clinical practice to improve patient outcomes

- learners will be able to apply an understanding of “individual treatment effect” and “personalized medicine” to the manner in which they implement the results of clinical trials into clinical practice

Critical care has historically relied on explanatory, parallel-group randomized trials to generate evidence to inform practice. Such designs can be inefficient and expensive. COVID-19 has changed the landscape of critical care trials by advancing alternative, innovative, and efficient approaches to trial design, conduct, and analysis. This session will review these new methods, including platform trials, adaptive trials, Bayesian methods, pragmatic trials, and trials informing personalized treatment choices. Clinicians will learn how to interpret and apply results of these trials to practice. Researchers will learn how to use these methods to generate real-world, personalized evidence, improving care for critically ill patients.

Chairing: M.W. Semler, MD, MSc, Nashville, TN
 C.S. Calfee, MD, MSCR, San Francisco, CA
 M.M. Churpek, MD, MPH, PhD, ATSF, Madison, WI

- 2:15 Introduction: ABCs of Next-Gen RCTs**
M.W. Semler, MD, MSc, Nashville, TN
- 2:20 Platform Trials**
M.N. Gong, MS, MD, Bronx, NY
- 2:35 Adaptive Trials and Bayesian Methods**
E. Goligher, MD, PhD, Toronto, Canada
- 2:50 Pragmatic Trials**
J.D. Casey, MD, MSCR, Nashville, TN
- 3:05 Using Biomarkers for Precision Medicine in Clinical Trials**
C.S. Calfee, MD, MSCR, San Francisco, CA
- 3:20 Using Machine Learning for Precision Medicine in Clinical Trials**
M.M. Churpek, MD, MPH, PhD, ATSF, Madison, WI
- 3:35 Roundtable Discussion**
M.W. Semler, MD, MSc, Nashville, TN

BASIC • TRANSLATIONAL
BASIC SCIENCE CORE
CME Credits Available: 1.5

B85 PROCESSING THE ENVIRONMENT: LUNG LYMPHATICS AND FOLLICLES IN DISEASE

Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology

2:15 PM - 3:45 PM **Marriott Marquis Washington**
Independence Ballroom Salons E-H (Level M4)

Target Audience

Lung health providers, trainees, and those involved in research or clinical care related to lung disease and immune response

Objectives

At the conclusion of this session, the participant will be able to:

- to learn new findings on lymphatics structure and function in the lung and how this is related to disease
- to be able to apply knowledge on lymphatics and follicles in management of patients treated with steroids and other immune modulators
- to be able to apply knowledge on lymphatics and follicles in management of patients who had undergone lung transplantation

Lymphatics and lymphoid follicles are integral to the lung immune response and for processing antigens from the environment. This sessions will review the biology of the lymphatic and associated lymphoid follicle and immune responses in the lung, discuss how changes in these structures are associated with different disease phenotypes. The learner will better understand how lymphatics are linked to the immune response and appreciate these understudied structures in the lung.

Chairing: J.E. McDonough, PhD, New Haven, CT
H. Outtz Reed, MD, PhD, New York,, NY

2:15 Lymphoid Follicles in COPD: An Unanswered Question
F. Polverino, MD, PhD, Houston, TX

2:30 Lymphoid Follicles: A Good Intention Turned Bad
A. Yildirim, PhD, Neuherberg, Germany

2:45 The Role of Lymphatic Function in the Pathogenesis of Lung Disease
H. Outtz Reed, MD, PhD, New York,, NY

3:00 Harnessing Lymphatic Transport for Drug Delivery
K. Maisel, PhD, Maryland, MD

3:15 Pulmonary Lymphatic Diseases: Novel Imaging and Interventional Treatment
M. Itkin, MD, Philadelphia, PA

3:30 Multiomics Approaches to Understand Lung Lymphatics and Its Role in Lymphangioliomyomatosis
M. Guo, PhD, Cincinnati, OH

CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

B86 PRECISION MEDICINE IN PNEUMONIA

Assemblies on Pulmonary Infections and Tuberculosis; Critical Care

2:15 PM - 3:45 PM **Walter E. Washington Convention Center**

Room 146 A-C (Street Level)

Target Audience

Pulmonary, critical care or infectious disease physicians/providers who

see patients hospitalized with pneumonia, and all basic, translational or clinical researchers with an interest in pneumonia, critical care, phenotypes and endotypes

Objectives

At the conclusion of this session, the participant will be able to:

- improve precision in the diagnosis and management of patients with pneumonia utilizing clinically available resources like guidelines and culture-independent diagnostic tools
- understand the existing phenotypes and endotypes in pneumonia and methods to evaluate their trajectory over time
- define and implement research strategies to characterize patients with pneumonia

Pneumonia is a leading cause of death globally. With the current approach to pneumonia, which includes diagnosis by symptoms and chest radiograph and management with antibiotics, morbidity and mortality remain high. Precision medicine calls for multidimensional characterization of a patient to identify factors that may indicate favorable responses to an intervention. The identification of phenotypes and endotypes are crucial for the development of targeted therapies in pneumonia. In this session, experts will introduce the audience to emerging research that supports the presence of phenotypes in pneumonia and discuss clinical tools that can enhance precision medicine in pneumonia.

Chairing: C. Pickens, MD, Chicago, IL
B.G. Wu, MD, MSc, New York, NY
R.P. Dickson, MD, Ann Arbor, MI

2:15 Matching Solutions to Complexity: The Role for Pneumonia Guidelines in Precision Medicine
B.E. Jones, MD, MSc, Salt Lake City, UT

2:33 Multiplex PCR to Enhance Precision in Diagnosing Pneumonia 2
D. Stolz, MD, Basel, Switzerland

2:51 Multi-Omics Approaches to Endotyping Pneumonia 3
C. Dela Cruz, MD, PhD, ATSF, New Haven, CT

3:09 Immunologic Phenotypes in Community Acquired Pneumonia 4
M.R. Menendez Villanueva, MD, Valencia, Spain

3:27 Mapping the Trajectory of Pneumonia Phenotypes Using Novel Clinical Endpoints 5
R.G. Wunderink, MD, Chicago, IL

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

B87 CONTROVERSIES IN PEDIATRIC OBSTRUCTIVE SLEEP APNEA: A PRO/CON DEBATE

Assemblies on Pediatrics; Sleep and Respiratory Neurobiology

2:15 PM - 3:45 PM

Marriott Marquis Washington

Marquis Ballroom Salon 5 (Level M2)

Target Audience

Clinicians and researchers who care for and study children with obstructive sleep apnea, including sleep medicine physicians, pediatric pulmonologists, and allied health professionals

Objectives

At the conclusion of this session, the participant will be able to:

- inform the clinicians and researchers about specific areas of debate in the evaluation and management of obstructive sleep apnea in children
- apply state of the science to help the audience decide on appropriate uses of diagnostic and treatment modalities related to pediatric obstructive sleep apnea
- identify key gaps for conditions mentioned in objectives 1 and 2 that should inform future research

There has been substantial new clinical research related to the evaluation and management of obstructive sleep apnea in children since clinical practice guidelines were most recently published. As a result, a number of controversies exist in this area, including 1) home sleep apnea testing for the evaluation of OSA in children, 2) adenotonsillectomy for treatment of mild sleep-disordered breathing in children, and 3) the use of drug-induced sleep endoscopy for etiology of residual OSA following adenotonsillectomy. In this session, a panel of experts will review the state of the science and evidence for these topics in a pro/con format.

Chairing: C.M. Cielo, DO, Philadelphia, PA
R. Amin, MD, Toronto, Canada

- 2:15 Introduction**
R. Amin, MD, Toronto, Canada
- 2:20 PRO: Home Sleep Apnea Testing Should Be Expanded to Include Children**
I. Tapia, MD, MS, Philadelphia, PA
- 2:30 CON: Home Sleep Apnea Testing Should Be Expanded to Include Children**
R. Bhattacharjee, MD, San Diego, CA
- 2:40 Discussion: Home Sleep Apnea Testing for the Evaluation of OSA in Children**
C.M. Cielo, DO, Philadelphia, PA

- 2:45 PRO: Adenotonsillectomy Should Be Used for the Treatment of Mild Sleep-Disordered Breathing in Children**

S.S. Redline, MD, MPH, Boston, MA

- 2:55 CON: Adenotonsillectomy Should Be Used for the Treatment of Mild Sleep-Disordered Breathing in Children**

S.L. Verhulst, MD, PhD, MSc, Edegem, Belgium

- 3:05 Discussion: Adenotonsillectomy for the Treatment of Mild Sleep-Disordered Breathing in Children**

R. Amin, MD, Toronto, Canada

- 3:10 PRO: Drug-Induced Sleep Endoscopy Should be Used for Etiology of Residual OSA Following Adenotonsillectomy**

C. Heubi, MD, Cincinnati, OH

- 3:20 CON: Drug-Induced Sleep Endoscopy Should Be Used for Etiology of Residual OSA Following Adenotonsillectomy**

Z. Ehsan, MD, Kansas City, MO

- 3:30 Discussion: Drug-Induced Sleep Endoscopy for Evaluation of the Etiology of Residual OSA Following Adenotonsillectomy.**

C.M. Cielo, DO, Philadelphia, PA

- 3:35 Future Directions**

R. Amin, MD, Toronto, Canada

TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

B88 LEAPS AND BOUNDS: REDUCING HEALTHCARE'S CARBON FOOTPRINT

Assemblies on Environmental, Occupational and Population Health; Critical Care; Nursing; Health Policy Committee

2:15 PM - 3:45 PM

Walter E. Washington Convention Center

Room 150 A-B (Street Level)

Target Audience

Researchers focused on healthcare delivery and/or environmental/occupational exposures, those with clinical, research or administrative responsibilities, and policy makers who focus on environmental regulations and healthcare delivery

Objectives

At the conclusion of this session, the participant will be able to:

- define the healthcare industry's contribution to emissions and climate change
- understand and apply interventions at the individual and system levels to reduce, eliminate, or reverse healthcare's environmental impact and emissions

- describe approaches and participate in effective advocacy to reduce the carbon footprint of healthcare both at a provider and system level

Climate change threatens human health with a disproportionate burden on vulnerable populations. Human activities contributing to climate change include burning of biomass fuels and resultant emission of greenhouse gasses. A 'carbon footprint' reflects the effect that a person, group of people, or industry has on emissions. Healthcare providers and systems directly contribute to and treat climate change's negative effects on health. Thus we are both responsible for and uniquely poised to take a leadership role in individual and industry response to the climate crisis. Presented are multiple potential points of healthcare system intervention to reduce the pace of global warming.

Chairing: E. Brigham, MD, MHS, Vancouver, Canada
J.M. Radbel, MD, New Brunswick, NJ
J.P. Castner, PhD, RN, Grand Island, NY
M.B. Rice, MD, MPH, Boston, MA

2:15 Scope of the Problem: Healthcare Sector Pollution and Climate Change

J. Sherman, MD, New Haven, CT

2:35 Changing How We Work: Hospital Operations

H. Shankar, MD, Philadelphia, PA

2:50 Treatment Choices: A Case Study in Inhalers

A. Rabin, MD, Ann Arbor, MI

3:05 The Commute: Implementing Climate Action Plans for Transportation

R.J. Laumbach, MD, MPH, Piscataway, NJ

3:20 We have an Important Voice: Care Providers as Climate Actors

Speaker To Be Announced

3:35 Group Discussion

BASIC • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

B89 TRANSCRIPTOMIC PROFILING OF PULMONARY VASCULAR LESIONS UNRAVEL MECHANISMS OF PULMONARY ARTERIAL HYPERTENSION

Assemblies on Pulmonary Circulation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

2:15 PM - 3:45 PM **Walter E. Washington Convention Center**

Room 207 A-B (Level 2)

Target Audience

Investigators and physician scientists interested in advanced techniques used to explore molecular mechanisms of pulmonary vascular remodeling, as well as clinicians, pharmacists and other caregivers engaged in treating patients with pulmonary hypertension

Objectives

At the conclusion of this session, the participant will be able to:

- describe new technologies that allow assessment of gene expression at the cellular and lesional level from animals and patients with pulmonary vascular disease
- apply new technologies for assessing cell specific gene expression to advance basic science research in pulmonary vascular biology
- apply new knowledge competence to better understand the pathophysiology of pulmonary vascular disease to help guide the diagnosis and treatment of pulmonary arterial hypertension

New techniques in RNA sequencing, spatial transcriptomics and proteomics have rapidly developed and allow for assessment of near complete gene expression at a microscopic lesional, and cellular level, focused on a precise area of interest making it possible to compare gene expression between different types of pulmonary vascular cells under baseline and disease conditions. This symposium will present novel findings from multiple laboratories demonstrating how these techniques are moving the field of pulmonary vascular biology forward, with a focus on methodology development, the required expertise to carry out such an analyses, bioinformatics, and interpretation of the data.

Chairing: J.R. Klinger, MD, ATSF, Providence, RI
J. Leopold, MD, Boston, MA
M.W. Geraci, MD, Pittsburgh, PA

2:15 Integrated Analysis of scRNAseq Data Sets to Develop a Comprehensive Atlas of Endothelial Gene Expression in the Normal Lung

N. Kaminski, MD, ATSF, New Haven, CT

2:35 Reactivation of Transcriptional Programs That Orchestrate Fetal Lung Development in Human Pulmonary Hypertension

S.S. Pullamsetti, PhD, Bad Nauheim, Germany

2:50 The Use of Single-Cell Transcriptomics in Animal Models of Pulmonary Hypertension to Identify Genetic Changes Relevant to Human Pulmonary Hypertension

J. Hong, MD, PhD, Los Angeles, CA

3:10 Combining Spatial Transcriptomics and Single Cell RNAseq to Examine Gene Expression in Pulmonary Vasculature Endothelial Cells

A. Brodsky, PhD, Providence, RI

3:30 Use of Spatial Transcriptomics to Examine Lesion-Specific Gene Expression in Human Pulmonary Arterial Hypertension

K.R. Stenmark, MD, Aurora, CO

This session and the International Conference are supported by an independent medical educational grant from Merck & Co. and United Therapeutics Corporation.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

MOC Points Available: 1.5

B90 IMPROVING THE DIAGNOSIS AND MANAGEMENT OF PEDIATRIC ACUTE RESPIRATORY DISTRESS SYNDROME

Assemblies on Critical Care; Pediatrics

2:15 PM - 3:45 PM

Marriott Marquis Washington

Marquis Ballroom Salon 6 (Level M2)

Target Audience

Clinicians and researchers who care for patients with ARDS

Objectives

At the conclusion of this session, the participant will be able to:

- improve the diagnosis of pediatric ARDS
- integrate new guidelines for the management of PARDS into current practice
- use informatics and data science techniques appropriately in the care of children with PARDS

Acute Respiratory Distress Syndrome (ARDS) occurs in both children and adults, but the management and diagnosis of Pediatric Acute Respiratory Distress Syndrome (PARDS) must consider factors which are unique to children and pediatric ICU practice. In 2015, the Pediatric Acute Lung Injury Consensus Conference (PALICC) published a definition of PARDS, along with clinical practice guidelines. Since then, there has been a wealth of new research focused on PARDS, which has prompted an update to PALICC, termed PALICC-2. This session focuses on important concepts and themes from PALICC-2 which are crucial for the clinical care of children with PARDS.

Chairing: R.G. Khemani, MD, MSCR, Los Angeles, CA
Y. Lopez-Fernandez, MD, PhD, Bizkaia, Spain

2:15 Introduction and Overview of PALICC-2
G. Emeriaud, MD, PhD, Montreal, Canada

2:20 Patient Speaker
C. Clark, Gainesville, FL

2:25 How Do We Account for Changing Practice with HFNC and NIV in Defining PARDS?
S. Shein, MD, Cleveland, OH

2:40 Lung Protective Bundles and Monitoring in PARDS
A. Bhalla, MD, MSc, Los Angeles, CA

2:55 What Are the Most Important Outcomes to Follow in PARDS Patients, and Can We Modulate Them with our Therapies?
E. Killien, MD, Seattle, WA

3:10 Understanding Phenotypic Heterogeneity: Can We Get to Precision-Based Care in PARDS?

J.R. Grunwell, MD, PhD, Atlanta, GA

3:25 PARDS in the Digital Era: Leveraging Informatics and Data Science

N. Sanchez-Pinto, MD, MCI, Chicago, IL

3:40 Question and Answer

R.G. Khemani, MD, MSCR, Los Angeles, CA

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

B91 LUNG AGING: WHY YOUR FEV1 IS FALLING AND PNEUMONIA IS YOUR FINAL FRIEND

Assemblies on Respiratory Cell and Molecular Biology; Respiratory Structure and Function

2:15 PM - 3:45 PM

Walter E. Washington Convention Center

Room 204 A-C (Level 2)

Target Audience

Clinicians, physiologists, molecular biologists, epidemiologists, and all points in between

Objectives

At the conclusion of this session, the participant will be able to:

- describe new findings about the major pathophysiologic elements of the aging lung
- apply the pathophysiology of lung aging to better manage the common clinical scenarios of ILD, COPD, Th1 asthma, lung carcinogenesis
- improve the healthspan of individuals at risk for age-related lung disorders, including the consideration of "senolytic" prevention maneuvers

We are all aging. Yet the machinery of aging is not well understood. Many disorders with which clinicians struggle are strongly age-associated (UIP/IPF, COPD, Th1 ASTHMA, Lung Cancer, others). Some central dysfunctions of aging include stochastic deterioration of biologic programs; senescence programming, oxidative damage, telomeric maintenance failure, immunologic exhaustion, and other processes. This symposium will review some of the known processes of aging as they relate to the lung, review some of the most salient studies, and reach for a unified theme for normal as well as accelerated lung aging that may be addressable with preventatives and therapeutics.

Chairing: S.D. Spivack, MD, MPH, Bronx, NY
J.L. Schneider, MD, PhD, Boston, MA
I. Rahman, PhD, ATSF, Rochester, NY

- 2:15 Overview of Lung Aging**
J.L. Schneider, MD, PhD, Boston, MA
- 2:30 Oxidative Shifts in the Aging Lung**
I. Rahman, PhD, ATSf, Rochester, NY
- 2:40 Signalling and Senescence in Lung Aging**
A.L. Mora, MD, Columbus, OH
- 2:50 Mutation and Epimutation Changes with Age**
S.D. Spivack, MD, MPH, Bronx, NY
- 3:00 Extracellular Matrix and Aging in the Lung**
J.K. Burgess, BSc, PhD, ATSf, Groningen, Netherlands
- 3:10 Distal Bronchoalveolar Region Changes in Aging and COPD**
R. Shaykhiev, MD, PhD, NEW YORK, NY
- 3:20 Immunologic Signaling and Exhaustion in the Aging Lung**
B. Ural, PhD, New York, NY
- 3:30 Multiomic Revelations in Lung Aging and IPF**
N. Kaminski, MD, ATSf, New Haven, CT
- 3:40 Panel Discussion**
S.D. Spivack, MD, MPH, Bronx, NY

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

B92 INNOVATIVE APPROACHES TO PERSONALIZED SEVERE ASTHMA MANAGEMENT

Assemblies on Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Pediatrics; Respiratory Cell and Molecular Biology

2:15 PM - 3:45 PM **Walter E. Washington Convention Center**

Ballroom B (Level 3)

Target Audience

Adult and pediatric asthma providers, including pulmonologists, allergists and APPs, as well as basic scientists interested in airway immunology, epithelial and airway smooth muscle biology and new companies in the severe asthma space

Objectives

At the conclusion of this session, the participant will be able to:

- apply home assessments to longitudinal asthma management
- describe new findings regarding androgens and other sex steroids in asthma
- describe new insights regarding the use of imaging in asthma

Biologic treatments have been beneficial for many severe asthma patients, but many others continue to have debilitating chronic dyspnea,

exacerbations and/or medication side effects. Recent advances in asthma biology and in technology have provided exciting opportunities to improve personalized severe asthma management. Leveraging insights from the NHLBI Precise network and ICAN meeting, we will provide an update on the latest insights in this field.

Chairing: H. Durrington, PhD, MA, MBChB, Manchester, United Kingdom
A.A. Zeki, MD, Davis, CA
B. Gaston, MD, Indianapolis, IN

- 2:15 Application of an Adaptive Trial Design to Severe Asthma Research**
A. Ivanova, PhD, Chapel Hill, NC
- 2:28 Questions and Answers**
- 2:33 Androgens and Other Sex Hormones in Severe Asthma**
D.C. Newcomb, PhD, Nashville, TN
- 3:46 Questions and Answers**
- 2:51 Potential Use of Genetics and Biomarkers to Personalize Severe Asthma Management**
V.E. Ortega, MD, PhD, ATSf, Scottsdale, AZ
- 3:04 Questions and Answers**
- 3:09 Asthma Imaging: Novel Insights**
E. Dunican, BM BCH, Dublin, Ireland
- 3:22 Questions and Answers**
- 3:27 Recent Advances in At-Home Assessments of Asthma Control**
P. Akuthota, MD, ATSf, La Jolla, CA
- 3:46 Questions and Answers**

BASIC • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

B93 BREAKTHROUGHS IN ILD: TRANSLATION TO THE BEDSIDE

2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Ballroom C (Level 3)

Chairing: J. Koenitzer, MD, PhD, Saint Louis, MO
W.P. Drake, MD, Nashville, TN
J. Joshua, MD, San Diego, CA

Oral Presentations:

- 2:15 Comprehensive Myositis Antibody Panels Improve Recognition of Myositis Related Interstitial Lung Disease/A.E. Davis, Nashville, TN**

- 2:27 **Soluble Mediators of Post-COVID-19 Fibrotic Lung Remodeling: A Proteomic Approach**/S. Holton, Seattle, WA
- 2:39 **A Polygenic Risk Score for Idiopathic Pulmonary Fibrosis and Interstitial Lung Abnormalities**/M. Moll, Boston, MA
- 2:51 **Activated T Regulatory Responses in Interstitial Lung Disease**/T.E. Velez, Charlottesville, VA
- 3:03 **Circulating T Cells in Sarcoidosis Have an Activated Phenotype That Correlates With Disease Outcome**/J.R. Miedema, Rotterdam, Netherlands
- 3:15 **Efzofitimod, a Novel Immunomodulator for Pulmonary Sarcoidosis, Modulates Patient Inflammatory Responses Through Myeloid Cells**/D. Siefker, San Diego, CA
- 3:27 **TRPV4 Is a Key Mechanosensor in Macrophages That Drives Myofibroblast Differentiation Through the TGF- β Pathway**/R.G. Scheraga, Cleveland, OH
- 3:39 **Preclinical Granzyme B PET Imaging for Pulmonary Fibrosis Detection and Treatment Response Evaluation**/Y. Zhang, Birmingham, AL
- 3:51 **Functional Imaging Signatures of Chronic Hypersensitivity Pneumonitis Utilizing Hyperpolarized ^{129}Xe MRI and Spectroscopy**/M. Kocher, Durham, NC
- 4:03 **Organic and Inorganic Exposures Are Associated With Radiologic Features in Patients With Fibrotic Interstitial Lung Disease**/S.D. Lok, Saskatoon, Canada
- 2:39 **Respiratory Exacerbations and Lung Function Decline in People With Normal Spirometry and Smoking Exposure**/S. Fortis, Iowa City, IA
- 2:51 **Loss of Airway Bacterial Phylogenetic Diversity in Mild to Moderate COPD Associates With Clinical and Pathobiological Markers of Disease Development**/Y.J. Huang, Ann Arbor, MI
- 3:03 ***Haemophilus*-Driven Microbial Networks in COPD Associates with Airflow Decline, Frequent Exacerbations and Altered Mucus**/O.W. Meldrum, Singapore, Singapore
- 3:15 **What a Lung Cancer Screening Cohort Can Tell Us About COPD: The University of Michigan Experience**/V.M. Scicluna, Ann Arbor, MI
- 3:27 **Serum Kynurenine/Tryptophan Ratio Is a Marker of Lung Disease Severity in Current and Former Tobacco Cigarette Users With and Without COPD**/W.W. Labaki, Ann Arbor, MI
- 3:39 **COPD With PH Secondary to Left Heart Disease Is Associated With Worse Survival**/R.C. Flowers, New York, NY
- 3:51 **Disentangling Predictors of Overall and COPD-specific Mortality With Probabilistic Graphical Models**/T.C. Lovelace, Pittsburgh, PA
- 4:03 **Impaired Exacerbation Recovery Is Associated With Reduced Resolvin D1 in Chronic Obstructive Pulmonary Disease**/L. Finney, London, United Kingdom

CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

B94 DISEASE PROGRESSION AND MORBIDITY ALONG THE SPECTRUM OF COPD: FROM EARLY TO ESTABLISHED2:15 p.m. - 4:15 p.m. **Marriott Marquis Downtown****Liberty Ballroom, Salons I-L (Level M4)**

Chairing: M.K. Han, MD, MS, ATSF, Ann Arbor, MI
R. Kalhan, MD, MS, Chicago, IL
D. Lafon, MD, Birmingham, AL

Oral Presentations:

- 2:15 **The Fev₁ as a Predictor of Future Health in Young Non-Obstructed Smokers**/Y. Tesfaigzi, Boston, MA
- 2:27 **Airway Epithelial Gene Expression Associated With Domains of Resilience in Smokers Without Airflow Obstruction**/A. Oh, San Francisco, CA

CLINICAL

MINI SYMPOSIUM

B95 TOWARDS IMPROVING ICU AND POST-ICU OUTCOMES2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center****Room 202 B (Level 2)**

Chairing: L.E. Ferrante, MD, MHS, ATSF, New Haven, CT
C.T. Hough, MD, MSc, ATSF, Portland, OR
T.J. Iwashyna, MD, PhD, Baltimore, MD

Oral Presentations:

- 2:15 **Clinician Familiarity Among Shift-level Interprofessional ICU Teams Is Associated With Lower Mortality: A Network Analysis of Linked Clinician-patient Data**/D.K. Costa, Orange, CT
- 2:27 **Associations Between Patient and Surrogate Assessments of Pre-critical Illness Physical Function**/J. Gordon, Columbus, OH

- 2:39 Physical Activity Changes Circulating MicroRNA Expression in Critically Ill Patients/J.T.W. Krall, Winston-Salem, NC**
- 2:51 Utilization, Prices, and Outcomes in Intensive Care Units/S. Kannan, Boston, MA**
- 3:03 Post ICU Syndrome, Return to Employment, and Healthcare Utilization Among Critically Ill COVID-19 Survivors/A.M.A.A. Eltarras, Indianapolis, IN**
- 3:15 Older Adults' Perspectives on Screening for Cognitive Impairment Following Critical Illness: Pre-implementation Qualitative Study/A. Keegan, Winston-Salem, NC**
- 3:27 Incidence and Associated Risk Factors for Falls in Adults Following Critical Illness: 12-month Post Hospital Prospective Cohort Study/S.M. Parry, Parkville, Australia**
- 3:39 Comparison of One-Year Mortality After Critical Illness in a Prospective Observational Study of ICU Survivors With and Without COVID-19/N. Bandealy, Chicago, IL**
- 3:51 Co-designed Peer Support to Improve Critical Care Recovery: ICU RESOLVE Pilot Randomised Controlled Trial/K.J. Haines, Melbourne, Australia**
- 4:03 Pre-illness Trajectory in Health-related Quality of Life and Functional Status May Confound Results of Intensive Care Unit Follow-up Studies/A.K. Bhalla, Los Angeles, CA**

BASIC • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

B96 BEST IN PEDIATRICS

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 147 A-B (Street Level)

Chairing: E. Forno, MD, MPH, ATSF, Pittsburgh, PA
B.T. Kopp, MD, MPH, ATSF, Atlanta, GA

Oral Presentations:

- 2:15 Arrested Development: Abnormal Differentiation of Airway Epithelial Cells From Patients With Evolving Bronchopulmonary Dysplasia/L.C. Eldredge, Seattle, WA**
- 2:27 Altered Differentiation of Proximal Airway Epithelium in Trisomy 21/C. Cherry, Torrance, CA**
- 2:39 High Ventilator Settings in Neonatal Bronchopulmonary Dysplasia May Not Necessarily Improve Alveolar Recruitment but Are Associated With Increased Hyperinflation: Early Evidence from Neonatal Chest MRI/N. Higano, Cincinnati, OH**

- 2:51 The Fungal Intestinal Microbiota Predict the Development of Bronchopulmonary Dysplasia in Very Low Birthweight Newborns/K.A. Willis, Birmingham, AL**
- 3:03 The Effect of the Pediatric Upper Respiratory Tract Fungal Microbiome on the Risk of Childhood Asthma/C. Rosas-Salazar, Nashville, TN**
- 3:15 Airway Disease Progression on Chest Computed Tomography in Children With Primary Ciliary Dyskinesia/B. Kinghorn, Seattle, WA**
- 3:27 A Transcriptome-wide Association Study of Total IgE in Nasal Epithelium From Youth With Asthma/Z. Xu, Pittsburgh, PA**
- 3:39 Neighborhood-level Child Opportunity Predicts Exacerbation-prone Status in a Cohort of Urban Children With Asthma/E. Skeen, Aurora, CO**
- 3:51 Associations Between Neighborhood Socioeconomic Status and Quality of Life in Children With Mild Sleep Disordered Breathing: A Six-city Analysis in the US/S. Gueye-Ndiaye, Boston, MA**

Featured Speaker:

- 4:03 Resilience in Research: Passion, People, Perseverance/ E. Forno, Pittsburgh, PA**

CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

B97 RISKY BUSINESS: TREATMENTS AND CLINICAL TARGETS IN PULMONARY HYPERTENSION

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 152 A-B (Street Level)

Chairing: M.J.C. Humbert, MD, PhD, Bicetre, France
S.M. Kawut, MD, MS, ATSF, Philadelphia, PA
A.R. Tonelli, MD, MSc, Cleveland, OH
C.E. Ventetuolo, MD, MS, Providence, RI

Oral Presentations:

- 2:15 Multivariable Risk Scores as Surrogate Outcomes in Randomized Trials in Pulmonary Arterial Hypertension/M.O. Harhay, Philadelphia, PA**
- 2:27 Baseline Phenotype Differences in Black and White Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Patients in the United States CTEPH Registry (US-CTEPH-R)/B. Desai, La Jolla, CA**

- 2:39 **Post-acute Sequelae of SARS-CoV-2 Infection Patients Have Metabolic Reprogramming and Reduced Mitochondrial Function at Peak Exercise**/M.G. Risbano, Pittsburgh, PA
- 2:51 **Minimal Clinically Important Difference in the Six-minute Walk Distance for Patients With Pulmonary Arterial Hypertension**/J. Moutchia, Philadelphia, PA
- 3:03 **Alpha Study: Pulmonary Arterial Hypertension Treated With Cardiosphere-derived Allogeneic Stem Cells**/M.I. Lewis, Los Angeles, CA
- 3:15 **Serial Acute Vasodilator Testing Uncovers Dynamic Clinical Sub-phenotypes of Pulmonary Arterial Hypertension**/A. Sweatt, Stanford, CA
- 3:27 **The Efficacy and Safety of Selexipag as an Add-On to Standard-of-Care Therapy in Patients With Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension After Surgical and/or Interventional Treatment (SELECT)**/N.H. Kim, La Jolla, CA
- 3:39 **“Super-responders” in Pulmonary Arterial Hypertension: An Individual Participant Data Meta-analysis**/H.-M. Pan, Philadelphia, PA
- 3:51 **Remodulin Induction Facilitates Rapid Achievement of Therapeutic Doses of Oral Treprostinil: Results From the EXPEDITE Study**/J.F. Kingrey, Oklahoma City, OK
- 4:03 **A PVOD Likelihood Estimation Tool and Clinical Management Pipeline**/A.M. Andruska, Palo Alto, CA
- 2:39 **Single-cell RNA Sequencing of Peripheral Blood Mononuclear Cells According to Clinical Courses of Mycobacterium Avium Complex Pulmonary Disease**/S. Zo, Seoul, Korea, Republic of
- 2:51 **Inflammatory Molecular Endotypes of Bronchiectasis Are Related to Microbiome Structure and Diversity: A European Multicenter Cohort Study**/H. Choi, Dundee, United Kingdom
- 3:03 **Distinct Microbiome Signature Predicts Early Treatment Response of Patients With Mycobacterium Abscessus Pulmonary Disease**/J.-Y. Kim, Seoul, Korea, Republic of
- 3:15 **Cftr Mutation and Increased Rates of Pulmonary Infections Among Patients From the US Bronchiectasis and NTM Research Registry**/C. Richards, Boston, MA
- 3:27 **Healthcare-associated Links in Transmission of Nontuberculous Mycobacteria in People With Cystic Fibrosis (HALT NTM): A Multi-center Study**/J.E. Gross, Denver, CO
- 3:39 **Long-term Hospitalization Burden Among Patients With Chronic Obstructive Pulmonary Disease With Possible Diagnostic Delays of Nontuberculous Mycobacterial Lung Disease**/P. Wang, Bridgewater, NJ
- 3:51 **Factors Associated With Guideline-based Therapy for Mycobacterium Avium Complex Pulmonary Disease in Rural and Urban US Veterans**/C.D. Varley, Portland, OR
- 4:03 **Bedaquiline Treatment as Salvage Therapy for Nontuberculous Mycobacterial Pulmonary Disease**/L. Farahani, Tyler, TX

BASIC • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

B98 THE HAPPY COUPLE: BRONCHIECTASIS AND NONTUBERCULOUS MYCOBACTERIA

2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center**
Room 145 A-B (Street Level)

Chairing: J.D. Chalmers, MD, PhD, Dundee, United Kingdom
 E. Henkle, PhD, MPH, Portland, OR
 B.S. Zha, MD, PhD, San Francisco, CA

Oral Presentations:

- 2:15 **Spatial Transcriptional Profiling of the Bronchiolectatic Lungs With Non-cystic Fibrosis Bronchiectasis (NCFB)**/T. Asakura, Chapel Hill, NC
- 2:27 **GM-CSF Is Essential for Effective Macrophage Killing of Nontuberculous Mycobacteria**/K.B. Hisert, Denver, CO

CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

B99 ALL THAT WHEEZES: TRANSLATIONAL STUDIES IN ASTHMA

2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center**
Room 143 A-C (Street Level)

Chairing: G.S. Skloot, MD, ATSF, Cary, NC
 M.D. Weckmann, PhD, MS, Luebeck, Germany

Oral Presentations:

- 2:15 **Sex Differences in Asthma Control, Lung Function and Exacerbations: The Atlantis Study**/S. Muiser, Groningen, Netherlands
- 2:27 **Mucus Plugged Airways in Fatal Asthma Are Marked by Prominent Airway Remodelling**/A. Hsieh, Vancouver, Canada
- 2:39 **Associations Between Birth Weight, Lung Function and Airway Responsiveness**/K.C.W. Wang, Crawley, Australia

- 2:51 Large Airway Mucus Plugs in Severe Asthma Are Spatially Associated With Air Trapping and Correlate With Airflow Obstruction in Proportion to Their Effect on Airway Resistance/B. Huang, San Francisco, CA**
- 3:03 Quantitative CT and Computational Fluid Dynamics (CFD) Tidal Breathing Simulation Associate Baseline Regional Lung Ventilation With Bronchial Thermoplasty Response in Asthma/D.H. Lee, Kansas City, KS**
- 3:15 Widespread Air Trapping in Asthma Is Associated With Airway Eosinophilia and Altered Airway Behavior During Expiration/C. Leung, San Francisco, CA**
- 3:27 Respiratory Impedance Corresponds to Clinical Outcomes in Children With Acute Asthma Exacerbations in the Pediatric Emergency Department/N. Navanandan, Aurora, CO**
- 3:39 The Reduction of Airway Smooth Muscle by Bronchial Thermoplasty Stands the Test of Time/P.-A. Gagnon, Québec, Canada**
- 3:51 Central Airways Resistance Increases in Pregnant Women With Obstructive Sleep Apnea and Asthma/C.D. Theroux, Providence, RI**
- 104 Lymphoid Follicle Transcriptome Identifies Off-targeted Immune Responses in Severe COPD/J.J. Rojas-Quintero, Houston, TX**
- 105 Networks of Host Proteins Associate With Haemophilus Burdens and COPD Exacerbation Risks/J. Kearley, Gaithersburg, MD**
- 106 Intestinal Microbiota Links to Allograft Stability After Lung Transplantation: A Prospective Cohort Study/J. Wu, Shanghai, China**
- 107 E-cigarette Vapor Extract Has a Substantial Effect on Human Eosinophil Transcription Mediated by Propylene Glycol and Glycerin/N. Hogan, La Jolla, CA**
- 108 Distinct Transcriptome Networks Define Early Life Longitudinal Wheezing Phenotypes/K. Phelan, Cincinnati, OH**
- 109 Plasma Protein Biomarkers of Lung Function and Respiratory Diseases/M. Aggarwal, Framingham, MA**
- 110 Heterogeneity in Neutrophil Transcriptomes During Streptococcus Pneumoniae Pneumonia Suggests Diverse Neutrophil Functions During Infection/J.C. Gomez, Chapel Hill, NC**
- 111 Longitudinal Single-cell Immune Profiling Using a Model of the Restrictive Phenotype of Chronic Lung Allograft Dysfunction Reveal Diverse B and T Cell Responses/A.P. Mclinden, Ann Arbor, MI**
- 112 Proteomic Analysis of IPF Patient Serum Using the Somascan® Platform Identifies Potential Biomarkers of Disease and Outcome/M. Nandakumar, Foster City, CA**
- 113 Overlap Between COPD Genetic Association Results and Transcriptional Quantitative Trait Loci/A. Saferali, Boston, MA**
- 114 Genetically Driven Splicing of MTCL1 in Lung Tissue and Airway Epithelial Cells Is Associated With COPD Case Control Status/A. Saferali, Boston, MA**
- 115 Metabolites Characteristics of Lower Respiratory Tract in Patients With Pneumoconiosis/D. Jine, Kunming, China**
- 116 Study of the Methylation Profile of Eosinophils Isolated From the Blood of People With Asthma/R. Dionne-Gagné, Saguenay, Canada**
- 117 Impdh Polymorphisms Are Associated With Increased Risk of Neutropenia in Transplant Patients Receiving Mycophenolic Acid/L.K. Tague, Saint Louis, MO**
- 118 Association of ORMDL3 Polymorphisms With Disease Outcomes and Severity in Patients With Pulmonary Alveolar Proteinosis (PAP)/F. Bonella, Essen, Germany**

BASIC • TRANSLATIONAL**POSTER DISCUSSION SESSION****B101 OMICS STUDIES OF IMMUNE CELLS AND THE LUNG**2:15 p.m. - 4:15 p.m. **Marriott Marquis Washington****Marquis Ballroom, Salons 1-2 (Level M2)****Poster Viewing 2:15-3:00****Discussion 3:00-4:15**

Chairing: S.-Y. Liao, MD, MPH, ScD, Denver, CO
 D. Okin, MD, PhD, Boston, MA
 J. Alladina, MD, Boston, MA
 I.R. Konigsberg, PhD, Aurora, CO

- 101 Unsupervised Clustering of Sputum Transcriptomes Identifies Three COPD Exacerbation Endotypes With Differing Susceptibilities and Pathobiology/A. Sarma, San Francisco, CA**
- 102 The Effect of Inhaled Corticosteroid Withdrawal on the Airway Metagenome and Antimicrobial Resistance: Data From the INCOGNITO Trial/H.R. Keir, Dundee, United Kingdom**
- 103 Association of Gut Microbiome Changes With Chronic Inflammation and Pulmonary Emphysema in a Nonhuman Primate Model of SIV Infection/S. Qin, Pittsburgh, PA**

- 119 **Single-cell Analysis of the Human Infant Airway Epithelium Reveals Heterogenous Cell Subpopulations With Susceptibility and Resistance Genes During RSV Infection**/B.S. Bera, Washington, DC
- 120 **Differences in the DNA Methylome of T Cells in Adult Asthmatics of Varying Severity and Exposure to Ambient Air Pollution**/S.K. Huang, Ann Arbor, MI
- 121 **Metabolomics Reveals Effects of miRNA Gene Regulation in Eosinophilia and Airflow Obstruction in Childhood Asthma**/R. Sharma, Boston, MA
- 122 **Macrophage Immune and Transcriptional Profiles in Response to Aero-allergens in Chronic Obstructive Pulmonary Disease**/N. Britton, Baltimore, MD
- 123 **Integrated Drivers of Basal Immunity and Acute Responses to Influenza Infection in Diverse Human Populations**/A. Souquette, Memphis, TN
- 124 **Unsupervised Clustering of Plasma Protein Biomarkers, Clinical Features, and Whole Blood Gene Expression Captures Prognostic and Predictive Heterogeneity in Critically Ill Patients With Sepsis**/L.P.A. Neyton, San Francisco, CA
- 125 **Single-cell RNA Sequencing of Pulmonary Neuroendocrine Cells Reveals Genetic Heterogeneity and Epithelial Adoption in Chronic Airway Inflammation**/M. Nemoto, Chiba, Japan

- 903 **Are Demographic Factors Predictive of PCCM Application Numbers or Match Rates?**/Z.B. Strumpf, Cleveland, OH
- 904 **Launching the Mednet in Pulmonary Medicine: An Online Platform for Expert Answers to Real World Clinical Questions**/A.N. Khan, Maywood, IL
- 905 **Development and Utilization of an Online Learning Community for Pulmonary and Critical Care Fellows and Faculty**/T.J. Rowe, Chicago, IL
- 906 **Mastery of Airway Bleeding Management Via Interprofessional Simulation-based Learning for Pulmonary Fellows**/T.J. Rowe, Chicago, IL
- 907 **Experience With a Virtual, Social-media-enhanced Respiratory Disease Journal Club at a Large Tertiary Referral Center**/M. Dalabih, Denver, CO
- 908 **Medical Students Awareness of Errors in Pulmonary Medicine to Ensure Patient Safety**/A. Gillissen, Witten, Germany
- 909 **Ready or Not, Here They Come: Internal Medicine Interns' Experience and Perceived Competency in Critical Care**/D.J. Gergen, Aurora, CO
- 910 **Implementing an Integrated Critical Care Curriculum to Improve Resident Education in the Medical Intensive Care Unit: A Quality Improvement Project**/A. Asghar, Springfield, MA
- 911 **5-Year Sustainability of a Virtual Flipped Classroom Intensive Care Unit (ICU) Intern Bootcamp**/T.A. Johnson, San Francisco, CA
- 912 **Quantitative Assessment of Pulmonary Procedural Training in Pulmonary and Critical Fellowships: A National Benchmark Survey**/A. El Haj Chehade, Oklahoma City, OK
- 913 **Implementation of a 3D-Printed Color-Coded Tracheobronchial Tree for Bronchoscopy Training and Anatomy Learning in a Pulmonary Critical Care Fellowship Program**/S.A. Vydro, San Francisco, CA
- 914 **Gastroesophageal Balloon Tamponade Simulation-based Training: An Unmet Curricular Need Across Specialties**/C. Mowry, Aurora, CO
- 915 **SEPSim: Simply Reviewing Sepsis Care With Medical Residents in the Medical Intensive Care Unit (MICU) Using Simulation**/L. Sankari, Cleveland, OH
- 916 **Virtual Deliberate Practice: Assessing Clinical Reasoning Using an Illness Script-based Simulator**/R.-E.E. Abdunour, Boston, MA
- 917 **An Attending-directed Intervention to Improve Interprofessional Teaching in the ICU**/C.R. Petri, Boston, MA

BEHAVIORAL • CLINICAL

POSTER DISCUSSION SESSION

B102 ADVANCES IN MEDICAL EDUCATION IN PULMONARY, CRITICAL CARE, AND SLEEP MEDICINE

2:15 p.m. - 4:15 p.m. **Marriott Marquis Washington**
Marquis Ballroom, Salons 3-4 (Level M2)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: S.M. Kassutto, MD, Philadelphia, PA
 L. Santhosh, MD, MEd, San Francisco, CA
 M.M. Hayes, MD, ATSF, Boston, MA

- 901 **Pulmonary and Critical Care Fellowship Program Directors' Perspective Regarding the Virtual Recruitment Process: A Survey Research**/R. Acharya, Roanoke, VA
- 902 **Effect of Virtual Interviews on PCCM Fellowship Match Outcomes: Analysis of NRMP Data From 2017-2021**/Z.B. Strumpf, Cleveland, OH

- 918 **Reflecting on Reflection Rounds: Discovering and Analyzing Elements of an ICU Team Group Discussion That Improve Provider Wellness/I.R. Krumm, San Francisco, CA**
- 919 **Implementation of a Short “On- Demand” Feedback Form for Fellows in the Medical Intensive Care Unit/G. Schroeder, St. Louis, MO**
- 920 **The Pipeline Is Running Dry: Survey Results From the Current Pool of Sarcoidosis Researchers and Clinicians/N. Arger, San Francisco, CA**
- 921 **A Novel Ambulatory Curriculum for Pulmonary and Critical Care Fellows Utilizing Adult Learning Theory and Multi-disciplinary Teachers/K. Mcavoy, New Haven, CT**
- 922 **Swipe for Success: A Novel Platform for the Humble Fellowship Manual/J. Alunilkummannil, Cleveland, OH**
- 923 **A Qualitative Study of Provider Perspectives on Cognitive Load During Intensive Care Unit Rounds/N. Held, Aurora, CO**
- 924 **Post-interview Communication Practices Among Critical Care Medicine/Pulmonary and Critical Care Medicine Fellowship Applicants and Program Directors and Impact on Rank Lists/M. John, Seattle, WA**
- 925 **Fellowship Applicant Perceptions and Preferences on Virtual Versus In-Person Interview Formats/L. Moore, Cleveland, OH**
- 803 **Clinical Features of Patients With an Eosinophilic Phenotype: An Analysis of the U.S Bronchiectasis and NTM Research Registry/D.J. Maselli, San Antonio, TX**
- 804 **Association of Baseline and Subsequent Bronchiectasis Exacerbations in Patients From the US Bronchiectasis and NTM Research Registry (BRR)/T.R. Aksamit, Rochester, MN**
- 805 **Longitudinal Changes in Forced Expiratory Volume 1 (FEV1) According to Exacerbation Frequency in Patients From the US Bronchiectasis and NTM Research Registry (BRR)/N. Lapinel, New Orleans, LA**
- 806 **Exercise Capacity as a Predictor of 3-year Mortality in Adult Bronchiectasis Patients/S.Z. Rached, Sao Paulo, Brazil**
- 807 **The Dipeptidyl Peptidase-1 Inhibitor Brensocatib Reduces Airway Azurocidin-1 Levels in Bronchiectasis/E. Johnson, Dundee, United Kingdom**
- 808 **Outcomes of Patients With Bronchiectasis by Disease Severity: Subgroup Analysis From the Brensocatib WILLOW Study/M.L. Metersky, Farmington, CT**
- 809 **Treatment Patterns and Adverse Events (AEs) Among Patients With Bronchiectasis (BE) Chronically Receiving Macrolides Over a 1-year Follow-up Period/A.F. Barker, Portland, OR**
- 810 **Clinical Cluster Analysis of Bronchiectasis-chronic Obstructive Pulmonary Diseases Overlap Syndrome (BCOS); Real World Evidence From a Developing Country/N. Bhatta, Dharan, Nepal**
- 811 **Origin of Sputum Elasticity/L. Esteban Enjuto, Gières, France**
- 812 **Evaluation of Procedures for Obtaining Cilia and Quantitative Parameters of Ciliary Beat Obtained by Nasal Brushing for the Diagnosis of Primary Ciliary Dyskinesia/T. Kido, Nagasaki, Japan**
- 813 **Diagnostic Confirmation Bias Delaying Cystic Fibrosis Diagnosis And Infertility Treatment/R. Zhang, Portland, OR**
- 814 **CFTR Modulator Therapy For N1303K Mutations/P. Barletta, Miami, FL**
- 815 **Severe Hyponatremia Due to Polyethylene Glycol-Electrolyte Ascorbic Acid Nasogastric Lavage Treatment in a Cystic Fibrosis Patient With Distal Intestinal Obstruction Syndrome/M. Eliliwi, Omaha, NE**
- 816 **An Unusual Cause Of Dyspnea In A Cystic Fibrosis Patient/S. Mcintyre, Nashville, TN**
- 817 **Transitions of Care Outcomes in Cystic Fibrosis at a Single Center/S. Mcintyre, Nashville, TN**
- 818 **Risk Factors for Increased 1-year Mortality in Cystic Fibrosis Patients Underwent Combined Lung-liver Transplantation in Post LAS Era/J. Gatus, Shreveport, LA**

CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

B103 HOT TOPICS IN CYSTIC FIBROSIS, BRONCHIECTASIS, AND BREATHLESSNESS

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 209 A-C (Level 2)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: J.L. Taylor-Cousar, MD, MSc, ATSF, Denver, CO
P. Krishnan, MD, Shreveport, LA
K. Montemayor, MD, Baltimore, MD

801 Biologic Therapy Management In Adult Patients With Bronchiectasis And Allergic Bronchopulmonary Aspergillosis: A Case Series/C. Iskandar, New York, NY

802 The Prevalence and Clinical Features of Eosinophilic Bronchiectasis in a Japanese Population/N. Fukuda, Yokohama, Japan

- 819 **Cystic Fibrosis Related Mortality in the United States From 1999 to 2020: An Observational Analysis From the CDC Wonder Database/H. Singh, Milwaukee, WI**
- 820 **Methicillin-resistant Staphylococcus Aureus Eradication Regimens for Children and Adults With Cystic Fibrosis/A. Toporek, Baltimore, MD**
- 821 **The Utility of Clinician-performed Cardiopulmonary Ultrasound Assessment of the Acutely Breathless Patient: Breathlessness Early Detection With Ultrasound (BED-US) Study/J.W. Kagima, Nairobi, Kenya**
- 822 **Comparison of Pulmonary Function Testing and Imaging Profiles of Non-hospitalized and Hospitalized Patients With Persistent Dyspnea in Post-acute Sequelae of COVID-19/A.D. Yuen, Los Angeles, CA**
- 823 **Multicenter Prospective Validation of a Clinical Prediction Tool for Respiratory Insufficiency in Amyotrophic Lateral Sclerosis/J. Ackrivo, Philadelphia, PA**
- 824 **Multicenter Validation of the CF-ABLE Score as a Predictor of Outcome and Therapeutic Response in Cystic Fibrosis/O. Mcelvaney, Seattle, WA**
- 825 **Evaluation of Exercise Responses During CPET Among Patients With Unexplained Dyspnea/W.T. Smith, Rochester, MN**
- 1004 **The Overlooked Side Effect - A Case of Inhaled Nitric Oxide-induced Methemoglobinemia in Severe Acute Respiratory Distress Syndrome/Y. Li, Stanford, CA**
- 1005 **Pseudohypoxemia Presenting As Severe Respiratory Failure: A Case Of Leukocyte Larceny/S.E. Pravinkumar, Houston, TX**
- 1006 **Real Time Bedside Echocardiography-guided Mechanical Ventilation Optimization In A Patient With Carcinoid Heart Disease, Right Ventricular Failure, And Severe Ards/G.E. Ortiz-Jaimes, Rochester, MN**
- 1007 **A Rare Case Of Adult-onset Idiopathic Pulmonary Hemosiderosis/C. Mowry, Aurora, CO**
- 1008 **Refractory Hypoxemia in a Mechanically Ventilated Patient With an Inferior ST-elevation Myocardial Infarction/N.L. Maris, New Haven, CT**
- 1009 **Extracorporeal Membrane Oxygenation for Asthma in Pregnancy/A.B. Nasir, Oklahoma City, OK**
- 1010 **Endotracheal Intubation Can Make You Un-intubatable in Future/M.I. Islam, Charlottesville, VA**
- 1011 **Acute Respiratory Distress Syndrome From Adenovirus Community-Acquired Pneumonia in Young Adult Effectively Treated With High-Dose Corticosteroids/P. Ho, Wynnewood, PA**
- 1012 **"Ondine's Curse?" A Rare Cause of Hypercarbia in the ICU/K.H. Young, Springfield, MA**
- 1013 **Case Series of Rapidly-Progressive Interstitial Lung Disease From Anti-MDA5 Dermatomyositis Requiring Venovenous ECMO: Outcomes and Limitations/A.A. Kabadi, La Jolla, CA**
- 1014 **Deferoxamine-Related Acute Respiratory Distress Syndrome/H.S. Khaira, New Orleans, LA**
- 1015 **Proning as an Effective Treatment for Refractory Hypoxemia Due to Intra-pulmonary Shunt/N. Ahmed, Rochester, MN**
- 1016 **Acute Lung Injury in the Setting of Severe Post-surgical Gastroparesis: Rare Complication of Relatively Safe Procedure/S. Ashfaq, Queens, NY**
- 1017 **An Unusual Presentation of Acute Respiratory Distress Syndrome (ARDS) Due to Adenovirus and Metapneumovirus/D. Ravi, Rochester, NY**
- 1018 **ARDS After a Dilatation and Curettage: A Unique Presentation/M. Heritage, Columbia, SC**
- 1019 **A Case Of A Pregnant Patient With Covid-19 Successfully Managed With Venovenous Extracorporeal Membrane Oxygenation/A. Qatanani, Hackensack, NJ**
- 1020 **A Positive Outcome In Prolonged VV-ECMO For COVID-19 ARDS/J. Meland, St. Louis, MO**

CLINICAL

POSTER DISCUSSION SESSION

B104 TOP CASE REPORTS OF MECHANICAL VENTILATION/ARDS FROM THE PAST YEAR2:15 p.m. - 4:15 p.m. **Marriott Marquis Washington****Marquis Ballroom, Salons 9-10 (Level M2)**

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: A.M. Esper, MD, MS, ATSF, Atlanta, GA
 F.A. Shah, MD, MPH, Pittsburgh, PA
 S. Sahetya, MD, MHS, Baltimore, MD

1001 **Under Little Pressure: A Case Series of Observed COVID-19 Barotrauma Events With Peculiar Data/C. Triggs, Santa Barbara, CA**

1002 **Pulmonary Tuberculosis Leading To Severe Acute Respiratory Distress Syndrome/A. Patel, Hackensack, NJ**

1003 **Henoch-Schönlein Purpura: ARDS Is In The Cards/K. Golubykh, Harrisburg, PA**

- 1021 **Cast of the Left Bronchial Tree on a Pregnant Lady With Influenza A Supported With Venovenous (VV) Extracorporeal Membrane Oxygenation (ECMO)/A.A. Alassim, Abha, Saudi Arabia**
- 1022 **Multiorgan Failure in the Aftermath of Pre-eclampsia With Intracerebral Hemorrhage and HELLP Syndrome/J. Shih, Las Vegas, NV**

CLINICAL • TRANSLATIONAL
RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION
B105 SICK ON THE JOB: UNCOVERING MODERN OCCUPATIONAL HAZARDS
2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center
Room 103 A-B (Street Level)
Viewing 2:15-3:00
Summaries/Discussion 3:00-4:15
Chairing: K.J. Cummings, MD, MPH, Richmond, CA
 R.A. Cohen, MD, Chicago, IL
 R.E. De La Hoz, MD, MPH, MSc, New York, NY

- 201 **Acute Occupational Respiratory Injuries and Fatalities, United States, 2016-2020/N.T. Myers, Morgantown, WV**
- 202 **Healthy Worker Survivor Effect in a Prospective Cohort Study of Cotton Textile Workers/H. Wang, Boston, MA**
- 203 **Effects of Particle Matter 2.5 and Carbon Monoxide on Arterial Stiffness Among Welders in Douala, Cameroon/B.H.M. Mbatchou Ngahane, Douala, Cameroon**
- 204 **Occupational Exposure to Insulating Materials Is Associated With Increased Risk of Coronary Artery Diseases in Insulators/S. Moitra, Edmonton, Canada**
- 205 **Identification of a Statewide Epidemic of Silicosis Among Engineered Stone Fabrication Workers - California/J.C. Fazio, Los Angeles, CA**
- 206 **The Association of Silica Deposition in the Lung With Acute Respiratory Failure After Lung Surgery/S. Hamada, Kumamoto, Japan**
- 207 **High Profusion Birefringent Particles Associated With Silica Related Pathology in Severe Coal Workers' Pneumoconiosis/C.D. Cool, Denver, CO**
- 208 **Differential Impact of Using NHANES III Versus Knudson Pulmonary Function Reference Values on Eligibility of White and Black Coal Miners for Black Lung Benefits/A. Sunderraj, Chicago, IL**
- 209 **Relationship Between Radiographic Disease, Spirometry Findings, and Diffusion Capacity in a Population of Former U.S. Coal Miners/K.S. Alberg, Chicago, IL**

- 210 **Unsafe Working Conditions Predict Injury Rates in U.S. Coal Mines/K.S. Alberg, Chicago, IL**
- 211 **Effectiveness of Frequent Point-of-Care Molecular Workplace COVID-19 Surveillance Among Miners/A. Sood, Albuquerque, NM**
- 212 **Change in Lung Function After Exposure to Smoke From a Mine Fire: A Clinical Follow-up/N. Holt, Melbourne, Australia**
- 213 **Effect of Systemic Metal Exposure on Pulmonary Function Testing Among Veterans With Embedded Metal Fragments/D.R. Glick, Baltimore, MD**
- 214 **Sinusitis and Rhinitis Symptoms Following Deployment-related Occupational and Environmental Exposures Among US Veterans/J. Maccarone, Boston, MA**
- 215 **Multidimensional Dyspnea Assessment Associated With Forced Oscillometry and Pulmonary Function Testing in Veterans in the Airborne Hazards and Open Burn Pit Registry/J. Chirco, Baltimore, MD**

BASIC • CLINICAL • TRANSLATIONAL
POSTER DISCUSSION SESSION
B106 FROM ACUTE TO LONG COVID-19
2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center
Room 201 (Level 2)
Poster Viewing 2:15-3:00
Discussion 3:00-4:15

- Chairing:** C. Dela Cruz, MD, PhD, ATSF, New Haven, CT
 S. Herold, MD, PhD, Giessen, Germany
 J. Sun, PhD, Charlottesville, VA
- 601 **Quantitative Proteomics in Exhaled Breath for Characterization and Diagnosis of COVID-19/G. Hirdman, Lund, Sweden**
- 602 **Evolution of the Proteomic Landscape in the Lungs of Patients With SARS-CoV-2 Infection/S.M. Kanth, Bethesda, MD**
- 603 **Eicosanoid Profiles in Exhaled Breath Condensate of Patients With COVID-19/N.J. Kenyon, Sacramento, CA**
- 604 **Ichikado CT Score and Inflammatory Markers: A Prognostic Tool in Coronavirus Disease 2019 (COVID-19) Patients/A. Almaguer, Houston, TX**
- 605 **Higher BMI Is Strongly Linked to Poor Outcomes in COVID-19 Hospitalizations: A National Inpatient Sample Study/A. Elkhapery, Rochester, NY**
- 606 **Inhibition of MPC Simultaneously Mitigates Hyperinflammation and Hyperglycemia in COVID-19/J. Sun, Charlottesville, VA**

- 607 **Clinical Characteristics and Outcomes of COVID-19 Waves in the Southeastern United States/O. Kandah, Myrtle Beach, SC**
- 608 **Proton Pump Inhibitor (PPI) Use and COVID-19 Outcomes in Hospitalized Patients/H. Shanmugavel Geetha, Worcester, MA**
- 609 **Efficacy and Safety of JAK Inhibitors in COVID-19 Patients: A Systematic Review and Meta-analysis/M. Mashina, Gainesville, FL**
- 610 **Dexamethasone Is Not Associated With Improved Outcomes Among COVID-19 Patients With Different Immunological Status/M.I. Restrepo, San Antonio, TX**
- 611 **Impact of Steroid Duration on Mortality and Major Adverse Cardiovascular Events in Critically Ill Patients With COVID-19: A Retrospective Cohort Study/M. Lozano, Inverness, FL**
- 612 **Steroid Use in Severely Ill COVID-19 Patients Does Not Blunt Procalcitonin or D-Dimer Response in Ventilator-associated Pneumonia and Ventilator-associated Events/L. Sakr, Weston, FL**
- 613 **Growth Hormone-releasing Hormone Receptor Antagonist MIA-602 Reduces Chimeric SARS-CoV-2-induced Cardiopulmonary Inflammation in K18-hACE2tg Mice/J.M. Condor Capcha, Miami, FL**
- 614 **Vancomycin Use on Admission Associated With Higher Mortality Independent of Renal Function in the Setting of Critically Ill COVID-19 Patients With Ventilator Associated Events/A.P. Van, Weston, FL**
- 615 **Mortality and Allograft Outcomes of Lung Transplant Recipients Diagnosed With Post-transplant COVID-19 Infection Between March to May 2020/A.A. Rahbari, New York, NY**
- 616 **Predictors of Pulmonary Fibrosis on Follow-up Chest Computed Tomography of COVID-19 Patients: A Meta-analysis of Cohort Studies/K. Cerda, Gainesville, FL**
- 617 **Multidisciplinary Care for Long COVID Syndrome - a Single Center Experience/J. Bailey, Chicago, IL**
- 618 **Profibrotic Monocyte-derived Alveolar Macrophages Are Increased in Pulmonary Post-acute Sequelae of COVID-19 With Persistent Lung Injury/J. Bailey, Chicago, IL**
- 619 **Risk of Mortality With COVID-19 in Chronic Lung Conditions: A Retrospective Study From National Inpatient Sample/S. Chandna, Cleveland, OH**
- 620 **Associations Between Micronutrient Deficiency and Post-acute Sequelae of COVID-19 After Acute Infection: A Multi-site Retrospective Study/J. Ponce, Omaha, NE**
- 621 **Sequelae After Surviving Hospitalisation With Severe Acute Respiratory Syndrome Coronavirus-2 Disease-2019 (COVID-19) - a Longitudinal Cohort Study/A. Mohan, Tirupati, India**
- 622 **Long-COVID Improves After a Year in 50% of Subjects Enrolled in a Rural Cohort/G. Stalker, Iowa City, IA**
- 623 **Impact of Underlying Comorbidities and Vaccination Status in Patients Who Received Casirivimab-Imdevimab Monoclonal Antibody Infusion During SARS-CoV-2 B.1.617.2 (Delta) Surge: A Real-world Outcome/P. Agrawal, Valdosta, GA**
- 624 **Diurnal Rhythms in COVID-19 Vaccine Efficacy/G. Hazan, St Louis, MO**
- 625 **A Controlled Pilot Study of the Efficacy of Upper Room Germicidal Uv (GUV) Air Disinfection to Prevent SARS-CoV-2 Transmission in Elementary Schools Using as the Primary Outcome Wastewater Monitoring for Viral RNA/E.A. Nardell, Boston, MA**

BASIC • TRANSLATIONAL

POSTER DISCUSSION SESSION

B107 COPD: FROM OMICS TO TREATMENT

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 206 (Level 2)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: M. Sauler, MD, New Haven, CT
P. Geraghty, PhD, New York, NY
V.K. Sidhaye, MD, Baltimore, MD

701 **Novel Designer Umbilical Cord-Derived Mesenchymal Stem Cells for COPD Treatment/M. Iwatake, Sakamoto, Japan**

702 **Divergent Fibroblast Composition, Differential Gene Expression, and Pathway Enrichment in ScRNA-seq to Explain Sexual Dimorphism During the Development of Emphysema in the Murine Model/M.I. Islam, Charlottesville, VA**

703 **Multi-omics Analysis of Emphysema Predominant and Non-emphysema Predominant COPD/Y.-H. Zhang, Boston, MA**

704 **Gene Polymorphisms Associated With Fat Free Mass Index (FFMI) in COPD May Induce Senescent Characteristics of Sarcopenia/A. Attaway, Cleveland, OH**

705 **Molecular COPD Heterogeneity Uncovered by Multi-layer Network Analysis/N. Olvera, Barcelona, Spain**

- 706 **Mitochondria-to-Nucleus Retrograde Signaling Via Mitochondrial DNA Encoded Non-coding RNA Regulates Mitochondrial Bioenergetics**/T.L. Joseph Mathuram, Buffalo, NY
- 707 **Metformin Protects Against Cigarette Smoke Induced Small Airway Fibrosis by Reducing Airway Muscle Sarcoglycan Assembly**/J.J. Rojas-Quintero, Houston, TX
- 708 **Metformin Protects Lung Epithelial Cells Against Cigarette Smoke-Induced Lipo-Peroxidation**/J.J. Rojas-Quintero, Houston, TX
- 709 **Metformin Rescues Cigarette Smoke-Induced Mucociliary Dysfunction Via P38 Signaling in Airway Epithelial Cells of COPD Donors**/N. Baumlín, Kansas City, KS
- 710 **p^{16INK4a} Deletion Exacerbates Lung Disease Progression Induced by Low-dose Exposure to Environmental Tobacco Smoke**/T. Muthumalage, Rochester, NY
- 711 **Pulmonary Delivery of PRS-400 Anti-Jagged-1 Anticalin Proteins Reduce Inflammation-driven Goblet Cell Metaplasia and Mucus Hypersecretion In Vivo**/M. Hagner, Hallbergmoos, Germany
- 712 **MCTR3 Mitigates Inflammation Induced by Pro-inflammatory Stimuli in Small Airway Epithelial Cells Through Distinct Changes in Micro RNA Expression**/Y.P.A. Myo, Richmond, VA
- 713 **Network Medicine Approaches Reveal Sex-biased Regulation of Extracellular Matrix Pathway in COPD**/C.M. Lopes-Ramos, Boston, MA
- 714 **Membrane-bound MUC1 Mucin Mediates Cigarette Smoke-induced Aberrant EGFR Activation and Airway Epithelial Remodeling In Vivo**/K. Kato, Atlanta, GA
- 715 **E-cigarette Aerosols of Propylene Glycol Impair BK Channel Conductance and Mucociliary Function**/M. Kim, Kansas City, KS
- 716 **Cigarette Smoke Exacerbates Bleomycin-induced Lung Injury and Collagen Deposition Via Lysyl Oxidase-dependent Mechanism in Mice**/Q. Wang, Rochester, NY
- 717 **Anti-CELA1 KF4 Antibody Inhibits Stretch-inducible Elastin Remodeling in Human Lung And Preserves Lung Structure in PPE, Cigarette Smoke, and Alpha-1 Antitrypsin Deficient Emphysema Models**/B.M. Varisco, Cincinnati, OH
- 718 **Lobar Specific Transcriptome of Combined Pulmonary Fibrosis and Emphysema Reveals Unexpected Contributions of Emphysema and Pulmonary Fibrosis Signatures**/F. Darawshy, New York, NY
- 719 **Mapping the Effect of Cigarette Smoke (CS) on the Lung Lymphatic Endothelium**/A. Trivedi, New York, NY

- 720 **Using Single Cell Sequencing to Understand Treatment Response to Anti-IL33 Treatment in Chronic Obstructive Pulmonary Disease (COPD)**/A. Faiz, Ultimo, Australia
- 721 **Maple: A Novel Computational Tool for Multi-Sample Spatial Transcriptomics Data Analysis**/D. Chung, Columbus, OH
- 722 **Role of Sphingosine-1-Phosphate in Stress Autophagy Induced by Cigarette Smoke Exposure in Lung Microvascular Endothelial Cells**/B. Dubois, Denver, CO
- 723 **Dissecting the Role of Endothelial Derived Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) In the Pathogenesis of Emphysema**/A.C. Racanelli, NY, NY

BASIC • TRANSLATIONAL

POSTER DISCUSSION SESSION

B108 IMMUNE CELLS TO THE RESCUE IN LUNG INJURY

2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Room 151 A (Street Level)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: B.D. Kraft, MD, ATSF, FCCP, Saint Louis, MO
B.D. Singer, MD, ATSF, Chicago, IL
S.J. Denstaedt, MD, Ann Arbor, MI

- 401 **Adoptive Transfer of Monocytes Protects Against Lung Injury by Connexin 43 Enrichment in Alveoli**/G.A. Gusarova, New York, NY
- 402 **Multi-dimensional Profiling of Alveolar T Cell Responses During Severe Pneumonia**/L. Morales-Nebreda, Chicago, IL
- 403 **Systematic Comparison of Murine Models of Chronic Lung Allograft Dysfunction**/M. Bueno, Pittsburgh, PA
- 404 **Secondary Lymphoid Organ Repopulation With Cytotoxic Tissue Resident Memory T Cells After Lung Transplantation**/K. Moghbeli, Pittsburgh, PA
- 405 **Impaired PPAR γ Activation Exacerbates Infection-Induced Lung Injury**/J.L. Larson-Casey, Birmingham, AL
- 406 **Supersurvivors After Lung Transplantation - Do Macrophages Play a Protective Role?**/M.P. Kuehnel, Hannover, Germany
- 407 **Neonatal Hyperoxia Induces Alveolar Macrophage Dysfunction And Dysregulated Type 1 Interferon Responses In Experimental Bronchopulmonary Dysplasia**/T.X. Cui, Ann Arbor, MI

- 408 **Complement-induced Local Inflammatory Priming and Upregulation of Pro-fibrotic Signaling Pathways in Mesenchymal Stromal Cells Derived From Lung Transplant Patients/R. Vittal, Ann Arbor, MI**
- 409 **Effect of Microbiome and Diet on Alveolar Macrophages and Lung Injury Following Ischemia Reperfusion (IR) Injury/A. Prakash, San Francisco, CA**
- 410 **Alveolar Epithelial Cells Mitigate Neutrophilic Inflammation in Acute Lung Injury Through Regulating Mitochondrial Fatty Acid Oxidation/K.-P. Chung, Taipei, Taiwan**
- 411 **Inflammatory Effects of Sleep Fragmentation in Mice With Acute Lung Injury/H. Ediriweera, Miami, FL**
- 412 **Regulation of Mesenchymal Cell Fate by Transfer of Active Gasdermin-D Via Monocyte-derived Extracellular Vesicles/A. Sarkar, Columbus, OH**
- 413 **Proteomic Analysis of Heat-moisture Exchange (HME) Filter Fluid Reveals Differences Between Donor Lungs Accepted or Declined for Transplantation/C.M. Shaver, Nashville, TN**
- 414 **Functional Heterogeneity of Neutrophils in the Lungs During Infection/L. Ghimire, Boston, MA**
- 415 **TRMT1 Preserves Transfer RNA Integrity and Macrophage Viability During Bacterial Infection/J.S. Bednash, Columbus, OH**
- 416 **Ventilator-Induced Lung Injury Promotes Inflammation Within the Pleural Cavity in a Mouse Model/R.F. Baldi, London, United Kingdom**
- 417 **TRMT1 Is Vital for Macrophage Cytokine Responses to Infection/J.D. Londino, Columbus, OH**
- 418 **Sex-specific Transcriptome Profiles and Cytokine Responses in Cystic Fibrosis Monocytes/H. Yin, New Haven, CT**
- 419 **MALAT1 Modulates HIV Immune Response Through MiR-150-5p/SOCS1 in Macrophages/Z. Yuan, Omaha, NE**
- 420 **Two Pore Potassium Channel TREK-1 Regulates K⁺ Efflux and Membrane Potential in Macrophages/C.N. Immanuel, Austin, TX**
- 421 **Increased Inflammation Protects From Lung Fibrosis in Siglec F Knock Out Mice/M. Orlov, Aurora, CO**
- 422 **Antenatal Corticosteroids Drive Maturation of the Epithelial and Endothelial Components of the Developing Primate Lung and Protect From Inflammatory Endothelial Injury/W. Zacharias, Cincinnati, OH**
- 423 **LPS Treatment Enhances the Immunomodulatory Effect of Mesenchymal Stromal Cells-derived Extracellular Vesicles/A. Areny-Balaguero, Sabadell, Spain**

BASIC • TRANSLATIONAL

POSTER DISCUSSION SESSION

B109 BIOMARKERS, GENETICS, AND OMICS IN SLEEP DISORDERED BREATHING2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Room 151 B (Street Level)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: B.E. Cade, PhD, Boston, MA
 C. Caballero, MD, PhD, Seville, Spain
 D. Gozal, MD, MBA, ATSF, Columbia, MO
 A. Alfini, Bethesda, MD
 A. Gileles-Hillel, MD, Jerusalem, Israel

- 501 **Circulating Plasma Exosomal Cargo in Long Term Adherence of Obstructive Sleep Apnea (OSA): Multi-omics/A. Khalyfa, Columbia, MO**
- 502 **Genetic Ablation of P16 Improves Cellular Senescence and Insulin Sensitivity in a Murine Model of Sleep Apnea/A. Khalyfa, Columbia, MO**
- 503 **Inflammation Biomarkers in COPD-OSA Overlap Syndrome/A. Sanchez Azofra, La Jolla, CA**
- 504 **Endothelial Cell-specific Deletion of Plasminogen Activator Inhibitor-1 Ameliorates Coronary Artery Function Under Intermittent Hypoxia Conditions/M. Badran, Columbia, MO**
- 505 **P16-mediated Senescence in Vascular Dysfunction in Murine Models of Obstructive Sleep Apnea/K. Cataldo, Columbia, MO**
- 506 **Epigenetic Alterations and Accelerated Biological Aging Associated With Impaired Ovarian Capacity in a Murine Model of OSA/R. Cortese, Columbia, MO**
- 507 **The Effects of Sleep Deprivation on a Stuttering Mouse Model/A. Turk, Bethesda, MD**
- 508 **Effect of Obesity in Combined Sustained and Intermittent (Overlap) Hypoxia/M. Hackbarth, La Jolla, CA**
- 509 **Impaired Intracellular Cholesterol Trafficking Promotes Endothelial Inflammation Observed in Sleep Apnea/V.K. Shah, New York, NY**
- 510 **Physical Activity Attenuates the Impact of Genetic Predisposition to Obesity on Risk of Obstructive Sleep Apnea: Results From Three Prospective US Cohorts/T. Huang, Boston, MA**

- 511 **Severe OSA and Ventricular Repolarization Heterogeneity During Sleep**/A.L. Koch, Miami, FL
- 512 **Exploratory Drug Discovery for OSA Based on a Drug Wide Association Study**/G. Parra, La Jolla, CA
- 513 **Obstructive Sleep Apnea May Impact Inflammation in People With HIV Through the Adenosine Pathway**/P.V. Borker, Pittsburgh, PA
- 514 **Intermittent Hypoxia Causes Differential Expression of Muscle Contraction Genes in Endothelial Cells From Aortic Arch**/A.Y. Meliton, Chicago, IL
- 515 **Intermittent Hypoxia Increases Ventricular Repolarization Heterogeneity**/A.R. Abreu, North Miami, FL

CLINICAL

RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

B110 PROBING THE LUNG: THE LATEST IN INTERVENTIONAL PULMONARY

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 144 A-C (Street Level)

Viewing 2:15-3:00
Summaries/Discussion 3:00-4:15

Chairing: J.A. Gorden, MD, Seattle, WA
C. Argento, MD, Baltimore, MD

- 301 **A Novel Atraumatic Endobronchial No-touch RF Ablation for the Peripheral Lung Nodules: A Pre-clinical Study in Porcine Model**/W. Ji, Seoul, Korea, Republic of
- 302 **Multicenter Prospective Study of Novel Biopsy Assessment System for the Intraprocedural Evaluation of Lung Biopsies by Robotic Assisted Bronchoscopy**/C. Manley, Philadelphia, PA
- 303 **Role of Frozen Section During Medical Thoracoscopy for Decision Making in a Country With Decreasing TB Burden**/Y. Hong, Incheon, Korea, Republic of
- 304 **Systematic Endoscopic Staging of Mediastinum to Determine Impact on Radiotherapy for Locally Advanced Lung Cancer (SEISMIC): Initial Findings of a Prospective Multicentre Interventional Study**/D. Steinfert, Melbourne, Australia
- 305 **Quantifying the Economic Value of Improvements in Diagnostic Accuracy of Advanced Bronchoscopy Procedures**/D.E. Ost, Houston, TX
- 306 **The Use of Rapid On-site Evaluation During Navigational Bronchoscopy for Peripheral Pulmonary Lesions: A Cost Effectiveness Model**/G.J. Dahlberg, Nashville, TN
- 307 **Intraoperative Cone-beam CT Scan Can Inform Short-timescale Drug Retention Following Intratumoral Delivery of Cisplatin in Non-small Cell Lung Cancer**/V. Mori, Burlington, VT
- 308 **Impact of Intra-operative Mobile Cone Beam CT on Shape-sensing Robotic-assisted Bronchoscopy: Improving Accuracy**/A. Menon, New York, NY
- 309 **Cancer Type and Initial Pleural Effusion Volume Affect the Rate of Pleurodesis in Patients With Tunneled Pleural Catheters**/Z. Hamdan, Atlanta, GA
- 310 **Volume Drained to Initial Dyspnea Relief in Malignant Compared to Nonmalignant Pleural Effusions**/Z. Hamdan, Augusta, GA
- 311 **Robotic-assisted Bronchoscopy Diagnostic Yield and Complications in a High-risk Patient Population**/B. Aronson, Chicago, IL
- 312 **Artificial Intelligence in Rapid On-Site Evaluation of Bronchoscopy Samples**/A. Koratala, Jacksonville, FL
- 313 **Electromagnetic Navigation Vs Robotic-assisted Bronchoscopy: A Comparison of Diagnostic Yield and Intervening Factors**/A.J. Duval, Newark, NJ
- 314 **Rapid On-site Evaluation of Biopsy Touch Preparation Slides in Addition to Needle Aspirates May Increase Diagnostic Yield of Robotic Bronchoscopy**/N. Sharma, Knoxville, TN
- 315 **Temporal Trends in Use of Indwelling Pleural Catheters or Chemical Pleurodesis for Treatment of Malignant Pleural Effusions in Ontario: A Population-based Study**/C. Kwok, Ottawa, Canada

ASSEMBLY MEMBERSHIP MEETINGS

Marriott Marquis Washington

The Sunday and Monday Assembly Membership Meetings will be held in the Marriott Marquis Washington.

Please click the bar below to access the date, time and room location for each Assembly meeting.



The Assembly Membership Meetings provide an update on the Assembly's activities via the Assembly's Leadership and provide Assembly members the chance to have input on future directions, information on how to get involved and networking opportunities. Voting results for the Assembly's future leaders will also be announced.



ATS
2023

INTERNATIONAL
CONFERENCE
WASHINGTON, DC
conference.thoracic.org

Tuesday Morning, May 23

[Click Here to Access the Program Itinerary and Add Tuesday Sessions and Presentations to Your Calendar](#)

MEET THE EXPERT SEMINARS

CME Credits Available: 1

R Pre-registration and additional fees required. Attendance is limited.
\$100 Member/Non-Members
\$70 LMIC Member/LMIC Non-Members

10:15 a.m. - 11:15 a.m. **Marriott Marquis Washington**

- MTE31 DETECTION OF ALPHA-1 ANTITRYPSIN DEFICIENCY - AN UNDERRECOGNIZED POPULATION**
J. Lascano, MD, Gainesville, FL
L. Riley, MD, Kansas City, MO
Gallaudet University (Level M1)
- MTE32 MANAGEMENT OF IMMUNE MEDIATED MYOSITIS RELATED LUNG DISEASE IN 2023**
S.K. Danoff, MD, PhD, ATSF, Baltimore, MD
S. Sehgal, MBBS, CLEVELAND, OH
Howard University (Level M1)
- MTE33 LUNG MOLECULAR ATLAS PROGRAM HUMAN TISSUE CORE (LUNGMAP HTC)**
G.S. Pryhuber, MD, Rochester, NY
Georgetown University (Level M1)
- MTE34 EEG FOR THE GENERAL INTENSIVIST**
D. Anderson, PhD, MD, Edmonton, Canada
K. Rosenblatt, MD, MHS, Baltimore, MD
Judiciary Square (Level M3)
- MTE36 REMOTE PHYSICAL ACTIVITY MONITORING IN PULMONARY VASCULAR DISEASE**
R.T. Zamanian, MD, FCCP, Stanford, CA
J. Minhas, MD, MS, MBBS, Philadelphia, PA
LeDroit Park (Level M3)

K3: KEYNOTE LECTURE

CME Credits Available: .75

8:00 a.m. -8:45 a.m.

Walter E. Washington Convention Center
Hall E (Level 2)

Title: Reducing Gun Violence through Advocacy and Action by Physicians and Policymakers

Moderators: L. Ferrante, MD, MHS, ATSF, New Haven, CT
E. Wilcox, MD, PhD, FRCPC, Toronto, Canada

Speakers: Emmy Betz, MD, MPH, Denver, CO
Fatimah Loren Dreier, BA, MSc, MBA, Boston, MA
Joseph Victor Sakran, MD, MPA, MPH, Baltimore, MD

YEAR IN REVIEW

CME Credits Available: 1.5

MOC Points Available: 1.5

C1 CLINICAL YEAR IN REVIEW 3

9:00 AM - 10:30 AM **Walter E. Washington Convention Center**

Hall E (Level 2)

Target Audience

Pulmonary, critical care and sleep providers. The program will discuss general topics of interest to a broad group of providers, inside and outside of these subspecialties. The program is relevant to not only clinicians, but also to researchers and administrators

Objectives

At the conclusion of this session, the participant will be able to:

- apply new clinical research knowledge to clinical practice.
- apply new findings about key conditions in pulmonary, critical care and sleep.
- learn new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

Pulmonary, critical care and sleep providers. The program will discuss general topics of interest to a broad group of providers, inside and outside of these subspecialties. The program is relevant to not only clinicians, but also to researchers and administrators.

Chairing: R.J. Shah, MD, MSCE, San Francisco, CA
J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil
S. Auld, MD, MSc, Atlanta, GA

9:00 Asthma
V.M. McDonald, PhD, New Lambton Heights, Australia

9:23 Sarcoidosis
M. Sharp, MD, MHS, Baltimore, MD

9:45 Sepsis
S. Bhavani, MD, Atlanta, GA

10:08 Sleep
C. Goldstein, MD, MS, Ann Arbor, MI

BEHAVIORAL • CLINICAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 1.5

C2 ENDPOINTS FOR THERAPEUTIC TRIALS IN ILD

Assemblies on Clinical Problems; Behavioral Science and Health Services Research

9:00 AM - 10:30 AM **Walter E Washington Convention Center**

Ballroom A (Level 3)

Target Audience

Providers of lung health; those with clinical and/or research responsibilities; those designing or conducting trials of therapies for patients with ILD; approval agency representatives; pharmaceutical company representatives

Objectives

At the conclusion of this session, the participant will be able to:

- more fully appreciate the need for patient-centric outcomes in trials of therapies for patients with ILD.
- consider the use of specific, supplemental oxygen-related outcomes in their studies and trials.
- implement patient-centric outcomes that assess how patients with ILD feel and function in their daily lives.

Identifying endpoints that meet requirements for patient centricity, applicability given the known or likely mechanisms of the therapeutic intervention and achievability within the constraints of therapeutic trials is key to the design of therapeutic trials for patients with ILD.

Chairing: J. Swigris, DO, MS, Denver, CO
M. Kalluri, MD, Edmonton, Canada

9:00 Introduction
J.J. Swigris, DO, MS, Denver, CO
M. Kalluri, MD, Edmonton, Canada

9:10 Patient reported outcomes as endpoints in trial
J.J. Swigris, DO, MS, Denver, CO

9:30 Supplemental Oxygen Needs as a Trial Endpoint
K.I. Aronson, MD, MSci, New York, NY

9:50 Improving Home Spirometry to Make It a Viable Trial Endpoint
A.O. Adegunsoye, MD, MS, Chicago, IL

10:10 Data from Wearables as Trial Endpoints
K. A. M. Johannson, MD, MPH, ATSF, Calgary, Canada

This session and the International Conference are supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 1.5

C3 PEDIATRIC CLINICAL CHEST ROUNDS

Assembly on Pediatrics

9:00 AM - 10:30 AM **Walter E. Washington Convention Center**

Ballroom C (Level 3)

Target Audience

Pediatric pulmonary clinicians and trainees (including students, physicians, advanced practice providers, nurses, therapists) interested in the diagnosis and management of challenging cases

Objectives

At the conclusion of this session, the participant will be able to:

- generate a broad differential diagnosis for challenging cases in pediatric pulmonary medicine;
- apply current diagnostic testing to the management of challenging cases in pediatric pulmonary medicine;
- discuss state of the art management of challenging pediatric pulmonary cases

Pediatric Clinical Chest Rounds is an annual symposium that focuses on the diagnosis and management of 4 challenging cases selected from case reports submitted to the Pediatric Assembly. Each case is presented by a trainee (typically Ped Pulm fellow) and a discussion of the main points of the case follows (typically an expert in the field).

Chairing: T.J. Moraes, MD, PhD, BSc, Toronto, Canada
S.C. Sadreameli, MD, MHS, Baltimore, MD
C.E. Loughlin, MD, Chapel Hill, NC

9:00 Bar None: The Oddest Case of Desaturations in a Term Infant
J. Lee, MD, St. Petersburg FL

9:12 Expert Discussant
J. Piccione, MS, DO, ATSF, Philadelphia, PA

9:22 Recurrent Respiratory Failure in a Patient With Sickle Cell Disease
M. Alsanjalawi, MD, Gainesville, FL

9:34 Expert Discussant
F. Ogunlesi, MBBS, Washington, D.C.

9:44 A Case of Difficult-to-Treat Asthma: When Steroids Aren't Enough

S. Saxena, MD, Nashville, TN

9:56 Expert Discussant

M. Hernandez, MD, Apex, NC

10:07 An Unusual Case of Hemoptysis

Speaker: Kelsey Gavin, DO – Kansas City, MO

10:19 Expert Discussant

D. Liptzin, MD, MS, Missoula, MT

CLINICAL**CRITICAL CARE TRACK**

CME Credits Available: 1.5

C4 FLUID AND VASOPRESSOR RESUSCITATION FOR EARLY SEPSIS: WHEN, WHICH, AND HOW MUCH?**Assemblies on Critical Care; Behavioral Science and Health Services Research; Clinical Problems; Nursing****9:00 AM - 10:30 AM Walter E. Washington Convention Center****West Salon G-I (Street Level)****Target Audience**

Clinicians, researchers, trainees, and other team members, including nurses and pharmacists, who care for patients with early sepsis.

Objectives

At the conclusion of this session, the participant will be able to:

- understand best practices for early sepsis resuscitation that are informed by high-quality evidence
- identify areas of early sepsis management for which high-quality evidence is lacking
- learn about trials currently in the field that will bring more data to inform practice for resuscitation and early sepsis management

Hemodynamic resuscitation is a core element of sepsis management and a focus of guidelines and care bundles, yet the optimal approach to IV fluid administration and vasopressor use remains controversial. With growing concern about the harms of fluid overload, long-standing dogma is being challenged and practice is evolving towards fluid-sparing, early vasopressor strategies. This symposium will provide a comprehensive update on current controversies in hemodynamic resuscitation for sepsis, including discussion of brand new evidence addressing the timing and selection of fluids and vasopressors and strategies for real-world implementation.

Chairing: E. Munroe, MD, Ann Arbor, MI
I.D. Peltan, MD, MSc, Murray, UT
I.S. Douglas, MD, FRCP, Denver, CO

9:00 Too Much of a Bad Thing? Pathophysiology of Harm from IV Fluids and Vasopressors in Sepsis

I.S. Douglas, MD, FRCP, Denver, CO

9:13 A World of New Evidence: Fluid Volume, Choice, Timing, and Reversal in Sepsis Resuscitation

T. Meyhoff, MD, Copenhagen, Denmark

9:26 Selecting and Adding Vasopressors in Septic Shock

E. Munroe, MD, Ann Arbor, MI

9:39 Making it Personal: Individualizing Resuscitation Targets

P. Bhatraju, MD, Seattle, WA

9:52 Unintended Consequences: Understanding Effects of New Resuscitation Strategies on Patient Care Processes

C. Permpikul, MD, Bangkok, Thailand

10:05 Evidence to Practice: Teamwork Makes Resuscitation Work

T. Hiller, BSN, RN, Denver, CO

10:18 Panel Discussion and Questions: What's Next for Sepsis Resuscitation?

This session and the International Conference are supported by an independent medical educational grant from AstraZeneca LP, Boehringer Ingelheim Pharmaceuticals, Inc., Inmed Incorporated, Vertex Pharmaceuticals, and United Therapeutics Corporation.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL**SCIENTIFIC SYMPOSIUM**

CME Credits Available: 1.5

C5 DISMANTLING STRUCTURAL RACISM FROM RISK AND DISEASE PREDICTION IN PULMONARY AND CRITICAL CARE MEDICINE**Assemblies on Behavioral Science and Health Services Research; Critical Care****9:00 AM - 10:30 AM Marriott Marquis Washington****Marquis Ballroom Salon 5 (Level M2)****Target Audience**

Practicing clinicians and other health care providers, health disparities researchers, quality improvement specialists or policy makers

Objectives

At the conclusion of this session, the participant will be able to:

- describe new findings about current biases in care delivery relevant to pulmonary/critical care medicine
- identify the limitations of current approaches to clinical decision-making tools and treatment recommendations and evidence derived from machine learning approaches

- apply expert-consensus mitigation strategies for bias to improve the quality of clinical care

Risk and disease prediction tools are common in clinical practice. They are vital to high-quality care—simplifying complexity in evidence-based fashion. Yet, despite being used everyday use, many tools are now recognized to be racially biased, skewing clinical judgments, to contribute to worse outcomes for minoritized populations. This session brings together experts in health equity and clinical/prediction testing to discuss this manifestation of structural racism in pulmonary and critical care medicine. Attendees will learn about real world examples of biased tools used every day in our field, build a framework for understanding how biased tools emerge, and review mitigation strategies.

Chairing: A.D. Baugh, MD, San Francisco, CA
D.C. Ashana, MD, MBA, MS, Durham, NC
T.S. Valley, MD, MSc, Ann Arbor, MI

- 9:00 Introduction**
A.D. Baugh, MD, San Francisco, CA
- 9:05 Color-Blind or Context Blind? Understanding Race in Pulmonary Function Testing**
A.D. Baugh, MD, San Francisco, CA
- 9:16 Hold Your Breath: The Journey to an Equitable Pulse Oximeter**
T.S. Valley, MD, MSc, Ann Arbor, MI
- 9:27 When Technology Imitates Life: How Bias Manifests in Risk Prediction and Artificial Intelligence**
D.C. Ashana, MD, MBA, MS, Durham, NC
- 9:38 Shortcomings of Standard Cystic Fibrosis Screening Tests Among Individuals of African Ancestry**
J.L. Taylor-Cousar, MD, MSc, ATSF, Denver, CO
- 9:49 Unequal Risk: Modifying Lung Cancer Screening Guidelines**
- 10:00 The Bias of Machines**
L.A. Perine, MBA, College Park, MD
- 10:11 Summary**
D.C. Ashana, MD, MBA, MS, Durham, NC
- 10:16 Discussion**
T.S. Valley, MD, MSc, Ann Arbor, MI

BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

C6 DISPARITIES IN RESPIRATORY GENOMICS RESEARCH: STRATEGIES TO ADVANCE SCIENCE AND CLINICAL CARE

Assemblies on Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Section on Genetics and Genomics

9:00 AM - 10:30 AM
Marriott Marquis Washington
Marquis Ballroom Salon 6 (Level M2)
Target Audience

Everyone in medicine and science has a sphere of influence that could contribute to mitigating health disparities -trainees, clinical faculty, research faculty, healthcare staff, research staff, and administration.

Objectives

At the conclusion of this session, the participant will be able to:

- gain awareness of current race- and sex-specific health inequities in complex lung diseases, the importance of addressing underrepresentation in genomic studies, and implications on the development of polygenic risk scores for disease and traits
- awareness of common misconceptions as it relates to minorities and Mendelian orphan lung diseases, with a focus on cystic fibrosis, how this can impair diagnosis, prognosis, and access to precision modulator therapies, and next best steps forward
- address scientific & clinical issues in genomics as they relate to health disparities in the context of genetic epidemiology, development of predictive genomic profiles, multi-omics approaches, gene-by-environment interactions, & clinical translation

Advances in genomic technologies have primarily applied to European descent whites with one-to-two percent of African descent minorities and Hispanics included in genetic studies of disease. These underrepresented groups experience a disproportionate burden of respiratory disease and have an underappreciated risk for orphan diseases traditionally considered to be white-only, such as cystic fibrosis. In addition, a minority of genomic studies address differences of respiratory disease risk and severity specific to sex. This workshop will address scientifically and clinically relevant issues in genomics as they relate to health disparities from the context of genetic epidemiology, the development of predictive genomic profiles, multi-omics approaches, gene-by-environment interactions, and clinical translation.

Chairing: A. Souquette, PhD, Memphis, TN
V.E. Ortega, MD, PhD, ATSF, Scottsdale, AZ
J. Pantaleón García, BS, MD, Houston, TX
D.L. Demeo, MD, Boston, MA

9:00 Introduction

A. Souquette, PhD, Memphis, TN

- 9:07 Patient Speaker**
Speaker To Be Announced
- 9:12 The Causes and Implication of the Under Recognition of Cystic Fibrosis as a Genetic Disease in Minority Groups**
J.L. Taylor-Cousar, MD, MSc, ATSF, Denver, CO
- 9:25 Intersectionality of Sex and Gender in Lung Disease Omics**
D.L. Demeo, MD, Boston, MA
- 9:38 Genomic and Social Determinants of Racial Inequality in Asthma**
J.G. Zein, MD, PhD, MBA, Cleveland, OH
- 9:51 “Omics” of Asthma and Disease Disparities**
E. Forno, MD, MPH, ATSF, Pittsburgh, PA
- 10:04 Ancestral Diversity is Important When Evaluating Respiratory Traits and Disease in Genetic Studies**
V.E. Ortega, MD, PhD, ATSF, Scottsdale, AZ
- 10:17 Insights into Ensuring Diversity in Recruitment and Representation in Science, a Take from the Immediate Past-Chair of the HDEC**
N. Thakur, MD, MPH, San Francisco, CA

This session and the International Conference are supported by an independent medical educational grant from Vertex Pharmaceuticals.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

C7 CANCER IN THOSE WHO HAVE NEVER SMOKED: NEW INSIGHTS FROM BENCH TO BEDSIDE

Assemblies on Thoracic Oncology; Environmental, Occupational and Population Health

9:00 AM - 10:30 AM **Walter E. Washington Convention Center**

Room 202 A (Level 2)

Target Audience

Those with clinical interest in lung cancer. Those with research interests in non-tobacco risks for lung cancer.

Objectives

At the conclusion of this session, the participant will be able to:

- describe new findings on the genetic and epidemiologic underpinnings of cancer in those with no tobacco history

- define new strategies for early detection of cancer in those with no tobacco smoking history
- better counsel patients about risk factors for lung cancer beyond tobacco smoking

Lung cancer is a common cause of cancer mortality even in those who have never used tobacco. Taken alone, lung cancer in those who have never smoked (LCNS) is the seventh leading cause of cancer death in the United States. This seminar will explore how LCNS differs epidemiologically and molecularly from lung cancer associated with tobacco use. Speakers will unique risk factors, strategies to identify those at risk, and novel treatment approaches.

Chairing: E. Ostrin, MD, PhD, Houston, TX
Q. Lan, MD, PhD, MPH, Bethesda, MD
J.J. Tsay, MD, MSc, New York, NY

9:00 Genomic Risks Behind Lung Adenocarcinoma in Those Who Have Never Smoked

Q. Lan, MD, PhD, MPH, Bethesda, MD

9:18 Calculating Risk for Lung Cancer in Those Who Have Never Smoked

C. Berg, MD, Bethesda, MD

9:36 The TALENT Trial: Lung Cancer Screening in a Population with Very Low Rates of Tobacco Use

P.-C. Yang, MD, Taipei, Taiwan

9:54 Air Pollution and Lung Cancer

J. Schiller, MD, Vienna, VA

10:12 New Directions in Treating Lung Cancer in Those Who Have Never Smoked

E. Shum, MD, New York, NY

This session and the International Conference are supported by an independent medical educational grant from Merck & Co.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

C8 NEW CONCEPTS AND UPDATE IN THE DIAGNOSIS AND MANAGEMENT OF NTM AND TB INFECTIONS

Assemblies on Pulmonary Infections and Tuberculosis; Clinical Problems

9:00 a.m. - 10:30 a.m.

Room/Location TBD

Target Audience

Clinicians caring for patients with non-tuberculous mycobacteria (NTM)

pulmonary disease and tuberculosis (TB), and/or working in the field of NTM and/or TB

Objectives

At the conclusion of this session, the participant will be able to:

- participants will be able to learn new diagnostic and therapeutic strategies, for the best management of patients with complex MAC- and MAbSc-lung disease, including novel and emergent treatment interventions in the United States and abroad
- participants will be able to learn new concepts from recent studies to optimally diagnose and manage latent, incipient, and subclinical TB infection in special settings in TB endemic areas and non-endemic areas
- participants will be able to learn new concepts from recent studies to optimally diagnose and manage patients with TB and MDR-TB/pre-XDR-TB (and their contacts) based on recent WHO guidelines, ATS/IDSA guidelines, and recent clinical trials data

This session will review recent translational and clinical data, including recent clinical trials results, to provide state of the art clinical perspective of new developments in prevention strategies, diagnostics and management of *M. avium* complex (MAC) and *M. abscessus* complex (MAbsC) lung disease, as well as of latent, incipient and subclinical TB infections, and multidrug-resistant TB in various groups of patients and settings.

Chairing: P. Escalante, MD, MSc, Rochester, MN
S.H. Kasperbauer, MD, Denver, CO
A. Cattamanchi, MD, San Francisco, CA

9:00 MAC Pulmonary Disease: Evolving Concepts and Best Individualized Management

C.L. Daley, MD, Denver, CO

9:20 M. Abscessus Complex Pulmonary Disease: Novel Treatment Interventions and Individualized Approach

M.P. Dalcolmo, MD, PhD, Rio De Janeiro, Brazil

9:40 Diagnostics and Therapeutic Interventions in Latent, Incipient, and Subclinical TB Infections

P. Escalante, MD, MSc, Rochester, MN

10:00 TB and MDR-TB: Evolving Concepts and Recent Guidelines-Based Therapies

C.A. Haley, MD, MPH, Gainesville, FL

10:20 Questions and Answers

This session and the International Conference are supported by an independent medical educational grant from Insmad Incorporated.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BEHAVIORAL • CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

C9 REHABILITATION FOR THE POST-COVID POPULATION

Assemblies on Pulmonary Rehabilitation; Behavioral Science and Health Services Research; Critical Care

9:00 AM - 10:30 AM

Walter E. Washington Convention Center

Room 146 A-C (Street Level)

Target Audience

Clinicians and researchers working in the field of pulmonary rehabilitation who have extended or wish to extend their scope to include those with COVID-19, and clinicians caring for patients with COVID-19/ long COVID/ post-COVID syndrome

Objectives

At the conclusion of this session, the participant will be able to:

- define the rationale for COVID-rehabilitation in terms of ongoing patient symptoms
- better understanding of the evidence underpinning rehabilitation in the post-COVID population and other treatment approaches available in order to better advise patients on treatment options
- utilize the most appropriate outcome measures in this field

Attendees can expect to learn about the rationale and evidence underpinning the inclusion of patients recovering from COVID-19 in pulmonary rehabilitation (PR). This sessions will also debate if PR is the best intervention for this population or if other forms of rehabilitation/ other treatments are better placed.

Chairing: R.A. Evans, MBChB, FRCP, PhD, Leicester, United Kingdom
F. Franssen, MD, PhD, Horn, Netherlands

9:00 Rationale for Rehabilitation in the Post-COVID-19 Population (Long COVID Symptoms)

M. Beauchamp, PT, PhD, Hamilton, Canada

9:15 Evidence for Post-COVID Exercise-Based Rehabilitation Programs

S.J. Singh, PhD, Leicester, United Kingdom

9:30 Evidence for Fatigue Management in Long COVID

T. Chalder, PhD, London, United Kingdom

9:45 Core Outcome Set for Long COVID

D.M. Needham, MD, PhD, Baltimore, MD

10:00 Argument 1: Patients Recovering from COVID Should Be Integrated into Existing Pulmonary Rehabilitation Services

R. Gloeckl, PhD, Schoenau am Koenigssee, Germany

10:10 Argument 2: There Is a Better Alternative to Integrating Patients with Long COVID into Pulmonary Rehabilitation
D. Wade, MD, Oxford, United Kingdom

10:20 Discussion Session

BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

MOC Points Available: 1.5

C10 OPIOID USE DISORDER, SLEEP DEFICIENCY, AND VENTILATORY CONTROL: BIDIRECTIONAL MECHANISMS AND THERAPEUTIC TARGETS

Assembly on Sleep and Respiratory Neurobiology

9:00 AM - 10:30 AM Walter E. Washington Convention Center

Room 145 A-B (Street Level)

Target Audience

Sleep providers, patients with sleep deficiency, opioid use disorder, Those who take care of patients on opioids, those interested in sleep phenotypes and control of breathing

Objectives

At the conclusion of this session, the participant will be able to:

- at the end of this session, the participants will have an improved understanding of the bidirectional mechanisms between opioid use disorder (OUD) and sleep deficiency.
- describe efforts to target sleep deficiency and control of breathing with therapeutic interventions to promote long-term healthy recovery among patients with OUD.
- outline an actionable research agenda to evaluate the basic mechanisms of the relationship between sleep deficiency and OUD and the potential for behavioral, pharmacologic, and positive airway pressure treatments to improve OUD treatment outcomes.

This session will highlight the bidirectional mechanisms between opioid use disorder (OUD) and sleep deficiency. It will discuss how targeting sleep deficiency and control of breathing with therapeutic interventions can promote long-term, healthy recovery among patients in OUD treatment. Current knowledge on the effects of opioids on sleep architecture, sleep-disordered breathing, sleep apnea endotypes, ventilatory control, and and clinical practice are highlighted. Finally, an actionable research agenda is provided to evaluate the basic mechanisms of the relationship between sleep deficiency and OUD and the potential for behavioral, pharmacologic, and positive airway pressure treatments targeting sleep deficiency to improve OUD outcomes.

Chairing: J.E. Orr, MD, La Jolla, CA
T. Kendzerska, MD, PhD, Ottawa, Canada

9:00 Current Knowledge on the Effects of Opioids on Sleep Quality, Sleep Architecture, Sleep-Disordered Breathing, Sleep Apnea Endotypes
D.J. Eckert, PhD, Bedford Park, Australia

9:15 Sleep Deficiency Across the Trajectory of OUD: Neuro-Biologic, Neuro-Psychiatric, and Social-Ecologic Mechanisms

H.K. Yaggi, MD, New Haven, CT

9:30 Targeting Insomnia in OUD: CBTi and Leveraging the Orexin System

C. Hsiao, MD, New Haven, CT

9:45 PAP Therapies for Sleep-Disordered Breathing OUD

S. Chowdhuri, MD, MS, ATSF, Detroit, MI

10:00 Novel Pharmacologic Treatments Targeting Control of Breathing in Opioid Use: Intranasal Leptin, Ampakines, and Other Potential Targets

V.Y. Polotsky, MD, PhD, Baltimore, MD

10:15 Sleep Deficiency as a Core Feature of OUD and Recovery: A Research Agenda

A. Laposky, PhD, Bethesda, MD

BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

C11 ADVANCING CLINICAL ISSUES TO ATS AND CAPITOL HILL: THE OXYGEN THERAPY EXEMPLAR

Assemblies on Clinical Problems; Environmental, Occupational and Population Health; Nursing; Pediatrics; Pulmonary Rehabilitation; International Health Committee; Health Policy Committee

9:00 AM - 10:30 AM Walter E. Washington Convention Center

Room 147 A-B (Street Level)

Target Audience

All ATS Members (This session is beneficial for all members as it provides a framework for taking a clinical issue, addressing it through ATS clinical, research and health policy groups, then engaging members in advocating for legislative changes.

Objectives

At the conclusion of this session, the participant will be able to:

- describe two challenges or barriers to patients' oxygen therapy as related to CMS regulations and/or DME Companies.
- incorporate approaches from ATS Clinical Oxygen Guidelines to address patients' oxygen therapy concerns.
- describe two strategies ATS members can use to effectively advocate for legislation related to oxygen therapy.

Do your patients face difficulty in getting adequate access to supplemental oxygen? This session will cover novel oxygen delivery systems for outpatient use and upcoming innovations in oxygen delivery. A particular focus will include current barriers to oxygen delivery, regulatory limitations which impair access to adequate oxygen, and ATS advocacy needed towards legislative change. ATS's involvement in advancing this clinical issue to health policy change will be addressed. Finally, the session covers the next frontier in access to home respiratory support, highlighting patients' and providers' challenges after the recent recall of non-invasive ventilation devices and advocating for those issues.

Chairing: N.A. Kolaitis, MD, MS, San Francisco, CA
S.S. Jacobs, RN, MS, Stanford, CA

- 9:00 Introduction of the Session**
N.A. Kolaitis, MD, S, San Francisco, CA
- 9:02 Setting the Tone: Capturing the Patient's Perspective 1**
N.A. Kolaitis, MD, MS, San Francisco, CA
- 9:04 Setting the Tone: Capturing the Patient's Perspective 2**
J.M. Rommes, PhD, West Des Moines, IA
- 9:10 Listening to the Demands for Improvements: Innovations in Oxygen Delivery**
D. Hayes, MD, MS, MEd, ATSF, Cincinnati, OH
- 9:25 It's Reality for Our Patients: Challenges/Barriers Related to CMS Regulations and DME Companies**
J.A. Krishnan, MD, PhD, ATSF, Chicago, IL
- 9:40 ATS Means Family and Family Means Nobody Gets Left Behind: ATS Responses to Oxygen issues**
S.S. Jacobs, RN, MS, Stanford, CA
- 9:50 To Capitol Hill and Beyond: ATS Government Relations and Your Advocacy on Capitol Hill**
G. Ewart, MHS, Washington, DC
- 10:00 Access, Recall and Care, Oh My!: The Next Frontier in Advocacy**
H. Schotland, MD, ATSF, New York, NY
- 10:15 QueMstions and Answers**
S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

**C12 IMMUNOLOGY IN CONTEXT:
MECHANISMS AND BIOMARKERS THAT
DETERMINE VIRAL DISEASE SEVERITY**

Assemblies on Allergy, Immunology and Inflammation;
Pediatrics; Pulmonary Infections and Tuberculosis; Respiratory
Cell and Molecular Biology; Section of Genetics and Genomics

9:00 AM - 10:30 AM **Walter E. Washington Convention Center**

Room 152 A-B (Street Level)

Target Audience

Adult and pediatric pulmonologists, critical care providers,
immunologists, cell biologists

Objectives

At the conclusion of this session, the participant will be able to:

- better understand and incorporate current and novel biomarkers for respiratory infection correlates of protection or severity, including SARS-CoV-2, into current practice
- gain knowledge of novel techniques for tracking pathogen-host interactions over the course of infection, including single cell approaches and cell-free analyses
- discuss comprehensive cohort study design that includes molecular, genetic, environmental, and epidemiological variables as components of immune modeling for host pathogenesis

Findings presented will highlight novel correlates of severity and protection during respiratory illness, including SARS-CoV-2 infection, that could be useful as biomarkers for viral illness outcome. The session will explore new aspects of the host pathogen interface that could be harnessed as a clinical tool and lead to host-targeted therapeutics. What biomarkers can be used to determine individuals at higher risk of severe illness outcome from respiratory viral infection?

Chairing: A. Rogers, MD, MPH, ATSF, Stanford, CA
T. Flerlage, MD, Memphis, TN
E.K. Allen, PhD, Memphis, TN
P. Thomas, PhD, Memphis, TN

- 9:00 Immunology in Context**
E.K. Allen, PhD, Memphis, TN
- 9:05 Host-Microbiome Interactions in Early in Life - Key to Respiratory Infections?**
Debby Bogaert, MD, PhD, Edinburgh, UK
- 9:20 Q&A**
- 9:25 SARS-CoV-2 Repeat Infections and Breakthroughs: Correlates of Immunity and Determinants of Severity**
A. Gordon, PhD, Ann Arbor, MI
- 9:40 Q&A**
- 9:45 Severe Respiratory Viral Infection Results in Persistent Immune Activation of Lung Fibroblasts Associated with Prolonged Respiratory Distress**
D.F. Boyd, PhD, Santa Cruz, CA
- 10:00 Q&A**
- 10:05 Profiling the Mucosal TCR Repertoire Landscape During Severe Pneumonia**
L. Morales-Nebreda, MD, Chicago, IL
- 10:20 Q&A**

BASIC

MINI SYMPOSIUM

C13 CYTOKINES: CYTOKINES IN THE AIRWAYS

9:00 a.m. - 11:00 a.m. **Marriott Marquis Downtown**
Independence Ballroom Salons A-D (Level M4)

Chairing: J. Alexander-Brett, MD, PhD, Saint Louis, MO
M. Gauthier, MD, Pittsburgh, PA
D.P. Albon, MD, Charlottesville, VA

Oral Presentations:

- 9:00 **Loss of CFTR Reprograms Airway Epithelial IL-33 Release and Regulates IL-33 Dependent Inflammation/D.P. Cook, Nashville, TN**
- 9:12 **Inhibition of Macrophage Migration Inhibitory Factor Signaling Prevents SARS-CoV-2 Infection/S.-J. Kim, Durham, NC**
- 9:24 **Interleukin-33 (IL-33) Drives Type 1 and Type 2 Inflammation and Instructs Airway Remodeling/S. Srivatsan, Tarrytown, NY**
- 9:36 **N-terminal Truncated Forms of the Cytokine IL-36 γ Derived From Host Proteases Induce Airspace Neutrophil Recruitment and CXCL-5 Production in the Lung/M. Tabary, Pittsburgh, PA**
- 9:48 **IL-18 Receptor-deficient Mice Have Enhanced Airway Hyperresponsiveness and Eosinophilia in a Model of Allergic Asthma/R. Murphy, Seattle, WA**
- 10:00 **Lung Lavage Cytokine Signatures in Preschool Children With Problematic Wheeze Infected With Rhinovirus Supports M1 and M2 Alveolar Macrophage Activation/W.G. Teague, Charlottesville, VA**
- 10:12 **IL-13 Induces Epigenetic Inflammatory Memory in a Subset of Airway Stem Cell Clones/G.C. Necker, Iowa City, IA**
- 10:24 **Itepekimab Binds to IL-33 With High Affinity, Prevents the Formation of IL-33/ST2/IL-1RAcP Signaling Complex and Blocks Mediators of Airway Inflammation/S. Asrat, Tarrytown, NY**
- 10:36 **Hillock Cells Are Immunoresponse Airway Epithelial Cells That Promote Type 2 Inflammation and Barrier Dysfunction in Asthmatics/J. Alladina, Boston, MA**

BEHAVIORAL • CLINICAL

MINI SYMPOSIUM

C14 SOCIAL DETERMINANTS OF HEALTH AND TREATMENT OF ASTHMA

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**
Room 204 A-C (Level 2)

Chairing: A.A. Pappalardo, MD, Chicago, IL
A. Volerman, MD, Chicago, IL
L.B. Gerald, PhD, MSPH, Chicago, IL

Oral Presentations:

- 9:00 **Markedly Higher Healthcare Utilization and Poor Disease Control Among Patients With Asthma-COPD Overlap Compared to Patients With Each Disease Alone/M.W. Sjoding, Ann Arbor, MI**
- 9:12 **Severe Asthma Exacerbations Across Disease Severities: Which Patients Are at Greatest Risk?/N.L. Lugogo, Ann Arbor, MI**
- 9:24 **Cost-effectiveness of a Portable HEPA Air Cleaner Distribution Program to Reduce Asthma Complications in British Columbia/C. Carlsten, Vancouver, Canada**
- 9:36 **Intensive Pest Management With HEPA Air Filtration Is a Cost-effective Intervention That Reduces Asthma Morbidity in Inner City Public Schools/C. Socolovsky, Boston, MA**
- 9:48 **Addressing Social Determinants of Health in Pediatric Asthma Care Through School-supervised Therapy: Perspectives From Participants and Community Partners/L. Al-Halbouni, Worcester, MA**
- 10:00 **The Sleep Environment, Napping, and Sleep Outcomes Among Urban Children With and Without Asthma/A.J. Yeo, Providence, RI**
- 10:12 **Pediatric Psychosocial Problems and Asthma Symptoms in an Urban Environment/R. Koehl, Baltimore, MD**
- 10:24 **Differences in Asthma Self-management Education Between English and Spanish Respondents: Findings From the 2017-2019 U.S. Asthma Call Back Survey/J.D. Rose, Philadelphia, PA**
- 10:36 **Comparative Effectiveness of Omalizumab, Mepolizumab, Benralizumab, and Dupilumab for Asthma in a Matched Retrospective Cohort/A. Akenroye, Boston, MA**
- 10:48 **Cost Analyses of a Symptom-driven Inhaled Corticosteroid-Formoterol Treatment Strategy for Patients With Mild Asthma From a United States Payor Perspective/C.J. Renaud, St. Louis, MO**

BEHAVIORAL • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

C15 EMERGING COPD DIAGNOSTICS AND TREATMENTS9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center****Ballroom B (Level 3)**

Chairing: M.B. Drummond, MHS, MD, ATSF, Chapel Hill, NC
 J. Bon, MD, MS, ATSF, Pittsburgh, PA
 A.A. Lambert, MD, MHS, Spokane, WA

Oral Presentations:

- 9:00 Clinical Consequences of Race Correction in PFTS: Comparison of the GLI Race-specific Coefficients With Use of Aggregate “Other” Category/D. Vyas, Boston, MA**
- 9:12 Pi-slope: A New Method for Quantifying Airway Disease/S.P. Bhatt, Birmingham, AL**
- 9:24 Recombinant Human Alpha-1 Antitrypsin (AAT) Protein INBRX-101 Demonstrates Potential to Achieve Lung Penetration and Normal Functional Serum AAT Levels in Patients With AAT Deficiency/B.T. Kuhn, Sacramento, CA**
- 9:36 Alvelestat, an Oral Neutrophil Elastase Inhibitor in Alpha-1 Antitrypsin Deficiency (AATD): Results of a Phase II Trial/R.A. Stockley, Birmingham, United Kingdom**
- 9:48 Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function and Reduces Exacerbation Rate and Risk in Phase 3 Enhance-2 Trial/A. Anzueto, San Antonio, TX**
- 10:00 Objectively Recorded Peak Inspiratory Flow (PIF), Inhalation Volume and Reliever Medication Use Preceding COPD Exacerbations/J.A. Ohar, Winston Salem, NC**
- 10:12 Vital Signs Remote Patient Monitoring in Real-life for Early Detection of Acute Exacerbations of Chronic Obstructive Pulmonary Disease/Y. Le Guillou, Cesson Sevigné, France**
- 10:24 The Impact of a Care Signature Pathway on COPD Hospitalizations/C.L. Rochester, New Haven, CT**
- 10:36 Scottish Patients Living Remotely and Rurally, With Acute Exacerbations of Chronic Obstructive Pulmonary Disease, Can Have Safe, Effective, Person-Centred Care in Their Own Home Through Innovative Use of Technology/R. Cooper, Inverness, United Kingdom**
- 10:48 Early Detection of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) Using At-home Lung Oscillometry/N. Hickman, Ventura, CA**

CLINICAL

MINI SYMPOSIUM

C16 THE ROAD TO RECOVERY: IMPROVING LONG-TERM OUTCOMES AFTER CRITICAL ILLNESS9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center****Room 143 A-C (Street Level)**

Chairing: K.C. Vranas, MD, MSCR, Portland, OR
 D.K. Costa, PhD, RN, Orange, CT
 S.D. Halpern, MD, PhD, Philadelphia, PA

Oral Presentations:

- 9:00 Physician Recommendations in the Setting of Code Status Discussions: A Multi-centre Cohort Study/R.G. Melvin, Toronto, Canada**
- 9:12 Family Member Role in Goal-concordant Care in the Intensive Care Unit (ICU)/W. Kiker, Seattle, WA**
- 9:24 Addressing Unmet Needs Among Family Members of Critically Ill Patients: The ICUconnect Randomized Clinical Trial/C.E. Cox, Durham, NC**
- 9:36 Post-tracheostomy Healthcare Trajectory for Patients With Acute Respiratory Failure/A.B. Mehta, Denver, CO**
- 9:48 Associations Between ICU Mobility Dose, Disability, and Quality of Life After Critical Illness/M.F. Mart, Nashville, TN**
- 10:00 Physical Activity During Critical Illness and Subsequent Disability in Survivors of Critical Illness/N.E. Brummel, Columbus, OH**
- 10:12 Collaboration With Survivors of Critical Illness to Support Long-term Recovery: An Experienced Based Co-design Study/A. Da Silva, Parkville, Australia**
- 10:24 The Association Between the Childhood Opportunity Index and the Social Vulnerability Index and Recovery After Pediatric Acute Respiratory Distress Syndrome/E. Rinaldi, Los Angeles, CA**
- 10:36 “Mind The Gap” - Improving the Integration Between Primary and Intensive Care After Critical Illness (Integrate) Study/N. Leggett, Footscray, Australia**
- 10:48 The Canadian COVID-19 Prospective Cohort Study/M.S. Herridge, Toronto, Canada**

BEHAVIORAL • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

C17 IN THIS TOGETHER: CONFRONTING ENVIRONMENTAL HEALTH CHALLENGES AROUND THE WORLD9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center****Room 150 A-B (Street Level)**

Chairing: A. Lee, MD, MS, New York, NY
 O.B. Ozoh, MBBS, MSc, ATSF, Lagos, Nigeria
 M.A. Alemayohu, BSc, MPH, PhD, Mekelle, Ethiopia

Oral Presentations:

- 9:00** Prevalence and Burden of PRISm in Population Cohorts From Three LMIC Settings/K. Grealis, Miami, FL
- 9:12** The Chemical Exposome and Lung Health of Adult Women in Rural Uganda/L. Chen, Boston, MA
- 9:24** Respiratory/Allergic Symptoms in Italian Children Living Close to Cultivations Sprayed With Pesticides/G. Viegi, Pisa, Italy
- 9:36** Characterizing Lung Function Trajectory in a Cohort of Adults in Rural Uganda/M. Hill Pierre-Louis, Boston, MA
- 9:48** Association Between High-density Lipoprotein Cholesterol Level and Forced Vital Capacity in Adults Residing in the United States and South Korea/Y. Cha, Baltimore, MD
- 10:00** Diversity of Indoor Fungi and Associated Respiratory Disorders in Nairobi and Busia Counties Kenya/O.M. Mashedi, Nairobi, Kenya
- 10:12** Exhaled Carbon Monoxide as a Marker of Environmental Exposures in Rural and Urban Uganda/S.E. Enoh, Baltimore, MD
- 10:24** Impact of Particle Matter 2.5 on the Arterial Stiffness Among Motorcycle Taxi Drivers in Douala, Cameroon/B.H.M. Mbatchou Ngahane, Douala, Cameroon
- 10:36** Effects of Smoking and Air Pollution on Tuberculosis Development and Treatment Outcomes: A Systematic Review and Meta-analysis/S. Carroll, Montreal, Canada
- 10:48** Projecting Global Indoor and Outdoor Air Pollution Through 2050/E. Boers, Halifax, Canada

BASIC • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

C18 BOSS BABY: EMERGING PRINCIPLES IN BPD AND LUNG DEVELOPMENT9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center****Room 102 A-B (Street Level)**

Chairing: A. Agarwal, MD, Little Rock, AR
 L.C. Eldredge, MD, PhD, Seattle, WA

Oral Presentations:

- 9:00** Antibiotic Treatment During Infancy Alters the Gut Microbiome and Metabolites in Conjunction With the Lung Transcriptome/L.A. Miller, Davis, CA
- 9:12** A Novel, Homozygous Duplication of the Surfactant Protein B Gene (SFTPB) Causes Progressive Neonatal Respiratory Failure Among Term Infant Siblings/J.A. Wambach, St. Louis, MO
- 9:24** Effect of Cannabinoids and Nicotine on Prenatal Human Lung? Development/I. El Alam, Torrance, CA
- 9:36** Extremely Premature Infants Who Experience Inflammatory Events Have Decreased Expiratory Flow Ratios at Hospital Discharge Than Peers Without Inflammatory Events/B.K. Jordan, Portland, OR
- 9:48** Predictors for Duration of Invasive Home Mechanical Ventilation in Chronic Lung Disease of Prematurity/C.C. Foster, Chicago, IL
- 10:00** Predictors of Recurrent Wheezing in Late Preterm Infants/B. Gustafson, Columbus, OH
- 10:12** The Effect of Neonatal Tracheomalacia on Aerosolized Drug Delivery/C.C. Gunatilaka, Cincinnati, OH
- 10:24** Cardiorespiratory Physiological Trajectories in Extremely Preterm Infants/D.E. Weese-Mayer, Chicago, IL
- 10:36** Cardiorespiratory Monitoring Data to Predict Respiratory Outcomes in Extremely Preterm Infants/N. Ambalavanan, Birmingham, AL

Featured Speaker:

- 10:48** Boss Baby, What Will the Future Bring?/A.I. Cristea, Indianapolis, IN

BASIC • TRANSLATIONAL**MINI SYMPOSIUM****C19 EMERGING MECHANISMS IN COPD AND ASTHMA**

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**
Room 202 B (Level 2)

Chairing: F. Polverino, MD, PhD, Houston, TX
M.R. Faner, PhD, BSc, Barcelona, Spain
E.R. Neptune, MD, ATSF, Baltimore, MD

Featured Speaker:

9:00 **Immune Targeted Therapies in COPD and Asthma**
A.O. Yildirim, Neuherberg, Germany

Oral Presentations:

9:12 **Single Cell RNA Sequencing Identifies Dysfunctional Alveolar Type II Subsets Derived by Club Cells in Chronic Obstructive Pulmonary Disease**/Y. Hu, Aurora, CO

9:24 **Loss of CD55 in Alveolar Type 2 Epithelial (AT2) Cells Results in Decreased Cell Proliferation and Increased Lung Complement Deposition During Cigarette Smoking**/E. Lundberg, Denver, CO

9:36 **Loss of P73 Is Common in Chronic Obstructive Pulmonary Disease Small Airways, Is Induced by Cigarette Smoke, and Contributes to Emphysema**/B.W. Richmond, Nashville, TN

9:48 **Cellular and Molecular Mechanisms Underlying FGF10-mediated Reversion of Experimental Emphysema and Pulmonary Hypertension in Mice**/S. Hadzic, Giessen, Germany

10:00 **Gene Environment Interaction in Chronic Obstructive Pulmonary Disease: Involvement of a Nicotinic Receptor Gene Polymorphism**/L. Massara, Lille, France

10:12 **Early COPD Risk Is Associated With Decreased Airway Basal Progenitor Function and Altered Cellular Bioenergetics in Younger Smokers**/K. Lkhagvadorj, Aurora, CO

10:24 **Steroid-resistant Severe Asthma and Fatal Asthma Small Airways Are Defined by Mucus Plugging and Heterogeneous MUC5AC Expression**/S. Schworer, Chapel Hill, NC

10:36 **Single-cell Transcriptomic Analysis Reveals an Altered Bronchial Epithelial Cell Differentiation in Asthma**/A.C. Gay, Groningen, Netherlands

10:48 **Mitochondrial Adenine Nucleotide Translocase 2 (Ant2) Regulates Alveolar Epithelial Cell Senescence and Repair in COPD**/C.R. Kliment, Pittsburgh, PA

CLINICAL • TRANSLATIONAL**POSTER DISCUSSION SESSION****C21 “CUTTING” EDGE: CLINICAL STUDIES IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE**

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**
Room 206 (Level 2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: S. Tomassetti, RCP, Florence, Italy
J. Thiboutot, MD, Baltimore, MD
A. Gangemi, MD, Philadelphia, PA

701 **Bronchial Rheoplasty Reduces Goblet Cell Hyperplasia and Airway Inflammation in Patients With Chronic Bronchitis**/A. Valipour, Vienna, Austria

702 **Emphysema Heterogeneity Impacts Response to Endobronchial Valve Treatment**/S. Roodenburg, Groningen, Netherlands

703 **Endobronchial Valve Placement and Functional Lung Imaging**/K. Nakrani, Miami, FL

704 **Pre-interventional Evaluation of Lobar Function of Endobronchial Valve Candidates**/A.B. Karanam, Philadelphia, PA

705 **Effect of Pre-procedure Cardiopulmonary Exercise Capacity and High Resolution Computerized Tomography Emphysema Pattern on Outcomes in Bronchoscopic Lung Volume Reduction**/A.B. Karanam, Philadelphia, PA

706 **Importance Of Right Heart Catheterization In The Assessment For Inclusion Criteria Regarding Endobronchial Valve Placement In Patients With Echocardiography Suggesting Probability Of Pulmonary Hypertension**/K. Alsheimer, Sayre, PA

707 **Response to Endobronchial Valve Treatment: It Is All About the Target Lobe**/J. Hartman, Groningen, Netherlands

708 **Temporary Worsening of Resting Hypoxemia After Bronchoscopic Lung Volume Reduction**/R.J. Vender, Philadelphia, PA

709 **Referral Patterns After Bronchoscopic Lung Volume Reduction Evaluation**/A.J. Gangemi, Philadelphia, PA

710 **Sequential Bilateral Bronchoscopic Lung Volume Reduction in Patients With Advanced Emphysema**/A.J. Gangemi, Philadelphia, PA

711 **Endobronchial Valves for Prolonged Air Leaks: A Systematic Review and Meta-analysis**/Z. Umar, Queens, NY

- 712 **Safety and Efficacy of Autologous Blood Patching for Persistent Air Leaks: A Systematic Review and Meta-analysis**/Z. Umar, Queens, NY
- 713 **Use of the Zephyr Endobronchial Valve for the Management of Persistent Air Leak: A Single Center Retrospective Analysis**/H. Singh, Milwaukee, WI
- 714 **Ambulatory Management of Spontaneous Pneumothorax; A Meta-analysis of Randomized Controlled Trials**/M. Mohamed, Saint Louis, MO
- 715 **Impact of Automated Drainage on Suction Pressure During Thoracentesis: An In-vitro and In-vivo Analysis**/A.A. Menon, Charleston, SC
- 716 **Therapeutic Thoracentesis Quality Improvement Pilot Study: Comparison Between Manual Aspiration, Wall Suction and Vacuum Bottle Drainage**/K. Capp, Minneapolis, MN
- 717 **Understanding the Clinical, Economic and Resource Utilization Impact of Different Longitudinal Treatment Pathways for Malignant Pleural Effusion**/D.E. Ost, Houston, TX
- 718 **Doxycycline Pleurodesis, DoxyDo or DoxyDon't?: A Retrospective Study of Its Efficacy and Side Effects**/N. Agrawal, Houston, TX
- 719 **A 90-day Mortality Prediction Model for Patients Presenting With Pleural Infection and Treated With Intrapleural Enzyme Therapy**/M. Diddams, Chapel Hill, NC
- 720 **A Multicenter Retrospective Cohort Study of Safety and Practice Patterns for Spray Cryotherapy in Benign Airway Stenosis**/A. Ratwani, Nashville, TN
- 721 **Cone-beam Computed Tomography and Augmented Fluoroscopy Guided Robotic Bronchoscopy for Sampling of Peripheral Ground Glass Pulmonary Nodules**/B.H. Lashari, Philadelphia, PA
- 722 **In Plain Sight: Utilization of Hounsfield Units in Determination of Pleural Fluid Characterization**/S. Sahni, New York, NY
- 723 **Long-Term Benefits of the Spiration® Valve System in Emphysema Patients: 5-Year Results from the EMPROVE Trial**/G.J. Criner, Philadelphia, PA
- 724 **Real-World Experiences of Robotic Bronchoscopy for Pulmonary Lesions: Insights From the FDA Manufacturer and User Facility Device Experience (MAUDE) Database**/A.S. Saini, New York, NY
- 725 **Incidence, Diagnosis and Impact of Pleural Adhesions in Bronchoscopic Lung Volume Reduction Patients Referred for Video Assisted Thoracoscopy**/T. Sinha, Philadelphia, PA

BASIC • CLINICAL • TRANSLATIONAL

RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

C22 CLINICAL AND TRANSLATIONAL STUDIES IN MECHANICAL VENTILATION

9:00 a.m. - 11:00 a.m. Walter E. Washington Convention Center

Room 144 A-C (Street Level)

Viewing 9:00-9:45

Summaries/Discussion 9:45-11:00

Chairing: P. Sinha, MB BCh, PhD, St. Louis, MO
J.A. Bastarache, MD, Nashville, TN
N. Qadir, MD, Los Angeles, CA

- 301 **Optimizing Positive End-expiratory Pressure by Maximal Compliance Improves Lung Homogeneity in Aeration and Strain: An Experimental Study in a Lavage Model of Lung Injury**/C. Zeng, New York, NY
- 302 **Mechanical Power During Prone Positioning in Critically Ill Patients**/S. Redaelli, Boston, MA
- 303 **Mechanical Power Is an Independent Risk Factor for Long-term Mortality in Critically Ill Patients Needing Mechanical Ventilation**/M.C. Chan, Taichung, Taiwan
- 304 **Frequent Ventilator Dyssynchrony Predicts Increases in Driving Pressure**/P.D. Sottile, Aurora, CO
- 305 **Microvesicles Induce Alveolar Epithelial Cell Death Via TNF-Caspase Signalling During Ventilator-induced Lung Injury**/R.F. Baldi, London, United Kingdom
- 306 **Diaphragm Neurostimulation During Mechanical Ventilation Reduces the Risk of Ventilator-induced Lung Injury**/E. Rohrs, New Westminster, Canada
- 307 **Oxygenation Thresholds for Invasive Ventilation in Hypoxemic Respiratory Failure: A Target Trial Emulation**/C.J. Yarnell, Toronto, Canada
- 308 **Effect of Arterial Oxygen Concentrations on Acute Kidney Injury Among Critically Ill Patients With Respiratory Failure**/N.A. Sathe, Seattle, WA
- 309 **Mortality Benefit of Vitamin C in ARDS Is Potentiated by Hyperoxia and Plasma Cell-free Hemoglobin, an Analysis of the CITRIS-ALI Trial**/C.M. Shaver, Nashville, TN
- 310 **Multicenter Deployment of a Real-time Ventilator Management Dashboard With Alerts: Sustained Improvement in Lung Protective Ventilation in 5 Hospital Centers**/P. Tandon, New York, NY
- 311 **Peripheral Vasopressor Use in Early Sepsis-Induced Hypotension: A Secondary Analysis of the CLOVERS Trial**/E. Munroe, Ann Arbor, MI

- 312 **Prolonged Mechanical Ventilation in Randomized Controlled Trials of Acute Respiratory Distress Syndrome/I.I. Siempos, Athens, Greece**
- 313 **A Modified Delphi Study to Develop Quality-weighted Hospital-free-days as an Acute Respiratory Failure Outcome Measure/C.L. Auriemma, Philadelphia, PA**
- 314 **Cause of Death Differs in the Hyperinflammatory and Hypoinflammatory Phenotypes of ARDS and Sepsis/B. Evrard, San Francisco, CA**
- 315 **Association Between Age and Mortality Across Pediatric and Adult Acute Respiratory Distress Syndrome/B.M. Patel, Philadelphia, PA**

CLINICAL

POSTER DISCUSSION SESSION

C23 BUILDING THE FUTURE OF CRITICAL CARE: STUDIES IN MEDICAL EDUCATION

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**

Room 151 B (Street Level)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: R. Adamson, MBBS, ATSF, Seattle, WA
G.R. Connors, MD, Aurora, CO
G.W. Garrison, MD, Burlington, VT

- 501 **Comparison of Demographic Trends Among IM Residents, Applicants and Matriculants to PCCM Fellowships: Analysis of ACGME and ERAS Data From 2017 - 2020/K.Z. Abbas, Cleveland, OH**
- 502 **The Impact of a Critical Care Boot Camp on Procedural Competence: A Developing Country Experience/M. Younis, Gainesville, FL**
- 503 **Comparison of an Online Simulator to a Traditional Lung Simulator for Teaching Mechanical Ventilation/S. Safadi, Minneapolis, MN**
- 504 **ICUlympics: A Pilot Study of the Effect and Role of Gamefication in Graduate Medical Education/R. Dasgupta, Aventura, FL**
- 505 **Barriers to the Professional Identity Formation of International Medical Graduates: A Qualitative Study/V. Jain, Washington, DC**
- 506 **-Developing a Procedural Competency-Based Assessment Tool for the Intensive Care Unit/A. Longino, Aurora, CO**
- 507 **Flipped Classroom Approach to Teaching Ultrasound-guided Peripheral Venous Access in Internal Medicine Residents Facilitates Instructor Efficiency Without Compromising Trainee Experience/M. Gorgone, Pittsburgh, PA**
- 508 **Overnight Emergencies Are Difficult to Predict: An Observational Study of a Just-in-Time Simulation Curriculum/R. Kogan, New York, NY**
- 509 **Accuracy of Pulmonary and Critical Care Fellows in the Measurement of Cardiac Output by Transthoracic Echocardiography/J.W. Talan, New York, NY**
- 510 **Pocus for Central Line Confirmation: An Educational Module and Skill Acquisition by Resident Physicians/A. Espinera, New Orleans, LA**
- 511 **Utilizing Airway Recording Function to Improve Pulmonary Critical Care Intubation Training/A.A. Jiang, San Diego, CA**
- 512 **An Interactive E-learning Based Curriculum in Non-invasive Ventilation for Pulmonary and Critical Care Fellows/A. Daoud, Detroit, MI**
- 513 **Needs Assessment of Early Residency Mechanical Ventilation Curriculum in an Era of Remote Learning/A.M. La, Chicago, IL**
- 514 **Leadership Curriculum for Critical Care Medicine Fellows/C. Irons, Cleveland, OH**
- 515 **Practice Makes Progress: Improving the Technical Skills of the Residents That Lead Rapid Medical Response Teams/K. Auge, Chicago, IL**
- 516 **Medical Student Critical Care Education: How Prepared Are Internal Medicine Residents for the Intensive Care Unit?/S. Astafiev, New Haven, CT**
- 517 **Call Vs No Call: A Pilot Study of Resident Choice in ICU Scheduling/A. Trainor, Boston, MA**
- 518 **Educational Outcomes on Internal Medicine Residents for Obstetric Critical Care and Rapid Response: A Before and After Study/D.Y. Wang, Newark, DE**
- 519 **Education of Mechanical Ventilation Management in the With-COVID-19-Era: Development of Teaching Strategy to Train Residents/K. Takeda, Chiba, Japan**
- 520 **A Track for Trachs: Implementation of a Formal Curriculum, Checklist, and Feedback Protocol in Trainees Performing Percutaneous Tracheostomy at a Tertiaryacademic Center/M.R. Jordan, Birmingham, AL**
- 521 **Improving Resident Confidence Through Mock Code Simulation/J. Purewal, Hialeah, FL**
- 522 **Medical Resident Education in the ICU: Ventilator Management/S. Shah, Maywood, IL**

- 523 **Assessing Effectiveness and Knowledge Decay of a Novel Physiology Based Medical Intensive Care Unit Curriculum/S.L. Dickey, Baltimore, MD**
- 524 **Comfort Level and Training in Serious Illness Conversation Among Medical and Surgical Residents/E. Stevenson, Boston, MA**
- 525 **Pitfalls of EMR: Recommendation and Implications From 177 Years of Bedside Teaching Experience/I. Ratnani, Houston, TX**

CLINICAL

POSTER DISCUSSION SESSION

C24 DISPARITIES IN THE HEALTH EFFECTS OF CLIMATE CHANGE AND POLLUTANTS

9:00 a.m. - 11:00 a.m. Marriott Marquis Washington

Marquis Ballroom, Salons 3-4 (Level M2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: C. Carlsten, MD, MPH, Vancouver, Canada
T.M. Parekh, DO, Austin, TX
G.Y.-H. Liu, MD, Chicago, IL

- 901 **Mechanisms to Explain Acute Cognitive Impairment Following Carbon Dioxide Inhalation/H.M. Kipen, Piscataway, NJ**
- 902 **Neurobehavioral Consequences of Early-Life Wildfire Smoke Exposure/L.A. Miller, Davis, CA**
- 903 **Early-life Wildfire Smoke Exposure Is Associated With Persistent Lung and Peripheral Blood Endoplasmic Reticulum Stress/L.A. Miller, Davis, CA**
- 904 **Early Gestational Ozone Exposure Impairs Lung Vascular and Alveolar Development in Peri-adolescent Female Rats: Potential Linkage to Later Life Lung Disease/J. Dye, Research Triangle Park, NC**
- 905 **Short-term Exposure to Pollen and Airway Inflammation in Adolescents/N.J. Nassikas, Boston, MA**
- 906 **Influence of Social Determinants in Asthma Climate Change and Environmental Pollution in Asthma Attacks at High Altitude/M.I. Escamilla, Bogota, Colombia**
- 907 **Inhalative Treatment Induces Vulnerability to Heat-related Exacerbations in COPD - a Prospective Study in the Metropolitan Area of Berlin, Germany/C.C. Witt, Berlin, Germany**

- 908 **Effect of a Single One-hour Teaching Session About Environmental Pollutants and Climate Change on the Understanding and Behavioral Choices of Adolescents: The BREATHE Pilot Study/Y.D. Abrham, San Francisco, CA**
- 909 **The Role of Weather and Climate in Cholera: A Systematic Review/R.N. Shade, Baltimore, MD**
- 910 **Overweight/Obese Status Associates With Exaggerated Symptomatic and Inflammatory Response to Indoor Ultrafine Particle Exposure Among Children With Asthma/E. Brigham, Vancouver, Canada**
- 911 **Characterizing Social and Environmental Factors in a Pediatric Asthma Cohort/M. Pavelack, Baltimore, MD**
- 912 **Asthma Prevalence and Correlates Among Individuals With Asthma-like Symptoms in Rural Uganda: A Cross-sectional Study/A. Araye, Mogadishu, Somalia**
- 913 **Long-term Exposure to Nitrogen Dioxide and Ozone and Respiratory Health in Children/H.L. Zetlen, Boston, MA**
- 914 **Examination of Real-time Impact of Residential Environmental Exposures on Asthma Symptoms Using Ecologic Momentary Assessment and Indoor Air Quality Sensors/S.M. Nyenhuis, Chicago, IL**
- 915 **Associations of Perceived Neighborhood Social Environment Stress With Decreased Asthma Control Among Adults With Asthma During the COVID-19 Pandemic/K. Eldeirawi, Chicago, IL**
- 916 **Neighborhood-level Characteristics and Association With Alignment of Inhaled Medications in Chronic Obstructive Pulmonary Disease/M.H.F. Lee, San Francisco, CA**
- 917 **Neighborhood Social Vulnerability and Lung Function Decline in Chronic Obstructive Pulmonary Disease: Longitudinal Analysis of Electronic Medical Records Data/G.R. Oates, Birmingham, AL**
- 918 **Factors Associated With Asthma Exacerbations Using Electronic Health Record Data Enhanced With Ambient Nitrogen Dioxide and Socioeconomic Measures/A. Schreiber, Philadelphia, PA**
- 919 **Association of Lung Cancer Incidence, Mortality, and Comorbidity With Social Vulnerability in the United States/Y. Lee, Buffalo, NY**
- 920 **Racial and Sex Disparities in Ambient PM_{2.5} Exposure Among People With Sarcoidosis/A.M. Mustafa, Baltimore, MD**
- 921 **Association of Air Pollution With Interstitial Lung Disease Incidence and Outcomes: A Systematic Review/S. Bala, Vancouver, Canada**
- 922 **Low Socioeconomic Status Is Linked to Increased Risk of Invasive Pneumococcal Disease/C. He, Birmingham, AL**
- 923 **Well Water Arsenic and Lung Function Among Rural Americans/M. Zavala, Iowa City, IA**

- 924 **Association of Urinary Metals With Right Ventricular Structure and Function: The Multi-Ethnic Study of Atherosclerosis**/J. Keen, Philadelphia, PA
- 925 **The Contribution of Gas Stoves to Indoor Nitrogen Dioxide Concentrations Among Individuals With Respiratory Disease**/A. Ayers, Baltimore, MD

CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

C25 OPPORTUNITIES AND ADVANCES IN PEDIATRIC GLOBAL HEALTH9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**

Room 201 (Level 2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: O. Yilmaz, MD, Manisa, Turkey
S.Z. Nasr, MD, ATSF, Ann Arbor, MI
L.E. Ellington, MD, MSc, Seattle, WA

- 601 **Effects of a Multi-component Liquefied Petroleum Gas Stove Intervention on Severe Pneumonia Incidence During Infancy: HAPIN Randomized Controlled Trial**/E.D. Mccollum, Baltimore, MD
- 602 **Oxygen Saturation as a Diagnostic Test for World Health Organization-defined Radiographic Pneumonia in Children: Outpatient Cross-sectional Study in Bangladesh**/A.M. Khan, Dhaka, Bangladesh
- 603 **Development and Internal Validation of Clinical Hypoxemia Scores for Outpatient Child Pneumonia Care Lacking Pulse Oximetry in Bangladesh and Malawi: A Pooled Analysis**/H. Schuh, Baltimore, MD
- 604 **Phefumla Project: Designing a Smartphone-based Pulse Oximeter for Children in South Africa- A Qualitative Analysis of Human Centered Design Workshops With Healthcare Workers**/E.I. Ilhan, Cape Town, South Africa
- 605 **Phefumla Project: Identifying Challenges and Barriers in Outpatient Pulse Oximeter Implementation for Children in South Africa - Thematic Analysis of Healthcare Worker Interviews**/L.N. Jola, Cape Town, South Africa
- 606 **Evaluation of a Novel Digital Stethoscope Prototype in a Low-resource Setting: Expert Listening Panel Agreement With Conventional Auscultation in Hospitalized Malawian Children With Severe Pneumonia**/Z. Smith, Palo Alto, CA
- 607 **Evaluating a Mobile Health Tool to Guide Management of Acute Pediatric Respiratory Illnesses: A Pilot Feasibility Study in 2 Ugandan Primary Care Health Centers**/L.E. Ellington, Seattle, WA
- 608 **Asthma Characteristics and Allergic Sensitization Among Adolescents With HIV and HIV-uninfected Adolescents in Nairobi, Kenya**/L.E. Ellington, Seattle, WA
- 609 **A Novel Program to Improve Diagnosis and Treatment of Primary Ciliary Dyskinesia in Latin America**/R.A. Mosquera, Houston, TX
- 610 **Frequency and Outcomes of Young Children With Difficult Breathing Unrecognized by Caregivers During Outpatient Visits in Bangladesh: A Cohort Study**/A.A. Islam, Dhaka, Bangladesh
- 611 **Severe SARS CoV 2 Related Disease in Hospitalized Children Aged 0-19 Years in Ethiopia, a Cohort Study**/R.A. Kebede, Addis Ababa, Ethiopia
- 612 **Factors Associated With Hospitalization of Children for Viral Bronchiolitis in Bogota-Colombia During the COVID19 Pandemic**/S.M. Restrepo, Bogota, Colombia
- 613 **Respiratory Infection by Rhinovirus Compared to Infection by Other Viruses, in a High Complexity Institution in Bogotá, Colombia**/S.M. Restrepo, Bogota, Colombia
- 614 **Sleep Problems in School-aged Children and Teenagers From Bogotá, Colombia Private Schools, and Screen Exposure During the COVID-19 Pandemic**/S. Abril Lombana, Bogota, Colombia
- 615 **Long Term Ventilation and Tracheostomy in Children With Down Syndrome: Predictors of Successful Weaning**/I. Oyarzun, Santiago, Chile
- 616 **Single-center Experience on Complications of Community-acquired Pneumonia on Immigrant Adolescents**/D. Rodriguez, El Paso, TX
- 617 **Pulmonary Function Testing in Healthy Bangladeshi Infants: A Pilot Study**/C. Verwey, Johannesburg, South Africa
- 618 **Experience in Congenital Diaphragmatic Hernia in a High Complexity Hospital at High Altitude in a Middle and Low Income Country**/J. Seba, Bogota, Colombia
- 619 **Menace of a Traditional Custom in South India**/S. Subramaniam, Thanjavur, India
- 620 **Phenotypic and Genotypic Characterization of Primary Ciliary Dyskinesia, Southwest Region of Saudi Arabia**/A.M. Asseri, Abha, Saudi Arabia
- 621 **Higher Levels of Insulin-like Growth Factor-1 in Cord Blood Associates With Risk of Asthma at Age 3**/J.A. Castro-Rodriguez, Santiago, Chile

622 **Are Italian Pediatric Educational Programs Suitable to Treat Obstructive Sleep Apnea?**/L.M. Nosetti, Varese, Italy

BASIC • TRANSLATIONAL

POSTER DISCUSSION SESSION

C26 UNRAVELING THE GORDIAN KNOT: MULTI-DIMENSIONAL -OMICs AND SIGNALING MOTIFS IN PULMONARY VASCULAR DISEASE

9:00 a.m. - 11:00 a.m. **Marriott Marquis Washington**

Marquis Ballroom, Salons 1-2 (Level M2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: T.V. Kudryashova, PhD, Davis, CA
Z. Dai, PhD, Phoenix, AZ
I. Al Ghouleh, PhD, Pittsburgh, PA

- 101 **Unraveling the Epigenetic Mechanisms as Potential Driver of Female Predominance in Pulmonary Arterial Hypertension**/A.K. Wawrzen, Graz, Austria
- 102 **Proteomic Signature of MicroRNA-126 Targets in COPD Individuals With Putative Pulmonary Hypertension**/K. Goel, Los Angeles, CA
- 103 **Endothelial Specific CARMIL1 Knockdown Exacerbates In Vivo Lung Injury**/C. Humpal, Chicago, IL
- 104 **Single Cell Transcriptomic Analysis Reveals Cooperation Between Activated Arterial ECs and Acta2+ Pericytes in Complex Arterial Remodeling in Pulmonary Arterial Hypertension**/N.D. Cober, Ottawa, Canada
- 105 **MicroRNA Regulation of the 3' Untranslated Region of COL18a1 in Pulmonary Arterial Hypertension**/T. Tuhy, Baltimore, MD
- 106 **Direct Delivery of MicroRNA-96 to the Lungs of Sugeng/Hypoxic Rats Reduces an Estrogen Metabolizing Enzyme and Fibrotic Markers Gene Expression in the Lungs**/H. Labazi, Glasgow, United Kingdom
- 107 **Age-related Changes in Structure, Function, and Transcriptomics of the Human Proximal Pulmonary Artery**/E.P. Manning, New Haven, CT
- 108 **Neonatal Hyperoxia Causes Vascular Smooth Muscle Specific Transcriptomic Changes and Pulmonary Hypertension**/D.T. Dinh, Palo Alto, CA
- 109 **Loss of Tet2 Associated Clonal Hematopoiesis Contributes to Hypoxia-induced Pulmonary Hypertension in a Mouse Model**/S.Y. Farha, Cleveland, OH

110 **TMEM100, a Lung-specific Endothelium Gene**/B. Liu, Phoenix, AZ

111 **Murine Model of Phenylhydrazine-Induced Chronic Hemolysis Combined With Hypoxia Leads to Development of Severe Pulmonary Hypertension**/J. Gonzales, Chicago, IL

112 **Mesenchymal Stem Cells-derived Microparticles Preserve RUNX1 Stability During the Intercellular Communication Leading to Endothelial Cell Recovery and Proliferation After Injury**/S.A. Predescu, Chicago, IL

113 **DLL4/NOTCH1 Induces PPAR γ , Suppressing AKT and the Proliferative, Apoptosis Resistant Phenotype of BMPR2-silenced Pulmonary Artery Endothelial Cells**/K. Awad, Bethesda, MD

114 **Intrinsic Deficiency of PAI-1 in Human Pulmonary Arterial Smooth Muscle Cells From Pulmonary Artery Hypertension (PAH) Patients Drives UPA-dependent Cell Proliferation and Induces Spontaneous Pulmonary Hypertension in Mice**/V. Stepanova, Philadelphia, PA

115 **Mutation of Akt1 Renders Pulmonary Hypertension Resistant Phenotype With Inhibited EndMT**/M. Valuparampil Varghese, Tucson, AZ

116 **Small Leucine-Rich Proteoglycan Asporin Represses Smooth Muscle Cell Proliferation and Regulates Pulmonary Hypertension Development**/L. Medzikovic, Los Angeles, CA

117 **Stretch Receptors Attenuate the Prothrombotic Transformation of the Endothelium**/K. Sack, Boston, MA

118 **RUNX1 Mediates Pulmonary Hypertension Associated With Impaired SOX17 Expression**/J.R. Klinger, Providence, RI

119 **CD39-bearing Extracellular Vesicles Regulate Pulmonary Thrombosis in Sickle Cell Disease**/T. Brzoska, Pittsburgh, PA

120 **Dysregulation of the Cytosolic Double Stranded RNA Receptor System and Interleukin-10 Signaling in Endothelial Dysfunction in Pulmonary Arterial Hypertension**/G.S. Newcomb, Columbus, OH

121 **Vps34 Activation Is Pulmonary Vascular Smooth Muscle Cell-specific and Akt-dependent in Pulmonary Arterial Hypertension**/Y. Shen, Davis, CA

122 **Aberrant Pulmonary Endothelial Cell Angiogenesis Driven by Constitutive Mesenchymal mTOR Activation**/S. Lin, Philadelphia, PA

123 **Chitinase 3-like-1 Protein Contributes to the Development of Pulmonary Vascular Remodeling in Pulmonary Hypertension**/C. Norbrun, Providence, RI

- 124 **Impaired Endothelial Purinergic-TRPV4 Channel Signaling Reduces Flow-Induced Dilation of Resistance Pulmonary Arteries in Pulmonary Hypertension/Z. Daneva, Charlottesville, VA**
- 125 **Augmentation of Kindlin-2 Expression Attenuates Endothelial Cell Permeability and Murine Acute Lung Injury/W. Chen, Chicago, IL**

BEHAVIORAL • CLINICAL**POSTER DISCUSSION SESSION****C27 OPTIMIZING THE INTERVENTIONS AND PROGRAM MODELS OF PULMONARY REHABILITATION**9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center****Room 151 A (Street Level)**

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: C.L. Goulart, PhD, Sao Carlos, Brazil
M. Steiner, MBBS, MD, FRCP, Leicester, United Kingdom

- 401 **Effectiveness of Oscillating Positive Expiratory Pressure Device in Bronchiectasis With Frequent Exacerbation/S.R. Kim, Cheongju-si, Korea, Republic of**
- 402 **Telerehabilitation in the 'Real World': Implementation of Remotely Delivered Pulmonary Rehabilitation/N.S. Cox, Melbourne, Australia**
- 403 **Are We Maximising the Potential of Occupational Therapists to In Deliver Patient Education In Pulmonary Rehabilitation?/N.J. Roberts, Edinburgh, United Kingdom**
- 404 **Comparison of Cardiopulmonary and Symptom Responses Between Three Types of Exercise Tests in Interstitial Lung Disease/A. Nakazawa, Yokohama, Japan**
- 405 **Understanding Provider-level Barriers and Enablers Impacting the Referral of Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease to Pulmonary Rehabilitation, in Safety-net Healthcare Settings/M.H. Siddeek, San Francisco, CA**
- 406 **Effect of Virtual Pulmonary Rehabilitation Among Patients With Chronic Obstructive Pulmonary Disease/A.J.S. Almario, Quezon City, Philippines**
- 407 **Assessment of the Clinical Value of an Oscillating Positive Expiratory Pressure (OPEP) Device for Chronic Obstructive Pulmonary Disease (COPD) Patients in India: A 6 Week Field Study Using the COPD Assessment Test (CAT)/J. Suggestt, London, Canada**

- 408 **Pulmonary Rehabilitation Uptake Following Hospitalization for COPD Exacerbation: Numbers Are Not so Dismal as We Might Think/O. Elsankary, North Haven, CT**

- 409 **The Effect of Obesity on Exercise Performance in a Cardiac Rehabilitation Program/N. Mittal, La Jolla, CA**
- 410 **Muscular Performance Is Impaired Relative to Disease Severity in Idiopathic Pulmonary Fibrosis and Is Associated With Reduced Levels of Moderate-to-Vigorous Physical Activity/M.B. Brown, Seattle, WA**

- 411 **A Pilot Study Using Aspects of Virtual Pulmonary Rehabilitation to Complement Remote Physiologic Monitoring in COPD/N. Moraveji, San Francisco, CA**

- 412 **Socioeconomic Status and Pulmonary Rehabilitation Completion/E. Vasko, North Haven, CT**

- 413 **Evaluation of Work of Breathing and Health Care Utilization in Patients Prescribed Daily Oscillation and Lung Expansion (OLE) Therapy at Home/B.C. Becker, St. Paul, MN**

BASIC • CLINICAL • TRANSLATIONAL**POSTER DISCUSSION SESSION****C28 FROM OMICS TO EX VIVO MODELS: A ROAD MAP FOR NOVEL THERAPIES IN LUNG FIBROSIS**9:00 a.m. - 11:00 a.m. **Marriott Marquis Washington****Marquis Ballroom, Salons 9-10 (Level M2)**

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: M. Koenigshoff, MD, PhD, ATSF, Pittsburgh, PA
D.J. Tschumperlin, PhD, Rochester, MN
K.-D. Alysandratos, MD, PhD, Boston, MA

- 1001 **Epithelial Outgrowth Through Mesenchymal Rings Drives Alveologenesis/N. Negretti, Nashville, TN**
- 1002 **Development and Characterization of a Feeder-free System to Study Goblet Cell Variant Basal Cells/T.S. Tufenkjian, Nashville, TN**
- 1003 **Establishing Airway Lung Organoids From Human Bronchoalveolar Lavage Fluid/M.Y. Liu, Boston, MA**
- 1004 **A Multi-Lineage Airway Culture System Using Human Induced Pluripotent Stem Cells/D.J. Wallman, Boston, MA**

- 1005 **Modelling Lung Aging in a Dish - Prolonged 3D Culture Causes Telomere Length Attrition in Induced Pluripotent Stem Cell-derived Type 2 Alveolar Epithelial Cells/A.** Schweikert, Dublin, Ireland
- 1006 **Fibroblasts From Hermansky-pudlak Syndrome Mice Contribute to Altered Growth in Alveolar Organoids/B.** Banaschewski, Philadelphia, PA
- 1007 **Use of an Organoid Model to Evaluate Drug Antifibrotic Responses in Interstitial Lung Diseases/K.G. Dsouza,** Birmingham, AL
- 1008 **Autocrine LIF/LIFR Loop Amplifies Multiple Pro-fibrotic Programs in Lung Fibroblasts and LIFR Blockade Reduces Fibrosis in Human IPF PCLS/H.N. Nguyen,** Boston, MA
- 1009 **Tissue-specific Single Cell RNA Sequencing of Human Lung Sub-compartments Defines Spatial Heterogeneity of Interstitial Macrophages and Other Leukocytes/P.** Hume, Denver, CO
- 1010 **High-dimensional Analysis of Cell-cell Signaling in Pulmonary Biology and Disease Using Niches/M.S.B.** Raredon, New Haven, CT
- 1011 **Fibrotic Cocktail Treated Human Precision Lung Slices Replicate the Cellular Diversity of the IPF Lung/A.** Justet, New Haven, CT
- 1012 **Preservation of Relevant Signaling Pathways in the Living Precision Cut Lung Slices of Patients With Pulmonary Fibrosis/C.** Hesse, Hannover, Germany
- 1013 **Dissecting Trigger-Specific Cellular Senescence in Human Precision-Cut Lung Slices/D.** Beaulieu, Pittsburgh, PA
- 1014 **Durable Alveolar Engraftment of PSC-derived Lung Tip-like Cells Into Immunocompetent Mice/M.** Herriges, Boston, MA
- 1015 **⁶⁴Cu-PEG-FUD for Non-Invasive Detection of Murine-Induced Pulmonary Fibrosis/K.** Bernau, Madison, WI
- 1016 **Noninvasive Quantification of Radiation Induced Lung Injury by Type 1 Collagen Probe- Translational Model With First in Human Study/E.D.** Abston, Boston, MA
- 1017 **Fibroblast Activation Protein Inhibitor, a Promising Radiotracer in Fibrogenesis/P.** Lavis, Brussels, Belgium
- 1018 **Novel Dual Action Peptide Therapeutic in Attenuation of Pulmonary Fibrosis/D.C.** Yang, Davis, CA
- 1019 **Adipose Derived Stromal Cells-Induced Regulation of Micro RNA Modulates Telomere Length in Mouse Lung/D.** Anderson-Terhune, Phoenix, AZ
- 1020 **Inhibiting a RNA Motif Binding Protein Attenuates Pulmonary Fibrosis in Mice/R.H.** Gomer, College Station, TX
- 1021 **Inhaled FGF19 Therapy in Pulmonary Fibrosis/M.** Ghanem, Paris, France
- 1022 **Metabolic Alterations in Bleomycin Induced Pulmonary Fibrosis in Mice/M.A.T.** Freeberg, Richmond, VA
- 1023 **Fibroblasts From Idiopathic Pulmonary Fibrosis Driving an Altered Phenotype in Healthy Alveolar Type II Cells in 3D Organoid/J.A.** Ovando Ricardez, Columbus, OH
- 1024 **Cell-subpopulations in Upper and Lower IPF Lobe at Spatial Transcriptomics Resolution/J.A.** Ovando Ricardez, Columbus, OH
- 1025 **Thyroid Hormone Receptor β Agonist Sobetirome Attenuates Pulmonary Fibrosis Via Promoting Hyperplastic Alveolar Epithelial Type 2 Cells Differentiation Into Type 1 Cells/G.** Yu, Xixiang, China

BASIC • CLINICAL • TRANSLATIONAL

RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

**C29 MORE THAN MEETS THE EYE:
ADVANCED LUNG IMAGING**

9:00 a.m. - 11:00 a.m. Walter E. Washington Convention Center

Room 103 A-B (Street Level)

Viewing 9:00-9:45

Summaries/Discussion 9:45-11:00

Chairing: S. Svenningsen, PhD, Hamilton, Canada
J.C. Woods, PhD, ATS, Cincinnati, OH
E.A. Hermann, MD, MPH, New York, NY

201 **Noninvasive Assessment of In Vivo Mouse Lung Microstructural Changes Due to Aging and PEEP/M.L.** Costa, Cincinnati, OH

202 **Hyperpolarized ¹²⁹Xe Pulmonary Magnetic Resonance Imaging and Multiple Breath Washout Response to Elexacaftor-Tezacaftor-Ivacaftor in Adults With Cystic Fibrosis/V.M.** Diamond, Vancouver, Canada

203 **Assessment of Lung Shrinking With Elastic Registration Technique on 3D-UTE Pulmonary MRI in Monitoring Idiopathic Pulmonary Fibrosis/X.** Yang, Beijing, China

204 **New CT-based Metrics of Rib Cage Dynamics Between Inspiration and Expiration Reveal Accelerated Aging in COPD Among Smokers/S.A.** Nadeem, Iowa City, IA

205 **Dictionary Learning to Predict COPD Progression Using Topological PRM/S.** Ram, Ann Arbor, MI

206 **Effect of Contrast Viscosity on Pulmonary Blood Flow Measurement Using Dynamic Contrast-enhanced Computed Tomography/Y.** Xin, Boston, MA

- 207 **Assessment of Ventilatory Heterogeneity by Measures Derived From 3D Functional Electrical Impedance Imaging of Patients With Acute Respiratory Distress Syndrome and Healthy Controls: A Pilot Study/N.**
Barbosa Da Rosa, Fort Collins, CO
- 208 **A Reproducibility Study of Hyperpolarized Dynamic Imaging in Healthy Subjects/H.** Hamedani, Philadelphia, PA
- 209 **Prediction of Emphysema Progression Using CT Radiomics/P.** Saha, Birmingham, AL
- 210 **Quantitative CT Analysis Using Combined Inspiratory and Expiratory CT Imaging in Progressive Fibrosing Interstitial Lung Disease/A.** Matsunashi, Kyoto, Japan
- 211 **The Influence of Body Position on Aerosol Deposition in Healthy Subjects Using Functional Respiratory Imaging/E.** Lauwers, Wilrijk, Belgium
- 212 **Interpretable Prediction of DLCO in Idiopathic Pulmonary Fibrosis from Quantitative CT and Computational Fluid Dynamics (CFD)-based Regional Lung Function/W.** Chung, Seoul, Korea, Republic of
- 213 **Four-dimensional Imaging Reveals That Eosinophils Drive Ventilation Heterogeneity in a Steroid-resistant Murine Model of Airway Inflammation/N.** Wanner, Cleveland, OH
- 214 **Quantification of Gas Trapping “Compactness” on Computed Tomography Is Associated With Clinically Relevant Outcomes in COPD/S.** Virdee, Toronto, Canada

- 803 **Real-World Treatment Patterns and Healthcare Expenditures in Patients With Surgically Resected Non-Small Cell Lung Cancer: A Population-based Analysis Using the SEER-Medicare Database/R.** Rajaram, Houston, TX
- 804 **Recurrence-free Survival (RFS) in Surgically-resected Non-small Cell Lung Cancer Patients - A Systematic Literature Review and Meta-analysis/R.** Rajaram, Houston, TX
- 805 **Timeliness of Surgery for Early-stage Lung Cancer: Perspectives From Surgeons and Patients/J.** Zhu, New York, NY
- 806 **Timeliness of Surgery for Early-stage Lung Cancer: Patient Factors and Predictors/J.** Zhu, New York, NY
- 807 **Combined Robotic Assisted Thoracic Surgery (CRATS)/E.D.** Anderson, Washington, DC
- 808 **Impact of Nutritional Status on Outcomes of Esophagectomy: An Analysis of National Surgical Quality Improvement Program Database/K.** Schwarzova, Baltimore, MD
- 809 **Risk Factors of Surgical Resection for Lung Cancer Patients With Idiopathic Pulmonary Fibrosis Incidentally Found on Preoperative Chest Computed Tomography/S.** Kim, Gwangju, Korea, Republic of
- 810 **The Association of Body Mass Index and Postoperative Complications in 1,578 Patients With Early-stage Lung Cancer Diagnosis - Evidence From the Brazilian Registry of Lung Cancer/F.M.** Silva, Florianopolis, Brazil
- 811 **Factors Contributing to a Benign Surgical Resection Rate for Lung Nodules in a Veteran’s Hospital in the Midsouth/K.** Lutchi, Memphis, TN
- 812 **Onionin A Inhibits Small-cell Lung Cancer Growth by Targeting Cell-cell Communications With Tumor-associated Macrophage/R.** Mito, Kumamoto, Japan
- 813 **Real-world Treatment Patterns and Clinical Outcomes Among Patients With Stage I-III Non-small Cell Lung Cancer in South Korea: A Single Center Retrospective Cohort Study/H.H.** Kim, Seoul, Korea, Republic of
- 814 **Outcomes of Veterans With Early-Stage Non-Small Cell Lung Cancer/D.E.** Espinoza Barrera, New Orleans, LA

CLINICAL

POSTER DISCUSSION SESSION

C30 LUNG CANCER SURGERY APPROACHES AND OUTCOMES

9:00 a.m. - 11:00 a.m. **Walter E. Washington Convention Center**

Room 209 A-C (Level 2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: L. Erhunmwunsee, md, , CA
K.A. Crothers, MD, Seattle, WA

- 801 **Sociodemographic Determinants of Lung Cancer: How Race and Income Affect Survival/A.J.** Duval, Newark, NJ
- 802 **Change in Quality of Life After Surgery or Stereotactic Body Radiation Therapy in Stage IA Non-small Cell Lung Cancer Patients/J.** Zhang, New York, NY

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

C31 BIOLOGICS WANT TO RULE THE (ASTHMA) WORLD

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area F, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P595** Long-term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: The Liberty Asthma Traverse Continuation Study/J.F. Maspero, Buenos Aires, Argentina
- P596** Dupilumab Reduced Severe Exacerbation Rates and Improved Pre-bronchodilator Fev₁ in Patients With Moderate-to-Severe Asthma Regardless of Exacerbation History of ≥ 1 , ≥ 2 , or ≥ 3 Prior Exacerbations: Liberty Asthma Traverse/J.F. Maspero, Buenos Aires, Argentina
- P597** Real-world Effectiveness of Dupilumab in Biologic Naïve Patients With Asthma: Analysis From the US Advantage Study/R.H. Stanford, Chapel Hill, NC
- P598** Efficacy of Dupilumab in Patients With and Without a Minimally Important Reduction in Fractional Exhaled Nitric Oxide After 2 Weeks of Treatment/I.D. Pavord, Oxford, United Kingdom
- P599** A Real-World Study to Evaluate the Effectiveness of Mepolizumab in Treating Severe Asthma in Taiwan (REMIT)/X. Xu, Singapore, Singapore
- P600** The Influence of Administering Mepolizumab by Autoinjector on Real-world Outcomes in Severe Asthma: Results From the REALITI-A Study at 2 Years/M.C. Liu, Baltimore, MD
- P601** Identifying Asthma Patients Eligible for Anti-IL5 Treatment Using Electronic Health Records/F. Yang, Glasgow, United Kingdom
- P602** Approaching Clinical Remission in Severe Asthma: An Analysis of Patients With Comorbid Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Treated With Benralizumab Across Five Clinical Trials/R.E. Louis, Liege, Belgium
- P603** Real-world Evidence of Benralizumab in Patients With Severe Eosinophilic Asthma and Nasal Polyps: Initial Results of the RANS Study/T. Le, Gaithersburg, MD
- P604** Effect of Tezepelumab on Airway Hyperresponsiveness by Baseline Blood Eosinophil Count in Patients With Severe, Uncontrolled Asthma in the Phase 2 CASCADE Study/C.E. Brightling, Leicester, United Kingdom
- P605** Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Sex: Results From the Phase 3 Navigator Study/M. Kraft, New York, NY
- P606** Tezepelumab Reduces Patient-reported Cough and Phlegm Production in Patients With Severe, Uncontrolled Asthma: Results From the Phase 3 NAVIGATOR Study/M. Castro, Kansas City, KS
- P607** Biologic Responders and Super-responders in the International Severe Asthma Registry/E. Denton, Melbourne, Australia
- P608** Demographic Characteristics of Patients Who Utilize Biologics for Severe Asthma: A Real-World European Perspective/S. Valliant, Collegeville, PA
- P609** Blood Eosinophil and IgE Levels at Initiation of Biologics for the Treatment of Severe Asthma, a Perspective From US, EU-4, and UK/S. Valliant, Collegeville, PA
- P610** Clinical Remission and Associated Reductions in Background Medication in Patients With Severe Asthma: An Analysis of the Phase 3b ANDHI in Practice Substudy/T.W. Harrison, Cambridge, United Kingdom
- P611** Month-to-Month Real-World Patterns of Inhaler Use in Patients With Controlled and Uncontrolled Severe Asthma Treated With Biologics/A. Mohan, Ann Arbor, MI
- P612** Effects of Biologics on Systemic and Airway Inflammation in Severe Asthma: A Comparison Between Phenotypes/F. Ardesi, Varese, Italy
- P613** The Use of Biologics in a Real-world Setting Reduces Hospitalizations/M. Mallozzi, Philadelphia, PA
- P614** Medication Adherence in Severe Asthma Patients Enrolling in the NHLBI Precise Study/P. Akuthota, La Jolla, CA
- P615** Safety Signals on Parasitic Infections Related to Monoclonal Antibodies for Moderate-Severe Asthma Patients: Results from the Food and Drug Administration's Adverse Event Reporting System/V. Pera, Rotterdam, Netherlands
- P616** Patterns of Inhaler Use Associated With Short-term and Long-term Use of Biologics by Patients With Severe Asthma/A. Boe, Parsippany, NJ
- P617** Clinical Remission in Oral Corticosteroid (OCS)-dependent Patients With Severe Asthma: An Analysis of the Andhi-IP and PONENTE Trials/A. Menzies-Gow, London, United Kingdom
- P618** Association Between T2-related Comorbidities and Effectiveness of Biologics in Adult Patients From the International Severe Asthma Registry/G. Scelo, Singapore, Singapore

- P619** CD62L Expression in Peripheral Blood Eosinophils in Severe Asthma Patients Concerning the Clinical Outcome of Biological Therapy/J. Novosad, Hradec Králové, Czech Republic
- P620** Efficacy and Safety of Mepolizumab as an Add-on Therapy in Chinese Patients With Severe Eosinophilic Asthma: A Randomized, Double-Blind, Parallel Group Phase 3 Study/R. Chen, Guangzhou, China
- P621** Efficacy and Safety of Dupilumab in Patients With Persistent Asthma From the Asia-Pacific Region: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study/Q. Zhang, Guangdong, China
- P622** Efficacy and Safety of Dupilumab in Patients From China With Persistent Asthma: A Subgroup Analysis of a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study/Q. Zhang, Guangdong, China

BASIC • TRANSLATIONAL
THEMATIC POSTER SESSION
C32 THE AIRWAY BATTLE FOR DOMINANCE: IMMUNE SYSTEM VERSUS INFECTIONS
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area F, Hall C (Lower Level)
Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P624** Effect of Influenza Immunization With Inactivated Trivalent Polymer-subunit Vaccine in Lung Transplant Recipients/I. Revenco, Chisinau, Moldova, Republic of
- P625** Immunity Against Haemophilus Influenzae Type B Infection in Patients With Severe Bronchopulmonary Disorders Who Are on a Waiting List for a Lung Transplant, and Effects of Vaccination in This Patient Population/I. Revenco, Chisinau, Moldova, Republic of
- P626** Novel iPS-derived MSCs Have Antibacterial Properties Against Pneumonia Relevant Pathogens/J. Fandiño Gómez, Galway, Ireland
- P627** Lung Th17 TRM Cells Require CCR2 for Host Defense Against Pulmonary Klebsiella Infection/T.P. Remcho, New Orleans, LA
- P628** TLR3 Signaling Is Required for Robust Extrafollicular B Cell Response (EF) in Influenza A/PR/8 Infection/E.J. Keller, Davis, CA
- P629** Autoregulation of the Multifunctional IL-6 Family Cytokine Oncostatin M During Acute Bacterial Pneumonia/Y. Lee, Boston, MA
- P630** Influenza A Infection in Aged Mice Is Associated With Impaired Viral Clearance and Dysregulated Immune Responses/Y. Matsunaga, New Orleans, LA
- P631** The Role of Exosomal PD-L1 in Nontuberculous Mycobacterial Lung Disease: Association With Disease, Treatment Response and Immune Cell Survival/C.-C. Shu, Taipei, Taiwan
- P632** Hepatitis C Viremia and Diffusing Capacity for Carbon Monoxide in Women With and Without Human Immunodeficiency Virus/A. Curnow, San Francisco, CA
- P633** Identification of Small Molecules Targeting One of the P38alpha MAPK Substrate-docking Domains With Endothelial-Barrier-Function-stabilizing and Immunomodulatory Activity/J.D. Hasday, Baltimore, MD
- P634** The Effects of Extracellular Heme on Coronaviruses Induced Pulmonary Inflammatory Responses/G. Qu, Gainesville, FL
- P635** Anti-CD20 Permits Secondary Lung Gene Transfer: Implications for Gene Therapy Approaches in Cystic Fibrosis/R.D.E. Clark, New Orleans, LA
- P636** Dysglycemia Affects the Airway Microbiome in Cystic Fibrosis/L. Brenner, Boston, MA
- P637** Cystic Fibrosis Transmembrane Conductance Regulator Triple Modulator Strongly Inhibits Phagocytosis by Primary Human Primary Lung Macrophages/D. Aridgides, Lebanon, NH
- P638** Neutrophil Elastase-Dependent Cleavage Dysregulates LTA4H Aminopeptidase Activity/X. Xu, Birmingham, AL
- P639** The Novel Orai1 Antagonist ELD607 Rescues the Hyperinflammatory Ca²⁺ Signaling Seen in CF Neutrophils/J. Wrennall, Chapel Hill, NC
- P640** The Impact of CFTR Modulator Triple Therapy on Type 2 Inflammatory Response in Patients With Cystic Fibrosis/A.M. Mehta, Charlottesville, VA
- P641** Single Cell Transcriptional Characterization of the Upper Airway in a Murine Model of Cystic Fibrosis/C.M. Bojanowski, New Orleans, LA
- P642** Th2-inflammation in the Sputum and Plasma of Cystic Fibrosis Patients/I. Simpson-Shelton, San Diego, CA
- P643** Patient Derived Airway Epithelial Basal Cells Reveal an Age Related Response to Respiratory Syncytial Virus Infection/P. Lerou, Boston, MA

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

C33 ADVANCES AND UNSOLVED MYSTERIES IN COPD9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area B, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session**11:30-1:15****Discussion:** 11:30-12:15 authors will be present for individual discussion

12:15-1:15 authors will be present for discussion with assigned facilitators.

- P143 Gene Expression Signature of Serpina1 Z Allele Dosage in Lung Epithelial Cells/J. Morrow, Boston, MA**
- P144 Regulatory T Cells Expressing Toll-like Receptor 2 in Blood From Smokers With Stable Chronic Obstructive Pulmonary Disease/A. Linden, Stockholm, Sweden**
- P145 Proton Pump Inhibitor-treatment of Gastroesophageal Reflux in Asthma-COPD Overlap Lessens Risk of Exacerbations More Than in Asthma Alone/B. Patchett, Philadelphia, PA**
- P146 Diurnal Description of Alpha 1 Antitrypsin Levels and Other Inflammatory Markers in Healthy Humans and Alpha 1 Antitrypsin Deficiency Patients/L. Alhaddah, Dublin, Ireland**
- P147 Circadian Protein Localisation in Monocytes of Severe Alpha 1 Antitrypsin Deficiency/L. Alhaddah, Dublin, Ireland**
- P148 The Swedish Broncho-Scapis Cohort: Characterization of Chronic Airflow Limitation in Adult Never-Smokers/T. Pincikova, Stockholm, Sweden**
- P149 Phenotypes of Blood and Sputum Eosinophils in Chronic Obstructive Pulmonary Disease and Asthma/K. Mycroft, Warszawa, Poland**
- P150 Blood Eosinophil Count Variability in Chronic Obstructive Pulmonary Disease and Severe Asthma/Y. Abe, Sapporo, Japan**
- P151 Positive Microbiologic Studies in Hospitalizations for COPD Exacerbation Are Associated With Longer Length of Stay and Increased Risk of Discharge to Skilled Nursing Facility/M. Burnim, Baltimore, MD**
- P152 Evaluation of Asthma-chronic Obstructive Pulmonary Disease Overlap Using a Mouse Model of Pulmonary Disease/J. Hur, Seoul, Korea, Republic of**
- P153 Characteristic of Patients With Obstructive Lung Disease From Tikur Anbessa Specialized Hospital (TASH) Addis Ababa Ethiopia/A.B. Binegdie, Addis Ababa, Ethiopia**

- P154 The microRNA-mediated Changes in Pulmonary Fibroblasts of Chronic Obstructive Pulmonary Disease/M.-J. Tsai, Kaohsiung, Taiwan**
- P155 Utilizing Veterans Health Affairs (VHA) Database to Evaluate Inhibition of IL-17a on Rates of Chronic Obstructive Pulmonary Disease (COPD) Hospitalization Through Matched Cohort Analysis; a Hypothesis Generating Study/C.B. Smith, Kansas City, KS**
- P156 Cigarette Smoke Delays Murine Innate Immune Response Against X31 Influenza Infection/J.R. Vlasma, Groningen, Netherlands**
- P157 Affect of Regional and Gender Disparities on Mortality Related to Chronic Obstructive Pulmonary Disease/S. Chaparala, Athens, GA**
- P158 Systematic Literature Review to Determine Herpes Zoster Incidence in Patients With Chronic Respiratory Diseases in the European Union, Switzerland, and the United Kingdom/A. Marijam, Wavre, Belgium**
- P159 Lactoperoxidase a Key Player in Immunity and Inflammation Upon HIV Infection and Cigarette Smoke Exposure/M.J. Santiago, Miami, FL**
- P160 Identification of Stable and Suppressive Murine Regulatory T Cell Subsets to Optimize Therapeutic Potential in COPD/C.M. Freeman, Ann Arbor, MI**
- P161 Elevated Sputum Group 2 Innate Lymphoid Cells Indicates Clinical Severity of Chronic Obstructive Pulmonary Disease and Involves IL-17A Plasticity/A. Linderholm, Davis, CA**
- P162 BLTR1 Is Decreased in Steroid Resistant Pro-inflammatory CD28nullCD8+ T Lymphocytes in Patients With COPD: The Spillover Hypothesis Explained?/G. Hodge, Adelaide, Australia**
- P163 Blood Gene Expression and Immune Cell Subtypes Associated With COPD Exacerbations/M.H. Ryu, Boston, MA**
- P164 Increased Frequency of the M3 SERPINA1 Variant for AAT in Patients With COPD/F. Kueppers, Philadelphia, PA**

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

C34 SARCOIDOSIS, FIBROSIS, AND PROTEINOSIS - OH MY!9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area F, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session**11:30-1:15****Discussion:** 11:30-12:15 authors will be present for individual discussion

12:15-1:15 authors will be present for discussion with assigned facilitators.

- P645** Exposure-Efficacy Analysis Supports Proof of Concept for Efzofitmod in Pulmonary Sarcoidosis/R. Adams, San Diego, CA
- P646** Diagnosing Sarcoidosis Associated Small Fiber Neuropathy/L.R.M. Raasing, Nieuwegein, Netherlands
- P647** Targeting Signal Regulatory Proteins (SIRPs) to Suppress Sarcoidosis Granuloma Responses/E.D. Crouser, Columbus, OH
- P648** Renin-angiotensin-aldosterone System Plays an Integral Role During Sarcoidosis Granuloma Formation/E.D. Crouser, Columbus, OH
- P649** High MTOR Activity in Bronchoalveolar Lavage Cells From Patients With Sarcoidosis/A. Prasse, Hannover, Germany
- P650** Residential Bioaerosol Concentrations and Serum Inflammatory Markers in Pulmonary Sarcoidosis/E.M. Stapleton, Iowa City, IA
- P651** The Role of Airway Epithelial Responses in Sarcoidosis/M. Hagner, Iowa City, IA
- P652** Relative Change in Plasma Anti-GM-CSF Antibody Levels May Correlate With Clinical Improvement in Autoimmune Pulmonary Alveolar Proteinosis/E. Lee, Los Angeles, CA
- P653** The Use of Procalcitonin in the Diagnosis of Idiopathic Acute Eosinophilic Pneumonia/A. Elkhapery, Rochester, NY
- P654** Experimental Models of Cough Hypersensitivity in Guinea Pig Useful to Study Novel Mechanisms for the Treatment of Chronic Cough/C. Martucci, Parma, Italy
- P655** Clinical Characteristics of Patients With Systemic Sclerosis and Early Pulmonary Involvement/I. Acosta Sanchez, Chicago, IL
- P656** Potential Biomarkers for the Diagnosis of Patients With Lung Fibrosis/M.-J. Cruz, Barcelona, Spain
- P657** A Phase I Study (Safety, Tolerability, and Pharmacokinetic Study) of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis/H. Doi, Tokyo, Japan
- P658** Multimodality Approach to Characterizing the Distinctive Hallmarks of Lung Fibrosis: A Mouse Model With Bleomycin and Indocyanine Green/A. Grandi, Parma, Italy
- P659** Suppression of Lung Nitrogen Mustard-induced Pulmonary Fibrosis, Oxidative Stress and Inflammatory Macrophage Activation by the Farnesoid X Receptor Agonist, Obeticholic Acid/J. Meshanni, Piscataway, NJ
- P660** The Prevalence of IPF and Progressive Pulmonary Fibrosis in South Africa/G.K. Soin, Cape Town, South Africa
- P661** Respiratory Status After Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency/H. Salvator, Suresnes, France
- P662** Programmed Cell Death Protein-1 Receptor Modulates Chemokine Ligand-18 Secretion in Macrophages: An Important Checkpoint Inhibitor Pneumonitis Chemokine/M.I. Ghanbar, Baltimore, MD
- P663** Role of Hemoxygenase-1 as a Central Mediator of Acute Radiation Pneumonitis Revealed in a Human Lung Alveolus-on-a-Chip/Q. Dasgupta, Boston, MA
- P664** Establishing a Diagnosis and the Prevalence of Eosinophilic Granulomatosis With Polyangiitis Through Claims Data Using Machine Learning/P.A. Merkel, Philadelphia, PA
- P665** Machine Learning Prediction of Severe Asthma and COPD Hospital Readmission/H. Li, New Haven, CT
- P666** Development and Validation of Deep Learning Models for Diagnosing Bronchial Asthma Using Methacholine Provocation Test, Induced Sputum Analysis and Exhaled Nitric Oxide Measurement/N. Kang, Seoul, Korea, Republic of

BEHAVIORAL • CLINICAL

THEMATIC POSTER SESSION

C35 HEALTH SERVICES AND EPIDEMIOLOGY RESEARCH IN HOSPITALIZED AND CRITICALLY ILL POPULATIONS

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area I, Hall C (Lower Level)

- Viewing:** Posters will be on display for entire session **11:30-1:15**
- Discussion:** **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.
- P851** To Consult Critical Care or Not: Evaluating Hospitalist Perceptions of Critical Care Consultations in the Intermediate Care Unit/M. Dunlop, Boston, MA
- P852** Utilizing a User-centered Design Approach in the Development of an Intensive Care Unit Triage Intervention for Patients Presenting to the Emergency Department With Acute Respiratory Failure/K.C. Vranas, Portland, OR
- P853** Characteristics of Rural Intensive Care Units in the United States Prior to the COVID-19 Pandemic/Y. Engeda, Ann Arbor, MI
- P854** Cost-sharing for Intensive Care Unit Admissions/S. Kannan, Boston, MA
- P855** Symptom Cluster Characterization Upon Inpatient Admission in Those With Independent or Comorbid Heart Failure and Chronic Obstructive Pulmonary Disease/A. Bugajski, Lakeland, FL

- P856** **The Medical and Economic Impact of Anemia in Patients With Admitted Acute Respiratory Failure: Could a Simple Fix Go a Long Way?**/M. El Labban, Mankato, MN
- P857** **Acute Kidney Injury Increases Rates of Mortality and Mechanical Intubations in Patients Admitted With Asthma Exacerbations, a Nationwide Study**/M. El Labban, Mankato, MN
- P858** **Eosinopenia in Hospitalized Patients With Community-acquired Pneumonia**/W.H. Farah, Rochester, MN
- P859** **Racial Disparities, Comorbidities, and Hospital Outcomes Among Alcohol Withdrawal Patients: A Nationwide Retrospective Study From 2015-2020**/A. Elkhapery, Rochester, NY
- P860** **Trends in Federal Research Investment for Sepsis**/I. Khurana, Ann Arbor, MI
- P861** **A Qualitative Study of How Clinicians Diagnose, Communicate About, and Treat Hospitalized Patients Suspected of Sepsis**/G.E. Weissman, Philadelphia, PA
- P862** **Outcomes of Patients Undergoing Inter-hospital Medical ICU Transfer During Times of Strain**/P. Wilcox, Ann Arbor, MI
- P863** **Differences in Preferences for Sharing Personal Health Information During an ICU Admission by Race and Ethnicity**/B. Harris, Salt Lake City, UT
- P864** **Disparities in Sedation After Rapid Sequence Intubation**/A. Wolfe, New Orleans, LA
- P865** **Patient-provider Evaluation of Driving Decisions After Critical Illness: Qualitative Analysis of Intensive Care Unit Recovery Clinic Visits**/V. Danesh, Dallas, TX
- P866** **Variation in Use of Steroids, Antibiotics, and Diuretics Among Hospitalized Patients**/J. Howe, Ann Arbor, MI
- P867** **Mechanical Circulatory Support (MCS) in Patients Undergoing Transcatheter Aortic Valve Repair (TAVR): A Review of the National Inpatient Sample (NIS) Database**/N. Gabriel, Philadelphia, PA
- P868** **Endovascular Repair Vs Traditional Repair of Stanford Type B Aortic Dissection: A Review of the National Inpatient Sample Database**/N. Gabriel, Philadelphia, PA
- P869** **Assessing Subspecialties' Utilization of a Pulmonary Embolism Response Team at a Single Tertiary Care Center**/A.N. Fuher, Aurora, CO
- P870** **Beta-Blockers Versus Calcium Channel Inhibitor as First Line Treatment for New Onset Non-Valvular Atrial Fibrillation in Patients With Sepsis and Septic Shock: A Retrospective Cohort Study in a Large Hospital System**/B. Aslanaj, Las Vegas, NV
- P871** **Hospital-level Variation in Corticosteroid Dosing for Patients With Acute Exacerbations of Idiopathic Pulmonary Fibrosis**/D. Shankar, Boston, MA

BEHAVIORAL • CLINICAL
THEMATIC POSTER SESSION
C36 HIGHLIGHTS IN BEHAVIORAL SCIENCES AND HEALTH SERVICES RESEARCH
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area I, Hall C (Lower Level)
Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P873** **The Comparative Humanistic Burden of Bronchiolitis Obliterans Syndrome (BOS) on Patients Undergoing Lung Transplant (LTX) or Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) in the United States**/M.E. Minshall, Cambridge, MA
- P874** **Longitudinal Lung Function Measurements in Observational Studies: A Systematic Review of Methodological Factors**/A. Moinuddin, Hamilton, Canada
- P875** **Lung Involvement in Recently Diagnosed Patients With Inflammatory Bowel Disease**/A. Elshazly, Alexandria, Egypt
- P876** **Clinical Characteristics of Drug-induced Interstitial Pneumonia in Japan**/M. Yamanaka, Matsumoto, Japan
- P877** **Factors Associated With Interstitial Lung Disease Testing and Outcomes in Patients With Systemic Sclerosis**/A. Tukpah, Boston, MA
- P878** **Rheumatoid Arthritis Associated Interstitial Lung Disease: Trends in Epidemiology and Mortality in Ontario From 2000-2018**/L. Fidler, Toronto, Canada
- P879** **Analysis of the Primary and Secondary Outcomes Reported in Controlled Trials of Home Health Care for Adults With Chronic Respiratory Diseases: Are They Capturing What Really Matters?**/S. Leite, Natal, Brazil
- P880** **Do the Country Income Economies Influence the Adherence to Measures for the Prevention of Respiratory Infectious Diseases?**/T.A. Santino, Campina Grande, Brazil
- P881** **Predictors of Diffuse Alveolar Hemorrhage in Patients With Systemic Lupus Erythematosus**/V. Sebanayagam, Cleveland, OH
- P882** **Acceptability and Feasibility of a Chronic Breathlessness Clinical Algorithm in Australian Primary Care**/A.P. Sunjaya, Sydney, Australia
- P883** **Tobacco Treatment: A Real World Experience**/J. Deepak, Baltimore, MD

- P884** **Assessment of Cigarette Smoking Patterns, Quit Attempts, and Self-reported Reasons for Failed Cigarette Smoking Abstinence**/M. Luna Hinojosa, Indianapolis, IN
- P885** **Association Between Neighborhood Homicide and Smoking Status in an Urban Area**/T. Kaplan, Annapolis, MD
- P886** **Impact of a Targeted Promotion on Lung Cancer Screening Uptake in an Urban Indigenous Community Clinic Indigenous**/A. Begnaud, Minneapolis, MN
- P887** **A Descriptive Analysis of Lung Cancer Screening in Baltimore, Maryland**/A. Larocco, Baltimore, MD
- P888** **Survival Analysis of Lung Cancer; A 10-year Real-life Experiences in a Non-university Tertiary Hospital in Thailand**/N. Nakwan, Songkhla, Thailand
- P889** **Lung Disease Prevalence, Risk Factors, and Screening Among the Uninsured of Tampa Bay: A Free Clinic Study**/D. Le, Tampa, FL
- P890** **Impact of Opioid Use on the Outcomes of Patients With Pulmonary Embolism: A Nationwide Observational Study**/K.U. Lio, Philadelphia, PA
- P891** **Delays in Lung Transplantation in Northwest Louisiana**/G. Mudigonda, Shreveport, LA
- P892** **Variability of Tuberculosis Screening Testing Practice in Patients Receiving Biologic Medications in a Low Prevalence Population of Upstate New York**/T. Maeda, Rochester, NY
- P893** **Respiratory Syncytial Virus (RSV) Knowledge, Attitudes, and Perceptions Among Adults With Chronic Pulmonary Conditions in the US**/E. La, Philadelphia, PA
- P894** **An Apple or Onion a Day Keeps the Doctor Away: Association of Dietary Quercetin With Less Acute Respiratory Illness and Chronic Cough (Road to Health Study)**/A. Norweg, New York, NY
- P895** **Development of Resource and Education Materials for Punjabi Speaking Farmworkers in California**/H.K. Gill, Davis, CA
- P896** **Development of the Adhere Questionnaire for Assessing Factors Influencing the Adherence to Prevention of Respiratory Infectious Diseases**/T. Santos, Natal - RN, Brazil
- P897** **Patients Living With Pulmonary Arterial Hypertension (PAH) Provide Essential Insights for Drug Development**/L. Loungani, Cary, NC
- P898** **The PAH Patient Perspective: Factors Influencing Treatment Initiation With Inhaled Prostacyclin Therapy**/K. El-Kersh, Omaha, NE
- P899** **Comparing Breath Actuated and Breath Enhanced Jet Nebulizers for the Delivery of Tobramycin**/M. Nagel, London, Canada

- P900** **Device Comparison and Needs Assessment of Pulse Oximetry Monitoring During Exercise for Patients With Interstitial Lung Diseases**/C. Child, Seattle, WA
- P901** **Real-world Data of Antibiotic Prescriptions for Sore Throat in the United Kingdom (UK) Primary Care Practice**/G. Coutinho, Slough, United Kingdom
- P902** **Guiding Principles for the Conduct of Violence Study of Healthcare Workers and System (VISHWAS)**/R. Kashyap, York, PA
- P903** **Understanding Burnout in Pulmonary, Critical Care and Sleep Medicine: An Initiative by the American Thoracic Society, Assembly on Sleep and Respiratory Neurobiology**/I. Gurubhagavatula, Philadelphia, PA
- P904** **Survey of Diagnostic Journey, Treatment Experience, and Impact on Daily Living of Patients With Alpha-1 Antitrypsin Deficiency**/C. Blair, Lexington, MA
- P905** **Using Photovoice to Inform Lung Cancer Screening Imagery: A Picture Really Is Worth a Thousand Words**/E. Hirsch, Aurora, CO

BEHAVIORAL • CLINICAL

THEMATIC POSTER SESSION

C37 ONGOING IMPACT OF THE COVID-19 PANDEMIC

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P115** **Inclusion of Racial and Ethnic Minority Populations in SARS-CoV-2 Vaccine Clinical Trials**/J. Lenka, Tucson, AZ
- P116** **Vaccination Against Influenza Virus in Health Workers of a Level IV Hospital in the City of Bogotá During the SARS-CoV-2 Pandemic**/A. Espinal Martínez, Bogota, Colombia
- P117** **Factors Decreasing the Uptake to Prevention of COVID-19 and Other Respiratory Infectious Diseases: A Qualitative Evidence Synthesis**/K.M.P. Mendonca, Natal, Brazil
- P118** **Home Health Care or Hospitalization for Adults With Chronic Respiratory Diseases and Post-COVID Syndrome: A Systematic Review**/K.P. Mendonca, Parnamirim, Brazil

- P119** Engaging Hispanic/Latino Community in Asthma and COVID-19 Patient Centered Outcomes and Clinical Effectiveness Research/D.D. Gardner, Vienna, VA
- P120** Incidence, Outcomes, and Trends of SARS-CoV-2 Sepsis Using Electronic Health Record Data/C.N. Shappell, Boston, MA
- P121** Paradoxical Impact of Obstructive Sleep Apnea in Admissions With COVID-19 Infection: A Nationwide Sample Analysis From 2020/Z.J. Gandhi, Wilkes-Barre, PA
- P122** Impact of COVID-19 Infection on In-hospital Cardiac Arrest Outcomes With Concomitant Heart Failure With Preserved Ejection Fraction/Z.J. Gandhi, Wilkes-Barre, PA
- P123** Predictors of Mortality Among Hospitalized Coronavirus Disease (COVID-19) Treatment Centre Patients With Confirmed SARS-CoV-2 Infection in Lesotho: A Retrospective Observational Study/T.D. Lekhela, Maseru, Lesotho
- P124** Clinical Outcome and Prognosis of a Nosocomial Outbreak of COVID-19/Y.S. Sim, Seoul, Korea, Republic of
- P125** The Experience of Patients During Hospitalization for Severe COVID-19: A Qualitative Multi-Center Study/Y. Jung, Portland, OR
- P126** The Omicron Surge Outpaces Previous Surges in Post-COVID Hospitalization Healthcare Usage/J. Leahy, New York, NY
- P127** Dying in COVID 19: A Retrospective Review on Dying COVID 19 Patients in the Intensive Care Unit/P.J. Baez, San Juan, PR
- P128** Health Care Utilization of Patients With Chronic Obstructive Pulmonary Disease Post-discharge From Coronavirus Disease 2019 Hospitalization/D.A. Puebla Neira, Phoenix, AZ
- P129** Disparities in Healthcare Utilization One Year After Hospitalization for Symptomatic COVID-19/B.K. McGarry, Portland, OR
- P130** The Effect of Sickle Cell Disease and Sickle Cell Trait on COVID-19 Infection Outcomes/A. Shah, Brooklyn, NY
- P131** Examining Changes in Depression and Anxiety Symptoms in Adolescents With Cystic Fibrosis Before and After the Height of the COVID-19 Pandemic/A. Wolfe, Aurora, CO
- P132** Sex Differences in Recovery Following COVID-19/G.P. Pappas, Seattle, WA
- P133** Predictors of Chronic Symptoms of Fatigue, Dyspnea and Reduced Activity Level After Recovery From COVID-19/M.A. Ghamloush, Boston, MA
- P134** The Overlap Between Depression and Fatigue 1-year After Prolonged, Severe COVID-19 Respiratory Failure in a National Multicenter Recovery Cohort/P. Pham, San Francisco, CA
- P135** Is Fatigue in a Community-based Long Haul COVID Cohort Myalgic Encephalitis?/K.P. Strohl, Cleveland, OH
- P136** Prevalence of Sleep Disturbances and Insomnia Symptoms in COVID-19 Survivors: A Systematic Review and Meta-Analysis/J.W. Deng, Toronto, Canada
- P137** Healthcare Student Volunteers' Experiences of Interprofessional Collaboration During the Fight Against COVID-19 in Vietnam/K.D. Duong, Ho Chi Minh City, Viet Nam
- P138** In-hospital Mortality Trend Analysis in Korea Before and During the COVID-19 Pandemic; an Observational Study From 2004 to 2022/S.Y. Kim, Seoul, Korea, Republic of
- P139** Evaluating Utilization of Outpatient Pulmonary Services Among Older Adults in the VA System Before and During the COVID-19 Pandemic/M.F. Griffith, Aurora, CO
- P140** Variation in Remote Monitoring Practices Implemented During the COVID-19 Pandemic: A National Qualitative Study/K. Hauschildt, Baltimore, MD
- P141** Rural and Urban Intensive Care Unit Resource Availability and Mortality During the COVID-19 Pandemic in Minnesota/R.W. Starcher, Minneapolis, MN

CLINICAL

THEMATIC POSTER SESSION

C38 CASE REPORTS IN RARE LUNG DISEASE: FIND YOUR ZEBRAS HERE

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area E, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P477** An Atypical Presentation of Adult Pulmonary Langerhans Cell Histiocytosis/S. Tulley, Kankakee, IL
- P478** Welding, Smoking, and COVID, Oh My: A Rare Case of Pulmonary Langerhans Cell Histiocytosis in an Adult/C. Shah, Gainesville, GA
- P479** A Rare Case of Birt Hogg Dube Syndrome/C. Shah, Gainesville, GA
- P480** Pulmonary Langerhans Cell Histiocytosis Presenting With Multiple Cavitory Nodules/J. Rha, Boston, MA
- P481** Cystic Lung Disease, An Enigmatic Diagnosis/D.S. Bustamante-Soliz, Cuenca, Ecuador

- P482 A Rare Cause Of Cystic Lung Disease/M. Baqir, Rochester, MN**
- P483 Severe Cystic Lung Disease In A Young Woman Requiring Lung Transplant/D. Sanborn, Rochester, MN**
- P484 An Unknown Association: Caroli Disease With Bullous Emphysema and Fibrocystic Lung Disease/S. Brahmandam, Louisville, KY**
- P485 Identifying Cystic Lung Disease: A Case Report Describing Lymphangiomyomatosis (LAM)/A.C. Gilmore, BALTIMORE, MD**
- P486 Lymphangiomyomatosis: From a Single Entity to a Spectrum of Disease/M. Salih Makawi, Flushing, NY**
- P487 Case Report of Lymphangiomyomatosis, a Cystic Lung Disease/T. Perez-Gutierrez, Guadalajara, Mexico**
- P488 Lymphangiomyomatosis With Bibasilar Subpleural Honeycombing: Sirolimus Induced Pneumonitis or Beginning of New Interstitial Lung Disease Process?/M. Azhar, Houston, TX**
- P489 Diffuse Pulmonary Nodules In A Patient With History Of Hysterectomy/V.P. Trelles, Gainesville, FL**
- P490 Eosinophilic Pulmonary Capillaritis In A Patient With HUVS/V.P. Trelles, Gainesville, FL**
- P491 Generalized Lymphatic Anomaly: Two Cases With Possible Response to Sirolimus/L.V. Luna Diaz, Stanford, CA**
- P492 Hermansky-pudlak Syndrome: Identification Of High-resolution Contrast Tomography Findings Of The Puerto Rican Founder Mutation/R. Mena-Ventura, Bayamon, PR**
- P493 Birt-Hogg-Dube Syndrome Presenting With Renal Tumor and Diffuse Lung Bullae/E. Arias Torres, Oakland, CA**
- P494 Parn-variant Familial Interstitial Pneumonia and ANCA-associated Vasculitis: A Challenging Case of ILD/C.A. Macko, Oakland, CA**
- P495 Premature Aging and Interstitial Lung Disease/G.M. Gonzalez Santiago, San Juan, PR**
- P496 Family Matters: Premature Greying In Interstitial Lung Disease/A. Hu, Rochester, MN**
- P497 Unique Variant of Epidermolysis Bullosa Affecting Lungs/A. AL Ani, Galveston, TX**
- P498 A Rare Case of Granulomatous Lymphocytic Interstitial Lung Disease in a Patient With Well-Controlled Human Immunodeficiency Virus/T. Selvam, Oakland, CA**
- P499 Not All Granulomatous ILDs Are Sarcoidosis - Granulomatous Lymphocytic-Interstitial Lung Disease (GL-ILD) In A Patient With Common Variable Immunodeficiency (CVID): Case Report/R.S. Cheema, Philadelphia, PA**
- P500 Granulomatous Lymphocytic Interstitial Lung Disease-A Diagnostic Dilemma/S. Sheenam, Boston, United Kingdom**
- P501 Granulomatous and Lymphocytic Interstitial Lung Disease: An Easily Missed Diagnosis/M. Barraza, Columbus, OH**
- P502 Safety First: Use Of A Mechanical Support Device In Whole Lung Lavage/J. Walder, Houston, TX**
- P503 Risk Of Autoimmune PAP Caused By Passive Transfer Of GM-CSF Autoantibodies During Breast Feeding: A Case Report/M. Roach, Cincinnati, OH**
- P504 An Unusual Case of a Rare Disease: Pulmonary Alveolar Proteinosis Secondary to Chronic Myeloid Leukemia and Acute Lymphocytic Leukemia/S. Schacht, Indianapolis, IN**
- P505 Pulmonary Alveolar Proteinosis Secondary to Sarcoidosis/S.I. King, Aurora, CO**
- P506 Pulmonary Alveolar Proteinosis In The Setting Of Covid-19: A Rare Presentation/P. Modi, Philadelphia, PA**
- P507 A Challenging Case Of Refractory Pulmonary Alveolar Proteinosis/C. Quiles-Cruz, San Juan, PR**
- P508 Pulmonary Alveolar Proteinosis - A Case Series/J. Allen, Dublin, Ireland**
- P509 Lung Transplant For Pulmonary Alveolar Proteinosis; A Report Of Two Cases/M. Zulty, Philadelphia, PA**
- P510 Protein in the Alveoli Leads to Mold in the Lung/S. Kumar, Tucson, AZ**
- P511 Pulmonary Alveolar Proteinosis Complicated by Pseudomonas Pneumonia After Allogeneic Stem Cell Transplantation/L.C. Beltran, Berwyn, IL**
- P512 Persistent Eosinophilia Due to Subcutaneous GM-CSF Therapy in a PAP/M. Khasawneh, Gainesville, FL**
- P513 CT Findings in Progressive Pulmonary Alveolar Proteinosis: A Case Report/J. Maurer, Flushing, NY**
- P514 Delayed-Onset Idiopathic Pneumonia Syndrome Post Hematopoietic Stem Cell Transplantation/K. Gharaibeh, Baltimore, MD**
- P515 Pulmonary Light Chain (AL) Amyloidosis in a Patient With Waldenstrom's Macroglobulinemia/V. Anekonda, Burlington, VT**
- P516 A Case of Severe Obstructive Ventilatory Impairment Due to Alveolar Septal Amyloidosis/O. Tahir, Jacksonville, FL**
- P517 Metastatic Pulmonary Calcification In A Renal Transplant Recipient: Long-term Radiographic Stability And Findings Of ¹⁸F-sodium Fluoride Positron Emission Tomography / Computed Tomography/T. Maeda, Rochester, NY**

- P518 Metastatic Pulmonary Calcification: An Exceptional Complication Associated With End-stage Renal Disease Mimicking Transbronchial Infection/N.** Jirawat, Pathum Wan, Bangkok, Thailand
- P519 Pneumothorax As An Unexpected Presentation Of Silicosis/C.** Tom, Los Angeles, CA
- P520 Are You Dyspneic or Is It Diffuse Idiopathic Pulmonary Neuroendocrine Hyperplasia (DIPNECH)?/J.** Hitchings, Philadelphia, PA
- P521 Tracheobronchopathia Osteochondroplastica: A Case of an Unexpected Encounter in the Airways/J.E.** Miller, Roanoke, VA
- P522 Tracheobronchial Amyloidosis in a Patient With More Than 16 Years of Follow-up/P.M.** Cavalcante Neto, Sao Paulo, Brazil
- P523 Hemophagocytic Lymphohistiocytosis Secondary to Sarcoidosis/V.** Hegde, Kansas City, KS
- P530 Patient and Physician Assessments of Clinical Status: A Mixed Methods Study of Interstitial Lung Disease/A.** Grant-Orser, Calgary, Canada
- P531 Bronchoalveolar Lavage Fluid and Radiographic Patterns in Patients With Fibrotic Interstitial Lung Disease/A.** Grant-Orser, Calgary, Canada
- P532 Whether Subspecialty Clinic Improves Screening for Causes of Interstitial Lung Disease/S.F.** Enam, Basildon, United Kingdom
- P533 Implementation of an Interstitial Lung Abnormality Clinic and Multidisciplinary Discussion/K.C.** Selvan, Chicago, IL
- P534 Exposure History and Autoimmune Serologic Profiles of Patients With Interstitial Lung Abnormalities/K.C.** Selvan, Chicago, IL
- P535 Prevalence of Environmental Antigens and Immunoglobulin Seropositivity in Fibrotic Hypersensitivity Pneumonitis/C.** Christian, Chicago, IL
- P536 Reporting of Exposures by Patients With Interstitial Lung Disease During an Unstructured Clinician Interview or on a Questionnaire/L.** Yun, Nashville, TN
- P537 Differences in Baseline Characteristics and Diagnostic Confidence Over Time Between Interstitial Lung Disease Subtypes in a Pulmonary Fibrosis Foundation Registry Cohort/D.** Zhu, Charlottesville, VA
- P538 Machine Learning Algorithm to Improve Cohort Identification in Interstitial Lung Disease/E.D.** Farrand, San Francisco, CA
- P539 Differences in Exertional Oxygen Needs in Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD): Use of a Ramped Protocol Treadmill Exercise Test/K.** Clark, Pittsburgh, PA
- P540 Recovery Rate From Exertional Desaturation Is Associated With Disease Severity in Patients With Fibrotic Interstitial Lung Disease/A.** Tyker, Hamilton, ON
- P541 Characteristics of Arterial Blood Gas in Patients With Fibrotic Interstitial Lung Disease/M.** Donaldson, Vancouver, Canada
- P542 Introduction of Home Spirometry in Tracking Disease Progression in Patients With IPF: Baseline Data From the Prospective Treatment Efficacy in IPF Using Genotype for NAC Selection (PRECISIONS) Clinical Trial/A.** Podolanczuk, New York, NY
- P543 Home Spirometry Monitoring in Patients With Interstitial Lung Disease/W.L.** Ng, Dublin, Ireland
- P544 Implementation and Performance of a Standardized 6-minute Walk Test in Idiopathic Pulmonary Fibrosis: Results From the Isabela Studies/S.D.** Nathan, Falls Church, VA

CLINICAL

THEMATIC POSTER SESSION

C39 CARE AND EVALUATION OF PATIENTS WITH INTERSTITIAL LUNG DISEASE

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**
Area E, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P525 Usability of a Smartphone Application for Patients With Interstitial Lung Disease (ILD): Early Results From the Registry for Better Understanding of ILD (RE-BUILD) Pilot Study/L.M.** Glenn, Camperdown NSW, Australia
- P526 Development of Duke Empower: A Platform to Engage, Inform, Probe, Promote Wellness, and Foster Community Among Patients With Rare Diseases/A.C.** Swaminathan, Durham, NC
- P527 Perceptions of Pulmonary Fibrosis Foundation Care Center Network Providers Caring for Rural Patients With Interstitial Lung Disease/A.M.** Dedent, San Francisco, CA
- P528 Preferences and Attitudes Regarding a Peer Support Intervention for Individuals With Chronic Hypersensitivity Pneumonitis: A Survey of Clinicians/N.M.** Holbrook, New York, NY
- P529 Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: A Quality Improvement Initiative/R.A.** Patel, Orange, CA

- P545** **Oscillometry and Spirometry in Fibrotic Versus Non-fibrotic Interstitial Lung Disease/F.** Gabrysz-Forget, Montreal, Canada
- P546** **Utility of Using Ultrasound and Spirometry in Predicting Transdiaphragmatic Pressure (Pdi) in Patients With Moderate to Severe IIP/K.R.** Thapa, Kathmandu, Nepal
- P547** **FVC/DLCO Ratio in Patients With Fibrotic HP Versus IPF/T.S.** Vongvivitpatana, San Antonio, TX
- P548** **Bilateral Bronchoalveolar Lavage in the Workup of Interstitial Lung Disease/G.** George, Philadelphia, PA
- P549** **Usefulness of Performing Two Bronchoalveolar Lavages in Patients With Interstitial Lung Diseases/S.A.M.** Alqahtani, Kingston, Canada
- P550** **Identifying Problems in the Morphological Evaluation of Bronchoalveolar Lavage/Y.** Waseda, Eiheiji, Japan
- P551** **Increased Bronchoalveolar Lavage (BAL) Chitin Levels in Patients With Idiopathic Pulmonary Fibrosis (IPF) Are Associated With Decreased Diffusion Capacity/F.** Mclafferty, San Francisco, CA
- P552** **The Impact of Diagnostic Guidelines on Clinician Diagnosis of Hypersensitivity Pneumonitis/J.** Gu, Durham, NC
- P553** **Computed Tomography Features Influencing Guideline-defined Radiologic Patterns In Interstitial Lung Disease/D.** Marinescu, Vancouver, Canada
- P554** **Radiologic Patterns and Leading Clinical Diagnoses in Unclassifiable Interstitial Lung Disease/L.** Minuk, Toronto, Canada
- P555** **The Impact of Genomic Classifier in Patients With Undiagnosed Interstitial Lung Disease/D.E.** Espinoza Barrera, New Orleans, LA
- P556** **Predicting Interstitial Pulmonary Fibrosis Using a Machine Learning Classifier in Cases Without Definite or Probable Usual Interstitial Pneumonia Pattern on Computed Tomography/Y.** Ahmad, Cincinnati, OH
- P557** **A Machine Learning System to Predict Diagnosis of Idiopathic Pulmonary Fibrosis Non-Invasively in Challenging Cases/Y.** Ahmad, Cincinnati, OH
- P558** **Association Between Histological Classification and Prognosis Using AI Classification for Lung Pathology of Diffuse Parenchymal Lung Disease/T.** Niwa, Yokohama, Japan
- P559** **Gene Signature of Acute Interstitial Pneumonia/H.J.** Yeo, Yangsan, Korea, Republic of
- P560** **Rural Versus Urban Disparities in Access to Care and Treatment of Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Patient Registry/R.** Boente, Indianapolis, IN

- P561** **Clinical Characteristics and Survival According to the Presence of Velcro Crackles in the European Multipartner IPF Registry (EMPIRE)/D.** Lang, Linz, Austria

CLINICAL

THEMATIC POSTER SESSION

C40 CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area B, Hall C (Lower Level)

- Viewing:** Posters will be on display for entire session **11:30-1:15**
- Discussion:** **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.
- P166** **Treatment With Ensifentrine, a Dual PDE3 and PDE4 Inhibitor, Significantly Reduced Exacerbation Rate and Risk in Subjects With COPD: Sub-group Results From the Phase 3 Trial, Enhance-2/A.** Anzueto, San Antonio, TX
- P167** **Ensifentrine, a Dual Inhibitor of PDE3 and PDE4, Reduces the Risk of Exacerbation Regardless of Background Medication Use: A Sub-group Analysis of ENHANCE-2, a Phase 3 Trial/G.T.** Ferguson, Fountain, MI
- P168** **Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, in Moderate and Severe COPD: Symptoms, Quality of Life and Health Status From the Phase 3 Trial Enhance-2/T.** Rheault, Cary, NC
- P169** **Oral Treatment With Quercetin Reduces Markers of Inflammation in COPD Patients/S.** Patel, Philadelphia, PA
- P170** **Safety, Efficacy, and Portrait of SARS-CoV-2 Vaccination in Chronic Obstructive Pulmonary Disease (COPD) Patients: A Cohort Study/É.** Pelletier, Québec, Canada
- P171** **Safety Results From Dual PDE3/4 Inhibitor Ensifentrine: Gastrointestinal and Cardiovascular Safety From a 24-week Phase 3 Trial, Enhance-2/T.M.** Siler, Saint Charles, MO
- P172** **Twice-daily, Nebulized Ensifentrine Significantly Improves Lung Function: Sub-group Analysis in the Phase 3 Trial ENHANCE-1/T.M.** Siler, Saint Charles, MO
- P173** **Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in Patients With COPD: Results From Replicate Phase 3 Trials/F.C.** Scirba, Pittsburgh, PA

- P174** **Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in the Enhance-1 Phase 3 Trial of Ensifentrine in COPD/F.C.** Scirba, Pittsburgh, PA
- P175** **Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Improves COPD Symptoms and Quality of Life in the Phase 3 Enhance-1 Trial/F.C.** Scirba, Pittsburgh, PA
- P176** **Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Reduces Annualized Exacerbations and Delays the Time to First Exacerbation in COPD: Pooled Sub-Group Analyses of Enhance-1 and Enhance-2 Phase 3 Trials/I.** Barjaktarevic, Los Angeles, CA

CLINICAL

THEMATIC POSTER SESSION

C41 A “PLEUR”ALITY OF ISSUES: CASE REPORTS IN PLEURAL DISEASE DIAGNOSTICS AND MANAGEMENT

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area L, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1201** **Chest Tube Placement Into a Giant Bulla/S.** Kim, Saint Louis, MO
- P1202** **A Young HIV Positive Male Smoker Presenting With Giant Bullous Emphysema Complicated By Secondary Spontaneous Pneumothorax/R.** Khan, Philadelphia, PA
- P1203** **Spontaneous Pneumomediastinum In A Young Man/A.** Mukherjee, New Brunswick, NJ
- P1204** **Bilateral Tension Pneumothorax In A Woman Causing Cardiac Arrest/A.** Mukherjee, New Brunswick, NJ
- P1205** **Poland Syndrome and Pneumothorax/P.** Nguyen, Atlanta, GA
- P1206** **Pneumomediastinum, Pneumopericardium and Bilateral Pneumothorax: A Rare Complication of Seizure/S.** Shireen Kanamgode, Worcester, MA
- P1207** **Hidden Agenda: A Case of Osteomyelitis Disguised as Pneumothorax Ex Vacuo/J.E.** Fesen, New Orleans, LA
- P1208** **An Unintentional Connection: Pneumothorax and Alveolopleural Fistula as an Uncommon Complication of Intrapleural TPA/DNase Administration for Empyema in the Setting of Necrotizing Pneumonia/M.C.** Manjunath, Brighton, MA
- P1209** **Lemierre’s Syndrome Complicated By Tension Hemothorax In The Setting Of The Concomitant Use Of Intrapleural Fibrinolytics And Systemic Anticoagulation/L.** Benes, New York, NY
- P1210** **Talc-Induced Acute Renal Failure After Talc Pleurodesis/G.** Collins, New Orleans, LA
- P1211** **Tunnel Vision: A Novel Approach to Use Cryotherapy Through a Flexible Bronchoscope to Restore the Patency of a Chest Tube Occluded by a Blood Clot/F.** Figueroa Rodriguez, Oklahoma City, OK
- P1212** **Candida Empyema In A Patient With Adenocarcinoma Of Gastroesophageal Junction/K.** Kaur, Johnson city, TN
- P1213** **A Rare Case of Empyema Associated With Pancreatic Pseudocyst-induced Esophagopleural Fistula/J.** Mak, Galveston, TX
- P1214** **Rare Case of Complicated Parapneumonic Effusion Secondary to Perihepatic Abscess/S.** Lashani, Rancho Mirage, CA
- P1215** **Spontaneous Bacterial Empyema (SPEM) With Concurrent Spontaneous Bacterial Peritonitis (SBP) In Liver Cirrhosis/M.U.Z.** Mirza, Lahore, Pakistan
- P1216** **Not Your Typical Chest Pain: A Case of Complicated Costosternal Septic Arthritis With Extensive Chest Wall And Mediastinum Extension/C.J.** Merino Gualan, Norwalk, CT
- P1217** **Xanthogranulomatous Pyelonephritis Leading to Empyema: A Renal Cell Carcinoma Mimic/J.** Renz, Pueblo, CO
- P1218** **A Case of Bronchopleural Fistula Formation Following Acute Pulmonary Embolism and Empyema/J.** Emberson, Wichita, KS
- P1219** **Loculated Parapneumonic Effusion: Diagnosis Per Point-of-Care Ultrasound/C.** Howdeshell, Spokane, WA
- P1220** **Rare Necessities: Two Cases Of Successful Nonoperatively Managed Empyema Necessitans/R.** Auth, Providence, RI
- P1221** **Tuberculous Empyema: Combined Intrapleural Therapy Might Be an Alternative/P.** Colares, Sao Paulo, Brazil
- P1222** **The Cryptic Case of a Pleural Effusion: Cryptococcosis as an Isolated Empyema/S.** George, Cleveland, OH
- P1223** **Aspergillus a Rare Cause of Empyema/T.** Roy, Stratford, NJ

CLINICAL

THEMATIC POSTER SESSION

C42 ZEBRAS AND PEANUTS: FOREIGN BODIES AND RARE CASES FROM IP AND PLEURAL DISEASE

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area L, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1225 This Cough Is Driving Me Nuts! An Unexpected Case of Foreign Body Aspiration Presenting as Recurrent Pneumonia/D. Booth, San Diego, CA**
- P1226 Unexpected Cause of Chronic Cough in the Otherwise Healthy Adult: Foreign Body Aspiration/M. Hanalla, Pontiac, MI**
- P1227 A Hard Pill to Swallow/J. Moore, Norwalk, CT**
- P1228 It's a Tough Pill to Swallow: A Case of Pill Aspiration/N. Philips, Phoenix, AZ**
- P1229 A Slippery Slope of Lipid Ingestion: A Case Report/C. Suh, La Jolla, CA**
- P1230 A Very Bad Esophagus: Leaving Me Breathless/G.M. Gonzalez Santiago, San Juan, PR**
- P1231 Foreign Body Aspiration Presenting With Tree-in-bud Pattern On Chest Ct Without Associated Lobar Atelectasis/H.A. Nayef, Detroit, MI**
- P1232 'Innumerable' Blast Cells In The Bronchoalveolar Lavage (pulmonary Leukostasis): A Case Report/L. Raymond, Sherbrooke, Canada**
- P1233 Pulmonary Nocardiosis in a Late-Onset SIgMD/H. Alrahamneh, las cruces, NM**
- P1234 Posttraumatic Thoracic Splenosis in a 77-year-old Patient After a Motor Vehicle Accident/S. Maddamma, Youngstown, OH**
- P1235 Aspiration of a Tweezer as a Foreign Body/M.H. Sarwar, Lubbock, TX**
- P1236 Foreign Body Aspiration Or Endobronchial Lesion? Only Bronchoscopy Will Tell/I. Laniado, New York, NY**
- P1237 "Narrowing Down" A Rare Case of Chronic Cough/A. Asharaf, Gainesville, FL**
- P1238 Is There a Baby in the Lung? A Case Report of Placental Transmogrification/J.G. Matta, Springfield, MA**
- P1239 A Rare Case of Follicular Bronchiolitis Secondary to Follicular Lymphoma/Y. Huang, Chicago, IL**
- P1240 A Rare Presentation: Acute Hypoxemic Respiratory Failure In Polycythemia Vera Evolving Into Acute Myeloid Leukemia/Z.M. Htet, Bronx, NY**
- P1241 An Incidental Case Of Benign Pulmonary Schwannoma Masquerading As FDG-Avid Mediastinal Lymphadenopathy In A Patient With Recent Covid-19 Pneumonia/S. Lee, La Jolla, CA**
- P1242 Nodular AL Amyloidosis - An Unusual Etiology Of A Solitary Pulmonary Nodule/B.B. Claxton, Philadelphia, PA**
- P1243 A Case Report Of Broncholithiasis/M.I. Khan, Lexington, KY**
- P1244 Cryptococcus Neoformans Infection as a Cause for Central Airway Obstruction in a Patient With Saber Sheath Trachea/M.I. Islam, Charlottesville, VA**
- P1245 Computerized Tomography-guided Transthoracic Biopsy - A Series Of Rare Benign Diagnosis/M.J. Cavaco, Torres Vedras, Portugal**
- P1246 Asymptomatic Thoracic Endometriosis: It Exists/Z.J. Gandhi, Wilkes-Barre, PA**
- P1247 Nodular Pulmonary Amyloidosis Diagnosed and Treated With Combined Robotic Assisted Thoracic Surgery/B. Gupta, Washington, DC**
- P1248 Minute Pulmonary Meningothelial-like Nodules as an Incidental Finding in Lung Biopsy: Case Report/P. Colares, Sao Paulo, Brazil**
- P1249 Electromagnetic Navigation Bronchoscopy Diagnosis of Neuroendocrine Tumor of the Lung/O. Idubor, Lawrenceville, GA**
- P1250 Pleuropericardial Effusions From Nontraumatic Breast Implant Rupture/L. Jain, San Bernardino, CA**
- P1251 A Rare Case of Primary Pulmonary Malignant Myoepithelioma of Soft Tissue/H. Rajevac, Burlington, MA**
- P1252 Septic Shock and Recurrent Sepsis From Purulent Pericarditis Due to Gastropericardial Fistula/Z. Babwani, Hialeah, FL**
- P1253 Patient With A Pleural Lipoma And Cough/M. Andreas, Newark, NJ**
- P1254 Castleman Disease Masquerading as Pleural Effusion and Polyserositis/R. Khullar, New Delhi, India**
- P1255 Shortness of Breath: A Hormonal Phenomena/D.H. West, Greenville, NC**

CLINICAL

THEMATIC POSTER SESSION

C43 THERAPEUTIC MISADVENTURES: PROCEDURAL COMPLICATIONS ENCOUNTERED IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area L, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1257 Cystic Lung Disease Secondary To Chronic Occult Aspiration In A Patient With Multiple Bariatric Surgeries/A.A. Chacko, Weslaco, TX**
- P1258 Esophageal Perforation Following Chest Tube Insertion: Uncommon Complication Of A Common Procedure/S. Dhungel, Chicago, IL**
- P1259 Bizarre Presence of Inferior Vena Cava Filter Fragmentation: What's the Next Move?/D. Golden, Kailua, HI**
- P1260 Uvular Necrosis: A Rare Complication After Fiberoptic Bronchoscopy via a Laryngeal Mask Airway/A. Chang, Bridgeport, CT**
- P1261 An Unexpected Complication of Navigational Bronchoscopy/H.K. Boppana, Rochester, NY**
- P1262 Spontaneous Tracheo-Innominate Artery Fistula/K. Kaur, Atlanta, GA**
- P1263 Tracheal Stent Complicated By Multiple Tracheoesophageal Fistulas/A. Shahid, St. Louis, MO**
- P1264 Bedside Percutaneous Dilatational Tracheostomy Associated Hemorrhage - A Cautionary Tale/J. Mohammad, Fairhope, AL**
- P1265 Size Matters: Complications of Long-Term Tracheostomy and the Importance of a Multidisciplinary Care Approach to Closely Monitor Customized Tracheostomy Tubes in a Patient With Amyotrophic Lateral Sclerosis/E. Tjong, Tucson, AZ**
- P1266 Breathing in All the Wrong Places/I.C. Ugalde, Tampa, FL**
- P1267 Fatal Oglivie's Syndrome Following Endobronchial Valve Placement/K.J. Admire, Roanoke, VA**
- P1268 Pneumothorax After Ventriculo-peritoneal Shunt Placement/M. Neinast, Springfield, IL**
- P1269 Bilateral Pneumothorax Following Computer-Tomography Guided Transthoracic Biopsy in Suspected Pulmonary Cancer/E.S.H. Hansen, Hvidovre, Denmark**

- P1270 Bilateral Spontaneous Pneumothoraces After Large Volume Paracentesis for Malignant Ascites/V.T. Gonuguntla, Elmhurst, NY**
- P1271 Intrapleural Instillation Causing a Cerebral Gas Embolism: A Rare But Increasingly Recognized Complication/Z. Rich, Iowa City, IA**
- P1272 A Case of Necrotizing Soft Tissue Infection of the Chest Wall/A. Asharaf, Gainesville, FL**
- P1273 Bronchocutaneous Fistula Without Pneumothorax: A Rare Complication Of Tube Thoracostomy/A.D. Patel, Little Rock, AR**
- P1274 Not So Pure Or Cute - A Case Of Pleurocutaneous Fistula Post-thoracostomy/C. Lafleur, New Orleans, LA**
- P1275 A Pleuro-peritoneal Abscess From Bariatric Surgery Gone Wrong/P. Bhide, Long Branch, NJ**
- P1276 Coronary Artery Bypass Graft Surgery, A Cause Of Recurrent Pleural Effusions?- A Clinical Dilemma/P. Bhide, Long Branch, NJ**
- P1277 Chylous Ascites and Chylothorax Presenting as a Delayed Complication of Liver Transplant/S. Sarkar, Morgantown, WV**
- P1278 A Case Of Recurrent Pleural Effusion From Cerebrospinal Fluid In A Patient With A Properly Placed Ventriculoperitoneal Shunt/L.P. Waldman, Worcester, MA**
- P1279 An Elusive Case of Buffalo Chest: Bilateral Chylothorax in the Setting of Central Venous Catheter Placement/K. Gupta, Brooklyn, NY**
- P1280 A Case of Symptomatic Moderate Pleural Effusion Secondary to Ventriculopleural Shunt/S.A. Elhag, Abudhabi, United Arab Emirates**
- P1281 Contralateral Reexpansion Pulmonary Edema After Thoracentesis/J.B. Patel, Rochester, NY**

CLINICAL

THEMATIC POSTER SESSION

C44 NOVEL TECHNIQUES AND PROCEDURAL INNOVATIONS IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area L, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1283 Necessity Is The Mother Of Innovation/M. Antic, Southfield, MI**

- P1284** Use of 1.1mm Cryoprobe for Transbronchial Biopsies in Patient With Lung Transplant/M. Ngo, Phoenix, AZ
- P1285** Tracheal And Bronchial Airway Stenting For Respiratory Failure Due To Post Thoracic Endovascular Repair Aortic Rupture/D.K. Mathew, Tampa, FL
- P1286** Rigid Bronchoscopy-guided Percutaneous Tracheostomy/S. Akbar, London, United Kingdom
- P1287** Multimodal Tissue Sampling: EBUS/EUS-B Combined With Cone Beam Computed Tomography and Augmented Fluoroscopy/D.E. Espinoza Barrera, New Orleans, LA
- P1288** When Cytology Leads You Astray: The Utility of P.O.C.U.S. in Diagnosing Malignant Pleural Effusions/A. Mahendra, Roanoke, VA
- P1289** A Successful Case of High Risk Medical Thoracoscopy, Partial Decortication, and Pleural Biopsy/S. Sultan, Philadelphia, PA
- P1290** Identification and Embolization of a Pulmonary Artery Pseudoaneurysm Following a Gunshot Wound/K. Foley, New Orleans, LA
- P1291** Endobronchial Tissue Plasminogen Activator Lavage in Airway Obstruction Secondary to Clot Burden/B. Schutte, Omaha, NE
- P1292** Foreign Body Removal Using Robotic Assisted Bronchoscopy/A. Al Tkrit, Toledo, OH
- P1293** An Irony Behind the Bronchus: A Case Report©. Suh, La Jolla, CA
- P1294** How I Net The Bronchus: The Carcinoid Tumors Of The Airway, A Case Report/C. Suh, La Jolla, CA
- P1295** Disposable Flexible Bronchoscopic Removal Of Tracheobronchial Tree Cast/U. Hochfeld, Hackensack, NJ
- P1296** Rocks Causing Asphyxiation: Evacuated With A Flexible Disposable Bronchoscope/U. Hochfeld, Hackensack, NJ
- P1297** Better Together: A Case of Extracorporeal Membrane Oxygenation Utilization for Placement of Endobronchial Valves to Treat Persistent Air Leak/F. Yazdi, Shreveport, LA
- P1298** Post Covid-19 Ards Persistent Air Leak Treated With Endobronchial Valve Placement/H.A. Nayef, Detroit, MI
- P1299** Shutting Off The Leak: Use Of Endobronchial Valves For Postoperative Persistent Air Leak/A. Clarke Kregor, Oak Lawn, IL
- P1300** A Return to 1992: Using the “Blow-Hole” Technique for Diffuse Emphysema and Pneumomediastinum/S. Murali, Syracuse, NY

- P1301** The Diagnostic Yield of Protected Specimen Brush Samples Versus Bronchoalveolar Lavage in Patients Undergoing Diagnostic Bronchoscopy - A Retrospective Analysis/A. Go, Saint Louis, MO

CLINICAL

THEMATIC POSTER SESSION

C45 COVID AND ITS CONSEQUENCES: PART II

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P178** Patients With Acute Hypoxemic Respiratory Failure Due to COVID-19 Have Lower Plasma Levels of Soluble ST2 Compared to Non-COVID Patients Suggesting Distinct Pathobiology of Lung Injury/B. Ulrich, Boston, MA
- P179** Effect of the Changes in Extravascular Lung Water Index and Pulmonary Vascular Permeability Index Onpost Viral Phase COVID-19 Acute Respiratory Distress Syndrome Patient Outcome/P. Deb, Shillong, India
- P180** Characteristics of Patients With Acute Respiratory Distress Syndrome (ARDS) Secondary to COVID-19 With Clinical PaO2 Response to Prone Positioning/L. Piccolo Serafim, Washington, DC
- P181** Relationship of Alcohol Misuse and Outcomes in Acute Respiratory Failure: Impact of COVID-19/P.J. Offner, Aurora, CO
- P182** Oxygenation Index, Adjusted Oxygenation Index and Saturation Index in Coronavirus Disease 2019 (COVID-19) Patients/C.M. Ramirez, Houston, TX
- P183** Change in Code Status Preference of Patients Admitted With COVID-19 Throughout the Pandemic at an Academic Medical Center: A Retrospective Cohort Study/B. Lenhan, Salt Lake City, UT
- P184** Airway Pressure Release Ventilation Versus Volume Assist Control in Severe COVID-19 Infections/C. Shah, Gainesville, GA
- P185** Cell-Free DNA to Identify Sources of Tissue Injury in COVID-19 Associated Complications/M.E. Richert, Bethesda, MD
- P186** Association Between Serum Nitric Oxide Consumption and Disease Severity in Patients With Coronavirus Disease 2019/T. Maeda, Rochester, NY

- P187 Analysis of Memory T-cell Subsets and Their Mitochondrial Status to SARS-CoV2 Spike Peptide Activation in COVID-19 Patient PBMC Samples/S.** Alagesan, Galway, Ireland
- P188 Quantitative Pulmonary Perfusion in Patients With COVID-19 by Using Dynamic Contrast Enhanced MRI at 0.55T/A.E.** Campbell-Washburn, Bethesda, MD
- P189 Effectiveness of Awake Self-Prone in Improving Oxygen Saturation in Patients With Acute Hypoxic Respiratory Failure Related to COVID-19 Pneumonia/G.J.** Hernandez Romero, Bronx, NY
- P190 The Kinetics of Blood-soluble Mediators in Hospitalized COVID-19 Patients Infected With the Omicron Variant Compared to the Alpha Variant/L.** Appleton, Chapel Hill, NC
- P191 ICU-19 Score as a Simplified Predictive Scoring Model for Intensive Care Unit Admissions in Patients With COVID-19/A.** Atasi, Southfield, MI
- P192 Differences in Health Care Outcomes Among Patients Diagnosed With COVID-19 Infection in 2020 Between Teaching and Non-teaching Hospitals- Nationwide Cohort Study/M.** Nguyen, Las Vegas, NV
- P193 Drivers of Mortality in COVID ARDS Depend on Patient Sub-type/N.** Hajizadeh, Madrid, Spain
- P194 Hyperglycemia on Admission Is Associated With Worse Outcomes and Severity of Illness in Critically Ill COVID-19 Patients/J.S.** Gonzalez-Lopez, San Luis Potosi, Mexico
- P195 Patients On and Off Metformin and Implications on Survival in Patients With COVID-19 Admitted to Mather Hospital/C.** Gearges, Port Jefferson, NY
- P196 Echocardiogram Characteristics and Outcome in Patients With COVID 19 Infection Admitted to ICU/C.** Gearges, Port Jefferson, NY
- P197 Impact of Antimicrobial Use at the Start of Mechanical Ventilation on Ventilator-associated Lower Respiratory Tract Infections in Patients With Acute Respiratory Distress Syndrome Related to Coronavirus Disease 2019/J.** Ishii, Hiroshima, Japan
- P198 Validation of the Modified ROX Index Incorporating Heart Rate in COVID 19 Patients on High Flow Nasal Cannula/R.** Rojo, Manila, Philippines
- P199 Effect on Glycemic Control in COVID-19 Patients in Multiple Community Hospital Intensive Care Units/S.** Choudhury, Corpus Christi, TX
- P200 Bacterial Pneumonia in COVID-19: Do We Have a Diagnostic Tool?/A.** Saha, Worcester, MA
- P201 Did the Omicron Variant Bring a New Wave of Pneumothorax and Pneumomediastinum in COVID-19?/F.** Aldaghlawi, Cleveland, OH
- P202 Is Elevated HbA1c Directly Proportional to COVID-19 Mortality?/F.** Badar, Port Jefferson, NY
- P203 Obesity: Risk Factor for High Morbidity and Mortality in COVID-19: A Single Institute Analysis/F.** Badar, Port Jefferson, NY
- P204 ACEI, ARB and Diuretic Usage: Implications on Survival in Patients With COVID-19 Admitted to Mather Hospital/F.** Badar, Port Jefferson, NY
- P205 High Flow Nasal Cannula in Hypoxemic Patients With COVID-19 in Philippine Heart Center: A Cross-sectional Study/K.** Sy, Quezon, Philippines
- P206 Transaminases and Their Association With Disease Severity and Mortality in Patients With Corona Virus Disease 2019 (COVID-19) in a Tertiary Hospital in the Philippines/J.R.** Camaquin, Batac City, Philippines
- P207 Undiagnosed Obstructive Sleep Apnoea as a Risk Factor for Requiring Critical Care Admission Due to COVID-19/S.J.** Patel, Warrington, United Kingdom
- P208 COVID-19-Related Hospitalization and Severe Outcomes Among Native Hawaiians and Pacific Islanders/C.** Nicholas, Honolulu, HI
- P209 Clinical Features of Pneumothorax, Pneumomediastinum, and Subcutaneous Emphysema in Hospitalized COVID-19 Patients/J.E.** Sinclair De Frias, Jacksonville, FL
- P210 Mechanical Power Components in COVID-19-induced Acute Respiratory Distress Syndrome/E.R.** Enric, Barcelona, Spain
- P211 Maternal and Fetal Outcomes in Pregnant Women With Severe SARS-CoV-2 Infection/J.M.** Habibullah, New Hyde Park, NY
- P212 Clinical Outcomes of New Onset Hyperglycemia in Non-diabetic Patients With COVID-19 Infection/H.** Shanmugavel Geetha, Worcester, MA
- P213 Fungemia as Cause of Death in Patients With COVID-19 Pneumonia Hospitalized in the Intensive Care Unit/A.L.** Chai, Los Angeles, CA
- P214 Comparative Study of Clinical Outcomes of Severe and Critical COVID 19 Patients Who Underwent and Did Not Undergo Hemoperfusion Admitted in a Referral Hospital/M.W.** Tibubos, Quezon City, Philippines

CLINICAL

THEMATIC POSTER SESSION

C46 STUDIES IN CARDIAC ARREST, ICU PHARMACY, AND ALCOHOL WITHDRAWAL9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area A, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1 Internal Targeted Hypothermia Versus Normothermia After Cardiac Arrest: Systematic Review and Meta-analysis, an Update/Y.B. Moreno, Fort Lauderdale, FL**
- P2 Outcomes of Outside In-hospital Cardiac Arrest Adult Patients After Post-resuscitation ECMO at a Referral Center/J. Buchner, Falls Church, VA**
- P3 Cardiac Output and Improved Patient Outcomes/J. Sahatjian, Deerfield, IL**
- P4 Novel Approach to Cardiac Arrest Prevention/A. Korus, New Haven, CT**
- P5 The Use of Ibutilide for Cardioversion of Atrial Fibrillation in Medical and Surgical Intensive Care Patients/A.T. Phan, Colton, CA**
- P6 Administration of Blood Products During In-hospital Cardiac Arrest Is Not Associated With Improved Survival/A.A. Gupta, San Diego, CA**
- P7 Cardiac Arrest Outcomes With or Without COVID-19 Infection in a Population of Veterans /K. Phillips, San Antonio, TX**
- P8 Epidemiology, Risk Factors and Outcomes Associated With In-hospital Reflex-mediated Cardiac Arrest/T. Pham, San Diego, CA**
- P9 Prognostication After Cardiac Arrest: Why Aren't We Using the Tools We Already Have?/M. Jenkins, Kingston, Canada**
- P10 Prediction of Drug Capturing by Lipid Emulsions In Vivo for the Treatment of a Drug Overdose/H. Sun, Nanjing, China**
- P11 Modified Minnesota Detoxification Scale (mMINDS) Protocol Assessment for Treatment of Patients With Severe Alcohol Withdrawal/S. Khan, Morgantown, WV**
- P12 Effect of Haloperidol on Mortality, Number of Adverse Effects and Length of Stay Among Patients in the Intensive Care Unit: An Updated Systematic Review and Meta-analysis/C.B. Marciano, Fort Lauderdale, FL**

- P13 Predicting Intensive Care Unit Admissions in Patients With Alcohol Withdrawal Using Electronic Health Record Data/D. To, Madison, WI**
- P14 Clinical Institute Withdrawal Assessment (CIWA) Scores and Benzodiazepine Dosing for Identifying Severe Alcohol Withdrawal/D. To, Madison, WI**
- P15 Enrichment of Mortality Events in Patients With Substance Misuse for Critical Care Research Utilizing Local, State, and National Data Sources/P. Gupta, Chicago, IL**
- P16 Practice Patterns and Outcomes Associated With the Intravenous Sodium Bicarbonate Shortage Among Critically Ill Patients With Acidosis/P. Murphy, Boston, MA**
- P17 Breaking the Myths About Phenobarbital for Alcohol Withdrawal: Retrospective Study/K. Golubykh, Harrisburg, PA**
- P18 Making the Cut During Codes: Time to Performance of Critical Actions by Rapid Medical Response Team Members During Simulated Cardiac Arrest/K. Auge, Chicago, IL**
- P19 Ketamine Infusion Compared to Dexmedetomidine for ICU Sedation: A Retrospective Study/B. Asllanaj, Las Vegas, NV**

CLINICAL

THEMATIC POSTER SESSION

C47 ORGAN FAILURES AND SHOCK: CASE REPORTS9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area A, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P21 What a Shock: An Unusual Presentation of Obstructive Shock/A. Martinez Nunez, Aventura, FL**
- P22 Refractory Undifferentiated Shock. Is Methylene Blue Our Last Option?/C. Arevalo, Rochester, NY**
- P23 An Atypical Presentation of Legionella Pneumonia With Obstructive Shock/R.P. Rane, Johnstown, PA**
- P24 Are We Missing the Source: A Case of Premature Closure in Septic Shock/K. Rai, Aurora, CO**
- P25 Fatal Predisposition for Toxic Shock Syndrome in Klippel-Trenaunay-Weber Syndrome/J.T. Tamizharasu, Sacramento, CA**

- P26 Hepatitis And Vasodilatory Shock Due To An Unsuspected Culprit: A Rare Presentation Of Langerhans Cell Histiocytosis/S. Bhatt, Scottsdale, AZ**
- P27 High Dose Insulin Therapy in Shock With an Unexpected Outcome: Iatrogenic Severe Acute Respiratory Distress Syndrome (ARDS)/N. Kumar, Miami, FL**
- P28 Multisystem Inflammatory Syndrome in Adults Successfully Treated With Steroids and Immunoglobulins/A.A. Abdalla, Phoenix, AZ**
- P29 Acute Non-exertional Hyperthermia With Multi-organ Failure in an Adult With Prader-willi Syndrome: A Case Report/N. Vahil, Albuquerque, NM**
- P30 Surviving Lactic Acidemia Of 30 And Apache II Mortality Risk Of 88%/A. Mahmoud, Paterson, NJ**
- P31 Multisystem Inflammatory Syndrome in a 50-year-old Adult Male/R. Umrani, Stratford, NJ**
- P32 Toxic Epidermal Necrolysis Presenting With Disseminated Intravascular Coagulopathy and Multiorgan Failure/G.C. Cerro Chiang, Los Angeles, CA**
- P33 High-dose Insulin Therapy in Management of Refractory Shock From Multiple Drug Overdose/A.Y. Soleiman, Bronx, NY**
- P34 Drug Abuse Leading To Severe Rhabdomyolysis And Multiple Organ System Failure: A Case Series/A. Singh, Overland Park, KS**
- P35 A Rare Case of Multiorgan Failure and Acidosis Following Massive Ibuprofen Ingestion/M. Aglan, Boston, MA**
- P36 Carboxyhemoglobin: A Little Known Application/N. Aamir, Toms River, NJ**
- P37 Community-Acquired Methicillin-Resistant Staphylococcus Aureus Leading To Necrotizing Pneumonia And Fulminant Multiorgan System Failure/K.U. Lio, Philadelphia, PA**
- P38 A Rare Presentation of Non-falciparum Plasmodium Species Resulting in Septic Shock in a Migrant Female/R. Bhatnagar, New York, NY**
- P39 Tragic Consequences : Mycoplasma Pneumoniae Septic Shock/M. Aurangzeb, NYC, NY**
- P40 Disseminated Nocardiosis as Cause for Septic Shock and Bacteremia in an Individual With Diabetes Mellitus and Chronic Kidney Disease/M. Lagina, Ann Arbor, MI**
- P41 Dog Bite: A Rare Cause of Septic Shock/S. Najeeb, Stamford, CT**
- P42 Sepsis Secondary to Streptococcus Pneumonia Treated With Intravenous Immunoglobulin Therapy/P.E. Amador Mejia, Odessa, TX**
- P43 Acinetobacter Baumannii, the Cloud on the Horizon: A Case of Resistant Infection and Rapidly Progressive Hemodynamic Compromise/J. Panthappattu, Hackensack, NJ**
- P44 Acute Hypoxic Respiratory Failure and Septic Shock Secondary to Mycetoma/S. Patel, Hemet, CA**
- P45 When to Step on the Gas: Management of Septic Shock Secondary to Salmonella Sepsis Complicated by Necrotizing Fasciitis, Emphysematous Aortitis, Emphysematous Splenitis, and Para Aortic Phlegmon/M. Khan, Honolulu, HI**
- P46 Pericardial Tamponade and Berger's Disease: An Unusual Association/M. Ghose, Long Branch, NJ**

CLINICAL

THEMATIC POSTER SESSION

C48 CASE REPORTS: TOXICOLOGY AND OTHER INVOLVING MEDICATIONS

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area A, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P48 Colchicine- "A Safe Anti-Inflammatory Drug"- But, How Safe Is It?/A. Sinha Ray, Omaha, NE**
- P49 An Interesting Case of Neutropenic Fever and Agranulocytosis Because of Dapsone Use/R. Sharma, Sioux Falls, SD**
- P50 Risperidone Induced Hypothermia And Thrombocytopenia/W. Ali, McKeesport, PA**
- P51 A Case Of Methamphetamine Induced Hepatic Artery Pseudoaneurysm/A.S. Adebola, Corvallis, OR**
- P52 The Role Of Dupilumab In Refractory Anaphylaxis Secondary To Food Allergy/A.S. Adebola, Corvallis, OR**
- P53 A Case of Lance- Adams Syndrome Following Peri Arrest and Severe Hypoxia From Opioid Overdose- A Case Report/G. Primera, Springfield, MA**
- P54 Naloxone-induced Noncardiogenic Pulmonary Edema Requiring ECMO- A Case Report/G. Primera, Springfield, MA**
- P55 Sleeping Beauty Is but a Fairy Tale: A Case of Trazodone Associated Neuroleptic Malignant Syndrome/A. Sulman, Pontiac, MI**
- P56 An Adverse Reaction to Coral Snake Antivenom/A. Kookoolis, Tampa, FL**

- P57 Watch Out For Last: Local Anesthetic Systemic Toxicity/J. Baek, Atlantis, FL**
- P58 False High Level of Vancomycin: A Therapeutic Misadventure in Critical Care/C. Bastola, Brooklyn, NY**
- P59 An Interesting Case of Stercoral Colitis in the Setting of Chronic Olanzapine Use: Importance of Medication Review/M. Gwiazdowski, Poughkeepsie, NY**
- P60 Cobalt Toxicity in a Metal-on-metal Hip Arthroplasty/H. Alaws, Gainesville, GA**
- P61 Brain Dead or Not: A Case of Baclofen Overdose/V. Barnwell, Pittsburgh, PA**
- P62 Why Isn't the Acetaminophen Level Improving?/I. Munawar, Syracuse, NY**
- P63 Management of Xylazine Withdrawal in a Patient Admitted to the Intensive Care Unit With Carbon Monoxide Poisoning/T. Boyce, Philadelphia, PA**
- P64 Multifocal Inflammatory Leukoencephalopathy Masquerading As Ischemic Stroke In Levamisole-laced Cocaine Overdose In A Young Adult/D. Laffita, Boca Raton, FL**
- P65 Complex Dysrhythmias Induced By Large Aconitum Ingestion/A. Arai, Aurora, CO**
- P66 Angiotensin II for Treatment of Calcium Channel Blocker Overdose/J.R. Felzer, Rochester, MN**
- P67 Intraperitoneal Absorption of Intravesical Gemcitabine Resulting in ARDS and Pancytopenia/S. Deleveaux, Oak Lawn, IL**
- P68 Rituximab Induced Delayed Cytokine Release Syndrome And Acute Respiratory Distress Syndrome Managed With Venoarterial Extracorporeal Membrane Oxygenation: A Case Report/A. Mohammed, Hackensack, NJ**
- P69 All That Wheeze Is Asthma, so Why Is My Primatene Mist Making My Asthma Worse?/K. Okoyeze, Abington, PA**
- P70 A Rare Case of Explosive Pustular and Hemorrhagic Bullous Dermatopathy From Iododerma/L.E. Leys, New York, NY**
- P71 Clonidine as a Therapeutic Option to Wean the Agitated Off Dexmedetomidine to Reduce ICU Length of Stay and Health Care Costs - A Successful Care Series/G. Mohan, Long Branch, NJ**
- P72 Diagnosing Neuroleptic Malignant Syndrome the Intensive Care Unit: Identifying the Signs in Mechanically Ventilated Patients/K. Cao, Chicago, IL**
- P73 Relapsing Multi-Organ Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Due to Allopurinol/R.K. Petit, Miami Beach, FL**

CLINICAL

THEMATIC POSTER SESSION

C49 HEMATOLOGY/ONCOLOGY CRITICAL CARE CASES**9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center****Area A, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session **11:30-1:15****Discussion:** **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P75 A Case of Pembrolizumab-induced Myasthenia-like Illness and Myositis/R. Mirchin, Flushing, NY**
- P76 A Case Of Spontaneous Tumor Lysis And Type B Lactic Acidosis In A Patient With Solid Malignancy/J.V. Rodriguez, Boston, MA**
- P77 Malaise, Anemia and Schistocytes, Oh My!/J.R. Dahl, Tallahassee, FL**
- P78 Small Cell Lung Carcinoma After Lung Transplant Listing: Need for Interval Testing/D. Sindu, Phoenix, AZ**
- P79 De Novo Prostate Adenocarcinoma in a Lung Transplant Recipient: Immune-surveillance or Immune-suppression?/D. Razia, Phoenix, AZ**
- P80 Anticoagulation Management in a Patient With Heterozygeous Polymorphism for Hyperhomocysteinemia/M.F. Goodwin, Youngstown, OH**
- P81 Incidental Deep Venous Thromboses Found Post-decannulation Of Large Extracorporeal Membrane Oxygenation Cannulas/A. Cypro, La Jolla, CA**
- P82 Thrombolytic Therapy For Malignancy-induced Hypercoagulability And Bioprosthetic Aortic Valve Thrombosis/T. Rizvi, Oak Lawn, IL**
- P83 Intermediate-High Risk PE With a Clot-In-Transit - Unanswered Questions/A. Shah, Rootstown, OH**
- P84 The Clot Thickens: Recurrent Deep Vein Thromboses in the Setting of Complete Atresia of the Inferior Vena Cava/C. Hsu, Dallas, TX**
- P85 Pneumocystis Pneumonia in a Patient With Follicular Lymphoma Treated With Bendamustine and Rituximab/J. Edmunds, Columbia, MO**
- P86 Hemolytic Anemia: The Horror of B12 Deficiency/M.Z. Siddiqui, Oak Lawn, IL**
- P87 A Rare Case Of Evans Syndrome With Antiphospholipid Antibodies And RSV Infection/W. Xiao, Bronx, NY**

- P88 Granulomatous Appendicitis, Dermatitis, and Encephalopathy: A Unique Case of Immune-Related Adverse Events in a Woman With Breast Cancer Treated With Pembrolizumab/H.V. Tran, New Orleans, LA**
- P89 Noncirrhotic Portal Vein Thrombosis/M.A. Amjad, Scranton, PA**
- P90 Tpa - Be Patient/V. Novoselova, St. Louis, MO**
- P91 Cerebral Fat Embolism Syndrome in an Adult Patient With Sickle Cell Disease/P. Solanki, Pittsburgh, PA**
- P92 A Case of Superior Vena Cava Syndrome With Extensive Thrombosis via Chemo Port Catheter/S.M. Sadiq, Johnson City, TN**
- P93 An Unusual Cause of Thrombocytopenia By Commonly Used Over the Counter Phenazopyridine/F. Farhat, Neptune, NJ**
- P94 Acute Neuromuscular Respiratory Failure Secondary to West Nile Infection in a Patient With CLL/A. Thota, New York, NY**
- P95 Thrombocytopenia in the Intensive Care Unit/M.L. Mccrary, Saint Louis, MO**
- P96 A High-Grade Poorly Differentiated Malignant Neoplasm Favoring Gliosarcoma With Extracranial Metastasis/M. Zane, Pontiac, MI**

CLINICAL

THEMATIC POSTER SESSION

C50 ALL THAT IS HLH

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area A, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P97 Beyond The Infection!/Z. Dhanani, Philadelphia, PA**
- P98 Hemophagocytic Lymphohistiocytosis With Hyperacute Liver Failure Due to Epstein-barr Viremia/O. Rahman, Indianapolis, IN**
- P99 Postpartum Hemophagocytic Lymphohistiocytosis/J. Suder, San Antonio, TX**
- P100 Hemophagocytic Lymphohistiocytosis Secondary to Infected Staghorn Renal Calculus/A.J. Arumairaj, New York, NY**
- P101 Hemophagocytic Lymphohistiocytosis (HLH) Diagnostic Dilemma: Ehrlichiosis or EBV?/P. Savsani, Indianapolis, IN**

- P102 A Rare Case of Herpes Simplex Virus Type1 Induced Hemophagocytic Lymphohistiocytosis in Adult Patient/C. Simone, Bethlehem, PA**
- P103 Hemophagocytic Lymphohistiocytosis Presenting as Acute Decompensated Heart Failure: A Novel Report/C. Wisecup, Dallas, TX**
- P104 A Case of Suspected Hemophagocytic Lymphohistiocytosis: The Calm Before the Storm/T. Ayyalu, Forest Hills, NY**
- P105 Unexpected Findings: A Case Of Suspected Hemophagocytic Lymphohistiocytosis/J. Fagg, Springfield, IL**
- P106 Hemophagocytic Lymphohistiocytosis Induced By Covid-19 Infection/R. Zudekoff, Aurora, CO**
- P107 Secondary Hemophagocytic Lymphohistiocytosis in a Patient With Hodgkin Lymphoma and Concurrent COVID-19 Infection/M. Cheema, Port Jefferson, NY**
- P108 Traveling Ticks: Ehrlichiosis Induced HLH in Colorado/J. Hershey, Aurora, CO**
- P109 Biventricular Dysfunction in Hemophagocytic Lymphohistiocytosis (HLH) Might Be Reversible/A.V. Jogimahanti, Houston, TX**
- P110 Two Zebras Make A Dazzle: Two Cases Of Hemophagocytic Lymphohistiocytosis In Two Days/B. Zahid, Houston, TX**
- P111 The Early Bird Avoids the (Cytokine)Storm: A Case Report Highlighting the Importance of Early Diagnosis in Hemophagocytic Lymphohistiocytosis/Y. Abouleish, Norfolk, VA**
- P112 Ticking Up the Immune System: A Case of Ehrlichiosis Complicated By Hemophagocytic Lymphohistiocytosis and Myocarditis/S. Kelley, Nashville, TN**
- P113 Early Recognition of Idiopathic Hemophagocytic Lymphohistiocytosis Complicated by Intracranial Hemorrhage, A Case Report/A. Chandra, Sacramento, CA**

CLINICAL

THEMATIC POSTER SESSION

C51 CASES OF COVID AND ITS COMPLICATIONS

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P216 Post COVID Pneumonia Complicated By Secondary MRSA Empyema/A.J. Arumairaj, New York, NY**
- P217 Pressure Ulcers in the Prone Ventilated Critically Ill Patient With COVID-19/L. Piccolo Serafim, Washington, DC**
- P218 A Case of COVID-19 Associated Mucormycosis Initially Thought to Be Bacterial Sinusitis/B. Wu, Morgantown, WV**
- P219 Spontaneous Hemothorax In A 48-year-old Man With Covid-19 Acute Respiratory Distress Syndrome/A.L. Chai, Los Angeles, CA**
- P220 COVID-19 Broke My Heart: A Case of COVID-19-induced Takotsubo Cardiomyopathy/T. Haque, Glendale, AZ**
- P221 Even Young Hearts Could Not Escape COVID19/V. Novoselova, St. Louis, MO**
- P222 Whispers In The Dark, A Silent Killer Comes Stark: A Rare Case Of Occlusive Basilar Artery Stroke Secondary To Thrombosis Due To Covid-19/D. Kalluru, Charleston, WV**
- P223 Mucus! What Is It Good For? Absolutely Something!/T.M. Kohal, New Orleans, LA**
- P224 A Case Series of Persistent SARS-CoV-2 Infection in Immunocompromised Pediatric Patients/M.Y. Ahmed, Indianapolis, IN**
- P225 Ischemic Cardiomyopathy Post COVID-19 In A Young Patient/M.W. Sharif, Odessa, TX**
- P226 A Case Of Catastrophic Antiphospholipid Syndrome With Intracardiac Thrombus After Covid 19 Infection/A. Alam, Kalamazoo, MI**
- P227 Patient With COVID-19 Pneumonia Treated With Steroids and Tocilizumab is Diagnosed With Aids/C. Burke, Olympia Fields, IL**
- P228 COVID-19 Pneumonia and Purpura Fulminans: A Whispering Coagulopathy/M. Siew, Worcester, MA**
- P229 A Life-Threatening Combination: A Case of Burkholderia Gladioli Pneumonia in a Patient With Coronavirus Disease 2019/P. Adderley, Atlantis, FL**
- P230 An Enigmatic Empyema In A Patient With Sars-CoV-2/A. Mari, Norfolk, VA**
- P231 Intestinal Perforation in COVID 19/D. Trelles, Weston, FL**
- P232 COVID-19 Induced Pheochromocytoma Multisystem Crisis/J. Crosby, Lexington, KY**
- P233 Refractory Shock in COVID-19 Pandemic, What Are We Mis-ing?/S. Muramoto, New Orleans, LA**
- P234 Acute Epiglottitis Due to Serratia Marcescens in the Setting of SARS-CoV-2 Infection in an Immunocompetent Patient/S. Abu-Baker, Staten Island, NY**
- P235 Isolated COVID-19 Myopericarditis in a Healthy Adult Leading to Tamponade and Cardiogenic Shock/J.T. Dent, Myrtle Beach, SC**
- P236 Hemorrhagic Pericardial Effusion and Atrial Fibrillation as Initial Presentation of COVID-19, A Case Report/S. Hussein, Chicago, IL**
- P237 Peripartum Pneumoperitoneum and Pneumoretroperitoneum in COVID-19/C.D. Theroux, Providence, RI**
- P238 A Healthy 27-year-old Multiparous Patient at 27 Weeks' Gestation Diagnosed With Severe COVID-19 Related Multisystem Inflammatory Syndrome in Adults (MIS-A)/C. Terry, Charleston, SC**
- P239 A Case Report of COVID-19 With an Uncommon Presentation and an Unfavorable Outcome/A. El-Tooney, Minia, Egypt**
- P240 A Red Herring Case of Listeria Meningitis in an Immunocompetent Individual With COVID-19/V. Dong, New York, NY**
- P241 A Bug Problem: Increased Incidence of Infections With Baricitinib Administration in Critically Ill Patients With COVID-19/M.C. Manjunath, Brighton, MA**
- P242 Prolonged SARS-CoV2 RNA Shedding and Persistent Inflammation, Immunosuppression and Protein Catabolism Syndrome (PICS) in a Heart Transplant Recipient With: A First Case Report/S. Sathitratanacheewin, Bangkok, Thailand**

CLINICAL

THEMATIC POSTER SESSION

C52 ENDOCRINOLOGY IN THE ICU: CASE REPORTS9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area K, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session **11:30-1:15****Discussion:** **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.**P1093 Grave's Disease Induced Thymic Hyperplasia Mimicking Thymoma/K. Fu, Gainesville, FL****P1094 Transient Diabetes Insipidus After Vasopressin Discontinuation/A.L. Chai, Los Angeles, CA****P1095 Thyrotoxic Periodic Paralysis: A Grave Disease/S. Hamid, Gulfport, MS****P1096 Pituitary Apoplexy, A Rare But Life Threatening Complication of Pituitary Adenoma/T. Thomas, Danbury, CT****P1097 Diagnosing Pheochromocytoma In The Intensive Care Unit/A.M. Heyder, Norfolk, VA**

- P1098 The Synergistic and Unpredictable Effects of Hyperglycemic Crisis Management: A Cautionary Tale/H.C. Lichota, Chicago, IL**
- P1099 Bilateral Pleural Effusion Secondary to Myxedema/A. Mujahid Ali, Queens, NY**
- P1100 Recognizing Cardiac Tamponade As A Rare And Fatal Cardiac Complication Of Systemic Lupus Erythematosus/S.I. Talib, Perth Amboy, NJ**
- P1101 Mild Groans Without “Moans, Stones, and Bones” Leading to Tombs/V. Novoselova, St. Louis, MO**
- P1102 Nonmaleficence in Adults With DKA-related Cerebral Edema/H. Hussain, Newark, NJ**
- P1103 Intraoperative Development of Severe Euglycemic Ketoacidosis in a Non-diabetic Patient/C.A.K. Pal, Albuquerque, NM**
- P1104 Atypical Presentation of Alcoholic Ketoacidosis With Profound Hyperglycemia/P. Purta, Omaha, NE**
- P1105 Hypokalemia to Hyperkalemia in 12 Hours: Thyrotoxic Periodic Paralysis/A. Farrukh, St. Louis, MO**
- P1106 A Cause of Hypercalcemia Overlooked in Tuberculosis Endemic Countries/L.P.V. Kattamuri, New Delhi, India**
- P1107 Management Of Refractory Hypoglycemia In Doege-Potter Syndrome Without An Option For Curative Surgery/K. Cuan, New York, NY**
- P1108 Acute Adrenal Crisis COVID19-Induced and Presented as Stress-Induced Cardiomyopathy/E. Magira, Athens, Greece**
- P1109 A Case Report of the Medication Behind Euglycemic Diabetic Ketoacidosis/S. Chetana Shanmukhappa, Rochester, NY**
- P1110 Enfortumab Vedotin Induced Hyperglycemia and Diabetic Ketoacidosis/J. Patel, Chicago, IL**
- P1111 Nonconvulsive Status Epilepticus Due to Thyroid Storm in a Patient With Lung Cancer on Pembrolizumab/A. Triana, Miami, FL**
- P1113 When the Liver Pops: Spontaneous Biliary Enteric Fistula as a Rare Cause of Acute Liver Failure/D. McCreary, Phoenix, AZ**
- P1114 Chylothorax Caused by Left Internal Jugular Vein Catheterization: A Path Through the Azygous Vein/K. Okazaki, New York, NY**
- P1115 Infected Chylothorax in the Setting of Severe Hypogammaglobulinemia/E. Graumann, Kansas City, KS**
- P1116 Novel Azygos To Right Atrial Surgical Bypass For The Decompression Of Exsanguinating Downhill Esophageal Varices/K.S. Lal, Maywood, IL**
- P1117 Hunger Strike Leading to an Acute Gastro Intestinal Bleed: A Rare Case of Posterior Gastric Wall Rupture/T. Walgamage, Danbury, CT**
- P1118 Acute Epiglottitis Caused by Gastric Acid From Protracted Vomiting/M. Zopey, Torrance, CA**
- P1119 Minnesota to Empyema: A Case of Esophageal Rupture and Persistent Pleural Infection Due to Esophagogastric Tamponade Device Misplacement/B. Hackett, Kansas City, KS**
- P1120 Methemoglobinemia After Topical Benzocaine In A Patient With Liver Disease/B. Zafar, Houston, TX**
- P1121 Infected Giant Aortic Aneurysm In The Setting Of Recent Upper Gastrointestinal Endoscopy/Y.B. Moreno, Fort Lauderdale, FL**
- P1122 The Goldilocks of Resuscitation: Treatment of Hemorrhagic Shock Resulting in Abdominal Compartment Syndrome/C. Snavelly, Baltimore, MD**
- P1123 Abdominal Compartment Syndrome: A Feared Fate in Acute Pancreatitis/I. Obrusnik, Stamford, CT**
- P1124 A Unique Case Of Refeeding Syndrome With 11meq Na Correction In 5 Hours After A 27 Day Fast/W. Xiao, Bronx, NY**
- P1125 Sickle Cell Intrahepatic Cholestasis Mimicking Acute Cholecystitis: A Case Report/I. Kovalenko, Harrisburg, PA**
- P1126 Amiodarone Induced Acute Liver Failure: A Case Report/S. Chetana Shanmukhappa, Rochester, NY**
- P1127 A Rerun: Newly Diagnosed Familial Hypertriglyceridemia Presenting as Recurrent Pancreatitis With Worsening Triglycerides Level With Each Episode/R.N. Tiperneni, Long Branch, NJ**
- P1128 A Slippery Slope and a Telescope: Gastroduodenal Intussusception in a Critically Ill Adult/V. Soetanto, New York, NY**
- P1129 Severe Hyperammonemia And Coma In A Post-partum Patient Secondary To A Urea Cycle Disorder/S. Gupta, Cleveland, OH**

CLINICAL

THEMATIC POSTER SESSION

C53 CRITICAL CARE GASTROENTEROLOGY: CASES

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area K, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1130 Abdominal Periaortic Lymphoma Mimicking an Aortic Aneurysm Sac Rupture: A Rare Case/E.J. Feghali, Wichita, KS**
- P1131 Rare Esophageal Rupture After Posterior Spinal Surgery/Z. Kattih, NEW YORK, NY**
- P1132 Emphysematous Gastritis: The Success Of Early Diagnosis And Conservative Management/M. Matis, Overland Park, KS**
- P1133 Glucagon-Induced Hypoglycemia In A Patient With Cirrhosis/M. Trieu, La Jolla, CA**
- P1134 Zollinger-ellison Syndrome With Hypovolemic Shock: A Victim of Modern Imaging Technique/C. Provenza, Memphis, TN**
- P1135 Stomach Perforation; Not Every Foreign Body Is Detected By Imaging, A Case Report/A. Mahmoud, Paterson, NJ**
- P1136 When the Colon Causes Suffocation: A Case of Respiratory Failure Triggered by Pseudo-Colonic Obstruction/F. Ghazal, Farmington, CT**
- P1137 Skate at Your Own Risk/H. Alrahamneh, Las Cruces, NM**
- P1138 Nutrition Support of Malnourished and Severe Vitamin D Deficiency in a Lung Transplant Recipient: A Case Report/Y.C. Hsieh, Taipei City, Taiwan**
- P1144 Friendly Kisses Can Be Deadly: A Case of Capnocytophaga Bacteremia/J.E. Miller, Roanoke, VA**
- P1145 Concomitant Pneumocystis Jirovecii Pneumonia and Cytomegalovirus Pneumonitis as Initial Presentation of Acquired Immune Deficiency Syndrome/O. Rahman, Indianapolis, IN**
- P1146 A Mass Of Fungus/N. Street, Knoxville, TN**
- P1147 Rip-roaring Aftermath Of Babesiosis And Lyme Coinfection/A. Javed, Pittsburgh, PA**
- P1148 The Chameleon: A Case of Subacute Granulicatella Adiacens Endocarditis/J.M. Levy, Mullica Hill, NJ**
- P1149 Catastrophic Complication of Streptococcus Mitus Endocarditis/J.M. Levy, Mullica Hill, NJ**
- P1150 Bacillus Thuringiensis Bacteremia in an IV Drug User/M. Kalinoski, Burnsville, MN**
- P1151 Anaerobiospirillum, Complications Of Pets And Alcohol/D.S. Bustamante-Soliz, Cuenca, Ecuador**
- P1152 Empyema and Meningitis as Rare Complications of Disseminated Mycobacterium Kansasii Infection/M. Assaad, Sayre, PA**
- P1153 A Case of Severe MRSA Pneumonia With a Discordant Nasal Swab, Exploring the Limitations of the Test/F. Ahmed, New York, NY**
- P1154 The Ominous Aspergillus: A Case Of Invasive Aspergillosis And Epitheloid Angiosarcoma Of The Lung/M.R. Baral, Danbury, CT**
- P1155 A Complicated Case Of Community Acquired Methicillin-resistant Staphylococcus Aureus Necrotizing Pneumonia/F. Poli, Miami Beach, FL**
- P1156 Cryptococcal Empyema in an Immunocompromised Patient on Chronic Corticosteroid Therapy With Recent Colectomy: A Case Report/M. Mizerak, Hershey, PA**
- P1157 Enterococcus Faecalis Bacteremia: The Driving Force Behind Septic Thrombophlebitis and Cavitory Pneumonia/I. Kovalenko, Harrisburg, PA**
- P1158 From The Tooth To The Heart And Beyond/Y. Patel, Scranton, PA**
- P1159 Prostate Abscess in an Insidious Treatment Resistant Complicated Urinary Tract Infection/M. Bermudez, The Bronx, NY**
- P1160 A Case of Cellulitis Complicating Lymphedema Masquerading as Necrotizing Fasciitis on Point of Care Ultrasound Exam/J.K. Drury, Roanoke, VA**
- P1161 Cardiac Implantable Electronic Device Endocarditis: A Rare Catastrophe in Streptococcus Agalactiae Sepsis/M.D. Chandra, Marshfield, WI**

CLINICAL

THEMATIC POSTER SESSION

C54 CASES OF INFECTIOUS DISEASES IN THE ICU - I

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area K, Hall C (Lower Level)

- Viewing:** Posters will be on display for entire session **11:30-1:15**
- Discussion:** **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.
- P1140 Unusual Cause of Necrotizing Pneumonia in Lung Transplant/S. Noh, Houston, TX**
- P1141 Pulmonary Mucormycosis in a Farmer With Recent Renal Transplantation/B.J. Hebert, Louisville, KY**
- P1142 Disseminated Coccidioidomycosis In A Patient With Acute Promyelocytic Leukemia And Suspected Differentiation Syndrome/K. Ulubabyan, La Jolla, CA**
- P1143 What's in a Smear? A Unique Case of Clostridium Perfringens Alpha Toxin-mediated Acute Massive Intravascular Hemolysis/D. Rink, Seattle, WA**

- P1162 Erysipelatoclostridium Ramosum: A Rare Cause of Fournier's Gangrene/D. Bergstedt, Denver, CO**
- P1163 Moldy Mutilation: A Case of Traumatic Mucormycosis After Crush Injury/S. Samuel, Omaha, NE**
- P1164 A Unique Case Of Necrotizing Fasciitis Of The Breast Complicated By Hyperosmolar Hyperglycemic State And Mild Diabetic Ketoacidosis/M. Gwiazdowski, Poughkeepsie, NY**
- P1165 Septic Pulmonary Embolism in Immunocompetent Patient Secondary to Cervical Epidural Abscess/A. Al Tkrit, Toledo, OH**
- P1166 Concurrent Disseminated Nocardia and Cryptococcus Infection in a Patient With Sulfa Allergy/P. Saad, Jonesboro, AR**
- P1177 A Rare Case of Legionella Rhabdomyolysis/J. Stojavljevic, Bronx, NY**
- P1178 A Severe Case Of Legionella Pneumonia Acquired From Home CPAP Use Requiring Mechanical Ventilation./S. Avera, Knoxville, TN**
- P1179 A Curious Case of Croup: Parainfluenza Positive Laryngotracheobronchitis in an Adult/S. Amin, Reading, PA**
- P1180 Klebsiella Pneumoniae in the Urine, Blood, and Pericardium: A Rare Case of Bacterial Pericardial Effusion Causing Cardiac Tamponade/O.W. Brooks, Farmington, CT**
- P1181 Candida Aortitis Complicating Boerhaave Syndrome: A Double-Edged Sword/R.D. Isern, Omaha, NE**
- P1182 Chryseobacterium Indologenes Ards In A Young, Previously Immunocompetent Patient Of Chinese Descent/R. Hoerle, Norfolk, VA**
- P1183 A Rare Case of Lactococcus Lactis Bacteremia in an Immunocompetent Patient Associated With Food Impaction/Q. Meng, Evanston, IL**
- P1184 An Unexpected Turn of Events: Chryseobacterium Indologenes Native Valve Endocarditis/B. Aronson, Chicago, IL**
- P1185 Purpura Fulminans Due to Streptococcus Gallolyticus Subspecies Pasteurianus Bacteremia in an Immunocompromised Host/M. Murray, Boston, MA**
- P1186 Clostridium Sporogenes: A Rare but Potent Pathogen/H. Safdar, Columbia, MO**
- P1187 Clostridium Perfringens - A Rare Cause of Spontaneous Bacterial Peritonitis/M.I. Islam, Charlottesville, VA**
- P1188 Legionnaire's Disease and the Leaky Lung: ARDS From Legionella Pneumophila/G. Ang, Forest Hills, NY**
- P1189 Methicillin-Resistant Staphylococcus Aureus Bacteremia Complicated by Antibiotic-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)/F. Altamirano, Austell, GA**
- P1190 The Curious Case of Black Buboos/A. Saha, Worcester, MA**
- P1191 Procalcitonin Elevation in Rhabdomyolysis Without Acute Bacterial Infection/L.S. Tremblay, Cleveland, OH**
- P1192 All That Is Avid Is Not Malignant/E. Tyree, Allentown, PA**
- P1193 Bacteroides Fragilis Associated Purpura Fulminans/N. Yosry, Toms River, NJ**
- P1194 Acinetobacter Lwoffii Sources and Risk Factors/Y. Sweedan, Johnstown, PA**
- P1195 When Clinical Findings Belittles a Septic Anterior Mediastinitis: Rare Case of Necrotizing Fasciitis/N. Zayas Schulze, San Juan, PR**

CLINICAL

THEMATIC POSTER SESSION

C55 CASES OF INFECTIOUS DISEASES IN THE ICU - II

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area K, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1169 Disseminated Cryptococcal Infection With Peritonitis, Choroiditis And Fungemia In A Patient With Liver Cirrhosis, Case Report And Literature Review/K. Mohamed Ahmed, Houston, TX**
- P1170 Mycotic Abdominal Aortic Aneurysm and Psoas Abscess Due to Mycobacterium Bovis After Intravesical BCG Therapy/C.J. Fernandez, Buffalo, NY**
- P1171 Rare Case of Staphylococcus Lugdunensis Malignant Otitis Externa With Osteomyelitis/M.A. Amjad, Scranton, PA**
- P1172 Extreme Survivor: Legionella Edition/D. Ahmed, Shreveport, LA**
- P1173 An Atypical Case of Fusobacterium Nucleatum Empyema Leading to Septic Shock/C. Gearges, Port Jefferson, NY**
- P1174 Candida Glabrata Empyema in a Cirrhotic Patient- A Rare Possibility/S. Sultan, Philadelphia, PA**
- P1175 A Fatal Case of Hidden Empyema/V. Dhillon, Muncie, IN**
- P1176 A Case of Severe Fusobacterium Necrophorum and Arcanobacterium Hemolyticus Pneumonia Complicated by Empyema, Pericardial Effusion, and Septic Shock in an Immunocompetent Patient/S.N. Garcia, Albuquerque, NM**

BEHAVIORAL • CLINICAL

THEMATIC POSTER SESSION

C56 TRENDS AND PREDICTORS OF RESPIRATORY HEALTH AROUND THE WORLD

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area I, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P907** Serum High-density Lipoprotein Cholesterol Level as a Protective Factor of Lung Function Decline in Adults: Population-based Cohort Study in South Korea/S. Jung, Seoul, Korea, Republic of
- P908** Seventeen-year Cumulative Incidence of Airflow Limitation and Lung Function Decline in Two Longitudinal Cohorts: The Japanese Red Cross Kumamoto Study/Y. Sato, Kumamoto, Japan
- P909** Airway-predominant and Emphysema-predominant Pulmonary Subtypes Exhibit Differential 10-year GOLD Stage Progression/K.A. Young, Aurora, CO
- P910** Prevalence and Description of Chronic Obstructive Pulmonary Disease Cohorts From 2000 to 2019/P. Stone, London, United Kingdom
- P911** Comorbidity Index Predictive Performance on Nationwide Acute Exacerbation of Chronic Obstructive Pulmonary Disease Data From Denmark/P.A. Jacobsen, Aalborg, Denmark
- P912** Feasibility of Developing an Urban Comprehensive Lung Cancer Screening Program for Lung Nodules Coupled With Detection of Comorbid Conditions: Temple Healthy Chest Initiative (THCI)/M.A. Seigo, Philadelphia, PA
- P913** Detection of Interstitial Lung Abnormalities (ILA) in an Urban Comprehensive Lung Cancer Screening Program for Lung Nodules Coupled With Detection of Comorbid Conditions: Temple Healthy Chest Initiative (THCI)/M.A. Seigo, Philadelphia, PA
- P914** Prevalence and Type of Comorbidities Found in an Urban Comprehensive Lung Cancer Screening Program for Lung Nodules Coupled With Detection of Comorbid Conditions: Temple Healthy Chest Initiative (THCI)/M.A. Seigo, Philadelphia, PA
- P915** Detection of Emphysema in an Urban Comprehensive Lung Cancer Screening Program for Lung Nodules Coupled With Detection of Comorbid Conditions: Temple Healthy Chest Initiative (THCI)/S. Dachert, Philadelphia, PA
- P916** Characteristics, Outcomes, and Predictors of Progression to Lung Transplantation in Hospitalisations With Cystic Fibrosis/G. Mohan, Long Branch, NJ
- P917** Validation of Coding of Idiopathic Pulmonary Fibrosis in Primary and Secondary Health Records in the UK/R. Shah, London, United Kingdom
- P918** Evaluation of Machine Learning Models to Project Global Indoor and Outdoor Air Pollution Through 2050/E. Boers, Halifax, Canada
- P919** Severe Acute Respiratory Syndrome and Particulate Matter Exposure: A Systematic Review/S. Podury, New York, NY
- P920** Association of Lifestyle-related Risk Factors With Lung Cancer Incidence and Mortality Rates in the United States/G. Mudigonda, Shreveport, LA
- P921** Trends in Carbon Monoxide Morbidity and Mortality in the United States From 1990 to 2019 - an Observational Analysis Using the Global Burden of Disease (GBD) Database/P.S. Bhatt, Cambridge, MA
- P922** Assessment of Socioeconomic Indicators in an Intensive Care Unit at a Safety-net Hospital in a Low-deprivation Area/M. Fernandes, Brooklyn, NY
- P923** Analysis of the Activity of a High Complexity Unit in Smoking Treatment: Results and Role of Comorbidity/A.D. Frino-Garcia, Barcelona, Spain
- P924** Correlations Between Patient Responses to Social Determinants of Health and Short-Form Health Survey (SF-36) Physical Functioning Questionnaires/G.S. Onar, Knoxville, TN
- P925** Burden of Disease in Patients With Chronic Cough in Canada: Results From a National Patients' Survey/T. Abraham, Kirkland, Canada
- P926** Right to Clean Air: Identifying Modifiable Targets for Reducing Indoor Fine Particulate Matter in Single Room Occupancies/N. Thakur, San Francisco, CA
- P927** Predictors of Longitudinal Lung Function Changes Following Deployment to Southwest Asia/L. Zell-Baran, Denver, CO
- P928** Association Between Peripheral Endothelial and Smooth Muscle Function With Cardiopulmonary Exercise Test Parameters Among Previously Deployed Military Veterans/M.J. Falvo, East Orange, NJ
- P929** Evaluating Inflammatory Risk Among Tobacco Product Users in New York City/K.R. Farrell, New York, NY
- P930** "Symptomatic Vapers": Association of E-cigarette Use With Respiratory Symptoms and Spirometry in Young Adults/E. Oelsner, New York, NY

CLINICAL

THEMATIC POSTER SESSION

C57 CASE REPORTS IN PULMONARY AND ENVIRONMENTAL HEALTH**9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center****Area E, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session**11:30-1:15****Discussion: 11:30-12:15** authors will be present for individual discussion**12:15-1:15** authors will be present for discussion with assigned facilitators.

- P563 Does Being a Surgeon Pose a Risk to My Lungs? An Unusual Case of Hypersensitivity Pneumonitis/S.** Alrasheed, Riyadh, Saudi Arabia
- P564 Thesaurosis Revealed By The COVID-19 Pandemic/S.** Macrae, New Orleans, LA
- P565 A Rare Case Of Eosinophilic Pneumonia Precipitated By E-cigarette Presenting As A Covid-19 Mimic/S.** Ruddaraju, Bronx, NY
- P566 Asthma With Pneumonia Secondary to Influenza/C.** Cajuste, New York, NY
- P567 Diffuse Pulmonary Calcification: A Forgotten History of Viral Infection in Childhood, A Case Report/S.** Jean Pierre, Huye, Rwanda
- P568 Foreign Body From Vaping/P.Y. Lai, Kingwood, TX**
- P569 All Granulomas Are Not Sarcoidosis/K.D. Gandhi, St Louis, MO**
- P570 Darier-Roussy Sarcoid/D. Gullapalli, Harlan, KY**
- P571 Alpha-1 Antitrypsin Deficiency and Interstitial Lung Disease- Is There Any Association?/D. Gullapalli, Harlan, KY**
- P572 A Rare Case Of Pulmonary Sarcoid Revealed By Coccidioidomycosis Infection/A. Puri, Phoenix, AZ**
- P573 Bird Fancier's Lung: A Pulmonologist's Dilemma/A. Puri, Phoenix, AZ**
- P574 A Rare Discovery Of Exogenous Lipoid Pneumonia In An Asymptomatic Patient Following Up For Concerns Of Malignancy/R. Patel, Toledo, OH**
- P575 Solitary Endobronchial Squamous Papilloma With Carcinoma in Situ Discovered on Low Dose Computer Tomography/L. Turbow, Washington, DC**
- P576 Non-small Cell Lung Cancer Presenting With Cerebral Metastases And Cardiac Tamponade/S. Chandna, Cleveland, OH**
- P577 The Clinical Spectrum of Lung Adenocarcinoma With Lepidic Growth and the Role of Navigational Bronchoscopy as a Diagnostic Tool - Case Series Review/A.T. Barbarovich, Warner Robins, GA**
- P578 Rare Case of Methemoglobinemia Following Hemodialysis in an End-stage Renal Disease Patient/B. Ramos Chaves, Louisville, KY**
- P579 Raided Lungs/S. Masood, Brighton, MA**
- P580 A Case of Hyphae-hypersensitivity/R. Wojcik, Pittsburgh, PA**
- P581 Rare Case of Pulmonary Alveolar Proteinosis Presented With Hemoptysis and Recurrent Fever/M. Zane, Pontiac, MI**
- P582 Synthetic Marijuana Small Airways Injury Responds To Pulse Methylprednisolone And Prolonged Prednisone Taper/S. Kemp, Fort Bliss, TX**
- P583 Don't Hold Your Breath: The Pulmonary Complications of Cocaine Inhalation/P. Shekar, Hartford, CT**
- P584 A Rare Case of Pneumomediastinum and Extensive Subcutaneous Emphysema Following Methamphetamine Use, A Case Report/S. Hussein, Chicago, IL**
- P585 Tetrahydrocannabinol Induced Venous Thromboembolism: Myth or Reality/A. Kohli, Springfield, IL**
- P586 A Rare Case of Chronic Radon Exposure Resulting in Advanced Pulmonary Fibrosis/E. Wasserman, Tampa, FL**
- P587 Not So Well Water - an Unusual Case of Pneumonitis/A. Tahir, Bethlehem, PA**
- P588 Detrimental Consequences of China White Synthetic Heroin Use in a Young Asthmatic Polysubstance Drug User/E. Fischer, Kailua, HI**
- P589 Vaping Associated Pulmonary Injury, A Case During the COVID-19 Pandemic in United States/A. Anwar, Sayre, PA**
- P590 A Late-onset Leg Rash, Unique Janeway Lesions or Jarisch-herxheimer Reaction? A Case Report/A. Kim, Las Vegas, NV**
- P591 Delayed Neurologic Sequelae in the Spinal Cord From Carbon Monoxide Poisoning/S. Natarajan, Scranton, PA**
- P592 The Emerging Role Of Hyperbaric Oxygen Therapy In Bacterial Keratitis/J.K. Khosa, Loma Linda, CA**

BEHAVIORAL • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

C58 HEALTH SERVICES RESEARCH IN DIVERSE SETTINGS9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area I, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15****Discussion:** 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P932** Implications of ABCDEF Bundle Adherence on 12-month Outcomes After Critical Illness: Secondary Analysis of MIND-USA Trial Data/L.M. Boehm, Nashville, TN
- P933** Physician-nurse Collaboration at a Crossroads: A Historical Case Study of One the First Coronary Care Units in the United States/C. Farrell, New York, NY
- P934** Heterogeneity of Intermediate Care Units Within a Large Tertiary Academic Hospital System/A.S. Case, Baltimore, MD
- P935** A Quality Initiative Shows the Lung Precision Oncology Program Is Able to Reduce Time to Treatment in NSCLC/R. Coraza, Brooklyn, NY
- P936** The Effect of SARS-CoV-2 Variants on Non-respiratory Features and Mortality Among Vaccinated and Non-fully Vaccinated Patients/S. Cotton, San Diego, CA
- P937** Developing an Educational Program to Improve Nurses' Knowledge of Infection Control and Perception of Isolated MDROs Patients/M. Saito, Shimotsugagun, Japan
- P938** Quality Nurse Rounds to Improve ICU Patient Safety and Nurse Education/A. Kannappan, Denver, CO
- P939** Supporting Survivors of Critical Illness in the Community: A National Survey of Acute and Primary Care Providers/K. Calkins, Milwaukee, WI

CLINICAL

THEMATIC POSTER SESSION

C59 CELLULAR DYSFUNCTION: PEDIATRIC CANCER, IMMUNODEFICIENCY, AND UNUSUAL INFECTIONS9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area H, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15****Discussion:** 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P771** An Approach To A Pediatric Patient With An Established Diagnosis Of Asthma, Has A Recent Finding Of Iga Deficiency./S. Al Qatarnah, Morgantown, WV
- P772** Case Of Persistent Wheeze And Atelectasis In An Adolescent Male/D. Saad, Little Rock, AR
- P773** Photolytic Measurement of Tissue S-nitrosothiols Non-invasively in Pediatric Sepsis/D. Cater, Indianapolis, IN
- P774** An Unusual Case of Bronchiectasis in a 10-year-old Female/D. Larrain, Houston, TX
- P775** Hyper-Ige Syndrome And Recurrent Pneumothoraces/K.A. Wallace, Houston, TX
- P776** Nontuberculous Mycobacteria Infection in Pediatric Patient With Chronic Corticosteroid Use/K.A. Wallace, Houston, TX
- P777** A Case of EML4-ALK Fusion Lung Adenocarcinoma in an 18-year-old Patient/A. Chang, New York, NY
- P778** Intratracheal T Cell Lymphoma: A Case Report/K.J. Kokesh, Gainesville, FL
- P779** Malignant Pleural Mesothelioma And Lung Cancer In A Very Young Age/N.T. Lopes, Dili, Timor-Leste
- P780** Unusual Etiology Of Mediastinal Mass In A Pediatric Patient: Extra-osseous Ewing's Sarcoma/K. Reiling, Houston, TX
- P781** Challenges In The Management Of Rare Pediatric Oncology Cases With Radiation Pneumonitis/S. Cohen, Utrecht, Netherlands
- P782** A Case of Post-traumatic Pneumonia/S.J. Deskins, Morgantown, WV
- P783** Primary Pulmonary Mucoepidermoid Carcinoma in a Pediatric Patient/M. Thanawala, Houston, TX
- P784** Endobronchial Mass In Patient With Very Early Onset Inflammatory Bowel Disease On JAK Inhibitor: TB Or Not TB/A. Espaillet, Chapel Hill, NC
- P785** Mycobacterium Avium Complex Associated Mediastinal Lymphadenitis And Endobronchial Lesion In A Previously Healthy Infant/R. Ronau, Columbus, OH
- P786** Severe Legionella Infection In A Neonate Resulting In Cheyne-Stokes Respiration(CSR) After ECMO Resuscitation/Y. Mandal, Dallas, TX
- P787** A Child With COVID-19 Complicated by Rapidly Progressive Severe Organizing Pneumonia/A. Dutta, Honolulu, HI
- P788** Post-COVID-19 Bronchiolitis Obliterans in a Neonate/S.J. Rose, Cincinnati, OH
- P789** Lung Abscess As A Delayed Complication In A Child With A Mild Covid-19 Pneumonia - A Case Report/S.G. Hamad, Doha, Qatar

- P790** Right Upper Lobe Round Opacity in Infant With COVID-19: An Uncommon Presentation of a Common Entity. A Case Report/L. Miller, Bronx, NY
- P791** COVID-19 and Pneumocystis Jirovecii Pneumonia in a Previously Healthy Pediatric Patient With Undiagnosed Human Immunodeficiency Virus/A.T. Meltzer-Bruhn, Philadelphia, PA
- P792** Pediatric Influenza and Respiratory Syncytial Virus (RSV) Rates During Anti-COVID-19 Public Health Measures in the West Virginia University (WVU) Health System/C.B. Lewandrowski, Morgantown, WV
- P793** Spontaneous Pneumomediastinum in a Previously Healthy Female Adolescent With Mild COVID-19 Infection/K. Zahradin, Doha, Qatar

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

C60 CHILDHOOD INTERSTITIAL LUNG DISEASE (chILD)

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area H, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P795** Estimating the Effect of Nintedanib on Forced Vital Capacity in Children and Adolescents With Fibrosing Interstitial Lung Disease: Extrapolation Using a Bayesian Borrowing Approach/T.M. Maher, Los Angeles, CA
- P796** A Division-wide Biobank and Patient Registry to Catalyst Pediatric Pulmonary Translational Research/C. Garcia De Alba Rivas, Boston, MA
- P797** Healthcare Utilization in Childhood Interstitial Lung Disease: A Report From a Major Tertiary Care Center/L.M. Feld, Philadelphia, PA
- P798** Validation of Diagnostic Coding for Children's Interstitial Lung Disease (chILD)/K. Garagozlo, New York, NY
- P799** Clinical Outcomes of Pediatric Patients With Post-infectious Bronchiolitis Obliterans (PIBO) Treated With Intravenous Immunoglobulin (IVIG)/A.T. Samad, Boston, MA
- P800** Exploring the Role of Steroid and Hydroxychloroquine Treatment in Child With Pulmonary Fibrosis/B.E. Kiraci, Ankara, Turkey
- P801** Polysomnography Findings in Children's Interstitial Lung Disease (chILD)/R.R. Inja, New York, NY

- P802** A Case of Diffuse Lung Disease Consistent With Surfactant Protein C Deficiency With a Single Splice Region Variant of Uncertain Significance as a Potential Genetic Etiology/L. Murray, New York, NY
- P803** An Additional ABCA3 Mutation May Worsen SFTPC Associated Childhood Interstitial Lung Disease./S. Karandashova, San Francisco, CA
- P804** Interstitial Lung Disease In A Patient Heterozygous For Two Previously Undescribed VUS In SFPTC./S. Karandashova, San Francisco, CA
- P805** A Rare Pediatric Case of Anti-melanoma Differentiation-associated Gene 5 Rapidly Progressive Interstitial Lung Disease/K. Gallagher, Seattle, WA
- P806** A Rare Case of Interstitial Lung Disease and Pulmonary Hypertension Associated With NKX2-1 Mutation/J. Ni, Palo Alto, CA
- P807** Pulmonary Hemorrhage and Massive Air-leak: An Atypical Presentation for Pulmonary Interstitial Glycogenosis/L.A. Garcia Bonilla, Toronto, Canada
- P808** Neonatal Presentation of Hermansky Pudlak Type 2 Lung Disease/T. Baumann, Boston, MA
- P809** Miliary Pattern Chest Imaging Presentation of COPA Syndrome in a Pediatric Patient/C. Mertens, Birmingham, AL
- P810** Nehi And Lows: A Case Of Persistent Nehi In A Seventeen Year Old/K. Jordan, Aurora, CO
- P811** Low Serum Progranulin Levels as a Biomarker in the First Reported Case of Progranulin (GRN) Variant Associated Fibrotic Lung and Liver Disease/J.C. Kennedy, Boston, MA

CLINICAL

THEMATIC POSTER SESSION

C61 CLINICAL CASES IN PEDIATRIC SLEEP

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area H, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P813** Novel PHOX2B Variant In An Infant With Congenital Central Hypoventilation Syndrome And Neuroblastoma/M.E. Fain, Atlanta, GA
- P814** Central Hypoventilation In A Child With SARS-CoV-2 Infection: A Diagnostic Challenge/H. Kammouh, Doha, Qatar

- P815** A Case of Rapid-Onset Obesity With Hypothalamic Dysfunction, Hypoventilation And Autonomic Dysregulation (ROHHAD) Diagnosed Perioperatively/M. Wyatt, Nashville, TN
- P816** Sleep And Respiration In An Infant With Joubert Syndrome/K.M.O. Bartolome, Quezon City, Philippines
- P817** Severe Sleep Apnea and Congenital Craniofacial Anomalies - Successful Use of Noninvasive Ventilation During Tracheostomy Decannulation Evaluation/C. Giles, Denver, CO
- P818** Polysomnography Should Be Part of Inpatient Management for Complex Metabolic Disorders/M.C. Ortiz, Washington, DC
- P819** Poison Hemlock Induced Central Apnea/S.J. Rose, Cincinnati, OH
- P820** An Unusual Etiology Of Persistent Stridor, Dysphagia And Severe OSA In An Infant/T. Chair, Madison, WI
- P983** An Unusual Case Of Acute Pulmonary Emboli And Methamphetamine Use Resulting In Acute Right Ventricular Failure Requiring Extracorporeal Membranous Oxygenation/A.A. Self, La Jolla, CA
- P984** Undiagnosed Lung Adenocarcinoma Causing Rapid Respiratory Failure: A Case Of Pulmonary Tumor Thrombotic Microangiopathy/L. Ward, Los Angeles, CA
- P985** Glue Embolism Following Variceal Sclerotherapy/S. Correa, Newark, NJ
- P986** Diagnostic Dilemma in the Pulmonary Arteries: IgG4 Related Vasculitis vs Takayasu Arteritis/D. Rongo, Dallas, TX
- P987** A Middle-aged Woman With Dyspnea, Weight Loss, And Pulmonary Hypertension/P.S. Bhatt, Cambridge, MA
- P988** Pulmonary Artery Angiosarcoma Masquerading as a Pulmonary Embolism/W. Ali, McKeesport, PA
- P989** Phlegmasia Cerulea Dolens in May-Thurner Syndrome and Lung Adenocarcinoma/C. Tseng, Danbury, CT
- P990** Concrete Evidence That Osteoporosis Can Make You Breathless/E. Wiltchik, Loma Linda, CA
- P991** The Straw That Broke the Camel's Back - Pulmonary Artery Dissection Following Discontinuation of Tadalafil in a Patient With Severe Pulmonary Hypertension and Recurrent Pulmonary Emboli/K. Gooding, Hartford, CT
- P992** When Pulmonary Embolism Encountered Cerebral Infraction, What Is Behind?/F. Xu, Beijing, China
- P993** The Clot Is Always Thicker on the Other Side - A Case of Pulmonary Venous Thrombosis/G. Boghdadi, Washington, DC
- P994** Pulmonary Artery Atresia With Non-opacification of Distal Branches as a Consequence of Pulmonary Thromboembolism/S. Price, Olympia Fields, IL
- P995** A Case of Iatrogenic Cardiac Tamponade as a Complication of Mechanical Thrombectomy for Pulmonary Embolism/B. Perez Gandara, Brooklyn, NY
- P996** Peripherally Inserted Catheter (PICC) Line Related Right Heart Thrombus And Pulmonary Embolism: A Rare Case/T.N. Jasty, West Reading, PA
- P997** A Case of Extrinsic Bronchial Obstruction By Pulmonary Vasculature/R. Ali, Harrisburg, PA
- P998** Takayasu Arteritis And Ulcerative Colitis: Rare Diseases With A Frequent Co-occurrence/G. Palmer, Madison, WI
- P999** Incidental Finding Of Air Embolism In Left Brachiocephalic Vein After Contrast Injection/R. Garg, Wilkes-Barre, PA
- P1000** Point Of Care Ultrasonography - One Step Ahead In Decreasing Mortality Of Acute Pulmonary Embolism/S. Pate, Paterson, NJ

CLINICAL

THEMATIC POSTER SESSION

C62 CANCER, CLOTS, AND OTHER PULMONARY VASCULAR OBSTRUCTIONS

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**
Area J, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P977** Unilateral Pulmonary Tumor Emboli And Lymphangitic Carcinomatosis From Pancreatic Neuroendocrine Tumor/D. Witt, Chapel Hill, NC
- P978** Disappearing Pulmonary Nodules With Developing Demyelination: A Case Of Myeloperoxidase Antibody Positive Vasculitis With IgA Deposition On Kidney Biopsy/A. Alam, Royal Oak, MI
- P979** Pulmonary Artery Stump Thrombosis Following Lobectomy/M. Agustin, Dededo, Guam
- P980** Mimicry On CT: When A Pulmonary Embolism Is Not What It Seems/H. Bakalli, Los Angeles, CA
- P981** Looking Back In Time: A Case Of Metastatic Pancreatic Cancer In A Patient With Chronic Thromboembolic Pulmonary Hypertension/A. Gottlieb, Boston, MA
- P982** Sub-massive Pulmonary Embolism Complicated By Massive Hemoptysis: Role Of Bronchial Artery Embolization/H.T. Khan, Morgantown, WV

- P1001 Pulmonary Embolism in Hemolysis Elevated Liver Enzyme Low Platelet Count (HELLP) Syndrome/A.** Thomas, Knoxville, TN
- P1002 A Melting Pot of Etiologies: A Curious Case of Pulmonary Embolism in Patient With Pleomorphic Sarcoma on Anticoagulation/P.** Shekar, Hartford, CT
- P1003 “Between Scylla and Charybdis” - Severe Right Ventricular Dysfunction Due to Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Life Threatening Thrombocytopenia/G.S.** Bodi, Abu Dhabi, United Arab Emirates
- P1004 A Rare Presentation of Provoked Symptomatic Subsegmental Pulmonary Embolism and Extensive Deep Venous Thrombosis Secondary to Enlarged Globular Uterus and Oral Contraceptive Use in a Young Black Woman With Multiple Sclerosis/P.** Makar, Olympia Fields, IL
- P1005 Old Clots, New Problem/G.** Habib, Syracuse, NY
- P1006 Hidden In Plain Sight: A Case Of Right Ventricular Thrombus/A.** Sekar, Worcester, MA
- P1007 A Case Of Rapidly Progressive Chronic Thromboembolic Pulmonary Hypertension/H.** Zhang, Boston, MA
- P1008 Two Cases of Pulmonary Vascular Lesions Presenting to the Rapid Access Lung Cancer Clinic (RALC)/P.** Ridge, Dublin, Ireland
- P1009 Groundglass Opacities in Pulmonary Embolism/A.** Schwartz, Iowa City, IA
- P1010 A Rare Case of Systemic Thrombolysis Failure in Massive Pulmonary Embolism Requiring Catheter-directed Intervention/S.S.** Rijal, West Reading, PA
- P1011 Pulmonary Embolism Diagnosed by Endobronchial Ultrasound/V.A.** Zavala Gonzalez, Providence, RI
- P1012 Now You See It, Now You Don't: The Faux PE/A.J.** Brownstein, Los Angeles, CA
- P1013 Not All Mediastinal Masses Are Cancer: A Case for Mediastinal Lipomatosis as a Nidus for Pulmonary Embolism/S.** Iriana, Fresno, CA
- P1014 Post-covid-19 Subsegmental Pulmonary Embolism With Hemoptysis/W.S.** Sango, Farmington, CT
- P1015 A Strain on My Heart: Saddle Pulmonary Embolism in a Patient Who Could Not Undergo Anticoagulation/J.P.** Im, Red Bank, NJ
- P1016 Uncommon Complication of a Common Procedure/J.** Hawkins, Athens, GA
- P1017 Diagnostic Dilemma Of Acute Coronary Syndrome Vs. Pulmonary Embolism/M.** Malik, Harrisburg, PA

- P1018 Therapeutic Dilemma in a Case of Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) With Direct Oral Anticoagulant (DOAC) Failure Complicated by a Hematoma/A.K.** Rayapureddy, Brooklyn, NY

CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

C63 THINKING OUTSIDE THE BOX: NEW INSIGHTS INTO SUBGROUPS OF PULMONARY HYPERTENSION

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area G, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P679 Review of Portopulmonary Hypertension Prevalence at Mayo Clinic in Arizona, Florida, and Minnesota/H.** Saunders, Jacksonville, FL
- P680 Methamphetamine Associated Pulmonary Hypertension Outcomes Report: A Literature Review/N.** Manjappachar, Annapolis, MD
- P681 Prevalence of Secondary Pulmonary Hypertension and Related In-hospital Mortality in Elderly Patients With Obstructive Sleep Apnea Among Demographically Matched Cohorts of Male and Female: National Inpatient Sample Analysis 2019/M.** Gudiwada, Chicago, IL
- P682 Effect of Targeted Pulmonary Arterial Hypertension Therapy on Arterial Oxygenation in Patients With Pulmonary Hypertension Associated With Lung Disease: A Systematic Review and Meta-analysis/I.** Blanco, Barcelona, Spain
- P683 Screening for Pulmonary Hypertension in Interstitial Lung Disease in Rural Appalachia/V.** Deepak, Morgantown, WV
- P684 Racial Differences In Pulmonary Arterial Hypertension/H.** Channa, Shreveport, LA
- P685 Clinical Outcomes in Patients With a History of Obstructive Sleep Apnea and Pulmonary Hypertension Who Were Hospitalized With Acute Respiratory Failure and Are Affected by Non-rheumatic Mitral Valve Stenosis/G.A.** Asmar Vargas, Cincinnati, OH
- P686 Clinical Outcomes in Patients With a History of Systemic Sclerosis and Pulmonary Hypertension Who Were Hospitalized With Acute Respiratory Failure and Were Affected by Protein-Calorie Malnutrition/G.A.** Asmar Vargas, Cincinnati, OH

- P687** Disproportionate Impairment in Diffusing Capacity Is a Predictor of Pulmonary Vascular Resistance in Chronic Obstructive Pulmonary Disease/A. Balasubramanian, Baltimore, MD
- P688** Sub-Maximal Exercise Testing in Interstitial Lung Disease: Assessing the Role of GXCAP to Detect Concomitant Pulmonary Hypertension/N. Moallem, Farmington, CT
- P689** Utility of Pulmonary Function Testing in Detection of Pulmonary Hypertension in COPD/M. Sameed, Cleveland, OH
- P690** Increased Risk of Post-liver Transplant Pulmonary Complications in Patients With Abnormal Non-invasive Hemodynamics, Even Without Significant Pulmonary Hypertension/A.C. Osuji, Chicago, IL
- P691** Characteristics of WHO Group 3 Pulmonary Hypertension Patients With Positive Vasoreactivity: Data From a Single Center/C. Tanba, Baltimore, MD
- P692** Association Between Pulmonary Hemodynamic Responses to General Anesthesia and Perioperative Outcomes in Congenital Heart Disease Associated Pulmonary Arterial Hypertension/H. Zhang, Beijing, China
- P693** Characteristics of Exercise Intolerance in Different Subgroups of Pulmonary Arterial Hypertension Associated With Congenital Heart Disease/H. Zhang, Beijing, China
- P694** Variability in the Calculation of Pulmonary Vascular Resistance in Patients With Idiopathic Pulmonary Fibrosis/O.J. Cantres, Fairfax, VA
- P698** Impact of Pulmonary Hypertension on In-hospital Outcomes and Healthcare Utilizations Among Patient Admitted With COVID-19 Infection in 2020/N.A.N. Patel, Valenzuela, Philippines
- P699** Pulmonary Hemorrhage in COVID-19: A Systematic Review/I. Ogbuka, Knoxville, TN
- P700** Pulmonary Vascular Effects of a Personalized Rehab Program in Patients With Post-Acute Sequelae of COVID-19 (PASC)/W. Dierckx, Kontich, Belgium
- P701** Complement Activation in Lung Endothelial Cells Contributes to Endothelial Inflammation Induced by SARS-CoV-2 in Hypoxia/H. Zhang, Aurora, CO
- P702** Echocardiographic Findings in Patients With COVID-19-related Venous Thromboembolism/A. Jones, Miami, FL
- P703** Right Ventricular Systolic Pressure in Coronavirus Disease 2019 (COVID-19) Patients/A.A. Vazquez-Suarez, Heroica Matamoros, Mexico
- P704** Characteristics of Patients With Post-COVID-19 Pulmonary Embolism/B.A. Milenkovic, Belgrade, Serbia
- P705** Post-COVID-19 Patients Show Vascular Sequelae That Last Up to 6 Months/P. Poyatos, Salt, Girona, Spain
- P706** Influence of the Day of Admission on Mortality and Other Outcomes Among Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With Acute Pulmonary Embolism: A Nationwide Analysis/B.A. Casipit, Philadelphia, PA
- P707** The Value of D-dimer Elevation for Prediction of Pulmonary Embolism in Patients With Baseline Elevation Due to COVID-19/S. Treat, Knoxville, TN

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

C64 EXPANDING THE VENN DIAGRAM: COVID-19 AND THE PULMONARY VASCULATURE

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**
Area G, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P696** Transcriptomic Signature of Acute VTE Associated With SARS-CoV-2 Infection; Single Center Retrospective Observational Study/S.B. Brosnahan, New York, NY
- P697** Role of Toll-like Receptor 3 Deficiency in the Pathobiology of SARS-CoV-2 Associated Lung Vascular Remodeling/L. Farkas, Columbus, OH

CLINICAL

THEMATIC POSTER SESSION

C65 A LOT OF FUNGI!

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**
Area C, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P249** Case Of Disseminated Blastomycosis With Laryngeal Involvement/P. Shelley, Louisville, KY
- P250** Disseminated Mucormycosis in a Non-neutropenic Patient: An Autopsy Case Report/C. Perez, Akron, OH
- P251** A Case of Severe Invasive Pulmonary Aspergillosis in COVID-19 Patient/S. Khan, Joplin, MO

- P252 Hemoptysis and Tree-in-bud Pattern: The Alarming Manifestations for Aspergillus Bronchitis**/G.M. Gonzalez Santiago, San Juan, PR
- P253 Creeping on the Cryptococcus: Use of Robotic Bronchoscopy in Diagnosis of Pulmonary Cryptococcus**/F.A. Yazdi, Shreveport, LA
- P254 Fungus Among Us: A Case of Disseminated Histoplasmosis in an Immunocompetent Patient**/M. Whittaker, Lexington, KY
- P255 Beware Of The Acute Respiratory Distress Syndrome In A Pulmonary Blastomycosis**!/A. Vangara, Harlan, KY
- P256 Cryptococcal Tracheitis in an Immunocompetent Adult**/M. Watson, Aurora, CO
- P257 Itraconazole Induced Bradycardia: A Quandary For Low Resource Settings**/T.T.R. Ayo-Olagunju, Lagos, Nigeria
- P258 Rare Diagnosis in Abscedate Lung Lesion: A Case of Pulmonary Mucormycosis**/F.F. Fernandes, Brasilia, Brazil
- P259 A Rare Case Of Co-infection With Escherichia Coli And Blastomycosis**/P. Patel, Allentown, PA
- P260 Chronic Pulmonary Aspergillosis In Patient With Post-Tuberculosis Treatment And Recurrent Hemoptysis**/A. Purwono, Jakarta, Indonesia
- P261 Fatal Acute Respiratory Distress Syndrome Secondary To Histoplasmosis In An Immunocompetent Patient**/J. Shupak, Winston-Salem, NC
- P262 Purpureocillium Iliacinum Pulmonary Infection In An Immunocompetent Patient**/H. Kramer, Richmond, VA
- P263 Invasive Aspergillosis Misdiagnosed as Malignancy, the Slow Brewing Catastrophe**/N. Madala, Athens, GA
- P264 Significant Weight Loss Secondary to Cryptococcus Pneumonia in Immunocompetent Patient**/E. Karem, Huntington, WV
- P265 An Unusual Case of Chronic Cough: Cladosporium Pneumonia**/E.-H. Hassanin, Tyler, TX
- P266 When Fun-gi Becomes the Bad Guy: A Fatal Case of Invasive Mucormycosis**/M. Shrestha, Reading, PA
- P267 Hyphae Hemorrhage: A Case of Pulmonary Aspergilloma**/B.D. Garcia, New York, NY
- P268 Cryptococcal Pneumonia in an Immunocompetent Adult**/R. Dalbah, Johnson city, TN
- P269 Inside The Cavity: A Case of Invasive Pulmonary Aspergillosis**/L.I. Mendez Morente, Miami Beach, FL
- P270 Masslike Consolidation in Allergic Bronchopulmonary Aspergillosis**/N. Siddiqui, Queens, NY
- P271 A New Host: A Case of Aspergillosis in a Patient on a Tyrosine Kinase Inhibitor**/B. Fitzgerald, Aurora, CO
- P272 A Lung Blasted With Blastomycosis: A Case of Necrotizing Pneumonia**/S. Nagpal, Johnson, TN
- P273 One Cavity, Many Inhabitants: A Case of Invasive Lung Aspergillosis and Recurrent Nontuberculous Mycobacterial Infection in a “New” Upper Lobe**/Z. Greenstein, Brooklyn, NY
- P274 A Rare Presentation of Pneumothorax Secondary to Pneumocystis Pneumonia**/S.M. Hussain, Rochester, MI
- P275 Pneumocystis Jirovecii Pneumonia Presenting As Diffuse Lung Cysts**/K. Muralidharan, Bridgeport, CT
- P276 Thrombocytopenia: A Unique Presentation of Invasive Aspergillosis**/J. Pangburn, Indianapolis, IN
- P277 A Rare Case of Pulmonary Mucormycosis in an Immunocompetent Patient**/S.K. Mahmood, Charleston, WV

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

C66 VIRAL INFECTIONS, COVID, AND BEYOND

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Area C, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P279 RESP Pilot of a Cohort of Healthy Individuals at Seasonal Risk for Viral Infection**/M. Glass, Philadelphia, PA
- P280 Viral Pneumonia Elicits a Lung Epithelial Repair Program in Transdifferentiating Alveolar Macrophages Characterized by Placenta-expressed Transcript 1 (PLET1) Expression, Therapeutic Implications**/L. Pervizaj-Oruqaj, Giessen, Germany
- P281 Modeling Inducible Epithelial Resistance Against Murine Betacoronavirus**/M.K. Longmire, Houston, TX
- P282 Mystery Pneumonia With Effusions - A Rare Complication of Coxsackie B Viral Infection**/M. Rehan, Atlantis, FL
- P283 Clinical Outcomes of COVID-19 in Patients With COPD or Asthma in Hawaii, 2020-2021**/S. Pyskir, Honolulu, HI
- P284 Covid-19: Persistent Refractory Hyperkalemia With Hemodialysis**/Z.T. Oo, Bronx, NY
- P285 Using D-dimer Levels to Predict the Likelihood of Venous Thromboembolism (VTE) in Hospitalized Patients With COVID-19**/A. Goldstein, Wilmington, NC
- P286 Measuring the Likelihood of Pneumothorax in COVID-19 Patients With Non-alcoholic Fatty Liver Diseases**/R. Ramachandran, Arlington, TX

- P287 An Uncommon Case of Shock in a Patient With COVID-19 Pneumonia/V. Somnay, Louisville, KY**
- P288 Spontaneous Pneumothorax Following COVID19 Infection With Recurrent Respiratory Failure/D. Bhattarai, Danbury, CT**
- P289 Prognostic Value of Albumin Globulin Ratio in COVID-19 Patients in a Community Hospital in Newark: A Retrospective Analysis/K.K. Trivedi, Newark, NJ**
- P290 Temporal Dynamics in SARS-CoV-2 Viral Shedding: A Report of 3 Cases Diagnosed With COVID-19 Pneumonia by BAL With Serial Negative NPS/F. Poli, Miami, FL**
- P291 Predictors of Mortality of Hospitalized Patients With COVID 19 Pneumonia/M.K. Ahmed, Assiut, Egypt**
- P292 COVID-19 Pneumonia Complicated by Pulmonary Embolism and Delayed Empyema/C. Tseng, Danbury, CT**
- P293 Neutralizing Antibody Response Against SARS CoV2 Among Adult Individuals Immunized With a COVID-19 Vaccine/R.S. Pagcatipunan, Quezon City, Philippines**
- P294 A Systematic Review and Meta-analysis of Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection With Mega Dose Vitamin D/M. Nguyen, Las Vegas, NV**
- P295 Complete Resolution of Lung Cavitory Mass Following COVID-19 Infection/E.L. Amaechi, Bronx, NY**
- P296 Possible and Confirmed COVID-19 Patients Data at Our Hospital/T. Ozlu, Trabzon, Turkey**
- P297 Pathogen-Agnostic Transcriptional Responses Are Preserved in Mouse and Human Lung Epithelium During Inducible Resistance Signaling Against Respiratory Infections/J. Pantaleón García, Houston, TX**
- P298 Toll-like Receptor-9 Activation Promotes Persistent Inflammation in the Lung During Influenza Infection/H. Essayas, New Haven, CT**
- P299 Efficacy of Bacterial Lysate OM-85 in Murine Rhinovirus1b-Infection Models/H. Obernolte, Hannover, Germany**
- P300 Secondary Acrocyanosis, the Only Visible Sign Present in a “Long COVID” Patient/S.M. Rosa Santiago, San Juan, Puerto Rico**
- P301 COVID-19 and Empyema: Review of an Uncommon Complication From a Case Report/A.J. Duval, Newark, NJ**
- P302 Metabolite Profiling of Unsaturated Fatty Acids in Bronchoalveolar Lavage in the Acute, Recovery and Convalescent Phases of SARS-CoV-2 Infection/H. Wang, Bethesda, MD**
- P303 A Novel Dry Powder, ABN101 Broad-spectrum, Anti-viral Inhaler to Avoid and Treat Global Respiratory Virus Pandemics/H.S. Choi, Seoul, Korea, Republic of**
- P304 12-Month Follow-up Study of Patients After Hospitalization for COVID-19/I.O. Rosas, Houston, TX**
- P305 Engineered Derivative of Soluble ACE2 for Enhanced Catalytic Activity and Pharmacokinetics Shows Profoundly Improved Therapeutic Efficacy for SARS-CoV-2-induced Lung Injury and Mortality/L. Zhang, Pittsburgh, PA**
- P306 The Impact of the Microbiome on Pathophysiology Following Early-life Respiratory Syncytial Virus Infection/K. Yagi, Ann Arbor, MI**
- P307 Differences in the Longitudinal Blood Proteomic Profiles of Vaccinated and Unvaccinated SARS-CoV-2 Patients/J.A. Huapaya, Bethesda, MD**
- P308 Chlorpheniramine Intranasal Spray (0.4%) to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: Accros III/F.R. Valerio Pascua, San Pedro Sula, Honduras**
- P309 Comparison of Patient-Reported Post-acute Sequelae SARS-CoV-2 (PASC) Respiratory Symptoms With Pulmonary Function Tests (PFTS) in a Post-COVID Patient Population/J. Cirillo, New York, NY**
- P310 Patient Characteristics and Clinical Outcomes of Adults Hospitalized With Viral Lung Infection: A US Claims Database Study/B. Emmanuel, Gaithersburg, MD**
- P311 Pulmonary Embolism (PE) in COVID-19 Patients at Five Scripps Health Hospitals, 2020-2021: Analysis of Clinical Characteristics and Outcome Indicators/C. Suh, La Jolla, CA**
- P312 Bacterial Coinfections in COVID-19 Patients With Acute Respiratory Failure: Japan National Registry Survey/K. Yamamoto, Okinawa, Japan**
- P313 Cannabis Smoke Exposure Hinders Viral Clearance and Suppresses Immune Responses to Influenza A Infection in Mice/N. Milad, Hamilton, Canada**
- P314 Severity of Dyspnea During Hospitalization and Post-hospitalization Among Mild and Moderate COVID-19 Patients at Persahabatan Hospital Jakarta, Indonesia/A.R. Dinni, Jakarta, Indonesia**

BASIC • CLINICAL • TRANSLATIONAL

THEMATIC POSTER SESSION

C67 DON'T FORGET ABOUT THESE UNUSUAL LUNG INFECTIONS9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area C, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session **11:30-1:15****Discussion:** 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P317 Clinical Spectrum of Pulmonary Melioidosis From an Eastern Indian Hospital/P.R. Mohapatra, Bhubaneswar, India**
- P318 Disseminated Pulmonary Hydatidosis/T.H. Ahmed Zobair, Cape Town, South Africa**
- P319 Extensive Bilateral Pulmonary Nodular Disease: A Rare Case of Leptospirosis With Widespread Pulmonary Involvement in New England/N. Korchemny, Brighton, MA**
- P320 Severe Disseminated Toxoplasmosis Pneumonia in an Immunocompetent Adult/L. Hayes, Tampa, FL**
- P321 Pulmonary Syphilis Masquerading as Sarcoidosis/V.V. Vaidya, Morgantown, WV**
- P322 A Case of Disseminated Nocardiosis in an Immunocompetent Host/A.R. Grassi, Rochester, MN**
- P323 Spatial Development of Human Papillomavirus (HPV)-associated Tracheal Papilloma, Cervical Intraepithelial Neoplasia, and Skin Squamous Cell Carcinoma/A. Lam, Urbana, IL**
- P324 Pulmonary Toxoplasmosis Diagnosed With Metagenomics/R.D. Struble, Iowa City, IA**
- P325 Pulmonary Nocardiosis: An Early Diagnosis Through Free DNA Testing/J. Gala, Champaign, IL**
- P326 Nocardia Pneumonia Presenting As Bacteremia/G. Stone, Los Angeles, CA**
- P327 Pet Dogs, Episodic Asthma-like Symptoms, and Eosinophilia: A Conundrum of Echinococcus, Strongyloidiasis, and Mycobacterium Gordonae/I. Ikwu, Washington, DC**
- P328 Pulmonary Nocardiosis in an Immunocompetent Man: A Diagnostic Challenge/V. Deenadayalan, Chicago, IL**
- P329 A Case of Nocardia Niwae Pulmonary Brain Syndrome in a Kidney Transplant Recipient Following COVID-19 Infection/L.I. Mendez Morente, Miami Beach, FL**
- P330 Actinomyces Meyeri Empyema: Evaluating New Diagnostics and Old Treatment Paradigms/N. Van Ochten, Aurora, CO**
- P331 Cavitory Pulmonary Lesions Caused By Actinomyces Odontolyticus In The Presence Of Haemophilus Parainfluenza Treated Successfully With Oral Antibiotics/K. Gharaibeh, Baltimore, MD**
- P332 Not So (Acid) Fast: Gordonia Species, an Emerging Respiratory Pathogen/G. Ang, Forest Hills, NY**
- P333 Case Report: Hemoptysis and Cavitory Lesions in a 14 y/o With Actinomyces Odontolyticus/E. Hernandez Caro, Valhalla, NY**
- P334 Pulmonary Actinomycosis : A Diagnostic Riddle/S. Mussarat, Norfolk, VA**
- P335 Disseminated Nocardiosis in an Immunocompetent Patient/R. Rangroo, Hudson, FL**
- P336 No Kidding, Nocardia?/I.C. Ugalde, Tampa, FL**
- P337 Legionella Pneumonia, Limitations of Urine Antigen Testing/M.F. Ahmed, New York, NY**
- P338 Extrapulmonary Legionella Pneumophila Presenting as Cerebellar Dysfunction and Severe Rhabdomyolysis in a Young, Healthy Male/L.M. De Rose, Detroit, MI**
- P339 Actinomyces Infection Presenting as an Endobronchial Mass/S.I. King, Aurora, CO**
- P340 Nocardia Beijingenesis Pneumonia Masquerading as a Lung Mass in an Immunocompetent Adult/K.M. Massad, Aurora, CO**
- P341 Perihilar Mass Revealing an Unusual Diagnosis of Actinomycosis: A Rare Case/A.S. Shaik, Darby, PA**
- P342 Legionnaires Disease Manifesting As An Acute Leukemoid Reaction/A.G. Isaac, Greenville, SC**
- P343 A Case of Neurocysticercosis With Pulmonary Involvement/R. Mirchin, Flushing, NY**
- P344 Disseminated Nocardiosis: Mimicking Metastatic Progression With Post-obstructive Pneumonia/M. Kabir, Kankakee, IL**
- P345 Ochrobactrum Anthropi: A Rare Case of Bizarre Pathogen Masquerading as Solitary Pulmonary Nodule/J. Lum, Kailua, HI**
- P346 Life Threatening Presentation of Weil's Syndrome Complicated by Diffuse Alveolar Hemorrhage/V. Xin, Royal Oak, MI**
- P347 Fever Of Unknown Origin Caused By Local Biohazard/K. Roth, Peoria, IL**
- P348 Pasteurella Multocida Pneumonia In An Immunocompetent Patient/A. Abdelmonem, Dallas, TX**

BASIC • TRANSLATIONAL

THEMATIC POSTER SESSION

C68 TOPICS IN AIRWAY AND ALVEOLAR EPITHELIAL CELL BIOLOGY9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area D, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session **11:30-1:15****Discussion:** 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P351 A Drug Screening System for Cystic Fibrosis Utilizing Stem-cell and Functional Imaging Technologies/Y.** Yamamoto, Kyoto, Japan
- P352 Rescue of Mutant CFTR Chloride Channels by a Mimetic Peptide Targeting the A-Kinase Anchoring Function of PI3K γ /A.** Della Sala, Turin, Italy
- P353 Cellular Senescence in the Cystic Fibrosis Bronchial Epithelium Is Inhibited by Fibroblast Growth Factor Receptor Blockade/M.** Easter, Birmingham, AL
- P354 Human Induced Pluripotent Stem Cell (hiPSC) Derived Lung Organoids for Disease Modelling/A.I.** Vazquez Armendariz, Giessen, Germany
- P355 Apical-out Airway Organoids and Airway-immune Co-cultures Are Suitable Models for Antiviral Compound Screenings and to Study Infectious Diseases/P.** Kramer, Vancouver, Canada
- P356 Lung Epithelial Redox Chaperones in Human Coronavirus Propagation/A.** Kumar, Burlington, VT
- P357 Annexin A2 Mediates Surfactant Dysfunction During Ventilator-Induced Lung Injury/I.D.** Bentley, Columbus, OH
- P358 Alveolar Type 2 Cell Growth Hormone Releasing Hormone Receptor (GHRH-R) Modulates Inflammatory and Fibrotic Signaling/R.M.** Jackson, Miami, FL
- P359 Late Response of Bronchial Epithelium to Rhinovirus in Severe Asthma/K.** Valette, Marseille, France
- P360 Aberrant Basaloid Cells and Closely Connected Intermediate State Cells Are Involved in the Injury Repair Process of the Fibrotic Lungs in the Aftermath of Severe COVID-19/A.** Balayev, New Haven, CT
- P361 Effect of Succinate Accumulation on GPR91 and Hypoxia Inducible Factor-1 α Expression in Airway Epithelial Cells/A.** Hudler, Aurora, CO
- P362 Ciliated Airway Epithelial Cell Numbers and Types Associate With 15 Lipoxygenase-1 (15LO1) Expression and Worse Asthma Outcomes/L.R.** Bradley, Pittsburgh, PA
- P363 Statins Block Hypercapnia- and Cigarette Smoke-induced Increases in ACE2 Protein Expression and Pseudo-SARS-CoV-2 Entry Into Airway Epithelial Cells/M.** Casalino-Matsuda, Chicago, IL
- P364 A Network-guided Analysis of P. Aeruginosa-infected Bronchial Epithelial Cells Reveals Putative Regulators of Viral-mediated Pulmonary Exacerbations/S.** Rousseau, Montreal, Canada
- P365 Hyperoxia-Induced Changes in Cell Survival Pathways Are Independent of Apoptosis Signal-Regulating Kinase 1 in Lung Epithelial Cells/S.** Dhar, Lexington, KY
- P366 In Vitro Pharmacological Characterization of TAVT-135, a Novel Chloride Ion Transporter for Pan-genotypic Treatment of Cystic Fibrosis/R.** Ilagan, King of Prussia, PA
- P367 Vitamin D Supplementation Decreases Liquid and Sodium Absorption Across Human Airway Epithelia/E.** Stapleton, Iowa City, IA
- P368 IL-13 Enhances Polyinosinic-polycytidylic Acid (Poly I:C)-induced Antiviral Responses Which Are Variably Modulated by the Mucin MUC4 in Human Airway Epithelial Cells (HAECs)/Q.** Wei, Pittsburgh, PA
- P369 Rothia Species Inhibit Rhinovirus-induced Moraxella Catarrhalis Cell Association in Airway Epithelium/E.** Dissanayake, Madison, WI
- P370 Airway Epithelial Cell pH Regulatory Protein Levels Differ Between Healthy Controls and Those With Cystic Fibrosis/J.L.** Saunders, Indianapolis, IN
- P371 Enhancement of rhCC10-mediated Anti-inflammatory Activity in Airway Epithelial and Vascular Endothelial Cells Through ROS- and RNS-mediated Modification/A.L.** Pilon, Rockville, MD
- P372 Interactions Between SCGB1A1 Protein and LPS/A.L.** Pilon, Rockville, MD
- P373 Autophagic Activity in Response to Nanoparticle Exposure of A549 Cells/A.** Sipos, Los Angeles, CA
- P374 Environmentally Persistent Free Radicals Modify Oxidative Stress Related Gene Expression in Well-Differentiated Human Nasal Epithelium/A.** Yamamoto, South Brisbane, Australia
- P375 Munc13-4 Complements Munc13-2 in Priming Granules for Stimulated Airway Mucin Secretion/J.R.** Flores Gonzalez, Harlingen, TX
- P376 Creation Bronchial of Epithelial Cell Lines Depleted of Mitochondrial DNA/M.V.** Novotny, Cleveland, OH
- P377 A Chronic Exposure of Endocrine Disruptors Cause the Cell Transformation in Human Lung Epithelial Cells/A.** Veerappan, New York, NY

- P378 RNA Sequencing Analysis: Exploring Genomic Effects of Safe Inhaled Alkaline Buffer Optate/I.A. Daniels, Indianapolis, IN**
- P379 Acidity Lowers the Purinergic Receptor Response by Protonating ATP/I. Thornell, Iowa City, IA**
- P380 RLS-0071, A Novel Dual-targeting Anti-inflammatory Agent, Demonstrates Proof of Mechanism in a Phase 1b Inhaled LPS Study Significantly Reducing Lung Neutrophils/J.M. Hohlfeld, Hannover, Germany**
- P381 Activation of Adam12-SDC4 and CCL22-CCR4 Pathways in the Airway in Asthma/G.L. Chupp, New Haven, CT**
- P382 Role of Fatty Acid Oxidation in Obesity Associated Acute Lung Injury/E. Kallinos, New York, NY**
- P383 Evaluating Pp2a B Subunits Ppp2r2b, Ppp2r2c, Ppp2r3a, and Ppp2r5d Cytokine Expression in Human Bronchiole Small Airway Epithelial Cells Smoke Damage Models/O. Ukponmwan, Brooklyn, NY**
- P384 Novel Fully Primary Human Airway Epithelium-Alveolar Macrophages In Vitro Co-cultures Models to Study Host Pathogen Interactions/X.-Y. Huang, Plan Les Ouates, Switzerland**
- P385 Regulation of Forkhead Box K2 (foxk2) By the E3-ligase F-box Only Protein 24 (fbxo24) Leads to Its Ubiquitination and Degradation in Lung Epithelia/R. Elmergawy, Columbus, OH**
- P386 Lung Extracellular Matrix Hydrogels - Derived Nanoparticles Contribute to Epithelial Lung Repair/A. Ulldemolins, Barcelona, Spain**
- P387 Development of Fully Primary Human 3D Alveolar Model (AlveolAir™)/C. Ferreira Lopes, Plan-les-Ouates, Switzerland**
- P388 All Cells That Wander in Monocle Are Not Lost: Trajectory Pathway Analysis of Airway Basal Cell After Chemical Inhalation Exposures/M.D. McGraw, Rochester, NY**
- P391 Association of Hair Follicle Gene Expression With Airway Lumen Size and Wall Area on CT in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)/K. Buschur, New York, NY**
- P392 Live Biotherapeutic Performs at Par With Steroids in Reducing Neutrophilic Inflammation in Models of COPD/C.V. Lal, Birmingham, AL**
- P393 A TP53 Genotype Affects Mucin Gene Expression and Survival of Female Embryos/M. Rahman, Boston, MA**
- P394 Loss of Cofilin-1 in an Unjammed Airway Epithelia of Chronic Obstructive Pulmonary Disease (COPD) Causes Mitochondrial Dysfunction/B. Ghosh, Baltimore, MD**
- P395 Targeting S100A9 Signaling Reduces Lung Cell Death and Inflammation in Alpha-1 Antitrypsin Deficiency/B. Jundi, Brooklyn, NY**
- P396 Nebulized Platelet-derived Extracellular Vesicles Attenuate Cigarette Smoke-induced Inflammation in a Murine Model/A. Alarcon-Calderon, Rochester, MN**
- P397 Lectin Complement Pathway Activation Is Necessary for Cigarette Smoke Induced Murine Lung Injury/I. Echelman, Denver, CO**
- P398 Novel Polycationic Glycopolymer Augments In Vitro Mucociliary Transport Rate in COPD Cell Cultures/K. Vijaykumar, Birmingham, AL**
- P399 Effects of Chronic Box Mod E-cigarette Aerosol Exposures on Organ Damage and Gene Expression in Mice/H. Chang, La Jolla, CA**
- P400 The Vascular Antiremodeling Effects of the Soluble Guanylate Cyclase Stimulator Bay 63-2521 Are Mediated by Inhibition of MAPK Pathways in Pulmonary Artery Smooth Muscle Cells/A. Bosacoma Armora, Madrid, Spain**
- P401 Lipid Peroxidation and Ferroptosis as Candidate Pathways of Heated Tobacco Product Toxicity in the Lung/K. Ganguly, Stockholm, Sweden**
- P402 Tozorakimab (Anti-IL-33) Rebalances COPD Epithelium Enhancing Club Cell Activities and Reshaping Viral Responses/X. Romero Ros, Cambridge, United Kingdom**
- P403 Characterizing the Role of Nephronectin in a Mouse Model of Emphysema/M. Jasicki, Madison, WI**
- P404 Monocyte Subsets and Their Mitochondrial Dynamics Are Disrupted in Alpha-1-Antitrypsin Deficiency/E. Leacy, Dublin, Ireland**
- P405 CEACAM6 as a Determinant of Lung Epithelial Cell Fate Upon Cigarette Smoke Exposure/C.-Y. Wu, Giessen, Germany**
- P406 Role of TGF- β in Cellular Senescence and Inflammaging by MicroRNA Mediated Gene Silencing/S. Chinnapaiyan, Miami, FL**

BASIC • TRANSLATIONAL
THEMATIC POSTER SESSION
C69 PRECLINICAL COPD MODELS: IN VITRO, EX VIVO, IN VIVO
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area D, Hall C (Lower Level)
Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P407** Oxidative State of Protein Disulfide Isomerase Regulates Mitochondrial Induced Apoptosis in Cigarette Smoke Exposed Cells/A. Blumental-Perry, Buffalo, NY
- P408** E-Cigarette Vaping Causes Mucociliary Dysfunction Through Impaired Autophagy/C.M. Royer, Davis, CA
- P409** Secretion Proteome Profiling of Airway Epithelial Cultures Exposed to Burn Pit Smoke Condensates Reveals Combustion Type Specific Toxicity Patterns and Cellular Damage/B. Reidel, Chapel Hill, NC
- P410** Inflammatory Profiling in Co-exposure of Ambient Particulate Matter (PM), Coronavirus Disease-2019 (COVID-19) and Lysophosphatidic Acid (LPA) a Ligand of the Receptor for Advanced Glycation End-product (RAGE)/S. Podury, New York, NY
- P411** Defining Volatile Organic Compound Signatures of Airway Epithelial Cells After Environmental Exposures/A. Linderholm, Davis, CA
- P412** Mimicking the Complex Phenotype of Chronic Obstructive Pulmonary Disease (COPD) in a Novel Pre-clinical Model: Combination of PPE, LPS and Poly IC in Mice/E. Tantillo, Parma, Italy
- P413** Circadian Reprogramming in Chronic Airway Disease/H. Mok, St. Louis, MO
- P414** Hypercapnia Induces Autophagy Arrest and Undermines Skeletal Myogenesis/A. Jaitovich, Albany, NY
- P415** Lysophosphatidylcholine Acyltransferase 2 Promotes Cigarette Smoke Induced Emphysema Via Platelet-activating Factor/H. Murano, Yamagata, Japan
- P416** Metabolomic Signatures in Mild COPD/K. Wong, New York, NY
- P417** Intermittent Hypoxia Alters Tissue-specific Circadian Transcriptome in a Mouse Model of Obstructive Sleep Apnea/B.S.C. Koritala, Cincinnati, OH
- P418** Type 1 Diabetes Accelerates Lung Damage in AAT Deficiency in Mice/S.S. Park, Brooklyn, NY
- P419** Alpha-1 Antitrypsin Deficiency Accelerates Progression of Smoke Induced Emphysema in a Ferret Model/S.S. Hussain, Birmingham, AL
- P420** Distinct Lung MicroRNA (miRNA) Signatures in Non-Small Cell Lung Cancer (NSCLC) and Chronic Obstructive Pulmonary Disease (COPD)/R. Esposito, Caserta, Italy

BASIC • TRANSLATIONAL

THEMATIC POSTER SESSION

C70 COPD (AND LUNG CANCER) CLINICAL AND TRANSLATIONAL STUDIES9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center****Area D, Hall C (Lower Level)****Viewing:** Posters will be on display for entire session**11:30-1:15****Discussion: 11:30-12:15** authors will be present for individual discussion**12:15-1:15** authors will be present for discussion with assigned facilitators.

- P423** Desert Particulate Matter From Afghanistan Increases Airway Obstruction in Human Distal Lungs Exposed to Type 2 Cytokine IL-13/D.L. Cervantes, Denver, CO
- P424** The BODE Index and Epigenetic Age Are Associated With All-cause and Cause-specific Mortality Among U.S. Veterans With COPD/E.S. Wan, Boston, MA
- P425** Association of Neutrophil Elastase-Rich Extracellular Vesicles With Lung and Systemic Inflammation in AATD Subjects/V.P. Trelles, Gainesville, FL
- P426** COPD Subtyping Using Graphical Models on Clinical and Biomedical Data/P.V. Benos, Gainesville, FL
- P427** Clinical Features of Genetic Resilience in COPD/A.J. Ghosh, Syracuse, NY
- P428** Unsupervised Discovery of Gene Expression Networks Associated With Pulmonary Function, Emphysema, and Smoking in COPD Gene/I.R. Konigsberg, Aurora, CO
- P429** Identification of Altered Protein and MicroRNA Signatures in Extracellular Vesicle-enriched Fractions of Bronchoalveolar Lavage Fluid From Patients With Chronic Obstructive Pulmonary Disease/M. Hylkema, Groningen, Netherlands
- P430** Expression Levels of MZB1 Reveal Two Distinct COPD Subtypes/Y. Lai, Pittsburgh, PA
- P431** Embryologic Origins of Obstructive Lung Disease: Perinatal Nicotine Exposure Promotes Expression of Tissue Remodeling Genes in Lung/J. Roman, Philadelphia, PA
- P432** Association of Clonal Hematopoiesis of Indeterminate Potential With Inflammatory Gene Expression in Patients With COPD/S. Mansouri, Bad Nauheim, Germany
- P433** Association of Immune Checkpoint Inhibitor Treatment and Emphysema Progression in Patients With Urothelial Cancer/S. Zo, Seoul, Korea, Republic of
- P434** ADAM-17 Concentration Is Increased in Severe Alpha-1-Antitrypsin Deficiency/E. Leacy, Dublin, Ireland

- P435** An Improved Method for Quantifying Emphysema and Establishing a Mouse Model of Emphysema Using Cigarette Smoke Exposure and H1N1 Influenza Virus Infection/Z.H. Negasi, Boston, MA
- P436** Comprehensive Analysis of Circulating Short Non-coding RNAs in the Plasma of Patients With Chronic Obstructive Pulmonary Disease/M. Shigematsu, Philadelphia, PA
- P437** Sputum Expression of AHRR Is Elevated Among Cigarette Smokers/M.F. Perez, Farmington, CT
- P438** Bronchial Field Basal Cells Show Methylome-Wide Characteristics Reflective of Smoking/K. Batbayar, Bronx, NY
- P439** A Potential Molecular Indicator of Emphysema/P. Pednekar, New Haven, CT
- P440** Systems Biology Analysis of Chronic Obstructive Diseases (COPD) Omics Data/S. Pontis, Parma, Italy
- P441** Blocking NOTCH3 Prevents Cigarette Smoke-induced Mucociliary Dysfunction in Airway Epithelial Cells of COPD Donors/N. Baumlin, Kansas City, KS
- P442** Different Responses of Human Endothelial Cells to E-cigarette Brands and Flavors/L. Martinez, Miami, FL
- P443** Spatial Transcriptomic Profiling Resolves Pulmonary Regional Specificity of Adam15 and Its Association With Emphysema Severity/J.D. Cala Garcia, Houston, TX
- P444** Role of Monocyte-related Chemokines in LPS Induced and COPD-related Lung Inflammation/C. Gress, Hannover, Germany
- P445** Sphingolipid Regulation of Lysosomal Initiation of Autophagy in Human Lung Microvascular Endothelial Cells Exposed to Cigarette Smoke/A. Borowiec, Denver, CO
- P446** Matrix Protein Tenascin-C May Promote the Airway Remodeling in Biomass Fuel Associated Chronic Obstructive Pulmonary Disease/B. Hao, Taiyuan, China
- P447** Single-cell RNA Sequencing Reveals Disease-specific Alterations in the Airway Epithelium of COPD/J.B. Blackburn, Nashville, TN
- P448** QKI Regulates Cell Proliferation and Cigarette Smoke-induced Cytotoxicity in Cultured Human Bronchial Epithelial Cells/K. Uemasu, Pittsburgh, PA
- P449** Biodistribution of Intravenously Administered Tozorakimab in Porcine Tissues/S.R. Krishnan, Gaithersburg, MD
- P450** Intranasal Administration of Genetically Modified Lactococcus Lactis Producing PD-L1 scFv Improves Survival in Lung Cancer Model Mice/N. Nomura, Nagano, Japan
- P451** The Prognostic Role of STAT5a Across Cancer Types/J. Li, La Jolla, CA
- P452** Identification of Exosomal microRNA 885 as Potential Biomarker of Lung Adenocarcinoma/D. Sanz Rubio, Zaragoza, Spain
- P453** Highly Sensitive Detection of ALK-TK Is Resistance Mutations by Oligoribonucleotide Interference-PCR (ORNi-PCR)/C. Tabe, Hiroasaki, Japan
- P454** The Role of BCL3 Dysregulation in the Pathogenesis of Asthma and Lung Cancer/L. Salameh, University of Sharjah, United Arab Emirates
- P455** Clinical Implications and Molecular Characterization of Drebrin-positive Tumor-infiltrating Exhausted T Cells in Lung Cancer/K. Imamura, Kumamoto, Japan
- P456** Extracellular Vesicles Selectively Purified From Exhaled Breath Condensates With EV-CATCHER Provide Deep Lung Tissue-specific miRNA Biomarkers/M. Mitchell, Nutley, NJ

BASIC • TRANSLATIONAL

THEMATIC POSTER SESSION

C71 NEW INSIGHTS IN BRONCHOPULMONARY DYSPLASIA

9:00 a.m. - 4:15 p.m. **Walter E. Washington Convention Center**
Area H, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P822** Whole Lung Proteomics in Bronchopulmonary Dysplasia/A.M. Dylag, Rochester, NY
- P823** The Role of Secreted Frizzled-Related Protein 1 in Lung Development and Bronchopulmonary Dysplasia/N.A. Rai, New York, NY
- P824** FGF Signaling Is Important for Prenatal Alveolar Fibroblast Specification/A. Perl, Cincinnati, OH
- P825** Pulmonary Live Biotherapeutic Product Reduces Neutrophilic Inflammation in Bronchopulmonary Dysplasia Through miR129-MMP-9 Pathway/C.V. Lal, Birmingham, AL
- P826** Alterations of Aerocyte Capillary Phenotype During Postnatal Development and in Response to Injury/D. Zhang, Palo Alto, CA
- P827** miR-17~92 Deletion in Alveolar Type 2 Epithelial Cells Versus Alveolar Fibroblasts Have Disparate Effects on Neonatal Alveolar Development/M.E. Robbins, Chicago, IL
- P828** Neonatal Hyperoxia Alters Monocyte Populations After Influenza Viral Infection in Wildtype Mice/Z.J. Johnson, Chicago, IL

- P829** **Transcriptional Characterization Suggests Dysregulated Mesenchymal ECM Production Is Associated With Compromised Branching in Trisomy 21 Lungs/S.**
Bhattacharya, Rochester, NY
- P830** **Single Cell RNASeq of Murine Developmental Mesenchymal Populations: Alveolar Myofibroblast Progenitors and Effects of Fgf18 Deficiency/J.** Koenitzer, Saint Louis, MO
- P831** **L-citrulline Mitigates the Pro-inflammatory Response of Neonatal Alveolar Type 1 Cells Exposed to Lipopolysaccharide and Tumour Necrosis Factor-alpha/A.** Mohammadi, Toronto, Canada

BASIC • CLINICAL • TRANSLATIONAL
THEMATIC POSTER SESSION
C72 HOUSE OF ARDS...AND MECHANICAL VENTILATORY SUPPORT
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area G, Hall C (Lower Level)
Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P709** **What Does the Ventilator Tell Us - Investigation of Position-dependent Lung Mechanics and Alveolar Dynamics in an ARDS Model in Rats/C.** Schnabel, Dresden, Germany
- P710** **Effect of Body Position and Body Mass Index (BMI) on Distribution of Ventilation/A.K.** Pearce, La Jolla, CA
- P711** **Lung Protective Ventilation in Occult Lung Injury/A.M.** Wallbank, Aurora, CO
- P712** **Alteration of PEEP Impacts End-expiratory Volume Variability and May Promote Ventilator Induced Lung Injury/E.K.** Smalley, Hobart, Australia
- P713** **Relationship Between Estimated Lung Volume and Expiratory Flow During Time-controlled Adaptive Ventilation/M.** Kollisch-Singule, Syracuse, NY
- P714** **The Role of Interspecies Variability on Positive- Versus Negative-pressure Ventilation Mechanics/M.** Eskandari, Riverside, CA
- P715** **Testing of Surfactant Preparations in the Ex Vivo Model Isolated Perfused Lung (IPL) Shows Very Good Recovery of Lung Function After Damage by Lavage/H.** Obernolte, Hannover, Germany
- P716** **Ventilation Strategies in Simulated Obstructive Lung Disease/U.** Majumdar, Cleveland, OH

- P717** **Comparison of Expert Recommended Ventilation Strategies in Simulated Obstructive Lung Disease/U.** Majumdar, Cleveland, OH
- P718** **Experimentally Induced Ventilator Dyssynchrony Increases Injury During Prolonged Ventilation of Endotoxin-injured Mice/H.** Farooqi, Aurora, CO
- P719** **Comorbid Obstructive Sleep Apnea in Patients Hospitalized With Acute Asthma Exacerbation/R.** Garikipati, Camden, NJ
- P720** **Clinical Characteristics of Patients With Amyotrophic Lateral Sclerosis at the Time of Non Invasive Ventilation Initiation/J.V.** Jimenez Ceja, New Haven, CT
- P721** **Oxygen Saturation-derived Ventilatory Drive for Non-invasive Quantification of Pharyngeal Pathophysiology/L.** Messineo, Boston, MA
- P722** **Evaluating the Capability of the Inspired Sinewave Technique to Measure Lung Deadspace and Volume in a Mechanical-ventilated Human Bench Lung Model/M.** Tran, Oxford, United Kingdom

TRANSLATIONAL
THEMATIC POSTER SESSION
C73 CHEST DISEASE CLINICAL CASES
9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center
Area G, Hall C (Lower Level)
Viewing: Posters will be on display for entire session **11:30-1:15**
Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P724** **Excessive Dynamic Airway Collapse Presenting as Cardiac Arrest: An Unusual Case/M.S.** Chhabria, Cleveland, OH
- P725** **Breath Taking Communications: An Unusual Case of Hypoxemia Secondary Left Subclavian Vein to Left Pulmonary Artery Shunt/S.T.** Virk, Pittsburgh, PA
- P726** **Idiopathic Recurrent Chyloptysis/J.** Tseng, Dallas, TX
- P727** **Mucolytics for Near-Fatal Asthma/E.C.** Thompson, Chapel Hill, NC
- P728** **The Birds: A Complex Case of Hypersensitivity Pneumonitis in a Pediatric Patient/V.** Danan, Boca Raton, FL
- P729** **Paratracheal Air Cysts in COVID-19, Large Airway Complication or a Predisposing Factor to Infection?/A.** Abo-Zed, Newark, NJ
- P730** **When a Routine Work-up for Cough Results in a Rare Diagnosis - A Case of Mounier-Kuhns Syndrome/R.** Patel, Norwalk, CT

- P731 Can Chronic Silent Micro-Aspirations Be the Culprit?: Achalasia Induced Interstitial Lung Disease/M.A. Khan, Long Branch, NJ**
- P732 When Food Takes Your Breath Away: Ingestion of an Allergen Manifesting as Pneumonitis/M.A. Khan, Long Branch, NJ**
- P733 The Clinical Decoding of Incidental Diffuse Dendritic Ossifications in a Patient With Lung Cancer/J. Dallarosa, Cleveland, OH**
- P734 Pulmonary Manifestations of a Rare Disease, Neurofibromatosis Type-1/H. Brar, Louisville, KY**
- P735 Diffuse Cavitating Pulmonary Meningotheliomatosis: A Rare and Elusive Pathology/C. Torrech Santos, San Juan, PR**
- P736 Rare Case of Asthma in Scimitar Syndrome/V. Moond, New Brunswick, NJ**
- P737 Near-Fatal Asthma and Extracorporeal Membrane Oxygenation: High-Risk High Reward/B. Ravichander, Harrisburg, PA**
- P738 Respiratory Failure Due to “Triple Overlap Syndrome” in a Young Woman With Obesity/S. Toth, Omaha, NE**
- P739 A Patient With Recurrent Breathlessness 1.5 Years After Diaphragmatic Plication/S. Shireen Kanamgode, Worcester, MA**
- P740 Out of Box and Out of Breath: A Case of Hemidiaphragmatic Paralysis Secondary to Removal of Central Venous Catheter/S. Shireen Kanamgode, Worcester, MA**
- P741 Catching Your Breath With ALS: A Rare Case of Bilateral Diaphragmatic Paralysis/M. Misiura, Allentown, PA**
- P742 A Case of Unilateral Diaphragm Paralysis After Trans-carotid Artery Revascularization (TCAR)/M.A. Faruqi, Lexington, KY**
- P743 Dyspnea and Dysphagia Due to Vascular Aberrancy/L.R. Ramirez, Rhode Island, RI**
- P744 A Breathtaking Trip to the Mountains: High-altitude Pulmonary Edema and Cor Pulmonale Complicate Chronic Obstructive Pulmonary Disease/C. Schott, Aurora, CO**
- P745 Large Intrapulmonary Bronchogenic Cyst Masquerading as Asthma/L. Appleton, Chapel Hill, NC**
- P746 Pneumorrhachis: A Rare Complication Of Asthma Exacerbation/G. Habib, Syracuse, NY**
- P747 Pneumomediastinum: A Complication of Acute Asthma Exacerbation/B. Ohiokpehai, Washington, DC**
- P748 A Case of Unidentified Relapsing Polychondritis of the Trachea in a Severe Asthmatic Patient/O. Iyamu-Osgiede, Philadelphia, PA**
- P749 Novel Regional Ventilation Imaging Effectively Assesses Biologic Treatment Response In COPD/P. Pirakalathanan, Carlton, Australia**
- P750 A Rare Case Of Swyer-james-macleod Syndrome Mimicking Pulmonary Embolism/Y. Sun, Montgomery, AL**
- P751 Post-COVID-19 Pulmonary Fibrosis: A Case Report/J. Cyriac, Tallahassee, FL**
- P752 Atraumatic Pulmonary Hernia, A Case Report/M.K. Vohra, Dallas, TX**
- P753 Tracheobronchomalacia in an Adult Patient With Rickets and Its Successful Treatment With Continuous Positive Airway Pressure (CPAP)/T.S. Alzahmi, Abu Dhabi, United Arab Emirates**
- P754 Documented but Not Uncommon: Case Report of Retropharyngeal and Mediastinal Abscess After Elective Intubation for Bariatric Surgery/J. Brown, Newark, NJ**
- P755 System for Asymmetric Flow Regulation (SAFR) In Compartmentalized Lung Ventilation/I. Barjaktarevic, Los Angeles, CA**
- P756 Uncommon but Not Unseen: An Unusual Cause of Stridor/M.D.U. Alam, Washington, DC**
- P757 Miller Fisher Syndrome and Respiratory Failure/D. Mehta, Chapel Hill, NC**
- P758 A Narrow Miss a Reminder of a Rare Asthma Mimic/L. Piggott, Dublin, Ireland**
- P759 Diaphragm Paralysis : A Rare Cause of Dyspnea/H. Reesha, Athens, GA**
- P760 A Tale Of Two Diaphragmatic Paralyses/J. Nicoletti, Antrim, United Kingdom**
- P761 Structural And Functional Proton Ultrashort Echo Time (UTE) Lung MRI In Pediatric Pectus Deformity Patients/F. Tan, San Francisco, CA**
- P762 Peculiar Chest Findings: Lobar Atelectasis Causing Hydropneumothorax Ex Vacuo/P. Shukla, Fort Wayne, IN**
- P763 A Case of Check Point Inhibitor Induced Pneumonitis/A. Sattar, Darby, PA**
- P764 Diffuse Large B Cell Lymphoma Presenting as Bronchial Mass/C.X. Chen, Las Vegas, NV**
- P765 Cocaine Induced Barotrauma: A Case Report and Review/W. Sadiq, Staten Island, NY**
- P766 Post-intubation Laryngotracheal Stenosis Presenting as Bronchial Asthma in Exacerbation/S.R. Foronda, Las Piñas, Philippines**

- P767** Presentation, Mode of Diagnosis and Management of Pulmonary Alveolar Proteinosis Syndrome in an Irish Population/M. Penugonda, Dublin, Ireland
- P768** Evaluation of Omalizumab in the Treatment of Allergic Rhinitis/Q. Shahzad, Burton on Trent, United Kingdom
- P769** The Hypercarbic Asthmatic: Rethinking the Paradigm/M.L. Bugayong, New York, NY

BEHAVIORAL • CLINICAL • TRANSLATIONAL
THEMATIC POSTER SESSION
C74 DO NOT MISS: SLEEP DISORDERS IN VULNERABLE POPULATIONS

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area I, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P941** Systematic Review of Current Policies and Their Barriers for Sleep Apnea Diagnosis, and the Implications for Underserved Populations/P. McLaurin, Toronto, Canada
- P942** Sleep Disorders and Chronic Rhinosinusitis in World Trade Center (WTC) Responders and a Sleep Clinic Population/A.E. Mullins, New York, NY
- P943** Prevalence of Fatigue and Sleepiness in a Post-Covid Clinic/C. Campbell, Dublin, Ireland
- P944** Features of Obstructive Sleep Disordered Breathing (SDB) and Cardiopulmonary Outcomes in Patients With Idiopathic Pulmonary Fibrosis (IPF)/I. Marquetti, Madison, WI
- P945** The Risk Factors of Postoperative Respiratory Hypoxemia/A. Yadollahi, Toronto, Canada
- P946** Self-reported Sleep Quality and Duration in Hospitalized Patients Screened for Sleep Apnea/E. Rojas, Morgantown, WV
- P947** Dysfunctional Breathing Patterns in Post-Acute Sequelae of SARS-CoV-2 (PASC) Patients Can Be Identified Using Approximate Entropy/E. Eschbach, New York, NY
- P948** The Relationship Between Obstructive Sleep Apnea and Adverse COVID-19 Outcomes at King Abdullah Medical City, Makkah, Saudi Arabia/I.S. Khallaf, Mecca, Saudi Arabia
- P949** Prevalence of Obstructive Sleep Apnea in India: A Systematic Review and Meta-analysis/T.M. Suri, New Delhi, India
- P950** Polysomnographic Characteristics in Healthy Children Aged 5 to 17 Years Who Live at High Altitude/J. Agudelo, Bogota, Colombia

- P951** A Pilot Study Evaluating Sleep Disordered Breathing Utilizing Arterial Tonometry in Individuals With Cystic Fibrosis/M.L. Chiu, Boston, MA
- P952** Habitual Sleep Duration in Men With and Without HIV Infection/P.M. Herrera Aldana, Miami, FL
- P953** Impact of Asthma on Breathing Pattern During Sleep in Children Aged 5 to 16 Living at High Altitude/D.C. Duarte Ojeda, Bogota, Colombia
- P954** Gender Differences in Prevalence of Sleepy Driving in Saudi Arabia/Y. Alqurashi, Dammam, Saudi Arabia

CLINICAL
THEMATIC POSTER SESSION
C75 SLEEP GEMS: CASE REPORTS FROM THE WORLD OF SLEEP MEDICINE

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area I, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P956** Respiratory Failure Now After Remote History Of Neck Surgery/A. Madhavan, New Brunswick, NJ
- P957** Sleep Apnea Due to Vagus Nerve Stimulator in a Patient With Lennox-Gastaut Syndrome/M. Fatima, Wilkes-Barre, PA
- P958** A Reversal of Day and Night- Percheron Infarct, a Bizarre Phenomenon!/P. Bhide, Long Branch, NJ
- P959** Rapid Eye Movement Sleep-related Bradyarrhythmia Syndrome With Severe Obstructive Sleep Apnea Syndrome: A Case Report/K.M. Bartolome, Quezon City, Philippines
- P960** A Case of Central Sleep Apnea Confined to REM Sleep/C. Afif, La Jolla, CA
- P961** Approach to the Management of Recurrent Spontaneous Pneumothoraces in Obstructive Sleep Apnea Patients Requiring Positive Airway Pressure Therapy/G. Dhanaraj, Saint Louis, MO
- P962** Sleep-disorders in Bardet-biedl Syndrome: Do Not Fall Asleep And Recognize It!/R.A. Cardona Quinones, San Juan, PR
- P963** Widely Used Beta-blocker Medication Causing Unusual Sleep Disorders: A Case Report and Literature Review/N. Guirguis, Peoria, IL
- P964** Arterial Line Waveform Tracing Variation in Cheyne Stokes Respiration/C.E. Durant, Los Angeles, CA

- P965 Late Clinical Presentation of Chiari Malformation Type 1**/F.P.G. Rizzatti, Sao Paulo, Brazil
- P966 Chicken and the Egg: REM Behavior Disorder and Obstructive Sleep Apnea**/N. Madala, Athens, GA
- P967 Obstructive Sleep Apnea in a Patient With Unilateral Pulmonary Agenesis**/A. Girish, Washington, DC
- P968 Non-24-hour Sleep-wake Rhythm Disorder in Sighted Individual Treated With Tasimelteon**/P.J. Connolly, Charlottesville, VA
- P969 Sleep Attacks: Undiagnosed Kleine-Levin Syndrome**/S. Brahmandam, Columbus, OH
- P970 Rohring 20s: A Rare Case of a Patient With Rohhad-net Syndrome Surviving Into Her Twenties**/A. Ghias, Mineola, NY
- P971 The Clinical Course of Sleep Disturbance Following Mild Traumatic Brain Injury: A Case Report**/M. Penugonda, Dublin, Ireland

CLINICAL

THEMATIC POSTER SESSION

C76 SARCOMA AND NEUROENDOCRINE TUMORS: CASES IN THORACIC ONCOLOGY

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area J, Hall C (Lower Level)

Viewing: Posters will be on display for entire session **11:30-1:15**

Discussion: **11:30-12:15** authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1020 It Takes Two to Tango: Squamous Cell and Neuroendocrine Carcinoma in the Same Lung**/A. Rajamohan, Long Branch, NJ
- P1021 Pneumocystis Jirovecii Pneumonia Secondary to ACTH-secreting Neuroendocrine Tumors**/A. Schwartz, Iowa City, IA
- P1022 Broncholithiasis in the Setting of a Lung Neuroendocrine Tumor**/B. Taylor, Morgantown, WV
- P1023 Neck Pain Due to an Atypical Neuroendocrine Mass**/J. Ariyaratnam, Queens, NY
- P1024 A Deeper Look Into Ground-glass Consolidations: A Case of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH)**/A.J. Duval, Newark, NJ
- P1025 Large Cell Neuroendocrine Carcinoma Of The Lung: A Study Of Clinical Symptoms, CT, And Pathological Features In 11 Cases**/M.A. Bouanzoul, Rouiba, Algeria
- P1026 Chronic Chest Pain Revealing A Voluminous Primary Synovial Sarcoma Of The Mediastinum**/M.A. Bouanzoul, Rouiba, Algeria
- P1027 Pulmonary Large Cell Neuroendocrine Carcinoma Complicated by Intracardiac Invasion**/C. Caglayan, Pittsburgh, PA
- P1028 Mediastinal Lymphadenopathy: A Unique Presenting Feature of Neuroendocrine Malignancy**/K. Lutchi, Memphis, TN
- P1029 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) in a Middle-aged Female Smoker**/R.P. Rane, Johnstown, PA
- P1030 Follicular Dendritic Cell Sarcoma of the Lung Associated With Thymoma**/Y. Kawaguchi, hachioji-shi, Japan
- P1031 A Case Of Metastatic Pulmonary Artery Intimal Sarcoma Consistent With Dedifferentiated Liposarcoma**/J. Townsley, Corvallis, OR
- P1032 Primary Pulmonary Myxoid Sarcoma in a Heart Transplant Recipient**/A.Z. Kiani, Rancho Mirage, CA
- P1033 Ventilatory Failure From Tumor Burden: A Case Of Invasive Angiosarcoma**/A.A. Chohan, Corpus Christi, TX
- P1034 Malignant Osteosarcoma, An Uncommon Cause Of A Pulmonary Mass In An 18-year-old**/D. Klocke, Kansas City, MO
- P1035 Undifferentiated Pleomorphic Sarcoma in a 49-year-old Female: A Case Report**/P.L. Nufuar, Iloilo City, Philippines
- P1036 Isolated Kaposi Sarcoma of Pharynx and Larynx With Airway Obstruction: Timely Management of a Difficult Airway**/F. Nasir, New York, NY
- P1037 Pulmonary Kaposi Sarcoma - Presenting as a Pulmonary Nodule**/M.I. Islam, Charlottesville, VA
- P1038 Uncharted Territories of Leiomyosarcoma**/K. Rajak, Harrisburg, PA
- P1039 Solitary Fibrous Tumor Of The Pleura, The Other Side Of The Coin**/M.V. Mcbrown, Bogota, Colombia
- P1040 Incidental Finding Of Pulmonary Adenofibroma: A Case Report**/M. Ntorinkansah, Nottingham, United Kingdom
- P1041 The Unpredictable Chest Wall Mass**/H.V. Cedeno, Danbury, CT
- P1042 Solitary Fibrous Tumor in an Asymptomatic Patient Followed for 14 Years**/P.M. Cavalcante Neto, Sao Paulo, Brazil
- P1043 Rapidly Advancing Leiomyosarcoma With Lung and Pleural Metastasis**/J.K. Sandhu, Jamaica, NY
- P1044 Mediastinal Liposarcoma: Case Report of an Uncommon Presentation of a Rare Tumor**/R. Malhotra, Newark, NJ

CLINICAL

THEMATIC POSTER SESSION

C77 LUNG NODULES, CAVITIES, AND LYMPHOMAS: CASES IN THORACIC ONCOLOGY

9:00 a.m. - 4:15 p.m. Walter E. Washington Convention Center

Area J, Hall C (Lower Level)

Viewing: Posters will be on display for entire session 11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion
12:15-1:15 authors will be present for discussion with assigned facilitators.

- P1046 Cavitory Lung Disease: Not Always What You Think/S.**
Quon, Sacramento, CA
- P1047 Multifocal Pulmonary Cavities in a Gentleman From Haiti/K.** Muralidharan, Bridgeport, CT
- P1048 Progressing Hepatic Herniation Mimicking A Malignant Lung Nodule/Y.** Sun, Montgomery, AL
- P1049 Innumerable Cavitory Lung Metastasis From Colorectal Cancer/M.** Abas, Chardon, OH
- P1050 Not Always Tuberculosis: Successful Treatment Of Miliary Lung Adenocarcinoma/M.** Salih Makawi, Flushing, NY
- P1051 When A Horse Meets A Zebra: Miliary Micronodular Opacities On Chest CT/P.M.** Cavalcante Neto, Sao Paulo, Brazil
- P1052 Biopsy of Thoracic Lymph Node Diagnosing Mystery of Distributive Shock Caused by Idiopathic Multicentric Castleman Disease With TAFRO Syndrome/R.A.** Memon, Abington, PA
- P1053 Incidental Posterior Mediastinal Mass Diagnosed as Hattori (Müllerian) Cyst With PAX-8 Immunohistochemistry After Left Thoracotomy Surgical Excision/C.** Walls, Memphis, TN
- P1054 A Curious Case of Isolated Mediastinal Prostate Cancer Recurrence/J.** Qu, Scranton, PA
- P1055 Synchronous Lung Cancer and Breast Cancer- an Opportunity to Optimize Screening/D.** Albano, Stony Brook, NY
- P1056 Anterior Mediastinal Thymoma With Metastasis to the Left Upper Lobe of the Lung/T.** Deiss, Hattiesburg, MS
- P1057 Well Differentiated Endometrioid Carcinoma Presenting With Early Miliary Pattern of Lung Metastases/A.**
Sithamraju, Roanoke, VA
- P1058 Not All Malignant Nodules Grow/R.** Singh, New York, NY
- P1059 Not Your Ordinary Nodule/K.M.** Capaccione, New York, NY
- P1060 Unusual Metastatic Pulmonary Nodule/S.** Acharya, Staten Island, NY
- P1061 Numerous Pulmonary Nodules: An Atypical Presentation of Pulmonary Plasmacytoma/T.** Roy, North Brunswick, NJ
- P1062 A Case of Cardiac Lymphoma/K.** Roth, Peoria, IL
- P1063 Pulmonary Marginal Cell Lymphoma as an Extraintestinal Manifestation of Ulcerative Colitis/S.**
Toor, Grand Rapids, MI
- P1064 Primary Pulmonary Marginal Zone Lymphoma/A.** Haj Abdulkader, Cleveland, OH
- P1065 Tissue Is The Issue - T Cell Lymphoma As A Cause Of Rapid Onset Respiratory Failure/J.** Wilkinson, Los Angeles, CA
- P1066 A Case Of Diffuse Large B-cell Lymphoma With Invasion Of The Airway/A.S.** Adebola, Corvallis, OR
- P1067 Kikuchi's Disease Masking Non-Hodgkin's Lymphoma: A Case of Recurrent Necrotizing Lymphadenitis/H.**
Sinawe, Boca Raton, FL
- P1068 Pulmonary Lymphomatoid Granulomatosis vs Diffuse Large B-cell Lymphoma (DLBCL): A Diagnostic and Management Dilemma/J.** Lenka, Tucson, AZ
- P1069 The Diagnostic Challenge Posed by Synchronous Primary Lung Cancer and Lymphoproliferative Disorder/C.** Ottewill, Dublin, Ireland
- P1070 The Road To Clinic Goes Through The Pathology Museum - A Curious Case Of Mediastinal Lymphadenopathy/H.** Grewal, New Orleans, LA
- P1071 Saved by the Birds: Suspicion for Hypersensitivity Pneumonitis Leading to the Diagnosis of Pulmonary Lymphangitic Carcinomatosis/S.** Deleveaux, Oak Lawn, IL
- P1072 Death by Extraction: Dental Manipulation Causing Mediastinitis and Subsequent Svc Syndrome in Newly Diagnosed Acute Myeloid Leukemia/A.A.** Shah, Pittsburgh, PA
- P1073 SVC Syndrome vs. Castleman Disease: A Clinical Dilemma on the Etiology of Idiopathic Angioedema/R.L.** Imel, Toledo, OH
- P1074 Hyperleukocytosis: A Hidden and Uncommon Presentation of Large Cell Lung Carcinoma - A Case Report/R.E.** Reinoso, New York, NY

MEDICAL EDUCATION SEMINAR

CME Credits Available: 1

ME103 GAME ON!: GAMIFICATION OF MEDICAL EDUCATION IN PCCM

Assembly on Behavioral Science and Health Services Research

10:15 a.m. - 11:15 a.m.

Target Audience

The intended target audience is clinician educators with experience or interest in medical education for all levels of learners. Although this session will cover the utility of gamification in education, no prerequisites are required.

Objectives

At the conclusion of this session, the participant will be able to:

- review the available literature for the benefits of using gamified training platforms for medical education (both preclinical and clinical) and training.
- identify available platforms suitable for the purpose of gamification with links to multimedia content.
- outline the challenges in the implementation of gamification and the strategies available to counteract them.

Technology is increasingly being used in medical education to supplement the delivery of learning resources. Gamification is defined as the use of game design elements in non-game contexts. Studies have shown that gamification may improve learning outcomes in health professionals, especially when employing game attributes that improve learning behaviors and attitudes towards learning. Our session will present the evidence behind the use of gamification in medical education for learners in Pulmonary and Critical Care Medicine. We will illustrate strategies for gamifying traditional didactic approaches to learning by using gamification methods within our session. Lastly, we will explore challenges behind the implementation of gamification as well as the strategies to overcome them.

Faculty: N. Sawal, MD, Rochester, MN
E.R. Camac, DO, Lexington, KY
J.B. Richards, MD, MA, ATSF, FACP, Cambridge, MA
S.M. Kassutto, MD, Philadelphia, PA

CME Credits Available: 1

SPS3 RESEARCH INTEGRITY IN MEDICAL EDUCATION: LESSONS FROM THE TUSKEGEE EXPERIMENT

10:45 AM –11:45 AM Walter E. Washington Convention Center

Room 207 A-B (Level 2)

Target Audience

Anyone with clinical, research, or administrative responsibilities. This session is of particular interest to trainees and individuals that oversee or participate in clinical and/or medical education and research.

Objectives

At the conclusion of this session, the participant will be able to:

- recognize the historical lessons from the Tuskegee Syphilis Study and how they apply to modern scientific investigation practice
- examine their own research participation to explore areas of potential unethical practice
- criticize unethical practice in clinical and research settings

This interactive session and facilitated panel discussion is a follow up to the ATS webinar on Research Integrity in Medical Education: Lessons from the Tuskegee Experiment. Prior attendance is not required. Together we will review the important lessons learned from the unethical practices of the Tuskegee Experiments and discuss how we can combat systematic racism collectively. We will discuss the risk of vulnerable populations both in research participants and investigators, the role that junior trainees play as both research participants and as future investigators, and the need for good leadership and mentorship to avoid future tragedies as experienced in Tuskegee.

Chairing: M. Matta, MD, Cleveland, OH
M. Lee, MD, ATSF, Los Angeles, CA

Panelists: M. Matta, MD, Cleveland, OH
M. Lee, MD, ATSF, Los Angeles, CA
M. Johnson, MD, San Francisco, CA
G. Tatem, MD, Detroit, MI
A. Baugh, MD, San Francisco, CA

CLINICAL

PEDIATRIC CLINICAL CORE CURRICULUM

MOC Points Available: 1

MOC Points Available: 1

PCC2 PEDIATRIC CLINICAL CORE CURRICULUM

Education Committee

12:00 p.m. - 1:00 p.m.

Target Audience

Clinicians who are engaged in maintenance of certification activities

Objectives

At the conclusion of this session, the participant will be able to:

- describe diagnosis and management of central and obstructive sleep disorders in infants
- identify best practices for management and treatment of pulmonary hypertension in infants
- describe best practices and standards of care for management of bronchopulmonary dysplasia in the neonatal intensive care unit and the post NICU period

Chairing: J. Gross, MD, PhD, Denver, CO
C. Okorie, MD, Paulo Alto, CA
M. McCown, MD, Bethesda, MD

12:00 Obstructive Sleep Disorders in Infants
M. Bedoya, MD, Nashville, TN

12:25 Central Sleep Disorders in Infants
M. Maloney, MD, FAAP, Salt Lake City, UT?

12:50 Questions and Answers



ATS
2023

**INTERNATIONAL
CONFERENCE**
WASHINGTON, DC
conference.thoracic.org

Tuesday Mid-day, May 23

11:30 a.m. - 1:00 p.m.

PLENARY SESSION



Walter E. Washington Convention Center
Hall E (Level 2)

The Plenary Session will feature a keynote address by **Timothy Caulfield**, professor of Health Law and Science Policy and best-selling author.

Timothy Caulfield is a Canada Research Chair in Health Law and Policy, a Professor in the Faculty of Law and the School of Public Health, and Research Director of the Health Law Institute at the University of Alberta. His interdisciplinary research on topics like stem cells, genetics, research ethics, the public representations of science, and public health policy has allowed him to publish over 350 academic articles. He has won numerous academic, science communication, and writing awards, and is a Fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences.

He contributes frequently to the popular press and is the author of two national bestsellers: *The Cure for Everything: Untangling the Twisted Messages about Health, Fitness and Happiness* (Penguin 2012) and *Is Gwyneth Paltrow Wrong About Everything?: When Celebrity Culture and Science Clash* (Penguin 2015). His most recent book is *Relax, Dammit!: A User's Guide to the Age of Anxiety* (Penguin Random House, 2020) (US Title: *Your Day, Your Way*).

Professor Caulfield is also the co-founder of the science engagement initiative #ScienceUpFirst and the host and co-producer of the award-winning documentary TV show, *A User's Guide to Cheating Death*, which has been shown in over 60 countries, including streaming on Netflix in North America.

The Plenary Session also will include the ratification of the 2023-2024 slate of officers as well as remarks from outgoing president **Greg Downey, MD, ATSF**, and incoming president **M. Patricia Rivera, MD, ATSF**.

In addition, four awards will be presented, including:

Outstanding Educator Award:

C. Rosen, MD, Wynnewood, PA

Research Innovation & Translation Award

R. Farre, PhD, ATSF, Barcelona, Spain

Outstanding Clinician Award

K. Gibson, MD, Pittsburgh, PA

Philip Hopewell Prize for Leaders in Global Respiratory Health

W. Worodria, MBChB, Kampala, Uganda

Many thanks to GSK for support of the Plenary Session

**ENVIRONMENTAL INFLUENCES ON
CHILD HEALTH OUTCOMES (ECHO)/NIH**

OUTSIDE ORGANIZATION SESSION

**L15 NIH ENVIRONMENTAL INFLUENCES ON
CHILD HEALTH OUTCOMES (ECHO):
NATIONAL LONGITUDINAL RESOURCE
FOR CHILD LUNG HEALTH
RESEARCHERS**

12:00 PM - 1:00 PM Walter E. Washington Convention Center

Room 202 B (Level 2)

Target Audience

Providers of maternal and child health; Providers of lung health; Researchers of Developmental Origins of Health and Development, Pediatric Pulmonologists; Environmental researchers and physicians

Objectives

At the conclusion of this session, the participant will be able to:

- learn ECHO's design to support developmental origins of health and disease research.
- learn how ECHO data has supported innovative epidemiologic studies of the origins of asthma and early onset of health disparities.
- learn the breadth and depth of available ECHO data from diverse participants across the nation spanning decades of data collection and how to access ECHO data from DASH for airways research.

The NIH-supported Environmental Influences on Child Health Outcomes (ECHO) program supports multiple synergistic, longitudinal cohort studies across the U.S. to investigate how early environmental exposures—including physical, chemical, social, behavioral, biological, natural, and built environments—affect genetic susceptibility, child health and development. The multiple cohorts share protocol-specified data elements from ~100,000 participants and ~50,000 children, including bioassay data analyzed by the NIH Human Health Exposure Analysis Resource (HHEAR). A de-identified near anonymized data set is now available as a national resource for research. This session will focus on how the ECHO data repository can support child health research particularly relevant to the development of airway diseases and health.

Chairing: C.J. Blaisdell, MD, North Bethesda, MD
C.L.M. Joseph, PhD, Detroit, MI

12:00 ECHO as a National Resource for Lung Research
M. Gillman, MD, SM, North Bethesda, MD

12:05 What have we learned from ECHO? Research from the Airways Group
J. Gern, MD, Madison, WI

12:15 What is in ECHO's Controlled Access Public Use Data Set, Now Available in the NICHD Data and Specimen Hub (DASH)?
D. Catellier, PhD, Research Triangle, NC

12:30 How Can Researchers Use ECHO's Controlled Access Public Use Data Set in DASH?
R. Rosen, PhD, Bethesda, MD

12:45 Panel Discussion
C.J. Blaisdell, MD, North Bethesda, MD

DIVISION OF LUNG DISEASES, NHLBI/DLD

OUTSIDE ORGANIZATION SESSION

**L16 IMPACT OF SEX AND GENDER ON
AUTOIMMUNE LUNG DISEASE**

12:00 PM - 1:00 PM Walter E. Washington Convention Center

Room 152 A-B (Street Level)

Target Audience

Basic scientists, physician-scientists, and healthcare providers with research interests related to the influence of sex and gender on autoimmune-associated lung diseases.

Objectives

At the conclusion of this session, the participant will be able to:

- create awareness, interest, and increase knowledge of the influence of sex and gender on autoimmune lung disease research.
- learn about innovative methods to eliminate gaps in the design, conduct, and analysis of sex and gender-related aspects of autoimmune lung disease research
- clinical Phenotyping of autoimmune ILD and diagnose, predict and improve clinical outcomes by re-purposing existing drugs

This session will highlight recent research advances involving the role of sex and gender in a number of autoimmune-related lung diseases, including systemic sclerosis-associated interstitial lung disease (SSc-ILD), rheumatoid arthritis-associated ILD (RA-ILD), systemic lupus erythematosus (SLE) pneumonitis/pleuritis, and interstitial pneumonia with autoimmune features (IPAF).

Chairing: L.J. Vuga, MD, MPH, PhD, Bethesda, MD
M.E. Lachowicz-Scroggins, PhD, Bethesda, MD

12:00 Influence of Sex/Gender on Scleroderma-Associated ILD
E. Volkman, MD, MSc, Los Angeles, CA

12:15 Sex/Gender Differences in Lung Inflammation and Rheumatoid Arthritis
J.A. Sparks, MD, Boston, United States

12:30 Role of B Cells Pulmonary Fibrosis Resulting from STING Gain-of-Function Autoinflammation
A. Marshak-Rothstein, PhD, Worcester, United States

12:45 The Influence of Sex/Gender on Treatment Effect in Interstitial Pneumonia with Autoimmune Features
A.O. Adegunsoye, MD, MS, Chicago, IL

NATIONAL CENTER FOR ENVIRONMENTAL HEALTH/CDC

OUTSIDE ORGANIZATION SESSION

L17 ENVIRONMENTAL HEALTH EQUITY UNDER THE RUBRIC OF VITAL CONDITIONS

12:00 PM - 1:00 PM Walter E. Washington Convention Center

Room 150 A-B (Street Level)

Target Audience

Clinicians who seek to understand how environmental health equity affects a patient's risk to exposures that result in adverse respiratory health.

Objectives

At the conclusion of this session, the participant will be able to:

- improve ATS member's knowledge about environmental conditions related to lung health in vulnerable populations.
- learn new findings about environmental health conditions that can inform ATS members about underlying factors (e.g., vital conditions) that may influence their patients' risk.
- raise awareness about diversity and health equity issues related to respiratory health.

This workshop provides a multidisciplinary perspective on how applied knowledge of environmental health exposure can be used to support the achievement of respiratory health equality. Attendees will receive updates on new trends in radon, asthma, Legionnaires' disease, wildfires, volatile organic compounds (VOC) exposure in homes, respiratory health quality improvement initiatives, and patient education for communities with greater vulnerability to harmful environmental exposures and lower access to resources. Presenters will highlight how the interaction of social determinants contributes to disparities in care quality and health outcomes, such as respiratory health using the Vital Conditions Framework, a nationally recognized health equity framework.

Chairing: A. Perkins, BPH, Atlanta, GA

12:00 Introduction of the Division of Environmental Health Science and Practice's Vital Conditions Health Equity Plan

A. Perkins, PhD, Atlanta, GA

12:10 Adverse Health Impacts Associated with Wildland Fire Smoke Exposure.

A. Vaidyanathan, PhD, Atlanta, GA

12:20 Trends in Risk for Legionnaires' Disease Based on Access to Economic Resources

N. Clemmons, MPH, Atlanta, GA

12:30 Radon: Reducing a Lung Cancer Risk Factor by Protecting Communities and Buildings

A. Salame-alfie, PhD, Atlanta, GA

12:40 Exploring Asthma Health Care Utilization Data to Reduce the Elevated Risk During the Pandemic

O. Idubor, MD, Atlanta, GA

12:50 Volatile Organic Compounds (VOCs) in Low-Income Housing in a Multi-Site Study

G. Chew, ScD, Atlanta, GA

VETERANS HEALTH ADMINISTRATION (VA)

OUTSIDE ORGANIZATION SESSION

L18 VA'S APPROACH TO POST-DEPLOYMENT RESPIRATORY HEALTH: RESEARCH, CLINICAL CARE AND EDUCATION

12:00 PM - 1:00 PM Walter E. Washington Convention Center

Room 147 A-B (Street Level)

Target Audience

Target audience includes: VA and non-VA providers of lung health; VA and non-VA pulmonary researchers; clinicians/scientists interest in environmental and occupational health; military Veterans and service members

Objectives

At the conclusion of this session, the participant will be able to:

- define new strategies to manage the care of Veterans with deployment-related exposures
- describe new findings about VA research on military exposures and respiratory health.
- integrate/incorporate new guidelines and requirements from the PACT Act of 2022 into current practice.

Respiratory health of U.S. Veterans, in particular adverse effects related to military deployment, is a priority area for the Department of Veterans Affairs (VA). Major research, clinical, and educational efforts are underway – many of which impact the ATS membership, both within and outside of the VA, who provide care to Veterans and servicemembers and/or conduct research on inhalational exposures. This session will provide updates on ongoing research and clinical programs, as well as inform all stakeholders on the implications of the new Congressional Honoring our Promise to Address Comprehensive Toxics Act of 2022 (PACT Act).

Chairing: M.J. Falvo, PhD, East Orange, NJ
E. Garshick, MD, West Roxbury, MA
P.D. Blanc, MD, San Francisco, CA

12:00 Military Occupational and Environmental Exposures

E. Garshick, MD, West Roxbury, MA

12:12 Best Practices for the Evaluation the Dyspneic Veteran

A.M. Sotolongo, MD, East Orange, NJ

- 12:24 The Airborne Hazards and Open Burn Pit Registry**
M.J. Falvo, PhD, East Orange, NJ
- 12:36 Impact of the PACT Act for VA and non-VA Providers**
P. Hastings, DO, Washington, DC
- 12:50 Summary and Question/Answer Session**
P.D. Blanc, MD, San Francisco, CA

DIVISION OF LUNG DISEASES, NHLBI/NIH

OUTSIDE ORGANIZATION SESSION

L19 NHLBI PREVENTION AND EARLY TREATMENT OF ACUTE LUNG INJURY (PETAL) NETWORK

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**
Room 204 A-C (Level 2)

Target Audience

Practicing critical care and emergency medicine clinicians and clinical researchers would benefit from this session

Objectives

At the conclusion of this session, the participant will be able to:

- understand the goals and structure of the PETAL network
- understand the questions being addressed in PETAL and the design/conducts of the studies
- learn new findings and results of PETAL studies

This session will provide an update on the NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) clinical trials network. The session will describe the structure and goals of the PETAL network, an overview of progress in ongoing studies, opportunities for additional studies using PETAL data and biospecimens, and results of studies to date.

Chairing: J.P. Kiley, Ph.D., Bethesda, MD
R.G. Brower, MD, Baltimore, MD

- 12:00 PETAL Overview**
R.G. Brower, MD, Baltimore, MD
- 12:12 Update on the CLOVERS trial**
I.S. Douglas, MD, FRCP, Denver, CO
- 12:24 Update on the ASTER trial**
M.A. Matthay, MD, San Francisco, CA
- 12:36 Update on the CORAL Studies**
C.T. Hough, MD, MSc, Portland, OR
- 12:48 Accessing PETAL Data, Images, and Specimens**
I.D. Peltan, MD, MSc, Murray, UT

**NIAID SYSTEMS BIOLOGY
OF ANTIMICROBIAL RESISTANCE**

OUTSIDE ORGANIZATION SESSION

L20 SYSTEMS BIOLOGY FOR ACUTE RESPIRATORY INFECTIONS

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**
Room 145 A-B (Street Level)

Target Audience

Basic and translational researchers interested in a systems biology approach to lung pathogens and the host response to them.

Objectives

At the conclusion of this session, the participant will be able to:

- apply a systems biology approach to studying clinical infectious disease outcomes
- define strategies to improve ability to model lung immunity
- be aware of NIH resources for studies of host immunity and microbial pathogenesis

The NIH/NIAID uses a variety of mechanisms to support research on respiratory infections, including influenza, SARS-CoV-2, fungi, and antibiotic resistant bacterial pathogens. A systems biology approach to these pathogens, resultant host response, and diseases relevant to the pulmonary and critical care community will be illustrated.

Chairing: L. Brown, PhD, Rockville, MD

12:00 NIAID's Systems Biology Program in Infectious Diseases

R. Shabman, PhD, Rockville, MD

12:15 Influenza Viral-Host Interactions

A. Garcia-Sastre, PhD, New York, NY

12:35 Host-Pathogen Relationship in Severe Pneumonia

R.G. Wunderink, MD, Chicago, IL

12:55 Questions and Panel Discussion

L. Brown, PhD, Rockville, MD

DIVISION OF LUNG DISEASES, NHLBI/NIH

OUTSIDE ORGANIZATION SESSION

L21 NEW FINDINGS FROM THE SUBPOPULATIONS AND INTERMEDIATE OUTCOME MEASURES IN COPD II (SPIROMICS II) STUDY

12:00 PM - 1:00 PM **Walter E. Washington Convention Center**
Room 143 A-C (Street Level)

Target Audience

Researchers, medical trainees, those with an interest in COPD pathogenesis

Objectives

At the conclusion of this session, the participant will be able to:

- learn about natural history of smokers with respiratory symptoms
- learn about biomarkers of COPD
- learn about social determinants influence on respiratory outcomes

SPIROMICS II is an NHLBI-sponsored study that supports the prospective collection and analysis of phenotypic, biomarker, genetic, genomic, and clinical data from subjects with COPD for the purpose of identifying subpopulations and the biological underpinnings of clinical phenotypes in COPD. Participants in this session will learn about the progress in SPIROMICS II including results and analyses of data.

Chairing: L. Postow, PhD, Bethesda, MD
P. Woodruff, MD, MPH, San Francisco, CA

12:00 Redefining Therapy in Early COPD (RETHINC)

M.K. Han, MD, MS, ATSF, Ann Arbor, MI

12:12 Bronchodilator Responsiveness in Smoked Tobacco-Exposed Persons with or without COPD

S. Fortis, MD, Iowa City, IA

12:24 Variation in Mendelian Genes and Risk for COPD

V.E. Ortega, MD, PhD, ATSF, Scottsdale, AZ

12:36 Clinical Relevance of Airway Mucin (MUC5AC and MUC5B) Concentrations in COPD

J. Kim, MD, MS, Charlottesville, VA

12:48 SPIROMICS Review and Summary

P. Woodruff, MD, MPH, San Francisco, CA

MTE40 CYSTIC FIBROSIS: CLINICAL CHALLENGES IN THE ERA OF HIGHLY EFFECTIVE MODULATOR THERAPY

C.M. Bojanowski, MD, MSCR, New Orleans, LA
Howard University (Level M1)

MTE42 SMOKING RELATED INTERSTITIAL LUNG DISEASES

M. Porteous, MD, MSCE, Philadelphia, PA
University of DC/Catholic University (Level M1)

MTE43 ORGANS-ON-CHIPS FOR THE LUNGS: PAST, CURRENT AND FUTURE

K. Hajipouran Benam, PhD, Pittsburgh, PA
LeDroit Park (Level M3)

MTE44 VIRTUAL PULMONARY REHABILITATION: IDENTIFYING KEY STRATEGIES AND CONQUERING THE CHALLENGES TO ESTABLISHING A SUCCESSFUL PROGRAM

S.K. Huang, MD, Ann Arbor, MI
Mount Vernon Square (Level M3)

MTE45 CENTRAL SLEEP APNEA, PATHOPHYSIOLOGICAL CLASSIFICATION AND RELATED MANAGEMENT

S. Javaheri, MD, Cincinnati, OH
Chinatown (Level M3)

MEET THE EXPERT SEMINARS

CME Credits Available: 1

 Pre-registration and additional fees required. Attendance is limited.

\$100 Member/Non-Members

\$70 LMIC Member/LMIC Non-Members

12:00 p.m. - 1:00 p.m. Marriott Marquis Washington

MTE37 EXERCISE TEST IN NEW ERA: UPDATED QUALITY IN PULMONARY REHABILITATION AFTER COVID-19

N. Cox, PT, MSci, PhD, Melbourne, Australia
Judiciary Square (Level M3)

MTE38 REFRACTORY SARCOIDOSIS: WHEN AND HOW TO USE TNF-INHIBITORS

W.E. James, MD, Charleston, SC
Gallaudet University (Level M1)



ATS
2023

INTERNATIONAL
CONFERENCE
WASHINGTON, DC
conference.thoracic.org

Tuesday Afternoon, May 23

CLINICAL

ADULT CLINICAL CORE CURRICULUM

CME Credits Available: 1.5
MOC Points Available: 1.5

CC4 CRITICAL CARE CLINICAL CORE CURRICULUM

Education Committee

2:15 p.m. - 3:45 p.m.

Target Audience

Clinicians who are engaged in maintenance of certification activities

Objectives

At the conclusion of this session, the participant will be able to:

- describe updates in the diagnosis and management of bacterial and viral respiratory infections
- identify best practices for treating infections in critically ill immunosuppressed patients
- describe diagnosis and management of hospital acquired infections in the intensive care unit

Chairing: S. Ahmed, MD, Albuquerque, NM
D. Kelm, MD, Rochester, MN
E. Kilb, MD, Charleston, SC

2:15. Rejecting Infection: Treatment of Patients After Transplantation

A. Lawrence, MD, Dallas, TX

2:40 HAART-less: Fighting Opportunistic Infections in HIV

S. Sellers, MD, MSCR, Chapel Hill, NC

3:05 Gut with the Program: What Every Intensivist Needs to Know About Abdominal Infections

J. Davis, MD, Ithaca, NY

3:30 Questions and Answers

CLINICAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 1.5

C82 BEYOND THE LUNG: ADDRESSING COMORBIDITIES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Assembly on Clinical Problems

2:15 PM - 3:45 PM

Walter E. Washington Convention Center

Room 207 A-B (Level 2)

Target Audience

Providers of lung health serving patients with COPD, Individuals involved in clinical or research activities related to COPD

Objectives

At the conclusion of this session, the participant will be able to:

- describe the burden and clinical implications of comorbidities in patients with COPD
- integrate comorbidity screening into the current management of COPD patients
- recognize research gaps in the management of COPD comorbidities

This session will focus on the prevalence, impact, and burden of comorbidities in chronic obstructive pulmonary disease, including a discussion of challenges and opportunities related to comorbidity screening in patients with COPD. This session also includes a more in-depth discussion of the more common COPD comorbidities, specifically depression, cardiovascular disease, and muscle dysfunction.

Chairing: A. Agusti, MD, Barcelona, Spain
N. Putch, BA, MD, Baltimore, MD
J.K. Krishnan, MD, MBA, MSc, New York, NY

2:15 Introduction

A. Agusti, MD, Barcelona, Spain

2:18 Patient Perspective

P. DiLorenzo, Jersey City, NJ

2:23 The Burden and Impact of Comorbidities in COPD

M.J. Divo, MD, MPH, Boston, MA

2:37 Anxiety and Depression in COPD: Prevalence, Risk Factors, and Clinical Implications

V. Kim, MD, ATSF, FAASM, Philadelphia, PA

2:51 Cardiovascular Disease in COPD: Burden, Mechanisms, and Implications for Clinical Practice

J.K. Quint, FRCP, MSc, PhD, London, United Kingdom

3:05 Skeletal Muscle Dysfunction in COPD: Mechanisms and Implications

H.B. Rossiter, PhD, Torrance, CA

3:19 Comorbidity Screening in COPD: Challenges and Opportunities

J. Bon, MD, MS, ATSF, Pittsburgh, PA

3:33 Panel Discussion

N. Putcha, BA, MD, Baltimore, MD

This session and the International Conference are supported by an independent medical educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL**CLINICAL TOPICS IN PULMONARY MEDICINE**

CME Credits Available: 1.5

C83 PRO/CON: HOT TOPICS IN INTERSTITIAL LUNG DISEASE**Assemblies on Clinical Problems; Behavioral Science and Health Services Research****2:15 PM - 3:45 PM Walter E. Washington Convention Center****Ballroom C (Level 3)****Target Audience**

Clinicians, researchers, trainees and industry stake-holders interested in interstitial lung disease

Objectives

At the conclusion of this session, the participant will be able to:

- analyze and understand IPF clinical trial results and endpoints and how these affect clinical practice and future research efforts
- integrate available data on formal testing and treatment of gastroesophageal reflux in progressive fibrotic lung disease in to clinical practice
- gauge the risks and potential benefits of bronchoalveolar lavage for patients with fibrotic lung disease

This session will feature PRO/CON debates on 4 topics in ILD that are relevant to cutting edge clinical practice and research. These will include the utility of bronchoalveolar lavage in fibrotic lung disease, change in FVC over 3 months as a clinical trial endpoint in IPF, formal testing for acid reflux in progressive pulmonary fibrosis, and whether IPF is an entity of the past.

Chairing: S. Montesi, MD, Boston, MA
G. Raghu, MD, Seattle, WA

2:15 PRO: Formal Testing for Abnormal Acid Reflux Should Be Performed in All Patients with IPF to Determine the Need for Anti-Reflux Therapy

M.B. Scholand, MD, Salt Lake City, UT

2:25 CON: Formal Testing for Abnormal Acid Reflux Should Be Performed in All Patients with IPF to Determine the Need for Anti-Reflux Therapy

A. Wilson, MD, FRCP, Norfolk, UK

2:35 PRO: Change in FVC at 3 Months is an Acceptable Primary Endpoint for IPF Clinical Trials

Tamera Corte, MBBS, BScM, FRACP, PhD, Sydney, Australia

2:45 CON: 2. Change in FVC at 3 Months is an Acceptable Primary Endpoint for IPF Clinical Trials

R.G. Jenkins, BM, MD, MRCP(UK), PhD, London, United Kingdom

2:55 PRO: BAL for Lymphocytosis Should be Performed in Patients with New Onset Fibrotic ILD

T. Kulkarni, MD, MPH, Birmingham, AL

3:05 CON: 3. BAL for Lymphocytosis Should Be Performed in Patients with New Onset Fibrotic ILD

N. Chaudhuri, MBChB, PhD, Ulster, Ireland

3:15 PRO: IPF is a Disease of the Recent Past

G. Raghu, MD, Seattle, WA

3:25 CON: IPF is a Disease of the Recent Past

J. Behr, MD, Munchen, Germany

3:35 Question and Answer

This session and the International Conference are supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL**CRITICAL CARE TRACK**

CME Credits Available: 1.5

MOC Points Available: 1.5

C84 CARDIAC ARREST: NEW SCIENCE AND CHANGING GUIDELINES**Assembly on Critical Care****2:15 PM - 3:45 PM Walter E. Washington Convention Center****Room 150 A-B (Street Level)****Target Audience**

Clinicians who treat patients experiencing in-hospital or out-of-hospital cardiac arrest or who are interested in the latest evidence and clinical practice standards on this topic

Objectives

At the conclusion of this session, the participant will be able to:

- understand the evidence (or in some cases lack thereof) behind current cardiac arrest and post-arrest treatment guidelines

- gain knowledge about long term outcomes of cardiac arrest and treatments that may improve these
- learn about cardiac arrest survivorship and the needs of individuals recovering after cardiac arrest

Randomized trials in cardiac arrest and post-arrest care have increased dramatically in recent years. Critical care personnel are commonly involved in cardiac arrest resuscitation and the ICU care that most patients who achieve return of spontaneous circulation require. The latest on cardiac arrest management and care of the post-arrest patient will be discussed, with a focus on topics where new evidence is available or where significant controversy remains, and a survivor's perspective will be presented.

Chairing: K.M. Berg, MD, Boston, MA
R.E. Sell, MD, Seattle, WA
A. Moskowitz, MD, Bronx, NY

- 2:15 Medications During Cardiac Arrest: Do They Really Help?**
L.W. Andersen, MD, PhD, Arhus, Denmark
- 2:35 E-CPR: Is It Ready for the Mainstream?**
J. Bartos, MD, PhD, Minneapolis, MN
- 2:55 Targeted Temperature Management in Confusing Times**
K.M. Berg, MD, Boston, MA
- 3:10 Addressing Disparities in Cardiac Arrest**
S. Perman, MD, Aurora, CO
- 3:30 A Survivor's Experience**
A. Uzendu, MD, Kansas City, MO

BEHAVIORAL • CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

C85 A PATH TOWARDS A MORE DIVERSE AND INCLUSIVE WORKFORCE

Assemblies on Pediatrics; Behavioral Science and Health Services Research

2:15 PM - 3:45 PM **Walter E. Washington Convention Center**
Room 147 A-B (Street Level)

Target Audience

Any provider of lung health (both adult and pediatrics); any multidisciplinary team member; trainees; ancillary support staff

Objectives

At the conclusion of this session, the participant will be able to:

- define the current demographic breakdown of the pediatric pulmonology workforce in the United States (trainees and faculty) and why diversity matters

- present barriers and opportunities for recruitment (student and resident level), training (fellow and junior faculty level) and career development (faculty level) of URiM in the field of pediatric pulmonology
- identify strategies and resources that have been or can be used to improve the recruitment of URiM residents to the field, the mentorship of trainees and junior faculty, and the career development of URiM faculty in academic centers

In response to the critical need to improve diversity, equity and inclusion (DEI) in academic medicine, the Pediatric Assembly developed a DEI Advisory Group in Spring 2020 with the overarching goal to increase workforce diversity in the pediatric pulmonology community and ultimately provide a framework for other medical specialties to follow. An ATS Pediatric Assembly Project Grant was funded in 2022, "ATS Workshop on DEI and the Pediatric Pulmonology Workforce," which included a needs assessment survey administered to the Pediatric Assembly in May 2022 and a virtual workshop. This symposium will present key findings from the survey and workshop.

Chairing: T.A. Laguna, MD, MSci, Chicago, IL
R.T. Cohen, MD, MPH, Boston, MA
N. Stephenson, MD, Chapel Hill, NC

- 2:15 Introduction - Brief Review of DEI in Pediatric Pulmonology Workforce**
T.A. Laguna, MD, MSci, Chicago, IL
- 2:24 Introduction - Brief Review of DEI in Pediatric Pulmonology Workforce**
J. Rama, MD, MEd, Houston, TX
- 2:33 Importance of a Diverse Workforce - Addressing Health Disparities**
B.J. Sheares, MD, MS, New Haven, CT
- 2:42 Importance of a Diverse Workforce - Addressing Health Disparities**
S. Lovinsky-Desir, MD, MS, New York, NY
- 2:51 Results of the Needs Assessment Survey - Key Findings**
R.T. Cohen, MD, MPH, Boston, MA
- 3:00 Results of the Needs Assessment Survey - Key Findings**
M. Udoko, MD, Aurora, CO
- 3:09 Strategies to Improve Recruitment and Retention of URiM Trainees and Faculty**
N. Stephenson, MD, Chapel Hill, NC
- 3:18 Strategies to Improve Recruitment and Retention of URiM Trainees and Faculty**
E. Forno, MD, MPH, ATSF, Pittsburgh, PA
- 3:27 What Can I Do - The Importance of Leadership, Allies and Advocates**
P.E. Moore, MD, ATSF, Nashville, TN
- 3:36 What Can I Do - The Importance of Leadership, Allies and Advocates**
I. Narang, MD, Toronto, Canada

BASIC • CLINICAL • TRANSLATIONAL**SCIENTIFIC SYMPOSIUM**

CME Credits Available: 1.5

C86 BEYOND THE TRANSCRIPTOME: HOW THE MULTI-“OMIC” UNIVERSE PROVIDES NOVEL INSIGHTS INTO IPF/ILD PATHOGENESIS**Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems****2:15 PM - 3:45 PM Walter E. Washington Convention Center****Room 207 A-B (Level 2)****Target Audience**

Basic scientists, clinicians, translational researchers in pulmonary fibrosis

Objectives

At the conclusion of this session, the participant will be able to:

- to understand and recognize how different biologic processes, including genomic, epigenomic, metabolomic, and microbiome changes contribute to the development and pathogenesis of IPF/ILD
- to learn how some of these diverse layers of biologic data can be integrated to derive new insights into IPF pathogenesis
- To identify challenges to integrating -omics data and identify areas for future research need in IPF/ILD

Studies utilizing RNA sequencing and single-cell approaches have identified new cell types, genes, and pathways that contribute to the pathogenesis of lung fibrosis. However, layers of biologic data beyond the transcriptome, including genomic, epigenomic, proteomic, and metabolomic studies have also enhanced our understanding of fibrotic mechanisms. Understanding these multi-omic “universes” and how they interact with the environment and microbiome can help address fundamental questions regarding etiology, prognosis, and strategies for personalized treatment. This session will highlight the current state of knowledge in these other areas and attempt to integrate these data into a cohesive understanding of IPF pathogenesis.

Chairing: S.K. Huang, MD, Ann Arbor, MI
M.N. Ballinger, PhD, ATSF, Columbus, OH
J. Kropski, MD, Nashville, TN

2:15 Into the Genomics and Epigenomics Universe of IPF
I.V. Yang, BS, PhD, Aurora, CO

2:28 “ATAC”-ing IPF: how Understanding Chromatin Biology Sheds Light on Fibrosis
G. Ligresti, PhD, Boston, MA

2:41 The Next Frontier: Proteomics of Post-translational Modifications in IPF
O. Eickelberg, MD, ATSF, Pittsburgh, PA

2:54 Importance of Metabolomic Changes in IPF Pathogenesis

F. Romero, PhD, Philadelphia, PA

3:06 How Pharmacogenomics and Drug Discovery can Provide New Insights into ILD Pathogenesis

L. Hecker, PhD, Atlanta, GA

3:19 Understanding the Systemic Microbiome in IPF

D.N. O'Dwyer, BM BCH, BMedSci, PhD, Ann Arbor, MI

3:32 The Multi-Omic Universe: How Do We Integrate These Datasets to Better Understand and Eventually Cure IPF

N. Kaminski, MD, ATSF, New Haven, CT

This session and the International Conference are supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BEHAVIORAL • CLINICAL**SCIENTIFIC SYMPOSIUM**

CME Credits Available: 1.5

C87 A MEASURED RESPONSE: ASSESSING TREATMENT OUTCOMES IN PULMONARY HYPERTENSION**Assemblies on Pulmonary Circulation; Behavioral Science and Health Services Research; Clinical Problems****2:15 PM - 3:45 PM Marriott Marquis Washington****Marquis Ballroom Salon 6 (Level M2)****Target Audience**

Providers of patients with pulmonary hypertension, researchers in pulmonary hypertension, clinicians and researchers needing instruction in the evaluation and management of pulmonary hypertension

Objectives

At the conclusion of this session, the participant will be able to:

- describe the strengths and weaknesses of currently employed outcome measures in pulmonary hypertension clinical trials
- describe novel outcome measures that focus on “feels, functions, and survives” and how these may be applied in PH clinical trials
- more appropriately interpret and integrate results from clinical trials into clinical practice

Multiple outcome measures are currently employed in the evaluation and management of patients with pulmonary hypertension (PH), creating confusion about which measure is most appropriate. In this session, we will discuss the state of the art approach to outcomes assessment in PH through in-depth analyses of the current and future measures of therapeutic response.

Chairing: S.C. Mathai, MD, MHS, Baltimore, MD
C.E. Ventetuolo, MD, MSCR, Providence, RI

2:15 Patient Speaker

Speaker To Be Announced

2:20 The Emperor Has No Clothes: Current Outcome Measures in PH

S.C. Mathai, MD, MHS, Baltimore, MD

2:35 Patient Reported Outcomes: The Missing Piece in Assessment of PH Outcomes

H.M. Dubrock, MD, Rochester, MN

2:55 Walking in Circles: Functional Assessment as an Outcome Measure in PH

J. Minhas, MD, MS, MBBS, Philadelphia, PA

3:15 Risk Scores and Survival as Outcome Measures in PH

S.M. Kawut, MD, MS, ATSF, Philadelphia, PA

3:35 Panel Discussion

This session and the International Conference are supported by an independent medical educational grant from Merck & Co., and United Therapeutics Corporation.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

MOC Points Available: 1.5

C88 BIOLOGICAL IMPACT OF COVID-19 ACROSS THE LIFESPAN

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Pulmonary Infections and Tuberculosis; Respiratory Cell and Molecular Biology

2:15 PM - 3:45 PM

Marriott Marquis Washington

Marquis Ballroom Salon 5 (Level M2)

Target Audience

Pediatric pulmonologists, adult pulmonologists, and basic and translational researchers

Objectives

At the conclusion of this session, the participant will be able to:

- to better understand the role and durability of passive immunity against COVID-19 and other infections in newborns
- understand immune responses in the airway in in circulation in response to acute SARS-CoV-2 infection

- to ascertain the clinical phenotype of long COVID-19 in kids and adults and review the latest research on pathogenicity

Despite very early assumptions, children are not spared from COVID-19. However, biological and clinical responses vary considerably across the age spectrum. In this session, we will assess biologic responses to SARS-CoV-2, which will serve as a foundation for comparisons with other common respiratory viruses. We will discuss the passive transfer of maternal antibodies to infants and their clinical protection; airway signals in the upper airway in response to infection in children as compared to adults; hematologic biomarkers of severe infection in children and adults infected with SARS-CoV-2; and clinical and molecular findings in long COVID-19.

Chairing: L. Yonker, MD, Boston, MA
M.A. Mall, MD, Berlin, Germany

2:15 Passive Immunity in Neonates
A. Edlow, MD, MSc, Boston, MA

2:35 Airway Responses to SARS-CoV-2
M.A. Mall, MD, Berlin, Germany

2:55 Hematologic Markers of Severe COVID-19 and MISC
O. Badaki-Makun, MD CM, PhD, Baltimore, MD

3:15 Long COVID-19
S.A. Mcgrath-Morrow, MD, Philadelphia, PA

3:35 Tying it Together
L. Yonker, MD, Boston, MA

BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

C89 ACHIEVING HEALTH EQUITY: REDUCING THE IMPACT OF SDOH THROUGH RESEARCH AND ADVOCACY

Assemblies on Behavioral Science and Health Services Research; Nursing; Pediatrics; Sleep and Respiratory Neurobiology; Health Equity and Diversity Committee; Health Policy Committee; International Health Committee

2:15 PM - 3:45 PM

Walter E. Washington Convention Center

Room 145 A-B (Street Level)

Target Audience

Interprofessional healthcare providers including clinicians, health system administrators, researchers focused on health care delivery science

Objectives

At the conclusion of this session, the participant will be able to:

- increase incorporation of SDOH in current clinical and translational research

- increase underrepresented minorities in research and increase workforce needed to support patients impacted by SDOH
- align SDOH related research proposals with NIH funding priorities for SDOH related initiatives

Attendees will learn about cutting edge research on the impact of SDOH on respiratory health, including patients affected by SDOH in clinical trials, reducing workforce gaps that exacerbate the impact of SDOH on outcome, ATS advocacy activities targeting reduction in SDOH and NIH research priorities directed at mitigating the impact of SDOH on health outcomes.

Chairing: F. Afolabi, MD, Dallas, TX
S.C. Sweet, MD, PhD, Saint Louis, MO

- 2:15 Addressing SDOH Through Research and Workforce Development: The Time is NOW**
S.C. Sweet, MD, PhD, Saint Louis, MO
- 2:20 Cutting Edge Research: The Impact of SDOH on Respiratory Disease, Sleep, Critical Illness, and Recovery**
S. Jain, MD, New Haven, CT
- 2:35 Addressing Maslow's Hierarchy: Integrating SDOH in Research**
T. Winders, MBA, Vienna, VA
- 2:50 The Workforce Meets SDOH**
I.L. Riley, MD, MPH, Durham, NC
- 3:05 Moving the SDOH Needle: Partnering with Patients and Other Organizations to Advocate for Policy Change**
E. Sward, BA, MA, Washington, DC
- 3:20 The Next Frontier: NIH Priorities and Resources to Address SDOH**
M. Freemer, MD, MPH, Bethesda, MD
- 3:35 Panel Discussion**

TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

C90 DOUBLE TROUBLE: AIR POLLUTANTS AND TUBERCULOSIS

Assemblies on Environmental, Occupational and Population Health; Behavioral Science and Health Services Research; Pulmonary Infections and Tuberculosis; International Health Committee

2:15 PM - 3:45 PM **Walter E. Washington Convention Center**
Room 202 A (Level 2)

Target Audience

Clinicians in pulmonary, infectious disease, environmental and

occupational health fields, as well as PhD scientists, and those working in global health

Objectives

At the conclusion of this session, the participant will be able to:

- raise awareness about the emerging epidemiologic and mechanistic evidence that suggests a causal relationship between air pollution exposures, tuberculosis development and worsened treatment outcomes
- review the state of the science for air pollution exposure assessment approaches, technologies and optimal measurement strategies
- explore translation of scientific discovery into actionable health preventative steps

This session reviews the current epidemiologic and mechanistic knowledge on associations between exposures to air pollution, tobacco smoke and risk for tuberculosis, three eminent health challenges of global importance, and how exposure risks relate to social determinants of health. Addressing the need for continued research on exposure dose response relationships as well as for translation of findings into regulatory policies, the session also discusses pitfalls and state of the art of exposure assessments as well as the translation of scientific findings into advocacy for policy change.

Chairing: C.M. North, MD, MPH, Boston, MA
S. Schwander, MD, PhD, Piscataway, NJ

- 2:15 The Global State of Air Pollution and Tuberculosis: What Does the Epidemiology Show?**
S. Carroll, BSc, Montreal, Canada
- 2:30 The State of the Art for Characterizing Air Pollution Exposure Among People at Risk for Tuberculosis**
Q. Meng, PhD, Reno, NV
- 2:45 The Influence of Social Determinants of Health on Air Pollution Exposure and Tuberculosis Risk - Triple Trouble in Resource-Limited Settings**
L. Atuyambe, PhD, Kampala, Uganda
- 3:00 Mechanistic Evidence - Air Pollutant Effects on Immune Responses to Mycobacterium Tuberculosis: Is the Sum Greater Than the Parts?**
S. Sarkar, PhD, Piscataway, NJ
- 3:15 Vaping and Smoking - the "Other Air Pollutants"**
R.N. Van Zyl Smit, MBChB, PhD, ATSF, Cape Town, South Africa
- 3:30 So, Air Pollutants Are Making Tuberculosis Worse - Now What? Activism and Policy Change**
N. Mistry, MD, Mumbai, India

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

C91 THE E-CIGARETTE AND VAPING PRODUCT EPIDEMIC: IT'S IN THE JUICE**2:15 p.m. - 3:45 p.m. Walter E. Washington Convention Center
Room 143 A-C****Target Audience**

Clinical, translational and basic science researchers; those involved with policy development; providers of lung health

Objectives

At the conclusion of this session, the participant will be able to:

- learn new findings about the biological and physiological impacts of e-cigarette and vaping use on the lung.
- improve understanding of the epidemiology, pathogenesis and clinical management of E-cigarette or vaping product use-associated lung injury (EVALI)
- learn about existing and needed effective policies for the regulation of e-cigarette and vaping product availability.

This session features speakers who will summarize up to date knowledge and future direction for research related to biological, physiological and social impacts of e-cigarette use, with particular focus on new users. Topics will include an overview of policy strengths and limitations related to regulation of e-cigarette and e-cigarette juice availability. Specific insight on molecular and cellular responses in the lung will be featured, including tissue remodeling, immunity and inflammation. A recent ATS workshop summary on EVALI will be featured, and the evolution of e-cigarette devices in the last decade will be discussed.

Chairing: A. Noel, PhD, Baton Rouge, LA
M. Perez, MD, Farmington, CT

2:15 Inhaling- Vaping Updates from Animal and Human Studies

A. Noel, PhD, Baton Rouge, LA

2:19 Results from the ATS EVALI Workshop Report - Critical Needs to Prevent Future Outbreaks of Vaping Induced Illness

M. Rebuli, PhD, Chapel Hill, NC

2:35 Q&A

M. Rebuli, PhD, Chapel Hill, NC

2:40 E-cigarettes: Mice, Humans, and Policy, Oh My!

L. Crotty-Alexander, PhD, La Jolla, CA

2:56 Q&A

L. Crotty-Alexander, PhD, La Jolla, CA

3:01 E-cigarette Use and Early Transcriptomic Alterations in Human Lung Tissue

C. Pascoe, PhD, Winnipeg, MB

3:16 Q&A

C. Pascoe, PhD, Winnipeg, MB

3:21 Vaping Old and New and how it Alters Your Respiratory Immune Responses

I. Jaspers, PhD, Chapel Hill, NC

3:37 Q&A

I. Jaspers, PhD, Chapel Hill, NC

3:42 Exhaling - Closing Remarks, What's Next?

M. Perez, MD, Farmington, CT

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

C92 ATS PRESIDENT'S SYMPOSIUM: EARLY LIFE DETERMINANTS (ANTECEDENTS) OF ADULT LUNG DISEASE**2:15 p.m. - 3:45 p.m. Walter E. Washington Convention Center
Room 153 A-B (Street Level)****Objectives**

At the conclusion of this session, the participant will be able to:

- review recent advances in our understanding of how premature birth affects lung development and predisposes the individual to childhood and adult diseases such as asthma, COPD, and pulmonary hypertension
- understand how early life exposures to airborne pollutants, allergens, cigarette smoke, and particulate matter from wild fires affects lung development and predisposes the individual to childhood and adult diseases such as asthma and COPD
- highlight the areas of research needed to reduce the impact of early life exposures disease on respiratory health in children and adults

This symposium will focus on the early life determinants of lung health throughout the lifespan beginning in utero and extending into childhood and adulthood. The lungs of babies born premature are not fully developed and are more susceptible to respiratory infections or inhaled toxicants. Diseases that manifest clinically in utero and in childhood such as cystic fibrosis and sickle cell anemia result in lung injury and these individuals are more susceptible to and have less reserve to withstand additional insults such as respiratory infections or exposure to pollutants such as automobile exhaust, ozone, aeroallergens, and airborne particulate matter from wildfires. In adulthood, these early life factors predispose to asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pulmonary hypertension. The mechanisms of lung injury and physiological consequences of these early life

exposures remain incompletely understood. This symposium will highlight recent advances in our understanding of the pathophysiological mechanisms by which these exposures damage the developing lung, the epidemiology of these early life exposures as well as highlight needed areas of research to advance treatment and prevention of these prevalent diseases.

Chairing: G. Downey, MD, FRCP(C), ATSF, Denver, CO
E. Forno, MD, MPH, ATSF, Pittsburgh, PA
B. Kopp, MD, MPH, ATSF, Atlanta, GA

- 2:15 The Children Are Not OK: Reframing Our Approach to Lung Health and Lung Disease**
M. Han, MD, MS, ATSF, Ann Arbor, MI
- 2:27 Tough Transitions: Sickle Cell Lung Disease Through the Ages**
B. Kopp, MD, MPH, ATSF, Atlanta, GA
- 2:42 Perinatal Pulmonary Vascular Insults: How Prematurity Primes the Pump for Pulmonary Hypertension**
K. Goss, MD, Dallas, TX
- 2:57 Childhood Interstitial Lung Disease: Coming of Age**
L. Young, MD, ATSF, Philadelphia, PA
- 3:12 The Changing Face of Cystic Fibrosis (CF)**
J. Taylor-Cousar, MD, MSc, ATSF, Denver, CO
- 3:27 Implications of Early Life Environmental Exposures to Adult Obstructive Lung Disease**
E. Forno, MD, MPH, ATSF, Pittsburgh, PA
- 3:42 Summary and Discussion**
G. Downey, MD, FRCP(C), ATSF, Denver, CO

BEHAVIORAL • CLINICAL

MINI SYMPOSIUM

C93 DISPARITIES, TREATMENTS, AND OUTCOMES IN COPD

2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center**
Room 146 A-C (Street Level)

Chairing: L.C. Feemster, MSc, MD, Seattle, WA
L.J. Harper, MD, MSCR, Cleveland, OH
T.M. Parekh, DO, Austin, TX

Oral Presentations:

- 2:15 Barriers to Cardiovascular Disease Prevention Among Black Individuals With Chronic Obstructive Pulmonary Disease/M.L. Murphy, Brooklyn, NY**
- 2:27 Association Between County-Level Social Vulnerability and Incident Chronic Obstructive Pulmonary Disease Among U.S. Veterans/S. Hayes, Seattle, WA**

- 2:39 Geography and Suboptimal Inhaler Regimens After COPD Hospitalization/A.K. Baldomero, Minneapolis, MN**
- 2:51 Association Between Rural Residence and Quality of Care Delivery Among Veterans Following Chronic Obstructive Pulmonary Disease Exacerbation/F. Picazo, Seattle, WA**
- 3:03 COPD Exacerbations in Patients With Type 2 Diabetes on Glucagon-like Peptide-1 Receptor Agonists/D. Foer, Boston, MA**
- 3:15 COPD Exacerbations, Resource Use, and Costs Among COPD Patients With Eosinophil Count ≤ 300 Cells/ μ L Who Initiate Therapy With Tiotropium/olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol/B. Clark, Ridgefield, CT**
- 3:27 Factors Associated With Home Oxygen Reassessment After an Inpatient COPD Exacerbation/K. Duan, Seattle, WA**
- 3:39 Comparing Alignment of Provider- and Patient-reported Treatment Regimens With Clinical Guidelines in Chronic Obstructive Pulmonary Disease (COPD)/M.A. Case, Baltimore, MD**
- 3:51 Reducing Diagnostic Error to Improve Patient Safety (REDEFINE) in COPD and Asthma Study: A Cluster Randomized Comparative Effectiveness Trial/E. Pacheco, Chicago, IL**
- 4:03 A Web-based Physical Activity Intervention Prevents Decline in Exercise Self-regulatory Efficacy Across 3 Months in Persons With Chronic Obstructive Respiratory Disease (COPD)/P. Bamonti, Boston, MA**

BASIC • CLINICAL

MINI SYMPOSIUM

C94 CLINICAL AND TRANSLATIONAL STUDIES IN SEPSIS

2:15 p.m. - 4:15 p.m. **Marriott Marquis Downtown**
Independence Ballroom Salons A-D (Level M4)

Chairing: D. Maslove, MD, MS, FRCP(C), Kingston, Canada
J.D. Casey, MD, MSCR, Nashville, TN
T.S. Meyhoff, MD, Copenhagen, Denmark

Oral Presentations:

- 2:15 The Association Between Time-to-Antibiotics and Mortality in Sepsis Is Sensitive to Four Common Biases in Observational Studies/T.R. Pak, Boston, MA**
- 2:27 The Effect of Fluid Resuscitation Strategy on Risk for Renal Replacement Therapy Differs Based on Presence of Acute Kidney Injury in the CLOVERS Trial/A. Khader, Seattle, WA**

- 2:39** Early Vs Late Initiation of Vasopressors in Sepsis: An Augmented Inverse Probability Weighting Approach/D.C. Marshall, London, United Kingdom
- 2:51** Does the Approach to Administration of Norepinephrine Matter? A Comparison of Weight-based Versus Non-weight-based Dosing in Patients With Septic Shock/O. Haun De Oliveira, Toronto, Canada
- 3:03** Patterns of Vasopressor Delivery and Potential for Reduction in Central Venous Catheter Use/B. Teja, Toronto, Canada
- 3:15** Premorbid Metabolic Syndrome Is Associated With the Hypoinflammatory Latent Class Analysis (LCA) Phenotype in Acute Respiratory Distress Syndrome (ARDS) and Sepsis/A.M. Bogart, Nashville, TN
- 3:27** Identifying Potentially Preventable Death From Sepsis/E. Munroe, Ann Arbor, MI
- 3:39** Effect of Automated Real-time Feedback on Early Sepsis Care - A Cluster Randomized Study/D. Leisman, Boston, MA
- 3:51** Machine Learning Methods to Address Confounding in Sepsis Mortality Rate/T. Basu, Ann Arbor, MI
- 4:03** Human Induced Pluripotent Stem Cell Microvascular Organoid Model of Endothelial Dysfunction in Sepsis/M.R. Atreya, Cincinnati, OH

BASIC • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

C95 NOT JUST GENES: ENVIRONMENTAL EXPOSURES AND INTERSTITIAL LUNG DISEASE

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Ballroom B (Level 3)

Chairing: K.A.M. Johannson, MD, MPH, ATSF, Calgary, Canada
R.M. Tighe, MD, ATSF, Durham, NC
G.C. Goobie, MD, PhD, Vancouver, Canada

Oral Presentations:

- 2:15** Interstitial Lung Abnormalities Are Associated With Increased Mortality in PRISM/S. Kalra, Boston, MA
- 2:27** The Impact of Occupational Exposures on the Risk of Idiopathic Pulmonary Fibrosis - A Systematic Review and Meta-analysis/S. Gandhi, San Francisco, CA
- 2:39** Occupational Exposures and Interstitial Lung Abnormalities and Disease in World Trade Center Workers and Volunteers/J. Johnson-Crooks, New York, NY
- 2:51** Screening for Beryllium Among U.S. Veterans With Sarcoidosis, 2002-2020/M.I. Seedahmed, San Francisco, CA

- 3:03** (P.2.5.)induced DNA Methylation Alterations in Patients With Fibrotic Interstitial Lung Disease/G.C. Goobie, Vancouver, Canada
- 3:15** MMP-7 Mediates PM2.5 and Mortality Associations in Patients With Idiopathic Pulmonary Fibrosis/S.E. Kim, Pittsburgh, PA
- 3:27** Long-term Exposure to Air Pollution and Lung Function in Cystic Fibrosis/J. Cogen, Seattle, WA
- 3:39** Racial and Ethnic Disparities in Antifibrotic Therapy in Idiopathic Pulmonary Fibrosis/J. Fares, Philadelphia, PA
- 3:51** Does Antacid Therapy in Idiopathic Pulmonary Fibrosis Patients Increase Risk of Pneumonia? An Observational Cohort Study/G. Massen, London, United Kingdom

Featured Speaker:

- 4:03** Environment and ILD: Tying It All Together/K.A.M. Johannson, Calgary, Canada

BEHAVIORAL • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

C96 THE SCIENCE AND CLINICAL PRACTICE OF PULMONARY REHABILITATION

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 204 A-C (Level 2)

Chairing: C. Burtin, PT, PhD, Diepenbeek, Belgium
A. Burge, PhD, Melbourne, Australia

Oral Presentations:

- 2:15** Pulmonary Rehabilitation After Severe Exacerbations of COPD: A Nationwide Population Study/M. Guecamburu, Pessac, France
- 2:27** Exercise Self-efficacy Barriers to Target for Clinically Meaningful Physical Activity Improvements in COPD/S.A. Robinson, Bedford, MA
- 2:39** Computer Aided Lung Sound Analysis to Detect Acute Effects of Airway Clearance Techniques in Patients With Cystic Fibrosis/E. Lauwers, Wilrijk, Belgium
- 2:51** Chronotropic Index and Heart Rate Response on Cardiopulmonary Exercise Testing in Patients With Advanced Lung Disease/D. Shah, New Hyde Park, NY
- 3:03** Poor Exercise Capacity and Physical Function in Patients Awaiting Lung Cancer Surgery/C.L. Granger, Melbourne, Australia
- 3:15** Effects of High Frequency Chest Wall Oscillation (HFCWO) on Clinical Symptoms in COPD/M. Bruner, Birmingham, AL

- 3:27 **COPD Education Phenotypes: Features That Impact Education for Patients With COPD**/B.J. Make, Denver, CO
- 3:39 **Prognostic Implications of Frailty and Charlson Comorbidity Index in Patients Admitted With Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)**/D. Rozenberg, Toronto, Canada
- 3:51 **Clinical Implications of Exercise Capacity at 3-months Post Lung Transplantation on 5-year Outcomes**/M. Khalil, Toronto, Canada
- 4:03 **Minimal Important Difference for the Incremental and Endurance Shuttle Walk Test After a 6-week Course of Pulmonary Rehabilitation in Patients With Interstitial Lung Disease**/L. Houchen-Wolloff, Leicester, United Kingdom

BASIC • TRANSLATIONAL**MINI SYMPOSIUM****C97 EPITHELIAL RESPONSES TO LUNG INJURY**

2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center**
Room 102 A-B (Street Level)

Chairing: J.L. Hook, MD, New York, NY
J.P. Mizgerd, ScD, ATSF, Boston, MA
R.L. Zemans, MD, Ann Arbor, MI

Featured Speaker:

2:15 **Macrophage-Epithelial Interactions Driving Lung Repair**/S. Herold, Giessen, Germany

Oral Presentations:

- 2:27 **Differential Single Cell Lung Epithelial Gene Expression During Lethal and Non-lethal SARS CoV-2 Infection**/G. Bandyopadhyay, Rochester, NY
- 2:39 **Associations of the IL-33 Signalling Pathway With Poor Clinical Outcomes and Lung Pathology in Patients With Respiratory Virus Infections at Risk of Acute Respiratory Failure**/I.C. Scott, Cambridge, United Kingdom
- 2:51 **COVID-19 Lungs Are Dominated by Functionally Impaired Airway Basal Stem Cells With a Sustained Inflammatory Phenotype**/X. Ai, Boston, MA
- 3:03 **Development of Alveolar Surface Proteome Enrichment (ASPE) for Characterization of the Pre-alveolar Transitional State (PATS) Within a Murine Model of Lung Injury**/M.T. Forrester, Durham, NC
- 3:15 **Live Imaging of Staphylococcal Retention Mechanisms in Alveoli of Influenza-infected Lungs**/S. Tang, New York, NY
- 3:27 **Bcl-2 Interacting Killer, Bik, Promotes Influenza A Virus Replication and Severity to Flu**/S. Soni, Columbus, OH

- 3:39 **Sinonasal Epithelial Functional and Transcriptional Responses to Long-term Highly Effective CFTR Modulator Therapy**/E.K. Vladar, Aurora, CO
- 3:51 **The Role of Glucocorticoids on Cluster of Differentiation 151 (CD151) Expression in Influenza A Virus Replication**/Z. Lee, Kent Ridge, Singapore
- 4:03 **Coronavirus Triggers Activation of Alveolar Epithelial ER Stress and Disruption of Surfactant Homeostasis; Implications for COVID-19 Respiratory Failure Pathogenesis in Mice**/A. Murthy, Philadelphia, PA

BEHAVIORAL • CLINICAL • TRANSLATIONAL**MINI SYMPOSIUM****C98 RISKY BUSINESS: PREDICTING CONSEQUENCES OF OSA**

2:15 p.m. - 4:15 p.m. **Marriott Marquis Downtown**
Independence Ballroom, Salons E-H (Level M4)

Chairing: T. Kendzerska, MD, PhD, Ottawa, Canada
S.P. Patil, MD, PhD, ATSF, Cleveland, OH
V. Kundel, MD, New York, NY
L.M. Donovan, MD, MS, Seattle, WA
J.C. Jun, MD, Baltimore, MD

Oral Presentations:

- 2:15 **Good Adherence to CPAP Decreases Recurrent Cardiovascular Events: A Systematic Review and Individual Participant Data Meta-analysis**/M. Sanchez De La Torre, Lleida, Spain
- 2:27 **Impact of Positive Airway Pressure (PAP)-therapy on Mortality in Obstructive Sleep Apnea (OSA): Analysis of a German Healthcare Database**/H. Woehrle, Ulm, Germany
- 2:39 **Prevalence and Determinants of CPAP Resumption After a First CPAP Termination and Impact on All-cause Mortality: A French Nationwide Database Analysis**/J. Pépin, Grenoble Cedex 9, France
- 2:51 **Risks of Non-benzodiazepine Benzodiazepine Receptor Agonists Among Patients With Chronic Obstructive Pulmonary Disease**/J.M. Castaneda, Seattle, WA
- 3:03 **Combination of Ventilatory, Hypoxic, and Arousal Burden Predicts Short- and Long-term Consequences of OSA Better Than the Apnea-hypopnea Index**/S. Wickramaratne, New York, NY
- 3:15 **Use of Machine Learning and Prediction Tools to Assess Cardiovascular Disease Risk in Obstructive Sleep Apnea**/M. Suárez-Fariñas, New York, NY

- 3:27 **Arousal Intensity Predicts Incident Dementia in Sleep Apnea: The Multiethnic Study of Atherosclerosis (MESA)**/G.P. Labarca, Boston, MA
- 3:39 **Polysomnography-derived Hypoxemic Markers Associated With Pulmonary Hypertension in Obstructive Sleep Apnea**/S. Hassan, Burlington, VT
- 3:51 **Polysomnographic Determinants of Nondipping Blood Pressure Pattern in Obstructive Sleep Apnea**/L. Pinilla Latorre, Lleida, Spain

Featured Speaker:

- 4:03 **Prognostic in Obstructive Sleep Apnea**/H.K. Yaggi, New Haven, CT

BASIC • CLINICAL • TRANSLATIONAL**MINI SYMPOSIUM****C99 ADVANCES IN BIOMARKERS ACROSS THE LUNG CANCER CONTINUUM**

2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Room 202 B (Level 2)

Chairing: A. Vachani, MD, MS, Philadelphia, PA
N.T. Tanner, MD, MSCR, Charleston, SC

Oral Presentations:

- 2:15 **Improved Lung Cancer Detection in Setting of Underutilized CT Screening: Combination of a Lung Cancer Biomarker With Clinical Risk Assessment**/P.B. Bach, Baltimore, MD
- 2:27 **Cell-free Tumor DNA in Blood and Bronchoalveolar Lavage (BAL) as a Biomarker in Non-Small Cell Lung Cancer**/K. Zhang, Hamilton, Canada
- 2:39 **Prospective Evaluation of cfDNA Fragmentomes for Lung Cancer Detection**/P.J. Mazzone, Cleveland, OH
- 2:51 **Mortality Benefit of a Blood-based Biomarker Panel for Lung Cancer Based on the PLCO Cohort**/E. Ostrin, Houston, TX
- 3:03 **The Role of Syndecan 4 and Cyfra 21.1 in the Diagnosis of Non-small Cell Lung Cancer**/A. Santoso, Makassar, Indonesia
- 3:15 **Assessment of an Integrated Classifier's Ability to Distinguish Benign From Malignant Nodules: Subgroup Analysis of the Oracle Registry**/K.J. Long, Charleston, SC
- 3:27 **Shifting the Intervention Probability Curve for Lung Cancer Diagnosis Following Biomarker Implementation: A Novel Clinical Endpoint for Biomarker Clinical Trials**/M.N. Kammer, Nashville, TN

- 3:39 **A Pilot Study of Diagnostic Value of Sentinel-10 Liquid Biopsy Assay for the Detection of Malignancy in Pleural Fluid**/J. Lenka, Tucson, AZ
- 3:51 **Use of Pleural Fluid Cell Free Deoxyribonucleic Acid (DNA) in Malignant Pleural Effusions**/M. Hagner, Iowa City, IA
- 4:03 **Variations in the Metabolomic Profile Following Thoracic Surgery With Curative Intent in Lung Cancer. Preliminary Results From a Longitudinal Prospective Study (Promoter)**/L. Seijo, Madrid, Spain

BASIC • CLINICAL • TRANSLATIONAL**RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION****C101 IMPACT OF BIOLOGICS ON ASTHMA OUTCOMES**

2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Room 103 A-B (Street Level)

Viewing 2:15-3:00

Summaries/Discussion 3:00-4:15

Chairing: L. Eggert, MD, Stanford, CA
P. Akuthota, MD, ATSF, La Jolla, CA
R.P. Ramonell, MD, Pittsburgh, PA

- 201 **Tezepelumab Efficacy by SNOT-22 Domain Scores in Patients With Severe, Uncontrolled Asthma and Comorbid Nasal Polyps in the Phase 3 Navigator Study**/J.D. Spahn, Wilmington, DE
- 202 **Characteristics of Biological Treatment Failure in Patients With Severe Eosinophilic Asthma**/E. Zehr, Aurora, CO
- 203 **Clinical Remission Achievement in Severe Asthma Following Mepolizumab Treatment: Results From the REALITI-A Study at 2 Years**/G. Brusselle, Ghent, Belgium
- 204 **Baseline Predictors of an Enhanced Response to Tezepelumab Treatment Versus Placebo: Results From the Phase 3 NAVIGATOR Study**/A. Menzies-Gow, London, United Kingdom
- 205 **Oral Corticosteroid-Sparing Effect of Tezepelumab in Adults With Severe Asthma: Results From the DESTINATION Study**/A. Menzies-Gow, London, United Kingdom
- 206 **Dupilumab Improved Long-term Lung Function in Children Aged 6 to 11 Years With Moderate-to-Severe Asthma: Liberty Asthma Excursion**/L.B. Bacharier, Nashville, TN

- 207 **Comparative Effectiveness of Dupilumab Versus Omalizumab in Asthma Among Biologic-Naïve Patients: Findings From the Real-World US Advantage Study/E.R. Bleecker, Tucson, AZ**
- 208 **Comparative Effectiveness of Dupilumab, Mepolizumab, and Benralizumab in Patients With Asthma/C. Kearney, Boston, MA**
- 209 **Dupilumab Improves Lung Function in Children With Moderate-to-Severe Type 2 Asthma at Week 12/T.W. Guilbert, Cincinnati, OH**
- 210 **Real-world Effectiveness of Dupilumab on Oral Corticosteroid Use and Asthma Exacerbations in Patients With Moderate-to-Severe Asthma/A. Pawar, Cambridge, MA**
- 211 **Mepolizumab Provides Real-World Clinical Benefits in Severe Eosinophilic Asthma Irrespective of Baseline Lung Function: Results From the REALITI-A Study at 2 Years/D. Bagnasco, Genoa, Italy**
- 212 **Exacerbation Burden and Biologic Outcomes in Us Patients With Severe Asthma by Obesity: Results From the Chronicle Study/R. Panettieri, New Brunswick, NJ**
- 213 **Dupilumab Induces Clinical Remission in Patients With Uncontrolled, Moderate-to-Severe, Type 2 Inflammatory Asthma/I.D. Pavord, Oxford, United Kingdom**
- 214 **Efficacy of Tezepelumab in Patients Grouped by Pre-treatment Percent Predicted FEV₁: A Pooled Analysis of the PATHWAY and NAVIGATOR Studies/M.E. Wechsler, Denver, CO**
- 215 **Biologic Outcomes in US Hispanic and Black Patients With Severe Asthma: Results From the CHRONICLE Study/J. Trevor, Birmingham, AL**
- 801 **Potential Impact of the European Union F-gas Regulation on Patients With Asthma and Chronic Lower Respiratory Diseases/J.P. Bell, Baar, Switzerland**
- 802 **Use of Spirometry and Biomarker Profiling in Severe Asthma: There Is Room for Improvement/H. Ortega, San Diego, CA**
- 803 **Addressing Uncontrolled Asthma Across Disease Severities Through Implementation of the Asthma Impairment and Risk Questionnaire (AIRQ®) and the Asthma Checklist/D.A. Beuther, Denver, CO**
- 804 **Rates of Asthma Exacerbations Among Severe, Persistent Asthma Patients in the US Following Event Indicating Uncontrolled Disease/A.F. Burnette, Washington, DC**
- 805 **Disparities in Adult Asthma Outcomes Among Disaggregated Asian Americans in the National Health Interview Survey/A. Zhang, Stanford, CA**
- 806 **Enhancing Adoption of New Targeted Agents and Empowering Patients With Severe Asthma: The Role of Tethered Education for Health Care Providers and Patients/C. Drexel, Needham, MA**
- 807 **Rate of Biologic Initiation in Patients With Severe Uncontrolled Asthma (SUA)/T.C. Corbridge, Research Triangle Park, NC**
- 808 **Beginning to Address an Implementation Gap in Asthma: Providers' Views of Reliever Usage of ICS-formoterol Inhalers in the United States/J.G. Krings, Saint Louis, MO**
- 809 **Clinical Practices and Barriers to the Use of Single Maintenance and Reliever Therapy for Asthma/S.E. Zaeh, New Haven, CT**
- 810 **Association of Anxiety and Depression With Adherence to Inhaler in Patients With Asthma/A.A. Alqarni, Jeddah, Saudi Arabia**
- 811 **Inspiring Health Advances in Lung Care (INHALE): An Opportunity to Address Pediatric Asthma Health Disparities in Michigan/T.C. Lewis, Ann Arbor, MI**
- 812 **Barriers and Facilitators to Stock Inhalers for Schools Programming in Illinois: Results From a Qualitative Data Analysis/A.A. Pappalardo, Chicago, IL**
- 813 **Factors Associated With Asthma Biologic Prescribing and Adherence Among Adults in a Major Multi-hospital Health System/P. Gleeson, Philadelphia, PA**
- 814 **Characterizing Inpatients With Asthma in the Intensive Care Unit From 2010-2018/S. Chokkara, Chicago, IL**
- 815 **Real-world Impact of Switching to Mepolizumab From Other Biologics in Patients With Asthma/A. Deb, Collegeville, PA**

BEHAVIORAL • CLINICAL
POSTER DISCUSSION SESSION
C102 ASTHMA AND COPD: ADVANCING BEHAVIORAL SCIENCES AND HEALTH SERVICES RESEARCH
2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center
Room 209 A-C (Level 2)
Poster Viewing 2:15-3:00
Discussion 3:00-4:15
Chairing: V.G. Press, MD, MPH, ATSF, Chicago, IL
 A.S. Gershon, MD, MSc, ATSF, Toronto, Canada
 L.J. Spece, MD, MS, Seattle, WA

- 816 **Comparative Effectiveness of Dupilumab and Mepolizumab in Eosinophilic Asthma/A. Akenroye, Boston, MA**
- 817 **Long-term Effectiveness of Nucala (4 Years) in Patients With Asthma: A Real-world Database Analysis/A. Stach-Klysh, Research Triangle Park, NC**
- 818 **Breaking Thresholds to Improve Screening Tools for Obstructive Lung Disease/A.T. Moffett, Philadelphia, PA**
- 819 **Evaluation of an Implementation Package to Deliver the COPD CARE Service/E. Portillo, Madison, WI**
- 820 **A Model to Improve COPD Care at a Regional Medical Center/K. Manzoor, Norwell, MA**
- 821 **“I’d Be Looking for Another Doctor” - a Mixed Methods Analysis of Patients’ Attitudes Towards Oxygen Discontinuation/L.C. Feemster, Seattle, WA**
- 822 **Exacerbations and Real-world Outcomes (EROS) Among Patients With COPD Receiving Single Inhaler Triple Therapy of Budesonide/glycopyrrolate/formoterol Fumarate/M. Pollack, Wilmington, DE**
- 823 **Real World Evidence: Severe Asthma Questionnaire (SAQ) and Asthma Control Questionnaire (ACQ) As Early Predictors of Biologic Response in Severe Asthma/J.W. Lanario, Plymouth, United Kingdom**
- 824 **A National Partnership With the COPD Foundation to Implement the COPD Virtual Medication Reconciliation and Education: COPD V-M(ED) Pilot - An Interim Analysis/S.E. Gray, Chicago, IL**
- 103 **Physiological Benefits of Pulmonary Rehabilitation in Patients Preparing for Lung Transplantation/D.R. Nunley, Columbus, OH**
- 104 **Acute Exacerbation of ILD Associated With Improved Lung Transplant Survival Compared to Other Inpatient ILD Transplants/D.M. Guidot, Durham, NC**
- 105 **A Comparison of Combined Double Lung-liver Transplant and Double Lung Transplant in Adult Cystic Fibrosis Patients/A. Ramirez, Shreveport, LA**
- 106 **Single Lung Transplant in Patients With Hypersensitivity Pneumonitis and Severe Secondary Pulmonary Hypertension/B.H. Lashari, Philadelphia, PA**
- 107 **Association Between Pre-transplant Emphysema Characteristics and Post-transplant Native Lung Hyperinflation in COPD Patients Following Single Lung Transplantation/B.H. Lashari, Philadelphia, PA**
- 108 **Impact of Pre-transplant Lung Function and Radiographic Abnormality on Post Lung Transplant Respiratory Failure and ICU Length of Stay in Patients With COPD Receiving Single Lung Transplant/B.H. Lashari, Philadelphia, PA**
- 109 **Short Term Outcomes of Patient With COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) Bridged to Lung Transplant From Advanced Life Support/A. Khan, Los Angeles, CA**
- 110 **Early Outcomes Following ECMO Bridged Lung Transplant in Patients With COVID-19 ARDS/C. Tanabe, Houston, TX**
- 111 **Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation: 5-year Outcomes From a High-volume Single Center/J. Daar, Philadelphia, PA**
- 112 **Post-operative Delirium Is Associated With Increased Mortality and Hospital Discharge Destination in Lung Transplant Recipients/A.G. Dragnich, Nashville, TN**
- 113 **Renal Function After Everolimus and Reduced Calcineurin Inhibitor in Immune Suppression of Lung Transplant Patients: A Meta-Analysis of Randomized Controlled Trials/A. Al-Akhras, Irbid, Jordan**
- 114 **An Emulated Multicenter Cluster-randomized Trial to Estimate the Impact of Basiliximab Induction Therapy on Acute Cellular Rejection in Lung Transplant Recipients/J.G. Rim, Durham, NC**
- 115 **Particle Flow Rate From Exhaled Breath Correlates With Primary Graft Dysfunction Following Lung Transplantation/G. Hirdman, Lund, Sweden**
- 116 **Lower Airway Microbial Signatures Associated With Primary Graft Dysfunction in Lung Transplantation/T. Malik, New York, NY**

CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

C103 MOVING THE NEEDLE FORWARD IN LUNG TRANSPLANTATION

2:15 p.m. - 4:15 p.m. **Marriott Marquis Washington**

Marquis Ballroom, Salons 1-2 (Level M2)

Poster Viewing **2:15-3:00**

Discussion **3:00-4:15**

Chairing: D.F. Dilling, MD, Maywood, IL
R. Jablonski, MD, Chicago, IL
M.B. Keller, MD, Baltimore, MD

- 101 **The Impact of Race-specific Reference Equations on the Lung Allocation Score Among Patients Listed for Lung Transplant/J.H. Brems, Baltimore, MD**
- 102 **Cell-free DNA Tissue Sources in Patients With Advanced Lung Diseases/S. Balasubramanian, Bethesda, MD**

- 117 **Lower Airway Microbial Signatures Associated With Acute Cellular Rejection in Lung Transplantation/N.** Nelson, New York, NY
- 118 **Cell Free Hemoglobin and Cell-Free DNA in Bronchoalveolar Lavage Fluid Are Associated With Acute Infection But Not Acute Cellular Rejection After Lung Transplantation/P.A. Merritt, Nashville, TN**
- 119 **The Impact of BMI on Mortality Following Primary Graft Dysfunction: A Lung Transplant Outcomes Group Study/R. Bennett, Philadelphia, PA**
- 120 **Cognitive Impairment Is Common in Lung Transplant Candidates and Is Associated With Frailty, Disability, Inflammation, and Health-Related Quality of Life/N.A. Kolaitis, San Francisco, CA**
- 121 **Increased Bone Marrow Dysfunction in Lung Transplant Recipients With Telomere-mediated Pulmonary Fibrosis/S. Hannan, Pittsburgh, PA**
- 122 **Diverse Clinicopathologic Features in Short Telomere Patients With Interstitial Lung Disease Undergoing Transplant/R. Sutton, Pittsburgh, PA**
- 123 **Immunologic Effects of SARS-CoV-2 Vaccination in Lung Transplant Recipients/P. Pamar, New York, NY**
- 124 **Changes in Body Weight Following Lung Transplantation/L.P. Vien, Los Angeles, CA**
- 125 **Overall Incidence and Risk Factors of Venous Thromboembolism Post Lung Transplant: A Single Center Retrospective Observational Trial/J. Yang, New York, NY**
- 602 **Primary Prevention of Lipopolysaccharide-induced Acute Lung Injury With Cardiosphere-derived Cells in a Large Animal Model/J.F. Dawkins, Los Angeles, CA**
- 603 **Plasma Matrix Metalloproteinase-3 Predicts Mortality in Acute Respiratory Distress Syndrome/T.W. Jones, Augusta, GA**
- 604 **Alveolar Cytokines Profile and Physiological Mechanisms for Ventilator-induced Lung Injury to the Lung Excluded From Ventilation: An Experimental Study/E. Spinelli, Milan, Italy**
- 605 **PEEP Moderates the Association Between Ventilator Dyssynchrony and Markers of Ventilator Induced Lung Injury/P.D. Sottile, Aurora, CO**
- 606 **Common SNPs in NK Cell NKG2D Receptor and Ligand Genes Are Associated With Improved Oxygenation in Critically Ill Adults/V.E. Kerchberger, Nashville, TN**
- 607 **Variation in Setting Low Tidal Volume Ventilation on Day 1 of Mechanical Ventilation by Provider/N.E. Ingraham, Minneapolis, MN**
- 608 **Hospital Level Variation in the Use of Bronchodilators in Patients With ARDS/M. Lesieur, Boston, MA**
- 609 **The Use of Steroids in Patients With Combined ARDS, Septic Shock, and Pneumonia Across US Hospitals/M. Lesieur, Boston, MA**
- 610 **Comparison of Pulmonary Blood Flow Models Using Dynamic Contrast-enhanced Computed Tomography/Y. Xin, Boston, MA**
- 611 **Blood Flow Rate and Drainage Cannula Size Impact the Outcome of Patients Receiving VV-ECMO for ARDS/T. Mauri, Milan, Italy**
- 612 **A Comparison of Invasive and Noninvasive Oxygen Support Strategies for the Acute Respiratory Distress Syndrome Under an Expanded Berlin Definition/R. Bennett, Philadelphia, PA**
- 613 **Three Novel Chest CT Subtypes Identified by Latent Class Analysis Among Severe ARDS Patients Requiring ECMO: Potential for Importance of Differential Management During ECMO According to the Subtype/M. Nishikimi, Hiroshima, Japan**
- 614 **Association of Dependent Cannabis Use With Acute Respiratory Distress Syndrome and Subsequent In-hospital Mortality in Hospitalizations With Sepsis: A Population-based Analysis in the United States/J. Jasti, Sioux Falls, SD**
- 615 **Effect of PEEP Setting With Minimal Driving Pressure on the Distribution of Voxel-level Lung Strain and Aeration Measured With Dynamic Computed Tomography (CT) in Large Animal Normal and Injured Lungs/C. Zeng, New York, NY**

BASIC • CLINICAL**POSTER DISCUSSION SESSION****C104 CLINICAL AND TRANSLATIONAL STUDIES IN ALI AND ARDS**2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center****Room 201 (Level 2)****Poster Viewing 2:15-3:00****Discussion 3:00-4:15**

Chairing: E. Fan, MD, PhD, Toronto, Canada
 N.R. Nadig, MD, MSci, ATSF, Chicago, IL
 A. Duggal, MD, MPH, Cleveland, OH

- 601 **Plasma Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) As a Sex-specific Biomarker for Acute Lung Injury/S.** Almontashiri, Augusta, GA

- 616 **Are We Practicing What Is Preached? A Single-center Retrospective Analysis of Compliance Rates to Low Tidal Volume Ventilation in Acute Respiratory Distress Syndrome/H. Nallamala, Indianapolis, IN**
- 617 **Negative Correlation Between Synaptophysin Hippocampal Concentration and Microglia and Astrocyte Percentages in the Hippocampus in Moderate-ARDS Pigs Ventilated for 12 Hours/T. Bassi, Vancouver, Canada**
- 618 **Greater Concentration of IL-1beta in the Brainstem in Moderate-ARDS Pigs Ventilated for 12 Hours/T. Bassi, Vancouver, Canada**
- 619 **Efficacy and Safety of Nebulized Surfactant-BL as a Part of Complex Therapy of COVID-19-associated ARDS: A Multicenter, Open-label Randomized Controlled Trial/S.N. Avdeev, Moscow, Russian Federation**
- 620 **Inflammasome Caspase-1 Signaling Promotes Pulmonary Fibrosis in Severe COVID-19/K. Peukert, Bonn, Germany**
- 621 **Anti-Anaerobic Antibiotics Contribute to Liver Injury and Metabolic Dysfunction in a Murine Model of Oxygen Toxicity/J.D. Metcalf, Ann Arbor, MI**
- 622 **Diaphragm Neurostimulation-Assisted Ventilation in ARDS: A Proof-Of-Concept Human Study/E. Rohrs, New Westminster, Canada**
- 704 **Fatal Case of Cryptococcal Arthritis/M. Fatima, Wilkes-Barre, PA**
- 705 **Disseminated Monkeypox as a Possible Cause of Acute Respiratory Distress Syndrome/J. Zhao, Chicago, IL**
- 706 **When to Reassess: A Case of Toxoplasma-induced Pneumonitis in a Bone Marrow Transplant Patient/B. Aronson, Chicago, IL**
- 707 **PJP Pneumonia and SJS: A Two-for-one Deal/T. Malik, New York City, NY**
- 708 **Taming The Beast: A Case Report of Pasteurella Multocida Epiglottitis in an Immunocompetent Patient With a Rapid Recovery/K. Golubkyh, Harrisburg, PA**
- 709 **A Rare and Unfortunate Case of Steven Johnson Syndrome (SJS) Potentiated By Cytomegalovirus (CMV) Reactivation/A. Singh, Overland Park, KS**
- 710 **West Nile Virus as the Rare Culprit of Acute Flaccid Paralysis and Respiratory Failure/F. Ghazal, Farmington, CT**
- 711 **A Case of Angioinvasive Gastrointestinal Mucormycosis With Duodenal Necrosis and Perforation/N. Hunter, Rochester, NY**
- 712 **Rare Presentation of a Rare Disease: A Case of Lemierre Syndrome Presenting With Pyomyositis and Complicated by Septic Arthritis/J.M. Levy, Mullica Hill, NJ**
- 713 **A Rare Cause Of Fungal Pericarditis/J. Moore, Philadelphia, PA**
- 714 **A Case Of Creutzfeldt- Jakob Disease Masked By Concomitant Mumps/A. Vahabzadeh, Detroit, MI**
- 715 **Devastating Extra-Pulmonary Manifestations of Legionella Pneumonia in a Young, Immunocompetent College Student/C. Kasianko, Newark, DE**
- 716 **Invasive Haemophilus Influenza A Bacteremia In A Healthy Adult- A Unique Manifestation/A. Tameez Ud Din, Buffalo, NY**
- 717 **Rats: Atypical Pulmonary Imaging In A Case Of Leptospirosis/H. Siddiqi, Baltimore, MD**
- 718 **Seeing Through the Smoke: Fulminant Mycoplasma Pneumoniae in a Young Adult With E-cigarette Use/C. Parker, Indianapolis, IN**
- 719 **A Case of Severe Disseminated Strongyloidiasis With Confirmed Diagnosis by Skin Biopsy, Small Bowel Biopsy and Bronchoalveolar Lavage/S.N. Garcia, Albuquerque, NM**
- 720 **CPR Gone Awry - A Case of Pulmonary Tularemia Acquired By Mouth-to-mouth Resuscitation of a Goat/P. Vasistha, Little Rock, AR**

CLINICAL

POSTER DISCUSSION SESSION

C105 INFECTIONS IN THE ICU: THE BEST OF THE BEST CASES

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 206 (Level 2)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: I.D. Peltan, MD, MSc, Murray, UT
G.L. Anesi, MD, MSCE, Philadelphia, PA
R. Estelite, MD, Saginaw, MI

- 701 **Airway Obstruction Due to Invasive Tracheobronchial Aspergillosis/M. Gillespie, Columbus, OH**
- 702 **A Case of Polymicrobial Purulent Pericarditis From a Pancreatico-pericardial Fistula/C. Richardson, Birmingham, AL**
- 703 **Intravenous Drug Use Induced Right Ventricular Air Embolism Treated Successfully With Air Embolectomy And Hyperbaric Oxygen Therapy/S.A. Mendelsohn, Camden, NJ**

- 721 **A Case of Probable Invasive Pulmonary Aspergillosis (IPA) Diagnosed by Bronchoscopy/S. Qureshi, Philadelphia, PA**
- 722 **Vibrio Vulnificus Necrotizing Fasciitis Leading to Septic Shock and Multiorgan Failure/Z. Ng, Lafayette, LA**
- 723 **Human Herpesvirus 6 Encephalitis in an Immunocompetent Adult/N. Touloumes, Louisville, KY**
- 724 **Severe Monkeypox With Airway Compromise Requiring Emergent Cricothyroidotomy/R.C. Flowers, New York, NY**

BASIC • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

C106 OUT OF THE 'MUC': UPDATES IN PCD AND CF

2:15 p.m. - 4:15 p.m. Marriott Marquis Washington

Marquis Ballroom, Salons 3-4 (Level M2)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: M.E. McGarry, MD, San Francisco, CA
S. Das, DO, Houston, TX
S.L. Martiniano, MD, MS, Aurora, CO

- 901 **Transcriptomic Prediction of Clinical Response to Trikafta in Patients With Cystic Fibrosis/M. Yue, Pittsburgh, PA**
- 902 **Tracking Regional Changes in CF Lung Disease After 1 Day of Airway-clearance Withdrawal, Using UTE and Xe MRI/M.E. West, Cincinnati, OH**
- 903 **Breathing Pattern During Sleep and Its Relationship With Expiratory Forced Volume in 1 Second in Pediatric Patients With Cystic Fibrosis Who Live at High Altitude/M.I. Escamilla, Bogota, Colombia**
- 904 **Linezolid Resistant Staphylococcus Aureus in Patients With Cystic Fibrosis/A.J. Fischer, Iowa City, IA**
- 905 **The Effect of CFTR Modulator Therapies on Inpatient Treatment for Acute Pulmonary Exacerbations in Cystic Fibrosis/M. Haag, Portland, OR**
- 906 **Improved Diagnosis of Early Aspergillus Lung Disease in CF (IDEAL) Study Design and First Results/F. Mollica, Rotterdam, Netherlands**
- 907 **The Predictive Value of Neutrophil Lymphocyte Ratio in Cystic Fibrosis Exacerbations: Pilot Study/O. Yilmaz, Manisa, Turkey**

- 908 **Correlation of Lung Function Using Forced Oscillation Technique With Spirometry in Children Aged (4-18 Years) With Cystic Fibrosis (CF) and Non CF Bronchiectasis/S. Singh, Chandigarh, India**
- 909 **Diagnosis Accuracy and Crosschecking Data Entries in Medical Records and Cystic Fibrosis Foundation Patient Registry: A Quality Improvement Project/K. Agoramurthi, Little Rock, AR**
- 910 **Effect of Disinfection With Baby-bottle Sterilizer of Reusable Breath-enhanced Nebulizers on Aerosolized Albuterol Output and Characteristics/K. Agoramurthi, Little Rock, AR**
- 911 **Variability of Physiologic Testing and Magnetic Resonance Imaging Outcomes in Paediatric Populations/V.M. Diamond, Vancouver, Canada**
- 912 **Bronchiectasis and Other Abnormal Computer Tomographic Chest Scan Findings in Paediatric Spinal Muscular Atrophy/A. Chacko, Brisbane, Australia**
- 913 **Treatment Response to Pulmonary Exacerbation in Primary Ciliary Dyskinesia/D. Gatt, Toronto, Canada**
- 914 **Genotype-phenotype Correlations of Primary Ciliary Dyskinesia in Siblings/D. Gatt, Beer-Sheva, Israel**
- 915 **Inclusivity of the North American Primary Ciliary Dyskinesia (PCD) Foundation Clinical Registry/M.G. O'Connor, Nashville, TN**
- 916 **Genotype to Phenotype: Measuring Mucociliary Clearance in Primary Ciliary Dyskinesia/S. Abu-Nasser, Chapel Hill, NC**
- 917 **Mild Phenotypes in French-Canadians With TT25-related Primary Ciliary Dyskinesia/M.K. Palani, Montreal, Canada**
- 918 **The Utility of Nasal Nitric Oxide in the Diagnostic Evaluation of Primary Ciliary Dyskinesia/K.A. Carr, Nashville, TN**
- 919 **Intra-day Test-retest Reliability of Multiple Breath Washout in Pediatric Primary Ciliary Dyskinesia/W.B. Wee, Toronto, Canada**
- 920 **Primary Ciliary Dyskinesia In Patients With CCNO Variants: A Case Series/K.A. Despotes, Chapel Hill, NC**
- 921 **Improvement of Lung Function After Implementation of Standardized Cystic Fibrosis Care Algorithm: Quality Improvement Project-International Collaboration/Y. Gökdemir, Istanbul, Turkey**

BASIC • TRANSLATIONAL

POSTER DISCUSSION SESSION

C107 AT THE CROSSROADS OF DISEASE: METABOLIC AND INFLAMMATORY DRIVERS IN PULMONARY VASCULAR DISEASE2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 151 A (Street Level)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: M.R. Maclean, PhD, ATSF, Glasgow, United Kingdom
L. Zhao, PhD, MD, London, United Kingdom
L. Zhang, PhD, Pittsburgh, PA

- 401 **2-HOBA Resolves Metabolic Problems in Two Pulmonary Hypertension Models**/J.D. West, Nashville, TN
- 402 **Low CYP1B1 Drives Pulmonary Arterial Hypertension Through Ubiquitination of PPARG**/J.D. West, Nashville, TN
- 403 **Increased MFGE8 and Decreased ApoA5 Associated With RV Lipotoxicity and Insulin Resistance**/M. Talati, Nashville, TN
- 404 **17 β -estradiol Regulates Angiogenesis and Metabolism in Cultured Human Cardiac Microvascular Endothelial Cells and in the Right Ventricle of Rats With Experimental Pulmonary Hypertension**/S. Bousseau, Denver, CO
- 405 **Frataxin Deficiency Is a Shared Driver of Endothelial Metabolic Dysfunction and Senescence Relevant to Pulmonary Hypertension**/M.P. Mehta, Pittsburgh, PA
- 406 **Arginine Metabolism Changes Hypoxia Responses in Mice Deficient for Arginase-2 (ARG2)**/W. Xu, Cleveland, OH
- 407 **Role for Transglutaminase 2 in Interleukin 6 and Glycolysis Mediated Cardiopulmonary Fibrogenesis**/Y. Sharma, Boston, MA
- 408 **Aging Mediated Cardiopulmonary Remodeling in Senescent Mouse Models**/Y. Sharma, Boston, MA
- 409 **Damaged Mitochondria Contribute to Hyperoxia-induced Impaired Angiogenesis and Lung Injury in Neonatal Mice**/H. Yao, Providence, RI
- 410 **The Critical Role of CD206+ Macrophages in Contributing to Severe Pulmonary Arterial Hypertension and Obliterative Vascular Remodeling**/J. Dai, Chicago, IL
- 411 **The Lectin Complement Pathway Contributes to Schistosoma-induced Pulmonary Hypertension**/C. Mickael, Aurora, CO

- 412 **Paired Related Homeobox 2 (Prrx2) Contributes to Pulmonary Vascular Remodeling and PH by Targeting IL-6/stat3 Signaling in Pulmonary Artery Smooth Muscle Cells**/T. Chen, Chicago, IL
- 413 **Cardiac Macrophages Are the Primary Complement C3a Receptor (C3aR) Expressing Cells in the Rat Myocardium and Remain Stable in Late Sugen Hypoxia Pulmonary Hypertension**/S. Gu, Aurora, CO
- 414 **Local Production and Activation of Complements by the Adventitial Fibroblast Play a Crucial Role in Pulmonary Hypertension**/R. Prasad, Aurora, CO
- 415 **TLR7 Activation Induces Autoimmune Vasculopathy and Causes Severe Pulmonary Arterial Hypertension**/C. Chen, London, United Kingdom
- 416 **SIRT3 Affects Adventitial Fibroblasts Phenotype in Pulmonary Hypertension Through Regulation of Mitochondrial Function**/M. Li, Aurora, CO
- 417 **BMP-Responsive Transcription Factor Expression Is Increased in Advanced PAH Lung Lesions**/A.M. Andruska, Palo Alto, CA
- 418 **Mitochondrial DNA Copy Numbers Reflect Different Suites of Adaptations in Two East African Highland Populations**/A.J. Janocha, Cleveland, OH
- 419 **Human Pulmonary Artery Endothelial Cells Isolated From Patients With Pulmonary Hypertension Exhibit Heterogeneous Sensitivity to Mechanical Sensing**/S. Subedi Paudel, Mobile, AL
- 420 **Pulmonary Hypertension-related Changes in Structure and Function of the Human Proximal Pulmonary Artery**/E.P. Manning, New Haven, CT
- 421 **Transaortic Constriction Improves Ventricular Performance in Mice With Right Ventricular Pressure Overload**/M.J. Lucero, Aurora, CO
- 422 **Epigenetic Mechanisms Mediate Cytochrome P450 1A1 Expression and Lung Endothelial Injury Caused by MRSA**/L. Meliton, Chicago, IL
- 423 **Oxidized Cell-free Hemoglobin and Low-density Lipoprotein Contribute to Lung Microvascular Endothelial Barrier Dysfunction and Poor Outcomes During Sepsis**/J.E. Meegan, Nashville, TN
- 424 **Role of Inflammatory Monocytes in Hypoxic Pulmonary Hypertension**/R. Kumar, San Francisco, CA
- 425 **IRG1/Itaconate Axis as an Immunometabolic Regulator of Pulmonary Hypertension**/G. Hesami, Bad Nauheim, Germany

BASIC • TRANSLATIONAL

POSTER DISCUSSION SESSION

C108 IMMUNITY AND INFLAMMATION IN COPD: NOVEL FINDINGS2:15 p.m. - 4:15 p.m. **Walter E. Washington Convention Center**

Room 151 B (Street Level)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: C.M. Freeman, PhD, Ann Arbor, MI
M.B. Fessler, MD, Research Triangle Park, NC
A.O. Yildirim, PhD, Neuherberg, Germany

- 501 **Profiling the Functional Microbiome in Mild COPD/B.** Isaacs, New York, NY
- 502 **Integrative Analysis of Extracellular Lipocalin-2 and the Lung Microbiome in Smoking and COPD/C.** Healy, Dublin, Ireland
- 503 **Chemical Activation of Protein Phosphatase 2A Slows Progression of Alpha-1 Antitrypsin Deficiency Associated Loss of Lung Function/H.** Ahmed, New York, NY
- 504 **Role of LIM Kinase 1 in Driving Epithelial Plasticity in COPD/C.** Swaby, Baltimore, MD
- 505 **Evaluating Novel Protein Phosphatase 2A Activators As Therapeutics for Cigarette Smoke Induced Loss of Lung Function/B.A.** Soto, Brooklyn, NY
- 506 **Pulmonary Epithelial Gain-of-Function Toxicity in Alpha-1 Antitrypsin Deficiency/K.** Abo, Boston, MA
- 507 **Morphometrics and Mucosal Immune Features in Lungs With End-stage Chronic Obstructive Pulmonary Disease/C.** De Fays, Brussels, Belgium
- 508 **Lack of Fatty Acid Binding Protein 5 Prevents the Establishment of Resident Memory T Cells in the Lungs/F.S.** Gally, Denver, CO
- 509 **Accumulation of PiZ Alpha-1 Antitrypsin Induces Pulmonary Toxicity/X.** Ma, New York, NY
- 510 **Lipid Profiling Reveals Key Lipid Mediators in Cigarette Smoke-induced Experimental COPD/S.F.** Rehman, Sydney, Australia
- 511 **A Baff-MYC Axis in the Vascular Niche Drives B Cell Recruitment and Proliferation in Severe Emphysema/N.** Mckenna, Houston, TX
- 512 **Extracellular Vesicles From Patients With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease Induce the Synthesis of Proinflammatory Cytokines by Bronchial Epithelial Cells/A.** Celi, Pisa, Italy

513 **Crosstalk Between Memory B Cells and Fibroblasts Contributes to COPD Pathogenesis/K.R.** Bracke, Ghent, Belgium

514 **Exhausted CD8+ T Cells Interacting With Myeloid and Non-immune Cells in the COPD Pathogenesis: Single-cell Analysis of Human Lung Tissue/S.** Shin, Seoul, Korea, Republic of

515 **Apoptosis Inhibitor of Macrophage (AIM)/CD51 Is Involved in the Pathogenesis of Emphysema/M.** Takimoto-Sato, Sapporo, Japan

516 **The Effect of HuR Depletion on Airway Obstruction in COPD/A.J.** Dabo, Brooklyn, NY

517 **The Effect of HuR Depletion in the Airway Epithelium in COPD/A.J.** Dabo, Brooklyn, NY

518 **Macrophage Inflammatory and Metabolic Function Is Reduced With Loss of Adenine Nucleotide Translocase 1 (ANT1) in COPD/J.** Sui, Pittsburgh, PA

519 **Proteomic Associations With Lung Function in COPD Gene and SPIROMICS/L.** Ruvuna, Aurora, CO

520 **Downregulation of MicroRNA-1, 133, and Let-7c Reduces to Control Prothymosin α Expression, A Novel Role in Chronic Obstructive Pulmonary Disease/B.** Su, Taipei, Taiwan

BASIC • TRANSLATIONAL

POSTER DISCUSSION SESSION

C109 EVEN BETTER THAN THE REAL THING: ADVANCED MODELS OF LUNG DISEASE2:15 p.m. - 4:15 p.m. **Marriott Marquis Washington**

Marquis Ballroom, Salons 9-10 (Level M2)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: R. Krishnan, PhD, MS, Boston, MA
R.L. Clifford, PhD, Nottingham, United Kingdom
R.D. Britt, PhD, ATSF, Columbus, OH

1001 **Building Epithelial Barrier in Whole-lung Tissue Engineering/A.M.** Greaney, Cambridge, MA

1002 **Cell-specific Noxo1 Deletion in a Mouse Model of Cigarette Smoke-induced Emphysema and Pulmonary Hypertension/S.** Doswada, Giessen, Germany

1003 **Using a Humanized Ventilator-on-a-chip to Investigate How Infectious Agents Alter Ventilation Induced Lung Injury/S.N.** Ghadiali, Columbus, OH

- 1004 **Mitochondrial Dysfunction Associated With Aging Contributes to Slowed Cilia Beat Frequency**/K.L. Bailey, Omaha, NE
- 1005 **The Secretome of Pulmonary Microvascular Endothelial Cells Supports Alveolar Epithelial Growth**/L. Van Der Koog, Groningen, Netherlands
- 1006 **Utilizing Human Precision-cut Lung Slices and a Neonatal Mouse Model to Study the Respiratory Syncytial Virus Infection-induced Airway Contractile Deregulation in Early Life**/Y. Bai, Boston, MA
- 1007 **Optogenetics Shines Light on Nerve-mediated Airway Hyperreactivity**/A.B. Pierce, Portland, OR
- 1008 **Muc5b Mediates Antiviral Immunity and Airway Hyperresponsiveness During Parainfluenza Virus Infection**/J.M. Kornfield, Portland, OR
- 1009 **Airway Eosinophils Modulate Purinergic Receptor P2X₃ Expression**/E.J. Mize, Portland, OR
- 1010 **Cough-induced Mitochondrial Mechanotransduction in Type II Alveolar Epithelial Cells**/B. Suki, Boston, MA
- 1011 **Piezo Channels Modulate Extracellular Matrix Remodeling in Developing Human Airway Smooth Muscle Cells**/E.Y. Zhang, Rochester, MN
- 1012 **Effects of Sulfur Dioxide Inhalation Exposure on Cardiopulmonary System**/S.S. Gutor, Nashville, TN
- 1013 **Targeting Glutathione and Ferroptosis With Hydrogen Sulfide Alleviates Effects of Oxygen on Developing ASM**/C.M. Bartman, Rochester, MN
- 1014 **KISS1 Receptor Knockout Exacerbate Airway Hyperreactivity and Remodeling in a Mouse Model of Allergic Asthma**/N.S. Ambhore, Fargo, ND
- 1015 **Rhinovirus C (RVC) Infection Induces a Remodeling Signature and Decreases Bronchodilator Responsiveness**/C. Spector, New Brunswick, NJ
- 1016 **Development of a 3D Bioprinted Airway Smooth Muscle Model for Manipulating Structure and Measuring Contraction**/A.R. West, Winnipeg, Canada
- 1017 **Effect of TNF α and IFN γ on Chromatin Accessibility in Human Airway Smooth Muscle Cells**/A.S. Ruwanpathirana, Columbus, OH
- 1018 **During the Epithelial Unjamming Transition of the Pseudostratified Bronchial Epithelium, Basal Stem Cells and Their Stress Fibers Remodel**/T. Phung, Boston, MA
- 1019 **Developing an In Vitro Model of Sensory Neurons Differentiated From Human Pluripotent Stem Cells for the Study of Neuroplasticity**/C. Koster, Groningen, Netherlands
- 1020 **Contributions of MUC5B to Mucociliary Clearance Using A Genetically Modified Pig Model**/G.S. Romano Ibarra, Iowa City, IA
- 1021 **Use of Bioengineered Rat Lungs for Novel Ex Vivo Human Lung Cancer Models**/S. Mizoguchi, Nagasaki, Japan
- 1022 **A Novel 3D Spring Network Representation of Alveolar Geometry Combined With Agent Based Modeling to Predict Ventilation Heterogeneity in Pulmonary Fibrosis**/J.K. Hall, Boston, MA
- 1023 **Modeling the Stiffness of Healthy and Diseased Lung Tissues by a Gel-Coated Air-Liquid-Interface Culture System With Tunable Substrate Stiffness**/Z. He, Charlottesville, VA
- 1024 **Respiratory Dysfunction in TDP-43^{A315T} Mice-Mouse Model of Amyotrophic Lateral Sclerosis**/D. Biswas, Durham, NC
- 1025 **The Relaxation Effect of Pitavastatin on Human Airway Smooth Muscle Cells: A Role for Acute F-actin Disruption**/A.A. Zeki, Davis, CA

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

C110 ADVANCED SIGNAL ANALYSIS: NEW DIAGNOSTICS AND PHYSIOLOGIC INSIGHTS FOR SDB

2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center

Room 144 A-C (Street Level)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: A. Parekh, PhD, New York, NY
A. Yadollahi, PhD, Toronto, Canada
C.D. Turnbull, BM BCH, PhD, Oxford, United Kingdom
M. Yamauchi, MD, PhD, ATSF, Kashihara, Japan

301 **Identifying Central Versus Obstructive Sleep Apnea in Patients With Heart Failure**/R.M. Alex, Boston, MA

302 **Pathophysiological Mechanisms Underlying Spontaneous Stable Breathing in OSA**/L. Gell, Boston, MA

303 **Hypoxic Burden Based on Automatically Identified Desaturations Predicts Cardiovascular Mortality**/N. Esmaeili, Boston, MA

304 **Prevalence, Pathophysiology, and Predictors of Expiratory Palatal Prolapse in Sleep Apnea**/J. Sumner, Boston, MA

- 305 **The Effect of Supplemental Oxygen on Central Sleep Apnea in Individuals With Spinal Cord Injuries and Sleep-disordered Breathing**/D.G. Venkat, Detroit, MI
- 306 **Race Specific Differences in Oxygen Desaturation Per Measured Decrement in Ventilation in Sleep Apnea**/A. Azarbarzin, Boston, MA
- 307 **Comparison of Night-to-Night and Inter-scorer Variability of Different Indices of Obstructive Sleep Apnea Severity in the MARIPOSA Trial**/H. Pho, Cambridge, MA
- 308 **Respiratory Effort During Sleep and Prevalent Diabetes in Obstructive Sleep Apnea**/J.G. Martinot, Namur, Belgium
- 309 **Mouth Breathing Negatively Affects Mouth Closure Maneuver in Patients With Obstructive Sleep Apnea**/H. Yang, Gwangju, Korea, Republic of
- 310 **A Method to Evaluate the Effects of Hypoglossal Nerve Stimulators in Obstructive Sleep Apnea**/Q. Xiao, Cincinnati, OH
- 311 **Lateral Epiglottic Collapse Is Associated With Laterally Directed Collapse at the Velum and Oropharynx**/T. Wang, Boston, MA
- 312 **Performance of a Commercial Smart Watch Compared to Polysomnography for SpO₂ Measurement and Sleep Apnea Evaluation**/S. Browne, La Jolla, CA
- 313 **Clinical Validation of a Wireless Patch-based Polysomnography System: A Pilot Study**/S.R. Coughlin, Eindhoven, Netherlands
- 314 **Effects of Non-respiratory Arousals on Arousal Threshold Estimated With Phenotyping Using Polysomnography**/T.M. Tolbert, New York, NY
- 315 **A Real-time Automated Sleep Scoring Algorithm to Detect Refreshing Sleep in Conscious Ventilated Critically Ill Patients**/X. Drouot, Poitiers, France
- 316 **Agreement and Relative Validity of Loop Gain Estimates From Different Flow Signals**/S.M. White, La Jolla, CA
- 317 **Multi-night Assessment of Snoring Is Associated With Hypertension Independent of OSA Severity**/B. Lechat, Adelaide, Australia



ATS
2023


INTERNATIONAL
CONFERENCE
WASHINGTON, DC
conference.thoracic.org

Wednesday Morning, May 24

[Click Here to Access the Program Itinerary and Add Wednesday Sessions and Presentations to Your](#)

MEET THE EXPERT SEMINARS

CME Credits Available: 1

 **Pre-registration and additional fees required. Attendance is limited.**
\$100 Member/Non-Members
\$70 LMIC Member/LMIC Non-Members.

9:15 a.m. - 10:15 a.m. Marriott Marquis Washington

- MTE49 PHENOTYPING SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY HYPERTENSION**
R.G. Argula, MBBS, MPH, Charleston, SC
Georgetown University (Level M1)
- MTE51 FAMILIAL PULMONARY FIBROSIS**
C. Newton, MD, MS, Dallas, TX
Shaw (Level M3)
- MTE52 LEVERAGING BIG DATA TO BRIDGE THE KNOWLEDGE-OUTCOME GAPS IN RARE LUNG DISEASE**
B. Kaul, MD, San Francisco, CA
H.R. Collard, MD, MS, San Francisco, CA
LeDroit Park (Level M3)

YEAR IN REVIEW

CME Credits Available: 1.5

D1 CLINICAL YEAR IN REVIEW 4

8:00 AM - 9:30 AM

Walter E. Washington Convention Center

Hall E (Level 2)

Target Audience

Pulmonary, critical care and sleep providers. The program will discuss general topics of interest to a broad group of providers, inside and outside of these subspecialties. The program is relevant to not only clinicians, but also to researchers and administrators

Objectives

At the conclusion of this session, the participant will be able to:

- apply new clinical research knowledge to clinical practice.
- apply new findings about key conditions in pulmonary, critical care and sleep.
- learn new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

Pulmonary, critical care and sleep providers. The program will discuss general topics of interest to a broad group of providers, inside and outside of these subspecialties. The program is relevant to not only clinicians, but also to researchers and administrators.

Chairing: R.J. Shah, MD, MSCE, San Francisco, CA
J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil
S. Auld, MD, MSc, Atlanta, GA

8:00 Lung Transplant
S. Agbor, MD, PhD, Bethesda, MD

8:23 Medical Education
J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil

8:45 Health Equity
D.C. Ashana, MD, MBA, MS, Durham, NC

9:08 CF/non-CF bronchiectasis
S. Visser, Camperdown, Netherlands

This session and the International Conference are supported by an independent medical educational grant from Insmad Incorporated, Vertex Pharmaceuticals, and Zambon.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 1.5

D2 COUGH IN PULMONARY FIBROSIS - ANNOYING SYMPTOM OR DRIVER/MARKER OF DISEASE PROGRESSION?

Assembly on Clinical Problems

8:00 AM - 9:30 AM **Walter E. Washington Convention Center****Room 207 A-B (Level 2)****Target Audience**

Healthcare providers that care for patients with fibrotic lung diseases, researchers studying cough in patients with pulmonary fibrosis, patients with pulmonary fibrosis and caregivers of patients with pulmonary fibrosis.

Objectives

At the conclusion of this session, the participant will be able to:

- describe the mechanisms of cough and treat cough in patients with pulmonary fibrosis
- to refer patients with pulmonary fibrosis to ongoing clinical trials
- measure cough in a standardized manner

This session will focus on the pathobiology, approach to treatment, the role of cough as a potential biomarker of disease activity/progression and current landscape of recent on ongoing research on cough in patients with pulmonary fibrosis.

Chairing: K.R. Flaherty, MD, Ann Arbor, MI
L.H. Lancaster, MD, Nashville, TN
K.K. Brown, MD, Denver, CO

8:00 Understanding the Pathobiology of Cough in Patients with Pulmonary Fibrosis

S.S. Biring, MD, London SE5 9RS, United Kingdom

8:20 Approach to Patient with Pulmonary Fibrosis and Cough, What Can We Learn from the Chronic Cough Field?

M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands

8:40 Cough as a Prognostic Biomarker, Should We Be Formally Measuring in Clinical Practice?

T.M. Maher, MD, MSc, PhD, FRCP, Los Angeles, CA

9:00 Cough in Pulmonary Fibrosis Clinical Trials: Nothing to Sneeze At

S.D. Nathan, MD, Falls Church, VA

9:20 Wrap up - Q & A with All Faculty and Audience

K.K. Brown, MD, Denver, CO

This session and the International Conference are supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL • TRANSLATIONAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 1.5

D3 IMAGING BIOMARKERS OF DISEASE MODIFICATION IN COPD

Assemblies on Clinical Problems; Respiratory Structure and Function

8:00 AM - 9:30 AM **Walter E. Washington Convention Center****Ballroom C (Level 3)****Target Audience**

Providers of lung health, clinical researchers, those designing and/or conducting clinical trials, those designing and evaluating therapies for COPD, industry executives, government and granting administrators

Objectives

At the conclusion of this session, the participant will be able to:

- define new applications of quantitative imaging for the management of COPD in clinical practice
- apply quantitative imaging approaches to guide pharmacotherapy and lung volume reduction for individuals with COPD
- incorporate quantitative CT in shared decision making for COPD management with patients and families

Disease progression and outcomes in COPD have been classically measured by assessing lung function and clinical symptoms. Advanced quantitative imaging is increasingly used to quantify the features of COPD, specifically emphysema, air trapping, and airway abnormality. Attendees of this session will understand how imaging biomarkers are currently related to disease modification framework in COPD related to prevention and treatments, such as: early diagnosis, inhaled therapies, surgical and bronchoscopic interventions, and pulmonary rehabilitation. Furthermore, this session will discuss the advanced methodologies for functional lung imaging in contrast and combination with physiological assessment of disease biomarkers.

Chairing: S.P. Bhatt, MD, MSPH, Birmingham, AL
T. Siddharthan, MD, Miami, FL

8:00 Ventilation Heterogeneity in COPD Patients

T. Siddharthan, MD, Miami, FL

- 8:10 Screening and Detection of COPD**
R. Vliegenthart, MD, EBCR, FNASCI, FICIS, Groningen, Netherlands
- 8:30 Heterogeneity of Ventilation in COPD**
I. Barjaktarevic, MD, PhD, Los Angeles, CA
- 8:50 Imaging for Bronchoscopic Lung Volume Reduction Valve Targeting**
M.G. Lester, MD, Nashville, TN
- 9:10 Panel Discussion and Closing Remarks**
S.P. Bhatt, MD, MSPH, Birmingham, AL

This session and the International Conference are supported by an independent medical educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL

CRITICAL CARE TRACK

CME Credits Available: 1.5

D4 THE LONG AND WINDING ROAD: THE FUTURE OF ICU OUTCOMES RESEARCH

Assemblies on Critical Care; Behavioral Science and Health Services Research

8:00 AM - 9:30 AM **Marriott Marquis Washington**

Independence Ballroom Salons A-D (Level M4)

Target Audience

Early Career Professionals, Clinicians, Interprofessionals, Nurses

Objectives

At the conclusion of this session, the participant will be able to:

- to summarize the latest research on long-term outcomes after critical illness, including describing newly recognized key domains of survivorship
- to examine the evidence for interventions aimed at improving long-term outcomes in ICU patients and explore barriers to their success
- to understand the strengths and limitations of commonly used measures to assess the long-term impact of ICU interventions

We aim to provide an update on the latest evidence and persistent challenges surrounding the field of improving long-term outcomes in critically ill patients. In recent years, trials aimed at improving long-term outcomes have largely been unsuccessful, suggesting that it may be time for a critical re-examination and “reboot” of our current conceptual models. In this session, speakers will discuss the current evidence base, lessons learned, implications for current practice, and crucial next steps to advance the field forward.

Chairing: M. Hua, MD, MS, New York, NY
C.L. Auriemma, MD, Philadelphia, PA
N. Khandelwal, MD, MS, Seattle, WA

- 8:00 Is It the Forest or the Trees: Prioritizing Short Versus Long-Term Outcomes After Critical Illness**
C.E. Cox, MD, MPH, MHA, Durham, NC
- 8:13 “She Just Needs More Rehab:” When and Why Aggressive Rehabilitation May Not Be Enough**
J. Falvey, PhD, DPT, PT, Baltimore, MD
- 8:26 Money Matters: Is Financial Hardship a Missing Key Outcome in Post-Critical Illness Studies?**
N. Khandelwal, MD, MS, Seattle, WA
- 8:39 Psychological Outcomes After Critical Illness: Is the Die Already Cast?**
W. Lichtenthal, PhD, New York, NY
- 8:52 To Consult or Not to Consult?: Why Palliative Care May or May Not Change Outcomes in Critically Ill Patients**
D.B. White, MD, Pittsburgh, PA
- 9:05 The Glass is Half?: Prognosticating Long-Term Outcomes**
A. Law, MD, MSci, Boston, MA
- 9:18 A Bump or a Fork in the Road: the Broader Impact of Critical Illness**
T.J. Iwashyna, MD, PhD, Baltimore, MD

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

D5 REVISITING BEST BUY INTERVENTIONS FOR THE DIAGNOSIS AND MANAGEMENT OF CHRONIC RESPIRATORY DISEASES IN LOW- AND MIDDLE-INCOME COUNTRIES

Assemblies on Clinical Problems; International Health Committee

8:00 AM - 9:30 AM **Walter E. Washington Convention Center**

Room 147 A-B (Street Level)

Target Audience

Pulmonary medicine researchers, Clinicians in low- and middle-income countries.

Objectives

At the conclusion of this session, the participant will be able to:

- review evidence and prioritize key risk factors for chronic respiratory diseases across a diverse range of LMICs.
- identify chronic disease management strategies with greatest potential impact, feasibility, and sustainability in LMICs, i.e., best buy interventions.

- develop a comprehensive framework of best buy interventions that mitigate risk factors and reduce risk for the development of chronic respiratory diseases or aid in

Chronic respiratory diseases are a significant but neglected public health problem in low- and middle-income countries. Moreover, current best buy interventions recommended by the World Health Organization are limited: they principally consist of inhaled bronchodilator therapy for symptom management and mitigation of household air pollution. Yet there are opportunities for primary and secondary prevention that could help both reduce the development of chronic respiratory diseases and improve management. This session aims to identify current unmet needs for chronic respiratory diseases in low- and middle-income countries and identify other potential best buy interventions that can improve diagnosis and management of chronic respiratory diseases.

Chairing: J. Hurst, MD, London, United Kingdom
W. Checkley, MD, PhD, Baltimore, MD
O.B. Ozoh, MBBS, ATSF, MSc, Lagos, Nigeria

8:00 The Burden of Chronic Respiratory Diseases in Low- and Middle-Income Countries and Unmet Needs for their Diagnosis and Management

R. Van Zyl Smit, MBChB, PhD, ATSF, Cape Town, South Africa

8:20 An Overview of Best Buy Interventions Recommended by the World Health Organization for the Diagnosis and Management of Chronic Respiratory Diseases.

S. Rylance, BMedSci, MBBS, PhD, Blantyre, Malawi

8:40 The Role of Multicomponent Interventions for Chronic Respiratory Disease Prevention and Management in Low- and Middle-Income Countries.

C. Jenkins, MD, Sydney, Australia

9:00 Infections and Lung Development: the Link Between Communicable and Non-Communicable Lung Disease

H. Zar, MD, PhD, ATSF, Cape Town, South Africa

9:20 Panel Discussion

W. Checkley, MD, PhD, Baltimore, MD

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

D6 OBESITY-RELATED ASTHMA: MECHANISTIC STUDIES BEGIN TO INFORM THERAPEUTICS

Assemblies on Allergy, Immunology and Inflammation; Respiratory Structure and Function

8:00 AM - 9:30 AM **Marriott Marquis Washington**

Independence Ballroom Salons E-H (Level M4)

Target Audience

Health care providers, translational and clinical science researchers, trainees, advanced healthcare practitioners

Objectives

At the conclusion of this session, the participant will be able to:

- to understand the cellular effects of obesity-mediated complications on the lung
- to understand the contribution of obesity-related metabolic complications and that of therapeutics targeted to these metabolic complications to asthma outcomes
- to understand the contribution of oxidative and nitrosative stress on obesity-related asthma and the dietary interventions to ameliorate these effects

Obesity-related asthma is a well-established distinct asthma phenotype that is poorly responsive to current asthma therapeutic approaches. The lack of responsiveness to medications highlights the need to identify alternative management strategies. This symposium will discuss breakthrough findings over the past 2-3 years on biologic mechanisms underlying obesity-related asthma that have directly informed therapeutic approaches distinct from traditional asthma management.

Chairing: D. Rastogi, MBBS, MS, ATSF, Washington, DC
F. Holguin, MD, MPH, Aurora, CO

8:00 The Devil Is in the Detail: Exploring the Cellular Effects of Obesity-Mediated Complications on Obesity-Related Asthma

J.L. Ingram, PhD, ATSF, Durham, NC

8:15 Discussion

8:18 Are Immune Perturbations Associated With Obesity-Related Asthma Ready for Prime Time Therapeutics?

D. Rastogi, MBBS, MS, ATSF, Washington, DC

8:33 Discussion

8:36 Is Obesity-Related Asthma a Bystander to Benefit From Treatment Strategies for Obesity-Mediated Metabolic Perturbations

A.E. Dixon, MA, BM BCH, ATSF, Burlington, VT

8:51 Discussion

8:54 Can Dietary Supplements Be Repurposed to Address the Contribution of Oxidative Stress to Obesity-Related Asthma

F. Holguin, MD, MPH, Aurora, CO

9:09 Discussion

9:12 The Role of Nitrosative Stress in Obesity-Related Asthma: A New Arena for Therapeutic Development

L.G. Que, MD, Durham, NC

9:27 Discussion

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

D7 WANT TO BE AN ADVOCATE FOR LUNG HEALTH? LEARN FROM SUCCESS!

Assemblies on Pediatrics; Behavioral Science and Health Services Research; Clinical Problems; Environmental, Occupational and Population Health; Nursing; Pediatric Advocacy Subcommittee

8:00 AM - 9:30 AM Walter E. Washington Convention Center

Room 204 A-C (Level 2)

Target Audience

Pulmonary, critical care, and sleep providers as well as trainees, researchers, and public health professionals

Objectives

At the conclusion of this session, the participant will be able to:

- identify a framework for approaching advocacy
- compare and distinguish the uses of various approaches to advocate for issues of importance in the field of lung health
- understand how to leverage advocacy activities as part of teaching and to support a promotion portfolio

The American Medical Association endorses advocacy, stating that physicians must “advocate for the social, economic, educational and political changes that ameliorate suffering and contribute to human well-being.” While physicians are well acquainted with their role as advocates for the individual patient, most have limited knowledge or experience with broad advocacy for public health. The literature and professional organizations also identify gaps in such advocacy among other health care professionals. This session will describe various routes for advocacy, provide training on advocating for public health issues, address interprofessional advocacy, and share exemplars of incorporating advocacy activities into teaching and promotion portfolios.

Chairing: A. Volerman, MD, Chicago, IL
V. Balasubramaniam, MD, Madison, WI
L.B. Gerald, PhD, MSPH, Tucson, AZ

8:00 Framework for Advocacy in Medicine
L.B. Gerald, PhD, MSPH, Tucson, AZ

8:10 Legislative Advocacy: Stock Albuterol in Schools
A. Volerman, MD, Chicago, IL

8:22 Regulatory Advocacy: Ozone and Particulate Matter standards
M.B. Rice, MD, MPH, Boston, MA

8:34 Advocacy Through the Courts: Clean Air and Climate
S. Colangelo, JD, Washington, DC

8:46 Fostering Advocacy Among Students, Trainees, Faculty, and Clinicians: A 3-Prong Approach

S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN

8:58 Academic Advocacy and Promotion: How to Climb a Ladder Not Yet Built

V. Balasubramaniam, MD, Madison, WI

9:10 Question and Answer Panel

G. Ewart, MHS, Washington, DC

BASIC • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

D8 UNDER THE MAGNIFYING GLASS: OMICS AND DEEP PHENOTYPING IN PULMONARY VASCULAR DISEASES

Assemblies on Pulmonary Circulation; Respiratory Cell and Molecular Biology

8:00 AM - 9:30 AM Walter E. Washington Convention Center

Room 145 A-B (Street Level)

Target Audience

Researchers from undergraduate student to postdoc and faculty, and PI Medical professionals from undergraduate to faculty

Objectives

At the conclusion of this session, the participant will be able to:

- define the novel unbiased and large scale Omics and phenotyping methods available to pulmonary vascular researchers
- increase understanding of pulmonary vascular cell phenotype and function through Omics, visualization and deep phenotyping
- acquire knowledge on how Omics and deep phenotyping can influence the clinical-translational understanding of patients with pulmonary vascular disease and can support precision-targeted therapy

The last years have seen a remarkable growth in methods that allow large scale insight into cell phenotypes, gene and protein changes. These methods become increasingly common in the field of pulmonary vascular research and carry great promise not only for a better understanding of the pathophysiology, but also for a phenotyping of subtypes of patients as a prerequisite for precision medicine. The session will demonstrate to the attendee how these methodologies can be used to receive a holistic view on pulmonary vascular diseases and thus lead to a better stratification of patients and a more targeted treatment.

Chairing: L. Farkas, MD, Columbus, OH
G. Kwapiszewska, PhD, Graz, Austria
S.Y. Chan, MD, PhD, Pittsburgh, PA

- 8:00** **Single Cell RNAseq Redefines Vascular Cell Heterogeneity in the Lung**
N. Kaminski, MD, ATSF, New Haven, CT
- 8:15** **Beyond RNA - Multi-Dimensional -Omics in the Pulmonary Circulation**
S.Y. Chan, MD, PhD, Pittsburgh, PA
- 8:30** **Advancing the Understanding of the Immune Response and Inflammation in the Lung Through Omics**
C. Dela Cruz, MD, PhD, ATSF, New Haven, CT
- 8:45** **PVDOMICs - Molecular-Based Phenotyping of Pulmonary Vascular Diseases**
A. Hennes, MD, ATSF, Nashville, TN
- 9:00** **From Omics to Targeted Treatment Options in Pulmonary Vascular Disease**
M. Rabinovitch, MD, Stanford, CA
- 9:15** **Panel Discussion**

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 1.5

D9 IT'S ABOUT TIME! THE CIRCADIAN CLOCK IN LUNG DISEASE, FROM BENCH TO BEDSIDE

Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Respiratory Cell and Molecular Biology; Sleep and Respiratory Neurobiology

8:00 AM - 9:30 AM **Walter E. Washington Convention Center**
Room 150 A-B (Street Level)

Target Audience

Researchers interested in understanding the molecular mechanisms that involve the circadian clock in chronic lung diseases, physicians, physician-scientists, trainees, clinical fellows, junior-senior investigators, etc.

Objectives

At the conclusion of this session, the participant will be able to:

- to learn on the newly and rapidly evolving paradigms about circadian clock regulation in innate immunity, sleep and pathogenesis of chronic lung diseases
- to identify potential clock targets that can modulate cellular functions and molecular pathways essential for lung development and for the treatment and management of chronic inflammatory lung diseases
- to identify novel biomarkers that supports circadian disruption causal-effect relationships in chronic lung diseases progression; Develop novel clock-based targeted therapies that can ameliorate pathophysiological phenotypes of chronic lung diseases

This exciting Scientific Symposium explores the role of the circadian clock in the development of chronic lung disease. This session is fully translational, providing a bench-to-bedside view of clock biology, basic mechanisms of circadian clock dysregulation in development of OSA, COPD, and IPF, and clinical translation drawing on results of chronotherapy trials in asthma, showing the role of environmental influences on circadian biology and learning from individuals with sleep disorders. We have assembled an impressive and diverse group of speakers from across the globe and this promises to be an exceptional session.

Chairing: H. Durrington, PhD, MA, MBChB, Manchester, United Kingdom
I.K. Sundar, BSc, MSc, PhD, Kansas City, KS
N.N. Jarjour, MD, ATSF, CPE, Madison, WI
M.P. Knauert, PhD, MD, New Haven, CT

- 8:00** **Sleep and Circadian Rhythms: Considerations for Diagnosis, Monitoring and Treatment**
V. Revell, PhD, Guildford, United Kingdom
- 8:15** **Impact of Intermittent Hypoxia on Circadian Dysregulation of Gene Expression and Physiology**
D.F. Smith, MD, PhD, Cincinnati, OH
- 8:30** **Asthma... It's a Matter of Time!**
H. Durrington, PhD, MA, MBChB, Manchester, United Kingdom
- 8:45** **Clock in the Lung: How Environmental Cues Tik Tok**
I. Rahman, PhD, ATSF, Rochester, NY
- 9:00** **Tik Tok of Pulmonary Fibrosis Using in Vitro and In Vivo models**
I.K. Sundar, BSc, MSc, PhD, Kansas City, KS
- 9:15** **Bringing Circadian Biology to Medicine**
J.B. Hogenesch, PhD, Cincinnati, OH

This session and the International Conference are supported by an independent medical educational grant from AstraZeneca LP and Boehringer Ingelheim Pharmaceuticals, Inc..

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BASIC • BEHAVIORAL • CLINICAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 1.5

D10 AN AGE-FRIENDLY FRAMEWORK FOR CARING FOR OLDER ADULTS WITH CHRONIC LUNG DISEASE

Assemblies on Behavioral Science and Health Services Research; Pulmonary Rehabilitation

8:00 AM - 9:30 AM **Walter E. Washington Convention Center**
Room 143 A-C (Street Level)

Target Audience

Pulmonary providers, pharmacists, pulmonary rehabilitation providers, and health policy makers who care for older adults with chronic lung diseases

Objectives

At the conclusion of this session, the participant will be able to:

- define the components of age-friendly healthcare (4Ms) in chronic lung disease
- apply the 4M framework and understanding of the physiology of aging to adapt diagnostic testing algorithms and treatment protocols for older adults with and without geriatric syndromes
- identify geriatrics assessments that should be routinely performed by pulmonologists or assessed by these experts prior to making diagnosis or treatment decisions for chronic lung diseases

Older adults are disproportionately affected by many chronic lung diseases (e.g. COPD, asthma, bronchiectasis). Developing diagnostic and treatment strategies for older adults in an age-friendly health system must consider diagnostic accuracy, likelihood of benefit, and the unique needs of this population. The John A. Hartford Foundation and the Institute for Healthcare Improvement have outlined a conceptual framework for age-friendly healthcare delivery called the 4Ms – Medication, Mobility, Mentation, and What Matters. The proposed symposium includes a diverse group of interprofessional and international experts in aging who will highlight the impact this framework has on caring for patients with chronic lung disease.

Chairing: M.F. Griffith, MD, MPH, Aurora, CO
L.J. Witt, MD, San Francisco, CA
A.S. Iyer, MD, MSPH, Birmingham, AL
S. Jain, MD, New Haven, CT

8:00 Public Advisory Roundtable Presentation**8:10 Overview of The Age-Friendly Health System (4M) Framework**

M. Bellantoni, MD, Baltimore, MD

8:22 Biology of Lung Aging

S. Krick, MD, PhD, Birmingham, AL

8:34 Diagnostic Dilemmas in Chronic Lung Disease for the Older Adult

J. Hurst, MD, London, United Kingdom

8:46 Pharmacotherapy in the Older Adult with Chronic Lung Disease

A.L. Martirosov, PharmD, Detroit, MI

8:58 Frailty, Falls and Chronic Lung Disease

A.M. Yohannes, PhD, ATSF, Azusa, CA

9:10 Caring for Chronic Lung Disease Patients in Nursing Homes

M.F. Griffith, MD, MPH, Aurora, CO

9:22 Moderated Q&A by Chairs

This session and the International Conference are supported by an independent medical educational grant from AstraZeneca LP, and Insmad Incorporated.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

D11 THE EVOLVING ROLE FOR IMMUNOTHERAPY IN LUNG CANCER**Assembly on Thoracic Oncology**

8:00 AM - 9:30 AM

Marriott Marquis Washington

Liberty Ballroom, Salons M-P (Level M-4)

Target Audience

Clinicians and researchers who care for thoracic oncology patients

Objectives

At the conclusion of this session, the participant will be able to:

- understand how immune checkpoint inhibitors are used to treat lung cancer
- summarize recent updates in cancer immunotherapy for lung cancer
- describe management approaches for difficult or refractory immune-related adverse events

Our understanding of the role of the immune system in lung cancer has changed dramatically over the past couple decades. Immune checkpoint inhibitors have revolutionized the treatment of lung cancer, leading to durable responses in a subset of non-small cell lung cancer patients. However, many patients with lung cancer fail to respond or develop resistance to immune checkpoint inhibitors, highlighting the need for novel immunotherapies. Immune checkpoint inhibitors are also associated with toxicities that will be managed by pulmonologists and intensivists, such as pneumonitis. The speakers, all world-class experts in lung immuno-oncology, will provide perspective on this quickly evolving field.

Chairing: S. Shojaee, MD, MPH, Nashville, TN
J. Deepak, MD, MBBS, FACP, Baltimore, MD
M. Acunzo, PhD, Richmond, VA

8:00 Introduction

S. Shojaee, MD, MPH, Nashville, TN

8:05 Immune Dynamics During Lung Cancer Development, from Premalignant to Invasive

S.M. Dubinett, MD, Los Angeles, CA

- 8:22 Adoptive T Cell Transfer and CAR T Cell Therapy for Lung Cancer**
S.M. Albelda, MD, Philadelphia, PA
- 8:39 Neoadjuvant Checkpoint Blockade for Lung Cancer Immunotherapy**
Susan Scott, MD, Baltimore, MD
- 8:56 Immune Escape and Contribution of Neutrophils to Immune Checkpoint Inhibitor Treatment Failures**
A.M. Houghton, MD, Seattle, WA
- 9:13 The Diagnosis and Management of Immune Checkpoint Inhibitor-Related Pneumonitis**
C.R. Sears, MD, ATSF, Indianapolis, IN

This session and the International Conference are supported by an independent medical educational grant from Merck & Co.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 1.5

D12 THE POST-COVID VIRAL SURGE: HOW DID VIRAL EXPOSURES, OR LACK THEREOF, INFLUENCE PEDIATRIC AND ADULT IMMUNITY?

8:00 a.m. - 10:00 a.m. Walter E. Washington Convention Center
Center Room152 A-B

Objectives

- At the conclusion of this session, the participant will be able to:
- be able to apply new clinical research knowledge to clinical practice
 - learn new findings about key conditions in pulmonary, critical care and sleep
 - have new strategies to manage the care of common conditions in pulmonary, critical care, and sleep

As cases and hospitalizations for COVID-19 waned over the winter, we experienced a dramatic surge of other respiratory viruses, leaving us with the question: how has viral exposures, or lack thereof, influenced pediatric and adult immunity? This session will tackle topics related to viral considerations of surges; the role of airway epithelial cell barriers in viral infections; the impact of persistent viral reservoirs and the altered microbiome post COVID-19; and how the immune system may have been shaped by COVID-19 and how these impacts aging health.

Chairing: Lael Yonker, MD, MGH, Boston, MA; Charles Dela Cruz, MD, PhD, ATSF, Yale New Haven Hosp, New Haven, CT; Tina V. Hartert, MD, MPH, ATSF, Vanderbilt Univ Ctr for Asthma Research, Nashville, TN

- 8:00 Introduction**
Lael Yonker, MD, MGH, Boston, MA
- 8:05 Respiratory Viral Considerations During Surges**
B. Petros, Boston, MA
- 8:26 Effects of Respiratory Viruses on the Airway**
F. Rezaee, MD, Cleveland, OH
- 8:47 Persistent Viral Reservoirs Post Infection**
C. Rosas-Salazar, MD, MPH, ATSF, Nashville, TN
- 9:08 Immune Shaping and Impact on Adults**
T. Hartert, MD, MPH, ATSF, Nashville, TN

BASIC • TRANSLATIONAL
MINI SYMPOSIUM

D13 INNATE AND ADAPTIVE IMMUNE MECHANISMS REGULATING LUNG DISEASE

8:00 a.m. - 10:00 a.m. Walter E. Washington Convention Center
Ballroom A (Level 3)

Chairing: C.M. Bojanowski, MD, MSCR, ATSF, New Orleans, LA; S.M. Cloonan, PhD, Dublin, Ireland; M. Cano, MD, PhD, Saint Louis, MO; C. Bonham, MD, Charlottesville, VA

Oral Presentations:

- 8:00 Tissue-resident Memory and TEMRA CD8+ T Cells in the Lungs of Patients With Mild-moderate COPD/**
A.B. Villaseñor-Altamirano, Boston, MA
- 8:12 Galanin-positive Macrophages Are Intimately Associated With the Pulmonary Vasculature During Late Embryogenesis/T.** Saito, Stanford, CA
- 8:24 Proximate Effects of Infant Lower Respiratory Tract Infections on Lung and Immune Dysfunction: Findings From the CHILD Study/M.V.** Medeleanu, Toronto, Canada
- 8:36 Neutrophil Efferocytosis Locks Alveolar Macrophages in a Pro-resolution Phenotype at the Cost of Bacterial Control/J.** Better, Giessen, Germany
- 8:48 Viral Infection and Age Determine the Production of B-cell Homing and Survival Factors in the Human Infant Airway Epithelium/E.** Chorvinsky, Washington, DC

- 9:00 **Safety, Tolerability, and Efficacy of Axatilimab, a Colony-stimulating Factor 1 Receptor (CSF-1R) Humanized Antibody, in Advanced Chronic Graft-versus-host Disease-related Bronchiolitis Obliterans Syndrome/V.** Radojicic, Waltham, MA
- 9:12 **Infants With Severe Viral Respiratory Illnesses and High Airway Epithelial Thymic Stromal Lymphopoietin (TSLP) Responses Have Enhanced Baseline Interferon (IFN) and Chemokine Signaling Activation/A.** Welham, Washington, DC
- 9:24 **A Rhinovirus-A16 VP0 Vaccine Induces Homotypic Humoral and Cellular Immunity, and Following Heterotypic Rhinovirus-A01 Infection, Accelerates Virus Clearance and Induces Cross-strain IFN- γ T Cell and Neutralising Antibody Responses/C.J.** Pyle, London, United Kingdom
- 9:36 **Single Cell Analysis of Human Nasal Mucosal IgE Antibody Secreting Cells Reveals Newly Minted Phenotype/R.P.** Ramonell, Pittsburgh, PA

BEHAVIORAL • CLINICAL
MINI SYMPOSIUM
D14 CUTTING EDGE CONCEPTS IN BEHAVIORAL SCIENCES AND HEALTH SERVICES RESEARCH

8:00 a.m. - 10:00 a.m. **Walter E. Washington Convention Center**
Room 102 A-B (Street Level)

Chairing: A.E. Turnbull, DVM, MPH, PhD, Baltimore, MD
 S.M. Nyenhuis, MD, Chicago, IL
 K.C. Vranas, MD, MSCR, Portland, OR

Oral Presentations:

- 8:00 **An EHR-based Artificial Intelligence Approach to Identifying Patient-level Interprofessional Clinician Teams in the ICU/H.** Ratliff, Ann Arbor, MI
- 8:12 **Artificial Intelligence-assisted Versus Clinician Only Evaluation of Indeterminate Pulmonary Nodules: A Comparative Effectiveness Study/C.M.** Godfrey, Nashville, TN
- 8:24 **Modeling Normal Pulmonary Function Using Latent Class Analysis/A.T.** Moffett, Philadelphia, PA
- 8:36 **Use of Latent Class Analysis to Identify Distinct Phenotypes of Long COVID/A.W.** Wong, Vancouver, Canada
- 8:48 **Crisis Standards of Care Exclusion and Triage Score Modifier Performance in Predicting Hospital Mortality/B.C.** Walsh, Los Angeles, CA

- 9:00 **Secondary Pulmonary Hypertension Is Not a Useful Diagnostic Category in the Lung Allocation Score/M.** Sonnicks, New York, NY
- 9:12 **Coping Phenotypes Are Associated With Health-related Quality of Life in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR)/K.** Courtright, Philadelphia, PA
- 9:24 **A 6-year Analysis of the Sustainability of an "Opt-out" EHR-triggered Tobacco Treatment Consult Service at a Large Safety-net Hospital/A.L.** Flores, Boston, MA
- 9:36 **Fidelity and Impact of a Team Based Chronic Obstructive Pulmonary Disease Service Across Rural and Urban Veterans Affairs Medical Centers/E.** Portillo, Madison, WI
- 9:48 **What Strategies Are Recommended for Potential Implementation of a National Lung Cancer Screening in Australia?/N.** Rankin, Carlton, Australia

CLINICAL • TRANSLATIONAL
MINI SYMPOSIUM
D15 OUTCOMES IN SARCOIDOSIS

8:00 a.m. - 10:00 a.m. **Walter E. Washington Convention Center**
Room 202 B (Level 2)

Chairing: D.A. Culver, DO, Cleveland, OH
 W.P. Drake, MD, Nashville, TN
 K. Buschulte, MD, Heidelberg, Germany

Featured Speaker:

8:00 **Outcomes in Sarcoidosis/L.A.** Maier, Denver, CO

Oral Presentations:

- 8:12 **Assessing Missed Opportunities To Diagnose Sarcoidosis: A Population-based Cohort Study/S.** De La Serna, Iowa City, IA
- 8:24 **Ocular Manifestations of Sarcoidosis in the United States: A Nationwide Registry Study/M.** Younis, Gainesville, FL
- 8:36 **Organ Involvement Clusters in Black and White Sarcoidosis Patients/A.M.** Tauquir, Cleveland, OH
- 8:48 **Impact of Insurance Type on Morbidity and Mortality in Patients With Sarcoidosis/A.** Randhawa, Newark, NJ
- 9:00 **Sarcoidosis: Racial Differences in Pulmonary Function Over Time/M.** Sharp, Baltimore, MD
- 9:12 **Longer Travel Distance to Subspecialty Clinic Associates With Lower Lung Function in Pulmonary Sarcoidosis/N.** Farah, Charlottesville, VA

- 9:24 **The Effect of Pulmonary Vasodilator Therapy in Patients With Sarcoidosis-associated Pulmonary Hypertension/S.** Gayen, Philadelphia, PA
- 9:36 **Changes in FDG-PET Scan Activity in Sarcoidosis and Pulmonary Function Studies/G.W. Soo Hoo,** Los Angeles, CA
- 9:48 **Serum Ace Levels and RAAS Modulation on Mortality in Patients With Sarcoidosis/J. Fares,** Philadelphia, PA

CLINICAL

MINI SYMPOSIUM

D16 ADVANCING THE SCIENCE OF ARDS AND ACUTE RESPIRATORY FAILURE8:00 a.m. - 10:00 a.m. **Walter E. Washington Convention Center**

Ballroom B (Level 3)

Chairing: C. O'Kane, MD, PhD, Belfast, United Kingdom
R.G. Khemani, MD, MSCR, Los Angeles, CA
N.J. Meyer, MD, MS, ATSF, Philadelphia, PA

Oral Presentations:

- 8:00 **A New Global Definition of Acute Respiratory Distress Syndrome/M.A. Matthay,** San Francisco, CA
- 8:12 **Hemodynamic Variations Are Associated With Increased Odds of Discrepancy Between Pulse Oximeter and Arterial Oxygen Saturation/R. Rovinski,** Miami, FL
- 8:24 **Endothelial Glycocalyx Degradation in Pediatric Acute Respiratory Distress Syndrome/C.J. Sallee,** Los Angeles, CA
- 8:36 **Glycocalyx Degradation Products in Pulmonary Edema Fluid Are Higher in ARDS Than Cardiogenic Edema and Are Associated With Poor Outcomes and Decreased Compliance of the Respiratory System/L. Yun,** Nashville, TN
- 8:48 **Patterns of Biomarker Dysregulation in Mortality Differ Between ARDS and Sepsis Phenotypes/M. Maddali,** Stanford, CA
- 9:00 **The Hyperinflammatory and Hypoinflammatory Phenotypes Have Divergent Clinical Outcomes in Sepsis and Differential Response to Activated Protein C/P.** Sinha, St. Louis, MO
- 9:12 **Plasma SARS-CoV-2 Nucleocapsid Antigen Levels Are Associated With In-hospital Mortality in Hospitalized Patients With COVID-19/K. Sullivan,** San Francisco, CA
- 9:24 **Latent Class Analysis Identifies Novel Phenotypes of Severe COVID-19 Pneumonia/N. Alipanah-Lechner,** San Francisco, CA

- 9:36 **Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study/M. Witzenthath,** Berlin, Germany
- 9:48 **Oxygen-saturation Targets for Adults Receiving Mechanical Ventilation After Cardiac Arrest: A Secondary Analysis of the PILOT Trial/K.P. Seitz,** Nashville, TN

BASIC • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

D17 BUGS, LUNGS, AND THE ENVIRONMENT: THE INTERPLAY BETWEEN AMBIENT EXPOSURES, MICROBIOME, AND RESPIRATORY INFECTION8:00 a.m. - 10:00 a.m. **Walter E. Washington Convention Center**

Room 202 A (Level 2)

Chairing: L. Smit, PhD, Utrecht, Netherlands
D. Croft, MD, MPH, ATSF, Rochester, NY
I. Jaspers, PhD, Chapel Hill, NC

Oral Presentations:

- 8:00 **Gut Microbiome Transplant Confers Predisposition to Asthma Triggered by Prenatal Exposure to Environmental Particles, Requires Viable Bacteria/A.V. Fedulov,** Providence, RI
- 8:12 **Infant Lower Respiratory Infections and the Premature Death of Adults From Respiratory Disease - a Seventy-three Year Longitudinal Nationally Representative Birth Cohort Study/J. Allinson,** London, United Kingdom
- 8:24 **Rates and Risk Factors for RSV Infection Among Term Healthy Infants in a Population-based US Cohort/F. Cacho,** Nashville, TN
- 8:36 **Organic Dust Exposure Enhances SARS-CoV-2 Entry in a PKC α - and ADAM-17-dependent Manner/T.A. Wyatt,** Omaha, NE
- 8:48 **Risk of Cardiovascular Events Post-COVID-19 in People With Pre-existing Chronic Respiratory Diseases/H. Whittaker,** London, United Kingdom
- 9:00 **The Effect of the COVID-19 Pandemic on Community Respiratory Virus Prevalence and Healthcare Utilization Related to Asthma, Chronic Obstructive Pulmonary Disease, and Respiratory Tract Infection/T. Ho,** Hamilton, Canada

- 9:12 **Nicotine in E-cigarette Aerosols Alters Pulmonary Gene Expression, Increases Lung Protein Permeability, and Impairs Virus Clearance During Influenza Infection in Mice**/M. Maishan, San Francisco, CA
- 9:24 **E-cigarette Whole Body Aerosol Exposure: Acute Cardiovascular Changes and Effects on Subsequent Pneumococcus Infection**/G. Grunig, New York, NY
- 9:36 **Use of Inhaled Corticosteroids and the Risk of Mortality and Hospitalisation for Pneumonia in a UK Cohort of Patients With Idiopathic Pulmonary Fibrosis**/A.D. Morgan, London, United Kingdom
- 9:48 **NF- κ B Inhibition Attenuates Human Rhinovirus Replication Following Corticosteroid and Diesel Exhaust Particulate Exposures**/R.D. Huff, Vancouver, Canada

BASIC • TRANSLATIONAL

MINI SYMPOSIUM

D18 MOLECULAR TRAFFIC HUBS IN PULMONARY VASCULAR DISEASE

8:00 a.m. - 10:00 a.m. **Marriott Marquis Downtown**

Liberty Ballroom, Salons I-L (Level M4)

Chairing: A.L. Frump, MS, PhD, Indianapolis, IN
S. Umar, MD, PhD, Los Angeles, CA
A.J. Bryant, MD, Gainesville, FL
J. Aman, MD, PhD, Amsterdam, Netherlands

Oral Presentations:

- 8:00 **Deoxyhypusine Synthase-mediated Hypusination of eIF5A Drives PASMC Proliferation and Vascular Remodeling in Pulmonary Arterial Hypertension**/S.-E. Lemay, Quebec, Canada
- 8:12 **ADAR1 Mediated RNA Editing Contributes to Vascular Remodeling in PAH**/Y. Kim, Boston, MA
- 8:24 **HIPK2/YAP/CEP55 Crosstalk Regulates Pulmonary Vascular Smooth Muscle Cell Proliferation, Survival and Pulmonary Hypertension**/L. Jiang, Davis, CA
- 8:36 **Hypomethylating Drugs Improve Pulmonary Vascular Remodelling and Alleviate Pulmonary Hypertension Development in a Preclinical Model of the Disease**/R. El-Kabbout, Quebec, Canada
- 8:48 **Small Molecule Readthrough Compound GJ103 Effectively Blocks the Development of Heritable Pulmonary Arterial Hypertension in a Mouse Model**/Y. Wang, Torrance, CA
- 9:00 **GALNT1-mediated O-GalNAc Glycosylation Is a Novel Mediator of Pulmonary Arterial Hypertension**/Y. Shi, Indianapolis, IN

- 9:12 **Targeting the Signaling Domain of Aminopeptidase N Ameliorates Pulmonary Hypertension**/J. James, Tucson, AZ
- 9:24 **Skeletal Muscle SIRT3 Deficiency Remotely Regulates Pulmonary Vascular Remodeling Via LOXL2-CNPY2-p53 Axis in Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction**/J.-R. Jheng, Indianapolis, IN
- 9:36 **Cybrid Analysis Delineates Nuclear and Mitochondrial Contributions to Oxidative Stress in Pulmonary Arterial Hypertension**/S. Balachandar, Indianapolis, IN
- 9:48 **SOX17 Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension**/R. Walters, London, United Kingdom

BASIC • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

D19 NEW PERSPECTIVES ON TRANSLATIONAL STUDIES FOR LUNG FIBROSIS

8:00 a.m. - 10:00 a.m. **Walter E. Washington Convention Center**

Room 146 A-C (Street Level)

Chairing: A. Pardo, PhD, Ciudad de Mexico, Mexico
T.M. Maher, MD, MSc, PhD, FRCP, Los Angeles, CA
M. Bhattacharya, MD, MSci, San Francisco, CA

Featured Speaker:

- 8:00 **Models to Test Airway Basal Cell Function in IPF**/A. Prasse, Hannover, Germany

Oral Presentations:

- 8:12 **Targeting MCT1-mediated Intercellular Lactate Shuttling Attenuates Pulmonary Fibrosis**/C. He, Birmingham, AL
- 8:24 **Targeting RAD51 for the Treatment of Pulmonary Fibrosis**/M. Choudhury, Rochester, MN
- 8:36 **Perivascular Neuronal β -III Tubulin (Tuj1) Diminishes the Severity of Pulmonary Fibrosis**/R. Sato, Bethesda, MD
- 8:48 **A First-in-Class IL-11 Receptor Blocking Antibody as a Treatment for Pulmonary Fibrosis**/J. Swaney, San Diego, CA
- 9:00 **Dual α v β ₆/ α v β ₁ Integrin Inhibitor PLN-74809 Attenuates Pathologic Fibroblasts in Human Fibrotic Lung Explant Tissue**/M.C. An, South San Francisco, CA
- 9:12 **Preclinical Pulmonary Fibrosis Models Identify AMP-kinase as a Candidate Druggable Target for Pulmonary Fibrosis Therapies**/K.-D. Alysandratos, Boston, MA
- 9:24 **First-in-class Small-molecule Inhibitor of Nox4 Promotes Reversal of Established Pulmonary Fibrosis**/L. Hecker, Atlanta, GA

- 9:36 **A 3D Co-culture System to Gain Insights Into Idiopathic Pulmonary Fibrosis and Perform Drug Screening/C. Sen, Los Angeles, CA**
- 9:48 **Chemokine Receptor 2 Lung Imaging to Monitor Nintedanib Treatment Response in a Fibrosis Model/H. Farooq, St. Louis, MO**

BEHAVIORAL • CLINICAL • TRANSLATIONAL**MINI SYMPOSIUM****D20 MECHANISTIC INSIGHTS IN SLEEP DISORDERED BREATHING**8:00 a.m. - 10:00 a.m. **Marriott Marquis Downtown**

Marquis Ballroom, Salon 6 (Level M2)

Chairing: S. Jelic, New York, NY
M. Sanchez De La Torre, PhD, Lleida, Spain
C. Heiser, MD, Munich, Germany
D.C. Lim, MD, Miami, FL
R.J. Schwab, MD, Philadelphia, PA

Oral Presentations:

- 8:00 **Impact of Continuous Positive Airway Pressure on Serum Angiopoietin-2 Following Coronary Revascularization in Patients With Obstructive Sleep Apnea: The RICCADSA Study/Y. Celik, Istanbul, Turkey**
- 8:12 **Elucidating Influence of Underlying Pulmonary Physiology in the Association of Sleep-Related Hypoxemia and Incident Atrial Fibrillation/C. Heinzinger, Cleveland, OH**
- 8:24 **Associations Among Sleep Apnea, Recurrence of Atrial Fibrillation, and Objective Sleep Duration in Patients Who Underwent Radiofrequency Catheter Ablation for Persistent Atrial Fibrillation/T. Minami, Kyoto, Japan**
- 8:36 **Flow-shape-derived Site of Pharyngeal Collapse Predicts Response to Hypoglossal Nerve Stimulation Therapy/D. Vena, Boston, MA**
- 8:48 **Site of Collapse During Drug-induced Sleep Endoscopy Is Associated With Polysomnographic Endotypes/S. Op De Beeck, Antwerp, Belgium**
- 9:00 **Comparison of Upper Airway Collapse in Drug-induced Sleep Endoscopy and Natural Sleep Endoscopy/K. Van Den Bossche, Antwerp, Belgium**
- 9:12 **Determinants of Transvenous Phrenic Nerve Stimulation-induced Improvements in Left Ventricular Systolic Function in Central Sleep Apnea and Heart Failure/A. Azarbarzin, Boston, MA**

- 9:24 **Mechanisms Underlying Efficacy of Acetazolamide for Sleep Apnea in Patients With Heart Failure/S.A. Sands, Boston, MA**
- 9:36 **All Apneas and Hypopneas Are Not Created Equal: Event-related Hypoxia Burden Affects Changes in Electroencephalographic Cortical Activity in Obstructive Sleep Apnea Patients/M. Hajjpour, Vancouver, Canada**

Featured Speaker:

- 9:48 **Unravelling the Pathway Towards Personalized Medicine for Sleep-Disordered Breathing: Novel Insights and Future Directions/B.A. Edwards, Melbourne, Australia**

BASIC • CLINICAL • TRANSLATIONAL**POSTER DISCUSSION SESSION****D21 TRANSLATIONAL COVID-19 STUDIES**8:00 a.m. - 10:00 a.m. **Walter E. Washington Convention Center**

Room 206 (Level 2)

Poster Viewing 8:00-8:45

Discussion 8:45-10:00

- Chairing:** E.K. Allen, PhD, Memphis, TN
B.D. Kraft, MD, ATSF, FCCP, Saint Louis, MO
- 701 **Longitudinal Evaluation of Blood Cellular Immune Markers and Lung Proteomics in Vaccinated Patients With SARS-CoV-2 Breakthrough Infections/J.A. Huapaya, Bethesda, MD**
- 702 **Respiratory Post Acute COVID-19 Sequelae (PACS)-A Phenotype of Long COVID/K. Zhang, Hamilton, Canada**
- 703 **Fibrinolysis and Inflammation in Convalescent Plasma Treated COVID-19 Patients/B. Yao, Tyler, TX**
- 704 **SARS-CoV-2 Infection in Severe Asthma Is Associated With Worsening of COVID-19 Through Respiratory NLRP3 Inflammasome Activation/J.S. Jeong, Jeonju, Korea, Republic of**
- 705 **Local and Systemic Antibody Response to SARS-CoV-2 Infection in Critically Ill COVID-19 Patients/C.R. Barnett, New York, NY**
- 706 **Meta-analysis of Single-cell RNA-seq Data Reveals Cell-intrinsic and -Extrinsic Dissemination of SARS-CoV-2 Viral RNA: Implications for COVID-19 Pathogenesis/M.S. Khatun, New Orleans, LA**
- 707 **Reduced Antibody and Cell-mediated Immune Responses to SARS-CoV-2 Vaccination in Sarcoidosis/P.H. Sporn, Chicago, IL**
- 708 **Inhaled Statins for the Treatment of COVID-19/A.A. Zeki, Davis, CA**

- 709 Immune Response to COVID-19 Vaccine in Patients with Asthma Biologics/S. Khurana, Rochester, NY
- 710 Risk Factors for Symptomatic SARS-CoV2 Infection, Severe COVID-19, and Vaccination Response in the Severe Asthma Research Program/A.M. Rusk, Phoenix, AZ
- 711 Autoantibodies Are Prevalent in Hospitalized COVID-19 Patients, But Are Not Associated With Short-term Outcomes/A. Pacheco-Navarro, Stanford, CA
- 712 Proteomic Analysis of Serum From IVIG-treated COVID-19 Patients Uncovered Suppression of Neutrophil-related Pathways/J.A. Masso Silva, La Jolla, CA
- 713 Effects of Primary Immunodeficiency on COVID Admission Outcomes in the United States: Nationwide Analysis/R. Dalbah, Johnson City, TN
- 714 Differences in Sterol Metabolites in Survivors of COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS)/L. Leuenberger, Columbus, OH
- 715 Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical and Biologic Effects of Anti-CD14 Treatment in Hospitalized Patients With COVID-19/L. Mabrey, Seattle, WA
- 716 The Therapeutic Path in the Post-COVID Thicket - Renaissance of Azithromycin/D. Gagiannis, Ulm, Germany
- 717 Safety and Tolerability of LYT-100 (Deupirfenidone) in Post-Acute Sequelae of SARS-CoV-2 (PASC) "Long COVID" Patients Presenting With Respiratory Complications/T. Kulkarni, Birmingham, AL
- 718 Pulmonary Function and Radiological Follow-up in Patients With CT Abnormalities After Virological Recovery From COVID-19/A. Jain, Valhalla, NY
- 719 Pathogenesis of Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) Accessory Protein Open Reading Frame 7b (Orf7b) in Thymus-cell (T-cell) Lymphopenia/R. Deshpande, Pittsburgh, PA
- 720 Pulmonary Function Testing in Recovered COVID-19 Omicron Variant Outpatients/S. Copen, Los Angeles, CA
- 721 Mortality Differences Among Patients With Airway Disease Hospitalized With COVID-19/Y. Liu, New Haven, CT
- 722 Mepolizumab Reduces Clinically Significant Exacerbations in Patients With Severe Asthma Prior to and During the COVID-19 Pandemic: Results From the Real-world REALITI-A Study/F. Schleich, Liège, Belgium
- 723 The Impact of Asthma and Metabolic Syndrome in COVID-19: An Analysis of the Virus COVID-19 Registry/J.L. Denson, New Orleans, LA
- 724 Impact of the COVID-19 Pandemic on Clinic Visit Behavior Among Adult Patients With Asthma/T. Tajiri, Nagoya, Japan

BEHAVIORAL • CLINICAL

POSTER DISCUSSION SESSION

D22 HOT TOPICS IN BEHAVIORAL SCIENCES AND HEALTH SERVICES RESEARCH8:00 a.m. - 10:00 a.m. **Walter E. Washington Convention Center****Room 151 A (Street Level)**

Poster Viewing 8:00-8:45

Discussion 8:45-10:00

Chairing: C.H. Weiss, MD, Evanston, IL
 A. Norweg, PhD, BS, MS, New York, NY
 R. Kohn, MD, MSCE, Philadelphia, PA

- 401 A Telehealth Approach to Addressing ICU Healthcare Worker Mental Health Distress: Initial Data and Uptake of Resiliency Services/N. Shah, Charleston, SC
- 402 Do Prognostic Scores Perform Differently in Surge-strained Hospitals? Impact of Surge Index on COVID-19 Mortality Prediction by the Modified 4C Score at 224 U.S. Hospitals, March-May 2020/C. Yek, Bethesda, MD
- 403 Association of Hospital Mortality With Initiation of Mechanical Ventilation on a Weekend: A Retrospective Cohort Study/K. Rai, Aurora, CO
- 404 Variation in Receipt of Imaging Among Patients Presenting With Dyspnea in Emergency and Ambulatory Settings/S. Cabral, Boston, MA
- 405 Endobronchial Ultrasound Transbronchial Needle Aspiration With Vs Without Rapid On-site Evaluation in Diagnosing Mediastinal and Pulmonary Lesions: A Systematic Review and Metanalysis/A. Elkhapery, Rochester, NY
- 406 Assessing the Robustness of a Machine Learning Model for Predicting Asthma Hospital Encounters During the COVID-19 Pandemic/X. Zhang, Seattle, WA
- 407 Assessing the Impact of AI Based Prioritization and Triage of Positive Non-CTPAs on Wait Time in the Outpatient Setting/D.A. Klein, Summit, NJ
- 408 Examining Changes in Antibiotic Usage Among Inpatients With Asthma Between 2010-2018/S. Chokkara, Chicago, IL
- 409 Exploring Provider Conceptualization of Limited Life Expectancy in the Context of Lung Cancer Screening: A Qualitative Study/L. Kearney, Boston, MA
- 410 Veteran Perceptions of Lung Cancer Risk and Implications for Lung Cancer Screening Programs/J. Boudreau, Bedford, MA

- 411 **Using Telehealth Strategies to Increase Shared Decision Making for Lung Cancer Screening: A Pilot Randomized Controlled Trial**/K. Rendle, Philadelphia, PA
- 412 **Lung Cancer Screening to Detect and Treat Undiagnosed Cardiovascular Disease and Chronic Obstructive Pulmonary Disease. An Analysis of the Canadian McGill Lung Cancer Screening Pilot Program Cohort**/C. Besson, Montréal, Canada
- 413 **The Impact of Comorbidities on Lung Cancer Screening Shared Decision-making**/M.S. Kale, New York, NY
- 414 **Chronic Breathlessness Management in Primary Care: Current Gaps and Practical Solutions**/A.P. Sunjaya, Sydney, Australia
- 415 **An Assessment of Pressurized Metered-dose Inhaler Use in Countries in Europe and the Rest of the World**/J.P. Bell, Baar, Switzerland
- 416 **Challenging Health Disparities in Sleep Medicine: Partnering With Community Organizations to Create a Comprehensive Sleep Clinic for Low-resource Individuals**/E. Gusman, Chicago, IL
- 417 **Validation of Predictive Tools for Obstructive Sleep Apnea Among Pregnant Women With Overweight and Obesity**/S. Petrillo, Providence, RI
- 418 **Use of a Behavior Change Model to Understand CPAP Usage at One Year**/L. Kaye, San Diego, CA
- 419 **Correlation of Therapeutic Pressure Between Home Automatic Positive Airway Pressure and In-laboratory Polysomnography Manual Titration in Patients With Obstructive Sleep Apnea**/N. Saiphoklang, PathumThani, Thailand
- 420 **Healthy Brain Ageing Education Program for Chronic Lung Disease Is Feasible in Rural Areas, Technological Challenges Notwithstanding - Pilot Randomized Controlled Trial**/R. Disler, Melbourne, Australia
- 421 **Developing and Evaluating the Living Better @home With COVID-19 Model: A Co-designed Home-based Management Model for People From Arabic-speaking Communities**/C.Y. Tang, Penrith, Australia
- 422 **Requirements for Home Oxygen After Hospitalization for COVID-19 in 2020 and 2021: Results From the U.S. Oxford Multicenter Retrospective Cohort Study**/M.B. Freedman, Chicago, IL
- 423 **Patient Subgroups Most Likely to Benefit From Shorter Time-to-antibiotics in Sepsis**/R.K. Hechtman, Ann Arbor, MI
- 424 **Physician and Patient Perspectives on Treatment Adherence in Asthma Management: Results From Apparent 1&2**/G. Walter Canonica, Milan, Italy

- 425 **Understanding Reliability of a Scarce Resource Allocation Policy: Assessing Agreement of Intensive Care Unit (ICU) Bed Allocation Priority Using Intra-class Correlation Coefficients (ICC)**/I.O. Emeruwa, Los Angeles, CA

CLINICAL

POSTER DISCUSSION SESSION

D23 **DIAGNOSTIC DILEMMAS: CASE REPORTS IN INTERSTITIAL LUNG DISEASE AND LUNG TRANSPLANTATION**

8:00 a.m. - 10:00 a.m. **Walter E. Washington Convention Center**

Room 209 A-C (Level 2)

Poster Viewing **8:00-8:45**

Discussion **8:45-10:00**

Chairing: N. Gupta, MD, Cincinnati, OH
A.L. Gray, MD, Aurora, CO
J.R. Miedema, MD, Rotterdam, Netherlands

- 801 **An Unusual Case of Blue Finger Syndrome and Interstitial Lung Disease Secondary Anti-PL7 Antibody Positive Antisynthetase Syndrome**/D. Gil-Calderon, Bogota, Colombia
- 802 **An Unusual Case Presentation of Clinically Amyopathic Dermatomyositis in a 63 Year Old Male**/M. Dasgupta, Chicago, IL
- 803 **RP ILD and Anti MDA5 Antibody Dermatomyositis, A Case Series**/S. Chakravorty, Falls Church, VA
- 804 **Prolonged Extracorporeal Membrane Oxygenation as a Bridge to a Successful Transplant in a Patient With Rapidly Progressive Interstitial Lung Disease**/J.M. Chowdhury, Falls Church, VA
- 805 **Acute Hypoxic Respiratory Failure in Setting of Bronchiolitis Obliterans After COVID-19 Infection Complicated by Pulmonary Hypertension**/M.F. Hajmurad, Greenville, SC
- 806 **The Use Of Human Immunoglobulin In The Treatment Of Covid-19 Pneumonia In Hematologic Patients: A Single-center Case Series**/P.M. Leone, Rome, Italy
- 807 **Progressive Fibrosis in Pre-existing Interstitial Lung Disease Following COVID-19 Infection**/M.P. Mohning, Denver, CO
- 808 **Robotic Lung Transplantation**/J. Thomas, Los Angeles, CA
- 809 **Lung Transplantation Following a Heart Transplantation**/J.Y. You, Cleveland, OH

- 810 **Right Lung Allograft Pneumonectomy For Treatment Recurrent Hypoxic Respiratory Failure Secondary To Recurrent Right Lung Allograft Collapse After Bilateral Lung Transplantation Followed By Redo Left Single Lung Transplantation/P. Modi, Philadelphia, PA**
- 811 **Carcinoid Tumorlets In Explanted Lung: To Care, Or Not To Care?/S. Biswas Roy, Phoenix, AZ**
- 812 **Hickam's Dictum Incarnate: A Case of Bronchorrhea/A. Grillini, Chicago, IL**
- 813 **Impact Of Ovulation Induction In A Patient With Lymphangioleiomyomatosis/M. Sridhar, Birmingham, AL**
- 814 **Lymphangioleiomyomatosis Presenting As Diffuse Alveolar Hemorrhage In The Setting Of Postcoital Hemoptysis/S. Toor, Grand Rapids, MI**
- 815 **A Rare Case Of Lymphoid Interstitial Pneumonia (LIP) With Transformation To High Grade Lymphoma/C. Kim, Los Angeles, CA**
- 816 **Thoracic Endometriosis Presented as Diffuse Cystic Lung Disease: A Rare Case Report/G.D. Bridi, Sao Paulo, Brazil**
- 817 **A Rare Case of Heterozygous Variant Associated With Congenital Interstitial and Cystic Lung Disease/L.E. Leys, New York, NY**
- 818 **Malignant Perivascular Epithelioid Cell Neoplasm (PEComa) Or Lymphangioleiomyomatosis (LAM)?/M. Wajid, Indianapolis, IN**
- 819 **Extrapulmonary Presentation Of Asymptomatic Male In Lymphangioleiomyomatosis/C. Quiles-Cruz, San Juan, PR**
- 820 **Intrapulmonary Administration of Recombinant Activated Factor VII in a Patient With Diffuse Alveolar Hemorrhage and Microscopic Polyangiitis/H. Naiditch, Pittsburgh, PA**
- 821 **Fulminant Form of Granulomatosis With Polyangiitis (Wegner) Mimicking Cavum Cancer/M. Moumkine, Tangier, Morocco**
- 822 **Double Edged Sword, Bilateral Mycotic Pulmonary Artery Aneurysm Presenting With Massive Hemoptysis/C.R. Tubig, Quezon City, Philippines**
- 823 **A Case Of Bilateral Intrapulmonary Benign Ectopic Thyroid Tissue/J. Mathew, Valhalla, NY**
- 824 **A Case of Castleman Disease Masquerading as Sarcoidosis/I.D. Bentley, Columbus, OH**

CLINICAL

POSTER DISCUSSION SESSION

D24 ADVENTURES IN "PROCEDURE-ING": CASE REPORTS IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE

8:00 a.m. - 10:00 a.m. **Walter E. Washington Convention Center**

Room 140 A-B (Street Level)

- Poster Viewing** 8:00-8:45
- Discussion** 8:45-10:00
- Chairing:** L.B. Yarmus, DO, ATSF, MBA, Baltimore, MD
E. Volker, MD, MSPH, Denver, CO
V. Luzzi, MD, Florence, Italy
- 1101 **Personalized Pulmonary: Novel Use of 3D Printed Silicone Stent for Non-healing Bronchopleural Fistula/I.R. Krumm, San Francisco, CA**
- 1102 **Refractory Tracheobronchomalacia in a Patient With Ehlers Danlos Syndrome/M. Alrjoob, Long Branch, NJ**
- 1103 **Emerging Techniques for Advanced Airway Management/C. Cox, London, United Kingdom**
- 1104 **Endobronchial Valves: A New Tool in the Management of Hemoptysis/R. Petrossian, Rochester, MN**
- 1105 **The Use of a 1.1mm Mini-cryoprobe for the Diagnosis of Isolated Mediastinal Lymphadenopathy - A Case Report/L.H. Vu, Rochester, MN**
- 1106 **The Missing Link: Roth Net Retriever Used For Bronchoscopic Foreign Body Extraction/S. Panda, Syracuse, NY**
- 1107 **Whole Lung Lavage Using VV ECMO Support in 2 Cases of Pulmonary Alveolar Proteinosis/C. Iyer, Rochester, NY**
- 1108 **A Curious Case Of A Migrating Lung Mass/A. Ashkin, Naples, FL**
- 1109 **Strongyloides Stercoralis Infection Mimicking Metastatic Lung Cancer Detected By Endobronchial Ultrasound - Transbronchial Needle Aspiration/A.A. Goizueta, Tampa, FL**
- 1110 **Coexistence of Right Intralobar Pulmonary Sequestration and Castleman Disease: A Case Report/A. Espinal Martínez, Bogotá, Colombia**
- 1111 **Buffalo Chest Syndrome: Bilateral Iatrogenic Pneumothoraces Post-dual Chamber Pacemaker Placement; A Case Report and Systematic Review/R. Sharma, Wilkes-Barre, PA**
- 1112 **Inadvertent Yet Complete Drainage of a Malignant Lung Abscess Using Linear Endobronchial Ultrasound (EBUS)/G.E. Ortiz-Jaimes, Rochester, MN**

- 1113 **Eloesser Flap - An Innovative Option to Treat Broncho-Pleural Fistula/A.** Sinha Ray, Omaha, NE
- 1114 **Gastric Mucormycosis in a Liver Transplant Patient Presenting With Perforation and Pleural Extension/S.** Mayer, Lone Tree, CO
- 1115 **Sealing the Leak: A Novel Multidisciplinary Approach to Non-surgical Management of Pancreaticobronchial Fistula/M.** Lucki, Los Angeles, CA
- 1116 **Pancreatopleural Fistula With Massive Pleural Effusion: A Case Report/J.** Rose, Dallas, TX
- 1117 **Four-year Follow-up of a Case of Yellow Nail Syndrome With IgM Deficiency/S.** Nagpal, Johnson, TN
- 1118 **High Low Chylo: A Case Demonstrating the Use of Lipoprotein Electrophoresis to Diagnose Chylothorax Following Endoscopic Sleeve Gastrectomy/F.** Plastikwala, Charlottesville, VA
- 1119 **Chylothorax After Thoracic Radiation Therapy/J.** Rowell, Burlington, VT
- 1120 **Malignant Myelomatous Pleural Effusion: An Indicator of Poor Prognosis/D.** Rongo, Dallas, TX
- 1121 **A Rare Cause Of Bilateral Pleural Effusions/B.** Reuland, New York, NY
- 1122 **Which Drug Is It? Valproic Acid Mediated Eosinophilic Pleural Effusion in a Patient on Multiple Anti-epileptics/K.Z.** Abbas, Cleveland, OH
- 1123 **Colchicine For Pleuritic Chest Pain Secondary to Pulmonary Infarction Caused by Pulmonary Embolism/R.** Rani, Washington, DC
- 102 **Characteristics and Mortality of Patients With Septic Cardiomyopathy Compared to Those With Septic Shock/M.M.** Cirulis, Salt Lake City, UT
- 103 **Validation of Lung Ultrasound to Predict Respiratory Failure Among Hospitalized Adults With Sepsis/E.** Ponce, Miami, FL
- 104 **Unsupervised Classification of Host Response Biomarkers Reveals HIV-driven Prognostic Subgroups Among Adults With Malaria-associated Sepsis in Uganda/P.** Seekaew, New York, NY
- 105 **Time-series Machine Learning Approach to Sepsis Prediction in the Intensive Care Unit/I.** Sears, Providence, RI
- 106 **Thiamine for Renal Protection in Septic Shock: A Randomized Trial/A.** Moskowitz, Bronx, NY
- 107 **Physician-Level Variation in Steroid Prescribing Practices in Septic Shock: A Retrospective Cohort Study Using a Multi-Hospital Electronic Health Record/J.S.** Minturn, Pittsburgh, PA
- 108 **Distinct Neutrophil Phenotypes in Sepsis Patients and Associations With Clinical Outcomes and Sources of Sepsis/S.** Pettigrew, Philadelphia, PA
- 109 **Use of Phenylephrine Compared to Norepinephrine in Patients With Sepsis; a Meta-analysis of Mortality and Review of Current Literature/Y.** Ishisaka, New York, NY
- 110 **In Septic Patients, Early Treatment With Anti-anaerobic Antibiotics Increases 90-day Mortality in an Instrumental Variable Analysis/R.** Chanderraj, Ann Arbor, MI
- 111 **A Retrospective Cohort Study Assessing Respiratory Outcomes in Patients With Sepsis Secondary to Pneumonia Who Achieved ≥ 30 CC/KG Fluid Goals/H.J.** Young, Fairborn, OH
- 112 **Diagnostic Utility of Urinary Glycosaminoglycan Levels in Septic Shock Patients: Secondary Analysis of Fluid Responsiveness Evaluation in Sepsis Hypotension and Shock (FRESH) Trial/A.** Longino, Aurora, CO
- 113 **Insurance Status and Illness Severity on Emergency Department Presentation Among Patients With Community-acquired Sepsis/A.** Bowman, Salt Lake City, UT
- 114 **Disseminated Intravascular Coagulation (DIC) in Septic Shock Patients: An Analysis of Disparities in Patient Demographics and In-hospital Outcomes/K.** Shankar, Darby, PA
- 115 **Understanding Practice Variation When the Evidence Is Uncertain: A Longitudinal Survey of Critical Care Providers Steroid Use in Septic Shock/K.** Soni, Pittsburgh, PA
- 116 **Hospital-based Sepsis Policies for Early Recognition and Treatment: A Multi-hospital Survey in Michigan/M.K.** Loser, Ann Arbor, MI

BASIC • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

D25 TOPICS IN SEPSIS AND SEPTIC SHOCK

8:00 a.m. - 10:00 a.m. **Marriott Marquis Washington**

Marquis Ballroom, Salons 1-2 (Level M2)

Poster Viewing 8:00-8:45

Discussion 8:45-10:00

Chairing: M.P. Kerlin, MD, MS, Philadelphia, PA
M.C. Ferrera, MD, Boston, MA
S. Bhavani, MD, Atlanta, GA

- 101 **The Presence of Malignancy Modifies the Association Between Inflammatory Phenotype and Mortality in a Prospective Study of Critically Ill Septic Patients/L.** Ronner, Philadelphia, PA

- 117 **Development and Validation of a Metabolomic Pipeline to Identify Novel Diagnostic and Therapeutic Targets in Antibiotic Resistant Bacterial Infections**/J.R. Mayers, Boston, MA
- 118 **Plasma Interleukin-6 Concentrations Demonstrate Genetic Regulation Without Causal Effect on Mortality**/T.K. Jones, Philadelphia, PA
- 119 **A New Model for Diagnosing Sepsis-induced Disseminated Intravascular Coagulation (DIC) in Patients With Coagulopathy of Liver Disease—Moving Away From Factor VIII (FVIII) and International Society on Thrombosis and Hemostasis (ISTH) DIC Scores**/C. Allen, New Haven, CT
- 120 **Characterization of the Gastric Microbiome in Sepsis Within a Randomized Clinical Trial of Early Enteral Nutrients**/S. Nath, Pittsburgh, PA
- 121 **Fluid Restriction Vs Higher Volume Resuscitation in Patients With Septic Shock: An Updated Systematic Review and Meta-analysis**/N. Wachter, Fort Lauderdale, FL
- 122 **Variation in Hospital Patterns of Early Testing for Sepsis-associated DIC**/B. Pang, Boston, MA
- 123 **Latent Class Phenotypes Predict Therapeutic Response to Acetaminophen in Sepsis Patients With Elevated Cell-Free Hemoglobin: A Reanalysis of the Across Trial**/L.B. Ware, Nashville, TN
- 124 **Diagnostic Performance of Monocyte Distribution Width for Early Sepsis Detection in the Hospital Setting: A Systematic Review and Meta-analysis**/G.J. Eisinger, Columbus, OH
- 1002 **Characteristics of Adults With a History of Severe Childhood Asthma - A Cohort Study With a 60-year Follow-up**/O. Savran, Hvidovre, Denmark
- 1003 **Analysis of Hospitalization Outcomes in Patients With Asthma-COPD Overlap Syndrome**/M. Modak, Oklahoma City, OK
- 1004 **Airway Tree Caliber and Progression of Emphysema in MESA Air and Lung Study**/C. Sack, Seattle, WA
- 1005 **Association of Airway Tree Caliber With Serum Interleukin-6 Among Older Adults: The Multi-ethnic Study of Atherosclerosis (MESA) Lung Study**/C.G. Murphy, New York, NY
- 1006 **The Association of Long-term PM2.5 Exposure and Racial Disparities in Mortality in COPD**/C. Robichaux, Minneapolis, MN
- 1007 **Association of Mucus Hydration and Indoor Air Pollution With Mucociliary Clearance in Individuals With COPD**/L.M. Paulin, Lebanon, NH
- 1008 **Air Pollution May Increase Respiratory Viral Infection in Patients With Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease**/K.H. Min, Seoul, Korea, Republic of
- 1009 **Profiles of Exposure to Air Pollution From Multiple Sources and Respiratory Outcomes in Middle Age**/D.S. Bui, Melbourne, Australia
- 1010 **Vitamin D Status Modifies the Association of Indoor Particulate Matter With Morbidity in Obese Adults With Chronic Obstructive Pulmonary Disease**/W. Lorzio, Baltimore, MD
- 1011 **The Contribution of Social and Environmental Factors for Lung Function Decline in Chronic Obstructive Pulmonary Disease: Longitudinal Analysis of Electronic Medical Records Data**/G.R. Oates, Birmingham, AL
- 1012 **Measuring Disparities in Virtual Healthcare and Outcomes in Chronic Obstructive Pulmonary Disease Patients During the COVID-19 Pandemic**/M.R. Cherabuddi, Detroit, MI
- 1013 **Sex, Tobacco, and Chronic Obstructive Pulmonary Disease: Multivariable Analysis of Two Large National Datasets**/A. Steinberg, Lebanon, NH
- 1014 **Sex-related Differences, Mortality and FEV1 Decline Among COPD Patients: The French Palomb Cohort**/N. Jestin-Guyon, Bordeaux, France
- 1015 **Rare Alpha-1 Antitrypsin Deficiency Variants Detected in Ireland**/T.P. Carroll, Dublin, Ireland

BEHAVIORAL • CLINICAL

POSTER DISCUSSION SESSION

D26 RISK FACTORS FOR COPD AND LUNG CANCER: BEYOND TOBACCO

8:00 a.m. - 10:00 a.m. **Marriott Marquis Washington**

Marquis Ballroom, Salons 9-10 (Level M2)

Poster Viewing 8:00-8:45

Discussion 8:45-10:00

Chairing: S. Raju, MD, MPH, Baltimore, MD
C. Sack, MD, MPH, Seattle, WA

1001 **Risk of Hospitalization Due to Lung Cancer Among Smokers Not Recommended for Annual LDCT Screening by the 2021 USPSTF Guidelines**/J.A. Nations, Washington, DC

- 1016** A Real-World Study Assessing the Medical Cost Burden of Chronic Obstructive Pulmonary Disease (COPD) in the United States From 2016-2019 and Projections Through 2029: Analysis of Medical Expenditure Panel Survey (MEPS) Data/D.M. Mannino, Lexington, KY
- 1017** Trends in Prevalence of Chronic Obstructive Pulmonary Disease in Immigrants to Ontario, Canada, 2002-2019/J. Sugarman, Toronto, Canada
- 1018** Gold 1 Is a Highly Transitory Disease Stage in COPD: A Multistate Transition Modelling Analysis of the COPD Gene Cohort/L.M. Sánchez Romero, Washington, DC
- 1019** Investigating the Impact of Using Definitions of Exacerbation of COPD of Varying Validity on Study Findings in Routinely Collected Electronic Healthcare Records/H. Whittaker, London, United Kingdom
- 1020** Disease Burden and Quality-of-Life (QoL) for Chronic Obstructive Pulmonary Disease (COPD) in the US - Evidence From the Medical Expenditure Panel Survey (MEPS) From 2016-2019/M.H. Roberts, Albuquerque, NM
- 1021** Effects of Capsaicin on Permeability and Ciliary Function of Bronchial Epithelial Cells of Patients With Chronic Obstructive Pulmonary Disease (COPD)/H. Bayram, Istanbul, Turkey
- 1022** The Association Between Inhaled Corticosteroid Therapy and Future Cardiovascular Events in People With Chronic Obstructive Pulmonary Disease (COPD)/A.E. Ioannides, London, United Kingdom
- 1023** The Relationship Between Cardiac Troponin in Hospitalised Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients With Major Adverse Cardiac Events (MACE) and COPD Readmissions/C. Kallis, London, United Kingdom
- 1024** Excess Incidence of Coronary Heart Disease Mortality Attributable to Lower Lung Function/S.P. Bhatt, Birmingham, AL
- Chairing:** C. Leon Astudillo, MD, Gainesville, FL
J.B. Taylor, MD, MSCR, ATSF, Pittsburgh, PA
J.M. Gaffin, MD, Boston, MA
- 901** Factors Associated With Functional Status Decline in Mechanically Ventilated PICU Bronchiolitis Patients Six Months Post-discharge/M. Fischer, Cleveland, OH
- 902** Epidemiology of Complications Among Hospitalized Children With Hereditary Hemorrhagic Telangiectasia: A Kids' Inpatient Database Study/P.-Y. Tsou, Boston, MA
- 903** Functional Status at Waitlist Registration Is Associated With Probability of Lung Transplant in Pediatrics/A. Himebauch, Philadelphia, PA
- 904** Determinants of Acceptance of COVID-19 Vaccine in Children: Does Pediatrician's Opinion Matter?/P. Mondal, Hershey, PA
- 905** COVID-19 Government Mandated Public Health Measures Associated With Increased Mask Use in Children/L. Hahn, Edmonton, Canada
- 906** Pediatric Patients Diagnosed as Overweight or Obese Are More Likely to Be Diagnosed With Dyspnea/L.L. Sandy, Dallas, TX
- 907** How Do Children and Adolescents Communicate the Experience of Dyspnea?/J.W. Holm, Minneapolis, MN
- 908** Evaluating Dyspnea in Adolescents and Young Adults Using a Combined Isaac Questionnaire and Dalhousie Pictorial Scale Survey/G. Alvernaz, Minneapolis, MN
- 909** Understanding the Experiences of Caregivers of Children With Spinal Muscular Atrophy in the Era of Disease-modifying Therapies/L. Xiao, Toronto, Canada
- 910** Improving Resident Knowledge and Comfort With Screening and Counseling of Adolescent Vaping/E. Sandler, Baltimore, MD
- 911** Developing an Entrustable Professional Activities-based Pediatric Pulmonology Fellowship Program/A. Singh, Kansas City, MO
- 912** Implementing Kern's Model to Define Strategies on Improving Fellow Recruitment and Quality of a Small Pediatric Pulmonology Fellowship Program/A. Singh, Kansas City, MO
- 913** Medical-scholastic Partnership for Youth Understanding of the Concerns Over Electronic Cigarette Information: A Community Engagement Project/G. Holder, Baltimore, MD
- 914** Participant Perspectives on the Implementation of a School-Linked Text Message Intervention to Improve Pediatric Asthma Medication Adherence/M. Trivedi, Worcester, MA
- 915** Creation of a Tracheostomy Emergency and Airway Management Card/J. White, Milwaukee, WI

CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

D27 IMPROVING PEDIATRIC PULMONOLOGY CARE: BEHAVIORAL AND HEALTH SERVICES RESEARCH

8:00 a.m. - 10:00 a.m. Marriott Marquis Washington

Marquis Ballroom, Salons 3-4 (Level M2)

Poster Viewing 8:00-8:45

Discussion 8:45-10:00

- 916** **The Role of a Pediatric Tracheostomy Committee: An Experience With a Dedicated Multi-disciplinary Counseling Committee at a Tertiary Referral Center/F.D. Birru, Edmonton, Canada**
- 917** **Reducing Hospitalizations for Children on Chronic Invasive Mechanical Ventilation/W.S. Stoudemire, Chapel Hill, NC**
- 918** **Continuous Positive Airway Pressure Weaning Guidelines Implementation Improves Respiratory Outcomes in Preterm Infants/S. Mattikalli, Hershey, PA**
- 919** **Using the Electronic Patient Portal to Collect Patient-reported Data for Pediatric Asthma Management/M.K. Ross, Los Angeles, CA**
- 920** **Project Breathe: Recurrent Admissions for Asthma Exacerbation. A Quality Improvement Project/B. Prasanna Kumar, Buffalo, NY**
- 921** **Characterization of Pediatric Chronic Cough Via Electronic Medical Record Database/K. Gavin, Kansas City, MO**
- 922** **Feasibility of Using Social Media to Provide Pediatric Pulmonary Patient Education/N. Ba Sharahil, Madison, WI**
- 923** **The Effects on Diet and Exercise in Teenagers: Results From a Social Media Survey/N. Malhotra, La Jolla, CA**
- 924** **Developing a Novel Pulmonary Assessment Module for Spinal Muscular Atrophy/O.H. Mayer, Philadelphia, PA**
- 925** **Parental Depression, Medication Adherence, and Asthma Control Among Children in Low-Income Urban Households/M.G. Mcinerney, Baltimore, MD**
- 502** **Transitioning Patients With Pulmonary Arterial Hypertension From Parenteral Prostacyclin Therapy to Oral Selexipag: A Multi-center Retrospective Cohort Study/B. Budhram, Calgary, Canada**
- 503** **A Mobile Health Intervention to Increase Physical Activity in Pulmonary Arterial Hypertension Is Associated With Alterations in Fatty Acid and Glucose Metabolism/N.J. Shelburne, Nashville, TN**
- 504** **Hemodynamic Characteristics of Patients With Exercise Pulmonary Hypertension: Data From a Single Center-/D.F. Condon, Boston, MA**
- 505** **The Safety and Efficacy of Inhaled Treprostinil in Patients With PH-ILD on Supplemental Oxygen: A Post-hoc Analysis of the INCREASE Study/S. Sahay, Houston, TX**
- 506** **Electrocardiography (ECG) Findings in Clinical Trials of Pulmonary Arterial Hypertension/J. Minhas, Philadelphia, PA**
- 507** **Validation Study for the Accuracy of Echocardiographic Indices of Right Ventricular Function in Pulmonary Hypertension/H. Shima, Sapporo, Japan**
- 508** **A Comparison of Clinical and Real-world Defined Pulmonary Arterial Hypertension (PAH) Cohorts in Electronic Health Records (EHR) From the Mayo Clinic/H.M. Dubrock, Rochester, MN**
- 509** **Pulmonary Blood Vessel Volume Is Distributed Into Smaller Vessels in Females Vs. Males/S.P. Wright, Kelowna, Canada**
- 510** **Derivation and Validation of PrePHerred Score to Predict Precapillary Pulmonary Hypertension/H. Deshwal, Morgantown, WV**
- 511** **Changes in the RC Time-constant in Response to Inhaled Nitric Oxide in People With Pulmonary Arterial Hypertension/C.J. Dennis, Stanford, CA**
- 512** **Blood-derived Molecular Signature Could Predict PH in Patients With ILD/D. Harrell, Sacramento, CA**
- 513** **Metabolic Profiling in Pulmonary Arterial Hypertension Associated With Congenital Heart Disease/H. Zhang, Beijing, China**
- 514** **Pulmonary Vascular Pruning on Computed Tomography as a Non-invasive Indicator of Pulmonary Arterial Pressure and Compliance/H. Robertson, Boston, MA**
- 515** **A Meta-analysis: Outcomes in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Congenital Heart Disease (CHD) Receiving PAH Medication/R.A. Krasuski, Durham, NC**
- 516** **Pharmacokinetic Profile of Imatinib Mesylate Formulation (AER-901) Demonstrates Potential for Therapeutic Exposure Levels at Low Doses After Pulmonary Administration/G.C. Burgess, Deerfield, IL**

BASIC • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

D28 HOW CAN WE DO BETTER: EMERGING DIAGNOSTICS AND THERAPEUTICS IN PULMONARY VASCULAR DISEASE

8:00 a.m. - 10:00 a.m. Walter E. Washington Convention Center

Room 151 B (Street Level)

Poster Viewing 8:00-8:45

Discussion 8:45-10:00

Chairing: R. Souza, MD, PhD, Sao Paulo, Brazil
S. Pugliese, MD, Philadelphia, PA
J. Minhas, MD, MS, MBBS, Philadelphia, PA
D. Lachant, DO, ATSF, Rochester, NY

501 A Novel Approach to Clinical Change Endpoints: A Win Ratio Analysis of the INCREASE Trial/S.D. Nathan, Falls Church, VA

- 517 **Predictors of Secondary Pulmonary Hypertension Admissions in Females: An Artificial Neural Network Analysis of a National Cohort in 2019**/Z.J. Gandhi, Wilkes-Barre, PA
- 518 **Patterns of Escalation to Oral Prostacyclin Pathway Agents Among Patients With Pulmonary Arterial Hypertension on Double Oral Therapy With Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor**/Y. Tsang, Titusville, NJ
- 519 **The Clinical Profiles Associated With Off-label Prescribing of Pulmonary Vasodilatory Therapy in Patients With Group 3 Pulmonary Hypertension: Implications for Pragmatic Clinical Trials**/S.W. Johnson, Boston, MA
- 520 **Cellular Indices May Be Predictive of Bleeding in Patients With Acute Pulmonary Embolism**/S. Gayen, Philadelphia, PA
- 521 **Pulmonary Hypertension: An Unexplored Risk Factor for Stroke in Patients With Atrial Fibrillation**/G. Khattar, Staten Island, NY
- 522 **Iron Status and Red Cell Indices in the Prognosis of Pulmonary Arterial Hypertension**/J. Wilkinson, Los Angeles, CA
- 523 **Can AI-based Pulmonary Vascular Phenotyping on Chest-CT Detect Volume Shifts in Pulmonary Arterial and Venous Blood Volume in Operable and Non-operable Chronic Thromboembolic Pulmonary Hypertension?**/K.A. Boomars, Rotterdam, Netherlands
- 524 **Mortality and Outcomes of Pulmonary Embolism in COVID-19 Hospitalizations, a National Analysis of NIS 2020**/N. Hakobyan, Brooklyn, NY
- 525 **Post-acute Sequelae of SARS Co-V2 and Chronic Fatigue/Myalgic Encephalitis Share Similar Pathophysiologic Mechanisms of Exercise Limitation**/S. Jothi, Tucson, AZ
- 601 **Age-associated Differences in Non-diseased Lung Fibroblast Inflammatory and Extracellular Matrix Processes**/K.O. Nwozor, Vancouver, Canada
- 602 **Primary Human Lung Fibroblasts Alter Collagen Fiber Structure in 3-D Lung Extracellular Matrix-derived Hydrogels in Response to a Fibrotic Microenvironment**/M. Nizamoglu, Groningen, Netherlands
- 603 **Remodeling of Small Airways and Associated Arterial Vasculature Is a Hallmark of Idiopathic Pulmonary Fibrosis**/N. Assadinia, Vancouver, Canada
- 604 **A Cocktail of Idiopathic Pulmonary Fibrosis Associated Soluble Factors Disrupts Epithelial Cell Differentiation**/R. Kortekaas, Groningen, Netherlands
- 605 **Novel Organotypic Lung Triculture Technologies Paving the Way to Personalized Medicine**/P.M. Van Ry, Provo, UT
- 606 **Effect of Local Intratracheal Therapy Using Particleized Nintedanib in a Murine Model of Pulmonary Fibrosis**/K. Suzuki, Nagano, Japan
- 607 **Distinct Idiopathic Pulmonary Fibrosis Associated Transcriptome and Methylome Changes in Airway and Parenchymal Fibroblasts**/P. Rajasekar, Nottingham, United Kingdom
- 608 **Potential Role of Circadian Clock Modulator in Bleomycin-induced Pulmonary Fibrosis**/C. Prasad, Kansas City, KS
- 609 **Interleukin-1 Alpha Counteracts Transforming Growth Factor- β 1 and β 2 Signaling in Lung Extracellular Matrix Remodeling**/K. Usman, Vancouver, Canada
- 610 **Development of Angiotensin II Type 2 Receptor Agonists 'ATrAGs' for Treatment of Pulmonary Fibrosis and Pulmonary Hypertension**/R. Batta, Stockholm, Sweden
- 611 **Developing Decellularized Tissue Hydrogel as a Culture Supplement for Building a Pulmonary Fibrosis Organoid Model**/A.J. Saxton, Provo, UT
- 612 **Endoplasmic Reticulum Stress Induces Cellular Senescence in Human Lung Fibroblasts**/M.L. Koloko Ngassie, Rochester, MN
- 613 **An Agent-based Model of Fibrosis on Lung Architecture**/D. Casey, Burlington, VT
- 614 **High-fat Diet Feeding Promotes More Severe and Durable Lung Fibrotic Injury in a Bleomycin-induced and Spirometry-confirmed Mouse Model of Idiopathic Pulmonary Fibrosis (IPF)**/J. Bousamaki, Hørsholm, Denmark
- 615 **Dual High-throughput, Automated Analysis of Histomorphometric Markers of Fibrosis and Emphysema in Two Bleomycin-induced Mouse Models of Idiopathic Pulmonary Fibrosis**/C. Serdjebi, Marseille, France

BASIC • TRANSLATIONAL**POSTER DISCUSSION SESSION****D29 TRANSLATIONAL RESEARCH IN IPF**8:00 a.m. - 10:00 a.m. Walter E. Washington Convention Center

Room 201 (Level 2)

Poster Viewing 8:00-8:45

Discussion 8:45-10:00

Chairing: J.E. Peabody Lever, BA, PhD, Birmingham, AL
J. Joshua, MD, San Diego, CA

- 616 **Clinical and Radiographic Predictors of Mortality or Transplant in Patients With Idiopathic Pulmonary Fibrosis**/S. Macisaac, Hamilton, Canada
- 617 **The Addition of Imaging Improves Mortality Prediction in IPF**/K.R. Kirov, Cambridge, United Kingdom
- 618 **Automated Image Analysis of Vascular and Fibrotic Lung Volumes Shows Association With IPF Mortality**/K.R. Kirov, Cambridge, United Kingdom
- 619 **Microscopic Validation of Deep Learning Based Texture Classification of Idiopathic Pulmonary Fibrosis Patterns Visible on Thoracic Computed Tomography**/D.M. Vasilescu, Vancouver, Canada
- 620 **Patient Specific Metrics of Tracheal Deformation, Predicted Toxicant Uptake and Histopathology in IPF**/S. Royce, Clayton, Australia
- 621 **Inhibition of Poly (ADP-Ribose) Polymerase Attenuates Bleomycin-Induced Pulmonary Fibrosis in a Sheep Model**/H.B. Derseh, Berwick, Australia
- 622 **Multifunctional Liposomes to Improve Pulmonary Administration of Antifibrotic Drugs**/M. Piñol, Madrid, Spain
- 623 **Brilaroxazine Efficacy in a Bleomycin-induced Rodent Model of Idiopathic Pulmonary Fibrosis**/L. Bhat, Cupertino, CA
- 624 **Magnetoliposomes for Monitoring Pulmonary Administration of Antifibrotic Drugs**/L. Fernández Méndez, Leioa, Spain
- 202 **Sleep-related Hypoxemia in COPD Patients Is Associated With Sarcopenia: An Analysis of the Cleveland Clinic Sleep Registry**/A. Attaway, Cleveland, OH
- 203 **Impact of Objective Positive Airway Pressure Adherence on Healthcare Resource Utilization and Costs Among Individuals With Comorbid Obstructive Sleep Apnea and Depression: A National Analysis**/E.M. Wickwire, Baltimore, MD
- 204 **Predictors of 90-day Adherence to Positive Airway Pressure Therapy Among a National Sample of Individuals With Comorbid Depression and Obstructive Sleep Apnea**/E.M. Wickwire, Baltimore, MD
- 205 **Sex Differences in Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease Overlap Syndrome**/M.M. Lowery, Gainesville, FL
- 206 **Dose-dependent Effects of Positive Airway Pressure Therapy on Daytime Sleepiness and Blood Pressure in Type 2 Diabetes and Obstructive Sleep Apnea**/R.N. Aurora, New York, NY
- 207 **Performance of Claims-Based Algorithms for Adherence to Positive Airway Pressure Therapy in Commercially Insured Patients With Obstructive Sleep Apnea**/N. Alpert, San Diego, CA
- 208 **Associations Between Sleep Apnea and Acute COVID-19 Infection Severity Are Sex- and Date-specific**/B.E. Cade, Boston, MA
- 209 **Longitudinal Maternal Sleep Position Patterns and Fetal Growth Velocity in Women With Overweight or Obesity**/J. Katz, Providence, RI
- 210 **The Long-term Impacts of the COVID-19 Pandemic on Obstructive Sleep Apnea (OSA)-related Healthcare**/T. Kendzerska, Ottawa, Canada
- 211 **Incident OSA Increases Repolarization Heterogeneity During Sleep**/A.L. Koch, Miami, FL
- 212 **Sleep Quality as a Novel Mediator of Reductions in Daytime Breathlessness With Low-dose Morphine in People With Chronic Obstructive Pulmonary Disease**/D.J. Eckert, Bedford Park, Australia
- 213 **Diagnosis and Management of Patients Hospitalized With Acute-on-Chronic Hypercapnic Respiratory Failure Due to Obesity Hypoventilation Syndrome**/J.M. Neborak, Chicago, IL
- 214 **Prevalence of Sleep Apnoea in Patients With Type 1 Diabetes and Its Association With Comorbidities and Diabetic Complications: A French Nationwide Prospective Study**/J.-L. Pépin, Grenoble Cedex 9, France
- 215 **Daytime Sleepiness and Subclinical Atherosclerosis in OSA**/J.M. Marin, Zaragoza, Spain

BEHAVIORAL • CLINICAL • TRANSLATIONAL
POSTER DISCUSSION SESSION
D30 INTEGRATING OSA AND COMORBIDITIES FOR EFFECTIVE THERAPIES
8:00 a.m. - 10:00 a.m. Walter E. Washington Convention Center
Room 103 A-B (Street Level)
Poster Viewing 8:00-8:45
Discussion 8:45-10:00

Chairing: H. Schotland, MD, ATSF, New York, NY
 S.R. Pendharkar, MD, MSc, ATSF, Calgary, Canada
 B.J. Yee, MBChB, PhD, Sydney, Australia
 B. Selim, MD, Rochester, MN
 M. Macrea, MD, Salem, VA

201 **Test Performance of Serum Bicarbonate in Identifying Hypercapnia Across Settings and Diseases**/B.W. Locke, Salt Lake City, UT

- 216 **OSA Interferes With Esketamine Treatment for PTSD in Veterans/B. Nokes, La Jolla, CA**
- 217 **SDB Is Associated With Worsened Pain and Poor Sleep in Patients Using Opioids/J.E. Orr, La Jolla, CA**
- 218 **Effect of Lemborexant Treatment on Polysomnographic Sleep Measures in Adults With Mild to Severe Obstructive Sleep Apnea/M. Moline, Nutley, NJ**
- 219 **Development and Validation of a Clinical Score to Estimate 10-year Mortality And Major Non-fatal Cardiovascular Events (MACE) in Obstructive Sleep Apnea Patients/M.J. Divo, Boston, MA**
- 220 **Modeling the Effects of Simulated Obstructive Apnea on Elastic Properties of Lung in Persons With Asthma/S. Chavoshian, Toronto, Canada**

CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

D31 IMAGING, BIOMARKERS, AND MACHINE LEARNING IN LUNG CANCER

8:00 a.m. - 10:00 a.m. Walter E. Washington Convention Center

Room 144 A-C (Street Level)

Poster Viewing 8:00-8:45

Discussion 8:45-10:00

Chairing: M.N. Kammer, PhD, Nashville, TN
P. Nana-Sinkam, MD, Richmond, VA

- 301 **Patient Tissue Derived Ex Vivo Lung Tumor Models for Investigation of Tumor-Stromal Interactions and Response to Immune Targeted Therapy/K. Goliwas, Birmingham, AL**
- 302 **Identifying Patients With Pulmonary Nodules From CT Radiology Reports Using Natural Language Processing (NLP)/T.L. Dotson, Winston-Salem, NC**
- 303 **A Modified Combined Biomarker Model for the Risk Stratification of Indeterminate Pulmonary Nodules/R. Paez, Nashville, TN**
- 304 **EHR-driven Machine-learning Model to Distinguish Benign From Malignant Pulmonary Nodules/T.A. Lasko, Nashville, TN**
- 305 **Usefulness of Protocadherin GA12 and Cysteine ? Dioxygenase Type 1 Methylation Biomarkers Analysis in the Diagnosis of Lung Cancer/D. Kang, Daejeon, Korea, Republic of**
- 306 **Theoretical Net Benefit of a Radiomics-based Computer Aided Diagnosis Tool for Risk Stratification of Pulmonary Nodules/R.Y. Kim, Philadelphia, PA**

- 307 **Characterization of Volume Doubling Times of Lung Adenocarcinomas With Automated, Artificial Intelligence Volumetric Lesion Segmentation and Tracking/A. Cypro, San Diego, CA**
- 308 **Liquid Biopsy in Lung Cancer. An Investigation of Methylated BCAT1 and IKZF-1 in Circulating Cell-free DNA in Lung Adenocarcinoma/A.R. Rose, Bedford Park, Australia**
- 309 **Image Reconstruction of Pulmonary Nodules to Interrogate Deep Neural Networks Using Masked Autoencoders/A.H. Masquelin, Burlington, VT**
- 310 **The Central Role Neck Ultrasound and Lymph Node Sampling Can Play in Modern Lung Cancer Diagnostics/L. Power, Galway, Ireland**
- 311 **Bronchoscopic Pathological Confirmation of Incidental Chest Lesions on Dedicated Nuclear Medicine Prostate Imaging: True and False Positives in the Detection of Metastatic Prostate Cancer/K. Kolbe, Ann Arbor, MI**
- 312 **Computerized Tomography-guided Transthoracic Biopsy in the Diagnosis of Hematologic Malignancies/M.J. Cavaco, Torres Vedras, Portugal**
- 313 **Exosomes Contribution to the Establishment of the Pre-Metastatic Niche Through the Induction of the Epithelial-to-Mesenchymal Transition in Lymphangiomyomatosis (LAM): Implication of the Complement Cascade/A. Jouida, Dublin, Ireland**
- 314 **Grape Seed Procyanidin Extract Modulates Inflammatory Mediators Within the Lungs of Heavy Active and Former Smokers/J.T. Mao, San Diego, CA**
- 315 **Kynureninase Upregulation Is a Feature of NRF2-upregulated Lung Cancers and Is Associated With Tumor Immunosuppression and Poorer Prognosis/E. Ostrin, Houston, TX**
- 316 **Cigarette Smoke Activates the Angiogenic Switch in the Lung Cancer Field by Downregulating MicroRNA-1/A. Korde, New Haven, CT**
- 317 **Demonstrating Clinical Utility for a Nasal Genomic Classifier for Lung Nodules: Addressing the Clinical Trial Learning Curve With a Familiarization Phase/F.K. Madhani-Lovely, Reno, NV**



ATS
2023

INTERNATIONAL
CONFERENCE
WASHINGTON, DC
conference.thoracic.org

Wednesday Mid-day, May 24

CLINICAL

ADULT CLINICAL CORE CURRICULUM

CME Credits Available: 1.5
MOC Points Available: 1.5

CC5 PULMONARY CLINICAL CORE CURRICULUM

Education Committee

10:00 AM - 11:30 AM **Walter E. Washington Convention Center**

Hall E (Level 2)

Target Audience

Clinicians who are engaged in maintenance of certification activities

Objectives

At the conclusion of this session, the participant will be able to:

- describe updates in the diagnosis and management of mild, moderate, and severe asthma in 2023
- identify the local and global impact of one's environment on asthma management
- describe best practices for asthma management in the pregnant and post-partum woman

Chairing: G. Garrison, MD, Burlington, VT
J. Cho, MD, Iowa City, IA

10:00 **Everyday Asthma: Updates to the Diagnosis, Classification, and Management of Mild to Moderate Asthma**

J. Barry, MD, MPH, San Diego, CA

10:25 **Stepping on the Pedal: Approaches to the Management of Severe and Uncontrolled Asthma**

L. Eggert, MD, Stanford, CA

10:50 **Exasperating Exacerbations: Management of Severe Asthma Exacerbations**

M.C. McGregor, MD, St. Louis, MO

11:15 **Questions and Answers**

DIVISION OF LUNG DISEASES, NHLBI/NIH

OUTSIDE ORGANIZATION SESSION

L22 THE NHLBI LUNG TRANSPLANT CONSORTIUM

10:30 AM - 11:30 AM **Walter E. Washington Convention Center**

Room 202 B (Level 2)

Target Audience

Those with research interests involving the study of lung transplant donors or recipients.

Objectives

At the conclusion of this session, the participant will be able to:

- learn about the impact of certain clinical practices on, and the value of collecting particular data elements to inform, donor lung utilization and early post-transplant outcomes in lung transplant recipients.
- increase awareness among the broader lung transplant research community of the availability of the consortium's resources to support ancillary studies.
- be able to more appropriately design and control for clinical variables during the conduct of multi-site research studies involving lung transplant donors or recipients.

This session will review recent research findings generated by investigators within the NHLBI Lung Transplant Consortium, which encompasses a series of observational cohort studies that aim to understand the impact of site-specific lung transplant selection criteria and clinical management strategies on donor lung utilization and/or early post-transplant outcomes in recipients.

Chairing: M. Craig, PhD, Bethesda, MD
J.D. Christie, MD, MS, ATSF, Philadelphia, PA

10:30 **The NHLBI Lung Transplant Consortium Data Coordinating Center**

S.M. Palmer, MD, MHS, Durham, NC

10:42 **Clinical and Biological Factors Predicting Lung Transplant Textbook Outcomes**

L.D. Snyder, MD, Durham, NC

10:54 **Peri-operative Factors That Drive Cell-Free Hemoglobin-mediated Primary Graft Dysfunction**

L.B. Ware, MD, ATSF, Nashville, TN

11:06 The Impact of Body Composition on Peri-Operative and Patient-Centered Outcomes in Lung Transplantation
J.P. Singer, MD, MSci, san francisco, CA

11:18 The Clinical and Molecular Impacts of Lung Primary Graft Dysfunction
J.F. Mcdyer, MD, Pittsburgh, PA

**NATIONAL INSTITUTE OF
ENVIRONMENTAL HEALTH SCIENCES, NIH**

OUTSIDE ORGANIZATION SESSION

**L23 INFLAMMATION RESOLUTION
PATHWAYS IN ENVIRONMENTAL
PULMONARY HEALTH AND MORBIDITY**

10:30 AM - 11:30 AM **Walter E. Washington Convention Center**
Room 152 A-B (Street Level)

Target Audience

Clinicians, clinician scientists, basic research scientists, fellows and residents

Objectives

At the conclusion of this session, the participant will be able to:

- gain knowledge on how exposure to environmental agents/chemicals may initiate and exacerbate preexisting inflammatory status
- role of chronic exposure to environmental agents in chronic lung diseases
- understanding of emerging and novel pathways involved in inflammation resolution

The emerging interplay between unresolved inflammation and environmentally induced perturbations to inflammation resolution suggests exposure and inflammatory activation or exacerbation contributes to chronic lung disease progression. This session will provide an overview on the current state-of-science on inflammation resolution biology, and how chronic exposure to air pollutants, ozone, and fine particulate matter impact these processes. It will also provide an overview on how NIEHS and other NIH Institutes encourage research in this area to support potential therapeutic and interventional strategies aimed at promoting inflammation resolution to reduce environmental contributions to pulmonary morbidity and mortality.

Chairing: S.S. Nadadur, PhD, Research Triangle Park, NC
B.D. Levy, MD, ATSF, Boston, MA

10:30 Introduction
S.S. Nadadur, PhD, Research Triangle Park, NC

10:36 SPM Pathway Responses to Lung Environmental Challenge
B.D. Levy, MD, ATSF, Boston, MA

10:52 Role of Pro-Resolution Macrophages in Chronic Ozone Exposure Pulmonary Effectss
D.L. Laskin, PhD, Piscataway, NJ

11:08 Arachidonic Acid Metabolic Pathways and Resolution Versus Progression of the Cardiometabolic Toxicity Induced by Particulate Matter.
J.A. Araujo, MD, PhD, Los Angeles, CA

11:24 Discussion
S.S. Nadadur, PhD, Research Triangle Park, NC

**AMERICAN LUNG ASSOCIATION
AIRWAYS CLINICAL RESEARCH CENTERS**

OUTSIDE ORGANIZATION SESSION

**L24 STUDY UPDATES FROM THE AMERICAN
LUNG ASSOCIATION'S AIRWAY CLINICAL
RESEARCH CENTERS NETWORK**

10:30 AM - 11:30 AM **Walter E. Washington Convention Center**
Room 202 A (Level 2)

Target Audience

Physicians, clinical scientists, nurses, paraprofessionals, educators, health care providers

Objectives

At the conclusion of this session, the participant will be able to:

- better counsel patients about the approach to management of asthma in obese patients.
- describe the use of biomarkers for assessing the progression of emphysema.
- incorporate home spirometry testing in management of patients with lung disease.

The purpose of the session is to discuss ongoing research initiatives within the American Lung Association Airways Clinical Research Centers network.

Chairing: L.J. Smith, MD, Chicago, IL
R.A. Wise, MD, Baltimore, MD

10:30 Introduction
L.J. Smith, MD, Chicago, IL

10:35 Relationship Between Cystic Fibrosis Transmembrane Conductance Regulator Function, Ventilation Heterogeneity, & Airway Obstruction in Young Adults
S.S. Krishnan, MD, MPH, Valhalla, NY

10:45 TRIM Results Update
C.R. Morris, PhD, Burlington, VT

10:55 Home Spirometry Validation Study
E. Sugar, PhD, Baltimore, MD

11:05 Markers of Lung Degradation and Emphysema: A Pilot Study

J.M. Wells, MD, MSPH, Birmingham, AL

11:15 Questions

R.A. Wise, MD, Baltimore, MD

DIVISION OF LUNG DISEASES, NHLBI/NIH**OUTSIDE ORGANIZATION SESSION****L25 ELAFIN: FROM TRANSLATIONAL PPG TO CLINICAL TRIAL****10:30 AM - 11:30 AM** **Walter E. Washington Convention Center****Room 147 A-B (Street Level)****Target Audience**

Clinicians, basic scientists, nurses, technologists and trainees interested in pulmonary vascular disease trials

Objectives

At the conclusion of this session, the participant will be able to:

- learn about ways to successfully translate preclinical laboratory findings into IND-enabling work for the development of therapeutics to treat PAH
- learn about Phase I and II clinical trial design for pulmonary arterial hypertension
- learn about the importance of biomarker design and inclusion in clinical studies to monitor disease progression and treatment effects

This session will discuss results derived from an NHLBI-funded Translational Program Project Grant (TPPG) that supported pre-clinical studies of elafin in chronic lung disease of infancy, lung transplant rejection, and pulmonary arterial hypertension, and successfully translated those findings into follow-on IND-enabling safety pharmacology and toxicology studies and a subsequent Phase I clinical trial of Elafin use in healthy subjects. Plans for a Phase II clinical trial in PAH patients will also be discussed, with a description of relevant biomarkers and planned endpoints.

Chairing: L. Xiao, MD, PhD, Bethesda, MD
A. Hemnes, MD, ATSF, Nashville, TN

10:30 The Role of Elastase and Elafin in PAH and Other Respiratory Diseases

M. Rabinovitch, MD, Stanford, CA

10:45 High-Dimensional Single-Cell Imaging Maps Distinct Inflammatory Cell Subsets to PAH Vasculopathy

S. Ferrian, PhD, Stanford, United States

11:00 Phase I and Phase II Clinical Trial Design and Implementation in PAH

R.T. Zamanian, MD, FCCP, Stanford, CA

11:15 Identifying Novel Biomarkers for Elafin and other PAH Therapies

A. Sweatt, MD, Stanford, CA

U.S. FOOD AND DRUG ADMINISTRATION**OUTSIDE ORGANIZATION SESSION****L26 PULMONARY UPDATE FROM THE US FOOD AND DRUG ADMINISTRATION****10:30 AM - 11:30 AM** **Walter E. Washington Convention Center****Room 204 A-C (Level 2)****Target Audience**

Clinicians in practice, academic researchers, pharmaceutical industry representatives, international regulators

Objectives

At the conclusion of this session, the participant will be able to:

- to provide a better understanding of the regulatory considerations and lessons learned in review of immunomodulators for COVID-19
- to provide a better understanding of regulatory considerations regarding potential changes in asthma management and treatment paradigms
- to provide an overview of recent approval actions, safety issues, and hot topics which arose over the past year in the pulmonary division at FDA.

The most recent FDA actions, including recent drug approvals for pulmonary diseases will be discussed, recent research endeavors, safety issues, and other hot topics that we have navigated over the past year in the Division of Pulmonology, Allergy, and Critical Care in the Office of New Drugs at FDA.

Chairing: B. Karimi-Shah, MD, Silver Spring, MD
S. Seymour, MD, Silver Spring, MD

10:30 Regulatory Considerations in COVID-19 Development Programs: Lessons Learned

K. Puthawala, MD, Silver Spring, MD

10:50 FDA Updates: Highlights From Recent Asthma Approvals

E. Boulos, MD, MPhil, Silver Spring, MD

11:10 Pulmonary Update from the US FDAM

R. Lim, MD, Silver Spring, MD

11:20 Question and Answers

B. Karimi-Shah, MD, Silver Spring, United States

**NATIONAL INSTITUTE OF
ALLERGY AND INFECTIOUS DISEASES, NIH**

OUTSIDE ORGANIZATION SESSION

**L27 AIRWAY OMICS FOR DISEASE
ENDOTYPING AND MANAGEMENT**

10:30 AM - 11:30 AM **Walter E. Washington Convention Center**

Room 145 A-B (Street Level)

Target Audience

Clinical researchers and clinicians

Objectives

At the conclusion of this session, the participant will be able to:

- describe new findings relating nasal airway transcriptomic signatures with disease outcomes in data obtained as part of a randomized placebo-controlled trial of mepolizumab in urban children with exacerbation prone asthma.
- describe the lower airway immune response in patients with severe COVID-19, compare transcriptomic signatures from upper and lower airways in these patients, and identify airway immune signatures associated with disease severity
- describe approaches to integrate nasal transcriptomic and microbiome data in infants with respiratory bronchiolitis to identify endotypes associated with asthma development.

This session will describe results from 3 NIAID-funded programs that utilize omics data collected from the upper and/or lower airway to define disease endotypes, to potentially inform personalized medicine approaches to disease prognosis and/or management.

Chairing: P.M. Becker, MD, Bethesda, MD

10:30 Using Airway Transcriptomics to Identify Pathways Associated with Exacerbation and Responsiveness to Mepolizumab Therapy in Children

M.C. Altman, MD, MPhil, Seattle, WA

10:50 Integrated Analysis of Airway Immune Responses in Severe COVID-19: Results from the IMPACC Cohort

R.R. Montgomery, PhD, New Haven, CT

11:10 Integrated Omics Investigation into the Mechanisms Linking Severe Bronchiolitis During Infancy and the Development of Asthma

K. Hasegawa, MD, MPH, PhD, Boston, MA

DIVISION OF LUNG DISEASES, NHLBI/NIH

OUTSIDE ORGANIZATION SESSION

**L28 COPDGENE: ADVANCES IN COPD
HETEROGENEITY AND PROGRESSION**

10:30 AM - 11:30 AM **Walter E. Washington Convention Center**

Room 143 A-C (Street Level)

Target Audience

Researchers, medical trainees, those with an interest in COPD pathogenesis

Objectives

At the conclusion of this session, the participant will be able to:

- learn about aging and mortality in the COPDGene study
- learn about COPD progression in the COPD study
- learn about reclassification of COPD in the COPDGene study

Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death in the United States in 2019, is a heterologous syndrome. The COPDGene study has created the largest cohort of well-characterized current and former smokers for respiratory disease research. The primary goals of COPDGene are: 1) to identify new genetic loci that influence the development of COPD and COPD-related phenotypes and 2) to reclassify COPD into subtypes that can ultimately be used to develop effective therapies. In this session, presenters will discuss new results from the COPDGene study, including new ways to diagnose the disease, deep learning approaches to imaging data, genetics, epigenetics, transcriptomics, proteomics, and an integrative Omics approach.

Chairing: L. Postow, PhD, Bethesda, MD
J.D. Crapo, MD, Denver, CO

10:30 Progression of COPD by Chest CT

S. Ash, MD, Boston, United States

10:42 Mortality in COPDGene

W.W. Labaki, MD, MS, Ann Arbor, MI

10:54 Cognitive Decline and Aging

K.F. Hoth, PhD, Iowa City, IA

11:06 Metabolomics and COPD Progression

S. Godbole, PhD, Denver, United States

11:18 Reclassifying COPD

G.L. Kinney, MPH, PhD, Aurora, CO

MEET THE EXPERT SEMINARS

CME Credits Available: 1

 Pre-registration and additional fees required. Attendance is limited.

\$100 Member/Non-Members

\$70 LMIC Member/LMIC Non-Members.

11:00 a.m. - 12:00 p.m. **Marriott Marquis Washington**

- MTE54 UNDERSTANDING SEVERE AND STEROID-REFRACTORY IMMUNE CHECKPOINT INHIBITOR PNEUMONITIS**
K. Ho, MD, Columbus, OH
J.D. Possick, MD, New Haven, CT
University of DC/Catholic University (Level M1)
- MTE55 RUNNING AN EFFECTIVE INTERSTITIAL LUNG DISEASE MULTIDISCIPLINARY MEETING: REACHING THE GOLD STANDARD**
E. Valenzi, MD, Pittsburgh, PA
C.T. Lee, MD, Chicago, IL
Georgetown University (Level M1)
- MTE56 COMPLEX IN VITRO MODELS OF THE LUNG: BRIDGING THE GAP BETWEEN DISEASE COMPLEXITY AND THERAPEUTICS**
E.T. Osei, PhD, Kelowna, Canada
J.K. Burgess, BSc, PhD, ATSF, Groningen, Netherlands
M. Koenigshoff, MD, PhD, ATSF, Pittsburgh, PA
Howard University (Level M1)
- MTE59 MOLECULAR DIAGNOSTICS IN SEVERE PNEUMONIA: THE EVIDENCE AND CASE-BASED DISCUSSION OF CLINICAL IMPLEMENTATION**
C. Pickens, MD, Chicago, IL
R. Wunderink, MD, Chicago, IL
LeDroit Park (Level M3)
- MTE60 EXTRACORPOREAL MEMBRANE OXYGENATION FOR CARDIAC ARREST: WHEN, WHY, AND HOW**
J. Tonna, MD, MS, Salt Lake City, UT
M. Goodwin, MD, MS, FACS, Salt Lake City, UT
Mount Vernon Square (Level M3)
- MTE61 FROM FEATHERS TO ANTIFIBROTICS: EXPOSURES, DIAGNOSIS, AND TREATMENT IN HYPERSENSITIVITY PNEUMONITIS**
B. Flashner, MD, Boston, MA
Chinatown (Level M3)

CLINICAL

PEDIATRIC CLINICAL CORE CURRICULUM

CME Credits Available: 1

MOC Points Available: 1

PCC3 PEDIATRIC CLINICAL CORE CURRICULUM

Education Committee

11:00 a.m. - 12:00 p.m.

Target Audience

Clinicians who are engaged in maintenance of certification activities

Objectives

At the conclusion of this session, the participant will be able to:

- describe diagnosis and management of central and obstructive sleep disorders in infants
- identify best practices for management and treatment of pulmonary hypertension in infants
- describe best practices and standards of care for management of bronchopulmonary dysplasia in the neonatal intensive care unit and the post NICU period

Chairing: J. Gross, MD, PhD, Denver, CO
C. Okorie, MD, Paulo Alto, CA
M. McCown, MD, Bethesda, MD

- 11:00. Interstitial Lung Disease in Infants**
D. Ezmigna, MD, FAAP, Los Angeles, CA
- 11:25 Pulmonary Hypertension in Infants**
D. Bush, MD, NYC, NY

11:50 Questions and Answers

This session and the International Conference are supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).



ATS
2023

INTERNATIONAL
CONFERENCE
WASHINGTON, DC
conference.thoracic.org

Wednesday Afternoon, May 24

CLINICAL

ADULT CLINICAL CORE CURRICULUM

CME Credits Available: 1.5
MOC Points Available: 1.5

CC6 PULMONARY CLINICAL CORE CURRICULUM

Education Committee

12:00 p.m. - 1:30 p.m.

Target Audience

Clinicians who are engaged in maintenance of certification activities

Objectives

At the conclusion of this session, the participant will be able to:

- describe updates in the diagnosis and management of mild, moderate, and severe asthma in 2023
- identify the local and global impact of one's environment on asthma management
- describe best practices for asthma management in the pregnant and post-partum woman

Chairing: G. Garrison, MD, Burlington, VT
J. Cho, MD, Iowa City, IA

- 12:00 Asthma Where We Live and Work: The Impact of Environmental Change on Asthma Control**
N. Nassikas, MD, Cambridge, MA
- 12:25 Inequities in Asthma Care: Addressing Social Determinants of Health and Disparities in Asthma Management**
A. Rusk, MD, Rochester, MN
- 12:50 An ICS for Two: Treating Asthma in the Prenatal and Perinatal Settings**
E. Batchelor, MD, Med, Phoenix, AZ
- 1:15 Questions and Answers**

BASIC • CLINICAL • TRANSLATIONAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 1.5

D82 REPURPOSING EXISTING MEDICATIONS FOR TREATMENT OF COPD

Assemblies on Clinical Problems; Respiratory Cell and Molecular Biology

12:00 PM - 1:30 PM

Marriott Marquis Washington

Marquis Ballroom Salon 6 (Level M2)

Target Audience

Providers who care for patients with COPD and individuals interested in COPD research

Objectives

At the conclusion of this session, the participant will be able to:

- describe findings from experimental and observational studies supporting the potential efficacy of angiotensin receptor blockers, metformin, and antiplatelet therapy in COPD
- understand the reason for discrepancies between experimental/observational studies and clinical trial results in COPD
- evaluate emerging research that investigates repurposing existing medications for the treatment of COPD

Researchers have struggled to identify effective systemic pharmacologic therapies for COPD. Current COPD management consists of inhaled bronchodilators with few add on therapies for certain patient populations. Recently, researchers have focused on whether systemic medications commonly prescribed for non-respiratory indications may be effective in the treatment of COPD. In this session we discuss the scientific and clinical evidence for repurposing angiotensin receptor blockers (ARBs), metformin, and antiplatelet therapy as disease-modifying agents in COPD. We will also review the disconnect between murine models and human observational studies compared to clinical trial results for statins and beta-blockers. A panel discussion will follow.

Chairing: I.M. Adcock, PhD, London, United Kingdom
S. Christenson, MD, MS, San Francisco, CA
C.L. Pistenmaa, MD, MS, Boston, MA
A. Fawzy, MD, MPH, Baltimore, MD

- 12:00 Introduction**
M.T. Dransfield, MD, Birmingham, AL
- 12:09 Murine Models to Study ARB in Emphysema**
E.R. Neptune, MD, ATSF, Baltimore, MD
- 12:18 Current Evidence for ARBs and Angiotensin II Pathway in COPD**
V. Tejwani, MD, Cleveland, OH
- 12:27 Mechanisms of Metformin in COPD**
F. Polverino, MD, PhD, Houston, TX
2023 Parker B. Francis Speaker

12:36 Epidemiologic Evidence for Metformin in COPD
T.D. Wu, MD, MHS, Houston, TX

12:45 Antiplatelet Therapy in COPD
A. Fawzy, MD, MPH, Baltimore, MD

12:54 Clinical Trial Considerations
F.J. Martinez, MD, MS, New York, NY

1:03 Panel Discussion

1:26 Concluding Remarks
I.M. Adcock, PhD, London, United Kingdom

This session and the International Conference are supported by an independent medical educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL

CLINICAL TOPICS IN PULMONARY MEDICINE

CME Credits Available: 1.5

D83 ESTABLISHING A PARADIGM FOR MULTIDISCIPLINARY CARE IN SARCOIDOSIS

Assemblies on Clinical Problems; Environmental, Occupational and Population Health

12:00 PM - 1:30 PM **Walter E. Washington Convention Center**
Room 145 A-B (Street Level)

Target Audience

Healthcare providers and trainees from across disciplines that care for patients with sarcoidosis or other chronic/systemic conditions.

Objectives

At the conclusion of this session, the participant will be able to:

- understand our current systems of practice, how they limit access and the specific concerns patient with sarcoidosis have
- learn about ways to improve multidisciplinary care and access to care
- discuss ways to improve our structure/practices/systems to reduce disparities

Sarcoidosis is an inflammatory multi-organ disease with a wide variety of clinical manifestations that requires a team approach to address the needs of patients. Oftentimes patients lack the resources to navigate the complex health care systems. The challenges are exacerbated by the fact that sarcoidosis disproportionately impacts Black patients and these patients are also impacted by entrenched institutional biases in medicine. This session will propose to improve our current models of care to meet the needs of the patients, and will propose the concept of "primary sarcoidosis specialist" as an alternative to current models of care.

Chairing: D.C. Patel, DO, MBA, Gainesville, FL
O.N. Obi, MD, MPH, MSc, Greenville, NC

12:00 My Experience with Getting a Diagnosis and Treatment for Sarcoidosis
Speaker To Be Announced

12:08 The State of Sarcoidosis Care
D.C. Patel, DO, MBA, Gainesville, FL

12:12 The "Primary Sarcoidosis Specialist"
P.H.S. Sporn, MD, ATSF, FCCP, Chicago, IL

12:22 The Burden of Sarcoidosis on Patients
L. Harper, MD, MSCR, Cleveland, OH

12:31 Non-Organ Related Manifestations of Sarcoidosis
V. Kahlmann, MD, Rotterdam, Netherlands

12:41 Social Determinants and How They Impact Sarcoidosis Care
Y. Cozier, DSc, MPH, Boston, MA

12:50 Measuring Outcomes to Improve Care in Sarcoidosis
M. Sharp, MD, MHS, Baltimore, MD

1:00 Discussions
C. Bonham, MD, Charlottesville, VA

BASIC • CLINICAL • TRANSLATIONAL

CRITICAL CARE TRACK

CME Credits Available: 1.5

D84 FROM GENES TO CLINICAL TRIALS: STATE-OF-THE-ART APPROACHES TO HETEROGENEITY IN THE ICU

Assemblies on Critical Care; Clinical Problems; Respiratory Structure and Function

12:00 PM - 1:30 PM **Marriott Marquis Washington**
Independence Ballroom Salons A-D (Level M4)

Target Audience

Clinicians (RN, NP, MD) who care for critically ill patients and researchers who wish to improve the rigor with which they understand clinical trial data.

Objectives

At the conclusion of this session, the participant will be able to:

- describe novel approaches to phenotyping in acute critical care syndromes
- describe new findings concerning the complexity of critical care syndromes
- define new strategies to manage the care of ARDS and septic shock

Heterogeneity is increasingly recognized as a central challenge in critical care research. Sub-phenotyping and endotyping efforts designed

to reduce heterogeneity in clinical trial populations and individualize treatment protocols are central to efforts to improve outcomes. In this session we discuss both established and novel techniques for phenotyping critically ill patients with the aim of familiarizing clinicians, clinical researchers and basic researchers with the latest in the field.

Chairing: C.C. Hardin, MD, PhD, ATSF, Boston, MA
P. Sinha, MB BCh, PhD, ST LOUIS, MO
T.K. Jones, MD, MPH, MSCE, Philadelphia, PA

12:00 Untangling Complexity in Critical Illness
C.C. Hardin, MD, PhD, ATSF, Boston, MA

12:15 It's Written in the Genes: Understanding the Susceptibilities to Critical Illness
T.K. Jones, MD, MPH, MSCE, Philadelphia, PA

12:30 Polygenic Risk Scores in Critical Care: A Tale of Two Post-Operative Complications
L. Bastarache, MS, Nashville, TN

12:45 Phenotypes in ICU Acquired Weakness
C.C. Dos Santos, MD, Toronto, Canada

1:00 Phenotypes Over Clinical Syndromes: A More Logical Lumping Paradigm
P. Sinha, MB BCh, PhD, ST LOUIS, MO

1:15 Clinical Trials and Treatment Effects: Don't be Average, Be an Individual
M.M. Churpek, MD, MPH, PhD, ATSF, Madison, WI

BASIC • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

D85 EARLY LIFE ENVIRONMENTAL EXPOSURES, EPIGENETICS, AND ASTHMA DEVELOPMENT

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Respiratory Cell and Molecular Biology

12:00 PM - 1:30 PM **Walter E. Washington Convention Center**

Room 152 A-B (Street Level)

Target Audience

Researchers in asthma/allergy, genetics, epigenetics, virology, and bioinformatics, as well as clinicians/nurses/RTs/advanced practice providers who treat asthma

Objectives

At the conclusion of this session, the participant will be able to:

- understand the potential and limitations of genetics, epigenetics, and integrated omics approaches in examining asthma pathogenesis

- gain an understanding of the link between early-life exposures and asthma development
- understand the integrated role of environmental exposures and multi-omics in incident asthma

Growing evidence suggests that early-life environmental exposures (e.g., airway infection, nutrition, air pollution) contribute to the risk of developing asthma in childhood and beyond. During early-life development, environmental exposures interact with both the expression and function of human genetic/epigenetic factors and lead to differential disease risks. This session will highlight examples of recent studies from the NIH-supported Environmental Influences on Child Health Outcomes (ECHO) Program that offer deeper insights into the integrated roles of early-life environmental exposures, genetics, and epigenetics in incident asthma and the development of primary prevention strategies for asthma providers.

Chairing: C.J. Blaisdell, MD, MEd, North Bethesda, MD
K. Hasegawa, MD, MPH, PhD, Boston, MA

12:00 DNA Methylation Signatures of Early Life Exposures and Genetic Variation as Mediators of Asthma and Allergies in Childhood
C. Ober, PhD, Chicago, IL

12:21 Vitamin C Supplementation to Maternal Smokers During Pregnancy: Stable Effects on Offspring Wheeze and Buccal DNA Methylation Through 5 Years of Age
L. Shorey-Kendrick, PhD, BA, Beaverton, OR

12:42 Viral Bronchiolitis, Nasal Airway MicroRNA, and Risk for Developing Asthma
Z. Zhu, ScD, Boston, MA

1:03 Integrative Metabolomics and the Early Life Origins of Asthma
R.S. Kelly, MPH, PhD, Boston, MA

1:24 Patient Speaker
L. Johnson-Law, Washington, D.C.

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5

D86 HUMANS, ANIMALS, THE ENVIRONMENT: WHY IS THE ONE HEALTH APPROACH NEEDED FOR EMERGING HEALTH ISSUES?

Assemblies on Environmental, Occupational and Population Health; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Nursing; Pulmonary Infections and Tuberculosis

12:00 PM - 1:30 PM **Walter E. Washington Convention Center**

Room 150 A-B (Street Level)

Target Audience

Scientists, clinicians (pulmonology, cardiology, pediatrics, gerontology), public health/global health practitioners, and trainees interested in environmental impacts on health

Objectives

At the conclusion of this session, the participant will be able to:

- explain how the One Health approach can promote multidisciplinary collaborations across scientific disciplines
- analyze at least two examples where clinicians and researchers can participate in research, policy or advocacy
- discuss and encourage ATS members and others to influence policy makers through One Health approach when they are responding to emerging health challenges

As the COVID-19 pandemic continues, researchers have observed the possible links and relationships between diseases and the environment. The One Health concept represents a holistic approach that encompasses the interactions between all living beings with their environments. These interactions are crucial to recognize this interconnectedness, which provides insight into where interventions can be implemented to mitigate disease risk and enhance preparedness efforts on emerging concerns. This session will focus on how living beings interact with the ecosystem that may lead to adverse impact on human health. Leading scientists will discuss the scale of the problem, evidence, vulnerability, and policy development.

Chairing: M. Akpınar-Elci, MD, MPH, ATSF, Reno, NV
H. Chapman, MD, PhD, Washington, DC
M. Rice, MD, MPH, Boston, MA
S. Singh, MD, PhD, New York, NY

- 12:00 Overview of One Health, Using Innovative Data**
H. Chapman, MD, PhD, Washington, DC
- 12:10 Environmental Pulmonary Pathology from a One Health Perspective**
J. Harkema, DVM, PhD, DACVP, ATSF, East Lansing, MI
- 12:24 A One Health Approach to Addressing Vector-borne and Zoonotic Diseases**
C. Beard, PhD, Fort Collins, CO
- 12:38 Climate Change Through the Lens of a One Health Approach**
M. Akpınar-Elci, MD, MPH, ATSF, Reno, NV
- 12:48 Health Impacts of Air Pollution; the One Health Concept**
H. Bayram, MD, PhD, ATSF, Istanbul, Turkey
- 1:02 Pneumonia, TB, Health Disparities, and One Health**
A. Videla, MD, Pilar, Argentina
- 1:16 One Health Collaboration**
B. Dunham, DVM, PhD, Washington, DC

CLINICAL • TRANSLATIONAL**SCIENTIFIC SYMPOSIUM**

CME Credits Available: 1.5

D87 THE UN HIGH LEVEL MEETING ON TB 2023: A CHANCE TO BEAT THIS PARTICULAR PANDEMIC

Assemblies on Pulmonary Infections and Tuberculosis; International Health Committee

12:00 PM - 1:30 PM

Walter E. Washington Convention Center

West Salon G-I (Street Level)

Target Audience

Clinicians, Public health researchers, Policy Makers, Patients, Administrators, Research sponsors

Objectives

At the conclusion of this session, the participant will be able to:

- Better understand that improving global health is everyone's business and involves reducing health disparities
- To appreciate the long-term consequences of TB disease and so improve detection and its management
- How to enable people with TB's voice to be heard

The second UN General Assembly High Level Meeting on tuberculosis (TB) is due to take place in September 2023. If we are to eliminate TB, we must engage our political leaders. This symposium will discuss priorities from the perspective of TB survivors, academics and clinicians. What are our policy demands? Where do we anticipate sticking points? How do we ensure our voices are heard?

Chairing: D.M. Lewinsohn, MD, PhD, ATSF, Portland, OR
D. Garcia, MA, Austin, TX

- 12:00 Living with TB**
K. O'Brien, BA, Rumson, NJ
- 12:22 Beyond Cure - Living With the Long-Term Effects of TB Disease**
J. Potter, PhD, London, United Kingdom
- 12:45 The United Nations High-Level Meeting - the Last Chance for the Sustainable Development Goal on TB?**
M. Oliver, BA, Cambridge, United Kingdom
- 1:08 Turning Policy into Practice to Make a Difference to People with TB**
P. Vera Bejarano, BA, Asuncion, Paraguay

BASIC • TRANSLATIONAL**SCIENTIFIC SYMPOSIUM**

CME Credits Available: 1.5

D88 BEYOND BIOENERGETICS: CELLULAR METABOLISM IN LUNG HEALTH AND DISEASE

Assemblies on Respiratory Cell and Molecular Biology; Critical Care; Pulmonary Circulation; Pulmonary Infections and Tuberculosis; Respiratory Structure and Function; Thoracic Oncology

12:00 PM - 1:30 PM **Marriott Marquis Washington**

Independence Ballroom Salons E-H (Level M4)

Target Audience

Basic and translational researchers, and clinicians who are interested in the mechanisms behind lung diseases

Objectives

At the conclusion of this session, the participant will be able to:

- describe metabolic changes that occur in various cell populations in lung diseases and lung cancer
- describe the role of mitochondria as signaling organelles in lung cancer
- recognize disease specific metabolic changes in lung cell and describe how metabolic pathways may potentially be targeted for treatment

Cellular metabolism is the fundamental step of bioenergetic process. Growing evidence demonstrates the importance of cellular metabolism in disease pathogenesis beyond energy production. In this session, we will provide key knowledge about major cellular metabolic pathways and present recent discoveries and future perspectives on how these pathways regulate the pathogenesis of pulmonary diseases, such as COPD, pulmonary hypertension, interstitial lung diseases and lung cancer and how they may be targeted to alter disease progression. This session brings together experts who are among the pioneers to explore the new paradigm of cellular metabolic dysregulation as a key manifestation of pulmonary diseases.

Chairing: G.M. Mutlu, MD, ATSF, Chicago, IL
S.C. Erzurum, MD, Cleveland, OH
G. Liu, MD, PhD, Birmingham, AL

12:00 Metabolic Changes in Immune Cells in COPD
S.M. Cloonan, PhD, Dublin, Ireland

12:18 Amino Acid Metabolism in Pulmonary Fibrosis
R.B. Hamanaka, PhD, Chicago, IL

12:36 Metabolism in Pulmonary Hypertension
S.C. Erzurum, MD, Cleveland, OH

12:54 Lipid Metabolism in Lung Diseases
R. Summer, MD, Philadelphia, PA

1:12 Macrophage Metabolism in ARDS
W.J. Janssen, MD, Denver, CO

BASIC • CLINICAL • TRANSLATIONAL**SCIENTIFIC SYMPOSIUM**

CME Credits Available: 1.5

D89 OSA-ASSOCIATED INFLAMMATION AND COMORBIDITIES: CAUSES AND CONSEQUENCES

Assemblies on Sleep and Respiratory Neurobiology; Allergy, Immunology and Inflammation

12:00 PM - 1:30 PM **Walter E. Washington Convention Center**

Room 207 A-B (Level 2)

Target Audience

Pulmonary critical care and sleep medicine practitioners (physicians, psychologists, nurse-practitioners) and researchers interested in the interactions between obstructive sleep apnea (OSA), inflammation, and comorbid chronic disease.

Objectives

At the conclusion of this session, the participant will be able to:

- describe the interplay of both biologic (genetic) and epidemiologic associations between OSA, chronic systemic inflammation and comorbid disease. This will improve medical knowledge and practice-based learning and improvement
- understand the contribution of OSA in chronic comorbid diseases, including asthma, interstitial lung disease, cardiovascular disease, and HIV. This will improve medical knowledge, practice-based learning and improvement, and evidence-based practice
- identify research goals for precision health and personalized medicine in patients with OSA and co-morbid chronic inflammatory disease. This will improve medical knowledge

This session will focus on the interplay between OSA-associated inflammation and chronic comorbidities. The session will begin by detailing both epidemiologic and genetic associations between OSA and inflammatory biomarkers, which are key mediators in the downstream cardiopulmonary consequences in OSA. Particular focus will be given to the contribution of OSA-associated inflammation in the acceleration of chronic comorbid diseases, including asthma, interstitial lung disease, cardiovascular disease, and HIV. The session will conclude with a discussion/Q&A that will explore future research areas for this important field.

Chairing: V. Kundel, MD, New York, NY
P.V. Borker, MD, Pittsburgh, PA
B.E. Cade, PhD, Boston, MA

- 12:00 Welcome and Introduction of Speakers**
V. Kundel, MD, New York, NY
- 12:05 Sleep Apnea, Biomarkers of Vascular Injury and Inflammation**
S. Jelic, MD, New York, NY
- 12:20 Role of Epigenetic Regulation in Sleep Apnea**
R. Cortese, PhD, Columbia, MO
- 12:35 Epidemiological and Genetic Associations Between Sleep-Disordered Breathing and Inflammatory Traits**
B.E. Cade, PhD, Boston, MA
- 12:50 Investigating the Impact of Sleep Health on HIV-Associated Inflammation**
P.V. Borker, MD, Pittsburgh, PA
- 1:05 OSA and Chronic Lung Disease**
M. Teodorescu, MD, MS, Madison, WI
- 1:20 Question and Answer/Panel Discussion**

CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

D91 LOOKING FOR THE CRYSTAL BALL: BIOMARKERS TO PREDICT DISEASE PROGRESSION AND MORTALITY IN ILD

12:00 p.m. - 2:00 p.m. **Walter E. Washington Convention Center**
Ballroom A (Level 3)

Chairing: D.A. Lynch, MB BCh, Denver, CO
A.E. Tzouveleakis, MD, PhD, Patras, Greece
M. Kang, MD, Atlanta, GA

Featured Speaker:

12:00 Biomarkers for Pulmonary Fibrosis; What Do We Know and What Do We Need to Know?/T.M. Maher, Los Angeles, CA

Oral Presentations:

- 12:12 In the Serial Assessment of Patients With Idiopathic Pulmonary Fibrosis, the Automated E-ILD CT Algorithm Outperforms Lung Function; a Validation Study/P.M. George, London, United Kingdom**
- 12:24 Proteomic Determinants of Idiopathic Pulmonary Fibrosis Survival/J. Oldham, Ann Arbor, MI**
- 12:36 Association of Circulating Metabolites With Disease Severity and Mortality in Patients With Idiopathic Pulmonary Fibrosis: Data From the IPF-PRO Registry/R.S. Summer, Philadelphia, PA**

- 12:48 Utility of the 52-Gene Risk Score to Identify Patients With Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy/J. Soellner, Biberach, Germany**
- 1:00 Validation of A 25-Gene Blood Transcriptomic Signature Predictive of Forced Vital Capacity Decline in Patients With Idiopathic Pulmonary Fibrosis/C. Bonham, Charlottesville, VA**
- 1:12 Increasing Honeycombing and Traction Bronchiectasis on Computed Tomography Are Independent Predictors of Survival Across All Interstitial Lung Disease Subtypes/D. Marinescu, Vancouver, Canada**
- 1:24 AI-based Model for the Automatized Quantification and Prognosis of IPF Patients/J. Guiot, Liege, Belgium**
- 1:36 Imaging Signature Idiopathic Pulmonary Fibrosis (IS-IPF): An Analytic Validation Study of Two CT Image-based Biomarkers in an Independent Cohort for Predicting Disease Progression in Non- IPF Interstitial Lung Diseases/G.J. Kim, Los Angeles, CA**
- 1:48 Chest Computed Tomography Machine Learning Classifier for Idiopathic Pulmonary Fibrosis Predicts Mortality in Interstitial Lung Diseases/O. Moran Mendoza, Kingston, Canada**

CLINICAL

MINI SYMPOSIUM

D92 NOVEL IMAGING AND PHYSIOLOGIC MEASURES IN COPD

12:00 p.m. - 2:00 p.m. **Walter E. Washington Convention Center**
Room 147 A-B (Street Level)

Chairing: C.B. Cooper, MD, Los Angeles, CA
B.M. Smith, MD, MS, Montreal, Canada
T. Lapperre, MD, Edegem, Belgium

Oral Presentations:

- 12:00 Computed Tomography Total Vessel Count in Chronic Obstructive Pulmonary Disease: Association With Pulmonary Function/G.V. Singh, Toronto, Canada**
- 12:12 Silent Airway Mucus Plugs in COPD and Association With Disease Severity and Outcomes/S.K. Mettler, Boston, MA**
- 12:24 Texture-based Computed Tomography Radiomics With Machine Learning Improves Predicting Chronic Obstructive Pulmonary Disease Outcomes/K. Makimoto, Toronto, Canada**
- 12:36 Topologic Parametric Response Mapping Identifies Emphysema Progression Subtypes in COPD Gene/J.M. Wang, Ann Arbor, MI**

- 12:48** COPD Deep-phenotype: Finding Single Radiographic Features for Prospective COPD Outcomes and Protein Levels Prognostication/A.H. Curiale, Somerville, MA
- 1:00** Parameter D: A New Measure of Airflow Obstruction/S.P. Bhatt, Birmingham, AL
- 1:12** FEV1Q Is a Race-agnostic Approach to Assessing Lung Function and Predicting Survival/A. Balasubramanian, Baltimore, MD
- 1:24** Prebronchodilator Spirometry Variability (PSV) as an Alternative to Bronchodilator Responsiveness Testing for COPD Prognostication/S. Bodduluri, Birmingham, AL
- 1:36** Impaired Cardiac Autonomic Function Is Associated With Higher Exacerbation Risk and Symptom Burden in Chronic Obstructive Pulmonary Disease/S. Raju, Baltimore, MD
- 1:48** Association of Physical Performance Measures With Clinical Characteristics of COPD in SPIROMICS/B.A. Dolezal, Los Angeles, CA
- 1:00** Association and Additive Risk of Respiratory and Viral Response Baseline Variables With Mortality in Therapeutics for Inpatients With COVID-19 (TICO) Platform Randomized Clinical Trial (RCT) Participants/N.R. Aggarwal, Aurora, CO
- 1:12** High Flow Nasal Cannula Oxygen Compared to Low-flow Oxygen Among Hospitalized Adult COVID-19 Treatment Center Patients in Lesotho: A Retrospective Observational Study/E.D. Mccollum, Baltimore, MD
- 1:24** Development and Validation of a Machine Learning Model to Predict Failure of High-flow Nasal Cannula Therapy in Patients With COVID-19/P. Yang, Atlanta, GA
- 1:36** Right Ventricular Dysfunction Phenotypes Among Patients With COVID-19 Hospitalized in the Intensive Care Unit/P.A. Sanchez, Stanford, CA
- 1:48** Mortality and Outcomes of Patients With COVID-19 Pneumonia on ECMO, National Analysis of NIS 2020/K. Meremikwu, Brooklyn, NY

BASIC • CLINICAL • TRANSLATIONAL**MINI SYMPOSIUM****D93 CLINICAL AND TRANSLATIONAL STUDIES OF COVID-19 CRITICAL ILLNESS****12:00 p.m. - 2:00 p.m.** Walter E. Washington Convention Center

Ballroom C (Level 3)

Chairing: M.N. Gong, MS, MD, Bronx, NY
R.S. Stephens, MD, ATSF, Baltimore, MD
B.D. Singer, MD, ATSF, Chicago, IL

Oral Presentations:

- 12:00** Association Between Hospital Surge Strain and Mortality During the COVID-19 Pandemic: Global Patterns From a Scoping Review/M. Neupane, Bethesda, MD
- 12:12** Increase in Burden of Patients With Severe COVID-19 Nationwide Was Associated With Higher Mortality Rate of Patients With COVID-19 Requiring Mechanical Ventilation: An Observational Study of a National Database in Japan/K. Kikutani, Minamiku, Hiroshima, Japan
- 12:24** Mortality and Survival of Mechanically Ventilated Patients With COVID-19 Pneumonia in the U.S. From NIS 2020/T. Chkhikvadze, Brooklyn, NY
- 12:36** Inclusion of Comorbidities and Prognosis in U.S. States' Triage Plans During COVID-19/J.S. Ennis, Rochester, MN
- 12:48** Host Response Profiling Across the Spectrum of Disease in Uganda Reveals Prognostic Immune Signatures for COVID-19 That Persist During HIV Co-infection and Diverge by Circulating Viral Variants/M.J. Cummings, New York, NY

BASIC • CLINICAL • TRANSLATIONAL**MINI SYMPOSIUM****D94 NOVEL REGULATORS AND MEDIATORS OF AIRWAY INFECTION AND INFLAMMATION****12:00 p.m. - 2:00 p.m.** Walter E. Washington Convention Center

Room 202 B (Level 2)

Chairing: F. Rezaee, MD, Cleveland, OH
M.D. McGraw, MD, Rochester, NY

Oral Presentations:

- 12:00** Bacterial-viral Co-infection and Outcomes in Pediatric Bacterial Tracheostomy-associated Infections: A Multicenter Prospective Cohort Study/C.J. Russell, Los Angeles, CA
- 12:12** Predictors of Frequent Acute Respiratory Illnesses in Children With Tracheostomies/N. Xia, Milwaukee, WI
- 12:24** Circadian Rhythms Regulate Genome-wide Transcription in Primary Human Airway Epithelial Cells and Modulate Viral Replication/W.T. Powell, Seattle, WA
- 12:36** Serum Biomarkers in Acute Lung Injury- Receptor for Advanced End Products/S. Bhela, Valhalla, NY
- 12:48** Electronic Cigarette-induced Airway Barrier Dysfunction of In Vitro, Ex Vivo, and In Vivo Models/A. Raduka, Cleveland, OH
- 1:00** Type III Interferon Is the Primary Response of the Human Infant Airway Epithelium During Respiratory Syncytial Virus (RSV) Infection/H. Abeyratne-Perera, Washington, DC

- 1:12 **Juvenile Regulatory T Cells Exhibit Decreased Capacity to Suppress Inflammation During Severe Viral Pneumonia**/A.D. Prigge, Chicago, IL
- 1:24 **Protein Kinase A (PKA) Signaling Contributes to Barrier Protection Effect of Vitamin D3 Against Respiratory Syncytial Virus Infection**/N. Gao, Cleveland, OH
- 1:36 **Respiratory Virus-specific Nasopharyngeal Lipidome Signatures and Severity in Infants Hospitalized for Bronchiolitis: A Prospective Multicenter Cohort Study**/M. Kyo, Boston, MA

Featured Speaker:

- 1:48 **New Insights into TSLP Airway Epithelial Biology During Early Life**/G.R. Nino, Washington, DC

BASIC • CLINICAL • TRANSLATIONAL

MINI SYMPOSIUM

D95 CHALLENGES AND ADVANCES IN COVID-19

12:00 p.m. - 2:00 p.m. Walter E. Washington Convention Center

Ballroom B (Level 3)

Chairing: J.P. Mizgerd, ScD, ATSF, Boston, MA
M. Mehedi, PhD, Grand Forks, ND
C.M. Luna, MD, PhD, Ciudad Autónoma de Buenos Aires, Argentina

Oral Presentations:

- 12:00 **COVID-19 Symptomatology in the Omicron Era: A Population-based Observational Study in Sapporo, Japan**/S. Nakakubo, Sapporo, Japan
- 12:12 **COVI-19 Hospitalizations and Mortality in the United States, National Analysis of the Year 2020**/I. Kryshal, Brooklyn, NY
- 12:24 **Mitochondrial DNA Is an Early Predictor of COVID19 Severity of Disease: Validation Cohort and Response to Targeted COVID19 Treatments**/M. Cano, Saint Louis, MO
- 12:36 **A Selective Leukotriene B4 Antagonist, Acebilustat, for Treatment of Outpatients With COVID-19 Disease: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial**/J.E. Levitt, Stanford, CA
- 12:48 **Prior Immune Checkpoint Inhibitor Therapy in Cancer Patients Presenting With COVID-19 Was Not Associated With Worse Outcomes but Potentially Decreased COVID-19 Related Hospitalizations and Complications: Results of a Propensity-Matched Analysis Using the IA**. Mostaghim, Bethesda, MD

- 1:00 **Tocilizumab Treatment Leads to Early Resolution of Myeloid Dysfunction and Lymphopenia in Patients Hospitalized With COVID-19**/R.N. Bauer, South San Francisco, CA
- 1:12 **Cova Results From a Double-blind, Placebo-controlled Phase 2/3 Study to Assess Efficacy and Safety of BIO101 in Hospitalized Severe COVID-19 Patients**/G.B. Nair, Royal Oak, MI
- 1:24 **Driving Pressure and Adjunctive Therapies in Pulmonary Sequelae of COVID-19 Patients Under Invasive Ventilation**/J. Gonzalez, Lleida, Spain
- 1:36 **Evaluating the Cardiovascular Event Profile After Administration of Tixagevimab and Cilgavimab (Evusheld) in Lung Transplant Recipients**/J.L. Bulger, Maywood, IL
- 1:48 **Evidence of Post-infection Vaccination Correlation With the Severity of Opacities and Consolidations on the Lung Parenchyma of Post-acute SARS-CoV-2 Patients**/D.S.D. Carmo, Iowa City, IA

BASIC • TRANSLATIONAL

MINI SYMPOSIUM

D96 NOVEL PATHWAYS IN INFLAMMATORY LUNG INJURY

12:00 p.m. - 2:00 p.m. Walter E. Washington Convention Center

Room 204 A-C (Level 2)

Chairing: G.S. Budinger, MD, ATSF, Chicago, IL
K. Hajjpouran Benam, PhD, Pittsburgh, PA
L. Morales-Nebreda, MD, Chicago, IL

Featured Speaker:

- 12:00 **Role of Osteoclasts in Silicosis**/F.X. McCormack, Cincinnati, OH

Oral Presentations:

- 12:12 **The Role of Innate B Cells as Progenitors of the Mzb1+ Plasma Cells in Chronic Rejection After Lung Transplantation**/M. Bueno, Pittsburgh, PA
- 12:24 **Connexin-43 Containing Gap Junctions in Sessile Alveolar Macrophages Determine Hyperinflation-induced Lung Injury**/L. Mthunzi, New York, NY
- 12:36 **Targeting Age-dependent Nox4 Dysfunction as a Novel Strategy to Improve Survival in Age-dependent Severe ARDS**/K. Kato, Atlanta, GA
- 12:48 **Monocyte-derived Interstitial Macrophages Stimulate Angiogenesis to Promote Lung Regeneration Following Pneumonectomy**/S. Watanabe, Kanazawa, Japan

- 1:00 **Lactylation Mediated Attenuation of Inflammation in Acute Lung Injury**/C.U. Vohwinkel, Aurora, CO
- 1:12 **Endothelial SDF1 Is the Endogenous Activator of Endothelial Pyroptosis Mediating Inflammatory Vascular Injury in Sepsis and Associated Acute Respiratory Distress Syndrome**/X. Zhang, Chicago, IL
- 1:24 **Fra-1 Activation by Neonatal Hyperoxia Maintains Proinflammatory Macrophage Phenotype and Obstructs the Pro-resolution Leading to Alveolar Remodeling**/S.P. Reddy, Chicago, IL
- 1:36 **Maintenance DNA Methylation Stabilizes Induced Regulatory T Cells**/A.M. Joudi, Chicago, IL
- 1:48 **ERG Deletion in Lymphatic Endothelial Cells Increases Inflammation and Lymphatic Remodeling in Mouse Lungs**/A. Chakraborty, Boston, MA

BASIC • CLINICAL • TRANSLATIONAL**MINI SYMPOSIUM****D97 IMPACT OF COPD ACROSS THE LIFESPAN**12:00 p.m. - 2:00 p.m. Walter E. Washington Convention Center

Room 202 A (Level 2)

Chairing: J.C. Woods, PhD, ATSF, Cincinnati, OH

Oral Presentations:

- 12:00 **Clinical Trajectory Analysis With Longitudinal Validation in COPD: A COPD Gene Study**/A.J. Bell, Ann Arbor, MI
- 12:12 **MRI and CT Measurements Uniquely Explain All-cause Mortality in Ex-smokers With and Without COPD**/M. Sharma, London, Canada
- 12:24 **Longitudinal Assessment of Ultrasound-derived Diaphragm Contractile Reserve in Acute Exacerbations of COPD**/A. Valin-Thorburn, Montreal, Canada
- 12:36 **Does Respiratory Muscle Strength Substantially Improve Prognostic Evaluation and Risk Stratification in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)? A 42-Month Follow-up Analysis**/R.N. Silva, Sao Carlos, Brazil
- 12:48 **Feature-based PRM for Robust Disease Classification in COPD**/S. Ram, Ann Arbor, MI
- 1:00 **PRM and Topological Imaging Features From HRCT Can Identify Prism Patients Who Progress to COPD**/R. Geng, South San Francisco, CA
- 1:12 **A Genome-wide Association Study of Dysanapsis Among Adults and Children**/C. Debban, Charlottesville, VA

- 1:24 **Lung Microstructure and Regional Function of Quantitative Emphysema Subtypes on Coregistered Computed Tomography and Hyperpolarized Gas Magnetic Resonance Imaging Scans: The MESA-COPD Study**/W. Shen, New York, NY
- 1:36 **Regional Alterations in Air-trapping Associated With the Early Progression of COPD**/R. Baron, Philadelphia, PA
- 1:48 **The Impact of Chronic Obstructive Lung Disease (COPD) on Lung Cancer in the Pittsburgh Lung Screening Study (PLUSS)**/H. Strollo, Pittsburgh, PA

BASIC • TRANSLATIONAL**MINI SYMPOSIUM****D98 UPDATE ON THE “OMICS” OF LUNG CANCER: A TRANSLATIONAL SESSION**12:00 p.m. - 2:00 p.m. Walter E. Washington Convention Center

Room 102 A-B (Street Level)

Chairing: E. Ostrin, MD, PhD, Houston, TX
N. Al Nasrallah, MD, Indianapolis, IN**Oral Presentations:**

- 12:00 **Lung Tissue Transcriptome as Predictor of Recurrence in Early-stage Non-small Cell Lung Cancer**/F. Darawshy, New York, NY
- 12:12 **Immune Tone of Tumor-draining Lymph Nodes in Non-small Cell Lung Cancer**/B. Kwok, New York, NY
- 12:24 **Elevated Derived Neutrophil-to-Lymphocyte Ratio Is Associated With Lower Airway Dysbiosis in Non-Small Cell Lung Cancer**/M.S. Dreier, New York, NY
- 12:36 **Mediastinal Lymph Node and Airway Microbiome Associations in Lung Cancer and Sarcoidosis**/S. Shojaee, Nashville, TN
- 12:48 **LKB1-LIF Signaling Axis Promotes an Immunosuppressive Microenvironment in Lung Adenocarcinoma**/R. Pillai, New York, NY
- 1:00 **Clinical Usefulness of Serum KL-6 Test for Predicting Occurrence and Assessing Severity of Treatment-related ILD**/H.K. Park, Hwasun, Korea, Republic of
- 1:12 **Tsc2 Heterozygosity Augments Wnt 1 Mediated Breast Tumor Initiation and Metastatic Colonization in the Lung**/U.J. Unachukwu, New York, NY
- 1:24 **Tumoral Genetic Mutations Correlated With Mast Cell Infiltration in Early-stage Lung Adenocarcinoma**/M.N. Kammer, Nashville, TN

- 1:36 **Using Gene Regulatory Networks to Understand Sex Differences in Lung Cancer Gene Regulation/C.M. Lopes-Ramos, Boston, MA**
- 1:48 **Performance and Reproducibility of a Deep-learning Derived Automated Algorithm to Detect, Segment and Measure Lung Cancer Lesions on Computed Tomography Scans/P.M. George, London, United Kingdom**

CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

D101 HOST DEFENSES AND IMMUNE CELLS

12:00 p.m. - 2:00 p.m. Walter E. Washington Convention Center

Room 206 (Level 2)

Poster Viewing 12:00-12:45

Discussion 12:45-2:00

Chairing: K. Traber, MD, PhD, ATSF, Boston, MA
J.E. McCombs, PhD, New Orleans, LA
M.T.Y. Lam, MD, PhD, La Jolla, CA

- 701 **Impact of Estrogen on Neutrophil Function and Inflammation in Cystic Fibrosis/S. Abid, Dallas, TX**
- 702 **Pseudomonas Aeruginosa Virulence Factors Sensitize the Piezo1 Cation Channel and Thereby Augment Piezo1-Dependent Macrophage Phagocytosis/E.M. Orsini, Cleveland, OH**
- 703 **CCR6+ CD4+ Lymphocytes and Innate-like Lymphocytes Are Depleted in Ventilator Associated Pneumonia/M. Orlov, Aurora, CO**
- 704 **Infection-induced Transfer RNA Half Molecules Activate Toll-like Receptor 7 In Innate Immune Response/Y. Kirino, Philadelphia, PA**
- 705 **The Scavenger Receptor LOX-1 Limits Immune Reactivity in Alveolar Macrophages/F.T. Korkmaz, Worcester, MA**
- 706 **Serum IgA and Gd-IgA1 Levels Associate With Chronic Lung Disease Phenotypes. The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study/T. Pottinger, New York, NY**
- 707 **Effects of Oxidative Stress on Pulmonary T Cell Immune Populations in Rhesus Macaques/G.K. Sanghar, Davis, CA**
- 708 **Differential Immune Cell Subsets in the Blood of Patients With Pulmonary Arterial Hypertension/A.P.M. Serezani, Nashville, TN**
- 709 **Interleukin-13 Impact on Cell Differentiation Patterns of Human Airway Epithelial Cell Subsets/M.R. Anand, Norfolk, VA**
- 710 **Basal Type III Interferon Expression Is Associated With Rhinovirus Replication Kinetics, Interferon Response Kinetics, and IL-33 Response in Asthmatic Epithelium/L.M. Rich, Seattle, WA**
- 711 **Lower Airway Immune Responses to Airway Compared to Gastrointestinal Challenge With Short Chain Fatty Acids/M. Chang, New York, NY**
- 712 **ELD607, a Novel Anti-Orai1 Peptide, Clears Methicillin-resistant Staphylococcus Aureus and Reduces Inflammation in the Lungs/S. Ahmad, Durham, NC**
- 713 **A Novel Two-hit Murine Model to Investigate Neutrophilic Inflammation and Tissue Damage in Pneumonia Patients Who Smoke/S.W. Robison, Birmingham, AL**
- 714 **Differential Responses to LPS Stimulation and Glutamine Inhibition Between Alveolar and Bone Marrow-derived Macrophages/C.L. Vigeland, Chapel Hill, NC**
- 715 **Alveolar Macrophages From Rhinovirus-infected Mice Acquire Memory-like Properties/Y. Li, Ann Arbor, MI**
- 716 **Mouse Model of Human Coronavirus (HCoV)-NLL63: Comparison With Rhinovirus-(RV)-A1B and Effects of Prior RV Infection/J.K. Bentley, Ann Arbor, MI**
- 717 **Anti-proteinase 3 Antibodies Augment Monocyte Activation and May Alter Monocyte Phenotype/L. Fussner, Columbus, OH**
- 718 **Immunosuppressive Effects of Mesenchymal Stem Cells and the Timing of Their Use in a Rat Lung Transplantation Model/Y. Tanoue, Nagasaki, Japan**
- 719 **Impact of Treatments Targeting the GM-CSF Pathway on Human Lung Macrophages and Monocytes/H. Salvador, Suresnes, France**
- 720 **Experimental Models to Characterize Pneumonia Sub-phenotypes/B. Hiller, Boston, MA**
- 721 **IL-4 Macrophage Reprogramming Promotes Resolution of Pneumonia in the Aging Host/A.F. Villabona-Rueda, Baltimore, MD**
- 722 **Inhibition of Carbonic Anhydrase Attenuates Influenza A Virus-induced Inflammatory Response in Macrophages/P.S. Woods, Chicago, IL**
- 723 **RIG-I Agonist SLR10 Induces a Balanced Innate Immune Response Against Influenza Virus in Smoking and Nonsmoking Mice/W. Wu, Oklahoma City, OK**
- 724 **Establishing and Boosting Lung-Resident Memory After Murine OC43 Coronavirus Infection/N. Sanders, Boston, MA**
- 725 **Role of T Lymphocyte Location in Schistosoma-induced Pulmonary Hypertension/D.C. Fonseca Balladares, San Francisco, CA**

BEHAVIORAL • CLINICAL

POSTER DISCUSSION SESSION

D102 HIGHLIGHTS OF EPIDEMIOLOGIC AND CLINICAL RESEARCH IN BEHAVIORAL SCIENCES

12:00 p.m. - 2:00 p.m. Walter E. Washington Convention Center

Room 151 B (Street Level)

Poster Viewing 12:00-12:45

Discussion 12:45-2:00

Chairing: E.K. Kross, MD, Seattle, WA
 M.P. Kerlin, MD, MS, Philadelphia, PA
 J. Hart, MD, MS, Philadelphia, PA

- 501 **Trends in the Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) in Never Smokers in Ontario/A.J. Blazer, Toronto, Canada**
- 502 **National Prevalence and Risk Factors for Loneliness and Social Isolation Among Adults With Chronic Obstructive Pulmonary Disease/A. Suen, San Francisco, CA**
- 503 **Mobility and Medication Usage Trends Surrounding High-Rescue Days in Patients With Chronic Obstructive Pulmonary Disease/A. Allen, San Diego, CA**
- 504 **Incidence and Association of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Amongst Patients With Substance Use Disorders - A National Burden of COPD/A. Raheem, Galveston, TX**
- 505 **Obstructive Sleep Apnea as a Risk Factor During Hospitalization for Acute Exacerbation of Chronic Obstructive Pulmonary Disease - a National Inpatient Sample Study/J.R. De La Fuente, New Brunswick, NJ**
- 506 **Mapping EQ5D Utilities From Forced Vital Capacity and Diffusing Capacity in Fibrotic Interstitial Lung Disease/A.W. Wong, Vancouver, Canada**
- 507 **Early Interstitial Lung Disease in Rheumatoid Arthritis: An Observational Study of Risk Factors and Mortality in Ontario, Canada/L. Fidler, Toronto, Canada**
- 508 **Impact of Cannabis Use Disorder on In-hospital Outcomes Among Smokers With Acute Myocardial Infarction: Insights From National Inpatient Sample 2019/M.C.V.B. Gudiwada, Chicago, IL**
- 509 **Association Between Exclusive Marijuana Use and Asthma Severity: Results From a Nationally Representative Study/T. Kaplan, Annapolis, MD**
- 510 **Characteristics, Healthcare Resource Use and Costs Among High-Risk Patients With COPD in the United States/A. Cameron, San Diego, CA**
- 511 **Predictors of Adherence to Asthma Controller Medication Among Pediatric, Adolescent, and Adult Patients in the United States/A.E. Cameron, San Diego, CA**
- 512 **Predictors of Exacerbations Among Pediatric, Adolescent, and Adult Patients With Asthma in the United States/A. Cameron, San Diego, CA**
- 513 **Changes in Asthma Medications, Symptom Control and Urgent Health Care for Asthma in Australia Between 2012 and 2021, From Nationally Representative Web Surveys/H. Reddel, Glebe, Australia**
- 514 **The Associations Between Attention-Deficit Hyperactivity Disorder Symptoms, Perceptions of Respiratory Compromise, and Illness Representations in Minority Children With Asthma/N. Fruchter, Bronx, NY**
- 515 **The Role of Biologics in Decreasing Asthma Exacerbation Rate: A Systematic Review and Meta-analysis/R. Ali, Harrisburg, PA**
- 516 **Impact of Extrafine Formulation Single-inhaler Triple Therapy on Asthma Control and Health-related Quality of Life After Three Months of Treatment in Patients With Asthma: Trimaximize - A Real-world View From Germany, United Kingdom, Austria and Denmark/C. Gessner, Leipzig, Germany**
- 517 **Comparative Effectiveness of Dupilumab and Omalizumab in Improving Exacerbations in Individuals With Allergic Asthma/T. Nopsopon, Boston, MA**
- 518 **Omalizumab, Mepolizumab, and Dupilumab Are Associated With Differing Lung Function Trajectories in Patients With Moderate to Severe Asthma/A. Akenroye, Boston, MA**
- 519 **Provider Perspectives on Cross-system Prescribing of High-risk Medications: Implications for Policy and Organizational Support/K.R. Gillmeyer, Boston, MA**
- 520 **Generic Vs. Brand-name Fluticasone-Salmeterol in the Prevention of COPD Exacerbations/W.B. Feldman, Boston, MA**
- 521 **Impact of COVID-19 Pandemic on Pneumococcal and Influenzae Vaccination Among Medicare and Medicaid Beneficiaries in the United States in 2020/H. Singh, Milwaukee, WI**

- 522 **Efficacy and Tolerability of AXA1125, an Endogenous Metabolic Modulator Composition, in Fatigue-predominant Long COVID: A Randomized, Double-blind, Placebo-controlled Study/L. Finnigan, Oxford, United Kingdom**
- 523 **Regional Differences in the Substance Use Epidemic Among Adult Intensive Care Unit Patients/K. Hills-Evans, Aurora, CO**
- 524 **Clinical Effort Against Smoke Exposure in CF (CEASE-CF): Feasibility, Acceptability, and Preliminary Efficacy/G.R. Oates, Birmingham, AL**
- 525 **Risk Factors for Increased Healthcare Utilization After Pediatric Sepsis Hospitalization/E.F. Carlton, Ann Arbor, MI**

CLINICAL

POSTER DISCUSSION SESSION

D103 THE DOUBLE EDGED SWORD: DRUG TOXICITY CASE REPORTS

12:00 p.m. - 2:00 p.m. Walter E. Washington Convention Center

Room 103 A-B (Street Level)

Poster Viewing 12:00-12:45

Discussion 12:45-2:00

Chairing: V. Cottin, MD, PhD, Lyon, France
S.E. Hines, MD, MSPH, Baltimore, MD
T. Paul, MD, Charlottesville, VA

- 201 **A Case of Naltrexone Induced Acute Eosinophilic Pneumonia/Y. Abdelghany, Baltimore, MD**
- 202 **Some Supplements Are Detriments of Health: A Case of Lysine Induced Eosinophilic Pneumonia/S. Jothi, Tucson, AZ**
- 203 **Acute Fibrinous and Organizing Pneumonia Due to Sirolimus Induced Lung Toxicity in a Bilateral Lung Transplant Patient/B. Goodman, Detroit, MI**
- 204 **A Case of Sarcoidosis-Like Reaction With Mediastinal Adenopathy in a Patient With Acinar Adenocarcinoma of the Lung Caused by Checkpoint Inhibitor Immunotherapy/J. Kent, Dallas, TX**
- 205 **A Cascade of Trouble/J. Kodela, Worcester, MA**
- 206 **Is It the Lung? Or the Heart? Or Both? - A Case of Pembrolizumab-Induced Cardiopulmonary Toxicity/M. Ghose, Long Branch, NJ**
- 207 **Clinical Course And Typical Chest CT Findings Of Olaparib-induced Lung Injury: A Case Series/M. Hattori, Tokyo, Japan**

- 208 **Drug Withdrawn Pneumonitis? A Case of an Acute Pneumonitis Associated With Ruxolitinib Withdrawal/J. Blount, Sacramento, CA**
- 209 **A Man With Palbociclib-Induced Pneumonitis: A Very Rare Entity/M. Alsharif, Springfield, IL**
- 210 **Belantamab Mafodotin Induced Pneumonitis and Pulmonary Fibrosis/D. Mehta, Chapel Hill, NC**
- 211 **Delayed Mitomycin-Induced Pulmonary Veno-Occlusive Disease/T. Papidze, Chapel Hill, NC**
- 212 **Pulmonary Hypertension in a Patient With Multiple Myeloma/B. Zafar, Houston, TX**
- 213 **Hydralazine Induced Pulmonary Renal Syndrome Via Anca Associated Vasculitis/S. Shireen Kanamgode, Worcester, MA**
- 214 **A Case of Rituximab-induced Interstitial Lung Disease/S. Nagpal, Johnson, TN**
- 215 **Vaping and Cystic Lung Disease: An Underrecognized Relationship/Q. Alitter, Hialeah, FL**
- 216 **How Harmful Is Cocaine? A Case Of Cocaine Induced Constrictive Bronchiolitis/R. Kumra, Phoenix, AZ**
- 217 **The Use of Prolonged Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) as a Lifesaving Therapy for a Patient With Chlorine Gas Inhalation Injury: A Case Report/S.A. Henry, Hershey, PA**
- 218 **Baby Powder and Protein in an Unexpected Cause of Dyspnea in Pregnancy/B. Berger, Durham, NC**
- 219 **Methemoglobinemia and Home Oximetry/M. Haley, Portland, OR**
- 220 **A Case Of Severe Colchicine Associated Vacuolar Myopathy And Respiratory Failure/D. Narayanan, Los Angeles, CA**

CLINICAL

POSTER DISCUSSION SESSION

D104 CARDIAC AND VASCULAR CRITICAL CARE: THE BEST CASE REPORTS FROM 2022

12:00 p.m. - 2:00 p.m. Walter E. Washington Convention Center

Room 209 A-C (Level 2)

Poster Viewing 12:00-12:45

Discussion 12:45-2:00

Chairing: M. Parotto, MD, PhD, Toronto, Canada
M.J. Lanspa, MD, MSCR, ATSF, Salt Lake City, UT
M.M. Hayes, MD, ATSF, Boston, MA

- 801 **Venoarterial Extracorporeal Membrane Oxygenation for Propofol-related Infusion Syndrome: A Case Report**/J.C. Grotberg, St. Louis, MO
- 802 **Ureteroarterial Fistula: A Challenging and Life-threatening Diagnosis**/H. Alaws, Gainesville, GA
- 803 **A Terminal Event**/A.T. Tabur, Jersey City, NJ
- 804 **Late Stage Epicardial Lead Migration With Massive Hemoptysis Compounded by Aspergillus Lead Infection**/V. Hoytfox, Naples, FL
- 805 **Broken Port-a-cath With Cardiac Migration**/S. Chandna, Cleveland, OH
- 806 **Longest Bridge To Transplant Veno-Venous Extracorporeal Membrane Oxygenation Run**/Y. Wang, Houston, TX
- 807 **Constrictive Pericarditis: A Rare Complication Of Noncardiac Thoracic Surgery**/P. Matta, Camden, NJ
- 808 **To Float Or Not To Float; The Risks Of Floating A Swan Ganz In Left Bundle Branch Block**/B. Ravichander, Harrisburg, PA
- 809 **Total Eclipse of the Aorta: A Novel Case of Spontaneous Abdominal Aorta Thrombosis**/Z. Shakir, Kingwood, TX
- 810 **The Vanishing Intracardiac Mass and the Importance of Multimodality Imaging**/Y. Abouleish, Norfolk, VA
- 811 **A Rapidly Obtainable Result That Can Change Management: The E-Point Septal Separation**/K.J. Mulhern, Washington, DC
- 812 **Profound Metformin-associated Lactic Acidosis Presenting With Shock and Wide-complex Bradycardia**/C. Tseng, Danbury, CT
- 813 **Thyroid Storm Leading To Cardiogenic Shock: To ECMO Or Not To ECMO**/T.I. Kennell, Birmingham, AL
- 814 **Butterflies And A Broken Heart: A Case Of Sepsis Due To Acalculous Cholecystitis In The Setting Of LV Noncompaction Cardiomyopathy**/A. Suarez Cruz, San Juan, PR
- 815 **Fulminant Salmonella Myocarditis Complicated By Cardiac Arrest and Requiring VA ECMO, With Complete Recovery**/L.A. Onofrey, Seattle, WA
- 816 **Bedside Echocardiographic Identification of Pericardial Tamponade: A Case Highlighting the Need For Enhanced Pocus Training For Residents in Intensive Care Units**/A. Jain, Johnstown, PA
- 817 **Rare Presentation Of Cardiac Arrest With Return Of Spontaneous Circulation Caused By Septic Purulent Pericarditis**/M. Dillon, Newark, DE
- 818 **Amiodarone Induced Myxedema Coma Presenting With Cardiogenic Shock and Junctional Rhythm**/B. Asllanaj, Las Vegas, NV
- 819 **Spontaneous Right Ventricular Rupture Following Drainage of Pericardial Effusion: An Unusual Case of Pericardial Decompression Syndrome**/B. Asllanaj, Las Vegas, NV
- 820 **A Case Of Mistaken Identity: Constrictive Pericarditis**/A.R. Patel, Nashville, TN
- 821 **Cannulation for Campy: Extracorporeal Membrane Oxygenation as a Rescue Therapy For Campylobacter Jejuni Associated Fulminant Myocarditis**/V. Lacmanovic, Marietta, GA
- 822 **A Case of Hypothyroidism-induced Life-threatening Refractory Torsades De Pointes**/K. Kumar, Baltimore, MD
- 823 **A Rare Case Of Pulmonary Valve Infective Endocarditis**/H. Zhang, Beijing, China
- 824 **First Case Of Nocardia Otitidiscaviarum-Associated Native Valve Endocarditis In An Intestinal Transplant Patient**/D. Azim, Karachi, Pakistan
- 825 **Emphasizing the Importance of POC-US for Confirmation Post-central Venous Line Placement Over Routine Chest Radiograph**/R. Ashraf, New York, NY

BASIC • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

D105 OVERCOMING OBSTACLES: APPROACHES TO PEDIATRIC SLEEP SCREENING AND TREATMENT

12:00 p.m. - 2:00 p.m. Walter E. Washington Convention Center

Room 140 A-B (Street Level)

Poster Viewing 12:00-12:45

Discussion 12:45-2:00

Chairing: I.A. Perez, MD, ATSF, Los Angeles, CA
J.S. Landeo Gutierrez, MD, MPH, San Diego, CA
I. Narang, MD, Toronto, Canada

1101 **Early Life Lower Respiratory Tract Infection Is a "Second-hit" That Greatly Increases the Susceptibility to Obstructive Sleep Apnea in Children Born Prematurely**/A.S. Montgomery, Washington, DC

1102 **The Risk of Pediatric Obstructive Sleep Apnea Is Increased Among Infants Hospitalized With Lower Respiratory Tract Infections During the First Two Years of Life**/M.G. Gayoso Liviach, Washington, DC

- 1103 **Obstructive Sleep Apnea Is Associated With Use of Assisted Ventilation Among Children With Bronchopulmonary Dysplasia Hospitalized With Respiratory Illness: A Kids' Inpatient Database Study**/P.-Y. Tsou, Boston, MA
- 1104 **Asthma, Atopy, and Sleep Disordered Breathing in the Pediatric Adenotonsillectomy Trial for Snoring (PATS)**/P.-Y. Tsou, Boston, MA
- 1105 **Cardiorespiratory Coupling in Extremely Preterm Infants**/N. Krishnamurthi, Chicago, IL
- 1106 **Sleep Disordered Breathing in Adolescents and Adults With History of Extreme Prematurity: A Pilot Study**/N.J. Sanchez Solano, Dallas, TX
- 1107 **Nocturnal Oximetry for the Diagnosis of Obstructive Sleep Apnea Syndrome (OSAS) in Infants**/A. Moudaki, Athens, Greece
- 1108 **Development and Validation of a Sleep-disordered Breathing Questionnaire for Infants**/G. Gupta, Ann Arbor, MI
- 1109 **The SHOOTS Questionnaire: A Pediatric Screening Tool for Obstructive Sleep Apnea**/K. Reiling, Houston, TX
- 1110 **Non-invasive Vision-based Pulmonary Evaluation of Sleep Disordered Breathing Through Visualization of Thermal and CO₂ Flow**/S. Transue, Denver, CO
- 1111 **The Effect of Adenotonsillectomy on Cortical Thickness and Hippocampal Subfield Volumes in Obese Adolescents With Obstructive Sleep Apnea**/H. Park, Bronx, NY
- 1112 **Does the Rate of Weight Gain Impact the Severity of Childhood Obstructive Sleep Apnea?**/Y. Mohamad, Los Angeles, CA
- 1113 **Identification of Children at High Risk for Obstructive Sleep Apnea: A Cluster Analysis Approach**/D. Gatt, Toronto, Canada
- 1114 **Disparities Obstructive Sleep Apnea and Excessive Daytime Sleepiness in Latino Adolescents**/J.S. Landeo Gutierrez, San Diego, CA
- 1115 **Polysomnography in Children With Sickle Cell Disease: Multicenter Comparative Study**/A.S. Alishlash, Birmingham, AL
- 1116 **Obstructive Sleep Apnea Screening in Children With Asthma**/M. Sowho, Baltimore, MD
- 1117 **Obstructive Sleep Apnea Association With Behavioral Insomnia of Childhood: Or Lack Thereof**/L. Yelov, Jerusalem, Israel
- 1118 **Screening for Non-invasive Ventilatory Requirements in Children With Spinal Muscular Atrophy**/A. Chacko, Brisbane, Australia
- 1119 **Children With Spinal Muscular Atrophy Treated With Nusinersen/Risdiplam**/A. Chacko, Brisbane, Australia
- 1120 **Outcomes of Children Treated With Nusinersen/Onasemnogene Apeparvovec for Pediatric Spinal Muscular Atrophy Type 1/A**. Chacko, Brisbane, Australia
- 1121 **Do People With Congenital Central Hypoventilation Syndrome Wake Up in Response to Ventilator or Monitor Alarms?**/R. Itani, Los Angeles, CA
- 1122 **Idiopathic Apnea in Term Newborns and Infants Under 6 Months of Age: A Multicenter Study**/J.-M. Gilardoni, Nice, France

BASIC • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

D106 HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE

12:00 p.m. - 2:00 p.m. **Walter E. Washington Convention Center**

Room 151 A (Street Level)

Poster Viewing 12:00-12:45

Discussion 12:45-2:00

Chairing: K. Yuan, PhD, Boston, MA
K.N. Goss, MD, Dallas, TX
N.A. Kolaitis, MD, MS, San Francisco, CA
B.B. Graham, MD, San Francisco, CA

401 **Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial**/R.P. Frantz, Rochester, MN

402 **Pulmonary Hypertension and Anastrozole (Phantom): A Randomized Clinical Trial**/S.M. Kawut, Philadelphia, PA

403 **Pulmonary Pericytes in Idiopathic Pulmonary Arterial Hypertension Fail to Maintain Lung Microvascular Networks in an Organ-On-A-Chip Model**/Q. Zhang, Berlin, Germany

404 **MGX292, A Novel Variant of Native Bone Morphogenetic Protein 9 (BMP9) That Lacks Osteogenic Activity, Reverses Vascular Remodelling and Pulmonary Arterial Hypertension in the Sugén-hypoxia Rat Model**/N.W. Morrell, Boston, MA

405 **Unpicking the Effects of General Control Non-depressible 2 (GCN2) Deficiency in Pulmonary Veno-Occlusive Disease**/M. Schwiening, Cambridge, United Kingdom

- 406 **Systematic Follow-up of Patients Following Acute Pulmonary Embolism Identifies High Incidence of Chronic Thromboembolic Pulmonary Hypertension: ASPIRE CTEPH/C.** Durrington, Sheffield, United Kingdom
- 407 **Enhanced Pulmonary Vascular Density in Bone Morphogenetic Protein-9 Deficient Rats Is Associated With an Increased Vascular Endothelial Growth Factor Signaling/N.** Berrebeh, Le Kremlin Bicêtre, France
- 408 **Comparative Exosomal microRNA Expression Profiles From Patients of Pulmonary Arterial Hypertension With Human Umbilical Mesenchymal Stem Cells Treatment/N.** Wang, Shanghai, China
- 409 **Genetic Landscape of Venous Thromboembolism Identified By Whole Genome Sequencing, An Analysis From Pedigree and Case-control Studies/Z.** Zhang, Beijing, China
- 106 **Moderate/Severe Impairment of the Diffusing Capacity for Carbon Monoxide (DLco) Is Independently Associated With All-Cause Mortality in People With HIV/M.** Zhang, San Francisco, CA
- 107 **Abnormal Spirometry Is Common Among Adults With and Without HIV in Botswana/S.M.** Patel, Durham, NC
- 108 **Lung Function and Frailty in People Living With HIV/S.** Macrae, New Orleans, LA
- 109 **Safety and Immunogenicity of a Quadrivalent, mRNA-based Seasonal Influenza Vaccine (MRNA-1010) in Adults: Interim Findings From a Phase 1/2 Randomized Clinical Trial/I.** Lee, Cambridge, MA
- 110 **Chitotriosidase in Influenza Lung Infection/J.** Kim, New Haven, CT
- 111 **Leukotriene Modifying Agent Prophylaxis to Prevent Excess Morbidity and Mortality From Influenza: Two Observational Cohort Studies Using Medicaid and Department of Defense Populations Over 22 Influenza Seasons/B.M.** Snyder, Nashville, TN

BASIC • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

D107 ADVANCING THE SCIENCE IN VIRAL INFECTIONS12:00 p.m. - 2:00 p.m. **Marriott Marquis Washington**

Marquis Ballroom, Salons 1-2 (Level M2)

Poster Viewing 12:00-12:45

Discussion 12:45-2:00

Chairing: G.W. Waterer, MBBS, MBA, PhD, Perth, Australia
S.M. Yeligar, MS, PhD, Decatur, GA
M. Bosmann, MD, Boston, MA

- 101 **Revisiting the Use of Race-Specific Reference Values in Studies of HIV-Associated Lung Disease. Analyses From the AIDS Linked to the Intravenous Experience (ALIVE) Cohort/S.** Raju, Baltimore, MD
- 102 **Women Have Higher Risk Than Men for Preserved Ratio Impaired Spirometry (PRISm) Among Ugandans With HIV/R.** Abelman, San Francisco, CA
- 103 **Tobacco Smoking, Smoking Cessation, and Life Expectancy Among People With HIV in South Africa/A.** Thielking, Boston, MA
- 104 **HIV, Respiratory, and Metabolic Factors Associated With 6-minute Walk Test Performance in a Cohort of Kenyan Men and Women/B.** Bunda, New Orleans, LA
- 105 **Risk of Respiratory Symptoms in People With HIV Compared to HIV-Uninfected Persons: A Systematic Review and Meta-Analysis/I.** Konstantinidis, Pittsburgh, PA
- 112 **Effects of Administering Intravenous Azithromycin Within 7 Days of Hospitalization on Influenza Virus Pneumonia Complicated With Acute Respiratory Distress Syndrome: A Propensity Score Analysis Using a Nationwide Administrative Database/T.** Tokito, Nagasaki, Japan
- 113 **MAVS Dependent Immune Responses in Cigarette Smoke Exposure and Influenza Viral Infection/G.** Gupta, New Haven, CT
- 114 **ELD403 as a Novel Anti-viral Therapy for RSV-related Infections in Cystic Fibrosis/R.** Tarran, Chapel Hill, NC
- 115 **Clinical Characteristics and Outcomes of Respiratory Syncytial Virus Pneumonia in Comparison to Influenza or Pneumococcal Pneumonia in Adults/S.** Khurana, Louisville, KY
- 116 **Parainfluenza Infection Can Be Efficiently Modelled in Highly Predictive Human Ex Vivo Lung Tissue/P.** Vollmer Barbosa, Hannover, Germany
- 117 **Rhinovirus C15 Infection Induces Necroptosis in Primary Human Airway Epithelium/M.** Miranda-Katz, Madison, WI
- 118 **Safety and Pharmacodynamics of a Novel Inhaled T1r Agonist Combination in Gold Stage 0 COPD Subjects During Experimental Rhinovirus Challenge/S.L.** Johnston, London, United Kingdom
- 119 **Human Cell Cultures as In Vitro Models to Elucidate How Pulmonary Diseases Alter Exhaled Breath Metabolites for Clinical Diagnostics/M.** McCartney, Davis, CA

- 120 **Targeting IL-1beta to Diminish Age-associated Chronic Lung Sequelae Following Respiratory Viral Infection/I.S. Cheon, Charlottesville, VA**
- 121 **Surfactant Protein A Alters Endosomal Trafficking and Susceptibility to Influenza A Virus in Macrophages/Z.C. Chroneos, Hershey, PA**
- 122 **The Role of Type I IFN and IL-27 in Murine Betacoronavirus Infection/M. Worley, Ann Arbor, MI**
- 123 **Glutamine Enhances Influenza A Virus Replication in Tissue-resident Alveolar Macrophages But Not in Bone Marrow-derived Macrophages/O.R. Shamaa, Chicago, IL**
- 124 **The Effects of pH Alteration on Human Metapneumovirus Infection in Human Airway Epithelial Cells/I.A. Daniels, Indianapolis, IN**
- 125 **Interferon Regulatory Factor 3 Is Activated in Lung Epithelial Cells Following Pam2/ODN Treatment/M.K. Longmire, Houston, TX**
- 906 **C/EBP Homologous Protein (CHOP) Is a Key Regulator of Lung Fibrosis in Alveolar Epithelial Type II (AT2)-specific Grp78 Knockout (KO) Mice/W. Chen, Los Angeles, CA**
- 907 **Deletion of Alveolar Epithelial Type 1 Cell-specific Epithelial Membrane Protein 2 Protects From Lung Fibrosis/W. Lopez Perez, Research Triangle Park, NC**
- 908 **ER Stress Induced PERK-Mediated Metabolic Reprogramming in Pulmonary Fibrosis/J. Pandey, Birmingham, AL**
- 909 **TIMP-3 Expression Is Dysregulated by the Gain-of-Function MUC5B IPF Risk Variant/J.S. Kurche, Aurora, CO**
- 910 **Dysfunctional Alveolar Repair and Pro-fibrotic Remodeling in Lymphangiomyomatosis (LAM)/K. Obratsova, Philadelphia, PA**
- 911 **Progression of Silica-induced Pulmonary Fibrosis Is Arrested After Selective Ablation of Col1a1+ Fibroblasts/D. Foster, Denver, CO**
- 912 **A Brg1/PRMT5 Nuclear Complex Epigenetically Regulates the FOXO1 Transcription Factor in IPF Mesenchymal Progenitor Cells Promoting Self Renewal/A. Jbeli, Minneapolis, MN**
- 913 **Prostaglandin F2α Signaling, a Novel Modulator of Adventitial Fibroblasts in a Preclinical Mouse Model of Idiopathic Pulmonary Fibrosis/L.R. Rodriguez, Philadelphia, PA**
- 914 **Profibrotic Fibroblasts Persist and Reactivate/C. Molina, San Francisco, CA**
- 915 **Macropinocytosis Contributes to Profibrotic Responses of Lung Fibroblasts/K. Tsoyi, Houston, TX**
- 916 **Discoidin Domain Receptor 2 Signaling Through PIK3C2α Regulates Fibrosis/K.K. Kim, Ann Arbor, MI**
- 917 **Ongoing Recruitment of Monocyte-derived Macrophages Is Necessary for the Maintenance of Chronic Pulmonary Fibrosis/K. Kase, Kanazawa, Japan**
- 918 **Classical Monocytes Mediate Air Pollution Induced Acute Exacerbations of Pulmonary Fibrosis/J.L. Larson-Casey, Birmingham, AL**
- 919 **Impaired Natural Killer Cell Function in the Lungs of Patients With Idiopathic Pulmonary Fibrosis/P.A. Agudelo Garcia, Columbus, OH**
- 920 **Targeting STAT3 in the Vascular Endothelium/B.J. Moss, Houston, TX**
- 921 **Expansion of Lung COL15A1+ Systemic Vasculature Is a Generalized Finding in Progressive Fibrotic Interstitial Lung Diseases/E. Engelbrecht, Louisville, KY**

BASIC • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

D108 CELLS, SIGNALING, AND MEDIATORS IN LUNG REMODELING AND FIBROSIS

12:00 p.m. - 2:00 p.m. **Marriott Marquis Washington**

Marquis Ballroom, Salons 3-4 (Level M2)

Poster Viewing 12:00-12:45

Discussion 12:45-2:00

Chairing: M. Lehmann, PhD, Neuherberg, Germany
M.N. Ballinger, PhD, ATSF, Columbus, OH
T.S. Blackwell, MD, Nashville, TN

- 901 **Epithelial Yap-Taz Deletion Promotes Maladaptive Alveolar Repair/J.J. Gokey, Nashville, TN**
- 902 **Directed Differentiation of Alveolar Basal Cells Towards Surfactant Protein B Expressing Cells/P. Khan, Basel, Switzerland**
- 903 **G-coupled Protein 87 (GPR87) a Cell Surface Orphan Receptor Expressed in Aberrant Basaloid Cells in IPF Mediates LPA Induced Fibrotic Gene Expression in Human iPSC Derived Basal Cells/J. Khoury, New Haven, CT**
- 904 **Dysregulation of FOXN4+ Cells in the Small Airway Epithelium of Interstitial Lung Disease/Y. Strulovici-Barel, New York, NY**
- 905 **A Novel Role for Primary Cilia in Fibrotic Lung Disease/C. Trempus, Research Triangle Park, NC**

- 922 **C5a Anaphylatoxin Receptor 1 Mediates Pleural Hypertrophy and Rheumatoid Lung Fibrosis in Collagen-induced Arthritic Mice**/P. Shivshankar, Houston, TX
- 923 **Defining the Pathogenic Role of Neural Crest Cells in Lymphangioleiomyomatosis: Mechanistic and Therapeutic Implications**/U.J. Unachukwu, New York, NY
- 924 **Divergent Lung Tissue Methylation Signatures of COPD and Pulmonary Fibrosis**/K.H. Shutta, Boston, MA
- 925 **Discovery of G-protein Biased APJ Agonist Small Molecule for Pulmonary Diseases**/S. Shi, South San Francisco, CA

BASIC • CLINICAL • TRANSLATIONAL

POSTER DISCUSSION SESSION

D109 THE LONG AND THE SHORT OF LONG COVID12:00 p.m. - 2:00 p.m. **Walter E. Washington Convention Center**

Room 201 (Level 2)


Poster Viewing 12:00-12:45

Discussion 12:45-2:00

Chairing: R.G. Jenkins, BM, MD, MRCP(UK), PhD, London, United Kingdom
R.G. Scheraga, MD, ATSF, Cleveland, OH

- 601 **Unique MRI Phenotypes Help Explain Post-Acute COVID-19 Syndrome**/J.M. Nicholson, London, Canada
- 602 **129Xe Magnetic Resonance Imaging-based Phenotypes of Long COVID: A Multi-center Evaluation**/R.L. Eddy, Vancouver, Canada
- 603 **Airway Mucosal Abnormalities in Post-COVID-19 Patients With Persistent Pulmonary Symptoms: Results From Single-cell RNA-sequencing**/F.V. Gerayeli, Vancouver, Canada
- 604 **Long-COVID Is Associated With Residual Functional Small Airway Disease and Parenchymal Changes Regardless of SARS-CoV-2 Variant**/R.A. Tudas, Iowa City, IA
- 605 **Evolution of Symptoms and Lung Function After SARS-CoV-2 Infection**/D. Collazo, New York, NY
- 606 **Changes in the Human Lung Extracellular Matrix Proteome After SARS-CoV-2 Infection**/J.A. Huapaya, Bethesda, MD
- 607 **Sex Differences in CT Airway Measurements and Their Relationship to Post-Acute COVID-19 Syndrome**/H.K. Kooner, London, Canada
- 608 **One-fourth of COVID-19 Patients Have an Impaired Pulmonary Function After 12 Months of Illness Onset**/H. Willigen, Amsterdam, Netherlands

- 609 **VQ-SPECT/CT Following Recovery From Non-critical COVID-19: 6 Month Longitudinal Follow-up**/C. Venegas Garrido, Hamilton, Canada
- 610 **Post-acute COVID-19 Imaging Abnormalities on Hyperpolarized ¹²⁹Xe MRI Persist Over 6 Months**/P.J. Niedbalski, Kansas City, KS
- 611 **Assessment of Gas Exchange in Long COVID Using Hyperpolarized 129-Xenon MRI and Dual Energy CT**/A.D. Hahn, Iowa City, IA
- 612 **Th17 Overexpression In Severe COVID-19 Pneumonia: A Prospective Observational Study**/A. Gupta, New Delhi, India
- 613 **Increased Intrapulmonary Shunt and Alveolar Dead Space in Patients Recovered From COVID-19 Pneumonitis**/K. Kairaitis, Westmead, Australia
- 614 **Longitudinal Assessment of Lung Function in COVID-19 Patients**/D.A. Kaminsky, Burlington, VT
- 615 **Long COVID-19 Severity and Its Impacts on Pulmonary Function A 1 Year Follow-Up Study**/G.D. Back, Sao Carlos, Brazil
- 616 **A Descriptive Study of Pulmonary Function Parameters and Respiratory Muscle Strength in Long COVID-19 Patients With Pre-existing Asthma**/K. Sankar, Los Angeles, CA
- 617 **Pulmonary Function Testing in Post-Acute Sequelae From COVID-19**/C. Walker, Washington, DC
- 618 **Clinical Significance of Asymmetric Lung Injury in ARDS in COVID-19**/I. Barjaktarevic, Los Angeles, CA



conference.thoracic.org

 **ATS**
2023